

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Comugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 22, 2004, 06:45:50 ; Search time 35 seconds
(without alignments)
3.942 Million cell updates/sec

Title: us-09-555-640-1

Perfect score: 5028
Sequence: 1 gacgcacaggaatgacgt.....acgtatctcctgtacgctc 5028

Scoring table: IDENTITY_NTC
Gapop 10.0 , Gapext 0.5

Searched: 103 seqs, 13720 residues

Total number of hits satisfying chosen parameters: 206

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database : US09555640.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	2343	46.6	2343	1	US-09-555-640-85
2	2013	40.0	2013	1	US-09-555-640-81
3	1662	33.1	1662	1	US-09-555-640-91
4	725	14.4	725	1	US-09-555-640-74
5	681	13.5	681	1	US-09-555-640-87
6	670	13.3	670	1	US-09-555-640-50
7	396	7.9	396	1	US-09-555-640-93
8	306	6.1	306	1	US-09-555-640-89
9	260	5.2	260	1	US-09-555-640-80
10	255	5.1	255	1	US-09-555-640-72
11	222	4.4	222	1	US-09-555-640-83
12	210	4.2	210	1	US-09-555-640-45
13	183	3.6	183	1	US-09-555-640-49
14	180	3.6	180	1	US-09-555-640-77
15	152	3.0	152	1	US-09-555-640-79
16	134	2.7	134	1	US-09-555-640-59
17	117	2.3	117	1	US-09-555-640-48
18	114	2.3	114	1	US-09-555-640-63
19	109	2.2	109	1	US-09-555-640-43
20	104	2.1	109	1	US-09-555-640-43
21	103	2.0	103	1	US-09-555-640-44
22	103	2.0	103	1	US-09-555-640-44
23	102	2.0	102	1	US-09-555-640-62
24	100	2.0	100	1	US-09-555-640-47
25	100	2.0	100	1	US-09-555-640-58
26	98	1.9	98	1	US-09-555-640-50
27	84	1.7	84	1	US-09-555-640-53
28	76	1.5	76	1	US-09-555-640-55
29	64	1.3	64	1	US-09-555-640-11
30	64	1.3	64	1	US-09-555-640-78
31	62	1.2	62	1	US-09-555-640-39
32	60	1.2	60	1	US-09-555-640-54
33	56	1.1	56	1	US-09-555-640-68

34	55	1.1	55	1	US-09-555-640-13	Sequence 13, App1
35	53	1.1	53	1	US-09-555-640-26	Sequence 26, App1
36	51	1.0	51	1	US-09-555-640-69	Sequence 69, App1
37	49	1.0	49	1	US-09-555-640-22	Sequence 22, App1
38	47	1.0	49	1	US-09-555-640-75	Sequence 75, App1
39	47	0.9	47	1	US-09-555-640-21	Sequence 21, App1
40	46	0.9	46	1	US-09-555-640-52	Sequence 52, App1
41	43	0.9	43	1	US-09-555-640-19	Sequence 19, App1
42	42	0.8	42	1	US-09-555-640-71	Sequence 71, App1
43	39	0.8	39	1	US-09-555-640-23	Sequence 23, App1
44	39	0.8	39	1	US-09-555-640-67	Sequence 67, App1
45	37	0.7	37	1	US-09-555-640-70	Sequence 70, App1
46	36	0.7	36	1	US-09-555-640-51	Sequence 51, App1
47	36	0.7	36	1	US-09-555-640-121	Sequence 121, App1
48	35	0.7	35	1	US-09-555-640-4	Sequence 4, App1
49	34	0.7	34	1	US-09-555-640-37	Sequence 37, App1
50	33	0.7	33	1	US-09-555-640-73	Sequence 73, App1
51	32	0.6	32	1	US-09-555-640-30	Sequence 30, App1
52	31	0.6	31	1	US-09-555-640-8	Sequence 8, App1
53	30	0.6	30	1	US-09-555-640-41	Sequence 41, App1
54	30	0.6	30	1	US-09-555-640-46	Sequence 46, App1
55	30	0.6	30	1	US-09-555-640-56	Sequence 56, App1
56	30	0.6	30	1	US-09-555-640-61	Sequence 61, App1
57	30	0.6	30	1	US-09-555-640-66	Sequence 66, App1
58	30	0.6	30	1	US-09-555-640-76	Sequence 76, App1
59	29.6	0.6	670	1	US-09-555-640-50	Sequence 50, App1
60	29.6	0.6	2013	1	US-09-555-640-81	Sequence 81, App1
61	29	0.6	29	1	US-09-555-640-3	Sequence 3, App1
62	29	0.6	29	1	US-09-555-640-40	Sequence 40, App1
63	28	0.6	28	1	US-09-555-640-57	Sequence 57, App1
64	26.4	0.5	255	1	US-09-555-640-72	Sequence 72, App1
65	26.4	0.5	260	1	US-09-555-640-80	Sequence 80, App1
66	26.4	0.5	1662	1	US-09-555-640-91	Sequence 91, App1
67	26.4	0.5	2343	1	US-09-555-640-85	Sequence 85, App1
68	26	0.5	26	1	US-09-555-640-16	Sequence 16, App1
69	26	0.5	26	1	US-09-555-640-33	Sequence 33, App1
70	26	0.5	26	1	US-09-555-640-12	Sequence 12, App1
71	25	0.5	25	1	US-09-555-640-13	Sequence 15, App1
72	24	0.5	24	1	US-09-555-640-32	Sequence 32, App1
73	24	0.5	24	1	US-09-555-640-35	Sequence 35, App1
74	23	0.5	23	1	US-09-555-640-10	Sequence 10, App1
75	23	0.5	23	1	US-09-555-640-25	Sequence 25, App1
76	23	0.5	23	1	US-09-555-640-27	Sequence 27, App1
77	23	0.5	23	1	US-09-555-640-29	Sequence 29, App1
78	23	0.5	23	1	US-09-555-640-38	Sequence 38, App1
79	23	0.5	23	1	US-09-555-640-35	Sequence 35, App1
80	23	0.5	23	1	US-09-555-640-65	Sequence 65, App1
81	23	0.5	23	1	US-09-555-640-49	Sequence 49, App1
82	22.4	0.4	183	1	US-09-555-640-93	Sequence 93, App1
83	22.4	0.4	725	1	US-09-555-640-74	Sequence 74, App1
84	22.2	0.4	396	1	US-09-555-640-94	Sequence 94, App1
85	22	0.4	22	1	US-09-555-640-24	Sequence 24, App1
86	22	0.4	22	1	US-09-555-640-64	Sequence 64, App1
87	21.4	0.4	681	1	US-09-555-640-87	Sequence 87, App1
88	21	0.4	21	1	US-09-555-640-7	Sequence 7, App1
89	21	0.4	21	1	US-09-555-640-36	Sequence 36, App1
90	21	0.4	21	1	US-09-555-640-42	Sequence 42, App1
91	21	0.4	21	1	US-09-555-640-106	Sequence 106, App1
92	21	0.4	21	1	US-09-555-640-115	Sequence 115, App1
93	21	0.4	21	1	US-09-555-640-119	Sequence 119, App1
94	21	0.4	29	1	US-09-555-640-117	Sequence 117, App1
95	20.6	0.4	33	1	US-09-555-640-5	Sequence 5, App1
96	20	0.4	20	1	US-09-555-640-6	Sequence 6, App1
97	20	0.4	20	1	US-09-555-640-14	Sequence 14, App1
98	20	0.4	20	1	US-09-555-640-31	Sequence 31, App1
99	20	0.4	20	1	US-09-555-640-107	Sequence 107, App1
100	20	0.4	20	1	US-09-555-640-112	Sequence 112, App1
101	20	0.4	20	1	US-09-555-640-116	Sequence 116, App1
102	20	0.4	20	1	US-09-555-640-55	Sequence 55, App1
103	19.8	0.4	76	1	US-09-555-640-79	Sequence 79, App1
104	19.6	0.4	152	1	US-09-555-640-79	Sequence 79, App1
105	19.6	0.4	152	1	US-09-555-640-79	Sequence 79, App1
106	19.4	0.4	114	1	US-09-555-640-63	Sequence 63, App1

```

107 19 0.4 19 1 US-09-555-640-18 Sequence 18, App1
108 19 0.4 19 1 US-09-555-640-20 Sequence 20, App1
109 19 0.4 19 1 US-09-555-640-105 Sequence 105, App
110 19 0.4 19 1 US-09-555-640-108 Sequence 108, App
111 19 0.4 19 1 US-09-555-640-111 Sequence 111, App
112 19 0.4 19 1 US-09-555-640-113 Sequence 113, App
113 19 0.4 19 1 US-09-555-640-114 Sequence 114, App
114 19 0.4 19 1 US-09-555-640-118 Sequence 118, App
115 27 0.4 26 1 US-09-555-640-110 Sequence 110, App
116 18.4 0.4 222 1 US-09-555-640-120 Sequence 120, App
117 18.4 0.4 306 1 US-09-555-640-83 Sequence 83, App1
118 18.2 0.4 53 1 US-09-555-640-26 Sequence 26, App1
119 18 0.4 18 1 US-09-555-640-17 Sequence 17, App1
120 18 0.4 18 1 US-09-555-640-34 Sequence 34, App1
121 17.6 0.4 98 1 US-09-555-640-58 Sequence 58, App1
122 17.4 0.3 180 1 US-09-555-640-77 Sequence 77, App1
123 17.2 0.3 34 1 US-09-555-640-37 Sequence 37, App1
124 17 0.3 134 1 US-09-555-640-9 Sequence 9, App1
125 16.2 0.3 102 1 US-09-555-640-59 Sequence 59, App1
126 16 0.3 210 1 US-09-555-640-62 Sequence 62, App1
127 16 0.3 62 1 US-09-555-640-45 Sequence 45, App1
128 15.6 0.3 100 1 US-09-555-640-39 Sequence 39, App1
129 15.6 0.3 100 1 US-09-555-640-47 Sequence 47, App1
130 15.6 0.3 100 1 US-09-555-640-60 Sequence 60, App1
131 15.6 0.3 117 1 US-09-555-640-48 Sequence 48, App1
132 15.2 0.3 36 1 US-09-555-640-51 Sequence 51, App1
133 14.8 0.3 84 1 US-09-555-640-53 Sequence 53, App1
134 14.4 0.3 21 1 US-09-555-640-36 Sequence 36, App1
135 14.4 0.3 46 1 US-09-555-640-52 Sequence 52, App1
136 14.4 0.3 49 1 US-09-555-640-75 Sequence 75, App1
137 14 0.3 64 1 US-09-555-640-78 Sequence 78, App1
138 13.6 0.3 51 1 US-09-555-640-69 Sequence 69, App1
139 13.6 0.3 60 1 US-09-555-640-54 Sequence 54, App1
140 13.4 0.3 39 1 US-09-555-640-67 Sequence 67, App1
141 13.4 0.3 55 1 US-09-555-640-13 Sequence 13, App1
142 13.2 0.3 47 1 US-09-555-640-61 Sequence 61, App1
143 13.2 0.3 64 1 US-09-555-640-21 Sequence 21, App1
144 13.2 0.3 31 1 US-09-555-640-8 Sequence 8, App1
145 13 0.3 33 1 US-09-555-640-73 Sequence 73, App1
146 13 0.3 32 1 US-09-555-640-30 Sequence 30, App1
147 12.8 0.3 23 1 US-09-555-640-29 Sequence 29, App1
148 12.2 0.2 35 1 US-09-555-640-4 Sequence 4, App1
149 12.2 0.2 49 1 US-09-555-640-22 Sequence 22, App1
150 12.2 0.2 20 1 US-09-555-640-5 Sequence 5, App1
151 12 0.2 23 1 US-09-555-640-25 Sequence 25, App1
152 12 0.2 23 1 US-09-555-640-35 Sequence 35, App1
153 12 0.2 26 1 US-09-555-640-33 Sequence 33, App1
154 12 0.2 30 1 US-09-555-640-46 Sequence 46, App1
155 12 0.2 37 1 US-09-555-640-70 Sequence 70, App1
156 12 0.2 56 1 US-09-555-640-68 Sequence 68, App1
157 12 0.2 24 1 US-09-555-640-32 Sequence 32, App1
158 11.8 0.2 36 1 US-09-555-640-121 Sequence 121, App1
159 11.8 0.2 42 1 US-09-555-640-71 Sequence 71, App1
160 11.6 0.2 43 1 US-09-555-640-19 Sequence 19, App1
161 11.6 0.2 21 1 US-09-555-640-106 Sequence 106, App1
162 11.4 0.2 33 1 US-09-555-640-117 Sequence 117, App1
163 11.4 0.2 22 1 US-09-555-640-24 Sequence 24, App1
164 11.2 0.2 23 1 US-09-555-640-10 Sequence 10, App1
165 11.2 0.2 19 1 US-09-555-640-18 Sequence 18, App1
166 11 0.2 20 1 US-09-555-640-107 Sequence 107, App1
167 11 0.2 29 1 US-09-555-640-40 Sequence 40, App1
168 11 0.2 20 1 US-09-555-640-112 Sequence 112, App1
169 10.8 0.2 23 1 US-09-555-640-38 Sequence 38, App1
170 10.8 0.2 29 1 US-09-555-640-66 Sequence 66, App1
171 10.8 0.2 30 1 US-09-555-640-23 Sequence 23, App1
172 10.8 0.2 39 1 US-09-555-640-6 Sequence 6, App1
173 10.6 0.2 26 1 US-09-555-640-57 Sequence 57, App1
174 10.6 0.2 28 1 US-09-555-640-29 Sequence 29, App1
175 10.6 0.2 18 1 US-09-555-640-34 Sequence 34, App1
176 10.2 0.2 21 1 US-09-555-640-42 Sequence 42, App1
177 10.2 0.2 21 1 US-09-555-640-42 Sequence 42, App1
178 10.2 0.2 21 1 US-09-555-640-42 Sequence 42, App1
179 10.2 0.2 21 1 US-09-555-640-42 Sequence 42, App1

```

```

c 180 10.2 0.2 23 1 US-09-555-640-2 Sequence 2, App1
c 181 10.2 0.2 23 1 US-09-555-640-65 Sequence 65, App1
c 182 10.2 0.2 26 1 US-09-555-640-118 Sequence 118, App
c 183 10.2 0.2 27 1 US-09-555-640-120 Sequence 120, App
c 184 10.2 0.2 29 1 US-09-555-640-119 Sequence 119, App
c 185 10 0.2 19 1 US-09-555-640-108 Sequence 108, App
c 186 10 0.2 21 1 US-09-555-640-110 Sequence 110, App
c 187 10 0.2 24 1 US-09-555-640-15 Sequence 15, App1
c 188 10 0.2 30 1 US-09-555-640-41 Sequence 41, App1
c 189 10 0.2 30 1 US-09-555-640-76 Sequence 76, App1
c 190 9.8 0.2 21 1 US-09-555-640-115 Sequence 7, App1
c 191 9.8 0.2 18 1 US-09-555-640-17 Sequence 17, App1
c 192 9.6 0.2 20 1 US-09-555-640-114 Sequence 14, App1
c 193 9.6 0.2 26 1 US-09-555-640-16 Sequence 16, App1
c 194 9.6 0.2 19 1 US-09-555-640-20 Sequence 20, App1
c 195 9.4 0.2 19 1 US-09-555-640-113 Sequence 113, App
c 196 9.4 0.2 20 1 US-09-555-640-64 Sequence 64, App1
c 197 9.4 0.2 22 1 US-09-555-640-105 Sequence 105, App
c 198 9.4 0.2 19 1 US-09-555-640-111 Sequence 111, App
c 199 9.2 0.2 19 1 US-09-555-640-27 Sequence 27, App1
c 200 9.2 0.2 23 1 US-09-555-640-12 Sequence 12, App1
c 201 9.2 0.2 25 1 US-09-555-640-9 Sequence 9, App1
c 202 9.2 0.2 20 1 US-09-555-640-109 Sequence 109, App
c 203 9.2 0.2 20 1 US-09-555-640-116 Sequence 116, App
c 204 9 0.2 20 1 US-09-555-640-116 Sequence 116, App
c 205 9 0.2 20 1 US-09-555-640-116 Sequence 116, App
c 206 8.8 0.2 20 1 US-09-555-640-116 Sequence 116, App

```

ALIGNMENTS

```

RESULT 1
US-09-555-640-85
Sequence 85, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARD-CHERON, Antoine
APPLICANT: AUGUSTE, Veronique
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555, 640
CURRENT FILING DATE: 2000-08-10

```

```

Query Match 46.6%; Score 2343; DB 1; Length 2343;
Best Local Similarity 100.0%; Pred. No. 9.5e-32;
Matches 2343; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

2336 ATGAGTAAACCACTAAACAAATGGTGGGAACCACTGACAAATTTGCCAGACGTGTAT 2395
1 ATGAGTAAACCACTAAACAAATGGTGGGAACCACTGACAAATTTGCCAGACGTGTAT 60
2396 AACCACTTTGTGCAATTTTATGAAAAAGCTACTGACACAGACTTAGAGCTTATCAATT 2455
61 AACCACTTTGTGCAATTTTATGAAAAAGCTACTGACACAGACTTAGAGCTTATCAATT 120
2456 TTAAGACCACTTAACCACTTTCTTATGATATCTTTAGAAAAACCCCTCTTTTATTT 2515
121 TTAAGACCACTTAACCACTTTCTTATGATATCTTTAGAAAAACCCCTCTTTTATTT 180
2516 GACTTAGTGTCTGCAATTAAGTAAATCTTAAAACTCCGACGCTTATGATCAT 2575
181 GACTTAGTGTCTGCAATTAAGTAAATCTTAAAACTCCGACGCTTATGATCAT 240
2576 TTTGAGACCACTGACAGCTTATGACACCCCGCTTATCATTCAGTACAGTAGT 2635
241 TTTGAGACCACTGACAGCTTATGACACCCCGCTTATCATTCAGTACAGTAGT 300
636 GCAAGACCTTAGAGAGAAATGACAGTATCTTAGTGAAGACTTACAGAGCTGGGCA 2695
301 GCAAGACCTTAGAGAGAAATGACAGTATCTTAGTGAAGACTTACAGAGCTGGGCA 360

```


QY 2696 GTTAGCATCAATTACCCGGTACTAATGTTGGGCTGGCAATGAGTACAGCTGGG 2755
 DB 361 GTTAGCATCAATTACCCGGTACTAATGTTGGGCTGGCAATGAGTACAGCTGGG 420
 QY 2756 CCTCCGCAAGTCTGTGCAAGTCTGCAGAGATTCATGATTTAGTATGCAATTTG 2815
 DB 421 CCTCCGCAAGTCTGTGCAAGTCTGCAGAGATTCATGATTTAGTATGCAATTTG 480
 QY 2816 GCTAAATGGGAATTAATCCTTATACATTTGACAGTGGTACAGATGAAGAAATGTTAAA 2875
 DB 481 GCTAAATGGGAATTAATCCTTATACATTTGACAGTGGTACAGATGAAGAAATGTTAAA 540
 QY 2876 AATATATAAATAATGAACAGGTTTCAAGCAACAGATGAAGATTAATCTTTAAAA 2935
 DB 541 AATATATAAATAATGAACAGGTTTCAAGCAACAGATGAAGATTAATCTTTAAAA 600
 QY 2936 GGTGAGCTGCCCCCTGTGGCCATTTTCAAGAAATTTACCGGAAGTCCCGGTAAC 2995
 DB 601 GGTGAGCTGCCCCCTGTGGCCATTTTCAAGAAATTTACCGGAAGTCCCGGTAAC 660
 QY 2996 GCCTCGAAAAATACCCCGAGATGACTTCACTTGAATCTGTGCAAGCCAGCACTGTGCA 3055
 DB 661 GCCTCGAAAAATACCCCGAGATGACTTCACTTGAATCTGTGCAAGCCAGCACTGTGCA 720
 QY 3056 GGGGGGGAGGTAGCAACCTTACAAAAGCATGTGAGTGAAGGGCTACATTTAGCT 3115
 DB 721 GGGGGGGAGGTAGCAACCTTACAAAAGCATGTGAGTGAAGGGCTACATTTAGCT 780
 QY 3116 AATCTGTAACTGTACATTTCTGAGCAATTTTAAATTCATATGATCAGAGCATCAT 3175
 DB 781 AATCTGTAACTGTACATTTCTGAGCAATTTTAAATTCATATGATCAGAGCATCAT 840
 QY 3176 TATTAAGTGTCTCTCAAGAGTATGATGTCACAAATCTGTGGAAAGGCAAAA 3235
 DB 841 TATTAAGTGTCTCTCAAGAGTATGATGTCACAAATCTGTGGAAAGGCAAAA 900
 QY 3236 GTGTGCACTATTAATGCTTATGAGGTAATCTACTCCGTGGAGATTAATGATTTAAAT 3295
 DB 901 GTGTGCACTATTAATGCTTATGAGGTAATCTACTCCGTGGAGATTAATGATTTAAAT 960
 QY 3296 GCTTAAATTTGTTTCTCACCATTAGAGTTTCAAGCATTTAAATGATGATG 3355
 DB 961 GCTTAAATTTGTTTCTCACCATTAGAGTTTCAAGCATTTAAATGATGATG 1020
 QY 3356 ATAGCTCCAGATCTTAACTGTATCTTCAAGAAATGCTGTAAAGATGTCAGAGAC 3415
 DB 1021 ATAGCTCCAGATCTTAACTGTATCTTCAAGAAATGCTGTAAAGATGTCAGAGAC 1080
 QY 3416 AAAACAGAGAGAGTGTGCAAGTTAATGACAGACCAAGAGCTTTGTATGATG 3475
 DB 1081 AAAACAGAGAGAGTGTGCAAGTTAATGACAGACCAAGAGCTTTGTATGATG 1140
 QY 3476 GATCATGATTAATTAATCAATATGCTATGATGTCAGAGCAAGACACATAGCTCCAGAA 3535
 DB 1141 GATCATGATTAATTAATCAATATGCTATGATGTCAGAGCAAGACACATAGCTCCAGAA 1200
 QY 3536 CTGCCATTTGGGTTTACTTTCCCGCCAGATGCTTACTTAACTAGTGAATGAAAC 3595
 DB 1201 CTGCCATTTGGGTTTACTTTCCCGCCAGATGCTTACTTAACTAGTGAATGAAAC 1260
 QY 3596 ACACAGAGAAATTCAGAGACAGCAAAAATTTGGCTAGTGAAGAAATCAGCTTTTATG 3655
 DB 1261 ACACAGAGAAATTCAGAGACAGCAAAAATTTGGCTAGTGAAGAAATCAGCTTTTATG 1320
 QY 3656 TTAGACACAGTTCAATTTGAATTTTGGGTACAGGGGATCTGCACTATGCTTACAAA 3715
 DB 1321 TTAGACACAGTTCAATTTGAATTTTGGGTACAGGGGATCTGCACTATGCTTACAAA 1380
 QY 3716 TTTTCAGCTGTGCCCCCAAGAAACCTAGAGAGCTGACAGCCAACTTTTATGAAATGATC 3775
 DB 1381 TTTTCAGCTGTGCCCCCAAGAAACCTAGAGAGCTGACAGCCAACTTTTATGAAATGATC 1440
 QY 3776 AACCTTTGATCGGTTCTGTTTAGGGGTACTGACACATTTAGAGGGAGCCTTAATTT 3835

DB 1441 AACCTTTGATCGGTTCTGTTTAGGGGTACTGACACATTTAGAGGGAGCCTTAATTT 1500
 QY 3836 AGATCATTAACACAGAAACCAAGCAATTCAGCCCAAAATTTATGCTGGCCACAT 3895
 DB 1501 AGATCATTAACACAGAAACCAAGCAATTCAGCCCAAAATTTATGCTGGCCACAT 1560
 QY 3896 ATTAATTCAGTGTCTACCAAGAGAGACATTTCTAATACAGGTCTGAAAAGCCTT 3955
 DB 1561 ATTAATTCAGTGTCTACCAAGAGAGACATTTCTAATACAGGTCTGAAAAGCCTT 1620
 QY 3956 ACGGGCTTATGATCTGACCAACCAAGAAATTTCCCTAGCCCGGGCCAGTA 4015
 DB 1621 ACGGGCTTATGATCTGACCAACCAAGAAATTTCCCTAGCCCGGGCCAGTA 1680
 QY 4016 TCTCAGCCATACATCACTGGGACACTGATTAATGTTTACAGAAATTAATGCAATTTCA 4075
 DB 1681 TCTCAGCCATACATCACTGGGACACTGATTAATGTTTACAGAAATTAATGCAATTTCA 1740
 QY 4076 CATGACAAACGATTAATGGAATGCTGAGCAAAAGATATCAGAGGGGTAGGAAG 4135
 DB 1741 CATGACAAACGATTAATGGAATGCTGAGCAAAAGATATCAGAGGGGTAGGAAG 1800
 QY 4136 TTTCCAAATGAAGAAAGACAGCTTAAGCAGTTACAAAGTCTTAAACATGACATATCTTC 4195
 DB 1801 TTTCCAAATGAAGAAAGACAGCTTAAGCAGTTACAAAGTCTTAAACATGACATATCTTC 1860
 QY 4196 CCTAATTAAGAAACCCCAATATACACAGCAAAATGAAAGCCCTCTTATGCTGGCTCT 4255
 DB 1861 CCTAATTAAGAAACCCCAATATACACAGCAAAATGAAAGCCCTCTTATGCTGGCTCT 1920
 QY 4256 GTTTGGAAGAAGAGCTCTTCACTATGAAGTCAAGCTGTGAGTAAATCCCTAATCTTA 4315
 DB 1921 GTTTGGAAGAAGAGCTCTTCACTATGAAGTCAAGCTGTGAGTAAATCCCTAATCTTA 1980
 QY 4316 GATGACAGTTTAAATCTCAATTTTGAGCCCTTAAAGCGGTGGGTTTGTGATCAACCAACC 4375
 DB 1981 GATGACAGTTTAAATCTCAATTTTGAGCCCTTAAAGCGGTGGGTTTGTGATCAACCAACC 2040
 QY 4376 CCTCAATATTTTAAATATCTACCAAAAGTGGGCCAATTTGAGATTAATTCATG 4435
 DB 2041 CCTCAATATTTTAAATATCTACCAAAAGTGGGCCAATTTGAGATTAATTCATG 2100
 QY 4436 GGAATTAATCTTGTGTTCAATATGCTGTGGAATTAATGACAGTATCAATGACCTTTAA 4495
 DB 2101 GGAATTAATCTTGTGTTCAATATGCTGTGGAATTAATGACAGTATCAATGACCTTTAA 2160
 QY 4496 TTGGGACCTGAAAGGCTACTGAAAGTGAATCCCAAGCTGCGCTTATCTCTCAT 4555
 DB 2161 TTGGGACCTGAAAGGCTACTGAAAGTGAATCCCAAGCTGCGCTTATCTCTCAT 2220
 QY 4556 GCAAGCTGTCAATTAATCATATGATCTATGACCCCAAGCTACAGATCAAGAAACAC 4615
 DB 2221 GCAAGCTGTCAATTAATCATATGATCTATGACCCCAAGCTACAGATCAAGAAACAC 2280
 QY 4616 CACAGACAGGATTAATGAAGCTGAAGAAATTTGGAAGTGGCCAAAACCGGTGACCA 4675
 DB 2281 CACAGACAGGATTAATGAAGCTGAAGAAATTTGGAAGTGGCCAAAACCGGTGACCA 2340
 QY 4676 TTG 4678
 DB 2341 TTG 2343

RESULT 2
 US-09-555-640-81
 ; Sequence 81, Application us/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications

FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 40.0%; Score 2013; DB 1; Length 2013;
 Best Local Similarity 100.0%; Pred. No. 4e-27;
 Matches 2013; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 328 ATGAGCTATTTTCGGGGTGTCTTGCACATTTCCCTTAACATTTCTGACATCTGTCTAATGAT
DB 1 ATGAGCTATTTTCGGGGTGTCTTGCACATTTCCCTTAACATTTCTGACATCTGTCTAATGAT
QY 388 AACGTGGTGTCTTAAGCTTAAGTATCTTGTGACTGGAGACCACTAAACCACTTCT
DB 61 AACGTGGTGTCTTAAGCTTAAGTATCTTGTGACTGGAGACCACTAAACCACTTCT
QY 448 AACGATTAATGCAATATATTTAAGCAGTGTCTTCTTAACTTGAATTTTCTGGGGG
DB 121 AACGATTAATGCAATATATTTAAGCAGTGTCTTCTTAACTTGAATTTTCTGGGGG
QY 508 CCGCTAGCAGTGTCTTAATCTTTTTCAGTGTGAATGTAAACAAATTTGAGGAAGCTAT
DB 181 CCGCTAGCAGTGTCTTAATCTTTTTCAGTGTGAATGTAAACAAATTTGAGGAAGCTAT
QY 568 CATATCCATGTATATTTGTTGCTCCAGACCTAAATGCTAGAAACTTAACTGTGCTGA
DB 241 CATATCCATGTATATTTGTTGCTCCAGACCTAAATGCTAGAAACTTAACTGTGCTGA
QY 628 GAAAGTTTATTTAATATGTTCTTTACATCTGTGAATGAAAGTTAACTTAAATTT
DB 301 GAAAGTTTATTTAATATGTTCTTTACATCTGTGAATGAAAGTTAACTTAAATTT
QY 688 TTGCCAGGATGATACCAAGAGAAATTTTGAAGATGAGAGCAGTTTAAAGAAAT
DB 361 TTGCCAGGATGATACCAAGAGAAATTTTGAAGATGAGAGCAGTTTAAAGAAAT
QY 748 TACTTAATGAAAAAATTCCTTTAAATGTGTGTGTGTGTGAACAAATATTGACGGGTAT
DB 421 TACTTAATGAAAAAATTCCTTTAAATGTGTGTGTGTGTGAACAAATATTGACGGGTAT
QY 808 ATAGACACCTGTATTTCCGCTCTTTTCGGAGAGAGCTGTCACTGTAAAGAACCCCGC
DB 481 ATAGACACCTGTATTTCCGCTCTTTTCGGAGAGAGCTGTCACTGTAAAGAACCCCGC
QY 868 ATTACTGCAAAATACAGACAGTGTACTTAATGAATCTGGGAGTCTGTGTGAGAGGGA
DB 541 ATTACTGCAAAATACAGACAGTGTACTTAATGAATCTGGGAGTCTGTGTGAGAGGGA
QY 928 GATGTGTGCAATTCGCTGGAAGAGGAAACAAAGCGGGTTAAAGTTTCAACCAATGTA
DB 601 GATGTGTGCAATTCGCTGGAAGAGGAAACAAAGCGGGTTAAAGTTTCAACCAATGTA
QY 988 AATTGGCTATGTGAAAAACAGAGTATTTACTGAAGATTAATGGAATTTAGATTTTAC
DB 661 AATTGGCTATGTGAAAAACAGAGTATTTACTGAAGATTAATGGAATTTAGATTTTAC
QY 1048 CAATATATCTTTAATAGTAGCACTCAAGTGGACGTTTCAAAATTCAAAGTGCCTTAAAG
DB 721 CAATATATCTTTAATAGTAGCACTCAAGTGGACGTTTCAAAATTCAAAGTGCCTTAAAG
QY 1108 TTAGCTATTTAATAGTAGCACTCAAGTGGACGTTTCAAAATTCAAAGTGCCTTAAAG
DB 781 TTAGCTATTTAATAGTAGCACTCAAGTGGACGTTTCAAAATTCAAAGTGCCTTAAAG
QY 1168 TTGAGCAGTATCTTGAATTAAGAAATTAATTAATTAATTTATGTGCAAAAC
DB 841 TTGAGCAGTATCTTGAATTAAGAAATTAATTAATTAATTTATGTGCAAAAC
QY 1228 TATGATCTCTTTTATGAGGTCAACATGTTAATAGTGAATTTGACAAATAATGTGTAA
DB 901 TATGATCTCTTTTATGAGGTCAACATGTTAATAGTGAATTTGACAAATAATGTGTAA
QY 1288 AAAAAACCCCTGTGTTTATGAGGCAACCAAGTACTGGAATAAATAATTTGGCAATGGCT
  
```

```

DB 961 AAAAAACCCCTGTGTTTATGAGGCAACCAAGTACTGGAATAAATAATTTGGCAATGGCT
QY 1348 ATTGCTAAACTGTACCAAGTGTATGAAATGTGAATTTGAAATTAATGAAATTTTCCATTT
DB 1021 ATTGCTAAACTGTACCAAGTGTATGAAATGTGAATTTGAAATTAATGAAATTTTCCATTT
QY 1408 AATGATGACGGGGGAAATTTTGTGTGTGTGTGTGGAATGAAGCAATTAATAGTCAATAT
DB 1081 AATGATGACGGGGGAAATTTTGTGTGTGTGTGTGGAATGAAGCAATTAATAGTCAATAT
QY 1468 GTGGAAGCTGCAAAAGCAATTTTATGAGTGTGCAAGCAACAGGGTGTATCAAGAAATGGCT
DB 1141 GTGGAAGCTGCAAAAGCAATTTTATGAGTGTGCAAGCAACAGGGTGTATCAAGAAATGGCT
QY 1528 GGCAGTGTGCAAGTGTGCTGTGCTGTGCTGTGTTAATACCAAGATGTGATTAATTTT
DB 1201 GGCAGTGTGCAAGTGTGCTGTGCTGTGCTGTGTTAATACCAAGATGTGATTAATTTT
QY 1588 GTTGTAGTGTATATACACTCAACTGCAATGCTAATAGCTTAAAGCAAGATGTGTA
DB 1261 GTTGTAGTGTATATACACTCAACTGCAATGCTAATAGCTTAAAGCAAGATGTGTA
QY 1648 AAGCTAACTTTTACCAATAGATGTATGCTGTGACATGAGTGTACTTAAAGAGCTGATGT
DB 1321 AAGCTAACTTTTACCAATAGATGTATGCTGTGACATGAGTGTACTTAAAGAGCTGATGT
QY 1708 CAACAATGCTTAATCTTGTGTATGCAACAAAGCTGTGAGCCACTATGAAATCTGGCAATA
DB 1381 CAACAATGCTTAATCTTGTGTATGCAACAAAGCTGTGAGCCACTATGAAATCTGGCAATA
QY 1768 AACTTCAATTTGATTTCCCTGGAATTAATGCAATGCTGTGACCAAGCTGTGAAAGCTC
DB 1441 AACTTCAATTTGATTTCCCTGGAATTAATGCAATGCTGTGACCAAGCTGTGAAAGCTC
QY 1828 ACCCCATTTGCTCCAGACACCAAGTATGAGCAAGTGTGTGTGAAAGCTGTGAAAGCTC
DB 1501 ACCCCATTTGCTCCAGACACCAAGTATGAGCAAGTGTGTGTGAAAGCTGTGAAAGCTC
QY 1888 AGTGAAGCAGCTTTTCAACTTATCATCTCAAGGCGCTGTGAACAGTAAACCCCGGCG
DB 1561 AGTGAAGCAGCTTTTCAACTTATCATCTCAAGGCGCTGTGAACAGTAAACCCCGGCG
QY 1948 TCTAGTACGCGCGCTCCCGGGAACAGTTCAGAGAAATCATTTGTGGAAGCCAGTTTCC
DB 1621 TCTAGTACGCGCGCTCCCGGGAACAGTTCAGAGAAATCATTTGTGGAAGCCAGTTTCC
QY 2008 TCCGAATGTATGCGCGCTGTGTGGAAGAACTTTTACACGCGCTGTGCGGATGATTT
DB 1681 TCCGAATGTATGCGCGCTGTGTGGAAGAACTTTTACACGCGCTGTGCGGATGATTT
QY 2068 CGTGAATGTTATGAGGGGTGACCTTTGTATGAGATGTGTGAGAGGGAATTCCTGTGTGC
DB 1741 CGTGAATGTTATGAGGGGTGACCTTTGTATGAGATGTGTGAGAGGGAATTCCTGTGTGC
QY 2128 TGTGTGAAACATTAATAACAAAGTGGGAGGTTGGGGCTTTGCGCTCATTTGATTAAT
DB 1801 TGTGTGAAACATTAATAACAAAGTGGGAGGTTGGGGCTTTGCGCTCATTTGATTAAT
QY 2188 GTGGAGCTGTGTATTAATGAGATGGAATTTTGAAGATTTACTGCAAGCTTATGAGCTGTC
DB 1861 GTGGAGCTGTGTATTAATGAGATGGAATTTTGAAGATTTACTGCAAGCTTATGAGCTGTC
QY 2248 AGTTGTATGTAAGAGCTCTTAACCAATTTCTGTGTTAATCTGTAAATAATGTGCTTAC
DB 1921 AGTTGTATGTAAGAGCTCTTAACCAATTTCTGTGTTAATCTGTAAATAATGTGCTTAC
QY 2308 CTGTGGAATTAACAAGTTTGTATGATTAATGAG 2340
DB 1981 CTGTGGAATTAACAAGTTTGTATGATTAATGAG 2013
  
```

RESULT 3

```

US-09-555-640-91
; Sequence 91, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-503-US
; CURRENT APPLICATION NUMBER: US/09/555, 640
; CURRENT FILING DATE: 2000-08-10

Query Match      33.1%; Score 1662; DB 1; Length 1662;
Best Local Similarity 100.0%; Pred. No. 3.4e-22;
Matches 1662; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3017 ATGACTTCAGTTAACTCTGCAAGAGCCAGACTGTGTGACGCGGGAGGTAGCAACCTT 3076
DB 1 ATGACTTCAGTTAACTCTGCAAGAGCCAGACTGTGTGACGCGGGAGGTAGCAACCTT 60
QY 3077 ACMAAAGCATGTGAGTGAAGGGGCTACTTACTGCTAATTCCTGAAGTGAATTC 3136
DB 61 ACMAAAGCATGTGAGTGAAGGGGCTACTTACTGCTAATTCCTGAAGTGAATTC 120
QY 3137 TCTAGGCAATTTTAAATTCATATGATCCAGAGCATATATAAGTGTCTCTCCAGCA 3196
DB 121 TCTAGGCAATTTTAAATTCATATGATCCAGAGCATATATAAGTGTCTCTCCAGCA 180
QY 3197 GCTAGTAGTGCACATGCTAGTGGGAAAGAGCAAAAGTGTGCACTATAGTCCATT 3256
DB 181 GCTAGTAGTGCACATGCTAGTGGGAAAGAGCAAAAGTGTGCACTATAGTCCATT 240
QY 3257 ATGGGGTACTCTACTCCGTGAGATCTTATGATTTTAAATTTGTTTTCTCA 3316
DB 241 ATGGGGTACTCTACTCCGTGAGATCTTATGATTTTAAATTTGTTTTCTCA 300
QY 3317 CCATAGAGTTTGAAGCACTTAATTTGAATTTATGATGATGATGATGATGATGATGAT 3376
DB 301 CCATAGAGTTTGAAGCACTTAATTTGAATTTATGATGATGATGATGATGATGATGAT 360
QY 3377 GTAATATTTTCAAGAAATTTGCTGTAAAGATGTCAAGCAAAAGAGAGGTGTGCA 3436
DB 361 GTAATATTTTCAAGAAATTTGCTGTAAAGATGTCAAGCAAAAGAGAGGTGTGCA 420
QY 3437 GTTACTGACAGCAGCAGAGAGCTTTGTATGTGTAGTGTATGATGATGATGATGAT 3496
DB 421 GTTACTGACAGCAGCAGAGAGCTTTGTATGTGTAGTGTATGATGATGATGATGAT 480
QY 3497 TATGCTAGTGTGAGGAGCAAGACACACTAGCTCCAGAACTGGCCATTGGGTTACTT 3556
DB 481 TATGCTAGTGTGAGGAGCAAGACACACTAGCTCCAGAACTGGCCATTGGGTTACTT 540
QY 3557 CCCCCCAGATGCTTACTTAAGATGATGATGATGATGATGATGATGATGATGATGAT 3616
DB 541 CCCCCCAGATGCTTACTTAAGATGATGATGATGATGATGATGATGATGATGATGAT 600
QY 3617 AGCAAAATTTGCTGTAGTGAAGATGATGATGATGATGATGATGATGATGATGATGAT 3676
DB 601 AGCAAAATTTGCTGTAGTGAAGATGATGATGATGATGATGATGATGATGATGATGAT 660
QY 3677 CTTTGGGATGAGGGGATGTCACATGTCCTTACAAATTTCCAGTGTGCCCCAGAA 3736
DB 661 CTTTGGGATGAGGGGATGTCACATGTCCTTACAAATTTCCAGTGTGCCCCAGAA 720
QY 3737 AACCTGAAGGCTGACAGCAATTTTATGAATGATGATGATGATGATGATGATGATGAT 3796
DB 721 AACCTGAAGGCTGACAGCAATTTTATGAATGATGATGATGATGATGATGATGATGAT 780
QY 3797 TTAGGGGTACTGACATTTAGAGGGGAGCCCTAAATTTGATGATGATGATGATGATGAT 3856
DB 781 TTAGGGGTACTGACATTTAGAGGGGAGCCCTAAATTTGATGATGATGATGATGATGAT 840
QY 3857 CAGCAATTCAGCAAAATTTATGCTGGGCACTAATAATTCAGTGTCTACCAA 3916

```

```

DB 841 CAGCAATTCAGCAAAATTTATGCTGGGCCATTAATAATTCAGTGTCTACCAA 900
QY 3917 GAAGAGCAATTTCTATACAGTGTGAGAAAGCCCTTAGGGGCTTGTACTGCACT 3976
DB 901 GAAGAGCAATTTCTATACAGTGTGAGAAAGCCCTTAGGGGCTTGTACTGCACT 960
QY 3977 AGCAAAATTCAGCAAAATTTCCCTAGGCCCCGGGAGATCTCAGCCATACATCACTGG 4036
DB 961 AGCAAAATTCAGCAAAATTTCCCTAGGCCCCGGGAGATCTCAGCCATACATCACTGG 1020
QY 4037 GACACTGATTAATATGTTACAGAAATTAATGTCATTTACATGACAAACCTTTGGA 4096
DB 1021 GACACTGATTAATATGTTACAGAAATTAATGTCATTTACATGACAAACCTTTGGA 1080
QY 4097 AATGCTGAGACAAAGATGATGACAGAGGGGTGAGAAATTTCCAAATGAAAAAGACG 4156
DB 1081 AATGCTGAGACAAAGATGATGACAGAGGGGTGAGAAATTTCCAAATGAAAAAGACG 1140
QY 4157 CTTAGCAATTCAGAGCTTAAATGACACATCTTCCCTAATAAGAAACCAACAA 4216
DB 1141 CTTAGCAATTCAGAGCTTAAATGACACATCTTCCCTAATAAGAAACCAACAA 1200
QY 4217 TACACAGACCAATTTGAAGCCCTCTTATGCTGAGCTGTTTGAACAGAAAGCTCTT 4276
DB 1201 TACACAGACCAATTTGAAGCCCTCTTATGCTGAGCTGTTTGAACAGAAAGCTCTT 1260
QY 4277 CACTATGAATGACGTGTGAGTAAATCCCTAATTAATGATGACATTTTAAATCTCA 4336
DB 1261 CACTATGAATGACGTGTGAGTAAATCCCTAATTAATGATGACATTTTAAATCTCA 1320
QY 4337 TTGCGAGCCCTTAGGCGGGGTGTTGATCAACACCCCTTCAATTTTAAATTA 4396
DB 1321 TTGCGAGCCCTTAGGCGGGGTGTTGATCAACACCCCTTCAATTTTAAATTA 1380
QY 4397 CTACCAAAAGTGGGCAATTTGAGAGTATTAATCATGAGGAATTTACTTTAGTTCAA 4456
DB 1381 CTACCAAAAGTGGGCAATTTGAGAGTATTAATCATGAGGAATTTACTTTAGTTCAA 1440
QY 4457 TATGCTGTGGAAATTAATGACATTAACATGACCTTTAAATTTGGAGCTTGAAAGCTACT 4516
DB 1441 TATGCTGTGGAAATTAATGACATTAACATGACCTTTAAATTTGGAGCTTGAAAGCTACT 1500
QY 4517 GGAAGTGAATTTCCAGGCTGCTTATCCTCTCAAGCCTGTGATTAACATAT 4576
DB 1501 GGAAGTGAATTTCCAGGCTGCTTATCCTCTCAAGCCTGTGATTAACATAT 1560
QY 4577 GTACTGTATGACCCCAAGCTACAGATGCAAAAGCAACACAGACAGGATATGAAG 4636
DB 1561 GTACTGTATGACCCCAAGCTACAGATGCAAAAGCAACACAGACAGGATATGAAG 1620
QY 4637 CCTGAAGAAATTTGAGCTGCCAAAGCGGTGTGACCCATTG 4678
DB 1621 CCTGAAGAAATTTGAGCTGCCAAAGCGGTGTGACCCATTG 1662

```

```

RESULT 4
US-09-555-640-74
; Sequence 74, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-503-US
; CURRENT APPLICATION NUMBER: US/09/555, 640
; CURRENT FILING DATE: 2000-08-10

Query Match      14.4%; Score 725; DB 1; Length 725;
Best Local Similarity 100.0%; Pred. No. 6.2e-09;
Matches 725; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 3341 GAAAAATTATGTATAGCTCCAGATGCTTAACTGTATCTATTTTCAGAAATGCTGTA 3400
DB 1 GAAAAATTATGTATAGCTCCAGATGCTTAACTGTATCTATTTTCAGAAATGCTGTA 60
QY 3401 AAGAATGTCAACACACAAAACAGAGAGAGGTGTCAAGTTAATGACACACACAGAGAGCT 3460
DB 61 AAGAATGTCAACACACAAAACAGAGAGAGGTGTCAAGTTAATGACACACACAGAGAGCT 120
QY 3461 TTGTGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTAT 3520
DB 121 TTGTGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTAT 180
QY 3521 ACACGTAGCTCCAGAACTGCCCATTTGGGTTTACTTTCCCTCCAGTATGCTTAACTA 3580
DB 181 ACACGTAGCTCCAGAACTGCCCATTTGGGTTTACTTTCCCTCCAGTATGCTTAACTA 240
QY 3581 GTAGTGAAGTAAACACACAGAGAAATTTAGAGAGACAGAAATTTGGCTATGTAGAA 3640
DB 241 GTAGTGAAGTAAACACACAGAGAAATTTAGAGAGACAGAAATTTGGCTATGTAGAA 300
QY 3641 TCAGCTTTTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTAT 3700
DB 301 TCAGCTTTTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTATGTAT 360
QY 3701 ACTATGTCTTAACTTTCCAGCTGTGCCCAAGAAAACCTTAAAGGCTGACCAACAT 3760
DB 361 ACTATGTCTTAACTTTCCAGCTGTGCCCAAGAAAACCTTAAAGGCTGACCAACAT 420
QY 3761 TTTTATGAATGTACACCCCTTTGTACGTTCTGCTTTAGAGGATGCTGACATTTGA 3820
DB 421 TTTTATGAATGTACACCCCTTTGTACGTTCTGCTTTAGAGGATGCTGACATTTGA 480
QY 3821 GGGAGCCCTAAATTTAGATCAATTTGACACAGAACACACGCAATTCAGCCACAAACTTT 3880
DB 481 GGGAGCCCTAAATTTAGATCAATTTGACACAGAACACACGCAATTCAGCCACAAACTTT 540
QY 3881 ATGCTGTGGCCACTAATTAATTTCACTGTCTTACCAAAAGAGAGACATTTTAATACAG 3940
DB 541 ATGCTGTGGCCACTAATTAATTTCACTGTCTTACCAAAAGAGAGACATTTTAATACAG 600
QY 3941 GCTGAAAAAGCCCTTACGGGGCTTATGATGTGGCACTAGCCAAAACACAGAAATTTCC 4000
DB 601 GCTGAAAAAGCCCTTACGGGGCTTATGATGTGGCACTAGCCAAAACACAGAAATTTCC 660
QY 4001 CGCCCCGGGCGAGTATCTACGACATACATCACTGGGACACTATTAATTTGTACAGA 4060
DB 661 CGCCCCGGGCGAGTATCTACGACATACATCACTGGGACACTATTAATTTGTACAGA 720
QY 4061 ATAAA 4065
DB 721 ATAAA 725

```

```

QY 2396 AAGCAGTTTGGCAATTTTATGAAAAAGCTGACACAGACTTATGAGCTTATTCAAAT 2455
DB 61 AAGCAGTTTGGCAATTTTATGAAAAAGCTGACACAGACTTATGAGCTTATTCAAAT 120
QY 2456 TTTAAAGACCATTTACAACTTTCTTTAGATTAATCCCTTTGAAAAACCCCTCTTTATTT 2515
DB 121 TTTAAAGACCATTTACAACTTTCTTTAGATTAATCCCTTTGAAAAACCCCTCTTTATTT 180
QY 2516 GACTTATGCTGTGCAATTTAAAGTATCTTAAATCTCCAGACTTATATAGTCAT 2575
DB 181 GACTTATGCTGTGCAATTTAAAGTATCTTAAATCTCCAGACTTATATAGTCAT 240
QY 2576 TTTCAAGCCATGACAGTATCTGACACACCCCATGCTTATCATCCATTAACAGTAT 2635
DB 241 TTTCAAGCCATGACAGTATCTGACACACCCCATGCTTATCATCCATTAACAGTAT 300
QY 2636 GCAGAACCTTAGAGAGAAATGCAAGTATTTACTAGTGAAGCTTACACAGCTGGGCA 2695
DB 301 GCAGAACCTTAGAGAGAAATGCAAGTATTTACTAGTGAAGCTTACACAGCTGGGCA 360
QY 2696 GTTAGCATCAATTTACCGGCTACTAATGTTGGGCTGCGCAATGACTTAACTGG 2755
DB 361 GTTAGCATCAATTTACCGGCTACTAATGTTGGGCTGCGCAATGACTTAACTGG 420
QY 2756 CCTCGGCAAGATCTGTGACAGTGTGCAAGATTCATGACTTATGATTAAGCAATTTG 2815
DB 421 CCTCGGCAAGATCTGTGACAGTGTGCAAGATTCATGACTTATGATTAAGCAATTTG 480
QY 2816 GCTAAGTTGGGAATTAATCTTATACATGACGCTGACAGATGAAGATTTGTTAAA 2875
DB 481 GCTAAGTTGGGAATTAATCTTATACATGACGCTGACAGATGAAGATTTGTTAAA 540
QY 2876 AATATTAATAATGAACAGGCTTCAAGCAACAGCTAATAAGTTACTTATTTAAA 2935
DB 541 AATATTAATAATGAACAGGCTTCAAGCAACAGCTAATAAGTTACTTATTTAAA 600
QY 2936 GGTGAGCTGCCCCCTGAGCCCATTTTCAAGAAATTTACCGAAGTCCCGGTACAC 2995
DB 601 GGTGAGCTGCCCCCTGAGCCCATTTTCAAGAAATTTACCGAAGTCCCGGTACAC 660
QY 2996 GCTTCAGAAAAATACCCACAGC 3016
DB 661 GCTTCAGAAAAATACCCACAGC 681

```

```

RESULT 5
US-09-555-640-87
; Sequence 87, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

RESULT 6
US-09-555-640-50
; Sequence 50, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

Query Match 13.5%; Score 681; DB 1; Length 661;
Best Local Similarity 100.0%; Pred. No. 2.6e-08;
Matches 661; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Query Match 13.3%; Score 670; DB 1; Length 670;
Best Local Similarity 100.0%; Pred. No. 3.8e-08;
Matches 670; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2336 ATGAGTAAACCACTTAAACAAATGTGGAGAAAGCAGTGAACAATTTGCCAGAGAGCTGTAT 2395
DB 1 ATGAGTAAACCACTTAAACAAATGTGGAGAAAGCAGTGAACAATTTGCCAGAGAGCTGTAT 60

```

```

QY 851 ATGCTAAAGACCCGCGCTTACTGCAATTAACAGACAGTCTACTAATGAACCTGGGAGT 910

```

```
Db 121 ATGCTAAAGAACCCCGCATTAAGTCAAAATACAGACAGTGTCTAATGAAGTGGGAGT 180
Qy 911 CTAGCTGTGAGGGGAGATGTTGTCCTTCCCTGGAAAGGAAACAAAAGCGGGTTAA 970
Db 181 CTAGCTGTGAGGGGAGATGTTGTCCTTCCCTGGAAAGGAAACAAAAGCGGGTTAA 240
Qy 971 AGTTTCAAAACAGATGTAAATTTGCTATGTGAAAACAGATATTAATCTGAAGATTAATGA 1030
Db 241 AGTTTCAAAACAGATGTAAATTTGCTATGTGAAAACAGATATTAATCTGAAGATTAATGA 300
Qy 1031 AATTAGTGAATTTTAAACAAATATCTTATTAATGAGTCAAGTGGAGCTTTCAAA 1090
Db 301 AATTAGTGAATTTTAAACAAATATCTTATTAATGAGTCAAGTGGAGCTTTCAAA 360
Qy 1091 TTCAAAGTGTCTAAAGTATGCTATTTATTAATGACTACTAATTAATGCTAATGATCAT 1150
Db 361 TTCAAAGTGTCTAAAGTATGCTATTTATTAATGACTACTAATTAATGCTAATGATCAT 420
Qy 1151 TCTTGTACATTCAGACTTGGAGAGGTTACTGCAATTAAGAAATTAATTAATTAAT 1210
Db 421 TCTTGTACATTCAGACTTGGAGAGGTTACTGCAATTAAGAAATTAATTAATTAAT 480
Qy 1211 TATTATTTGTCTAAACCTATGATCTCTTTAGTGGGTCAACATGTGTTAAGTGAATG 1270
Db 481 TATTATTTGTCTAAACCTATGATCTCTTTAGTGGGTCAACATGTGTTAAGTGAATG 540
Qy 1271 ACMAAAATGTGTGTAATAAAACACCTGTGTGTTTTCGGGCGCAACGATCTGAAAAA 1330
Db 541 ACMAAAATGTGTGTAATAAAACACCTGTGTGTTTTCGGGCGCAACGATCTGAAAAA 600
Qy 1331 CAAATTTGGCAATGGCTATGCTAAACGTACACAGTATGAGATGGAATGGAAT 1390
Db 601 CAAATTTGGCAATGGCTATGCTAAACGTACACAGTATGAGATGGAATGGAAT 660
Qy 1391 ATGAAAACTT 1400
Db 661 ATGAAAACTT 670

RESULT 7
US-09-555-640-93
; Sequence 93, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 7.9%; Score 396; DB 1; Length 396;
Best Local Similarity 100.0%; Pred. No. 0.00035;
Matches 396; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4488 CTTTAAATTTGGACCTCGAAAGGCTAAGTGAATTCCTCCAGCTGCGGTTATC 4547
Db 1 CTTTAAATTTGGACCTCGAAAGGCTAAGTGAATTCCTCCAGCTGCGGTTATC 60
Qy 4548 CTCCTATGAGCTGTGCTATTAACATATGTAAGTGAATTCCTCCAGCTGCGGTTATC 4607
Db 61 CTCCTATGAGCTGTGCTATTAACATATGTAAGTGAATTCCTCCAGCTGCGGTTATC 120
Qy 4608 AGCAACACACAGACAGATATGAAAAGCTGAAAGATTTGTGACTGCCAAAAGCCGTG 4667
Db 121 AGCAACACACAGACAGATATGAAAAGCTGAAAGATTTGTGACTGCCAAAAGCCGTG 180
Qy 4668 TGCAACCATTTGTAAACATTTCCCAACGCTGTCTTCAAGCAGAAACCTGACCCGCGCA 4727
Db 181 TGCAACCATTTGTAAACATTTCCCAACGCTGTCTTCAAGCAGAAACCTGACCCGCGCA 240
Qy 4728 CCGTGTCCGCGCAAGATATATATGTGCCCCCTCAATACCCGCTAGGCAACCATCTATAAA 4787
```

```
Db 241 CCGTGTCCGCGCAAGATATATATGTGCCCCCTCAATACCCGCTAGGCAACCATCTATAAA 300
Qy 4788 GATACAGACGCTGTAGATATATTAATTTACTATGATATGAACACATGTAATTAATG 4847
Db 301 GATACAGACGCTGTAGATATATTAATTTACTATGATATGAACACATGTAATTAATG 360
Qy 4848 CTAGATTAATGTAATATGTACCAAGTTTGGAAAAA 4883
Db 361 CTAGATTAATGTAATATGTACCAAGTTTGGAAAAA 396

RESULT 8
US-09-555-640-89
; Sequence 89, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 5.1%; Score 306; DB 1; Length 306;
Best Local Similarity 100.0%; Pred. No. 0.0073;
Matches 306; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2523 TTGCTGCAATTAATAATCTTAAATCTTCACAGACCTATATAGTCATCTTTTACA 2582
Db 1 TTGCTGCAATTAATAATCTTAAATCTTCACAGACCTATATAGTCATCTTTTACA 60
Qy 2583 GCCATGACAGTATCTGACACACCCCATGCTTATCATCTGATACAGTATGCGAAG 2642
Db 61 GCCATGACAGTATCTGACACACCCCATGCTTATCATCTGATACAGTATGCGAAG 120
Qy 2643 CTAGAGAGAAAAATGAGATATATCTAGAGACTTACACAAAGCTGGGCAAGTTAGCA 2702
Db 121 CTAGAGAGAAAAATGAGATATATCTAGAGACTTACACAAAGCTGGGCAAGTTAGCA 180
Qy 2703 TACAATTAACCGGTAATTAATGTTGGCTGCAATGAGTACAAAGCTGCGCTCCG 2762
Db 181 TACAATTAACCGGTAATTAATGTTGGCTGCAATGAGTACAAAGCTGCGCTCCG 240
Qy 2763 AGAATCTGTGACAGTGTGCAAGGATTCATGACTTTAGTATGACCAATGGCTAAGT 2822
Db 241 AGAATCTGTGACAGTGTGCAAGGATTCATGACTTTAGTATGACCAATGGCTAAGT 300
Qy 2823 TGGGAA 2828
Db 301 TGGGAA 306

RESULT 9
US-09-555-640-80
; Sequence 80, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 5.2%; Score 260; DB 1; Length 260;
Best Local Similarity 100.0%; Pred. No. 0.036;
Matches 260; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4672 CCCATGTAACATTTCCCAACGCTGTCTCAGCAGAAACCGTCAACCCGCGCACTG 4731
```

Db 1 CCCATTGTAAACATTCCCAACCGTGTCTCAGCCAGGAAACCGTACCACCCGACCTG 60
Qy 4732 TGCAGCCAGATTAATATGTCCTCCCTCCATACCCCTGAGGACCACTATTAAGATA 4791
Db 61 TGGCGCCCAATTAATATGTCCTCCCTCCATACCCCTGAGGACCACTATTAAGATA 120
Qy 4792 CAGACCTGTAAATTAATTAATTAATAGATATGACCACTGTAATTAAGATGCTAA 4851
Db 121 CAGACCTGTAAATTAATTAATTAATAGATATGACCACTGTAATTAAGATGCTAA 180
Qy 4852 GATTATGTAATATGTAACAGACTTTGAAATAAAGCTTAATTAATTAATTAATGAT 4911
Db 181 GATTATGTAATATGTAACAGACTTTGAAATAAAGCTTAATTAATTAATTAATGAT 240
Qy 4912 GTATGTTCTTTAAATTT 4931
Db 241 GTATGTTCTTTAAATTT 260

RESULT 10
US-09-555-640-72
; Sequence 72, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 5.1%; Score 255; DB 1; Length 255;
Matches 255; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3043 CAGCACTGTGTGACGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 3102
Db 1 CAGCACTGTGTGACGCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG 60
Qy 3103 TACATTTTACTGTAATTTCTGTAACTGTAACTGTAACTGTAACTGTAACTGTAA 3162
Db 61 TACATTTTACTGTAATTTCTGTAACTGTAACTGTAACTGTAACTGTAACTGTAA 120
Qy 3163 TCCAGACATCATATTAAGGTCTCTCCAGAGGAGGAGGAGGAGGAGGAGGAGGAG 3222
Db 121 TCCAGACATCATATTAAGGTCTCTCCAGAGGAGGAGGAGGAGGAGGAGGAGGAG 180
Qy 3223 GAAAGAGGCAAAAGTGTGACTATTAATCCATTAATGAGGAGGAGGAGGAGGAG 3282
Db 181 GAAAGAGGCAAAAGTGTGACTATTAATCCATTAATGAGGAGGAGGAGGAGGAG 240
Qy 3283 CTTAGATTTTAATGC 3297
Db 241 CTTAGATTTTAATGC 255

RESULT 11
US-09-555-640-83
; Sequence 83, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 4.4%; Score 222; DB 1; Length 222;
Matches 222; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1796 ATGCAGATGCCCTCCACCCAGATCTCCCAACCAACCCCACTTGTCCAGACACCACTATCA 1855
Db 1 ATGCAGATGCCCTCCACCCAGATCTCCCAACCAACCCCACTTGTCCAGACACCACTATCA 60
Qy 1856 GCACAGCTGTGTGTAAGAGCTCTGAAGAACTAGTGAAGAGAGCTTTTCAACCTATCA 1915
Db 61 GCACAGCTGTGTGTAAGAGCTCTGAAGAACTAGTGAAGAGAGCTTTTCAACCTATCA 120
Qy 1916 CTCAGGCGCTGGAACAGAGAAACCCCGGCTCTAGTACGCGCGTCCCGGAGCACTT 1975
Db 121 CTCAGGCGCTGGAACAGAGAAACCCCGGCTCTAGTACGCGCGTCCCGGAGCACTT 180
Qy 1976 CAGAGAAATCATTTGTGGAAGCCAGTTCTCTCCGAAGTG 2017
Db 181 CAGAGAAATCATTTGTGGAAGCCAGTTCTCTCCGAAGTG 222

RESULT 12
US-09-555-640-45
; Sequence 45, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 4.2%; Score 210; DB 1; Length 210;
Matches 210; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 91 CTTTGTGAATTTTGGCGGCGCTTTTCCCGCTTANGCAATAAGCGGCACTTTATG 150
Db 1 CTTTGTGAATTTTGGCGGCGCTTTTCCCGCTTANGCAATAAGCGGCACTTTATG 60
Qy 151 TTATTTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 210
Db 61 TTATTTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 120
Qy 211 TATATTAAGAGCTGCGTCTCCCTGACACTTCTTTCTGTGCTTTTGACTGAACTCAC 270
Db 121 TATATTAAGAGCTGCGTCTCCCTGACACTTCTTTCTGTGCTTTTGACTGAACTCAC 180
Qy 271 TTGCTGTTCTTTGCTGCTGTAAGTACAGT 300
Db 181 TTGCTGTTCTTTGCTGCTGTAAGTACAGT 210

RESULT 13
US-09-555-640-49
; Sequence 49, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 3.6%; Score 183; DB 1; Length 183;
Matches 183; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 548 ACAAAATTTGAGAGAGCTATCATATCATATGATTAATGTTGTCGAGACTAATAGCTA 607
Db 1 ACAAAATTTGAGAGAGCTATCATATCATATGATTAATGTTGTTGTTGTTGTTGTTGTT 60

QY 608 GAACTTAACGTGTCGCTGAGAGTTTATTAATGTTCTTACCATCTTGAACG 667
DB 61 GAACTTAACGTGTCGCTGAGAGTTTATTAATGTTCTTACCATCTTGAACG 120
QY 668 AAGGTGTTAACTTAATTTTCCAGGAGTACACAAAGAAAATATTTAGAGATG 727
DB 121 AAGGTGTTAACTTAATTTTCCAGGAGTACACAAAGAAAATATTTAGAGATG 180
QY 728 GAG 730
DB 181 GAG 183

RESULT 14
US-09-555-640-77
; Sequence 77, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 3.6%; Score 180; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 0.59;
Matches 180; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4145 GAAAAAGACAGCTTAAGCAGTTACAGTCAATGACATGACATCTCCCTAATAAA 4204
DB 1 GAAAAAGACAGCTTAAGCAGTTACAGTCAATGACATGACATCTCCCTAATAAA 60
QY 4205 GGAACCAACATATACAGACCAATTTGAAGCCCTCTTATGTGTGGCTCTGTTGGAC 4264
DB 61 GGAACCAACATATACAGACCAATTTGAAGCCCTCTTATGTGTGGCTCTGTTGGAC 120
QY 4265 AGAAGAGCTTTCACTATGAAAGTCAGCTGTGAGTAAATCCCTAATGATGACAGT 4324
DB 121 AGAAGAGCTTTCACTATGAAAGTCAGCTGTGAGTAAATCCCTAATGATGACAGT 180

RESULT 15
US-09-555-640-79
; Sequence 79, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 3.0%; Score 152; DB 1; Length 152;
Best Local Similarity 100.0%; Pred. No. 1.6;
Matches 152; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4420 AGGTATTAATCAATGGAGTAATCTACTTATGTTCAATATGCTGTGGAAATATGACAGT 4479
DB 1 AGGTATTAATCAATGGAGTAATCTACTTATGTTCAATATGCTGTGGAAATATGACAGT 60
QY 4480 TACATGACCTTTAAATTTGGACCTCGAAGGCTACTGGAAGTGAATCCGACGCTGG 4539
DB 61 TACATGACCTTTAAATTTGGACCTCGAAGGCTACTGGAAGTGAATCCGACGCTGG 120
QY 4540 CGTTTATCTCTTCATGACAGCTGCTCAATTTAC 4571
DB 121 CGTTTATCTCTTCATGACAGCTGCTCAATTTAC 152

RESULT 16
US-09-555-640-59
; Sequence 59, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 2.7%; Score 134; DB 1; Length 134;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 134; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2072 AACTGTTAGAGGGGTGACCTTTGTATGGAGATGTTGAGGGATTCCTGTTGCTGTG 2131
DB 1 AACTGTTAGAGGGGTGACCTTTGTATGGAGATGTTGAGGGATTCCTGTTGCTGTG 60
QY 2132 TGGACATATTAACAACAGTGGGGGAGGGTTGGGGCTTTGCCCTCATTTATTAATGTGG 2191
DB 61 TGGACATATTAACAACAGTGGGGGAGGGTTGGGGCTTTGCCCTCATTTATTAATGTGG 120
QY 2192 GAGCTTGATTAAT 2205
DB 121 GAGCTTGATTAAT 134

RESULT 17
US-09-555-640-48
; Sequence 48, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 2.3%; Score 117; DB 1; Length 117;
Best Local Similarity 100.0%; Pred. No. 5.9;
Matches 117; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 431 AACCACTAACCCATTTCTAACAGATTAATGCAATATATTTAAGCAGTGTCTTAAAC 490
DB 1 AACCACTAACCCATTTCTAACAGATTAATGCAATATATTTAAGCAGTGTCTTAAAC 60
QY 491 TTGATTTTACTGGGGGGCCGCTAGACAGTTGCTTAATCTTTTTCAGGTGAATGTA 547
DB 61 TTGATTTTACTGGGGGGCCGCTAGACAGTTGCTTAATCTTTTTCAGGTGAATGTA 117

RESULT 18
US-09-555-640-63
; Sequence 63, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 2.3%; Score 114; DB 1; Length 114;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 114; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2438 TTAGAGCTTATTCAAATTTTAAAGACCTTACCAATTTCTTGTAGTATTCCTTAA 2497
 DB 1 TTAGAGCTTATTCAAATTTTAAAGACCTTACCAATTTCTTGTAGTATTCCTTAA 60
 QY 2498 AACCCCTCTTCTTTTGTAGCTTATGCTGCGCATTTAAAGTATCTTAAAAAC 2551
 DB 61 AACCCCTCTTCTTTTGTAGCTTATGCTGCGCATTTAAAGTATCTTAAAAAC 114

RESULT 19

US-09-555-640-43 ✓
 ; Sequence 43, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 2.2%; Score 109; DB 1; Length 109;
 Best Local Similarity 100.0%; Pred. No. 8;
 Matches 109; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4920 CTTTAAAAATTTCAAAAAGAACACCAATCAGATCCCGCGGCTAGGCG 4979

DB 1 CTTTAAAAATTTCAAAAAGAACACCAATCAGATCCCGCGGCTAGGCG 60

QY 4980 GGACTCCGGTACAAAGATGGCGGACATTCATTTCTGTAGCTC 5028

DB 61 GGACTCCGGTACAAAGATGGCGGACATTCATTTCTGTAGCTC 109

RESULT 20

US-09-555-640-43/c
 ; Sequence 43, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 2.1%; Score 104; DB 1; Length 109;
 Best Local Similarity 100.0%; Pred. No. 9.3;
 Matches 104; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GACGTACAGAAATGACGTAATGTCGCCATCTTGTACCGGAAGTCCCGCTACCGGC 60

DB 109 GACGTACAGAAATGACGTAATGTCGCCATCTTGTACCGGAAGTCCCGCTACCGGC 50

QY 61 GGCGACCGGCGGATCTGATTTGGTGTCTTTTGAATTTT 104

DB 49 GGCGACCGGCGGATCTGATTTGGTGTCTTTTGAATTTT 6

RESULT 21

US-09-555-640-44
 ; Sequence 44, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 2.0%; Score 103; DB 1; Length 103;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 103; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GACGTACAGAAATGACGTAATGTCGCCATCTTGTACCGGAAGTCCCGCTACCGGC 60

DB 1 GACGTACAGAAATGACGTAATGTCGCCATCTTGTACCGGAAGTCCCGCTACCGGC 60

QY 61 GGCGACCGGCGGATCTGATTTGGTGTCTTTTGAATTT 103

DB 61 GGCGACCGGCGGATCTGATTTGGTGTCTTTTGAATTT 103

RESULT 22

US-09-555-640-44/c
 ; Sequence 44, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 2.0%; Score 103; DB 1; Length 103;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 103; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4926 AATTTCAAAAAGAACACCAATCAGATCCCGCGGCTAGGCGGACTT 4985

DB 103 AATTTCAAAAAGAACACCAATCAGATCCCGCGGCTAGGCGGACTT 44

QY 4986 CCGGTACAAAGATGGCGGACATTCATTTCTGTAGCTC 5028

DB 43 CCGGTACAAAGATGGCGGACATTCATTTCTGTAGCTC 1

RESULT 23

US-09-555-640-62
 ; Sequence 62, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 2.0%; Score 102; DB 1; Length 102;
 Best Local Similarity 100.0%; Pred. No. 10;
 Matches 102; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2336 ATGAGTAAACCACTAACAATGTTGGGAAAGAGTGACAAATTTGGCCGAGACGTAT 2395

DB 1 ATGAGTAAACCACTAACAATGTTGGGAAAGAGTGACAAATTTGGCCGAGACGTAT 60

QY 2396 AAGCAGTTTGTGCAATTTTGAAGAAAGTACTGGAACAGAC 2437

DB 61 AAGCAGTTTGTGCAATTTTGAAGAAAGTACTGGAACAGAC 102

RESULT 24

US-09-555-640-47
 ; Sequence 47, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique

```
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10
```

```
Query Match 2.0%; Score 100; DB 1; Length 100;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 331 GACCTATTTGGGGGTGCTTGCACATTTCTCTAACATTTGACCTGTGTAATGATAC 330
DB 1 GACCTATTTGGGGGTGCTTGCACATTTCTCTAACATTTGACCTGTGTAATGATAC 60
QY 391 TGGTGGTGGCTCTATGCTAGACTTAACTCTGACTGGG 430
DB 61 TGGTGGTGGCTCTATGCTAGACTTAACTCTGACTGGG 100
```

```
RESULT 25
US-09-555-640-60
; Sequence 60, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10
```

```
Query Match 2.0%; Score 100; DB 1; Length 100;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 100; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2206 GGATGGAATTTTGAAGATTACTCCAGACTAGTGCGTGCAGTTGTCTAGAGAGCC 2265
DB 1 GGATGGAATTTTGAAGATTACTCCAGACTAGTGCGTGCAGTTGTCTAGAGAGCC 60
QY 2266 TCTAACCCATTTTCTGTGTTAACTGTAAAAATGTGCTT 2305
DB 61 TCTAACCCATTTTCTGTGTTAACTGTAAAAATGTGCTT 100
```

```
RESULT 26
US-09-555-640-58
; Sequence 58, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10
```

```
Query Match 1.9%; Score 98; DB 1; Length 98;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 98; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1974 TTGAGAGAAATCTTTGTGCGAAGCCGAGTTTCTCCGAAGTGTAGCCGCTGCGGGA 2033
DB 1 TTGAGAGAAATCTTTGTGCGAAGCCGAGTTTCTCCGAAGTGTAGCCGCTGCGGGA 60
QY 2034 GGAAGCTTTTACAGCGCGCTGCGGATGAGTTTGGG 2071
DB 61 GGAAGCTTTTACAGCGCGCTGCGGATGAGTTTGGG 98
```

```
RESULT 27
US-09-555-640-53
```

```
; Sequence 53, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10
```

```
Query Match 1.7%; Score 84; DB 1; Length 84;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 84; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1483 GCCATTTTGGTGTGTACCAACAGGTTAGATCAGAAAATGCTGCGATGCGAGTG 1542
DB 1 GCCATTTTGGTGTGTACCAACAGGTTAGATCAGAAAATGCTGCGATGCGAGTG 60
```

```
QY 1543 CCCGGTGGCTGTGTGTTAAACC 1566
DB 61 CCCGGTGGCTGTGTGTTAAACC 84
```

```
RESULT 28
US-09-555-640-55
; Sequence 55, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10
```

```
Query Match 1.5%; Score 76; DB 1; Length 76;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 76; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1627 GCCTTAAAGGAACGATGTAAAGCTTAACTTACCATAGATGAGCCCTGACATGGGT 1686
DB 1 GCCTTAAAGGAACGATGTAAAGCTTAACTTACCATAGATGAGCCCTGACATGGGT 60
```

```
QY 1687 TTACTTACAGAGGCTG 1702
DB 61 TTACTTACAGAGGCTG 76
```

```
RESULT 29
US-09-555-640-11
; Sequence 11, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10
```

```
Query Match 1.3%; Score 64; DB 1; Length 64;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 64; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1841 CAGACACCAAGTATCAGACAGAGTGCGTGAAGCTCTGAAGAACTCAGTGAAGAGGCT 1900
DB 1 CAGACACCAAGTATCAGACAGAGTGCGTGAAGCTCTGAAGAACTCAGTGAAGAGGCT 60
QY 1901 TTTT 1904
DB 1
```



```

; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          1.0%; Score 51; DB 1; Length 51;
Best Local Similarity 100.0%; Pred. No. 78;
Matches 51; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2881 AAAAAATGAACGCGGTTTCACGACAGCTAAAGATTACTTACTTT 2931
DB      1 AAAAAATGAACGCGGTTTCACGACAGCTAAAGATTACTTACTTT 51

RESULT 37
US-09-555-640-22
; Sequence 22, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          1.0%; Score 49; DB 1; Length 49;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 49; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2709 TACCCTGTAACCTATGTTGGGCTGGCAATGAGCTACAAAGCTGGGCC 2757
DB      1 TACCCTGTAACCTATGTTGGGCTGGCAATGAGCTACAAAGCTGGGCC 49

RESULT 38
US-09-555-640-75
; Sequence 75, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          1.0%; Score 49; DB 1; Length 49;
Best Local Similarity 100.0%; Pred. No. 85;
Matches 49; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4066 TGCATTTCATGACCAACCACTATATGGAATGCTGAGACAAGAG 4114
DB      1 TGCATTTCATGACCAACCACTATATGGAATGCTGAGACAAGAG 49

RESULT 39
US-09-555-640-21
; Sequence 21, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US

```

```

; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.9%; Score 47; DB 1; Length 47;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 47; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2655 ATGCAGTATATCTAGTGAAGCTTACACAGCGCTGGCAAGTTAGC 2701
DB      1 ATGCAGTATATCTAGTGAAGCTTACACAGCGCTGGCAAGTTAGC 47

RESULT 40
US-09-555-640-52
; Sequence 52, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.9%; Score 46; DB 1; Length 46;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 46; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1437 CTGGAGTAAGGCAATTATTAAGTCCACTATGTGTGAGCTGCAGAA 1482
DB      1 CTGGAGTAAGGCAATTATTAAGTCCACTATGTGTGAGCTGCAGAA 46

RESULT 41
US-09-555-640-19
; Sequence 19, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.9%; Score 43; DB 1; Length 43;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 43; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2585 CATGACAGTATCTGACCAACCCCATGCTTATCATCCAGTA 2627
DB      1 CATGACAGTATCTGACCAACCCCATGCTTATCATCCAGTA 43

RESULT 42
US-09-555-640-71
; Sequence 71, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.8%; Score 42; DB 1; Length 42;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 42; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      3001 AGAAAAATACCCGACATGACTTCAGTTAACTCTGCAGAAAC 3042
DB      1 AGAAAAATACCCGACATGACTTCAGTTAACTCTGCAGAAAC 42

RESULT 43
US-09-555-640-23
; Sequence 23, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.8%; Score 39; DB 1; Length 39;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 39; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2774 GACAGTGTGCAAGATTCTGACTTAACTTAAAGCCAA 2812
DB      1 GACAGTGTGCAAGATTCTGACTTAACTTAAAGCCAA 39

RESULT 44
US-09-555-640-67
; Sequence 67, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.8%; Score 39; DB 1; Length 39;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 39; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2747 CAAGCTGGGCTCCGACAGATGCTGTGACAGTGTGCA 2785
DB      1 CAAGCTGGGCTCCGACAGATGCTGTGACAGTGTGCA 39

RESULT 45
US-09-555-640-70
; Sequence 70, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.7%; Score 37; DB 1; Length 37;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 37; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2964 AAGGAAGTTACCGAAGTCCCGGCTTACAGGCTTC 3000
DB      1 AAGGAAGTTACCGAAGTCCCGGCTTACAGGCTTC 37

RESULT 46
US-09-555-640-51

```

```

; Sequence 51, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.7%; Score 36; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1401 TCCATTATATGATGTCGCGGGAAGTTGGTGT 1436
DB      1 TCCATTATATGATGTCGCGGGAAGTTGGTGT 36

RESULT 47
US-09-555-640-121
; Sequence 121, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.7%; Score 36; DB 1; Length 36;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 36; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1846 ACCAGTATCAGCAGCGTGTGTGAAGCTTGAA 1881
DB      1 ACCAGTATCAGCAGCGTGTGTGAAGCTTGAA 36

RESULT 48
US-09-555-640-4
; Sequence 4, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.7%; Score 35; DB 1; Length 35;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1384 TGGATTAATGAAAACCTTCATTATATGATGTAC 1418
DB      1 TGGATTAATGAAAACCTTCATTATATGATGTAC 35

RESULT 49
US-09-555-640-37
; Sequence 37, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications

```

; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.7%; Score 34; DB 1; Length 34;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 34; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4398 TACCACAAAGTGGGCAATTGAGGTATTAATC 4431
Db 1 TACCACAAAGTGGGCAATTGAGGTATTAATC 34

RESULT 50
US-09-555-640-73
; Sequence 73; Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.7%; Score 33; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 33; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3298 TTTAAATTTGTTTTCTCACCATTAGAGTTTCA 3330
Db 1 TTTAAATTTGTTTTCTCACCATTAGAGTTTCA 33

RESULT 51
US-09-555-640-30
; Sequence 30; Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.6%; Score 32; DB 1; Length 32;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 32; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3320 TTAGAGTTTGAGCACTTAATGAAATTAATG 3351
Db 1 TTAGAGTTTGAGCACTTAATGAAATTAATG 32

RESULT 52
US-09-555-640-8
; Sequence 8; Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.6%; Score 31; DB 1; Length 31;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1746 CCACTATGAAAACCTGGCAATAAATACTACACA 1776
Db 1 CCACTATGAAAACCTGGCAATAAATACTACACA 31

RESULT 53
US-09-555-640-41
; Sequence 41; Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4655 GCCAAAAGCCGTGTGACCCCAATTGTAAACA 4684
Db 1 GCCAAAAGCCGTGTGACCCCAATTGTAAACA 30

RESULT 54
US-09-555-640-46
; Sequence 46; Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 301 ATTATACACTTAATTTAATTACTTAACATG 330
Db 1 ATTATACACTTAATTTAATTACTTAACATG 30

RESULT 55
US-09-555-640-56
; Sequence 56; Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1703 ATGTACACAAAGCTAAGTGTGTATG 1732
Db 1 ATGTACACAAAGCTAAGTGTGTATG 30

RESULT 56

```
US-09-555-640-61
; Sequence 61, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 100.0%; Score 30; DB 1; Length 30;
Pred. No. 2.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2306 ACCGTCTGATTTCAAGTTTGTAGATT 2335
Db 1 ACCGTCTGATTTCAAGTTTGTAGATT 30

RESULT 57
US-09-555-640-66
; Sequence 66, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 100.0%; Score 30; DB 1; Length 30;
Pred. No. 2.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2617 ATCATCCAGTACAGTAGTGACAGAACTAG 2646
Db 1 ATCATCCAGTACAGTAGTGACAGAACTAG 30

RESULT 58
US-09-555-640-76
; Sequence 76, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 100.0%; Score 30; DB 1; Length 30;
Pred. No. 2.1e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4115 TATCAGCAGGGGTAGAGATTTCCAAT 4144
Db 1 TATCAGCAGGGGTAGAGATTTCCAAT 30

RESULT 59
US-09-555-640-50/c
; Sequence 50, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
```

```
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 59.5%; Score 29.6; DB 1; Length 670;
Pred. No. 18; Mismatches 34; Indels 0; Gaps 0;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1147 ACATTCTGTTCACATTCAGACTTTGAGCAGGTTACTTCATTAAAGAAATTAATAGTA 1206
Db 500 ATAGTTTGACACAAATAATTAATTTACTATTATTTCTTAATGCAAGTAACCTGCTC 441

Qy 1207 AAATTATTTATTTGTCAAACTAT 1230
Db 440 AAAGTCTGAATGTAAACAAGAAATGT 417

RESULT 60
US-09-555-640-81/c
; Sequence 81, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 59.5%; Score 29.6; DB 1; Length 2013;
Pred. No. 7.2; Mismatches 34; Indels 0; Gaps 0;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1147 ACATTCTGTTCACATTCAGACTTTGAGCAGGTTACTTCATTAAAGAAATTAATAGTA 1206
Db 903 ATAGTTTGACACAAATAATTAATTTACTATTATTTCTTAATGCAAGTAACCTGCTC 844

Qy 1207 AAATTATTTATTTGTCAAACTAT 1230
Db 843 AAAGTCTGAATGTAAACAAGAAATGT 820

RESULT 61
US-09-555-640-3
; Sequence 3, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 100.0%; Score 29; DB 1; Length 29;
Pred. No. 2.2e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 718 TTTAGAGATGAGAGCAGTTTATAGAAA 746
Db 1 TTTAGAGATGAGAGCAGTTTATAGAAA 29

RESULT 62
US-09-555-640-40
; Sequence 40, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
```


4793 AGACGCTGTAAGATAATAATTATTTACTAGATATGAAACACATGTAATTAGAA--TGCTA 485


```
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      418 ACTCTGACTGGGAGACCACTAAC 440
DB      1 ACTCTGACTGGGAGACCACTAAC 23

RESULT 75
US-09-555-640-10
; Sequence 10, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1795 AATGAGATGCTCCACCCAGA 1817
DB      1 AATGAGATGCTCCACCCAGA 23

RESULT 76
US-09-555-640-25
; Sequence 25, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2870 TTAATAAATATAAATAATGAAC 2892
DB      1 TTAATAAATATAAATAATGAAC 23

RESULT 77
US-09-555-640-27
; Sequence 27, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
```

```
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2990 TACAAGCCTCGAATAATATACC 3012
DB      1 TACAAGCCTCGAATAATATACC 23

RESULT 78
US-09-555-640-29
; Sequence 29, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3284 TTGATTTTAATGCTTAATTT 3306
DB      1 TTGATTTTAATGCTTAATTT 23

RESULT 79
US-09-555-640-35
; Sequence 35, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4313 TTGATGACAGTTTAAACTCA 4335
DB      1 TTGATGACAGTTTAAACTCA 23

RESULT 80
US-09-555-640-38
; Sequence 38, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 4433 ATGGGAATTACTACTTACTTCA 4455
|||
Db 1 ATGGGAATTACTACTTACTTCA 23

RESULT 81
US-09-555-640-65
; Sequence 65, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2574 ATTTGAGACCATGACACTTA 2596
|||
Db 1 ATTTGAGACCATGACACTTA 23

RESULT 82
US-09-555-640-49/c
; Sequence 49, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 22.4; DB 1; Length 183;
Best Local Similarity 66.7%; Pred. No. 60;
Matches 32; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 3857 CACGCAATTCAGCCAACTTTATGCTGGCGCACTATAATTTCA 3904
|||
Db 76 CACGCAATTCAGCTTTAGCATTTAGTCTCGACCACTATACTACA 29

RESULT 83
US-09-555-640-74/c
; Sequence 74, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 22.4; DB 1; Length 725;
Best Local Similarity 66.7%; Pred. No. 19;
Matches 32; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 576 TGTAGTTATGTTGTCCTCAGACTAAATGCTAGAACTTAATCTGTG 623
|||
Db 564 TGAATTTATAGTGCCAGCATAAAGTTTGTGCTGAATGCTG 517

RESULT 84
US-09-555-640-93/c

; Sequence 93, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 22.2; DB 1; Length 396;
Best Local Similarity 48.1%; Pred. No. 32;
Matches 63; Conservative 0; Mismatches 68; Indels 0; Gaps 0;
QY 263 GAACCTACTGCTGTTCTTCTGCTGCTAGTACAGGATTTATCTTAATTTA 322
|||
Db 381 GTACATATTACATTAATCTTACGATTTATCATGTTCTATCTAGTTAATTTA 322
QY 323 CTAACTGAGGCTAATTTGGGGTCTTGCACATTTCTTAACATTCGACGCTGCTA 382
|||
Db 321 ATTTCTACAGCGCTGCTGATCTTTATAGATGTTGCTACGGGATTTGGAGGGCAC 262
QY 383 ATGATAACTCG 393
|||
Db 261 ATATAATCTGG 251

RESULT 85
US-09-555-640-24
; Sequence 24, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2814 TGGCTAAGTTGGGATAATCC 2835
|||
Db 1 TGGCTAAGTTGGGATAATCC 22

RESULT 86
US-09-555-640-64
; Sequence 64, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2552 TCTCCAGACTATATAGTCATC 2573
|||
Db 1 TCTCCAGACTATATAGTCATC 22

RESULT 87

```
US-09-555-640-87/c
; Sequence 87, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
0.4%; Score 21; DB 1; Length 681;
Best Local Similarity 58.7%; Pred. No. 21;
Matches 37; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1047 CCATATCTTATTAATGAGCAGTGCAGTGCAGCTTCAATTCAGTCCCTTAA 1106
DB 643 CCGTAACTCTCTGAAATGGCCACAGGGCAGCTGCACCTTTAAAGTAAAT 584
QY 1107 GTT 1109
DB 583 CTT 581

RESULT 88
US-09-555-640-7
; Sequence 7, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1723 TGGTATATGACACAAAGCTGG 1743
DB 1 TGGTATATGACACAAAGCTGG 21

RESULT 89
US-09-555-640-36
; Sequence 36, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4376 CCTCAATATTTTAAATA 4396
DB 1 CCTCAATATTTTAAATA 21

RESULT 90
US-09-555-640-42
; Sequence 42, Application US/09555640
; GENERAL INFORMATION:
```

```
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4686 TCCCCACGCGTCTCAGCCA 4706
DB 1 TCCCCACGCGTCTCAGCCA 21

RESULT 91
US-09-555-640-106/c
; Sequence 106, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1879 GAAGAACTCAGTAAAGCAGC 1899
DB 21 GAAGAACTCAGTAAAGCAGC 1

RESULT 92
US-09-555-640-110/c
; Sequence 110, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2041 TTTTACAGCGCGCTTCCGAT 2061
DB 21 TTTTACAGCGCGCTTCCGAT 1

RESULT 93
US-09-555-640-115
; Sequence 115, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
```

```

; CURRENT FILING DATE: 2000-08-10
Query Match          0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1755 AACTGGGCAATAAATACAC 1775
DB      1 AACTGGGCAATAAATACAC 21

RESULT 94
US-09-555-640-119
; Sequence 119, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.4%; Score 21; DB 1; Length 29;
Best Local Similarity 82.8%; Pred. No. 2.6e+02;
Matches 24; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      2998 CTCAGAAAATACCCGACATGACTTCAG 3026
DB      1 CACGATCCATACCCGACATGACTTCAG 29

RESULT 95
US-09-555-640-117
; Sequence 117, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.4%; Score 20.6; DB 1; Length 33;
Best Local Similarity 85.2%; Pred. No. 2.4e+02;
Matches 23; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      2320 CAAAGTTTGTAGATTATGATTAAC 2346
DB      7 CTAGATCTGTAGATTATGATTAAC 33

RESULT 96
US-09-555-640-5
; Sequence 5, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1429 TTGTTGTCTGGAGTGAAG 1448

```

```

DB      1 TTGTGTCTGGATGAAG 20

RESULT 97
US-09-555-640-6
; Sequence 6, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1693 ACAGAGGCTGATGTACACA 1712
DB      1 ACAGAGGCTGATGTACACA 20

RESULT 98
US-09-555-640-14
; Sequence 14, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2062 CAGTTTCTGAAGTGTAGT 2081
DB      1 CAGTTTCTGAAGTGTAGT 20

RESULT 99
US-09-555-640-31
; Sequence 31, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4055 ACAGATTAATGCCATTTC 4074
DB      1 ACAGATTAATGCCATTTC 20

RESULT 100
US-09-555-640-107
; Sequence 107, Application US/09555640

```

```
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1968 GACCACTTCAGGAGATCAT 1987
DB      1 GACCACTTCAGGAGATCAT 20
|||||

RESULT 101
US-09-555-640-109/c
; Sequence 109, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2298 ATGTGCTTACTGTCTGGAT 2317
DB      20 ATGTGCTTACTGTCTGGAT 1
|||||

RESULT 102
US-09-555-640-112/c
; Sequence 112, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2793 ATGACTTAGTATAGCCAA 2812
DB      20 ATGACTTAGTATAGCCAA 1
|||||

RESULT 103
US-09-555-640-116/c
; Sequence 116, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
```

```
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.6e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2845 TTGGACGGTGAAGATGAAG 2864
DB      20 TTGGACGGTGAAGATGAAG 1
|||||

RESULT 104
US-09-555-640-55/c
; Sequence 55, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 19.8; DB 1; Length 76;
Best Local Similarity 57.1%; Pred. No. 1.3e+02;
Matches 36; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY      1631 TAAAGAACGATGTGAAGCTTAACCTTACATTAAGATGATGACCTGATGAGTTTAC 1690
DB      67 TAAAGTAACCATGTCAGGCTTACATTTATGTGAAGTTTACCTTACATCCGTTCC 8
|||||

QY      1691 TTA 1693
DB      7 TTA 5
|||||

RESULT 105
US-09-555-640-79/c
; Sequence 79, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 19.6; DB 1; Length 152;
Best Local Similarity 54.1%; Pred. No. 74;
Matches 40; Conservative 0; Mismatches 34; Indels 0; Gaps 0;

QY      1726 TGTATGCACAAAGCTGGAGCCACTATGAAACTGGGCAATTAACATGATTTGTTTC 1785
DB      76 TTTAAAGTCATGATGATCTGATTAATCCACAGATTAATGAAGTAAGTAAATTC 17
|||||

QY      1786 CCTGAATAATGC 1799
DB      16 CATGATTTAATTC 3
|||||

RESULT 106
US-09-555-640-63/c
; Sequence 63, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
```


FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 19.4; DB 1; Length 114;
Best Local Similarity 70.3%; Pred. No. 94;
Matches 26; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 4902 AATCATAGTGTATGTTTAAATTTCAAAAG 4938
DB 43 AAGAAATGTTGAATGCTTTTAAATTTCAATG 7

RESULT 107
US-09-555-640-18
Sequence 18, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARG-CHENON, Antoine
APPLICANT: AUGUSTE, Veronique
APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2562 TATATGTCATCATTTTCA 2580
DB 1 TATATGTCATCATTTTCA 19

RESULT 108
US-09-555-640-20
Sequence 20, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARG-CHENON, Antoine
APPLICANT: AUGUSTE, Veronique
APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2635 TGCAGAACTAGAGAGAA 2653
DB 1 TGCAGAACTAGAGAGAA 19

RESULT 109
US-09-555-640-105
Sequence 105, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARG-CHENON, Antoine
APPLICANT: AUGUSTE, Veronique
APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1797 TGCAGATGCCCTCCACCA 1815
DB 1 TGCAGATGCCCTCCACCA 19

RESULT 110
US-09-555-640-108/C
Sequence 108, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARG-CHENON, Antoine
APPLICANT: AUGUSTE, Veronique
APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2043 TTACAGCGCGCTTGCCGAT 2061
DB 19 TTACAGCGCGCTTGCCGAT 1

RESULT 111
US-09-555-640-111
Sequence 111, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARG-CHENON, Antoine
APPLICANT: AUGUSTE, Veronique
APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2609 CATGCTTATCATCCAGTA 2627
DB 1 CATGCTTATCATCCAGTA 19

RESULT 112
US-09-555-640-113
Sequence 113, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARG-CHENON, Antoine
APPLICANT: AUGUSTE, Veronique
APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 45636-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1747 CACTATGAAAACCTGGCAA 1765
DB 1 CACTATGAAAACCTGGCAA 19

RESULT 113

```
US-09-555-640-114/c
; Sequence 114, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2852 GTACGAGATGAAATGTTGT 2870
DB      19 GTACGAGATGAAATGTTGT 1

RESULT 114
US-09-555-640-118/c
; Sequence 118, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 19; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4705 CAGGAACCGTCACCCACCG 4723
DB      26 CAGGAACCGTCACCCACCG 8

RESULT 115
US-09-555-640-120/c
; Sequence 120, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 19; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4705 CAGGAACCGTCACCCACCG 4723
DB      27 CAGGAACCGTCACCCACCG 9

RESULT 116
US-09-555-640-83/c
; Sequence 83, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
```

```
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 18.4; DB 1; Length 222;
Best Local Similarity 63.6%; Pred. No. 56;
Matches 28; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY      1827 CACCCCATTTGTCACGACGATGACGACGAGTGTG 1870
DB      75 CACCACTGCTGTGATGATGATGATGATGATGATGATG 32

RESULT 117
US-09-555-640-89/c
; Sequence 89, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 18.4; DB 1; Length 306;
Best Local Similarity 48.1%; Pred. No. 43;
Matches 52; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY      2633 AGTCGAACTTGTGAGGAGAAATGATATATCTAGTGAACCTTACAGACCTGG 2692
DB      218 ATGCGAGGCGCCAACTATGATGATGATGATGATGATGATGATGATGATGATG 159

QY      2693 CAGTTAGCATCAATTAACCGTACTACTATGTTGGCTGGCAAT 2740
DB      158 TAAGTCTTCACTGATTAATCTGCAATTTCTCTCTAGGTTGCACT 111

RESULT 118
US-09-555-640-26/c
; Sequence 26, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.4%; Score 18.2; DB 1; Length 53;
Best Local Similarity 61.7%; Pred. No. 1.8e+02;
Matches 29; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY      1052 ATACTTATTAATAGCACTGACGAGTGTGCACTTTCAAAATCAAGT 1098
DB      53 AACTTCCTTTGAATAATGGGACAGAGGCGAGCTGTCACTTTTAAAGT 7

RESULT 119
US-09-555-640-17
; Sequence 17, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
```

; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2543 CTTAAAACTCTCCAGAC 2560
Db 1 CTTAAAACTCTCCAGAC 18

RESULT 120
US-09-555-640-34

; Sequence 34, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4288 TCAGCTGTGAGTAAAT 4305
Db 1 TCAGCTGTGAGTAAAT 18

RESULT 121
US-09-555-640-58/c

; Sequence 58, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.4%; Score 17.6; DB 1; Length 98;
Best Local Similarity 65.0%; Pred. No. 1.1e+02;
Matches 26; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 2001 AGTTTCTCGAGTGTAGCCGCTGCGGAGAACT 2040
Db 67 AGCTTCTCCAGCGCGGTACCACTTCGAGGAACT 28

RESULT 122
US-09-555-640-77/c

; Sequence 77, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 17.4; DB 1; Length 180;
Best Local Similarity 45.8%; Pred. No. 67;
Matches 60; Conservative 0; Mismatches 71; Indels 0; Gaps 0;

Qy 4157 CTTAAGCACTTAAGCTTAACTGCAACACTTCCCTAATAAGAAACCAACA 4216

Db 143 CTTTCATGAGAGACTTCTGTTCCAAAGAGCCCAATAGAGGCGTTCAATT 84

Qy 4217 TACAGACCAATTAAGAGCCCTTTATGTGTGGCTGTTGAGAGAGAGCTCT 4276
Db 83 TGGTCTGTGATGTGTGGGCTTCTTTATAGGAAGATGTGTGATTTAGAGAGCTTGT 24

Qy 4277 CACTATGAAG 4287
Db 23 AACTGCTTAAG 13

RESULT 123
US-09-555-640-37/c

; Sequence 37, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 17.2; DB 1; Length 34;
Best Local Similarity 73.3%; Pred. No. 2.6e+02;
Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 4395 TACTACCAAAAGTGAGCCCAATTGAGGTA 4424
Db 30 TATACCTCCAAATTTGGCCCACTTTGTGTA 1

RESULT 124
US-09-555-640-9

; Sequence 9, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1777 TTTGATTTCCCTGGAAT 1793
Db 1 TTTGATTTCCCTGGAAT 17

RESULT 125
US-09-555-640-59/c

; Sequence 59, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 16.2; DB 1; Length 134;
Best Local Similarity 60.0%; Pred. No. 89;
Matches 27; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 4917 GTTCCTTAAATTTCCAAAAGACACCAATTCAGATCCGCC 4961
DB 77 GTTGTATTATATTTCACACAGCAACGCAATCCCTCAGACC 33

RESULT 126

US-09-555-640-62/c
; Sequence 62, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoinette
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 16; DB 1; Length 102;

Best Local Similarity 58.3%; Pred. No. 1.1e+02;
Matches 28; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 2371 TGACAAATTTGCCAGACGCTGTAAGAAGATTGTGCAATTTATGA 2418
DB 83 TCATTAATTTGCACAACTGCTATACAGTCTCGGCAATTTGTCA 36

RESULT 127

US-09-555-640-45/c
; Sequence 45, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoinette
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 16; DB 1; Length 210;

Best Local Similarity 53.1%; Pred. No. 61;
Matches 34; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 4134 GATTTCCAAATGAAAAGACAGCTTAAGCAAGTTTACATGCAACATCTACT 4193
DB 178 GAGTTCACAGTCAAAAGCAACGAAAAGAGTGTGAGGAGCAGCTGCTATATACC 119

QY 4194 TCCC 4197
DB 118 GCCC 115

RESULT 128

US-09-555-640-39/c
; Sequence 39, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoinette
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 15.6; DB 1; Length 62;

Best Local Similarity 55.6%; Pred. No. 1.7e+02;
Matches 30; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 909 GTCTAGCTGTGAGGGAGAGATGTTGTCATTCGCTGGAAGGAAACCAAGC 962
DB 54 GTCTTGCTTTGACATCTGTAGCTGTGGGTCATACAGTACATATGTAAATGACC 1

RESULT 129

US-09-555-640-47/c
; Sequence 47, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoinette
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 15.6; DB 1; Length 100;

Best Local Similarity 53.2%; Pred. No. 1.1e+02;
Matches 33; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 673 GTTAACCTTAATTTTGCAGAGAGTACCAAGAAAATATTTAGATGAGAG 732
DB 81 GTTCAGCATAGACACCAACAGTTATCATTTAGCAGTCCAGAAATTTAGAGAAATGTG 22

QY 733 CA 734
DB 21 CA 20

RESULT 130

US-09-555-640-60/c
; Sequence 60, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoinette
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 15.6; DB 1; Length 100;

Best Local Similarity 81.8%; Pred. No. 1.1e+02;
Matches 18; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 4293 TGTGAGTAATAATCCCTTAATT 4314
DB 29 TCTGAGTAACCTCTTAATT 8

RESULT 131

US-09-555-640-48/c
; Sequence 48, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoinette
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 15.6; DB 1; Length 117;

Best Local Similarity 47.9%; Pred. No. 99;
Matches 45; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 1121 AAGCTACTAAGTACAGCACTAGTACATTTCTGTTACATTCAGACTTGAGCAGTTA 1180
DB 94 AAGCAACTGCTAGCGGCCCCAGTAATATCAAGTTTGAAGCAACACGCTTAATAT 35
QY 1181 CTGCACTTAAGAAATTAATAGTAATTAATT 1214

Db 34 ATTGCATTAACTGTAGAAAGGTTAGTGGTT 1

RESULT 132
US-09-555-640-51/c
; Sequence 51, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 15.2; DB 1; Length 36;
Best Local Similarity 63.9%; Pred. No. 2.6e+02;
Matches 23; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1603 ACCACTCAACTGTGCATGCTAAAGCCTTAAGGAA 1638
Db 36 ACCACCAAACTTTCCCGCTACATCATTAATATGA 1

RESULT 133
US-09-555-640-53/c
; Sequence 53, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 14.8; DB 1; Length 84;
Best Local Similarity 59.5%; Pred. No. 1.3e+02;
Matches 25; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 3683 GGTCAGAGGGGAGTCTGCACTATGTCTTCAATTTCCAGCT 3724
Db 71 GGCAACCCGGCAGCTGCCACATGCCAGCATTTCTGATCT 30

RESULT 134
US-09-555-640-36/c
; Sequence 36, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 14.4; DB 1; Length 21;
Best Local Similarity 93.8%; Pred. No. 4e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4383 TATTTTAAATAACT 4398
Db 21 TATTTTAAATAATTT 6

RESULT 135
US-09-555-640-52/c
; Sequence 52, Application US/09555640
; GENERAL INFORMATION:

; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 14.4; DB 1; Length 46;
Best Local Similarity 65.6%; Pred. No. 2.2e+02;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 4635 AGCCTAAGAAATTTGTGACTGCCAAAGCCGT 4666
Db 40 AGCTTCACAAATATGAGACTTAATATATGCTT 9

RESULT 136
US-09-555-640-75/c
; Sequence 75, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 14.4; DB 1; Length 49;
Best Local Similarity 65.6%; Pred. No. 2e+02;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 2378 TTTGCCAGAGAGCTGTATATAGCATTTGTGCA 2409
Db 44 TGTCTCAGCATTTTCATATAGTGTTGTCCA 13

RESULT 137
US-09-555-640-78/c
; Sequence 78, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match 0.3%; Score 14; DB 1; Length 64;
Best Local Similarity 66.7%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1796 ATGCAGATGCCCTCACCCAGATCTCCAA 1825
Db 42 ATGCMAACCCACCCGCTAGGGCTGCATA 13

RESULT 138
US-09-555-640-69/c
; Sequence 69, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640

```
; CURRENT FILING DATE: 2000-08-10
Query Match      0.3%; Score 13.6; DB 1; Length 51;
Best Local Similarity 56.8%; Pred. No. 2e+02;
Matches 25; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 3914 AAGAAGAGACAAATCTAATACAGGTGCTGAAACCCCTTAC 3957
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 51 AAGTAAGTAATCTTTACTGTGTGCTTGAAACCCCTTTC 8

RESULT 139
US-09-555-640-54/c
; Sequence 54, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.3%; Score 13.6; DB 1; Length 60;
Best Local Similarity 61.1%; Pred. No. 1.8e+02;
Matches 22; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 2856 CAGATGACAAATTTTAAAAAATATATAAATGAAA 2891
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 49 CAGTTGAGTGATATACCACTCAACAATATATA 14

RESULT 140
US-09-555-640-67/c
; Sequence 67, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.3%; Score 13.4; DB 1; Length 39;
Best Local Similarity 73.9%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1983 ATCATTGTCGGAAGCCCACTTT 2005
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 24 AGCATTCTCGGAGCCCACTT 2

RESULT 141
US-09-555-640-13/c
; Sequence 13, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.3%; Score 13.4; DB 1; Length 55;
Best Local Similarity 73.9%; Pred. No. 1.9e+02;
Matches 17; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2748 AAGCTGGCCTCCGACAAATGCT 2770
```

```
Db 45 AAGCTGGCCTCCGACAAATGAT 23

RESULT 142
US-09-555-640-61/c
; Sequence 61, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.3%; Score 13.2; DB 1; Length 30;
Best Local Similarity 83.3%; Pred. No. 3.1e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3769 AATGTACAACCTTTGTA 3786
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 30 AATGTACAACCTTTGTA 13

RESULT 143
US-09-555-640-21/c
; Sequence 21, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.3%; Score 13.2; DB 1; Length 47;
Best Local Similarity 57.1%; Pred. No. 2.2e+02;
Matches 24; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 2450 CAAATTTTAAAGACCATACAACTTCTTATGATATCT 2491
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 46 CTAACCTGCCAGCGCTGTGTAGTCTTCACTAGATATACT 5

RESULT 144
US-09-555-640-11/c
; Sequence 11, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.3%; Score 13.2; DB 1; Length 64;
Best Local Similarity 69.2%; Pred. No. 1.7e+02;
Matches 18; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 216 AAGCAGCTGCTTCCCTGACACTTC 241
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 64 AAAAGCTGCTTCTCACTAGATCTTC 39

RESULT 145
US-09-555-640-8/c
; Sequence 8, Application US/09555640
```

```

; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 0.3%; Score 13; DB 1; Length 31;
Best Local Similarity 65.5%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1051 TATACCTTATTAAGTACAGTACAGTGG 1079
DB 29 TGTAGTTTATTTGCCACGTTTCAATGAG 1

RESULT 146
US-09-555-640-73/c
; Sequence 73, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 0.3%; Score 13; DB 1; Length 33;
Best Local Similarity 100.0%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1325 GAAAAACAATTT 1337
DB 16 GAAAAACAATTT 4

RESULT 147
US-09-555-640-30/c
; Sequence 30, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 0.3%; Score 12.8; DB 1; Length 32;
Best Local Similarity 70.8%; Pred. No. 3e+02; 7; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 155 ATTTAATTTAATTGACAAAGC 178
DB 27 ATTTCAATTAAGTGCTGAAGTC 4

RESULT 148
US-09-555-640-29/c
; Sequence 29, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
```

```

; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 0.2%; Score 12.2; DB 1; Length 23;
Best Local Similarity 82.4%; Pred. No. 3.9e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4880 AAAATAAAGCCTTAA 4896
DB 23 AAATTAAGCACTTAA 7

RESULT 149
US-09-555-640-4/c
; Sequence 4, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 0.2%; Score 12.2; DB 1; Length 35;
Best Local Similarity 82.4%; Pred. No. 2.8e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1390 AATGAAACTTTCATT 1406
DB 23 AATGAAAGTTTTCATT 7

RESULT 150
US-09-555-640-22/c
; Sequence 22, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 0.2%; Score 12.2; DB 1; Length 49;
Best Local Similarity 53.1%; Pred. No. 2.1e+02;
Matches 26; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 2690 GGGCAAGTTACATACATTCACCGGTACTACTATGTGGGCTGGCA 2738
DB 49 GACCCAGCTTGTAGCTCATTCACGCGCCACATCATGTTAGTACGGGTA 1

RESULT 151
US-09-555-640-5/c
; Sequence 5, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match
Best Local Similarity 0.2%; Score 12; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 4.4e+02;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```


QY	1805	CCCTCCACCAGATCTCCAA	1824
Db	20	CCCTCATCCAGACCACCA	1

RESULT 152
 US-09-555-640-25/c
 Sequence 25. Application US/09555640
 GENERAL INFORMATION:
 APPLICANT: NGUYEN, Quang Tri
 APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match	0.2%	Score 12	DB 1	Length 23
Best Local Similarity	75.0%	Pred. No.	3.9e+02	
Matches 15	Conservative	0	Mismatches 5	Indels 0
				Gaps 0

Qy	3290	TTTAATGCTTTAAATTGTT	3309
Db	22	TTTCATTTTTTATATTTT	3

RESULT 153
 US-09-555-640-35/c
 : Sequence 35 Application US/09555640
 :
 : GENERAL INFORMATION:
 :
 : APPLICANT: NGUYEN, Quang Tri
 :
 : APPLICANT: GARBARD-CHENON, Antoine
 :
 : APPLICANT: AUGUSTE, Veronique
 :
 : APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 :
 : TITLE OF INVENTION: Erythrovirus and its applications
 :
 : FILE REFERENCE: 45636-5-033-US
 :
 : CURRENT APPLICATION NUMBER: US/09/555,640
 :
 : CURRENT FILING DATE: 2000-08-10

Query Match	0.2%	Score 12;	DB 1;	Length 23;
Best Local Similarity	100.0%	Pred. No. 3.9e+02;		
Matches 12;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	4322	AGTTTAAACT	4333
Db	21	AGTTTAAACT	10

RESULT 154
US-09-555-640-33/c
; Sequence 33 Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUDUST, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match	0.2%	Score 12	DB 1	Length 26
Best Local Similarity	75.0%	Pred. No.	3.6e+02	
Matches 15	Conservative	0	Mismatches 5	Indels 0
				Gaps 0

Qy	645	TGTTCTTACCATCTGTAA	664
Db	23	TGTTCTTTTTCATTTGAAA	4

RESULT 155
US-09-555-640-46/C

```

: Sequence 46, Application US/09555640
: GENERAL INFORMATION:
:
: APPLICANT: NGUYEN, Quang Tri
: APPLICANT: GARBARD-CHENON, Antoine
: APPLICANT: ADUSETE, Veronique
: APPLICANT: ASSISTANCE PUBLIQUE-HOPIAUX DE PARIS
: TITLE OF INVENTION: Erythrovirus and its applications
: FILE REFERENCE: 45636-5033-US
: CURRENT APPLICATION NUMBER: US/09/555,640
: CURRENT FILING DATE: 2000-08-10

```

Query Match	0.2%	Score 12	DB 1	Length 30
Best Local Similarity	64.3%	Pred. No.	3 2e+02	
Matches 18	Conservative	0	Mismatches 10	Indels 0
				Gaps 0

```

Qy      3464 TGTATGTTAGTGGATCATGAGTATAAT 3491
          |||  |||  |  |||||
Db      28  TGTAGTAAATTAAAAAGTTAGTATAAT 1

```

RESULT 156
US-09-555-640-70/c
Sequence 70, Application US/09555640
GENERAL INFORMATION:
APPLICANT: NGUYEN, Quang Tri
APPLICANT: GARBARG-CHENON, Antoinette
APPLICANT: AUCUSTE, Veronique
APPLICANT: ASSISTANCE PUBLIQUE-HOPITALX DE PARIS
TITLE OF INVENTION: Erythrovirus and its applications
FILE REFERENCE: 46563-5033-US
CURRENT APPLICATION NUMBER: US/09/555,640
CURRENT FILING DATE: 2000-08-10

Query Match	0.2%	Score 12	DB 1	length 37
Best Local Similarity	64.3%	Pred. NO.	2.7e+02	
Matches 18	Conservative	0	Mismatches 10	Indels 0
				Gaps 0

OY 4966 GCCGCCGCTAGCGGCACCTTCCGGTACA 4993
 | | | | | | | |
Db 35 GCGCTGTACGCGGCACCTTCCGGTAAA 8

RESULT 157
 US-09-555-640-68/c
 ; Sequence 68, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUCUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45635-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match	0.2%	Score 12	DB 1	length 56
Best Local Similarity	64.3%	Pred. No.	1.5e+02	
Matches 18, Conservative	0	Mismatches	10	Indels 0
				Gaps 0

Qy	302	TTTATACCTTTTAA	TTTACTACAT	329
Db	52	TTTTTACAATTC	TCATCTGCTACCGT	25

RESULT 158
 US-09-555-640-32/c
 ; Sequence 32, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHERON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrolyse and its applications

FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 11.8; DB 1; Length 24;
 Best Local Similarity 86.7%; Pred. No. 3.8e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 519 TTGCTATACCTTT 533
 DB 18 TTGCTATACCTTT 4

RESULT 159
 US-09-555-640-121/c
 Sequence 121, Application US/09555640
 GENERAL INFORMATION:
 APPLICANT: NGUYEN, Quang Tri
 APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 11.8; DB 1; Length 36;
 Best Local Similarity 69.6%; Pred. No. 2.8e+02;
 Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1851 TATCAGACGAGCGTGTGATA 1873
 DB 28 TTTCACCACTGCTGTGATA 6

RESULT 160
 US-09-555-640-71/c
 Sequence 71, Application US/09555640
 GENERAL INFORMATION:
 APPLICANT: NGUYEN, Quang Tri
 APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 11.8; DB 1; Length 42;
 Best Local Similarity 61.3%; Pred. No. 2.4e+02;
 Matches 19; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 2215 TTTAGAGTTTACTCCAGACTTATGCGCT 2245
 DB 39 TCTGACAGTTTACTGAATCATGCTGGGT 9

RESULT 161
 US-09-555-640-19/c
 Sequence 19, Application US/09555640
 GENERAL INFORMATION:
 APPLICANT: NGUYEN, Quang Tri
 APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 11.6; DB 1; Length 43;
 Best Local Similarity 77.8%; Pred. No. 2.4e+02;
 Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2587 TGGACAGTATCTGACCA 2604
 DB 20 TGGTCAGATTAATCTGCA 3

RESULT 162
 US-09-555-640-106
 Sequence 106, Application US/09555640
 GENERAL INFORMATION:
 APPLICANT: NGUYEN, Quang Tri
 APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 11.4; DB 1; Length 21;
 Best Local Similarity 71.4%; Pred. No. 4.3e+02;
 Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 221 GCTGCTTCTCTGACACTTTC 241
 DB 1 GCTGCTTCTCTGAGTTCTTC 21

RESULT 163
 US-09-555-640-117/c
 Sequence 117, Application US/09555640
 GENERAL INFORMATION:
 APPLICANT: NGUYEN, Quang Tri
 APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 11.4; DB 1; Length 33;
 Best Local Similarity 71.4%; Pred. No. 3e+02;
 Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2445 TTATCAATTTTAAAGACC 2465
 DB 30 TTACTCATATCTACAGATC 10

RESULT 164
 US-09-555-640-24/c
 Sequence 24, Application US/09555640
 GENERAL INFORMATION:
 APPLICANT: NGUYEN, Quang Tri
 APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 11.2; DB 1; Length 22;
 Best Local Similarity 81.2%; Pred. No. 4.1e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2224 TTTACTCCAGACTTAG 2239
 DB 19 TTTATCCCAACTTAG 4

RESULT 165

```

US-09-555-640-10/c
; Sequence 10, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; TITLE OF INVENTION: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.2%; Score 11.2; DB 1; Length 23;
Best Local Similarity 81.2%; Pred. No. 4e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1436 TCTGGATGAGGCAAT 1451
DB      23 TCTGGGTGAGGCGCAT 8

RESULT 166
US-09-555-640-18/c
; Sequence 18, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; TITLE OF INVENTION: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.2%; Score 11; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.7e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      3340 TGAATAATATGCTAGTATA 3358
DB      19 TGAATAATGATGACTATATA 1

RESULT 167
US-09-555-640-107/c
; Sequence 107, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; TITLE OF INVENTION: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.2%; Score 11; DB 1; Length 20;
Best Local Similarity 73.7%; Pred. No. 4.5e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      2060 ATCAGTTCTGTGTAAGTGT 2078
DB      20 ATGATTCTCTGTAAGTGT 2

RESULT 168
US-09-555-640-40/c
; Sequence 40, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS

```

```

; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.2%; Score 11; DB 1; Length 29;
Best Local Similarity 73.7%; Pred. No. 3.3e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY      1458 GTCCACTATTGCGAAGCT 1476
DB      29 GTCCACAAATCTTCAGGCT 11

RESULT 169
US-09-555-640-112
; Sequence 112, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; TITLE OF INVENTION: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.2%; Score 10.8; DB 1; Length 20;
Best Local Similarity 85.7%; Pred. No. 4.5e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1343 TGGCTATTGCTTAA 1356
DB      2 TGGCTATTAAGCTTAA 15

RESULT 170
US-09-555-640-38/c
; Sequence 38, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; TITLE OF INVENTION: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.2%; Score 10.8; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 4e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1194 AATAAATAATGATA 1207
DB      21 AACTAAAGTAGTAA 8

RESULT 171
US-09-555-640-3/c
; Sequence 3, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; TITLE OF INVENTION: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match      0.2%; Score 10.8; DB 1; Length 29;
Best Local Similarity 85.7%; Pred. No. 3.4e+02;

```

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 3176 TATAAGTGTCTC 3189
 |||||
 Db 24 TATAACTGCTCTC 11

RESULT 172
 US-09-555-640-66/c
 ; Sequence 66, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.8; DB 1; Length 30;
 Best Local Similarity 85.7%; Pred. No. 3.3e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3468 TGTATGCGATCAT 3481
 |||||
 Db 14 TGTACTGATGAT 1

RESULT 173
 US-09-555-640-23/c
 ; Sequence 23, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.8; DB 1; Length 39;
 Best Local Similarity 85.7%; Pred. No. 2.7e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1343 TGGCTATGCTTAA 1356
 |||||
 Db 38 TGGCTATGCTTAA 25

RESULT 174
 US-09-555-640-6/c
 ; Sequence 6, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.6; DB 1; Length 20;
 Best Local Similarity 76.5%; Pred. No. 4.5e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 817 TGTATTCGCGCTTT 833
 |||||
 Db 17 TGTATTCGCGCTTT 1

RESULT 175
 US-09-555-640-28/c
 ; Sequence 28, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.6; DB 1; Length 26;
 Best Local Similarity 76.5%; Pred. No. 3.7e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3042 CCAGCACTGTGACGC 3058
 |||||
 Db 26 CCGACACGAGTGTGCG 10

RESULT 176
 US-09-555-640-57/c
 ; Sequence 57, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.4; DB 1; Length 28;
 Best Local Similarity 70.0%; Pred. No. 3.5e+02;
 Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 4904 TTCATAGGTATGCTTT 4923
 |||||
 Db 23 TTCATAGGTGCTCCAGCTTT 4

RESULT 177
 US-09-555-640-56/c
 ; Sequence 56, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.4; DB 1; Length 30;
 Best Local Similarity 91.7%; Pred. No. 3.3e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1105 AAGTTAGCTATT 1116
 |||||
 Db 21 AAGTTAGCTATT 10

RESULT 178
 US-09-555-640-34/c
 ; Sequence 34, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique

APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.2; DB 1; Length 18;
 Best Local Similarity 80.0%; Pred. No. 4.9e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4583 TATGACCCACAGCT 4597
 DB 17 TTTTACTCCACAGCT 3

RESULT 179
 US-09-555-640-42/c
 ; Sequence 42, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.2; DB 1; Length 21;
 Best Local Similarity 80.0%; Pred. No. 4.4e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4100 GCTGAGACAAAG 4114
 DB 19 GCTGAGACACGGTG 5

RESULT 180
 US-09-555-640-2/c
 ; Sequence 2, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.2; DB 1; Length 23;
 Best Local Similarity 65.2%; Pred. No. 4.1e+02;
 Matches 15; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3215 GCTAGTGGGAAAGCAAGT 3237
 DB 23 GTTAGTGTTCCAGTCAGAGT 1

RESULT 181
 US-09-555-640-65/c
 ; Sequence 65, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.2; DB 1; Length 23;

Best Local Similarity 65.2%; Pred. No. 4.1e+02;
 Matches 15; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 3372 TAACGTACTATTGCAAAAT 3394
 DB 23 TAACGTCAATGCTCTGAAAT 1

RESULT 182
 US-09-555-640-118
 ; Sequence 118, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.2; DB 1; Length 26;
 Best Local Similarity 80.0%; Pred. No. 3.7e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2148 CAGTGGGAGAGGTT 2162
 DB 8 CGGTGGGTGACGGTT 22

RESULT 183
 US-09-555-640-120
 ; Sequence 120, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.2; DB 1; Length 27;
 Best Local Similarity 80.0%; Pred. No. 3.6e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2148 CAGTGGGAGAGGTT 2162
 DB 9 CGGTGGGTGACGGTT 23

RESULT 184
 US-09-555-640-119/c
 ; Sequence 119, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 10.2; DB 1; Length 29;
 Best Local Similarity 80.0%; Pred. No. 3.4e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4353 GGTGGGTTTGATC 4367
 DB 19 GCTGGGTATGATC 5

```

RESULT 185
US-09-555-640-108
; Sequence 108, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

Query Match          0.2%; Score 10; DB 1; Length 19;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```

```

QY      834 TCGGCGAGGAGCTTGCA 851
DB      2 TCGGCAAGCGCGCTGTAA 19

```

```

RESULT 186
US-09-555-640-110
; Sequence 110, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

Query Match          0.2%; Score 10; DB 1; Length 21;
Best Local Similarity 72.2%; Pred. No. 4.4e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```

```

QY      834 TCGGCGAGGAGCTTGCA 851
DB      2 TCGGCAAGCGCGCTGTAA 19

```

```

RESULT 187
US-09-555-640-15/C
; Sequence 15, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

Query Match          0.2%; Score 10; DB 1; Length 24;
Best Local Similarity 72.2%; Pred. No. 4e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```

```

QY      970 AAGTTCAACCATGCTGA 987
DB      24 AATTTCCATCCATTTATA 7

```

```

RESULT 188
US-09-555-640-41/C
; Sequence 41, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine

```

```

; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

Query Match          0.2%; Score 10; DB 1; Length 30;
Best Local Similarity 61.5%; Pred. No. 3.3e+02;
Matches 16; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

```

```

QY      1238 TTTAGCGGCTCAACATGCTTAAG 1263
DB      27 TTCAATGGGTGCACAGCGCTTTGG 2

```

```

RESULT 189
US-09-555-640-76/C
; Sequence 76, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

Query Match          0.2%; Score 10; DB 1; Length 30;
Best Local Similarity 72.2%; Pred. No. 3.3e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

```

```

QY      2830 AATCTTATACACATTTG 2847
DB      24 AATCTTCTACCCCTTG 7

```

```

RESULT 190
US-09-555-640-7/C
; Sequence 7, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

```

Query Match          0.2%; Score 9.8; DB 1; Length 21;
Best Local Similarity 66.7%; Pred. No. 4.4e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```

```

QY      1829 CCCCATTGTCCAGACACCA 1849
DB      21 CCAGCTTTGTGATACACCA 1

```

```

RESULT 191
US-09-555-640-115/C
; Sequence 115, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

```

Query Match 0.2%; Score 9.8; DB 1; Length 21;
 Best Local Similarity 66.7%; Pred. No. 4.4e+02;
 Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3548 GTTACTTCCCGCCAGTAT 3568
 DB 21 GTCTAGTTATTGCCAGTTT 1

RESULT 192

US-09-555-640-17/c
 ; Sequence 17, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.6; DB 1; Length 18;
 Best Local Similarity 75.0%; Pred. No. 5e+02;
 Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 3137 TCTAGGCATTTTTAA 3152
 DB 17 TCTGAGAGTTTTAA 2

RESULT 193

US-09-555-640-14/c
 ; Sequence 14, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.6; DB 1; Length 20;
 Best Local Similarity 75.0%; Pred. No. 4.6e+02;
 Matches 12; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1969 ACCAGTTCCAGAGAT 1984
 DB 17 AACGTTCCAGAACT 2

RESULT 194

US-09-555-640-16/c
 ; Sequence 16, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.6; DB 1; Length 26;
 Best Local Similarity 62.5%; Pred. No. 3.8e+02;
 Matches 15; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 2554 TCCAGACCTATATAGTCATCTT 2577
 DB 24 TCCAGACAGGTAGACATTTT 1

RESULT 195

US-09-555-640-20/c
 ; Sequence 20, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.4; DB 1; Length 19;
 Best Local Similarity 68.4%; Pred. No. 4.8e+02;
 Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 3928 TTCTATACAGGTCTGCA 3946
 DB 19 TTCTCTTAGGTCTGCA 1

RESULT 196

US-09-555-640-113/c
 ; Sequence 113, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.4; DB 1; Length 19;
 Best Local Similarity 90.9%; Pred. No. 4.8e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1997 GCCCAGTTTC 2007
 DB 17 GCCCAGTTTC 7

RESULT 197

US-09-555-640-31/c
 ; Sequence 31, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.4; DB 1; Length 20;
 Best Local Similarity 90.9%; Pred. No. 4.6e+02;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4063 AATGCCATTT 4073
 DB 19 AATGCCATTT 9

RESULT 198

US-09-555-640-64/c
 ; Sequence 64, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri

APPLICANT: GARBARG-CHENON, Antoine
 APPLICANT: AUGUSTE, Veronique
 APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 TITLE OF INVENTION: Erythrovirus and its applications
 FILE REFERENCE: 45636-5033-US
 CURRENT APPLICATION NUMBER: US/09/555,640
 CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.4; DB 1; Length 22;
 Best Local Similarity 68.4%; Pred. No. 4.3e+02;
 Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 2315 GATTACAAAGTTTGTGAGA 2333
 DB 19 GACTATATATAGTGTGAGA 1

RESULT 199
 US-09-555-640-105/c
 ; Sequence 105, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.2; DB 1; Length 19;
 Best Local Similarity 78.6%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1438 TGGGATGAGGCAT 1451
 DB 19 TGGGTGAGGCAT 6

RESULT 200
 US-09-555-640-111/c
 ; Sequence 111, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.2; DB 1; Length 19;
 Best Local Similarity 78.6%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3471 TAGTGATCATGAG 3484
 DB 19 TACTGATGATGAG 6

RESULT 201
 US-09-555-640-114
 ; Sequence 114, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.2; DB 1; Length 19;
 Best Local Similarity 78.6%; Pred. No. 4.9e+02;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 277 TTCTTTCGCTGCTA 290
 DB 5 TTCTTCATCTGCTA 18

RESULT 202
 US-09-555-640-27/c
 ; Sequence 27, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.2; DB 1; Length 23;
 Best Local Similarity 78.6%; Pred. No. 4.2e+02;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 494 ATTTTACTGGGGGG 507
 DB 19 ATTTTCTGAGGG 6

RESULT 203
 US-09-555-640-12/c
 ; Sequence 12, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9.2; DB 1; Length 25;
 Best Local Similarity 78.6%; Pred. No. 3.9e+02;
 Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4989 GTACAGATGGCGG 5002
 DB 21 GTACTAGAGGGCGG 8

RESULT 204
 US-09-555-640-9/c
 ; Sequence 9, Application US/09555640
 ; GENERAL INFORMATION:
 ; APPLICANT: NGUYEN, Quang Tri
 ; APPLICANT: GARBARG-CHENON, Antoine
 ; APPLICANT: AUGUSTE, Veronique
 ; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
 ; TITLE OF INVENTION: Erythrovirus and its applications
 ; FILE REFERENCE: 45636-5033-US
 ; CURRENT APPLICATION NUMBER: US/09/555,640
 ; CURRENT FILING DATE: 2000-08-10

Query Match 0.2%; Score 9; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 5.3e+02;
 Matches 12; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1318 AGTACTGGAAGAAACAA 1334

Db 17 ATTCCAGGGAATCAAA 1

RESULT 205

US-09-555-640-109
; Sequence 109, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match

0.2%; Score 9; DB 1; Length 20;
Best Local Similarity 70.6%; Pred. No. 4.7e+02;
Matches 12; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 420 TTCTGACTGGGACAC 436

Db 2 TCCAGACGGTAAGCAC 18

RESULT 206

US-09-555-640-116
; Sequence 116, Application US/09555640
; GENERAL INFORMATION:
; APPLICANT: NGUYEN, Quang Tri
; APPLICANT: GARBARG-CHENON, Antoine
; APPLICANT: AUGUSTE, Veronique
; APPLICANT: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
; TITLE OF INVENTION: Erythrovirus and its applications
; FILE REFERENCE: 45636-5033-US
; CURRENT APPLICATION NUMBER: US/09/555,640
; CURRENT FILING DATE: 2000-08-10

Query Match

0.2%; Score 8.8; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 4.7e+02;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 31 CATCTGTACCG 42

Db 4 CATCTGTACCG 15

Search completed: April 22, 2004, 06:46:29
Job time : 38 secs

THIS PAGE BLANK (USPTO)

107	18	0.4	18	1	AX003454	ACCESSION:AX003454
108	18	0.4	18	1	BD087053	ACCESSION:BD087053
109	18	0.4	18	1	BD087070	ACCESSION:BD087070
110	17	0.3	17	1	AX003429	ACCESSION:AX003429
111	17	0.3	17	1	BD087045	ACCESSION:BD087045
112	15.4	0.3	17	1	AR046079	ACCESSION:AR046079
113	15.4	0.3	17	1	137575	ACCESSION:137575
114	15.4	0.3	17	1	153131	ACCESSION:153131
115	15.4	0.3	17	1	194425	ACCESSION:194425
116	15.4	0.3	17	1	AR186282	ACCESSION:AR186282
117	15.4	0.3	17	1	AR188765	ACCESSION:AR188765
118	15.4	0.3	17	1	AR190335	ACCESSION:AR190335
119	15.4	0.3	17	1	AR322913	ACCESSION:AR322913
120	15.4	0.3	17	1	AR322913	ACCESSION:AR322913
121	15.4	0.3	17	1	AX099963	ACCESSION:AX099963
122	15.4	0.3	17	1	AX691246	ACCESSION:AX691246
123	15.4	0.3	17	1	AX724252	ACCESSION:AX724252
124	15.4	0.3	17	1	AX724252	ACCESSION:AX724252
125	14.4	0.3	21	1	AX003456	ACCESSION:AX003456
126	14.4	0.3	21	1	BD087072	ACCESSION:BD087072
127	13.2	0.3	30	1	AX003481	ACCESSION:AX003481
128	13.2	0.3	30	1	BD087097	ACCESSION:BD087097
129	13	0.3	14	1	AR7941	ACCESSION:AR7941
130	13	0.3	14	1	AR8908	ACCESSION:AR8908
131	13	0.3	14	1	BD065454	ACCESSION:BD065454

ALIGNMENTS

RESULT 1
LOCUS AX003461
DEFINITION Sequence 41 from Patent WO928439.
VERSION AX003461
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 41 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source location/Qualifiers
1..30
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
Best Local Similarity 100.0%; Pred.No.11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4655 GCCAAGCCGCTGCGACCCATTGTAAACA 4684
DB 1 GCCAAGCCGCTGCGACCCATTGTAAACA 30

RESULT 2
LOCUS AX003466
DEFINITION Sequence 46 from Patent WO928439.
VERSION AX003466
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.

TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 46 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source location/Qualifiers
1..30
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
Best Local Similarity 100.0%; Pred.No.11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 301 ATTATCTACTTAACTTACTACATG 330
DB 1 ATTATCTACTTAACTTACTACATG 30

RESULT 3
LOCUS AX003476
DEFINITION Sequence 56 from Patent WO928439.
VERSION AX003476
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 56 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source location/Qualifiers
1..30
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
Best Local Similarity 100.0%; Pred.No.11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1703 ATGTACAACATGGCTACTGTTGTTATG 1732
DB 1 ATGTACAACATGGCTACTGTTGTTATG 30

RESULT 4
LOCUS AX003481
DEFINITION Sequence 61 from Patent WO928439.
VERSION AX003481
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 61 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source location/Qualifiers
1..30
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
0.6%; Score 30; DB 1; Length 30;

Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2306 ACCTGCTGATTAACAAGTTTGTAGATT 2335
DB 1 ACCTGCTGATTAACAAGTTTGTAGATT 30

RESULT 5
LOCUS AX003486 30 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 66 from Patent WO928439.
ACCESSION AX003486
VERSION AX003486.1 GI:9227339
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 66 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
LOCATION/Qualifiers

FEATURES

1..30
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2617 ATCATCCAGTACAGTAGTCAGAACCTAG 2646
DB 1 ATCATCCAGTACAGTAGTCAGAACCTAG 30

RESULT 6
LOCUS AX003496 30 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 76 from Patent WO928439.
ACCESSION AX003496
VERSION AX003496.1 GI:9227349
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 76 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
LOCATION/Qualifiers

1..30
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4115 TATCAGCAAGGGGTAGAGATTTCCAAT 4144
DB 1 TATCAGCAAGGGGTAGAGATTTCCAAT 30

RESULT 7
LOCUS BD087077 30 bp DNA linear PAT 27-AUG-2002

DEFINITION Erythrovirus and application thereof.
ACCESSION BD087077
VERSION BD087077.1 GI:22632687
KEYWORDS JP 2001525163-A/41.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE 1 (bases 1 to 30)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 41 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/41
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PI 03-DEC-1997 FR 97/15197
PC QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53

FEATURES

1..30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4655 GCCAAAGCCGTGTGCACCCATTGTAAACA 4684
DB 1 GCCAAAGCCGTGTGCACCCATTGTAAACA 30

RESULT 8
LOCUS BD087082 30 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087082
VERSION BD087082.1 GI:22632692
KEYWORDS JP 2001525163-A/46.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE 1 (bases 1 to 30)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 46 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/46
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PI 03-DEC-1997 FR 97/15197
PC QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53

FEATURES

1..30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 301 ATTATTAACCTTTTAACTTACTACATG 330
Db 1 ATTATTAACCTTTTAACTTACTACATG 30

RESULT 9
LOCUS BD087092 30 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087092
VERSION BD087092.1 GI:22632702
KEYWORDS JP 2001525163-A/56.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES: ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE 1 (bases 1 to 30)
AUTHORS Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof.
JOURNAL Patent: JP 2001525163-A 56 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/56
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
CI2N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53, PC
CI2N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1.30
FT Location/Qualifiers
1.30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source location/Qualifiers
1.30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1703 ATGTACAACATGCTTAAGTGTATG 1732
Db 1 ATGTACAACATGCTTAAGTGTATG 30

RESULT 10
LOCUS BD087097 30 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087097
VERSION BD087097.1 GI:22632707
KEYWORDS JP 2001525163-A/61.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES: ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE 1 (bases 1 to 30)
AUTHORS Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof.
JOURNAL Patent: JP 2001525163-A 61 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/61
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197

PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
CI2N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53, PC
CI2N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1.30
FT Location/Qualifiers
1.30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source location/Qualifiers
1.30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2306 ACCTGCTGGATTAAGTTTGTAGAT 2335
Db 1 ACCTGCTGGATTAAGTTTGTAGAT 30

RESULT 11
LOCUS BD087102 30 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087102
VERSION BD087102.1 GI:22632712
KEYWORDS JP 2001525163-A/66.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES: ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE 1 (bases 1 to 30)
AUTHORS Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof.
JOURNAL Patent: JP 2001525163-A 66 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/66
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
CI2N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53, PC
CI2N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1.30
FT Location/Qualifiers
1.30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source location/Qualifiers
1.30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 11;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2617 ATCATCCAGTAAGTAGGAGAACTG 2646
Db 1 ATCATCCAGTAAGTAGGAGAACTG 30

RESULT 12
LOCUS BD087112 30 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087112
VERSION BD087112.1 GI:22632722
KEYWORDS JP 2001525163-A/76.

SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 30)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 76 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/76
PD 11-DEC-2001 JP 2000523317
PF 03-DEC-1998 JP 97/15197
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53, PC
C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..30
/organism='Erythrovirus'.
Location/Qualifiers
1..30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4115 TATCAGCAGGGGTAGAGATTCCCAAT 4144
DB 1 TATCAGCAGGGGTAGAGATTCCCAAT 30

RESULT 13
AX003423
LOCUS AX003423 29 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 3 from Patent WO9928439.
ACCESSION AX003423
VERSION AX003423.1 GI:99272227
KEYWORDS B19 virus
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 3 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1..29
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

FEATURES
source
1..29
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 TTTAGAGATGAGAGCAGTTTATGAAA 746
DB 1 TTTAGAGATGAGAGCAGTTTATGAAA 29

RESULT 14
AX003460 29 bp DNA linear PAT 07-SEP-2000
LOCUS AX003460
DEFINITION Sequence 40 from Patent WO9928439.
ACCESSION AX003460
VERSION AX003460.1 GI:99272264

KEYWORDS B19 virus
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 40 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1..29
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

FEATURES
source
1..29
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4625 GGATATGAAAAGCCTGAAGATTGTGAC 4653
DB 1 GGATATGAAAAGCCTGAAGATTGTGAC 29

RESULT 15
BD087039 29 bp DNA linear PAT 27-AUG-2002
LOCUS BD087039
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087039
VERSION BD087039.1 GI:22632649
KEYWORDS JP 2001525163-A/3.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 29)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof.
JOURNAL Patent: JP 2001525163-A 3 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/3
PD 11-DEC-2001 JP 2000523317
PF 03-DEC-1998 JP 97/15197
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53, PC
C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..29
/organism="Erythrovirus".
Location/Qualifiers
1..29
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source
1..29
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 TTTAGAGATGAGAGCAGTTTATGAAA 746
DB 1 TTTAGAGATGAGAGCAGTTTATGAAA 29

RESULT 16
BD087076 29 bp DNA linear PAT 27-AUG-2002
LOCUS BD087076
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087076

```

VERSION      BD087076.1 GI:22632686
KEYWORDS     JP 2001525163-A/40.
SOURCE       Erythrovirus
ORGANISM     Erythrovirus
REFERENCE    1 (bases 1 to 29)
AUTHORS      Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE        Erythrovirus and application thereof
JOURNAL      Patent: JP 2001525163-A 40 11-DEC-2001;
              ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT      OS Erythrovirus
              PN JP 2001525163-A/40
              PD 11-DEC-2001
              PR 03-DEC-1998 JP 2000523317
              PR 03-DEC-1997 FR 97/15197
              PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG VERONIQUE AUGUSTE PC
              C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
              GOIN33/53,
              PC C12N15/00
              CC Erythrovirus and application thereof
              FH Key
              FT source
              Location/Qualifiers
                location= 'Erythrovirus'.
                /organism= 'Erythrovirus'.
                /mol_type= 'genomic DNA'
                /db_xref= 'taxon:40121'

FEATURES
  source
    Query Match
    Best Local Similarity 0.6%; Score 29; DB 1; Length 29;
    Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4625 GCATATGAAAGAGCTGAGAAATTGCGAC 4653
Db      1 GGATATGAAAGAGCTGAGAAATTGCGAC 29

RESULT 17
LOCUS      AX003477
DEFINITION Sequence 57 from Patent WO9928439.
ACCESSION  AX003477
VERSION     AX003477.1 GI:9927330
KEYWORDS    B19 virus
SOURCE      B19 virus
ORGANISM    B19 virus
REFERENCE    1
AUTHORS      Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE        Erythrovirus and its applications
JOURNAL      Patent: WO 9928439-A 57 10-JUN-1999;
              ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
              CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
  source
    Query Match
    Best Local Similarity 0.6%; Score 28; DB 1; Length 28;
    Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1733 CACAAGCTGGAGCCACTATGAAAACGTG 1760
Db      1 CACAAGCTGGAGCCACTATGAAAACGTG 28

RESULT 18
LOCUS      BD087093
DEFINITION Erythrovirus and application thereof.

```

```

ACCESSION    BD087093
VERSION      BD087093.1 GI:22632703
KEYWORDS     JP 2001525163-A/57.
SOURCE       Erythrovirus
ORGANISM     Erythrovirus
REFERENCE    1 (bases 1 to 28)
AUTHORS      Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE        Erythrovirus and application thereof
JOURNAL      Patent: JP 2001525163-A 57 11-DEC-2001;
              ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT      OS Erythrovirus
              PN JP 2001525163-A/57
              PD 11-DEC-2001
              PR 03-DEC-1998 JP 2000523317
              PR 03-DEC-1997 FR 97/15197
              PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG VERONIQUE AUGUSTE PC
              C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
              GOIN33/53,
              PC C12N15/00
              CC Erythrovirus and application thereof
              FH Key
              FT source
              Location/Qualifiers
                location= 'Erythrovirus'.
                /organism= 'Erythrovirus'.
                /mol_type= 'genomic DNA'
                /db_xref= 'taxon:40121'

FEATURES
  source
    Query Match
    Best Local Similarity 0.6%; Score 28; DB 1; Length 28;
    Matches 28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1733 CACAAGCTGGAGCCACTATGAAAACGTG 1760
Db      1 CACAAGCTGGAGCCACTATGAAAACGTG 28

RESULT 19
LOCUS      AX003436
DEFINITION Sequence 16 from Patent WO9928439.
ACCESSION  AX003436
VERSION     AX003436
KEYWORDS    B19 virus
SOURCE      B19 virus
ORGANISM    B19 virus
REFERENCE    1
AUTHORS      Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE        Erythrovirus and its applications
JOURNAL      Patent: WO 9928439-A 16 10-JUN-1999;
              ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
              CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
  source
    Query Match
    Best Local Similarity 0.5%; Score 26; DB 1; Length 26;
    Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2293 AAAAATGCTTACCTACTGCTGGAATT 2318
Db      1 AAAAATGCTTACCTACTGCTGGAATT 26

RESULT 20
LOCUS      AX003448
DEFINITION Erythrovirus and application thereof.

```


DEFINITION Sequence 28 from Patent WO928439.
ACCESSION AX003448
VERSION AX003448.1 GI:9927252
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 28 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
location/Qualifiers
FEATURES
source 1..26
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"
Query Match 0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3032 TCTGCAGAGCCAGCACTGCTGCAGG 3057
DB 1 TCTGCAGAGCCAGCACTGCTGCAGG 26
RESULT 21
AX003453
LOCUS AX003453 26 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 33 from Patent WO928439.
ACCESSION AX003453
VERSION AX003453.1 GI:9927257
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 33 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
location/Qualifiers
FEATURES
source 1..26
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"
Query Match 0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4133 AGATTTCCAAATGAAAAAGAACGCT 4158
DB 1 AGATTTCCAAATGAAAAAGAACGCT 26
RESULT 22
BD087052 26 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087052
VERSION BD087052.1 GI:22632662
KEYWORDS JP 2001525163-A/16.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 16 11-DEC-2001;

COMMENT ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/16
PD 11-DEC-2001 JP 2000523317
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key location/Qualifiers
FT source 1..26
/organism="Erythrovirus".
location/Qualifiers
FEATURES
source 1..26
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"
Query Match 0.5%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3032 TCTGCAGAGCCAGCACTGCTGCAGG 3057
DB 1 TCTGCAGAGCCAGCACTGCTGCAGG 26
RESULT 24
BD087064 26 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087064
VERSION BD087064.1 GI:22632674
KEYWORDS JP 2001525163-A/28.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 28 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/28
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key location/Qualifiers
FT source 1..26
/organism="Erythrovirus".
location/Qualifiers
FEATURES
source 1..26
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

BD087069 26 bp DNA linear PAT 27-AUG-2002
 LOCUS BD087069
 DEFINITION Erythrovirus and application thereof.
 ACCESSION BD087069.1 GI:22632679
 VERSION JP 2001525163-A/33.
 KEYWORDS Erythrovirus
 SOURCE Erythrovirus
 ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
 REFERENCE 1 (bases 1 to 26)
 AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
 TITLE Erythrovirus and application thereof
 JOURNAL Patent: JP 2001525163-A 33 11-DEC-2001;
 ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
 COMMENT OS Erythrovirus
 PN JP 2001525163-A/33
 PD 11-DEC-2001
 PP 03-DEC-1998 JP 2000523317
 PR 03-DEC-1997 FR 97/15197
 PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
 C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
 G01N33/53,
 PC C12N15/00
 CC Erythrovirus and application thereof
 FH Key Location/Qualifiers
 FT source 1..26 /organism='Erythrovirus'.
 FEATURES location/Qualifiers
 source 1..26 /organism='Erythrovirus'
 /mol_type='genomic DNA'
 /db_xref='taxon:40121'

Query Match 0.5%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4133 AGATTCCAAATGAAAAGACAGCT 4158
 |||||
 1 AGATTCCAAATGAAAAGACAGCT 26

Db 1 AGATTCCAAATGAAAAGACAGCT 26

RESULT 25
 AX003432 25 bp DNA linear PAT 07-SEP-2000
 LOCUS AX003432
 DEFINITION Sequence 12 from Patent WO928439.
 ACCESSION AX003432
 VERSION AX003432.1 GI:9927236
 KEYWORDS B19 virus
 SOURCE B19 virus
 ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
 REFERENCE 1
 AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 TITLE Erythrovirus and its applications
 JOURNAL Patent: WO 9928439-A 12 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
 FEATURES location/Qualifiers
 source 1..25 /organism='B19 virus'
 /mol_type='unassigned DNA'
 /db_xref='taxon:10798'

Query Match 0.5%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 23;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1935 TGAACCCCGCGCTCTAGTAGCCCC 1959
 |||||
 1 TGAACCCCGCGCTCTAGTAGCCCC 25

Db 1 TGAACCCCGCGCTCTAGTAGCCCC 25

RESULT 26
 BD087048 25 bp DNA linear PAT 27-AUG-2002
 LOCUS BD087048
 DEFINITION Erythrovirus and application thereof.
 ACCESSION BD087048.1 GI:22632658
 VERSION JP 2001525163-A/12.
 KEYWORDS Erythrovirus
 SOURCE Erythrovirus
 ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
 REFERENCE 1 (bases 1 to 25)
 AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
 TITLE Erythrovirus and application thereof
 JOURNAL Patent: JP 2001525163-A 12 11-DEC-2001;
 ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
 COMMENT OS Erythrovirus
 PN JP 2001525163-A/12
 PD 11-DEC-2001
 PP 03-DEC-1998 JP 2000523317
 PR 03-DEC-1997 FR 97/15197
 PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
 C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
 G01N33/53,
 PC C12N15/00
 CC Erythrovirus and application thereof
 FH Key Location/Qualifiers
 FT source 1..25 /organism='Erythrovirus'.
 FEATURES location/Qualifiers
 source 1..25 /organism='Erythrovirus'
 /mol_type='genomic DNA'
 /db_xref='taxon:40121'

Query Match 0.5%; Score 25; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 23;
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1935 TGAACCCCGCGCTCTAGTAGCCCC 1959
 |||||
 1 TGAACCCCGCGCTCTAGTAGCCCC 25

Db 1 TGAACCCCGCGCTCTAGTAGCCCC 25

RESULT 27
 E35607 26 bp DNA linear PAT 18-JUN-2001
 LOCUS E35607
 DEFINITION Method for detecting high viral concentration in plasma and/or
 ACCESSION E35607
 VERSION E35607.1 GI:13019101
 KEYWORDS serum by using polymerase chain reaction.
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 26)
 AUTHORS Thomas,V. and Albrecht,G.
 TITLE Method for detecting high viral concentration in plasma and/or
 JOURNAL serum by using polymerase chain reaction
 Patent: JP 1999225797-A 3 24-AUG-1999;
 CENTERON PHARMA GMBH
 COMMENT OS unidentified
 PN JP 1999225797-A/3
 PD 24-AUG-1999
 PP 27-NOV-1998 JP 1998336431
 PR 28-NOV-1997 DE 19752898.8
 PI THOMAS VAIMA,ALBRECHT GROENR
 PC C12Q1/68//C12N15/09,C12N15/00
 CC Strandedness: Single;
 CC Topology: Linear;
 FH key Location/Qualifiers
 FT source 1..26 /organism='Unidentified'.
 FEATURES location/Qualifiers

```
source
1..26
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.5%; Score 24.4; DB 1; Length 26;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1430 TGGTGGCTCGGATGGAAGCATTTATT 1455
1 TGGTGGCTCGGATGGAAGCATTTATT 26

RESULT 28
AX022850 AX022850 26 bp DNA linear PAT 24-NOV-2000
LOCUS Sequence 3 from Patent EP0922771.
ACCESSION AX022850
VERSION AX022850.1 GI:10046343
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Groener,A.D. and Weimer,T.D.
TITLE Method for the detection of large concentrations of a virus in
reaction blood plasma and/ or blood serum using the polymerase chain
Patent: EP 0922771-A 3 16-JUN-1999;
JOURNAL CENTEON PHARMA GMBH (DE)
FEATURES
source location/Qualifiers
1..26
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.5%; Score 24.4; DB 1; Length 26;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1430 TGGTGGCTCGGATGGAAGCATTTATT 1455
1 TGGTGGCTCGGATGGAAGCATTTATT 26

Db 1 TGGTGGCTCGGATGGAAGCATTTATT 26

RESULT 29
AX003435 AX003435 24 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 15 from Patent WO9928439.
ACCESSION AX003435
VERSION AX003435.1 GI:9927239
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
PATENT: WO 9928439-A 15 10-JUN-1999;
JOURNAL ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
source location/Qualifiers
1..24
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
Best Local Similarity 0.5%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2194 GCTTGTATATGATGGAATTT 2217
```

```
Db 1 GCTTGTATATGATGGAATTT 24

RESULT 30
AX003452 AX003452 24 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 32 from Patent WO9928439.
ACCESSION AX003452
VERSION AX003452.1 GI:9927256
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
PATENT: WO 9928439-A 32 10-JUN-1999;
JOURNAL ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
source location/Qualifiers
1..24
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
Best Local Similarity 0.5%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4106 GACAAAGATATCAGCAGGGGTA 4129
1 GACAAAGATATCAGCAGGGGTA 24

RESULT 31
BD087051 BD087051 24 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
ACCESSION BD087051
VERSION BD087051.1 GI:22632661
KEYWORDS JP 2001525163-A/15.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
PATENT: JP 2001525163-A 15 11-DEC-2001;
JOURNAL ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/15
PD 11-DEC-2001
PR 03-DEC-1998 JP 2000523317
PT QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/66, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key location/Qualifiers
FT source 1..24
/organism="Erythrovirus"
location/Qualifiers
1..24
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match
Best Local Similarity 0.5%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 2194 GCTTGATATATGATGGAATTT 2217
 DB 1 GCTTGATATATGATGGAATTT 24

RESULT 32
 LOCUS BD087068 24 bp DNA linear PAT 27-AUG-2002
 DEFINITION Erythrovirus and application thereof.
 ACCESSION BD087068 GI:22632678
 VERSION JP 2001525163-A/32.
 KEYWORDS Erythrovirus
 SOURCE Erythrovirus
 ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE
 1 (bases 1 to 24)
 Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
 Erythrovirus and application thereof
 Patent: JP 2001525163-A 32 11-DEC-2001;
 ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
 OS Erythrovirus
 PN JP 2001525163-A/32
 PD 11-DEC-2001
 PF 03-DEC-1998 JP 2000523317
 PI 03-DEC-1997 FR 97/15197
 P1 QUANG TRI NGUYEN,CHENON ANTOINE,GARBARG,VERONIQUE,AUGUSTE PC
 C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
 G01N33/53,
 PC C12N15/00
 CC Erythrovirus and application thereof
 FH Key Location/Qualifiers
 FT source 1..24
 FT Location/Qualifiers
 1..24
 /organism="Erythrovirus"
 /mol_type="genomic DNA"
 /db_xref="taxon:40121"

FEATURES
 source

Query Match 0.5%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 27;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4106 GACAAAGATATGACGAGGGGTA 4129
 DB 1 GACAAAGATATGACGAGGGGTA 24

RESULT 33
 LOCUS AX003422 23 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 2 from Patent WO928439.
 ACCESSION AX003422
 VERSION AX003422.1 GI:9927226
 KEYWORDS
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE
 1
 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 Erythrovirus and its applications
 Patent: WO 928439-A 2 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
 Location/Qualifiers
 1..23
 /organism="B19 virus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10798"

FEATURES
 source

Query Match 0.5%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 ACTTGTGACTGGGAGACCACTAAC 440
 DB 1 ACTTGTGACTGGGAGACCACTAAC 23

RESULT 34
 LOCUS AX003430 23 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 10 from Patent WO928439.
 ACCESSION AX003430
 VERSION AX003430.1 GI:9927234
 KEYWORDS
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE
 1
 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 Erythrovirus and its applications
 Patent: WO 928439-A 10 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
 Location/Qualifiers
 1..23
 /organism="B19 virus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10798"

FEATURES
 source

Query Match 0.5%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1795 AATGCAGATGCCCTCCACCCAGA 1817
 DB 1 AATGCAGATGCCCTCCACCCAGA 23

RESULT 35
 LOCUS AX003445 23 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 25 from Patent WO928439.
 ACCESSION AX003445
 VERSION AX003445.1 GI:9927249
 KEYWORDS
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE
 1
 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 Erythrovirus and its applications
 Patent: WO 928439-A 25 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
 Location/Qualifiers
 1..23
 /organism="B19 virus"
 /mol_type="unassigned DNA"
 /db_xref="taxon:10798"

FEATURES
 source

Query Match 0.5%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 31;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2870 TTTAAATAATATTAATAAATGAAC 2892
 DB 1 TTTAAATAATATTAATAAATGAAC 23

RESULT 36
 LOCUS AX003447 23 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 27 from Patent WO928439.
 ACCESSION AX003447

VERSION AX003447.1 GI:9927251
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
FEATURES
1 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
AUTHORS Erythrovirus and its applications
TITLE Patent: WO 9928439-A 27 10-JUN-1999;
JOURNAL ASSIST PUBL HOPITLUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
LOCATION/Qualifiers
1.23
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"
FEATURES
source
Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2990 TACACGCCTCAGAAAAATACCC 3012
Db 1 TACACGCCTCAGAAAAATACCC 23
RESULT 37
AX003449 23 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 29 from Patent WO9928439.
DEFINITION AX003449
ACCESSION AX003449
VERSION AX003449.1 GI:9927253
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
FEATURES
1 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
AUTHORS Erythrovirus and its applications
TITLE Patent: WO 9928439-A 29 10-JUN-1999;
JOURNAL ASSIST PUBL HOPITLUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
LOCATION/Qualifiers
1.23
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"
FEATURES
source
Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3284 TTGATTTTAAATGCTTAAATTT 3306
Db 1 TTGATTTTAAATGCTTAAATTT 23
RESULT 38
AX003455 23 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 35 from Patent WO9928439.
DEFINITION AX003455
ACCESSION AX003455
VERSION AX003455.1 GI:9927259
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
FEATURES
1 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
AUTHORS Erythrovirus and its applications
TITLE Patent: WO 9928439-A 35 10-JUN-1999;
JOURNAL ASSIST PUBL HOPITLUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source Location/Qualifiers
1.23
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"
Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4313 TTGATGACAGTTTAAACTCA 4335
Db 1 TTGATGACAGTTTAAACTCA 23
RESULT 39
AX003458 23 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 38 from Patent WO9928439.
DEFINITION AX003458
ACCESSION AX003458
VERSION AX003458.1 GI:9927262
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
FEATURES
1 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
AUTHORS Erythrovirus and its applications
TITLE Patent: WO 9928439-A 38 10-JUN-1999;
JOURNAL ASSIST PUBL HOPITLUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
LOCATION/Qualifiers
1.23
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"
FEATURES
source
Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4433 ATGGAAATTAATCTTAACTTCA 4455
Db 1 ATGGAAATTAATCTTAACTTCA 23
RESULT 40
AX003485 23 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 65 from Patent WO9928439.
DEFINITION AX003485
ACCESSION AX003485
VERSION AX003485.1 GI:9927338
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
FEATURES
1 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
AUTHORS Erythrovirus and its applications
TITLE Patent: WO 9928439-A 65 10-JUN-1999;
JOURNAL ASSIST PUBL HOPITLUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
LOCATION/Qualifiers
1.23
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"
FEATURES
source
Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2574 ATTTGAGAGCATGACAGTTA 2596

Db 1 ATTTCAGAGCCATGACAGTTA 23

RESULT 41
BD087038

LOCUS BD087038 23 bp DNA linear PAT 27-AUG-2002

DEFINITION Erythrovirus and application thereof.

ACCESSION BD087038

VERSION BD087038.1 GI:22632648

KEYWORDS JP 2001525163-A/2.

SOURCE Erythrovirus

ORGANISM Erythrovirus

REFERENCE 1 (bases 1 to 23)
Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
Erythrovirus and application thereof.
Patent: JP 2001525163-A 2 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

COMMENT OS Erythrovirus
PN JP 2001525163-A/2
PD 11-DEC-2001
PE 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..23
/organism='Erythrovirus'.
location/Qualifiers
1..23
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 418 ACTTGTGACTGGAGACCACTTAC 440
1 ACTTGTGACTGGAGACCACTTAC 23

RESULT 42
BD087046

LOCUS BD087046 23 bp DNA linear PAT 27-AUG-2002

DEFINITION Erythrovirus and application thereof.

ACCESSION BD087046

VERSION BD087046.1 GI:22632656

KEYWORDS JP 2001525163-A/10.

SOURCE Erythrovirus

ORGANISM Erythrovirus

REFERENCE 1 (bases 1 to 23)
Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
Erythrovirus and application thereof.
Patent: JP 2001525163-A 10 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

COMMENT OS Erythrovirus
PN JP 2001525163-A/10
PD 11-DEC-2001
PE 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers

FT source 1..23
/organism='Erythrovirus'.
location/Qualifiers
1..23
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1795 AATGCAGATGCTCCACCCAGA 1817
1 AATGCAGATGCTCCACCCAGA 23

RESULT 43
BD087061

LOCUS BD087061 23 bp DNA linear PAT 27-AUG-2002

DEFINITION Erythrovirus and application thereof.

ACCESSION BD087061

VERSION BD087061.1 GI:22632671

KEYWORDS JP 2001525163-A/25.

SOURCE Erythrovirus

ORGANISM Erythrovirus

REFERENCE 1 (bases 1 to 23)
Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
Erythrovirus and application thereof.
Patent: JP 2001525163-A 25 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

COMMENT OS Erythrovirus
PN JP 2001525163-A/25
PD 11-DEC-2001
PE 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..23
/organism='Erythrovirus'.
location/Qualifiers
1..23
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2870 TTAATAAATATATAAATGAAC 2892
1 TTAATAAATATATAAATGAAC 23

RESULT 44
BD087063

LOCUS BD087063 23 bp DNA linear PAT 27-AUG-2002

DEFINITION Erythrovirus and application thereof.

ACCESSION BD087063

VERSION BD087063.1 GI:22632673

KEYWORDS JP 2001525163-A/27.

SOURCE Erythrovirus

ORGANISM Erythrovirus

REFERENCE 1 (bases 1 to 23)
Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
Erythrovirus and application thereof.

JOURNAL Patent: JP 2001525163-A 27 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/27
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..23
/organism='Erythrovirus',
Location/Qualifiers

FEATURES
source 1..23
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2990 TACAACGCTCAGAAAATATCC 3012
DB 1 TTACACGCTCAGAAAATATCC 23

RESULT 45
BD087065 23 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087065
ACCESSION BD087065.1 GI:22632675
VERSION JP 2001525163-A/29.
KEYWORDS Erythrovirus
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 23)
AUTHORS Nguyen, O.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 29 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/29
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..23
/organism='Erythrovirus',
Location/Qualifiers

FEATURES
source 1..23
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3284 TTGATTTTAACTTTAAATTT 3306
DB 1 TTGATTTTAACTTTAAATTT 23

RESULT 46
BD087071 23 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087071
ACCESSION BD087071.1 GI:22632681
VERSION JP 2001525163-A/35.
KEYWORDS Erythrovirus
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 23)
AUTHORS Nguyen, O.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 35 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/35
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..23
/organism='Erythrovirus',
Location/Qualifiers

FEATURES
source 1..23
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4313 TTGATGACGTTTAACTCA 4335
DB 1 TTGATGACGTTTAACTCA 23

RESULT 47
BD087074 23 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087074
ACCESSION BD087074.1 GI:22632684
VERSION JP 2001525163-A/38.
KEYWORDS Erythrovirus
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 23)
AUTHORS Nguyen, O.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 38 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/38
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..23
/organism='Erythrovirus',
Location/Qualifiers

FEATURES
source 1..23
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4433 ATGGGAATTACTACTTACTTCA 4455
DB 1 ATGGGAATTACTACTTACTTCA 23

RESULT 48

BD087101 23 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087101
ACCESSION BD087101.1 GI:22632711
VERSION JP 2001525163-A/65.
KEYWORDS Erythrovirus
SOURCE Erythrovirus
ORGANISM

REFERENCE 1 (bases 1 to 23)
AUTHORS Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 65 11-DEC-2001;
COMMENT ASSISTANCE PUBLIQUE HOPITALUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/65
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PI QUNANG TRI NGUYEN, CHENON ANTOINE, GARBARG, VERONIQUE, AUGUSTE, PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..23
location/Qualifiers
1..23
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES

source
1..23
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2574 ATTTTCAGAGCCATGACAGTTA 2596
DB 1 ATTTTCAGAGCCATGACAGTTA 23

RESULT 49

A22327/c 24 bp DNA linear PAT 05-DEC-1994
LOCUS Primer O-2 (reverse complement) from patent WO91/12269.
DEFINITION A22327
ACCESSION A22327
VERSION A22327.1 GI:833184
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE artificial sequences.
AUTHORS 1 (bases 1 to 24)
TITLE IMMUNOLOGICALLY ACTIVE PEPTIDES OR POLYPEPTIDES FROM THE PARVOVIRUS
JOURNAL Patent: WO 9112269-A 15 22-AUG-1991;
FEATURES location/Qualifiers
1..24

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 37;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3039 AACCCAGCACTGGTGACGCGGG 3062
DB 24 AACCCAGCACTGGTGACGCGGG 1

RESULT 50

A66531/c 24 bp DNA linear PAT 29-MAR-1999
LOCUS Sequence 2 from Patent WO9740861.
DEFINITION A66531
ACCESSION A66531
VERSION A66531.1 GI:4538085
KEYWORDS
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 24)
AUTHORS Barrett, N., Eibl, J., Dörner, F., Poelsler, G. and Haemmerle, T.
TITLE BIOLOGICAL MATERIAL FREE OF VIRAL AND MOLECULAR PATHOGENS AND A
JOURNAL PROCESS FOR THE PRODUCTION THEREOF
Patent: WO 9740861-A 2 06-NOV-1997
COMMENT IMMUNO AG (AT)
Other publication AT 403477B 19980225
location/Qualifiers
1..24
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

FEATURES
source
1..24
/organism="unassigned DNA"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.4%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 37;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1398 CTTTCATTAAATGATGACGGG 1421
DB 24 CTTTCATTAAATGATGACGGG 1

RESULT 51

AR430269 22 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 1 from patent US 6649339.
DEFINITION AR430269
ACCESSION AR430269
VERSION AR430269.1 GI:40191038
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 22)
AUTHORS Zerlauch, G., Gessner, M., Koeltzitz, K. and Gross, P.
TITLE Method for producing a quality assured biological sample and
JOURNAL composition containing the same
Patent: US 6649339-A 1 18-NOV-2003;
FEATURES location/Qualifiers
1..22
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2589 GACAGTATCTGACACCCCA 2610
DB 1 GACAGTATCTGACACCCCA 22


```

RESULT 52
AX003444      AX003444      22 bp      DNA      linear      PAT 07-SEP-2000
LOCUS          Sequence 24 from Patent WO928439.
DEFINITION     AX003444
ACCESSION      AX003444
VERSION        AX003444.1  GI:9927248
KEYWORDS
SOURCE
ORGANISM       B19 virus
               B19 virus
               Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
AUTHORS        Erythrovirus and its applications
TITLE          Patent: WO 928439-A 24 10-JUN-1999;
               ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
               CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
JOURNAL
FEATURES
source         1..22
               /organism="B19 virus"
               /mol_type="unassigned DNA"
               /db_xref="taxon:10798"

Query Match    0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2814 TGCTAAGTTGGGAAATTAATCC 2835
Db      1 TGCTAAGTTGGGAAATTAATCC 22

RESULT 53
AX003484      AX003484      22 bp      DNA      linear      PAT 07-SEP-2000
LOCUS          Sequence 64 from Patent WO928439.
DEFINITION     AX003484
ACCESSION      AX003484
VERSION        AX003484.1  GI:9927337
KEYWORDS
SOURCE
ORGANISM       B19 virus
               B19 virus
               Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
AUTHORS        Erythrovirus and its applications
TITLE          Patent: WO 928439-A 64 10-JUN-1999;
               ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
               CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
JOURNAL
FEATURES
source         1..22
               /organism="B19 virus"
               /mol_type="unassigned DNA"
               /db_xref="taxon:10798"

Query Match    0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2552 TCTCAGACCTATATAGTCATC 2573
Db      1 TCTCAGACCTATATAGTCATC 22

RESULT 54
AX088167      AX088167      22 bp      DNA      linear      PAT 17-MAR-2001
LOCUS          Sequence 1 from Patent WO0114593.
DEFINITION     AX088167
ACCESSION      AX088167
VERSION        AX088167.1  GI:13397080
KEYWORDS        synthetic construct
SOURCE          synthetic construct
ORGANISM

```

```

REFERENCE
1 Zierlauch,G., Gessner,M., Koettnitz,K. and Gross,P.
AUTHORS        A method for producing quality assured biological sample and
TITLE          composition containing the same
JOURNAL        Patent: WO 0114593-A 1 01-MAR-2001;
               Baxter Aktiengesellschaft (AT)
FEATURES
source         1..22
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
               /note="PCR primer"

Query Match    0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2589 GACAGTTATCTGACACCCCA 2610
Db      1 GACAGTTATCTGACACCCCA 22

RESULT 55
BD087060      BD087060      22 bp      DNA      linear      PAT 27-AUG-2002
LOCUS          Erythrovirus and application thereof.
DEFINITION     BD087060
ACCESSION      BD087060.1  GI:22632670
VERSION        JP 2001525163-A/24.
KEYWORDS        Erythrovirus
SOURCE          Erythrovirus
ORGANISM       Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE
1 (bases 1 to 22)
AUTHORS        Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE          Erythrovirus and application thereof
JOURNAL        Patent: JP 2001525163-A 24 11-DEC-2001;
               ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT        OS Erythrovirus
               PN JP 2001525163-A/24
               PD 11-DEC-2001
               PF 03-DEC-1998 JP 2000523317
               PR 03-DEC-1997 FR 97/15197
               PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
               CI2N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12O1/68, PC
               G01N33/53,
               PC C12N15/00
               CC Erythrovirus and application thereof
               FH Key
               FT source
               Location/Qualifiers
               1..22
               /organism="Erythrovirus"
               /mol_type="genomic DNA"
               /db_xref="taxon:40121"

Query Match    0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2814 TGCTAAGTTGGGAAATTAATCC 2835
Db      1 TGCTAAGTTGGGAAATTAATCC 22

RESULT 56
BD087100      BD087100      22 bp      DNA      linear      PAT 27-AUG-2002
LOCUS          Erythrovirus and application thereof.
DEFINITION     BD087100
ACCESSION      BD087100
VERSION        BD087100.1  GI:22632710
KEYWORDS        JP 2001525163-A/64.
ORGANISM

```

SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

Erythrovirus
Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
1 (bases 1 to 22)
Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
Erythrovirus and its applications
Patent: WO 9928439-A 64 10-JUN-1999;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS
Erythrovirus
PN JP 2001525163-A/64
PD 11-DEC-2001
PR 03-DEC-1998 JP 2000523317
PI 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/66, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key
FT source
FT Location/Qualifiers
1..22
/organism="Erythrovirus".
Location/Qualifiers
1..22
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source
1..22
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match
Best Local Similarity 0.4%; Score 21; DB 1; Length 22;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2552 TCTCCAGACCTATATAGTCATC 2573
DB 1 TCTCCAGACCTATATAGTCATC 22

RESULT 57
LOCUS AR371201 23 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 6 from patent US 6395472.
ACCESSION AR371201
VERSION AR371201.1 GI:34608131
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

Unclassified.
1 (bases 1 to 23)
Leary,T.P., Erker,J., Chalmers,M., Simons,J., Birkenmeyer,L.,
Muerhoff,S., Pilot-Matias,T., Desai,S. and Mushahwar,I.,
Methods of utilizing the TR virus
Patent: US 6395472-A 6 28-MAY-2002;
Location/Qualifiers
1..23
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 0.4%; Score 21.4; DB 1; Length 23;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3015 GCATGACTTCAGTTAACTCTGCA 3037
DB 1 GCATGACTTCAGTTAACTCTGCA 23

RESULT 58
LOCUS AX003427 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 7 from Patent WO9928439.
ACCESSION AX003427
VERSION AX003427.1 GI:9927231
KEYWORDS
SOURCE
B19 virus

ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

B19 virus
Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
1
Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
Erythrovirus and its applications
Patent: WO 9928439-A 7 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1..21
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
Best Local Similarity 0.4%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1723 TGCTGTATGCAAGCTGG 1743
DB 1 TGCTGTATGCAAGCTGG 21

RESULT 59
LOCUS AX003456 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 36 from Patent WO9928439.
ACCESSION AX003456
VERSION AX003456.1 GI:9927260
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

B19 virus
Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
1
Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
Erythrovirus and its applications
Patent: WO 9928439-A 36 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1..21
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match
Best Local Similarity 0.4%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4376 CCTCAATATTTTAAATA 4396
DB 1 CCTCAATATTTTAAATA 21

RESULT 60
LOCUS AX003462 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 42 from Patent WO9928439.
ACCESSION AX003462
VERSION AX003462.1 GI:9927266
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

B19 virus
Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
1
Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
Erythrovirus and its applications
Patent: WO 9928439-A 42 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1..21
/organism="B19 virus"

/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4686 TCCCGACCGGTCTCCAGCCA 4706
DB 1 TCCCGACCGGTCTCCAGCCA 21

RESULT 61
AX003526/c
LOCUS AX003526 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 106 from Patent WO928439.
ACCESSION AX003526
VERSION AX003526.1 GI:9927362
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 106 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1. 21
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1879 GAGAACTCAGTGAAGCAGC 1899
DB 21 GAGAACTCAGTGAAGCAGC 1

RESULT 62
AX003530/c
LOCUS AX003530 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 110 from Patent WO9928439.
ACCESSION AX003530
VERSION AX003530.1 GI:9927366
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 110 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1. 21
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2041 TTTTACACGCGCTTGCCGAT 2061
DB 21 TTTTACACGCGCTTGCCGAT 1

RESULT 63
AX003535
LOCUS AX003535 21 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 115 from Patent WO9928439.
ACCESSION AX003535
VERSION AX003535.1 GI:9927371
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 115 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1. 21
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1755 AAATGGGCAATTAATCACTAC 1775
DB 1 AAATGGGCAATTAATCACTAC 21

RESULT 64
BD087043
LOCUS BD087043 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087043
VERSION BD087043.1 GI:22632653
KEYWORDS JP 2001525163-A/7.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE 1 (bases 1 to 21)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 7 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/7
PD 11-DEC-2001 JP 2000523317
PF 03-DEC-1998 JP 97/15197
PI 03-DEC-1997 FR 97/15197
P1 QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1. 21
/organism="Erythrovirus"
Location/Qualifiers
1. 21
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1723 TGGTGTATGCAAAAGCTGG 1743
DB 1 TGGTGTATGCAAAAGCTGG 21

RESULT 65
LOCUS BD087072 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087072.1 GI:22632682
VERSION JP 2001525163-A/36.
KEYWORDS Erythrovirus
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 21)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 36 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/36
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..21
/organism='Erythrovirus'.
Location/Qualifiers
1..21
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4376 CCTCAATATTTTAAATA 4396
Db 1 CCTCAATATTTTAAATA 21

RESULT 66
LOCUS BD087078 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087078.1 GI:22632688
VERSION JP 2001525163-A/42.
KEYWORDS Erythrovirus
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 21)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 42 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/42
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..21
/organism='Erythrovirus'.
Location/Qualifiers
1..21
/organism='Erythrovirus'

FEATURES
source Location/Qualifiers
1..21
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4686 TCCCAACCGTGTCTCAGCCA 4706
Db 1 TCCCAACCGTGTCTCAGCCA 21

RESULT 67
LOCUS BD087125 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087125
VERSION BD087125.1 GI:22632735
KEYWORDS JP 2001525163-A/89.
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 21)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 89 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/89
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..21
/organism='Erythrovirus'.
Location/Qualifiers
1..21
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1879 GAAGAATCTAGTGAAGCAGC 1899
Db 21 GAAGAATCTAGTGAAGCAGC 1

RESULT 68
LOCUS BD087129 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087129
VERSION BD087129.1 GI:22632739
KEYWORDS JP 2001525163-A/93.
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 21)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 93 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

COMMENT OS Erythrovirus
PN JP 2001525163-A/93
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53, PC
C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..21
/organism='Erythrovirus'.
Location/Qualifiers
1..21
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2041 TTTTACAGCCGCTTGCCTGAT 2061
DB 21 TTTTACAGCCGCTTGCCTGAT 1

RESULT 69
BD087134
LOCUS BD087134 21 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087134
VERSION BD087134.1 GI:22632744
KEYWORDS JP 2001525163-A/98.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 21)
AUTHORS Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 98 11-DEC-2001;
COMMENT ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/98
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
G01N33/53, PC
C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..21
/organism='Erythrovirus'.
Location/Qualifiers
1..21
/organism='Erythrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:40121'

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1755 AAATGGGCAATAACTACAC 1775
DB 1 AAATGGGCAATAACTACAC 21

RESULT 70
AR371205/c

LOCUS AR371205 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 10 from patent US 6395472.
ACCESSION AR371205
VERSION AR371205.1 GI:34608135
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Leary, T.P., Erker, J., Chalmers, M., Simons, J., Birkenmeyer, L.,
Muerthoff, S., Pilot-Matias, T., Desai, S. and Mushahwar, I.,
TITLE Methods of utilizing the TT virus
JOURNAL Patent: US 6395472-A 10 28-MAY-2002;
FEATURES
source 1..20
/organism='unknown'
/mol_type='genomic DNA'

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1992 CGGAGCCCAAGTTCTCCG 2011
DB 20 CGGAGCCCAAGTTCTCCG 1

RESULT 71
AR430270/c
LOCUS AR430270 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 2 from patent US 6649339.
ACCESSION AR430270
VERSION AR430270.1 GI:40191039
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zerlauth, G., Gessner, M., Koettwitz, K. and Gross, P.
TITLE Method for producing a quality assured biological sample and
JOURNAL composition containing the same
PATENT: US 6649339-A 2 18-NOV-2003;
FEATURES
source 1..20
/organism='unknown'
/mol_type='genomic DNA'

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2682 ACNAGCCTGGGCAAGTTAGC 2701
DB 20 ACNAGCCTGGGCAAGTTAGC 1

RESULT 72
AX003425
LOCUS AX003425 20 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 5 from Patent WO9928439.
ACCESSION AX003425
VERSION AX003425.1 GI:9927229
KEYWORDS B19 virus
SOURCE B19 virus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE 1
AUTHORS Auguste, V., Garbarg, Chenon, A. and Nguyen, Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 5 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
Location/Qualifiers

source 1.20
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1429 TTGGTGTCTGGATGAGG 1448
|||||
1 TTGGTGTCTGGATGAGG 20

Db 1 TTGGTGTCTGGATGAGG 20

RESULT 73
AX003426 20 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 6 from Patent WO9928439.
DEFINITION AX003426
ACCESSION AX003426
VERSION AX003426.1 GI:9927230
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
TITLE Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
JOURNAL Erythrovirus and its applications
Patent: WO 9928439-A 6 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1.20
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1693 ACAGAGGCTGATGTACACA 1712
|||||
1 ACAGAGGCTGATGTACACA 20

Db 1 ACAGAGGCTGATGTACACA 20

RESULT 74
AX003434 20 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 14 from Patent WO9928439.
DEFINITION AX003434
ACCESSION AX003434
VERSION AX003434.1 GI:9927238
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
TITLE Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
JOURNAL Erythrovirus and its applications
Patent: WO 9928439-A 14 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1.20
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2062 CAGTTTCGTAAGTGTAGT 2081
|||||
1 CAGTTTCGTAAGTGTAGT 20

Db 1 CAGTTTCGTAAGTGTAGT 20

RESULT 75
AX003451 20 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 31 from Patent WO9928439.
DEFINITION AX003451
ACCESSION AX003451
VERSION AX003451.1 GI:9927255
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
TITLE Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
JOURNAL Erythrovirus and its applications
Patent: WO 9928439-A 31 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1.20
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4055 ACAGGATTAATGCCATTTC 4074
|||||
1 ACAGGATTAATGCCATTTC 20

Db 1 ACAGGATTAATGCCATTTC 20

RESULT 76
AX003527 20 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 107 from Patent WO9928439.
DEFINITION AX003527
ACCESSION AX003527
VERSION AX003527.1 GI:9927363
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
TITLE Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
JOURNAL Erythrovirus and its applications
Patent: WO 9928439-A 107 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1.20
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1968 GACGAGTTCAGAGATCAT 1987
|||||
1 GACGAGTTCAGAGATCAT 20

Db 1 GACGAGTTCAGAGATCAT 20

RESULT 77
AX003529/c 20 bp DNA linear PAT 07-SEP-2000
LOCUS Sequence 109 from Patent WO9928439.
DEFINITION AX003529
ACCESSION AX003529
VERSION AX003529.1 GI:9927365
KEYWORDS
SOURCE B19 virus

ORGANISM B19 virus
viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 109 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source 1..20
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2298 ATGTGCTTACTGCTGAT 2317
20 ATGTGCTTACTGCTGAT 1

RESULT 78
LOCUS AX003532/c 20 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 112 from Patent WO9928439.
ACCESSION AX003532
VERSION AX003532.1 GI:9927368
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 112 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source 1..20
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2793 ATGACTTTAGCTATGCCAA 2812
20 ATGACTTTAGCTATGCCAA 1

RESULT 79
LOCUS AX003536/c 20 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 116 from Patent WO9928439.
ACCESSION AX003536
VERSION AX003536.1 GI:9927372
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 116 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
source 1..20
/organism="B19 virus"
Location/Qualifiers

/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2845 TTGACGCTAGCAGATGAAG 2864
20 TTGACGCTAGCAGATGAAG 1

RESULT 80
LOCUS AX088168/c 20 bp DNA linear PAT 17-MAR-2001
DEFINITION Sequence 2 from Patent WO0114593.
ACCESSION AX088168
VERSION AX088168.1 GI:13397081
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.

REFERENCE 1
AUTHORS Zierlauch,G., Gessner,M., Koeltzitz,K. and Gross,P.
TITLE A method for producing quality assured biological sample and
JOURNAL composition containing the same
Patent: WO 0114593-A 2 01-MAR-2001;
Baxter Aktiengesellschaft (AT)

FEATURES
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2682 ACAAGCCTGGCGCAAGTTAGC 2701
20 ACAAGCCTGGCGCAAGTTAGC 1

RESULT 81
LOCUS BD087041 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087041
VERSION BD087041.1 GI:22632651
KEYWORDS JP 2001525163-A/5.
SOURCE Erythrovirus
ORGANISM Erythrovirus
viruses; ssDNA viruses; Parvoviridae; Parvovirinae.

REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof.
JOURNAL Patent: JP 2001525163-A 5 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

COMMENT OS Erythrovirus
PN JP 2001525163-A/5
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12O1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH key Location/Qualifiers
FT source 1..20
/organism="Erythrovirus".
Location/Qualifiers

source 1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1429 TTGGTGGCTGGGATGAAGG 1448
|||||
1 TTGGTGGCTGGGATGAAGG 20

Db 1 TTGGTGGCTGGGATGAAGG 20

RESULT 82
BD087042 20 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087042
VERSION BD087042.1 GI:22632652
KEYWORDS JP 2001525163-A/6.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 6 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
FN JP 2001525163-A/6
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC.
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
/organism='Erythrovirus'.
Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1693 ACAGAGCGTGAATGACACG 1712
|||||
1 ACAGAGCGTGAATGACACG 20

Db 1 ACAGAGCGTGAATGACACG 20

RESULT 83
BD087050 20 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087050
VERSION BD087050.1 GI:22632660
KEYWORDS JP 2001525163-A/14.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 14 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
FN JP 2001525163-A/14
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC.
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
/organism='Erythrovirus'.
Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

source 1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4055 ACAGAGTAATGCAATTC 4074
|||||
1 ACAGAGTAATGCAATTC 20

Db 1 ACAGAGTAATGCAATTC 20

RESULT 85
BD087126 20 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087126
VERSION BD087126.1 GI:22632677
KEYWORDS JP 2001525163-A/31.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 31 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
FN JP 2001525163-A/31
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC.
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
/organism='Erythrovirus'.
Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2062 CAGTTTCGTAAGTGTAGT 2081
|||||
1 CAGTTTCGTAAGTGTAGT 20

Db 1 CAGTTTCGTAAGTGTAGT 20

RESULT 84
BD087067 20 bp DNA linear PAT 27-AUG-2002
LOCUS Erythrovirus and application thereof.
DEFINITION BD087067
VERSION BD087067.1 GI:22632677
KEYWORDS JP 2001525163-A/31.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 31 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
FN JP 2001525163-A/31
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC.
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
/organism='Erythrovirus'.
Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

DEFINITION Erythrovirus and application thereof.
ACCESSION BD087126
VERSION BD087126.1 GI:22632736
KEYWORDS JP 2001525163-A/90.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 90 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/90
PD 11-DEC-2001 JP 2000523317
PF 03-DEC-1998 JP 2000523317
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
FEATURES
source Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1968 GACCACTTCAGAGAAATCAT 1987
DB 1 GACCACTTCAGAGAAATCAT 20
|||||

RESULT 86
LOCUS BD087128
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087128
VERSION BD087128.1 GI:22632738
KEYWORDS JP 2001525163-A/92.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 92 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/92
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
FEATURES
source Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2298 ATGTGCTTACTGTCTGTGAT 2317
DB 20 ATGTGCTTACTGTCTGTGAT 1
|||||

RESULT 87
LOCUS BD087131/c
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087131
VERSION BD087131.1 GI:22632741
KEYWORDS JP 2001525163-A/95.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 95 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/95
PD 11-DEC-2001 JP 2000523317
PF 03-DEC-1998 JP 2000523317
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
FEATURES
source Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2793 ATGACTTAGGTATGCCAA 2812
DB 20 ATGACTTAGGTATGCCAA 1
|||||

RESULT 88
LOCUS BD087135/c
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087135
VERSION BD087135.1 GI:22632745
KEYWORDS JP 2001525163-A/99.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1 (bases 1 to 20)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 99 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/99
PD 11-DEC-2001 JP 2000523317
PF 03-DEC-1998 JP 2000523317
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C1201/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..20
FEATURES
source Location/Qualifiers
1..20
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
 C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
 G01N33/53, PC
 C12N15/00
 CC Erythrovirus and application thereof
 FH Key Location/Qualifiers
 FT source 1..20
 /organism='Erythrovirus',
 Location/Qualifiers
 1..20
 /organism='Erythrovirus'
 /mol_type='genomic DNA'
 /db_xref='taxon:40121'

FEATURES

source

Query Match 0.4%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 46;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

2845 TTGACGGTACGATGAG 2864

Db

20 TTGACGGTACGATGAG 1

RESULT 89
 AX003438 19 bp DNA linear PAT 07-SEP-2000
 LOCUS
 DEFINITION Sequence 18 from Patent WO928439.
 ACCESSION AX003438
 VERSION AX003438.1 GI:9927242
 KEYWORDS
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
 AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 TITLE Erythrovirus and its applications
 JOURNAL Patent: WO 928439-A 18 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
 source Location/Qualifiers
 1..19
 /organism='B19 virus'
 /mol_type='unassigned DNA'
 /db_xref='taxon:10798'

Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 53;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

2562 TATATAGTCATCTTTCA 2580

Db

1 TATATAGTCATCTTTCA 19

RESULT 90
 AX003440 19 bp DNA linear PAT 07-SEP-2000
 LOCUS
 DEFINITION Sequence 20 from Patent WO928439.
 ACCESSION AX003440
 VERSION AX003440.1 GI:9927244
 KEYWORDS
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
 AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 TITLE Erythrovirus and its applications
 JOURNAL Patent: WO 928439-A 20 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
 source Location/Qualifiers
 1..19
 /organism='B19 virus'

/mol_type='unassigned DNA'
 /db_xref='taxon:10798'

Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 53;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

2635 TGCAGAACCTAGAGAGAA 2653

Db

1 TGCAGAACCTAGAGAGAA 19

RESULT 91
 AX003525 19 bp DNA linear PAT 07-SEP-2000
 LOCUS
 DEFINITION Sequence 105 from Patent WO928439.
 ACCESSION AX003525
 VERSION AX003525.1 GI:9927361
 KEYWORDS
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
 AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 TITLE Erythrovirus and its applications
 JOURNAL Patent: WO 928439-A 105 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
 source Location/Qualifiers
 1..19
 /organism='B19 virus'
 /mol_type='unassigned DNA'
 /db_xref='taxon:10798'

Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 53;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1797 TGCAGATGCTCCACCCA 1815

Db

1 TGCAGATGCTCCACCCA 19

RESULT 92
 AX003528 19 bp DNA linear PAT 07-SEP-2000
 LOCUS
 DEFINITION Sequence 108 from Patent WO928439.
 ACCESSION AX003528
 VERSION AX003528.1 GI:9927364
 KEYWORDS
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
 AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
 TITLE Erythrovirus and its applications
 JOURNAL Patent: WO 928439-A 108 10-JUN-1999;
 ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
 CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)

FEATURES
 source Location/Qualifiers
 1..19
 /organism='B19 virus'
 /mol_type='unassigned DNA'
 /db_xref='taxon:10798'

Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 53;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

2043 TTACAGCGCGCTTGGCGAT 2061

Db

19 TTACAGCGCGCTTGGCGAT 1

FEATURES
 source Location/Qualifiers
 1..19
 /organism='B19 virus'

```

RESULT 93
AX003531          19 bp   DNA      linear   PAT 07-SEP-2000
LOCUS              Sequence 111 from Patent WO928439.
DEFINITION
ACCESSION          AX003531
VERSION            AX003531.1 GI:9227367
KEYWORDS
SOURCE
ORGANISM           B19 virus
                   Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
  Erythrovirus and its applications
  Patent: WO 928439-A 111 10-JUN-1999;
  ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
  CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
  Location/Qualifiers
    1..19
      /organism="B19 virus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:10798"
FEATURES
source
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1747 CACTATGAAACTGGGCAA 1765
Db      1 CACTATGAAACTGGGCAA 19

RESULT 95
AX003534          19 bp   DNA      linear   PAT 07-SEP-2000
LOCUS              Sequence 114 from Patent WO928439.
DEFINITION
ACCESSION          AX003534
VERSION            AX003534.1 GI:9227370
KEYWORDS
SOURCE
ORGANISM           B19 virus
                   Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
  Erythrovirus and its applications
  Patent: WO 928439-A 113 10-JUN-1999;
  ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
  CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
  Location/Qualifiers
    1..19
      /organism="B19 virus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:10798"
FEATURES
source
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1747 CACTATGAAACTGGGCAA 1765
Db      1 CACTATGAAACTGGGCAA 19

```

```

REFERENCE
1 Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
  Erythrovirus and its applications
  Patent: WO 928439-A 114 10-JUN-1999;
  ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
  CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
  Location/Qualifiers
    1..19
      /organism="B19 virus"
      /mol_type="unassigned DNA"
      /db_xref="taxon:10798"
FEATURES
source
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2852 GTAGCAGATGAGAAATTGT 2870
Db      19 GTAGCAGATGAGAAATTGT 1

RESULT 96
BD087054          19 bp   DNA      linear   PAT 27-AUG-2002
LOCUS              Erythrovirus and application thereof.
DEFINITION
ACCESSION          BD087054
VERSION            BD087054.1 GI:22632664
KEYWORDS
SOURCE
ORGANISM           Erythrovirus
                   Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE
1 (bases 1 to 19)
  Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
  Erythrovirus and application thereof
  Patent: JP 2001525163-A 18 11-DEC-2001;
  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
  OS Erythrovirus
  PN JP 2001525163-A/18
  PD 11-DEC-2001
  PP 03-DEC-1998 JP 2000523317
  PR 03-DEC-1997 FR 97/15197
  PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
  CI2N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
  G01N33/53,
  PC C12N15/00
  CC Erythrovirus and application thereof
  FH Key
  FT source
  FT 1..19
    Location/Qualifiers
      /organism="Erythrovirus"
      /mol_type="genomic DNA"
      /db_xref="taxon:40121"
FEATURES
source
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2562 TATATGTCATCATTTTCA 2580
Db      1 TATATGTCATCATTTTCA 19

RESULT 97
BD087056          19 bp   DNA      linear   PAT 27-AUG-2002
LOCUS              Erythrovirus and application thereof.
DEFINITION
ACCESSION          BD087056
VERSION            BD087056.1 GI:22632666
KEYWORDS
SOURCE
ORGANISM           Erythrovirus
                   Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 (bases 1 to 19)
  Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
  Erythrovirus and application thereof
  Patent: JP 2001525163-A 18 11-DEC-2001;
  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
  OS Erythrovirus
  PN JP 2001525163-A/18
  PD 11-DEC-2001
  PP 03-DEC-1998 JP 2000523317
  PR 03-DEC-1997 FR 97/15197
  PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
  CI2N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
  G01N33/53,
  PC C12N15/00
  CC Erythrovirus and application thereof
  FH Key
  FT source
  FT 1..19
    Location/Qualifiers
      /organism="Erythrovirus"
      /mol_type="genomic DNA"
      /db_xref="taxon:40121"
FEATURES
source
Query Match      0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 53;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2562 TATATGTCATCATTTTCA 2580
Db      1 TATATGTCATCATTTTCA 19

```

```

REFERENCE
  1 (bases 1 to 19)
  Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
AUTHORS
  Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE
  Erythrovirus and application thereof
JOURNAL
  Patent: JP 2001525163-A 20 11-DEC-2001;
  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT
  OS Erythrovirus
  PN JP 2001525163-A/20
  PD 11-DEC-2001
  PF 03-DEC-1998 JP 2000523317
  PR 03-DEC-1997 FR 97/15197
  PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
  C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
  G01N33/53,
  PC C12N15/00
  CC Erythrovirus and application thereof
  FH Key Location/Qualifiers
  FT source 1..19
  FT Location/Qualifiers
  FT /organism='Erythrovirus'.

FEATURES
  source
    1..19
    /organism="Erythrovirus"
    /mol_type="genomic DNA"
    /db_xref="taxon:40121"

Query Match
  Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2635 TGCGAAGCTGAGGAGAA 2653
Db 1 TGCGAAGCTGAGGAGAA 19

RESULT 98
LOCUS BD087124 19 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087124.1 GI:22632734
VERSION JP 2001525163-A/88.
KEYWORDS Erythrovirus
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE
  1 (bases 1 to 19)
  Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 88 11-DEC-2001;
  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT
  OS Erythrovirus
  PN JP 2001525163-A/88
  PD 11-DEC-2001
  PF 03-DEC-1998 JP 2000523317
  PR 03-DEC-1997 FR 97/15197
  PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
  C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
  G01N33/53,
  PC C12N15/00
  CC Erythrovirus and application thereof
  FH Key Location/Qualifiers
  FT source 1..19
  FT Location/Qualifiers
  FT /organism='Erythrovirus'.

FEATURES
  source
    1..19
    /organism="Erythrovirus"
    /mol_type="genomic DNA"
    /db_xref="taxon:40121"

Query Match
  Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1797 TGCGATGCGCTCCACCA 1815

```

```

Db 1 TGCGATGCGCTCCACCA 19

RESULT 99
LOCUS BD087127/c 19 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087127
VERSION BD087127.1 GI:22632737
KEYWORDS JP 2001525163-A/91.
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE
  1 (bases 1 to 19)
  Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 91 11-DEC-2001;
  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT
  OS Erythrovirus
  PN JP 2001525163-A/91
  PD 11-DEC-2001
  PF 03-DEC-1998 JP 2000523317
  PR 03-DEC-1997 FR 97/15197
  PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
  C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
  G01N33/53,
  PC C12N15/00
  CC Erythrovirus and application thereof
  FH Key Location/Qualifiers
  FT source 1..19
  FT Location/Qualifiers
  FT /organism='Erythrovirus'.

FEATURES
  source
    1..19
    /organism="Erythrovirus"
    /mol_type="genomic DNA"
    /db_xref="taxon:40121"

Query Match
  Best Local Similarity 100.0%; Score 19; DB 1; Length 19;
  Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2043 TTACAGCGCGCTGCCGAT 2061
Db 19 TTACAGCGCGCTGCCGAT 1

RESULT 100
LOCUS BD087130 19 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087130
VERSION BD087130.1 GI:22632740
KEYWORDS JP 2001525163-A/94.
SOURCE Erythrovirus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE
  1 (bases 1 to 19)
  Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 94 11-DEC-2001;
  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT
  OS Erythrovirus
  PN JP 2001525163-A/94
  PD 11-DEC-2001
  PF 03-DEC-1998 JP 2000523317
  PR 03-DEC-1997 FR 97/15197
  PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
  C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
  G01N33/53,
  PC C12N15/00
  CC Erythrovirus and application thereof
  FH Key Location/Qualifiers
  FT source 1..19
  FT Location/Qualifiers
  FT /organism='Erythrovirus'.

FEATURES
  source
    1..19
    /organism="Erythrovirus"
    /mol_type="genomic DNA"
    /db_xref="taxon:40121"

```

FT source 1.19
 /organism='Erythrovirus'.
 Location/Qualifiers
 1.19
 /organism="Erythrovirus"
 /mol_type="genomic DNA"
 /db_xref="taxon:40121"

Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 53;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2609 CATGCTTATCATCCAGTA 2627
 1 CATGCTTATCATCCAGTA 19

Db 1 CATGCTTATCATCCAGTA 19

RESULT 101
 BD087132 19 bp DNA linear PAT 27-AUG-2002
 LOCUS Erythrovirus and application thereof.
 ACCESSION BD087132.1 GI:22632742
 VERSION JP 2001525163-A/96.
 KEYWORDS Erythrovirus
 SOURCE Erythrovirus
 ORGANISM Erythrovirus
 viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Nguyen.Q.T., Garbarg,C.A. and Auguste,V.
 TITLE Erythrovirus and application thereof
 JOURNAL Patent: JP 2001525163-A 96 11-DEC-2001;
 ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
 OS Erythrovirus
 PN JP 2001525163-A/96
 PD 11-DEC-2001
 PE 03-DEC-1998 JP 2000523317
 PR 03-DEC-1997 FR 97/15197
 PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
 C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C1201/68, PC
 G01N33/53,
 PC C12N15/00
 CC Erythrovirus and application thereof
 FH Key Location/Qualifiers
 FT source 1.19
 /organism='Erythrovirus'.
 Location/Qualifiers
 1.19
 /organism="Erythrovirus"
 /mol_type="genomic DNA"
 /db_xref="taxon:40121"

Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 53;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1747 CACTATGAAGCTGGCAA 1765
 1 CACTATGAAGCTGGCAA 19

Db 1 CACTATGAAGCTGGCAA 19

RESULT 102
 BD087133 19 bp DNA linear PAT 27-AUG-2002
 LOCUS Erythrovirus and application thereof.
 ACCESSION BD087133.1 GI:22632743
 VERSION JP 2001525163-A/97.
 KEYWORDS Erythrovirus
 SOURCE Erythrovirus
 ORGANISM Erythrovirus
 viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Nguyen.Q.T., Garbarg,C.A. and Auguste,V.
 TITLE Erythrovirus and application thereof

JOURNAL Patent: JP 2001525163-A 97 11-DEC-2001;
 ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
 OS Erythrovirus
 PN JP 2001525163-A/97
 PD 11-DEC-2001
 PE 03-DEC-1998 JP 2000523317
 PR 03-DEC-1997 FR 97/15197
 PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
 C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C1201/68, PC
 G01N33/53,
 PC C12N15/00
 CC Erythrovirus and application thereof
 FH Key Location/Qualifiers
 FT source 1.19
 /organism='Erythrovirus'.
 Location/Qualifiers
 1.19
 /organism="Erythrovirus"
 /mol_type="genomic DNA"
 /db_xref="taxon:40121"

Query Match 0.4%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 53;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2852 GTAGCAGATGAGAAATTGT 2870
 19 GTAGCAGATGAGAAATTGT 1

Db 19 GTAGCAGATGAGAAATTGT 1

RESULT 103
 AR428702 20 bp DNA linear PAT 18-DEC-2003
 LOCUS Sequence 2 from patent US 6642033.
 DEFINITION AR428702
 ACCESSION AR428702.1 GI:40188432
 VERSION AR428702.1 GI:40188432
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Lazo,A., Zhao,X., Tassello,J.A. and Gibaja,V.
 TITLE Nucleic acids for detecting parvovirus and methods of using same
 JOURNAL Patent: US 6642033-A 2 04-NOV-2003;
 Location/Qualifiers
 1.20
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 63;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGTACTTCTGACTGGGAA 433
 20 AGTACTTCTGACTGGGAA 1

Db 20 AGTACTTCTGACTGGGAA 1

RESULT 104
 AX080219 20 bp DNA linear PAT 22-FEB-2001
 LOCUS Sequence 2 from Patent WO0106019.
 DEFINITION AX080219
 ACCESSION AX080219.1 GI:13159699
 VERSION AX080219.1 GI:13159699
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Lazo,A., Zhao,J.X., Tassello,J.A. and Gibaja,V.
 TITLE Nucleic acids for detecting parvovirus and methods of using same
 JOURNAL Patent: WO 0106019-A 2 25-JAN-2001;
 V.I. Technologies, Inc. (US)

FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="VINS-3R PRIMER"

Query Match 0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 63;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGATCTCTGCTGGGAC 433
DB 20 AGACACTTCTGCTGGGAC 1

RESULT 105
LOCUS BD090940 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Method for quantifying DNA binding activity of DNA binding proteins.
ACCESSION BD090940
VERSION BD090940.1 GI:22636550
KEYWORDS JP 2001321199-A/5.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Martin M.F.K. and Liu Y.
TITLE Method for quantifying DNA binding activity of DNA binding proteins
JOURNAL Patent: JP 2001321199-A 5 20-NOV-2001;
HEALTH RESEARCH INC
OS Artificial Sequence
PN JP 2001321199-A/5
PD 20-NOV-2001
PF 02-APR-2001 JP 2001103067
PI 31-MAR-2000 US 09/539945
PC MOLLY F KUIESZ MARTIN, YUANGANG LIU
PC C1201/68, C07K14/47, C12N15/09, G01N33/15, G01N33/50, G01N33/53, PC
G01N33/566//
PC C12M1/00, C12M1/20, C12M1/34, C12N15/00
CC Method for quantifying DNA binding activity of DNA binding proteins
FH Key Location/Qualifiers
FT source 1..20
Location/Qualifiers
1..20
/organism="Artificial Sequence".
/mol_type="synthetic construct"
/db_xref="taxon:32630"

FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 63;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 948 AAAGGGAACAAAGCGGT 967
DB 1 AAAGGGAACAAAGCGGT 20

RESULT 106
LOCUS AX003437 18 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 17 from Patent WO9928439.
ACCESSION AX003437
VERSION AX003437.1 GI:9927241
KEYWORDS B19 virus
SOURCE B19 virus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE 1
AUTHORS Auguste, V., Garbarg-Chenon, A. and Nguyen, Q.T.
JOURNAL Auguste, V., Garbarg-Chenon, A. and Nguyen, Q.T.

TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 17 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
source
Location/Qualifiers
1..18
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2543 CTTAAAACTCTCCAGAC 2560
DB 1 CTTAAAACTCTCCAGAC 18

RESULT 107
LOCUS AX003454 18 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 34 from Patent WO9928439.
ACCESSION AX003454
VERSION AX003454.1 GI:9927258
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE 1
AUTHORS Auguste, V., Garbarg-Chenon, A. and Nguyen, Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 34 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
source
Location/Qualifiers
1..18
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4288 TCAGCTGTGAGTAAAT 4305
DB 1 TCAGCTGTGAGTAAAT 18

RESULT 108
LOCUS BD087053 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087053
VERSION BD087053.1 GI:22632663
KEYWORDS JP 2001525163-A/17.
SOURCE Erythrovirus
ORGANISM Erythrovirus
Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 18)
AUTHORS Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 17 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/17
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PI 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN, CHENON ANTOINE, GARBARG, VERONIQUE, AUGUSTE PC
C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C1201/68, PC
G01N33/53,

PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..18
/organism='Erythrovirus'
Location/Qualifiers
1..18
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2543 CTTAAACTCTCCAGAC 2560
Db 1 CTTAAACTCTCCAGAC 18

RESULT 109
LOCUS BD087070 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087070
VERSION BD087070.1 GI:22632680
KEYWORDS JP 2001525163-A/34.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 18)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 34 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/34
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..18
/organism='Erythrovirus'.
Location/Qualifiers
1..18
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source

Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 59;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4288 TCAGCTGTGAGTAAAT 4305
Db 1 TCAGCTGTGAGTAAAT 18

RESULT 110
LOCUS AX003429 17 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 9 from Patent WO9928439.
ACCESSION AX003429
VERSION AX003429.1 GI:9927233
KEYWORDS B19 virus
SOURCE B19 virus
ORGANISM Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.

REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,Q.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 9928439-A 9 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
Location/Qualifiers
1..17
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

FEATURES
source

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1777 TTGATTTCCCTGGAAT 1793
Db 1 TTGATTTCCCTGGAAT 17

RESULT 111
LOCUS BD087045 17 bp DNA linear PAT 27-AUG-2002
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087045
VERSION BD087045.1 GI:22632655
KEYWORDS JP 2001525163-A/9.
SOURCE Erythrovirus
ORGANISM Erythrovirus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae.
REFERENCE 1 (bases 1 to 17)
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 9 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
OS Erythrovirus
PN JP 2001525163-A/9
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
C12N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
G01N33/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH Key Location/Qualifiers
FT source 1..17
/organism='Erythrovirus'.
Location/Qualifiers
1..17
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

FEATURES
source

Query Match 0.3%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1777 TTGATTTCCCTGGAAT 1793
Db 1 TTGATTTCCCTGGAAT 17

RESULT 112
LOCUS AR046079 17 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 872 from patent US 5817796.
ACCESSION AR046079
VERSION AR046079.1 GI:5967544
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 Unclassified.
 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
 TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
 JOURNAL Patent: US 5817796-A 872 06-OCT-1996;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match: 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 90;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4379 CAAATATTTTAAAT 4395
 1 CACTATTTTAAAT 17

RESULT 113
 LOCUS 137575 17 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 588 from patent US 5612215.
 ACCSSION 137575
 VERSION 137575.1 GI:2085535
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.
 TITLE Stromelysin targeted ribozymes
 JOURNAL Patent: US 5612215-A 588 18-MAR-1997;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match: 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 90;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2738 AATGAGCTCAAGCTCG 2754
 1 AATGAGTACAGCTCG 17

RESULT 114
 LOCUS 153131 17 bp DNA linear PAT 07-OCT-1997
 DEFINITION Sequence 872 from patent US 5646042.
 ACCSSION 153131
 VERSION 153131.1 GI:2474334
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
 TITLE C-myb targeted ribozymes
 JOURNAL Patent: US 5646042-A 872 08-JUL-1997;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match: 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 90;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4379 CAAATATTTTAAAT 4395
 1 CACTATTTTAAAT 17

Db 1 CATATATTTTAAAT 17

RESULT 115
 LOCUS 194425 17 bp DNA linear PAT 01-DEC-1998
 DEFINITION Sequence 588 from patent US 5731295.
 ACCSSION 194425
 VERSION 194425.1 GI:3938895
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.
 TITLE Method of reducing stromelysin RNA via ribozymes
 JOURNAL Patent: US 5731295-A 588 24-MAR-1998;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match: 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 90;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2738 AATGAGCTCAAGCTCG 2754
 1 AATGAGTACAGCTCG 17

RESULT 116
 LOCUS ARI86282 17 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 1770 from patent US 6346398.
 ACCSSION ARI86282
 VERSION ARI86282.1 GI:20232247
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
 TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
 JOURNAL Patent: US 6346398-A 1770 12-FEB-2002;
 FEATURES Location/Qualifiers
 source 1.17
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match: 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 90;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2282 TGTACTTGTAAAAA 2298
 1 TGTAACTTGAAAAA 17

RESULT 117
 LOCUS ARI88765 17 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 4253 from patent US 6346398.
 ACCSSION ARI88765
 VERSION ARI88765.1 GI:20234730
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.

QY 2282 TGTACTTGTAAAAA 2298
 1 TGTAACTTGAAAAA 17

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6346398-A 4253 12-FEB-2002;

FEATURES Location/Qualifiers

1.17

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.3%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 90;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 703 ACCAAGGAAATATTT 719

Db 17 ACCTAAGGAAATATTT 1

RESULT 118

LOCUS AR190335 17 bp DNA linear PAT 20-APR-2002

DEFINITION Sequence 5823 from patent US 6346398.

ACCESSION AR190335

VERSION AR190335.1 GI:20236300

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6346398-A 5823 12-FEB-2002;

FEATURES Location/Qualifiers

1.17

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.3%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 90;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 703 ACCAAGGAAATATTT 719

Db 17 ACCTAAGGAAATATTT 1

RESULT 119

LOCUS AR322913 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 315 from patent US 6566127.

ACCESSION AR322913

VERSION AR322913.1 GI:33708721

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 315 20-MAY-2003;

FEATURES Location/Qualifiers

1.17

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.3%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 90;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2282 TGTTAACCTGTAATAA 2298

Db 1 TGTTAACCTGTAATAA 17

RESULT 120

LOCUS AR324618 17 bp RNA linear PAT 17-AUG-2003

DEFINITION Sequence 2020 from patent US 6566127.

ACCESSION AR324618

VERSION AR324618.1 GI:33710426

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 17)

AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

JOURNAL Patent: US 6566127-A 2020 20-MAY-2003;

FEATURES Location/Qualifiers

1.17

/organism="unknown"

/mol_type="unassigned RNA"

Query Match 0.3%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 90;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 703 ACCAAGGAAATATTT 719

Db 17 ACCTAAGGAAATATTT 1

RESULT 121

LOCUS AX099963 17 bp DNA linear PAT 02-APR-2001

DEFINITION Sequence 23 from Patent WO0120034.

ACCESSION AX099963

VERSION AX099963.1 GI:13538973

KEYWORDS

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

REFERENCE 1

AUTHORS Voss,J. and Timm,J.

TITLE Methods and compositions for the screening of cell cycle modulators

JOURNAL Patent: WO 0120034-A 23 22-MAR-2001;

FEATURES Location/Qualifiers

1.17

/organism="Mus musculus"

/mol_type="unassigned DNA"

/db_xref="taxon:10090"

Query Match 0.3%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 90;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2483 GATTAATCTTTAGAAA 2499

Db 17 GATTAATCTTTAGAAA 1

RESULT 122

LOCUS AX691246 17 bp DNA linear PAT 31-MAR-2003

DEFINITION Sequence 3978 from Patent EP1281758.

ACCESSION AX691246

VERSION AX691246.1 GI:29414182

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE 1

AUTHORS Fukayota,Y., Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

```

REFERENCE
  1
  AUTHORS
    Shannon, M., Gu, Y. and Nguyen, C.T.
  TITLE
    Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
  JOURNAL
    Patent: EP 1281758-A 3978 05-FEB-2003;
    Aeomica, Inc. (US)
  FEATURES
    source
      Location/Qualifiers
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
  0.3%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 90;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 3937 AGGTGCGGAAAGCC 3953
Db 17 AGGTGATGAAAGCC 1

RESULT 123
LOCUS
  AX724252 17 bp DNA linear PAT 08-MAY-2003
DEFINITION
  Sequence 1939 from Patent WO03025176.
ACCESSION
  AX724252
VERSION
  AX724252.1 GI:30503595
KEYWORDS
  Mus musculus (house mouse)
SOURCE
  Mus musculus
  ORGANISM
    Mus musculus
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  1
  Telerman, A., Amson, R. and Tuijnder, M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  JOURNAL
    Patent: WO 03025176-A 1939 27-MAR-2003;
    Molecular Engines Laboratories (FR)
  FEATURES
    source
      Location/Qualifiers
        1..17
        /organism="Mus musculus"
        /mol_type="unassigned DNA"
        /db_xref="taxon:10090"

Query Match
  0.3%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 90;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 78 GATTGGTGTCTTCTT 94
Db 1 GATCTGTGTCTTCTT 17

RESULT 124
LOCUS
  AX724252/c 17 bp DNA linear PAT 08-MAY-2003
DEFINITION
  Sequence 1939 from Patent WO03025176.
ACCESSION
  AX724252
VERSION
  AX724252.1 GI:30503595
KEYWORDS
  Mus musculus (house mouse)
SOURCE
  Mus musculus
  ORGANISM
    Mus musculus
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  1
  Telerman, A., Amson, R. and Tuijnder, M.
  Sequences involved in phenomena of tumour suppression, tumour
  reversion, apoptosis and/or virus resistance and their use as
  medicines
  JOURNAL
    Patent: WO 03025176-A 1939 27-MAR-2003;
    Molecular Engines Laboratories (FR)
  FEATURES
    Location/Qualifiers

```

```

source
  1..17
  /organism="Mus musculus"
  /mol_type="unassigned DNA"
  /db_xref="taxon:10090"

Query Match
  0.3%; Score 15.4; DB 1; Length 17;
  Best Local Similarity 94.1%; Pred. No. 90;
  Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 4935 AAAGAACACCAATC 4951
Db 17 AAAGAACACCGATC 1

RESULT 125
LOCUS
  AX003456/c 21 bp DNA linear PAT 07-SEP-2000
DEFINITION
  Sequence 36 from Patent WO928439.
ACCESSION
  AX003456
VERSION
  AX003456.1 GI:9927260
KEYWORDS
  B19 virus
SOURCE
  B19 virus
  ORGANISM
    B19 virus
    Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
  1
  Auguste, V., Garbarg-Chenon, A. and Nguyen, Q.T.
  Erythrovirus and its applications
  Patent: WO 928439-A 36 10-JUN-1999;
  ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
  CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
  Location/Qualifiers
    1..21
    /organism="B19 virus"
    /mol_type="unassigned DNA"
    /db_xref="taxon:10798"

Query Match
  0.3%; Score 14.4; DB 1; Length 21;
  Best Local Similarity 93.8%; Pred. No. 1.3e+02;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Cy 4383 TATTTTAAATAACT 4398
Db 21 TATTTTAAATAATT 6

RESULT 126
LOCUS
  BD087072/c 21 bp DNA linear PAT 27-AUG-2002
DEFINITION
  Erythrovirus and application thereof.
ACCESSION
  BD087072
VERSION
  BD087072.1 GI:22632682
KEYWORDS
  JP 2001525163-A/36.
SOURCE
  Erythrovirus
  ORGANISM
    Erythrovirus
    Viruses; ssDNA viruses; Parvoviridae; Parvovirinae.
    1 (bases 1 to 21)
    Nguyen, Q.T., Garbarg, C.A. and Auguste, V.
    Erythrovirus and application thereof.
    Patent: JP 2001525163-A 36 11-DEC-2001;
    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    OS
    Erythrovirus
    PN JP 2001525163-A/36
    PD 11-DEC-2001
    PF 03-DEC-1998 JP 2000523317
    PR 03-DEC-1997 FR 97/15197
    PI QUANG TRI NGUYEN, CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
    C1N1S/09, A6IK39/12, A6IK48/00, C07K14/015, C07K16/08, C12Q1/68, PC
    G01N33/53.
    PC C12N15/00
    CC Erythrovirus and application thereof
    FH Key Location/Qualifiers
    FT source
      1..21
      /organism="Erythrovirus".

```

FEATURES
source Location/Qualifiers
1..21
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.3%; Score 14.4; DB 1; Length 21;
Best Local Similarity 93.8%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4383 TATTTTAAATAACT 4398
DB 21 TATTTTAAATAATAT 6

RESULT 127
AX003481/c 30 bp DNA linear PAT 07-SEP-2000
LOCUS
DEFINITION Sequence 61 from Patent WO928439.
ACCESSION AX003481
VERSION AX003481.1 GI:9927334
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
REFERENCE 1
AUTHORS Auguste,V., Garbarg-Chenon,A. and Nguyen,O.T.
TITLE Erythrovirus and its applications
JOURNAL Patent: WO 928439-A 61 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG
CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
source Location/Qualifiers
1..30
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

Query Match 0.3%; Score 13.2; DB 1; Length 30;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3769 AATGTACAACCTTTGTA 3786
DB 30 AATCTACAAACTTTGTA 13

RESULT 128
BD087097/c 30 bp DNA linear PAT 27-AUG-2002
LOCUS
DEFINITION Erythrovirus and application thereof.
ACCESSION BD087097
VERSION BD087097.1 GI:22632707
KEYWORDS JP 2001525163-A/61.
SOURCE Erythrovirus
ORGANISM Erythrovirus
REFERENCE 1
AUTHORS Nguyen,Q.T., Garbarg,C.A. and Auguste,V.
TITLE Erythrovirus and application thereof
JOURNAL Patent: JP 2001525163-A 61 11-DEC-2001;
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
COMMENT OS Erythrovirus
PN JP 2001525163-A/61
PD 11-DEC-2001
PF 03-DEC-1998 JP 2000523317
PR 03-DEC-1997 FR 97/15197
PI QUANG TRI NGUYEN,CHENON ANTOINE GARBARG,VERONIQUE AUGUSTE PC
CI2N15/09,A61K39/12,A61K48/00,C07K14/015,C07K16/08,C12Q1/68, PC
GOIN3/53,
PC C12N15/00
CC Erythrovirus and application thereof
FH key Location/Qualifiers
FT source 1..30

FEATURES
source Location/Qualifiers
1..30
/organism="Erythrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:40121"

Query Match 0.3%; Score 13.2; DB 1; Length 30;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3769 AATGTACAACCTTTGTA 3786
DB 30 AATCTACAAACTTTGTA 13

RESULT 129
A87941/c 14 bp DNA linear PAT 22-JAN-2000
LOCUS
DEFINITION Sequence 89 from Patent WO9833504.
ACCESSION A87941
VERSION A87941.1 GI:6736511
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 89 06-AUG-1998;
BIOGHOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source Location/Qualifiers
1..14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.3%; Score 13; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3730 CCCAGAAACCTTA 3742
DB 14 CCCAGAAACCTTA 2

RESULT 130
A89908/c 14 bp DNA linear PAT 22-JAN-2000
LOCUS
DEFINITION Sequence 89 from Patent EP0856579.
ACCESSION A89908
VERSION A89908.1 GI:6738422
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 14)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 89 05-AUG-1998;
BIOGHOSTIK GES (DE)
FEATURES
source Location/Qualifiers
1..14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.3%; Score 13; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3730 CCCAGAAACCTTA 3742

DB 14 CCCAGAAACCTA 2

RESULT 131

BD065454/c 14 bp DNA linear PAT 27-AUG-2002

LOCUS An antisense oligonucleotide preparation method.

DEFINITION BD065454

ACCESSION BD065454.1 GI:22611057

VERSION JP 2001511000-A/89.

KEYWORDS unidentified

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 14)

AUTHORS Schlingensiepen,K.H. and Brysch,W.

TITLE An antisense oligonucleotide preparation method

JOURNAL Patent: JP 2001511000-A 89 07-AUG-2001;

COMMENT BIOLOGISTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH

OS Unknown

PN JP 2001511000-A/89

PD 07-AUG-2001

PR 30-JAN-1998 JP 1998532533

PI 31-JAN-1997 EP 97101531.8

PC C12N15/11,C07H21/04,A61K31/70

CC An antisense oligonucleotide preparation method FH

Location/Qualifiers

FT source 1..14

Location/Qualifiers

1..14

/organism="unidentified"

/mol_type="genomic DNA"

/db_xref="taxon:32644"

Query Match 0.3%; Score 13; DB 1; Length 14;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 14 CCCAGAAACCTA 2

Search completed: April 22, 2004, 06:30:17

Job time : 8 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 22, 2004, 06:32:50 ; Search time 12 Seconds
(without alignments)
3.595 Million cell updates/sec

Title: us-09-555-640-1
Perfect score: 5028
Sequence: 1 gacgtcacaggaatgacgt.....acgtcatctcctgtgacgtc 5028

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 270 seqs, 4290 residues

Total number of hits satisfying chosen parameters: 540

Minimum DB seq length: 10
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 291 summaries

Database : rng.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	30	0.6	30	1	AAx81642
2	30	0.6	30	1	AAx81647
3	30	0.6	30	1	AAx81652
4	30	0.6	30	1	AAx81662
5	30	0.6	30	1	AAx81632
6	30	0.6	30	1	AAx81627
7	29	0.6	29	1	AAx81589
8	29	0.6	29	1	AAx81626
9	28	0.6	28	1	AAx81643
10	27.4	0.5	28	1	ACCA3286
11	27	0.5	28	1	ACCA3294
12	27	0.5	28	1	ACCA3273
13	26	0.5	26	1	AAx81602
14	26	0.5	26	1	AAx81614
15	26	0.5	26	1	AAx81619
16	25	0.5	25	1	AAx81598
17	25	0.5	25	1	ACCA3288
18	24.4	0.5	26	1	AAx81630
19	24	0.5	24	1	AAx81601
20	24	0.5	24	1	AAx81618
21	23.4	0.5	25	1	ACCA3287
22	23.4	0.5	25	1	ACCA3309
23	23	0.5	23	1	AAx81613
24	23	0.5	23	1	AAx81615
25	23	0.5	23	1	AAx81624
26	23	0.5	23	1	AAx81621
27	23	0.5	23	1	AAx81588
28	23	0.5	23	1	AAx81596
29	23	0.5	23	1	AAx81611
30	23	0.5	23	1	AAx81651
31	22.4	0.4	24	1	ABZ59580
32	22	0.4	22	1	AAx81650
33	22	0.4	22	1	AAx81610

34	22	0.4	22	1	AAH03067	Microorganism dete
35	22	0.4	22	1	AAH75351	Parvovirus B19 PCR
36	22	0.4	22	1	ACCA3300	Nucleotide sequenc
37	22	0.4	22	1	ACCA33280	Nucleotide sequenc
38	22	0.4	22	1	ADA27491	Microorganism sequ
39	21.4	0.4	23	1	AAH53613	B19-reverse primer
40	21	0.4	21	1	AAx81672	Probe used to isol
41	21	0.4	21	1	AAx81622	PCR primer used to
42	21	0.4	21	1	AAx81593	PCR primer used to
43	21	0.4	21	1	AAx81628	PCR primer used to
44	21	0.4	21	1	AAx81628	Microorganism dete
45	21	0.4	21	1	AAH03068	Nucleotide sequenc
46	21	0.4	21	1	ACCA3302	Nucleotide sequenc
47	21	0.4	21	1	ACCA3303	Nucleotide sequenc
48	21	0.4	21	1	ACCA3304	Nucleotide sequenc
49	21	0.4	21	1	ADA27492	Microorganism sequ
50	20	0.4	20	1	AAx81617	PCR primer used to
51	20	0.4	20	1	AAx81591	PCR primer used to
52	20	0.4	20	1	AAx81600	PCR primer used to
53	20	0.4	20	1	AAx81669	PCR primer used to
54	20	0.4	20	1	AAx81671	PCR primer used to
55	20	0.4	20	1	AAx81674	PCR primer used to
56	20	0.4	20	1	AAx81592	PCR primer used to
57	20	0.4	20	1	AAH53611	Parvovirus B19 PCR
58	20	0.4	20	1	AAH75352	PCR primer used to
59	19	0.4	19	1	AAx81667	PCR primer used to
60	19	0.4	19	1	AAx81604	PCR primer used to
61	19	0.4	19	1	AAx81606	PCR primer used to
62	19	0.4	19	1	AAx81673	PCR primer used to
63	19	0.4	19	1	AAx81670	PCR primer used to
64	18.4	0.4	20	1	AAH57981	Human parvovirus B
65	18.4	0.4	20	1	AAH21304	3' primer used to
66	18.4	0.4	20	1	ABZ59579	Human parvovirus B
67	18.4	0.4	20	1	ACCA3289	Nucleotide sequenc
68	18.4	0.4	20	1	AAx81603	PCR primer used to
69	18	0.4	18	1	AAx81620	PCR primer used to
70	18	0.4	18	1	AAx81620	Nucleotide sequenc
71	18	0.4	18	1	ACCA3312	Nucleotide sequenc
72	18	0.4	18	1	ACCA3311	Nucleotide sequenc
73	17.4	0.3	19	1	AAH95711	Parvovirus strain
74	17.4	0.3	19	1	ABZ59601	Human parvovirus B
75	17	0.3	17	1	AAx81595	PCR primer used to
76	16.4	0.3	18	1	AAQ23988	VP-1/VP-2 gene pri
77	16.4	0.3	18	1	ACCA3310	Nucleotide sequenc
78	15.4	0.3	17	1	AAH81447	Human c-myc hamster
79	15.4	0.3	17	1	AAH63956	Rabbit stromelysin
80	15.4	0.3	17	1	AAH73073	Mouse Flk-1 VEGF r
81	15.4	0.3	17	1	AAH71503	Human KDR VEGF rec
82	15.4	0.3	17	1	AAH69020	Human Flt1 VEGF re
83	15.4	0.3	17	1	AAH57372	Murine Cdc25A intr
84	15.4	0.3	17	1	ADH02992	Human MD24 scanlin
85	15.4	0.3	17	1	ACCA4692	Murine oligonucleo
86	15.4	0.3	17	1	ACCA4692	Murine oligonucleo
87	14.6	0.3	15	1	AAH42963	Human cerberus 1 (
88	14.6	0.3	15	1	AAH42984	Human cerberus 1 (
89	14.6	0.3	15	1	AAH24984	Human AANAT gene p
90	14.6	0.3	15	1	AAH81622	PCR primer used to
91	13.6	0.3	15	1	AAH45213	Human PON-1 gene p
92	13.6	0.3	15	1	ABA99286	Human ALDH5 allele
93	13.6	0.3	15	1	AAH99335	Aldehyde dehydroge
94	13.2	0.3	30	1	AAH81647	Probe used to isol
95	13	0.3	13	1	ABCA4830	Oligonucleotide SE
96	13	0.3	13	1	ABCA2817	Oligonucleotide SE
97	13	0.3	13	1	ABCA5713	Oligonucleotide SE
98	13	0.3	13	1	ABCA87118	Oligonucleotide SE
99	13	0.3	13	1	ABCA87968	Oligonucleotide SE
100	13	0.3	13	1	ABH74977	Oligonucleotide SE
101	13	0.3	13	1	ABH02517	Oligonucleotide SE
102	13	0.3	13	1	ABH83464	Oligonucleotide SE
103	13	0.3	13	1	ABH45580	Oligonucleotide SE
104	13	0.3	13	1	ABH61839	Oligonucleotide SE
105	13	0.3	13	1	ABH93518	Oligonucleotide SE
106	13	0.3	13	1	ABH39196	Oligonucleotide SE

Best Local Similarity 100.0%; Pred. No. 3.7;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2306 ACCGTCTCGATTACAAAGTTTGTAGATT 2335
1 ACCTGCTCGATTACAAAGTTTGTAGATT 30

RESULT 3
AAx81652

ID AAX81652 standard; DNA; 30 BP.

AC AAX81652;

DT 26-AUG-1999 (first entry)

DE Probe used to isolate erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;

KM erythrovirus screening; typing; immunoassay; probe; ss.

OS Synthetic.

OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.

PS Claim 3; Page 38; 80pp; French.

XX AAX81630-X81666 represent probes used to isolate erythrovirus V9

CC polynucleotide sequences. Probes and primers derived from erythrovirus V9

CC polynucleotide sequences (AAX81580) can be used for differential

CC diagnosis of erythrovirus (parvovirus) infections by a combination of

CC amplification and hybridisation assay. The probes can also be used to

CC assess susceptibility to erythrovirus infection and for erythrovirus

CC screening and typing. The antibodies can be used in immunoassays for

CC diagnosis of erythrovirus V9 infections

CC Sequence 30 BP; 11 A; 7 C; 6 G; 6 T; 0 U; 0 Other;

QY 2617 ATCATCCAGTAACAGTAGTGCAACCTAG 2646
1 ATCATCCAGTAACAGTAGTGCAACCTAG 30

RESULT 4
AAX81662
ID AAX81662 standard; DNA; 30 BP.

AC AAX81662;

DT 26-AUG-1999 (first entry)

DE Probe used to isolate erythrovirus V9 nucleotide sequences.

KM Erythrovirus V9; differential diagnosis; parvovirus; infection;

KM erythrovirus screening; typing; immunoassay; probe; ss.

OS Synthetic.

OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

XX Erythrovirus V9 and its nucleic acid sequences - can be used in the

PT diagnosis of its infections.

PS Claim 3; Page 41; 80pp; French.

XX AAX81630-X81666 represent probes used to isolate erythrovirus V9

CC polynucleotide sequences. Probes and primers derived from erythrovirus V9

CC polynucleotide sequences (AAX81580) can be used for differential

CC diagnosis of erythrovirus (parvovirus) infections by a combination of

CC amplification and hybridisation assay. The probes can also be used to

CC assess susceptibility to erythrovirus infection and for erythrovirus

CC screening and typing. The antibodies can be used in immunoassays for

CC diagnosis of erythrovirus V9 infections

CC Sequence 30 BP; 11 A; 4 C; 8 G; 7 T; 0 U; 0 Other;

QY 4115 TATCCGACAGGGGTAGCAAGATTTCCAAT 4144
1 TATCCGACAGGGGTAGCAAGATTTCCAAT 30

RESULT 5
AAX81632
ID AAX81632 standard; DNA; 30 BP.

AC AAX81632;

DT 26-AUG-1999 (first entry)

DE Probe used to isolate erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;

KM erythrovirus screening; typing; immunoassay; probe; ss.

OS Synthetic.

OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI, 1999-349543/30.
XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
PS Claim 3, Page 32, 80pp; French.
XX
XX AAX81630-X81666 represent probes used to isolate erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections
XX
SQ Sequence 30 BP, 11 A; 4 C; 1 G; 14 T; 0 U; 0 Other;
Query Match 0.6%; Score 30; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.7;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 301 ATTTATACACTTAAATTACTACATG 330
DB 1 ATTTATACACTTAAATTACTACATG 30
RESULT 6
AAX81627
ID AAX81627 standard; DNA; 30 BP.
XX
AC AAX81627;
XX
DT 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
OS Erythrovirus.
XX
PN FR2771751-A1.
XX
PD 04-JUN-1999.
XX
PF 03-DEC-1997; 97FR-00015197.
XX
PR 03-DEC-1997; 97FR-00015197.
XX
PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI Nguyen QT, Garbarg CA, Auguste V;
XX
DR WPI, 1999-349543/30.
XX
PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
XX
PS Claim 3, Page 31, 80pp; French.
XX
XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections
XX
SQ Sequence 30 BP, 10 A; 9 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 29; DB 1; Length 30;
Best Local Similarity 100.0%; Pred. No. 3.7;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4655 GCCAAAAGCCGTGTGACCCATTGTAAACA 4684
DB 1 GCCAAAAGCCGTGTGACCCATTGTAAACA 30
RESULT 7
AAX81589
ID AAX81589 standard; DNA; 29 BP.
XX
AC AAX81589;
XX
DT 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
OS Erythrovirus.
XX
PN FR2771751-A1.
XX
PD 04-JUN-1999.
XX
PF 03-DEC-1997; 97FR-00015197.
XX
PR 03-DEC-1997; 97FR-00015197.
XX
PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI Nguyen QT, Garbarg CA, Auguste V;
XX
DR WPI, 1999-349543/30.
XX
PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
XX
PS Claim 3, Page 22, 80pp; French.
XX
XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections
XX
SQ Sequence 29 BP, 12 A; 1 C; 8 G; 8 T; 0 U; 0 Other;
Query Match 0.6%; Score 29; DB 1; Length 29;
Best Local Similarity 100.0%; Pred. No. 4.8;
Matches 29; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 718 TTTAGAGATGAGAGAGCTTTATAGAAA 746
DB 1 TTTAGAGATGAGAGAGCTTTATAGAAA 29
RESULT 8
AAX81626
ID AAX81626 standard; DNA; 29 BP.
XX
AC AAX81626;
XX
DT 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM Erythrovirus screening; typing; immunoassay; PCR primer; ss.
 OS Synthetic.
 OS Erythrovirus.
 XX
 PN FR2771751-A1.
 XX
 PD 04-JUN-1999.
 XX
 PF 03-DEC-1997; 97FR-00015197.
 XX
 PR 03-DEC-1997; 97FR-00015197.
 XX
 PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
 XX
 PI Nguyen QT, Garbarg CA, Auguste V;
 XX
 DR WPI; 1999-349543/30.
 XX
 PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 XX
 PS Claim 3; Page 31; 80pp; French.
 XX
 CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX
 SQ Sequence 29 BP; 11 A; 3 C; 9 G; 6 T; 0 U; 0 Other;
 XX
 QY
 Db 4625 GGATATGAAAAGCCTGAGAAATTGTGAC 4653
 1 GGATATGAAAAGCCTGAGAAATTGTGAC 29
 XX
 RESULT 9
 AAX81643
 ID AAX81643 standard; DNA; 28 BP.
 XX
 AC AAX81643;
 XX
 DT 26-AUG-1999 (first entry)
 XX
 DE Probe used to isolate erythrovirus V9 nucleotide sequences.
 XX
 KM Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; probe; ss.
 XX
 OS Synthetic.
 OS Erythrovirus.
 XX
 PN FR2771751-A1.
 XX
 PD 04-JUN-1999.
 XX
 PF 03-DEC-1997; 97FR-00015197.
 XX
 PR 03-DEC-1997; 97FR-00015197.
 XX
 PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
 XX
 PI Nguyen QT, Garbarg CA, Auguste V;
 XX

XX WPI; 1999-349543/30.
 DR Erythrovirus V9 and its nucleic acid sequences - can be used in the
 XX diagnosis of its infections.
 PT
 PT diagnosis of its infections.
 XX
 PS Claim 3; Page 35; 80pp; French.
 XX
 CC AAX81630-X81666 represent probes used to isolate erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX
 SQ Sequence 28 BP; 11 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 QY
 Db 1733 CACAAAGCTGAGCCACTATGAAACTG 1760
 1 CACAAAGCTGAGCCACTATGAAACTG 28
 XX
 RESULT 10
 ACC43286
 ID ACC43286 standard; DNA; 29 BP.
 XX
 AC ACC43286;
 XX
 DT 27-OCT-2003 (revised)
 XX
 DT 11-AUG-2003 (first entry)
 XX
 DE Nucleotide sequence of a PCR primer for human parvovirus B19 DNA.
 XX
 KM Parvovirus detection; PCR; primer; ss.
 XX
 OS B19 virus.
 XX
 PN WC2003020742-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 30-AUG-2002; 2002WC-US027734.
 XX
 PR 31-AUG-2001; 2001US-0316691P.
 XX
 PA (GENP-) GEN-PROBE INC.
 XX
 PI Brenzano ST, Batranita-Kaminsky M, Hasselkus-Light CS, Kolik DP;
 XX
 DR WPI; 2003-300859/29.
 XX
 KM Detecting human parvovirus B19 nucleic acid in biological sample involves
 KM carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.
 PT
 PT
 XX
 PS Claim 1; Page 43; 54pp; English.
 XX
 CC The present sequence represents a primer for parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.
 CC The method is useful for detecting human parvovirus B19 nucleic acid in
 CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 29 BP; 7 A; 8 C; 2 G; 12 T; 0 U; 0 Other;
 XX

Query Match 0.5%; Score 27.4; DB 1; Length 29;
 Best Local Similarity 96.6%; Pred. No. 8.2;
 Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2551 CTCTCCAGACCTATATAGTCATCTTTC 2579
 |||||
 DB 1 CTCTCCAGACTTATATAGTCATCTTTC 29

RESULT 11
 ACC43294
 ID ACC43294 standard; DNA; 28 BP.
 XX
 AC ACC43294;

XX 27-OCT-2003 (revised)
 DT 11-AUG-2003 (first entry)
 XX

DE Nucleotide sequence of a target from human parvovirus B19 DNA.

XX Parvovirus detection; ss.

XX B19 virus.

XX MO2003020742-AL.

PD 13-MAR-2003.

PF 30-AUG-2002; 2002WO-US027734.

XX 31-AUG-2001; 2001US-0316691P.

XX (GENP-) GEN-PROBE INC.

PI Brentano ST, Batranina-Kaminsky M, Hasselkus-Light CS, Kolk DP;

DR WPI; 2003-300859/29.

PT Detecting human parvovirus B19 nucleic acid in biological sample involves
 PT carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.

XX Disclosure; Page 44; 54pp; English.

XX The present sequence represents a target from parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.
 CC The method is useful for detecting human parvovirus B19 nucleic acid in
 CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)

XX Sequence 28 BP; 9 A; 5 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 27; DB 1; Length 28;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2786 AGGATTCATGACTTTAGTATAGCCAA 2812
 |||||
 DB 1 AGGATTCATGACTTTAGTATAGCCAA 27

RESULT 12
 ACC43273/c
 ID ACC43273 standard; DNA; 28 BP.
 XX
 AC ACC43273;

XX 27-OCT-2003 (revised)
 DT 11-AUG-2003 (first entry)

XX Nucleotide sequence of a capture probe for human parvovirus B19 DNA.
 DE Parvovirus detection; probe; ss.
 XX
 KM Parvovirus detection; probe; ss.
 XX

Qy B19 virus.
 |||||
 DB 1 MO2003020742-AL.

PD 13-MAR-2003.
 PF 30-AUG-2002; 2002WO-US027734.
 XX
 PR 31-AUG-2001; 2001US-0316691P.

XX (GENP-) GEN-PROBE INC.

PI Brentano ST, Batranina-Kaminsky M, Hasselkus-Light CS, Kolk DP;

DR WPI; 2003-300859/29.

PT Detecting human parvovirus B19 nucleic acid in biological sample involves
 PT carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.

XX Claim 1; Page 40; 54pp; English.

XX The present sequence represents a probe for parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.
 CC The method is useful for detecting human parvovirus B19 nucleic acid in
 CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)

XX Sequence 28 BP; 8 A; 6 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 27; DB 1; Length 28;
 Best Local Similarity 100.0%; Pred. No. 8.6;
 Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2786 AGGATTCATGACTTTAGTATAGCCAA 2812
 |||||
 DB 28 AGGATTCATGACTTTAGTATAGCCAA 2

RESULT 13
 AAX81602
 ID AAX81602 standard; DNA; 26 BP.
 XX
 AC AAX81602;

XX 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9, differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.
 OS Erythrovirus.

XX FR2771751-AL.

XX 04-JUN-1999.

XX 03-DEC-1997; 97FR-00015197.

XX 03-DEC-1997; 97FR-00015197.

XX (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;
 XX WPI, 1999-349543/30.
 XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 XX
 PS Claim 3; Page 25; 80pp; French.
 XX
 CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX
 SQ Sequence 26 BP; 8 A; 4 C; 5 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 9.9;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2293 AAAAATGCTTACCTGCTGATT 2318
 DB 1 AAAAATGCTTACCTGCTGATT 26
 RESULT 14
 AAX81614
 ID AAX81614 standard; DNA; 26 BP.
 AC AAX81614;
 XX 26-AUG-1999 (first entry)
 DT
 XX
 DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
 KW Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
 XX
 OS Synthetic.
 OS Erythrovirus.
 PN FR2771751-A1.
 PD 04-JUN-1999.
 PF 03-DEC-1997; 97FR-00015197.
 XX 03-DEC-1997; 97FR-00015197.
 PR (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
 PA
 XX
 PI Nguyen QT, Garbarg CA, Auguste V;
 XX WPI, 1999-349543/30.
 DR Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 XX
 PS Claim 3; Page 28; 80pp; French.
 XX
 CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

SQ Sequence 26 BP; 6 A; 7 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 9.9;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 3032 TCTGCAAGCCAGCAGCTGTCAGG 3057
 DB 1 TCTGCAAGCCAGCAGCTGTCAGG 26
 RESULT 15
 AAX81619
 ID AAX81619 standard; DNA; 26 BP.
 AC AAX81619;
 XX 26-AUG-1999 (first entry)
 DT
 XX
 DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
 KW Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
 XX
 OS Synthetic.
 OS Erythrovirus.
 PN FR2771751-A1.
 PD 04-JUN-1999.
 PF 03-DEC-1997; 97FR-00015197.
 XX 03-DEC-1997; 97FR-00015197.
 PR (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
 PA
 XX
 PI Nguyen QT, Garbarg CA, Auguste V;
 XX WPI, 1999-349543/30.
 DR Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 XX
 PS Claim 3; Page 29; 80pp; French.
 XX
 CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX
 SQ Sequence 26 BP; 13 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 9.9;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4133 AGATTTCAAATGAAAAGAACGCT 4158
 DB 1 AGATTTCAAATGAAAAGAACGCT 26
 RESULT 16
 AAX81598
 ID AAX81598 standard; DNA; 25 BP.
 AC AAX81598;
 XX 26-AUG-1999 (first entry)
 DT

```

XX PCR primer used to amplify erythrovirus V9 nucleotide sequences.
DE
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
XX Synthetic.
OS Erythrovirus.
XX
XX FR2771751-A1.
PN
XX
XX 04-JUN-1999.
PD
XX
XX 03-DEC-1997; 97FR-00015197.
PF
XX
XX 03-DEC-1997; 97FR-00015197.
PR
XX
XX (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
PA
XX
XX Nguyen QT, Garbarg CA, Auguste V;
PI
XX
XX WPI; 1999-349543/30.
DR
XX
XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
XX
XX Claim 3; Page 24; 80pp; French.
RS
XX
XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections
XX
SQ Sequence 25 BP; 5 A; 11 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1935 TGAACCCCGCGCTAGTAGGCC 1959
Db 1 TGAACCCCGCGCTAGTAGGCC 25

RESULT 17
ACCA3289
ID ACCA3289 standard; DNA; 25 BP.
XX
XX ACCA3289;
AC
XX
XX 27-OCT-2003 (revised)
DT 11-AUG-2003 (first entry)
XX
XX Nucleotide sequence of a capture probe for human parvovirus B19 DNA.
DE
XX
XX Parvovirus detection; probe; ss.
KM
XX
XX B19 virus.
OS
XX
XX WO2003020742-A1.
PN
XX
XX 13-MAR-2003.
PD
XX
XX 30-AUG-2002; 2002WO-US027734.
PF
XX
XX 31-AUG-2001; 2001US-0316691P.
PR
XX
XX (GENP-) GEN-PROBE INC.
PA
XX

```

```

PI Brentano ST, Batranina-Kaminsky M, Hasselkus-Light CS, Kolk DP;
XX WPI; 2003-300859/29.
XX
XX Detecting human parvovirus B19 nucleic acid in biological sample involves
PT carrying out amplification reaction of parvovirus B19 nucleic acid using
XX human parvovirus specific nucleic acid oligomers.
XX
XX Claim 1; Page 43; 54pp; English.
PS
XX
XX The present sequence represents a probe for parvovirus B19 DNA. It is
CC used in the method of the invention. The specification describes a method
CC of detecting human parvovirus B19 nucleic acid in a biological sample.
CC The method comprises amplifying in vitro a portion of human parvovirus
CC B19 nucleic acid, and detecting an amplified product using a labeled
CC detection probe that hybridizes specifically with the amplified product.
CC The method is useful for detecting human parvovirus B19 nucleic acid in
CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)
XX
SQ Sequence 25 BP; 6 A; 10 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2589 GACAGTTATCTGACCAACCCCATGC 2613
Db 1 GACAGTTATCTGACCAACCCCATGC 25

RESULT 18
AAX57350
ID AAX57350 standard; DNA; 26 BP.
XX
XX AAX57350;
AC
XX
XX 22-JUL-1999 (first entry)
DT
XX
XX Parvovirus detecting oligonucleotide 3.
DE
XX
XX Detection; viral concentration; blood plasma; serum; PCR sensitivity;
KM extraction; amplification; detection; PCR primer; ss.
XX
XX Synthetic.
OS Parvovirus.
XX
XX Key Location/Qualifiers
FH modified_base 1
FT /*tag= a
FT /note= "5'-end modified by FAM group"
FT modified_base 26
FT /*tag= b
FT /note= "3'-end modified by TAMRA group"
XX
XX BP922771-A2.
PN
XX
XX 16-JUN-1999.
PD
XX
XX 03-NOV-1998; 98EP-00120799.
PF
XX
XX 28-NOV-1997; 97DE-01052898.
PR
XX
XX (CENT-) CENTEON PHARMA GMBH.
PA
XX
XX Weimer T, Groener A;
PI
XX
XX WPI; 1999-329400/28.
DR
XX
XX Process to detect high concentrations of virus in blood plasma or serum,
PT by restricting the sensitivity of PCR.
XX
XX Example 1; Page 7; 8pp; German.
XX

```

CC This invention describes a novel method for for detection of high viral
 CC concentrations in blood plasma or serum by restriction of PCR sensitivity
 CC through suboptimal nucleic acid extraction, amplification and detection
 CC conditions. The method described is used to detect high concentrations of
 CC parvovirus in the blood plasma or serum of humans. The method detects
 CC parvovirus DNA with a content in humans of greater than 106 to 107 genome
 CC equivalents
 CC
 SQ Sequence 26 BP; 5 A; 1 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.5%; Score 24.4; DB 1; Length 26;
 Best Local Similarity 96.2%; Pred. No. 17;
 Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1430 TGGTGGTCTGGAGTGAAGCATTTATT 1455
 DB 1 TGGTGGTCTGGAGTGAAGCATTTATT 26

RESULT 19
 AAX81601
 ID AAX81601 standard; DNA; 24 BP.

AC AAX81601;
 DT 26-AUG-1999 (first entry)

XX PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

XX FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.

PS Claim 3; Page 25; 80pp; French.

CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

XX Sequence 24 BP; 7 A; 1 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 16;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2194 GCTTGGTATATGATGGAATTT 2217
 DB 1 GCTTGGTATATGATGGAATTT 24

RESULT 20

AAX81618
 ID AAX81618 standard; DNA; 24 BP.

AC AAX81618;

DT 26-AUG-1999 (first entry)

XX PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.

PS Claim 3; Page 29; 80pp; French.

CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

XX Sequence 24 BP; 10 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 16;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4106 GACAAAGATATCAGCAGGCGTA 4129
 DB 1 GACAAAGATATCAGCAGGCGTA 24

RESULT 21

ACC43287
 ID ACC43287 standard; DNA; 25 BP.

AC ACC43287;

DT 27-OCT-2003 (revised)

DT 11-AUG-2003 (first entry)

DE Nucleotide sequence of a PCR primer for human parvovirus B19 DNA.

XX Parvovirus detection; PCR; primer; ss.

OS B19 virus.

PN W02003020742-A1.

PD 13-MAR-2003.
 XX 30-AUG-2002; 2002WO-US027734.
 XX 31-AUG-2001; 2001US-0316691P.
 XX (GENP-) GEN-PROBE INC.
 PA Brentano ST, Batranina-Kaminsky M, Hasselkus-Light CS, Kolk DP;
 PI WPI; 2003-300859/29.
 DR
 XX
 PT Detecting human parvovirus B19 nucleic acid in biological sample involves
 PT carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.
 XX
 XX Claim 1; Page 43; 54pp; English.
 XX
 CC The present sequence represents a primer for parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.
 CC The method is useful for detecting human parvovirus B19 nucleic acid in
 CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 25 BP; 7 A; 7 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 23.4; DB 1; Length 25;
 Best Local Similarity 96.0%; Pred. No. 21;
 Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2551 CTCTCCAGACCTTATATAGTCATCAT 2575
 DB 1 CTCTCCAGACCTTATATAGTCATCAT 25
 RESULT 22
 ACC43309
 ID ACC43309 standard; DNA; 25 BP.
 AC ACC43309;
 XX
 XX 27-OCT-2003 (revised)
 DT 11-AUG-2003 (first entry)
 DE Nucleotide sequence of a probe for human parvovirus B19 DNA.
 XX
 XX Parvovirus detection; probe; ss.
 KM
 XX B19 virus.
 OS
 XX WO2003020742-A1.
 PN
 XX
 PD 13-MAR-2003.
 PD 30-AUG-2002; 2002WO-US027734.
 PF 31-AUG-2001; 2001US-0316691P.
 PR (GENP-) GEN-PROBE INC.
 PA Brentano ST, Batranina-Kaminsky M, Hasselkus-Light CS, Kolk DP;
 PI WPI; 2003-300859/29.
 DR
 XX
 PT Detecting human parvovirus B19 nucleic acid in biological sample involves
 PT carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.
 XX
 XX Claim 1; Page 33; 54pp; English.

CC The present sequence represents a probe for parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.
 CC The method is useful for detecting human parvovirus B19 nucleic acid in
 CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 25 BP; 7 A; 7 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 23.4; DB 1; Length 25;
 Best Local Similarity 96.0%; Pred. No. 21;
 Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2551 CTCTCCAGACCTTATATAGTCATCAT 2575
 DB 1 CTCTCCAGACCTTATATAGTCATCAT 25
 RESULT 23
 AAX81613
 ID AAX81613 standard; DNA; 23 BP.
 AC AAX81613;
 XX
 XX 26-AUG-1999 (first entry)
 DT
 DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
 XX
 XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
 XX
 OS Synthetic.
 OS Erythrovirus.
 XX
 PN FR2771751-A1.
 PN
 XX
 PD 04-JUN-1999.
 PD 03-DEC-1997; 97PR-00015197.
 PF 03-DEC-1997; 97PR-00015197.
 PR (ASST-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
 PA Nguyen QT, Garbary CA, Auguste V;
 PI WPI; 1999-349543/30.
 DR
 XX
 PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 PT
 XX
 XX Claim 3; Page 28; 80pp; French.
 PS
 XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX
 SQ Sequence 23 BP; 10 A; 8 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2990 TACAACGCTCAGAAAAATACCC 3012
 DB 1 TACAACGCTCAGAAAAATACCC 23

```

RESULT 24
AAx81615
ID AAX81615 standard; DNA; 23 BP.
XX
XX
AC AAX81615;
XX
XX
DT 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
XX Erythrovirus.
XX
PN FR2771751-A1.
XX
PD 04-JUN-1999.
XX
PF 03-DEC-1997; 97FR-00015197.
XX
PR 03-DEC-1997; 97FR-00015197.
XX
PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI Nguyen QT, Garbarg CA, Auguste V;
XX
DR WPI; 1999-349543/30.
XX
PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
XX
XX
PS Claim 3; Page 28; 80pp; French.
XX
CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections
XX
SQ Sequence 23 BP; 7 A; 1 C; 2 G; 13 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3284 TTAGATTTAATGCTTTAAATTT 3306
DB 1 TTAGATTTAATGCTTTAAATTT 23

RESULT 25
AAx81624
ID AAX81624 standard; DNA; 23 BP.
XX
XX
AC AAX81624;
XX
XX
DT 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
XX Erythrovirus.
XX

```

```

PN FR2771751-A1.
XX
XX
PD 04-JUN-1999.
XX
XX
PF 03-DEC-1997; 97FR-00015197.
XX
XX
PR 03-DEC-1997; 97FR-00015197.
XX
XX
PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI Nguyen QT, Garbarg CA, Auguste V;
XX
DR WPI; 1999-349543/30.
XX
PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
XX
XX
PS Claim 3; Page 30; 80pp; French.
XX
CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections
XX
SQ Sequence 23 BP; 7 A; 3 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4433 ATGGGAATTACTACTTACTTCA 4455
DB 1 ATGGGAATTACTACTTACTTCA 23

RESULT 26
AAx81621
ID AAX81621 standard; DNA; 23 BP.
XX
XX
AC AAX81621;
XX
XX
DT 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
XX Erythrovirus.
XX
PN FR2771751-A1.
XX
PD 04-JUN-1999.
XX
PF 03-DEC-1997; 97FR-00015197.
XX
PR 03-DEC-1997; 97FR-00015197.
XX
PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI Nguyen QT, Garbarg CA, Auguste V;
XX
DR WPI; 1999-349543/30.
XX
PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
XX
XX
PS Claim 3; Page 29; 80pp; French.
XX

```


XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX

Sequence 23 BP; 9 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4313 TTGATGACAGCTTTAAACTCA 4335
 DB 1 TTGATGACAGCTTTAAACTCA 23

RESULT 27
 AAX81588

ID AAX81588 standard; DNA; 23 BP.

AC AAX81588;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

OS Synthetic.
 OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

XX (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.

PS Claim 3; Page 22; 80pp; French.

XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX

Sequence 23 BP; 7 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 418 ACTTGTACTGGAGACCACTAAC 440

Db 1 ACTTGTACTGGAGACCACTAAC 23

RESULT 28
 AAX81596

ID AAX81596 standard; DNA; 23 BP.

AC AAX81596;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

OS Synthetic.
 OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

XX (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.

PS Claim 3; Page 24; 80pp; French.

XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX

Sequence 23 BP; 7 A; 9 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1795 AATGACAGTCCCTCCACCCAGA 1817
 DB 1 AATGACAGTCCCTCCACCCAGA 23

RESULT 29
 AAX81611

ID AAX81611 standard; DNA; 23 BP.

AC AAX81611;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

OS Synthetic.
 OS Erythrovirus.

```

XX  FR2771751-A1.
XX
XX  04-JUN-1999.
XX
XX  03-DEC-1997; 97FR-00015197.
XX
XX  03-DEC-1997; 97FR-00015197.
XX
XX  (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
XX  Nguyen QT, Garbarg CA, Auguste V;
XX
XX  WPI; 1999-349543/30.
XX
XX  Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX  diagnosis of its infections.
XX
XX  Claim 3; Page 27; 80pp; French.
XX
XX  AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
XX  polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX  polynucleotide sequences (AAX81580) can be used for differential
XX  diagnosis of erythrovirus (parvovirus) infections by a combination of
XX  amplification and hybridisation assay. The probes can also be used to
XX  assess susceptibility to erythrovirus infection and for erythrovirus
XX  screening and typing. The antibodies can be used in immunoassays for
XX  diagnosis of erythrovirus V9 infections
XX
XX  Sequence 23 BP; 16 A; 1 C; 1 G; 5 T; 0 U; 0 Other;
XX
XX  Query Match 0.5%; Score 23; DB 1; Length 23;
XX  Best Local Similarity 100.0%; Pred. No. 20;
XX  Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX  2870 TTTAAAAATTTAAAAATGAAAC 2892
XX  1 TTTAAAAATTTAAAAATGAAAC 23
XX
XX  RESULT 30
XX  AAX81651
XX  ID AAX81651 standard; DNA; 23 BP.
XX
XX  AAX81651;
XX
XX  26-AUG-1999 (first entry)
XX
XX  Probe used to isolate erythrovirus V9 nucleotide sequences.
XX
XX  Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX  erythrovirus screening; typing; immunoassay; probe; ss.
XX
XX  Synthetic.
XX  Erythrovirus.
XX
XX  FR2771751-A1.
XX
XX  04-JUN-1999.
XX
XX  03-DEC-1997; 97FR-00015197.
XX
XX  03-DEC-1997; 97FR-00015197.
XX
XX  (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
XX  Nguyen QT, Garbarg CA, Auguste V;
XX
XX  WPI; 1999-349543/30.
XX
XX  Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX  diagnosis of its infections.
XX

```

```

PS  Claim 3; Page 38; 80pp; French.
XX
XX  AAX81630-X81666 represent probes used to isolate erythrovirus V9
XX  polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX  polynucleotide sequences (AAX81580) can be used for differential
XX  diagnosis of erythrovirus (parvovirus) infections by a combination of
XX  amplification and hybridisation assay. The probes can also be used to
XX  assess susceptibility to erythrovirus infection and for erythrovirus
XX  screening and typing. The antibodies can be used in immunoassays for
XX  diagnosis of erythrovirus V9 infections
XX
XX  Sequence 23 BP; 7 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
XX
XX  Query Match 0.5%; Score 23; DB 1; Length 23;
XX  Best Local Similarity 100.0%; Pred. No. 20;
XX  Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX  2574 ATTTTCAGAGCCATGACAGTTA 2596
XX  1 ATTTTCAGAGCCATGACAGTTA 23
XX
XX  RESULT 31
XX  ABZ59580
XX  ID ABZ59580 standard; DNA; 24 BP.
XX
XX  ABZ59580;
XX
XX  22-APR-2003 (first entry)
XX
XX  Human parvovirus B19 VP2 PCR primer VP2-5 SEQ ID NO:38.
XX
XX  Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma;
XX  PCR primer; ss.
XX
XX  B19 virus.
XX  Synthetic.
XX
XX  WO2003002753-A2.
XX
XX  09-JAN-2003.
XX
XX  28-JUN-2002; 2002W0-US020684.
XX
XX  28-JUN-2001; 2001US-0302077B.
XX  19-MAR-2002; 2002US-0365956P.
XX  29-MAR-2002; 2002US-0369224P.
XX
XX  (CHIR ) CHIRON CORP.
XX
XX  Pichuanes S, Shyamala V;
XX
XX  WPI; 2003-201510/19.
XX
XX  Detecting a human parvovirus B19 infection in a biological sample to
XX  prevent viral transmission, comprises reacting a parvovirus B19 nucleic
XX  acid with a primer complementary to the 3'-terminal portion of the RNA
XX  target sequence.
XX
XX  Example 2; Page 42; 148pp; English.
XX
XX  The present invention describes a method for detecting a human parvovirus
XX  B19 infection in a biological sample. The method comprises reacting the
XX  isolated parvovirus B19 nucleic acid with a first oligonucleotide
XX  consisting of a first primer containing a complexing sequence
XX  sufficiently complementary to the 3'-terminal portion of the RNA target
XX  sequence to complex with. Also described: (1) amplifying a target
XX  parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
XX  of 47 700 base pair sequences (see ABZ59549 to ABZ59569, and ABZ59604 to
XX  ABZ59629); (3) a polynucleotide comprising either of 2 4678 base pair
XX  sequences (see ABZ59570 and ABZ59571); (4) an oligonucleotide primer
XX  consisting of a promoter region recognised by a DNA-dependent RNA
XX  polymerase operably linked to a human parvovirus B19-specific complexing
XX

```

CC sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
 CC parvovirus B19-specific hybridizing sequence of 10-50 nucleotides linked
 CC to an acridinium ester label; and (6) a diagnostic test kit comprising an
 CC oligonucleotide primer of (4), and instructions for conducting the
 CC diagnostic test. The method is useful for detecting parvovirus infection
 CC in a biological sample, such as in blood products, to prevent
 CC transmission of the virus through blood and plasma derivatives or by
 CC close personal contact. AB259549 to AB259634 and ABP57262 to ABP57267
 CC represent sequences used in the exemplification of the present invention
 XX

Sequence 24 BP, 10 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 22.4; DB 1; Length 24;
 Best Local Similarity 95.8%; Pred. No. 27;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4620 GACACCGATATGAAAAGCCTGAAG 4643
 DB 1 GACATGATATGAAAAGCCTGAAG 24

RESULT 32
 AAX81650
 ID AAX81650 standard; DNA; 22 BP.

AC AAX81650;

DT 26-AUG-1999 (first entry)

DE Probe used to isolate erythrovirus V9 nucleotide sequences.

KW Erythrovirus V9; differential diagnosis; parvovirus; infection;
 XX erythrovirus screening; typing; immunoassay; probe; ss.

OS Synthetic.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASST-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.

PI Nguyen QT, Garbary CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 XX diagnosis of its infections.

PS Claim 3; Page 37; 80pp; French.

CC AAX81630-X8166 represent probes used to isolate erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

Sequence 22 BP, 6 A; 7 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.4%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2552 TCTCCAGACCTATATAGTCATC 2573
 ||||||||||||||||||||

DB 1 TCTCCAGACCTATATAGTCATC 22

RESULT 33

ID AAX81610 standard; DNA; 22 BP.

AC AAX81610;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

KW Erythrovirus V9; differential diagnosis; parvovirus; infection;
 XX erythrovirus screening; typing; immunoassay; PCR primer; ss.

OS Synthetic.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASST-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.

PI Nguyen QT, Garbary CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 XX diagnosis of its infections.

PS Claim 3; Page 27; 80pp; French.

CC AAX81580-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

Sequence 22 BP, 7 A; 3 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 25;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2814 TGGCTAGTGGGAATTAATCC 2835
 DB 1 TGGCTAGTGGGAATTAATCC 22

RESULT 34
 AAH03067
 ID AAH03067 standard; DNA; 22 BP.

AC AAH03067;

DT 15-JUN-2001 (first entry)

DE Microorganism detection method related oligonucleotide SEQ ID NO: 91.

KW Microorganism identification; pathogen; DNA sequencing; HLA type;
 XX bi-directional sequencing; infection; mutation detection; PCR primer; ss.

OS Unidentified.

```

PN US6214555-B1.
XX
XX 10-APR-2001.
PD
XX 13-MAY-1999; 99US-00311260.
PF
XX 01-MAY-1996; 96US-00640672.
PR 19-JUL-1996; 96US-00684498.
PR 27-FEB-1997; 97US-00807138.
PR 20-JAN-1998; 98US-00009483.
XX
XX (VISI-) VISIBLE GENETICS INC.
XX Leushner J, Hui M, Dunn JM, Lacroix J;
XX WPI, 2001-289718/30.
XX
XX Composition for detecting microorganisms, comprising deoxynucleotide
XX triphosphates, dideoxynucleotide triphosphate, and thermostable
XX polymerase to incorporate dideoxynucleotide triphosphate into extending
XX polymer.
XX
XX Disclosure; Col 67; 62pp; English.
XX
XX The present invention provides a composition containing 4 dNTPs and at
XX least one ddNTP and a thermally stable polymerase which incorporates
XX ddNTPs into an extending nucleic acid polymer at a rate of not less than
XX 0.4 times the rate of dNTP incorporation. This can be used with the PCR
XX primers provided in the invention to detect the presence of
XX microorganisms, such as Chlamydia trachomatis, HIV or human
XX papillomavirus, in a sample. In addition, it can be used to detect
XX mutations in a specific gene, to determine HLA type, and to produce
XX sequencing fragments for further study
XX
XX Sequence 22 BP; 7 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2429 GGACGACTTACGCTTATTC 2450
DB 1 GGACGACTTACGCTTATTC 22
XX
XX RESULT 35
XX AAF75351
XX ID AAF75351 standard; DNA; 22 BP.
XX
XX AAF75351;
XX
XX 11-SEP-2003 (revised)
XX 11-MAY-2001 (first entry)
XX
XX Parvovirus B19 PCR primer P1.f.
XX
XX Parvovirus B19; quality assurance; nucleic acid amplification;
XX microorganism detection; contamination identification; PCR primer; ss.
XX
XX B19 virus.
XX
XX WO200114593-A2.
XX
XX 01-MAR-2001.
XX
XX 14-AUG-2000; 2000WO-EP007892.
XX
XX 20-AUG-1999; 99AT-00001443.
XX
XX (BAXT) BAXTER AG.
XX
XX Zerlauch G, Gessner M, Koettnitz K, Gross P;
XX

```

```

DR WPI, 2001-218460/22.
XX
XX Producing a pool of biological samples that is quality assured with
XX regard to the load of microorganisms, especially viruses, comprises
XX employing two nucleic acid amplification processes that differ in their
XX sensitivity.
XX
XX Example; Page 13; 19pp; English.
XX
XX The present sequence was used in a method for producing a pool of
XX biological samples that is quality assured with respect to the load of
XX microorganisms, especially viruses. The method comprises testing a
XX screening pool with a high sensitivity nucleic acid amplification method
XX and dividing the pool into subpools, which are tested with a less
XX sensitive nucleic acid amplification method. Individual samples are then
XX picked out and eliminated. The method enables a reliable identification
XX of contaminated individual samples, especially highly contaminated
XX individual samples, as well as adherence to certain limit values for such
XX contaminants in the pool. The method is also less expensive and is
XX simpler to use than other known pool testing methods. (Updated on 11-SEP-
XX 2003 to standardise OS field)
XX
XX Sequence 22 BP; 6 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2589 GACAGTTATTCAGCCACCCCA 2610
DB 1 GACAGTTATTCAGCCACCCCA 22
XX
XX RESULT 36
XX ACC43300
XX ID ACC43300 standard; DNA; 22 BP.
XX
XX ACC43300;
XX
XX 27-OCT-2003 (revised)
XX 11-AUG-2003 (first entry)
XX
XX Nucleotide sequence of a probe for human parvovirus B19 DNA.
XX
XX Parvovirus detection; probe; ss.
XX
XX B19 virus.
XX
XX WO2003020742-A1.
XX
XX 13-MAR-2003.
XX
XX 30-AUG-2002; 2002WO-US027734.
XX
XX 31-AUG-2001; 2001US-0316691P.
XX
XX (GENE-) GEN-PROBE INC.
XX
XX Brenano ST, Batranina-Kaminsky M, Hasselkus-Light CS, Kolb DP;
XX WPI, 2003-300859/29.
XX
XX Detecting human parvovirus B19 nucleic acid in biological sample involves
XX carrying out amplification reaction of parvovirus B19 nucleic acid using
XX human parvovirus specific nucleic acid oligomers.
XX
XX Claim 1; Page 33; 54pp; English.
XX
XX The present sequence represents a probe for parvovirus B19 DNA. It is
XX used in the method of the invention. The specification describes a method
XX of detecting human parvovirus B19 nucleic acid in a biological sample.
XX The method comprises amplifying in vitro a portion of human parvovirus
XX B19 nucleic acid, and detecting an amplified product using a labeled
XX

```

CC detection probe that hybridizes specifically with the amplified product.
CC The method is useful for detecting human parvovirus B19 nucleic acid in
CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)

XX Sequence 22 BP; 7 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 22; DB 1; Length 22;

Best Local Similarity 100.0%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2660 GATTATCTAGTGAAGACTTAC 2661

DB 1 GATTATCTAGTGAAGACTTAC 22

RESULT 37

ACC43290
ID ACC43290 standard; DNA; 22 BP.

AC ACC43290;

XX 27-OCT-2003 (revised)

DT 11-AUG-2003 (first entry)

DE Nucleotide sequence of a capture probe for human parvovirus B19 DNA.

XX Parvovirus detection; probe; ss.

XX B19 virus.

XX MO2003020742-A1.

XX 13-MAR-2003.

XX 30-AUG-2002; 2002MO-US027734.

XX 31-AUG-2001; 2001US-0316691P.

XX (GENP-) GEN-PROBE INC.

XX Brentano ST, Batranina-Kaminsky M, Hasselkus-Light CS, Kolk DP;

XX WPI; 2003-300859/29.

XX Detecting human parvovirus B19 nucleic acid in biological sample involves

XX carrying out amplification reaction of parvovirus B19 nucleic acid using

XX human parvovirus specific nucleic acid oligomers.

XX Claim 1; Page 43; 54pp; English.

XX The present sequence represents a probe for parvovirus B19 DNA. It is

XX used in the method of the invention. The specification describes a method

XX of detecting human parvovirus B19 nucleic acid in a biological sample.

XX The method comprises amplifying in vitro a portion of human parvovirus

XX B19 nucleic acid, and detecting an amplified product using a labeled

XX detection probe that hybridizes specifically with the amplified product.

XX The method is useful for detecting human parvovirus B19 nucleic acid in

XX biological samples. (Updated on 27-OCT-2003 to standardise OS field)

XX Sequence 22 BP; 6 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 22; DB 1; Length 22;

Best Local Similarity 100.0%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2585 CARGACAGTTATCTGACGACC 2606

DB 1 CARGACAGTTATCTGACGACC 22

RESULT 38

AD27491
ID ADA27491 standard; DNA; 22 BP.

XX ADA27491;

XX 20-NOV-2003 (first entry)

XX Microorganism sequencing primer #91.

XX microorganism detection; bi-directional DNA sequencing;

XX HLA determination; human leukocyte antigen; reduced error risk;

XX reduced contamination risk; sequencing; primer; ss.

XX B19 virus.

XX US2003082535-A1.

XX 01-MAY-2003.

XX 07-MAR-2001; 2001US-00802110.

XX 01-MAY-1996; 96US-00640672.

XX 19-JUL-1996; 96US-00684498.

XX 27-FEB-1997; 97US-00807138.

XX 29-APR-1997; 97MO-US007134.

XX 20-JAN-1998; 98US-00009483.

XX 13-MAY-1999; 99US-00311260.

XX (LEUS/) LEUSHNER J.

XX (HUIM/) HUI M.

XX (DUNN/) DUNN J M.

XX (LACR/) LACROIX J.

XX Leushner J, Hui M, Dunn JM, Lacroix J;

XX WPI; 2003-576607/54.

XX Microorganism detecting composition comprises dideoxynucleotide

XX triphosphate(s) corresponding to one of four dideoxynucleotide

XX triphosphate, and thermally stable polymerase enzyme.

XX Disclosure; Page 21; 94pp; English.

XX The invention relates to a microorganism detecting composition. The

XX composition is used for detecting a target microorganism. It is used in a

XX bi-directional DNA sequencing method in several contexts including

XX detection of mutations, particularly mutations of medical significance,

XX in samples derived from a human patient, animal, plant, or microorganism;

XX determination of HLA (human leukocyte antigen) type ancillary to

XX transplant procedures; detection and identification of microorganisms,

XX particularly pathogenic microorganisms, in a sample and in situ

XX sequencing reactions to produce sequencing fragments within a

XX histological specimen which are then removed from a selected location on

XX the tissue preparation and loaded onto a gel for sequence analysis. The

XX invention allows an evaluation to be directly performed on a natural

XX abundance DNA sample. It provides for bi-directional sequencing of DNA

XX which requires combining a complex DNA-containing sample with only a

XX single reaction mixture, thus reducing risk of error and contamination,

XX and increasing the ease with which the procedure can be automated. The

XX present sequence represents a sequencing primer for identification of a

XX microorganism.

XX Sequence 22 BP; 7 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 22; DB 1; Length 22;

Best Local Similarity 100.0%; Pred. No. 25;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2429 GGAACGACTTAGAGCTTATTC 2450

DB 1 GGAACGACTTAGAGCTTATTC 22

RESULT 39

AA53613
ID AA53613

```

ID   AAA53613 standard; DNA; 23 BP.
XX
AC   AAA53613;
XX
DT   15-SEP-2003 (revised)
DT   04-DEC-2000 (first entry)
XX
DE   B19-reverse primer for parvovirus B19 genomic DNA amplification.
XX
KM   TTV; TTV virus; blood transmission; detection; amplification; primer;
XX   transplantation; xenotransplantation; vector; ss.
XX
OS   B19 virus.
XX
PN   WO200046407-A2.
XX
PD   10-AUG-2000.
XX
PF   04-FEB-2000; 2000WO-US002982.
XX
PR   05-FEB-1999; 99US-00245248.
XX
PA   (ABBO ) ABBOTT LAB.
XX
PI   Leary TP, Simons JN, Erker JC, Chalmers ML, Birkenmeyer LG;
PI   Muerthoff AS, Pilot-Matias TJ, Desai SM, Mushahwar IK;
XX
DR   MPI; 2000-514969/46.
XX
PT   New oligomer primer useful for the detection of TTV virus in test samples
PT   and tissues and organs for use in (xeno)transplantation.
XX
PS   Example 2; Page 103; 139pp; English.
XX
CC   Filtration studies to determine the approximate size of TTV virus (TTV)
CC   virion were carried out using parvovirus B19-containing human serum as a
CC   comparison. Primers were used to detect the presence of the viruses in
CC   resulting filtrates. The TTV virions appear to exist in serum with a
CC   particle diameter between 30 and 50 nm. The TTV (3739 bp) was isolated
CC   from serum of a Japanese patient with cryptogenic hepatitis. The genome
CC   is circular and single-stranded. TTV DNA can be transmitted by blood or
CC   blood products. It is also possible that TTV is transmitted by a faecal-
CC   oral route, demonstrated by the presence of TTV in the faeces of infected
CC   humans. Detection of TTV in test samples can be enhanced by use of DNA
CC   amplification assays that use DNA oligomers as primers. The primers are
CC   useful for detecting the presence of TTV target nucleotides in biological
CC   samples and tissues and organs to be used in transplantation and
CC   xenotransplantation (claimed). The TTV genome itself can be used as a
CC   vector in order to introduce heterologous DNA into a host cell. (Updated
CC   on 15-SEP-2003 to standardise OS field)
XX
SQ   Sequence 23 BP; 6 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
Query Match      0.4%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 34;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY   3015 GCATGACTTCAGTTACTCGCA 3037
DB   1 GCATGACTTCAGTTACTCGCA 23

```

```

KM   erythrovirus screening; typing; immunoassay; probe; ss.
XX
OS   Synthetic.
OS   Erythrovirus.
XX
PN   FR2771751-A1.
XX
PD   04-JUN-1999.
XX
PF   03-DEC-1997; 97FR-00015197.
XX
PR   03-DEC-1997; 97FR-00015197.
XX
PA   (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI   Nguyen QT, Garbarg CA, Auguste V;
XX
DR   MPI; 1999-349543/30.
XX
PT   Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT   diagnosis of its infections.
XX
PS   Claim 3; Page 64; 80pp; French.
XX
CC   The present probe was used to isolate erythrovirus V9 polynucleotide
CC   sequences. Probes and primers derived from erythrovirus V9 polynucleotide
CC   sequences (AAx81580) can be used for differential diagnosis of
CC   erythrovirus (parvovirus) infections by a combination of amplification
CC   and hybridisation assay. The probes can also be used to assess
CC   susceptibility to erythrovirus infection and for erythrovirus screening
CC   and typing. The antibodies can be used in immunoassays for diagnosis of
CC   erythrovirus V9 infections
XX
SQ   Sequence 21 BP; 7 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
Query Match      0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY   2041 TTTTACAGCGCGCTGGCGAT 2061
DB   21 TTTTACAGCGCGCTGGCGAT 1

```

```

RESULT 41
ID   AAX81622 standard; DNA; 21 BP.
XX
AC   AAX81622;
XX
DT   26-AUG-1999 (first entry)
XX
DE   PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
KM   Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX   erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS   Synthetic.
OS   Erythrovirus.
XX
PN   FR2771751-A1.
XX
PD   04-JUN-1999.
XX
PF   03-DEC-1997; 97FR-00015197.
XX
PR   03-DEC-1997; 97FR-00015197.
XX
PA   (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI   Nguyen QT, Garbarg CA, Auguste V;
XX
DR   MPI; 1999-349543/30.

```

XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.

PS Claim 3; Page 30; 80pp; French.

CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections

XX Sequence 21 BP; 10 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4376 CCTCAAAATTTTAAATA 4396
DB 1 CCTCAAAATTTTAAATA 21

RESULT 42
AAX81593

ID AAX81593 standard; DNA; 21 BP.

AC AAX81593;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;

KW erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

XX FR2771751-A1.

PN 04-JUN-1999.

PD 03-DEC-1997; 97FR-00015197.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PS (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

XX Nguyen QT, Garbary CA, Auguste V;

PI WPI; 1999-349543/30.

DR Erythrovirus V9 and its nucleic acid sequences - can be used in the

PT diagnosis of its infections.

XX Claim 3; Page 23; 80pp; French.

CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAX81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections

XX Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.4%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 30;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1723 TGGTGAATGACAAAGCTGG 1743
DB 1 TGGTGAATGACAAAGCTGG 21

RESULT 43

ID AAX81668/C

AC AAX81668;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;

KW erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

XX FR2771751-A1.

PN 04-JUN-1999.

PD 03-DEC-1997; 97FR-00015197.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PS (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

XX Nguyen QT, Garbary CA, Auguste V;

PI WPI; 1999-349543/30.

DR Erythrovirus V9 and its nucleic acid sequences - can be used in the

PT diagnosis of its infections.

XX Claim 3; Page 63; 80pp; French.

CC The present PCR primer is used to amplify erythrovirus V9 polynucleotide
CC sequences. Probes and primers derived from erythrovirus V9 polynucleotide
CC sequences (AAX81580) can be used for differential diagnosis of
CC erythrovirus (parvovirus) infections by a combination of amplification
CC and hybridisation assay. The probes can also be used to assess
CC susceptibility to erythrovirus infection and for erythrovirus screening
CC and typing. The antibodies can be used in immunoassays for diagnosis of
CC erythrovirus V9 infections

XX Sequence 21 BP; 2 A; 6 C; 4 G; 9 T; 0 U; 0 Other;

Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1879 GAAGAACTCAGTGAAGCAGC 1899
DB 21 GAAGAACTCAGTGAAGCAGC 1

RESULT 44

ID AAX81628

AC AAX81628;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

KW Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
 OS Synthetic.
 OS Erythrovirus.
 PN FR2771751-A1.
 PD 04-JUN-1999.
 PF 03-DEC-1997; 97FR-00015197.
 PR 03-DEC-1997; 97FR-00015197.
 PA (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
 PI Nguyen QT, Garbarg CA, Auguste V;
 DR WPI; 1999-349543/30.
 XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 PS Claim 3; Page 31; 80pp; French.
 CC AX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX Sequence 21 BP; 3 A; 11 C; 3 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.4%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 30;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4686 TCCCCACCGTGTCTCTCAGCCA 4706
 DB 1 TCCCCACCGTGTCTCTCAGCCA 21
 RESULT 45
 AAH03068/c
 ID AAH03068 standard; DNA; 21 BP.
 XX
 AC AAH03068;
 XX
 DT 15-JUN-2001 (first entry)
 XX
 DE Microorganism detection method related oligonucleotide SEQ ID NO: 92.
 XX
 KM Microorganism identification; pathogen; DNA sequencing; HLA type;
 KM bi-directional sequencing; infection; mutation detection; PCR primer; ss.
 OS Unidentified.
 XX
 PN US6214555-B1.
 PD 10-APR-2001.
 PF 13-MAY-1999; 99US-00311260.
 PR 01-MAY-1996; 96US-00640672.
 PR 19-JUL-1996; 96US-00684498.
 PR 27-FEB-1997; 97US-00807138.
 PR 20-JAN-1998; 98US-00009483.
 XX
 PA (VIST-) VISIBLE GENETICS INC.
 XX

PI Leusner J, Hui M, Dunn JM, Lacroix J;
 XX
 DR WPI; 2001-289718/30.
 XX
 PT Composition for detecting microorganisms, comprising deoxynucleotide
 PT triphosphates, dideoxynucleotide triphosphate, and thermostable
 PT polymerase to incorporate dideoxynucleotide triphosphate into extending
 PT polymer.
 XX
 PS Disclosure; Col 67; 62pp; English.
 XX
 CC The present invention provides a composition containing 4 dNTPs and at
 CC least one ddNTP and a thermally stable polymerase which incorporates
 CC ddNTPs into an extending nucleic acid polymer at a rate of not less than
 CC 0.4 times the rate of dNTP incorporation. This can be used with the PCR
 CC primers provided in the invention to detect the presence of
 CC microorganisms, such as Chlamydia trachomatis, HIV or human
 CC papillomavirus, in a sample. In addition, it can be used to detect
 CC mutations in a specific gene, to determine HLA type, and to produce
 CC sequencing fragments for further study
 XX
 SQ Sequence 21 BP; 4 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
 Query Match 0.4%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 30;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2667 CTAGTGAGACCTTACACAGC 2687
 DB 21 CTAGTGAGACCTTACACAGC 1
 RESULT 46
 ACC43302
 ID ACC43302 standard; DNA; 21 BP.
 XX
 AC ACC43302;
 XX
 DT 27-OCT-2003 (revised)
 DT 11-AUG-2003 (first entry)
 XX
 DE Nucleotide sequence of a probe for human parvovirus B19 DNA.
 XX
 KM Parvovirus detection; probe; ss.
 OS B19 virus.
 XX
 PN WO2003020742-A1.
 PD 13-MAR-2003.
 PF 30-AUG-2002; 2002WO-US027734.
 PR 31-AUG-2001; 2001US-0316691P.
 XX
 PA (GENP-) GEN-PROBE INC.
 XX
 PI Brenano ST, Batranina-Kaminsky M, Hasselkus-light CS, Kolk DP;
 DR WPI; 2003-300859/29.
 XX
 PT Detecting human parvovirus B19 nucleic acid in biological sample involves
 PT carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.
 XX
 PS Claim 1; Page 33; 54pp; English.
 XX
 CC The present sequence represents a probe for parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.


```

PR 01-MAY-1996; 96US-00640672.
PR 19-JUL-1996; 96US-00684498.
PR 27-FEB-1997; 97US-00807138.
PR 29-APR-1997; 97MO-US007134.
PR 20-JAN-1998; 98US-00009483.
PR 13-MAY-1999; 99US-00311260.
XX
PA (LEUS/) LEUSHNER J.
PA (HUTM/) HUI M.
PA (DUNN/) DUNN J M.
PA (LACR/) LACROIX J.
PI Leushner J, Hui M, Dunn JM, Lacroix J;
XX
XX WPI; 2003-576607/54.
XX
PT Microorganism detecting composition comprises dideoxynucleotide
PT triphosphate(s) corresponding to one of four deoxynucleotide
PT triphosphate, and thermally stable polymerase enzyme.
XX
PS Disclosure; Page 21; 94pp; English.
XX
XX The invention relates to a microorganism detecting composition. The
XX composition is used for detecting a target microorganism. It is used in a
XX bi-directional DNA sequencing method in several contexts including
XX detection of mutations, particularly mutations of medical significance,
XX in samples derived from a human patient, animal, plant, or microorganism;
XX determination of HLA (human leukocyte antigen) type ancillary to
XX transplant procedures; detection and identification of microorganisms,
XX particularly pathogenic microorganisms, in a sample and in situ
XX sequencing reactions to produce sequencing fragments within a
XX histological specimen which are then removed from a selected location on
XX the tissue preparation and loaded onto a gel for sequence analysis. The
XX invention allows an evaluation to be directly performed on a natural
XX abundance DNA sample. It provides for bi-directional sequencing of DNA
XX which requires combining a complex DNA-containing sample with only a
XX single reaction mixture, thus reducing risk of error and contamination,
XX and increasing the ease with which the procedure can be automated. The
XX present sequence represents a sequencing primer for identification of a
XX microorganism.
XX
SQ Sequence 21 BP; 4 A; 4 C; 5 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2667 CTAGTGAAGACTTACACAAGC 2687
DB 21 CTAGTGAAGACTTACACAAGC 1
XX
RESULT 50
AAx81617
ID AAx81617 standard; DNA; 20 BP.
XX
AC AAx81617;
XX
XX 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
XX Erythrovirus.
XX
XX FR2771751-A1.
XX
XX 04-JUN-1999.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX

```

```

XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX (ASST-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
XX
XX Nguyen QT, Garbary CA, Auguste V;
XX
XX WPI; 1999-349543/30.
XX
XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX diagnosis of its infections.
XX
XX Claim 3; Page 29; 80pp; French.
XX
XX AAx81588-X81630 represent PCR primers used to amplify erythrovirus V9
XX polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX polynucleotide sequences (AAx81580) can be used for differential
XX diagnosis of erythrovirus (parvovirus) infections by a combination of
XX amplification and hybridisation assay. The probes can also be used to
XX assess susceptibility to erythrovirus infection and for erythrovirus
XX screening and typing. The antibodies can be used in immunoassays for
XX diagnosis of erythrovirus V9 infections
XX
SQ Sequence 20 BP; 8 A; 4 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 4055 ACAGGATTAATGCGCATTC 4074
DB 1 ACAGGATTAATGCGCATTC 20
XX
RESULT 51
AAx81591
ID AAx81591 standard; DNA; 20 BP.
XX
AC AAx81591;
XX
XX 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
XX Erythrovirus.
XX
XX FR2771751-A1.
XX
XX 04-JUN-1999.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX (ASST-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
XX
XX Nguyen QT, Garbary CA, Auguste V;
XX
XX WPI; 1999-349543/30.
XX
XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX diagnosis of its infections.
XX
XX Claim 3; Page 22; 80pp; French.
XX
XX AAx81588-X81630 represent PCR primers used to amplify erythrovirus V9
XX polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX polynucleotide sequences (AAx81580) can be used for differential
XX diagnosis of erythrovirus (parvovirus) infections by a combination of
XX

```

CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

XX Sequence 20 BP; 3 A; 1 C; 10 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1429 TTGGTGTCTGGAGTGAAGG 1448
 DB 1 TTGGTGTCTGGAGTGAAGG 20

RESULT 52
 AAX81600
 ID AAX81600 standard; DNA; 20 BP.

XX AAX81600;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.

PS Claim 3; Page 25; 80pp; French.

CC AAX81586-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

XX Sequence 20 BP; 4 A; 3 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2062 CAGTTTCTGACTGTTAGT 2081
 DB 1 CAGTTTCTGACTGTTAGT 20

RESULT 53
 AAX81669

ID AAX81669 standard; DNA; 20 BP.

XX AAX81669;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

PF 03-DEC-1997; 97FR-00015197.

PR 03-DEC-1997; 97FR-00015197.

PA (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.

PI Nguyen QT, Garbarg CA, Auguste V;

DR WPI; 1999-349543/30.

PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.

PS Claim 3; Page 63; 80pp; French.

CC The present PCR primer is used to amplify erythrovirus V9 polynucleotide
 CC sequences. Probes and primers derived from erythrovirus V9 polynucleotide
 CC sequences (AAX81580) can be used for differential diagnosis of
 CC erythrovirus (parvovirus) infections by a combination of amplification
 CC and hybridisation assay. The probes can also be used to assess
 CC susceptibility to erythrovirus infection and for erythrovirus screening
 CC and typing. The antibodies can be used in immunoassays for diagnosis of
 CC erythrovirus V9 infections

XX Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.4%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 37;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1968 GACCACTTCAGAGATCAT 1987
 DB 1 GACCACTTCAGAGATCAT 20

RESULT 54

ID AAX81671/c

XX AAX81671 standard; DNA; 20 BP.

AC AAX81671;

DT 26-AUG-1999 (first entry)

DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

PN FR2771751-A1.

PD 04-JUN-1999.

```

PF 03-DEC-1997; 97FR-00015197.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
XX Nguyen QT, Garbarg CA, Auguste V;
XX
XX WPI; 1999-349543/30.
XX
XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX diagnosis of its infections.
XX
XX Claim 3; Page 64; 80pp; French.
XX
XX The present PCR primer is used to amplify erythrovirus V9 polynucleotide
XX sequences. Probes and primers derived from erythrovirus V9 polynucleotide
XX sequences (AAx81580) can be used for differential diagnosis of
XX erythrovirus (parvovirus) infections by a combination of amplification
XX and hybridisation assay. The probes can also be used to assess
XX susceptibility to erythrovirus infection and for erythrovirus screening
XX and typing. The antibodies can be used in immunoassays for diagnosis of
XX erythrovirus V9 infections
XX
XX Sequence 20 BP; 8 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 37;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 2298 ATGTGCTTACTGCTGTGAT 2317
XX |||||
XX 20 ATGTGCTTACTGCTGTGAT 1
XX
XX RESULT 55
XX AAX81674/C
XX ID AAX81674 standard; DNA; 20 BP.
XX
XX AAX81674;
XX
XX 26-AUG-1999 (first entry)
XX
XX PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
XX Synthetic.
XX Erythrovirus.
XX
XX FR2771751-A1.
XX
XX 04-JUN-1999.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
XX Nguyen QT, Garbarg CA, Auguste V;
XX
XX WPI; 1999-349543/30.
XX
XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX diagnosis of its infections.
XX
XX Claim 3; Page 64; 80pp; French.
XX
XX The present PCR primer is used to amplify erythrovirus V9 polynucleotide
XX sequences. Probes and primers derived from erythrovirus V9 polynucleotide
XX sequences (AAX81580) can be used for differential diagnosis of

```

```

CC erythrovirus (parvovirus) infections by a combination of amplification
CC and hybridisation assay. The probes can also be used to assess
CC susceptibility to erythrovirus infection and for erythrovirus screening
CC and typing. The antibodies can be used in immunoassays for diagnosis of
CC erythrovirus V9 infections
XX
XX Sequence 20 BP; 6 A; 4 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 37;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 2793 ATGACTTTAGGTATAGCCAA 2812
XX |||||
XX 20 ATGACTTTAGGTATAGCCAA 1
XX
XX RESULT 56
XX AAX81592
XX ID AAX81592 standard; DNA; 20 BP.
XX
XX AAX81592;
XX
XX 26-AUG-1999 (first entry)
XX
XX PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
XX Synthetic.
XX Erythrovirus.
XX
XX FR2771751-A1.
XX
XX 04-JUN-1999.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX 03-DEC-1997; 97FR-00015197.
XX
XX (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
XX Nguyen QT, Garbarg CA, Auguste V;
XX
XX WPI; 1999-349543/30.
XX
XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX diagnosis of its infections.
XX
XX Claim 3; Page 23; 80pp; French.
XX
XX AAX81586-X81630 represent PCR primers used to amplify erythrovirus V9
XX polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX polynucleotide sequences (AAX81580) can be used for differential
XX diagnosis of erythrovirus (parvovirus) infections by a combination of
XX amplification and hybridisation assay. The probes can also be used to
XX assess susceptibility to erythrovirus infection and for erythrovirus
XX screening and typing. The antibodies can be used in immunoassays for
XX diagnosis of erythrovirus V9 infections
XX
XX Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 37;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1693 ACAGAGGCTGATGATACAA 1712
XX |||||
XX 1 ACAGAGGCTGATGATACAA 20
XX
XX RESULT 57

```

```

AAAS3611/c
ID AAA53611 standard; DNA; 20 BP.
XX
AC AAA53611;
XX
DT 15-SEP-2003 (revised)
DT 04-DEC-2000 (first entry)
XX
DE Primer B19.1699-al for parvovirus B19 genomic DNA amplification.
XX
KM TTV, TT virus; blood transmission; detection; amplification; primer;
KM transplantation; xenotransplantation; vector; ss.
XX
OS B19 virus.
XX
PN WO200046407-A2.
XX
PD 10-AUG-2000.
XX
PF 04-FEB-2000; 2000MO-US002982.
XX
PR 05-FEB-1999; 99US-00245248.
XX
PA (ABBO ) ABBOTT LAB.
XX
PI Leary TP, Simons JN, Erker JC, Chalmers ML, Birkemeyer LG;
PI Muerhoff AS, Pilot-Matias TJ, Desai SM, Mushahwar IK;
XX
DR WPI; 2000-514969/46.
XX
PT New oligomer primer useful for the detection of TT virus in test samples
PT and tissues and organs for use in (xeno)transplantation.
XX
PS Example 2; Page 103; 139pp; English.
XX
CC Filtration studies to determine the approximate size of TT virus (TTV)
CC virion were carried out using parvovirus B19-containing human serum as a
CC comparison. Primers were used to detect the presence of the viruses in
CC resulting filtrates. The TTV virions appear to exist in serum with a
CC particle diameter between 30 and 50 nm. The TTV (3739 bp) was isolated
CC from serum of a Japanese patient with cryptogenic hepatitis. The genome
CC is circular and single-stranded. TTV DNA can be transmitted by a faecal-
CC oral route, demonstrated by the presence of TTV in the faeces of infected
CC humans. Detection of TTV in test samples can be enhanced by use of DNA
CC amplification assays that use DNA oligomers as primers. The primers are
CC useful for detecting the presence of TTV target nucleotides in biological
CC samples and tissues and organs to be used in transplantation and
CC xenotransplantation (claimed). The TTV genome itself can be used as a
CC vector in order to introduce heterologous DNA into a host cell. (Updated
CC on 15-SEP-2003 to standardise OS field)
XX
SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1992 CGGAGCCCAAGTTCTCCG 2011
DB 20 CGGAGCCCAAGTTCTCCG 1
XX
RESULT 58
AAAF5352/c
ID AAF75352 standard; DNA; 20 BP.
XX
AC AAF75352;
XX
DT 11-SEP-2003 (revised)
DT 11-MAY-2001 (first entry)
XX
DE Parvovirus B19 PCR primer PTL.r.

```

```

XX
KM Parvovirus B19; quality assurance; nucleic acid amplification;
KM microorganism detection; contamination identification; PCR primer; ss.
XX
OS B19 virus.
XX
PN WO200114593-A2.
XX
PD 01-MAR-2001.
XX
PF 14-AUG-2000; 2000MO-EP007892.
XX
PR 20-AUG-1999; 99AT-00001443.
XX
PA (BAXT ) BAXTER AG.
XX
PI Zerlauth G, Gessner M, Koestnitz K, Gross P;
XX
DR WPI; 2001-218460/22.
XX
PT Producing a pool of biological samples that is quality assured with
PT regard to the load of microorganisms, especially viruses, comprises
PT employing two nucleic acid amplification processes that differ in their
PT sensitivity.
XX
PS Example; Page 13; 19pp; English.
XX
CC The present sequence was used in a method for producing a pool of
CC biological samples that is quality assured with respect to the load of
CC microorganisms, especially viruses. The method comprises testing a
CC screening pool with a high sensitivity nucleic acid amplification method
CC and dividing the pool into subpools, which are tested with a less
CC sensitive nucleic acid amplification method. Individual samples are then
CC picked out and eliminated. The method enables a reliable identification
CC of contaminated individual samples, especially highly contaminated
CC individual samples, as well as adherence to certain limit values for such
CC contaminants in the pool. The method is also less expensive and is
CC simpler to use than other known pool testing methods. (Updated on 11-SEP-
CC 2003 to standardise OS field)
XX
SQ Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2682 ACAAGCCTGGGCAAGTTAGC 2701
DB 20 ACAAGCCTGGGCAAGTTAGC 1
XX
RESULT 59
AAAX81667
ID AAX81667 standard; DNA; 19 BP.
XX
AC AAX81667;
XX
DT 26-AUG-1999 (first entry)
XX
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
KM Erythrovirus V9; differential diagnosis; parvovirus; infection;
KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
XX
OS Erythrovirus.
XX
PN FR2771751-A1.
XX
PD 04-JUN-1999.
XX
PF 03-DEC-1997; 97FR-00015197.
XX

```

```

XX 03-DEC-1997; 97FR-00015197.
XX (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX PA Nguyen QT, Garbarg CA, Auguste V;
XX PI WPI; 1999-349543/30.
XX DR Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX PT diagnosis of its infections.
XX PS Claim 3; Page 63; 80pp; French.
XX
XX The present PCR primer is used to amplify erythrovirus V9 polynucleotide
XX sequences. Probes and primers derived from erythrovirus V9 polynucleotide
XX sequences (AAx81580) can be used for differential diagnosis of
XX erythrovirus (parvovirus) infections by a combination of amplification
XX CC and hybridisation assay. The probes can also be used to assess
XX CC susceptibility to erythrovirus infection and for erythrovirus screening
XX CC and typing. The antibodies can be used in immunoassays for diagnosis of
XX CC erythrovirus V9 infections
XX
XX Sequence 19 BP; 4 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.4%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 46;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0.
XX
XX QY 1797 TGCAGATGCCCTCCACCCCA 1815
XX 1 TGCAGATGCCCTCCACCCA 19
XX DB
XX
XX RESULT 60
XX AAx81604
XX ID AAx81604 standard; DNA; 19 BP.
XX AC AAx81604;
XX DT 26-AUG-1999 (first entry)
XX
XX PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX DE Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX KW erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX OS Synthetic.
XX OS Erythrovirus.
XX PN FR2771751-A1.
XX PD 04-JUN-1999.
XX PF 03-DEC-1997; 97FR-00015197.
XX PR 03-DEC-1997; 97FR-00015197.
XX
XX (ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX PA Nguyen QT, Garbarg CA, Auguste V;
XX PI WPI; 1999-349543/30.
XX DR Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX PT diagnosis of its infections.
XX PS Claim 3; Page 26; 80pp; French.
XX
XX AAx81588-X81630 represent PCR primers used to amplify erythrovirus V9
XX CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX CC polynucleotide sequences (AAx81580) can be used for differential
XX CC diagnosis of erythrovirus (parvovirus) infections by a combination of
XX CC amplification and hybridisation assay. The probes can also be used to

```

```

CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections
XX
SQ Sequence 19 BP; 6 A; 3 C; 1 G; 9 T; 0 U; 0 Other;
QY
    2562 TATATAGTCATCATTTCA 2580
    |||||
    1 TATATAGTCATCATTTCA 19
DB
    1 TATATAGTCATCATTTCA 19
RESULT 61
AAx81606
ID AAx81606 standard; DNA; 19 BP.
XX
AC AAx81606;
XX
DT 26-AUG-1999 (first entry)
DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX
XX Erythrovirus V9; differential diagnosis; parvovirus; infection;
KW erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX
OS Synthetic.
XX Erythrovirus.
XX
PN FR2771751-A1.
XX
PD 04-JUN-1999;
XX
PF 03-DEC-1997; 97FR-00015197.
XX
PR 03-DEC-1997; 97FR-00015197.
XX
PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX
PI Nguyen QT, Garbary CA, Auguste V;
XX
DR WPI; 1999-349543/30.
XX
PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
PT diagnosis of its infections.
XX
PS Claim 3; Page 26; 80pp; French.
XX
AAx81588-X81630 represent PCR primers used to amplify erythrovirus V9
CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
CC polynucleotide sequences (AAx81580) can be used for differential
CC diagnosis of erythrovirus (parvovirus) infections by a combination of
CC amplification and hybridisation assay. The probes can also be used to
CC assess susceptibility to erythrovirus infection and for erythrovirus
CC screening and typing. The antibodies can be used in immunoassays for
CC diagnosis of erythrovirus V9 infections.
XX
SQ Sequence 19 BP; 8 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
QY
    Query Match 0.4%; Score 19; DB 1; Length 19;
    Best Local Similarity 100.0%; Pred. No. 46;
    Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
    2635 TGCAGAACTTAGAGAGAA 2653
    |||||
    1 TGCAGAACTTAGAGAGAA 19
DB
    1 TGCAGAACTTAGAGAGAA 19
RESULT 62
AAx81673
ID AAx81673 standard; DNA; 19 BP.

```

```

XX AC AAX81673;
XX XX
XX DT 26-AUG-1999 (first entry)
XX DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX DE Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX OS Synthetic.
XX OS Erythrovirus.
XX PN FR2771751-A1.
XX PD 04-JUN-1999.
XX PF 03-DEC-1997; 97FR-00015197.
XX PR 03-DEC-1997; 97FR-00015197.
XX PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX PI Nguyen QT, Garbarg CA, Auguste V;
XX PI WPI; 1999-349543/30.
XX PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX PT diagnosis of its infections.
XX PS Claim 3; Page 64; 80pp; French.
XX CC The present PCR primer is used to amplify erythrovirus V9 polynucleotide
XX CC sequences. Probes and primers derived from erythrovirus V9 polynucleotide
XX CC sequences (AAX81580) can be used for differential diagnosis of
XX CC erythrovirus (parvovirus) infections by a combination of amplification
XX CC and hybridisation assay. The probes can also be used to assess
XX CC susceptibility to erythrovirus infection and for erythrovirus screening
XX CC and typing. The antibodies can be used in immunoassays for diagnosis of
XX CC erythrovirus V9 infections
XX SQ Sequence 19 BP; 5 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2609 CATGCTTATCATCCAGTA 2627
DB 1 CATGCTTATCATCCAGTA 19

RESULT 63
AAX81670/c
ID AAX81670 standard; DNA; 19 BP.
XX AC AAX81670;
XX DT 26-AUG-1999 (first entry)
XX DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX DE Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX OS Synthetic.
XX OS Erythrovirus.
XX PN FR2771751-A1.
XX PD 04-JUN-1999.
XX PF 03-DEC-1997; 97FR-00015197.

```

```

XX PR 03-DEC-1997; 97FR-00015197.
XX XX
XX PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX PI Nguyen QT, Garbarg CA, Auguste V;
XX PI WPI; 1999-349543/30.
XX PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX PT diagnosis of its infections.
XX PS Claim 3; Page 63; 80pp; French.
XX CC The present PCR primer is used to amplify erythrovirus V9 polynucleotide
XX CC sequences. Probes and primers derived from erythrovirus V9 polynucleotide
XX CC sequences (AAX81580) can be used for differential diagnosis of
XX CC erythrovirus (parvovirus) infections by a combination of amplification
XX CC and hybridisation assay. The probes can also be used to assess
XX CC susceptibility to erythrovirus infection and for erythrovirus screening
XX CC and typing. The antibodies can be used in immunoassays for diagnosis of
XX CC erythrovirus V9 infections
XX SQ Sequence 19 BP; 5 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.4%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 46;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2043 TTTACAGCCGCTTGCCGAT 2061
DB 19 TTTACAGCCGCTTGCCGAT 1

RESULT 64
AAA95712
ID AAA95712 standard; DNA; 20 BP.
XX AC AAA95712;
XX DT 14-FEB-2001 (first entry)
XX DE Parvovirus strain B19 primer.
XX KM Parvovirus strain B19; serum; blood; PCR primer; diagnostic; medicine;
XX KM virology; ss.
XX OS Parvovirus.
XX PN RU2146372-Cl.
XX PD 10-MAR-2000.
XX PF 16-APR-1998; 98RU-00107396.
XX PR 16-APR-1998; 98RU-00107396.
XX PA (AMHA-) A MED HAEMATOLOGY RES CENTRE.
XX PI Fevralleva IS, Sudarikov AB;
XX PI WPI; 2000-585773/55.
XX PT Method of assay of parvovirus b 19.
XX PS Disclosure; Col 3; 4pp; Russian.
XX CC The invention relates to an effective and highly specific method of
XX CC assaying for parvovirus strain B19 in blood serum. The method is based on
XX CC the use of a two-stage polymerase chain reaction (PCR) involving a
XX CC preliminary heat treatment of the sera at 95 deg. C for 10 min. The
XX CC method involves the use of sera which have not been treated with an
XX CC proteinase K. The first PCR uses primers AAA95708-95709 with an

```

CC annealing temperature of 44 deg. C. The second stage uses PCR primers
 CC AAA5710-AB5711 with an annealing temperature of 56 deg. C. The two PCRs
 CC are carried out in a single tube. The method is used in medicine and
 CC virology. This sequence is used as a primer in the method of the
 CC invention

XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 63;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2797 CTTAGTATAGCCATG 2816
 DB 1 CTTAGTATAGCCACTG 20

RESULT 65
 AAF57981/C
 ID AAF57981 standard; DNA; 20 BP.

XX AAF57981;

XX 20-APR-2001 (first entry)

XX Human parvovirus B19/porcine parvovirus detection PCR primer PRV2.

XX Human parvovirus B19; diagnosis; erythema infectiosum; aplastic crisis;
 XX polyarthralgia syndrome; hydrops; myocarditis; neurological disease;
 XX porcine parvovirus; PCR primer; probe; ss.

XX B19 virus.

XX Porcine parvovirus.

XX WO200106019-A2.

XX 25-JAN-2001.

XX 20-JUL-2000; 2000WO-US019896.

XX 20-JUL-1999; 99US-0144721P.

XX 19-JUL-2000; 2000US-00619420.

XX (VITE-) VI TECHNOLOGIES INC.

XX Lazo A, Zhao JX, Tassello JA, Gidaja V;

XX WPI; 2001-147359/15.

XX New PRVX nucleic acid molecule useful as a probe for detecting and
 PT amplifying parvovirus in sample of nucleic acid molecules and for
 PT diagnosing a disease or a condition associated with parvovirus infection
 PT in a subject.

XX Claim 10; Page 6; 30pp; English.

XX The present invention provides a number of PCR primers and probes which
 CC can be used to detect the presence of human parvovirus B19 (also known as
 CC B19 virus) and porcine parvovirus. This is useful as it enables the
 CC diagnosis of diseases associated with B19 virus, including transient
 CC aplastic crises, erythema infectiosum, polyarthralgia syndrome, hydrops,
 CC myocarditis and neurological disease

XX Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 63;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGATCTTCTGACTGGGAC 433
 DB 20 AGACACTTCTGACTGGGAC 1

RESULT 66

AD21304
 ID AAD21304 standard; DNA; 20 BP.

XX AAD21304;

XX 28-JAN-2002 (first entry)

XX 3' primer used to amplify DNA template with p53 or ER binding site.

XX DNA binding protein; therapy; cancer; p53 protein; estrogen receptor; ER;
 XX PCR primer; ss.

XX Synthetic.

XX EP1138781-A2.

XX 04-OCT-2001.

XX 19-MAR-2001; 2001EP-00106806.

XX 31-MAR-2000; 2000US-00539945.

XX (HEAL-) HEALTH RES INC.

XX Kulesz-Martin MF, Liu Y;

XX WPI; 2001-649890/75.

XX Quantifying DNA binding protein in a sample in absence of radioisotopes
 PT comprising contacting the protein with DNA having binding site for
 PT protein, separating DNA with bound protein and quantifying protein by
 PT immunoreaction.

XX Disclosure; Page 10; 26pp; English.

XX The invention relates to a method for quantifying DNA binding protein in
 CC a sample. The method is useful for identifying sequence specific DNA
 CC binding proteins, for screening compounds, proteins and reagents that
 CC target DNA-protein interactions and for simultaneously detecting multiple
 CC DNA binding protein having different molecular weights. The index
 CC reflecting proportion of bound and unbound protein in total protein is
 CC useful to determine the course of treatment for a patient or prognosis
 CC for a patient, to screen for activity of therapies and agents that alter
 CC activity of DNA binding protein favourable to treatment of disease,
 CC preferably cancer. The method is useful for research, for prognostic
 CC indicators in many diseases e.g. cancer and for detecting and quantifying
 CC the functional status of DNA binding protein that are significant in
 CC human disease by reflecting severity, prognosis and integrity of the
 CC cellular response to treatments. The present sequence is a PCR primer
 CC used to amplify a DNA template with p53 or ER (estrogen receptor) binding
 CC site. This sequence is used to measure the DNA binding of p53 protein

XX Sequence 20 BP; 9 A; 2 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 63;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 948 AAAGGAAACAAAGCGGCT 967
 DB 1 AAAGGAAACAAAGCTGGGT 20

RESULT 67

AB259579/C
 ID AB259579 standard; DNA; 20 BP.

XX AB259579;

XX 22-APR-2003 (first entry)

DE Human parvovirus B19 VP1 PCR primer VP-3 SEQ ID NO:37.
 XX
 KW Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma;
 XX PCR primer; ss.
 XX
 OS B19 virus.
 OS Synthetic.
 XX
 PN MO2003002753-A2.
 XX
 PD 09-JAN-2003.
 XX
 PF 28-JUN-2002; 2002MO-US020684.
 XX
 PR 28-JUN-2001; 2001US-0302077P.
 PR 19-MAR-2002; 2002US-0365956P.
 PR 29-MAR-2002; 2002US-0369224P.
 XX
 PA (CHIR) CHIRON CORP.
 XX
 PI Pichuanes S, Shyamala V;
 XX
 DR WPI; 2003-201510/19.
 XX
 PT Detecting a human parvovirus B19 infection in a biological sample to
 PT prevent viral transmission, comprises reacting a parvovirus B19 nucleic
 PT acid with a primer complementary to the 3'-terminal portion of the RNA
 PT target sequence.
 PS
 XX Example 2; Page 42; 148pp; English.
 CC The present invention describes a method for detecting a human parvovirus
 CC B19 infection in a biological sample. The method comprises reacting the
 CC isolated parvovirus B19 nucleic acid with a first oligonucleotide
 CC consisting of a first primer containing a complexing sequence
 CC sufficiently complementary to the 3'-terminal portion of the RNA target
 CC sequence to complex with. Also described: (1) amplifying a target
 CC parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
 CC of 4' 700 base pair sequences (see AB259549 to AB259569, and AB259604 to
 CC AB259629); (3) a polynucleotide comprising either of 2 4678 base pair
 CC sequences (see AB259570 and AB259571); (4) an oligonucleotide primer
 CC consisting of a promoter region recognised by a DNA-dependent RNA
 CC polymerase operably linked to a human parvovirus B19-specific complexing
 CC sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
 CC parvovirus B19-specific hybridising sequence of 10-50 nucleotides linked
 CC to an acridinium ester label; and (6) a diagnostic test kit comprising an
 CC oligonucleotide primer of (4), and instructions for conducting the
 CC diagnostic test. The method is useful for detecting parvovirus infection
 CC in a biological sample, such as in blood products, to prevent
 CC transmission of the virus through blood and plasma derivatives or by
 CC close personal contact. AB259549 to AB259634 and AB257262 to AB257267
 CC represent sequences used in the exemplification of the present invention
 CC
 XX
 SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 QY
 DB
 Query Match. 0.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 63;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 3315 CACCATAGAGTTTCAGAC 3334
 20 CACCTTAGAGTTTCAGAC 1
 RESULT 68
 ACC43299
 ID ACC43299 standard; DNA; 20 BP.
 XX
 AC ACC43299;
 XX
 DT 27-OCT-2003 (revised)
 DT 11-AUG-2003 (first entry)
 XX

DE Nucleotide sequence of a probe for human parvovirus B19 DNA.
 XX
 KW Parvovirus detection; probe; ss.
 XX
 OS B19 virus.
 OS
 PN MO2003020742-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 30-AUG-2002; 2002MO-US027734.
 XX
 PR 31-AUG-2001; 2001US-0316691P.
 XX
 PA (GENP-) GEN-PROBE INC.
 XX
 PI Brentano ST, Batranina-Kaminsky M, Hasselkus-right CS, Kolk DP;
 XX
 DR WPI; 2003-300859/29.
 XX
 PT Detecting human parvovirus B19 nucleic acid in biological sample involves
 PT carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.
 PS
 XX Claim 1; Page 33; 54pp; English.
 CC The present sequence represents a probe for parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.
 CC The method is useful for detecting human parvovirus B19 nucleic acid in
 CC biological samples. (Updated on 27-Oct-2003 to standardise OS field)
 CC
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 QY
 DB
 Query Match. 0.4%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 63;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 2583 GCCATGACAGTTATCTGAC 2602
 1 GTCATGACAGTTATCTGAC 20
 RESULT 69
 AAX81603
 ID AAX81603 standard; DNA; 18 BP.
 XX
 AC AAX81603;
 XX
 DT 26-AUG-1999 (first entry)
 XX
 DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
 XX
 KW Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KW erythrovirus screening; typing; immunoassay; PCR primer; ss.
 XX
 OS Synthetic.
 OS Erythrovirus.
 XX
 PN FR2771751-A1.
 XX
 PD 04-JUN-1999.
 XX
 PF 03-DEC-1997; 97FR-00015197.
 XX
 PR 03-DEC-1997; 97FR-00015197.
 XX
 PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
 XX
 PI Nguyen QT, Garbarg CA, Anguste V;

```

XX DR WPI; 1999-349543/30.
XX PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX PT diagnosis of its infections.
XX PS Claim 3; Page 25; 80pp; French.
XX CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
XX CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX CC diagnosis of erythrovirus (parvovirus) infections by a combination of
XX CC amplification and hybridisation assay. The probes can also be used to
XX CC assess susceptibility to erythrovirus infection and for erythrovirus
XX CC screening and typing. The antibodies can be used in immunoassays for
XX CC diagnosis of erythrovirus V9 infections
XX SQ Sequence 18 BP; 7 A; 6 C; 1 G; 4 T; 0 U; 0 Other;

Query Match      0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2543 CTTAAAACTCTCCAGAC 2560
Db      1 CTTAAAACTCTCCAGAC 18

RESULT 70
AAX81620
ID AAX81620 standard; DNA; 18 BP.
XX AC AAX81620;
XX DT 26-AUG-1999 (first entry)
XX DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX KW Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX KW erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX OS Synthetic.
XX OS Erythrovirus.
XX PN FR2771751-A1.
XX PD 04-JUN-1999.
XX PF 03-DEC-1997; 97FR-00015197.
XX PR 03-DEC-1997; 97FR-00015197.
XX PA (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
XX PI Nguyen QT, Garbary CA, Auguste V;
XX DR WPI; 1999-349543/30.
XX PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX PT diagnosis of its infections.
XX PS Claim 3; Page 29; 80pp; French.
XX CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
XX CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX CC polynucleotide sequences (AAX81580) can be used for differential
XX CC diagnosis of erythrovirus (parvovirus) infections by a combination of
XX CC amplification and hybridisation assay. The probes can also be used to
XX CC assess susceptibility to erythrovirus infection and for erythrovirus
XX CC screening and typing. The antibodies can be used in immunoassays for
XX CC diagnosis of erythrovirus V9 infections
XX SQ Sequence 18 BP; 6 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

```

```

Query Match      0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      4288 TCAGCTGTGAGTAAAT 4305
Db      1 TCAGCTGTGAGTAAAT 18

RESULT 71
ACC43312
ID ACC43312 standard; DNA; 18 BP.
XX AC ACC43312;
XX DT 27-OCT-2003 (revised)
XX DT 11-AUG-2003 (first entry)
XX DE Nucleotide sequence of a probe for human parvovirus B19 DNA.
XX KW Parvovirus detection; probe; ss.
XX OS B19 virus.
XX PN WO2003020742-A1.
XX PD 13-MAR-2003.
XX PF 30-AUG-2002; 2002WO-US027734.
XX PR 31-AUG-2001; 2001US-031691P.
XX PA (GENP-) GEN-PROBE INC.
XX PI Brentano ST, Battrana-Kaminsky M, Haseljus-Light CS, Kolk DP;
XX DR WPI; 2003-300859/29.
XX PT Detecting human parvovirus B19 nucleic acid in biological sample involves
XX PT carrying out amplification reaction of parvovirus B19 nucleic acid using
XX PT human parvovirus specific nucleic acid oligomers.
XX PS Claim 10; Page 48; 54pp; English.
XX CC The present sequence represents a probe for parvovirus B19 DNA. It is
XX CC used in the method of the invention. The specification describes a method
XX CC of detecting human parvovirus B19 nucleic acid in a biological sample.
XX CC The method comprises amplifying in vitro a portion of human parvovirus
XX CC B19 nucleic acid, and detecting an amplified product using a labeled
XX CC detection probe that hybridizes specifically with the amplified product.
XX CC The method is useful for detecting human parvovirus B19 nucleic acid in
XX CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)
XX SQ Sequence 18 BP; 6 A; 2 C; 4 G; 6 T; 0 U; 0 Other;

Query Match      0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2660 GTATTATCTAGTGAAGAC 2677
Db      1 GTATTATCTAGTGAAGAC 18

RESULT 72
ACC43311
ID ACC43311 standard; DNA; 18 BP.
XX AC ACC43311;
XX DT 27-OCT-2003 (revised)
XX DT 11-AUG-2003 (first entry)

```

CC sequence to complex with. Also described: (1) amplifying a target
 CC parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
 CC of 47 700 base pair sequences (see AB259549 to AB259569, and AB259604 to
 CC AB259622); (3) a polynucleotide comprising either of 2 4678 base pair
 CC sequences (see AB259570 and AB259571); (4) an oligonucleotide primer
 CC consisting of a promoter region recognised by a DNA-dependent RNA
 CC polymerase operably linked to a human parvovirus B19-specific complexing
 CC sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
 CC parvovirus B19-specific hybridising sequence of 10-50 nucleotides linked
 CC to an acridinium ester label; and (6) a diagnostic test kit comprising an
 CC oligonucleotide primer of (4), and instructions for conducting the
 CC diagnostic test. The method is useful for detecting parvovirus infection
 CC in a biological sample, such as in blood products, to prevent
 CC transmission of the virus through blood and plasma derivatives or by
 CC close personal contact. AB259549 to AB259634 and AB259634 to AB259726
 CC represent sequences used in the exemplification of the present invention
 CC
 SQ Sequence 19 BP; 6 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 76;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3316 ACCATTAGATTTCAGCAC 3334
 19 ACCTTAGATTTCAGCAC 1

RESULT 75
 AAX81595
 ID AAX81595 standard; DNA; 17 BP.

XX AAX81595;

XX 26-AUG-1999 (first entry)

XX PCR primer used to amplify erythrovirus V9 nucleotide sequences.

XX Erythrovirus V9; differential diagnosis; parvovirus; infection;

KW erythrovirus screening; typing; immunoassay; PCR primer; ss.

XX Synthetic.

OS Erythrovirus.

XX FR27171751-A1.

XX 04-JUN-1999.

XX 03-DEC-1997; 97FR-00015197.

XX 03-DEC-1997; 97FR-00015197.

XX (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.

XX Nguyen QT, Garbarg CA, Auguste V;

XX WPI, 1999-349543/30.

XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.

XX Claim 3; Page 23; 80pp; French.

XX AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9

XX polynucleotide sequences. Probes and primers derived from erythrovirus V9

XX polynucleotide sequences (AAX81580) can be used for differential

XX diagnosis of erythrovirus (parvovirus) infections by a combination of

XX amplification and hybridisation assay. The probes can also be used to

XX assess susceptibility to erythrovirus infection and for erythrovirus

XX screening and typing. The antibodies can be used in immunoassays for

SQ Sequence 17 BP; 3 A; 3 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 17; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 66;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1777 TTTGATTTCCCTGAAT 1793
 1 TTTGATTTCCCTGAAT 17

RESULT 76
 AAO23988
 ID AAO23988 standard; DNA; 18 BP.

XX AAO23988;

XX 27-AUG-2003 (revised)

XX 26-OCT-1992 (first entry)

XX VP-1/VP-2 gene primer (4).

XX VP-1; VP-2; parvo; virus; antigen; diagnosis; ss.

XX B19 virus.

XX JP0408985-A.

XX 23-MAR-1992.

XX 31-JUL-1990; 90JP-00202827.

XX 31-JUL-1990; 90JP-00202827.

XX (MITU) MITSUBISHI KASEI CORP.

XX WPI, 1992-147290/18.

XX Human parvovirus structural protein VP-1 and VP-2 genes - and recombinant
 PT antigen useful for the diagnosis of infectious erythema virus.

XX Disclosure; Fig 1; 7pp; Japanese.

XX The primers represented in AAO23985-90 are used in PCR for the

XX amplification of human parvovirus VP-1 and VP-2 gene fragments. Human

XX parvovirus VP-1 gene has the partial base sequence given in AAO23980-82.

XX Human parvovirus VP-2 gene has the partial base sequence given in

XX AAO23981-82. The gene can be used to prepare a recombinant antigen which

XX can be used for the diagnosis of parvovirus infection by radio-

XX immunoassay and enzyme immunoassay. (Updated on 27-AUG-2003 to correct OS

XX field.)

SQ Sequence 18 BP; 5 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 92;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4279 CTATGAAGTCAGCTGTG 4296
 1 CTATGAAGTCAGCTGTG 18

RESULT 77
 ACC43310
 ID ACC43310 standard; DNA; 18 BP.

XX ACC43310;

XX 27-OCT-2003 (revised)

XX 11-AUG-2003 (first entry)

XX Nucleotide sequence of a probe for human parvovirus B19 DNA.

```
XX Nucleotide sequence of a probe for human parvovirus B19 DNA.
DE Parvovirus detection; probe; ss.
XX B19 virus.
XX WO2003020742-A1.
XX 13-MAR-2003.
XX 30-AUG-2002; 2002WO-US027734.
XX 31-AUG-2001; 2001US-0316691P.
XX (GENP-) GEN-PROBE INC.
XX Brentano ST, Batranina-Kaminsky M, Hasselkus-light CS, Kolk DP;
XX WPI; 2003-300859/29.
XX
XX Detecting human parvovirus B19 nucleic acid in biological sample involves
XX carrying out amplification reaction of parvovirus B19 nucleic acid using
XX human parvovirus specific nucleic acid oligomers.
XX Claim 12; Page 47; 54pp; English.
XX
XX The present sequence represents a probe for parvovirus B19 DNA. It is
XX used in the method of the invention. The specification describes a method
XX of detecting human parvovirus B19 nucleic acid in a biological sample.
XX The method comprises amplifying in vitro a portion of human parvovirus
XX B19 nucleic acid, and detecting an amplified product using a labeled
XX detection probe that hybridizes specifically with the amplified product.
XX The method is useful for detecting human parvovirus B19 nucleic acid in
XX biological samples. (Updated on 27-OCT-2003 to standardise OS field)
XX
XX Sequence 18 BP; 7 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 55;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2670 GTGAAGACTTACACAGC 2687
DB 1 GTGAAGACTTACACAGC 18
RESULT 73
AAA95711/c
ID AAA95711 standard; DNA; 19 BP.
XX
XX AAA95711;
AC 14-FEB-2001 (first entry)
XX
XX Parvovirus strain B19 detection primer #4.
DE Parvovirus strain B19; serum; blood; PCR primer; diagnostic; medicine;
XX virology; ss.
XX Parvovirus.
XX RU2146372-C1.
XX 10-MAR-2000.
XX
XX 16-APR-1998; 98RU-00107396.
XX
XX 16-APR-1998; 98RU-00107396.
XX
XX 16-APR-1998; 98RU-00107396.
XX
XX (AMIA-) A MED HAEMATOLOGY RES CENTRE.
XX Fevralева IS, Sudarikov AB;
XX PI
```

```
XX WPI; 2000-585773/55.
XX
XX Method of assay of parvovirus b 19.
XX Claim; Col 8; 4pp; Russian.
XX
XX The invention relates to an effective and highly specific method of
XX assaying for parvovirus strain B19 in blood serum. The method is based on
XX the use of a two-stage polymerase chain reaction (PCR) involving a
XX preliminary heat treatment of the sera at 95 deg. C for 10 min. The
XX method involves the use of sera which have not been treated with
XX proteinase K. The first PCR uses primers AAA95708-A95709 with an
XX annealing temperature of 44 deg. C. The second stage uses PCR primers
XX AAA95710-A95711 with an annealing temperature of 56 deg. C. The two PCRs
XX are carried out in a single tube. The method is used in medicine and
XX virology
XX
XX Sequence 19 BP; 7 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 76;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2303 CTACCTGTCTGGATTACA 2321
DB 19 CTACCTGTCTGGATTACA 1
RESULT 74
ABZ59601/c
ID ABZ59601 standard; DNA; 19 BP.
XX
XX ABZ59601;
AC 22-APR-2003 (first entry)
XX
XX Human parvovirus B19 PCR primer VSP2 SEQ ID NO:59.
DE Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma;
XX PCR primer; ss.
XX
XX B19 virus.
XX Synthetic.
XX
XX WO2003002753-A2.
XX
XX 09-JAN-2003.
XX
XX 28-JUN-2002; 2002WO-US020684.
XX
XX 28-JUN-2001; 2001US-0302077P.
XX 19-MAR-2002; 2002US-0365956P.
XX 29-MAR-2002; 2002US-0369224P.
XX
XX (CHIR ) CHIRON CORP.
XX
XX Pichuanes S, Shyamala V;
XX WPI; 2003-201510/19.
XX
XX Detecting a human parvovirus B19 infection in a biological sample to
XX prevent viral transmission, comprises reacting a parvovirus B19 nucleic
XX acid with a primer complementary to the 3'-terminal portion of the RNA
XX target sequence.
XX
XX Example 5; Page 52; 148pp; English.
XX
XX The present invention describes a method for detecting a human parvovirus
XX B19 infection in a biological sample. The method comprises reacting the
XX isolated parvovirus B19 nucleic acid with a first oligonucleotide
XX consisting of a first primer containing a complexing sequence
XX sufficiently complementary to the 3'-terminal portion of the RNA target
```


KM Parvovirus detection; probe; ss.
 XX
 OS B19 virus.
 XX
 PN WO2003020742-A1.
 XX
 PD 13-MAR-2003.
 XX
 PF 30-AUG-2002; 2002MO-US027734.
 XX
 PR 31-AUG-2001; 2001US-0316691P.
 PA (GENP-) GEN-PROBE INC.
 XX
 PI Brentano ST, Batrannina-Kaminsky M, Hasselkus-light CS, Kolk DP;
 DR WPI; 2003-300859/29.
 XX
 PT Detecting human parvovirus B19 nucleic acid in biological sample involves
 PT carrying out amplification reaction of parvovirus B19 nucleic acid using
 PT human parvovirus specific nucleic acid oligomers.
 XX
 PS Disclosure; Page 47; 54PD; English.
 XX
 CC The present sequence represents a probe for parvovirus B19 DNA. It is
 CC used in the method of the invention. The specification describes a method
 CC of detecting human parvovirus B19 nucleic acid in a biological sample.
 CC The method comprises amplifying in vitro a portion of human parvovirus
 CC B19 nucleic acid, and detecting an amplified product using a labeled
 CC detection probe that hybridizes specifically with the amplified product.
 CC The method is useful for detecting human parvovirus B19 nucleic acid in
 CC biological samples. (Updated on 27-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 18 BP; 4 A; 3 C; 5 G; 6 T; 0 U; 0 Other;

Query Match	0.3%	Score 16.4	DB 1	Length 18
Best Local Similarity	94.4%	Pred. No. 92		
Matches 17, Conservative	0	Mismatches 1	Indels 0	Gaps 0

2583 GCCATGGACGTTATCTG 2600

RESULT 78
AAT81447
ID AAT81447 standard; RNA; 17 BP

AC AAT81447

DT 07-DEC-1997 (first entry)

DE	Human c-myc hammerhead ribozyme target sequence (nt. position 2526)
XX	
KM	Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KM	smooth muscle cell; hyperproliferation; restenosis; cancer; c-myc;
KM	coronary angioplasty; ss.
XX	

05 Homo sapiens

PN W09531541-A2

PD 23-NOV-1995.

PF 18-MAY-1995;

PR 18-MAY-1994; 94US-00245466.

PR 13-JAN-1995;
YY

PA (RIBO-) RIBOZYME PHARM INC.
YY

PI Stinchcomb DT, Draper K, McSwiggan J, Jarvis T,
XX

DR WPI; 1996-010927/01.

PT New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myc
PT for treating restenosis or cancer.

PS Claim 1; Page 75; 128pp; English.

The present sequence represents the preferred target sequence for an enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves the human c-myc sequence at the base position indicated in the descriptor line. The c-myc sequence was screened for optimal ribozyme target sites using a computer folding algorithm, and regions of the mRNA which did not form secondary folding structures and contained potential ribozyme cleavage sites were identified. Ribozymes were synthesised and their activities optimised by either varying the length of the binding arms or by modification to prevent degradation by nucleases. The ribozymes cleave the c-myc sequence and can be used to prevent smooth muscle cell hyperproliferation in restenosis, especially after coronary angioplasty, and in cancers

Sequence 17 BP; 8 A; 1 C; 0 G; 0 T; 8 U; 0 Other;

Query Match	0.3%;	Score 15.4;	DB 1;	Length 17;
Best Local Similarity	52.9%;	Pred. No. 1,1e+02;		
Matches	9;	Conservative	1;	Indels 0; Gaps 0
		Mismatches	7;	

QY	4379	CAATATTTTAAAAAT	4395
		::: :	
Db	1	CAUAUAUUUUAAAAAU	17

RESULT 75

ID AAX63956 standard; RNA; 17 BP

AC AAX63956

DT 20-JUL-1999 (first entry)

DE Rabbit stromelysin hammerhead target SEQ ID NO:588.

Arthritic condition; graft tolerance; immune response; target; cleavage; hammehead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase; streptomycin; synovial membrane; joint; arthritis; osteoarthritis; rheumatoid arthritis; autoimmune disease; allergy; inflammation; diagnosis; ss.

Oryctolagus cuniculus.

PN W09618736-A2

PD 20-JUN-1996

PF 22-NOV-1995; 95WO-US015516

PR 13-DEC-1994; 94US-00354920

PR 23-DEC-1994; 94US-00363254

PR 20-APR-1995; 95US-00426124

PR 04-MAY-1995; 95US-00434509

PR 07-JUL-1995; 95US-0000974P

PR 05-OCT-1995; 95US-00541365

PA (RIBO-) RIBOZYME PHARM INC.

PI Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;

PI Karpelsky A, Thompson JD, Modak A, Burgin A;
.....

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention

XX SQ. Sequence 17 BP; 5 A; 2 C; 2 G; 0 T; 8 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 703 ACCAAGGAAATATTT 719
 DB 17 ACCTAAGGAAATATTT 1

RESULT 82
 AAX69020
 ID AAX69020 standard; RNA; 17 BP.

AC AAX69020;

DT 28-JUL-1999 (first entry)

DE Human flt1 VEGF receptor hammethead ribozyme substrate #315.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KM KDR; hammethead ribozyme; hairpin ribozyme; cleavage;
 KM tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KM fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KM foetal liver kinase 1; ss.

OS Homo sapiens.

PN WO9715662-A2.

PD 01-MAY-1997.

PF 25-OCT-1996; 96WO-US017480.

PR 26-OCT-1995; 95US-0005974P.

PR 11-JAN-1996; 96US-00584040.

PA (RIBO-) RIBOZYME PHARM INC.

PA (CHTR) CHIRON CORP.

PI Pavco P, Mcswigen J, Stinchcomb D, Escobedo J;

PI WPI; 1997-259017/23.

PT Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA

PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.

PS. Claim 4; Page 56; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention

XX SQ. Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 1.1e+02;
 Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2282 TGTTAAGTGTAAAAA 2298
 DB 1 TGTUAAACUUGAAAAA 17

RESULT 83
 AAF57372/C
 ID AAF57372 standard; DNA; 17 BP.

AC AAF57372;

DT 11-JUN-2001 (first entry)

DE Murine Cdc25A intron 10/exon 11 splice junction sequence.

KM Cdc25; Cdc25 phosphatase; transcription; modulator; murine; Cdc25A; exon;
 KM intron; ds.

OS Mus sp.

PN MO200120034-A2.

PD 22-MAR-2001.

PF 11-SEP-2000; 2000WO-US024838.

PR 13-SEP-1999; 99US-0153639P.

PA (BAD1) BASF AG.

PI Voss J, Tlamm J;

PI WPI; 2001-244825/25.

PT Assay for screening modulators of Cdc25 activity by using a cell having a
 PT recombinant Cdc25 phosphatase gene whose expression alters the
 PT transcription of a selected gene in the presence of a modulator.

PS Example 1; Page 15; 55pp; English.

XX The invention relates to a method of identifying a modulator of Cdc25
 CC activity that comprises contacting a test cell having a recombinant Cdc25
 CC phosphatase gene whose expression alters transcription of a selected
 CC gene, with a compound under conditions where recombinant Cdc25
 CC phosphatase gene is expressed and alters the transcription of a selected
 CC gene as an indication of the compound being a modulator of Cdc25-mediated
 CC transcription. The method is useful for identifying modulators of Cdc25
 CC activity. Sequences AAF57363-376 represent intron/exon splice junction
 CC sequences of the murine Cdc25A gene

XX SQ. Sequence 17 BP; 4 A; 2 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2483 GATTAATCCTTGAAGA 2499
 DB 17 GATTAACCTTTGAAAA 1

RESULT 84
 ADB02992/C
 ID ADB02992 standard; DNA; 17 BP.

AC ADB02992;

DT 20-NOV-2003 (first entry)

DE Human MD24 scanning oligonucleotide SEQ ID 3978.

KM Cytostatic; immunostimulant; gene therapy; vaccine; human;
 KM zinc finger protein; MD23; MD24; MD27; MD212; chromosome 7q22.1;

KM chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
 KM developmental disorder; ss.
 XX
 OS Homo sapiens.
 XX
 XX EPI281758-A2.
 PN
 XX 05-FEB-2003.
 PD
 XX 30-JUL-2002; 2002EP-00016874.
 PF
 XX 02-AUG-2001; 2001US-00922181.
 PR
 XX (AEOM-) AEOMICA INC.
 PA
 XX Shannon M, Gu Y, Nguyen C;
 PI
 XX WPI; 2003-423107/40.
 DR
 XX
 XX New zinc finger-containing proteins and nucleic acids, useful in
 PT manufacturing a medicament for treating or preventing a disorder
 associated with decreased or increased expression or activity of MD23,
 PT MD24, MD27 or MD212, e.g. cancer.
 PS
 XX Example 8; SEQ ID NO 3978; 103pp; English.
 CC The present invention relates to novel human zinc finger-containing
 CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
 CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
 CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
 CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
 CC or in manufacturing a medicament for treating or preventing a disorder
 CC associated with decreased or increased expression or activity of MD23,
 CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
 CC acids and proteins are also useful for diagnosing or monitoring a disease
 CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
 CC acids can also be used as probes to detect and characterize gross
 CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
 CC useful in constructing microarrays for measuring gene expression. The
 CC proteins are useful as therapeutic agents for gene therapy or as
 CC vaccines. The present sequence was used to illustrate the invention.
 CC
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 3937 AGGTGCTGAAAAGCCC 3953
 Db 17 AGGTGATGAAAAGCCC 1
 RESULT 85
 ACC64692
 ID ACC64692 standard; DNA; 17 BP.
 AC ACC64692;
 XX
 DT 01-JUL-2003 (first entry)
 XX
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1939.
 XX
 KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KM tumour suppression; tumour reversion; apoptosis; virus resistance;
 KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KM schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 XX WO2003025176-A2.
 PN
 XX 27-MAR-2003.
 PD

XX
 PF 17-SEP-2002; 2002WO-IB004210.
 XX
 XX 17-SEP-2001; 2001FR-00011979.
 FR
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA
 XX
 XX Teلمان A, Amson R, Tuijnder M;
 PI
 XX WPI; 2003-333167/31.
 DR
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 PS
 XX Disclosure; Page 257; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC68806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip, in vitro as (anti)sense reagents; and (2) for production of a
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 CC
 XX
 SQ Sequence 17 BP; 1 A; 3 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 78 GATTGCTGCTCTTT 94
 Db 1 GATTGCTGCTCTTT 17
 RESULT 86
 ACC64692/c
 ID ACC64692 standard; DNA; 17 BP.
 AC ACC64692;
 XX
 DT 01-JUL-2003 (first entry)
 XX
 DE Murine oligonucleotide associated with tumour suppression, SEQ ID 1939.
 XX
 KM Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 KM tumour suppression; tumour reversion; apoptosis; virus resistance;
 KM viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KM schizophrenia; ss.
 XX
 OS Mus musculus.
 XX
 XX WO2003025176-A2.
 PN
 XX 27-MAR-2003.
 PD
 XX 17-SEP-2002; 2002WO-IB004210.
 PF
 XX 17-SEP-2001; 2001FR-00011979.
 PR
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA
 XX Teلمان A, Amson R, Tuijnder M;
 PI
 XX WPI; 2003-333167/31.
 DR
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.

XX PS Disclosure; Page 257; 738bp; French.
 XX CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC68806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of a
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 SQ Sequence 17 BP; 1 A; 3 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 1.1e+02;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 4935 AAGAGACACCAATC 4951
 DB |||||
 17 AAGAGACACCAATC 1
 RESULT 87
 AAL42963/C
 ID AAL42963 standard; DNA; 15 BP.
 AC AAL42963;
 XX
 DT 08-AUG-2002 (first entry)
 XX
 DE Human cerberus 1 (CER1) gene allele-specific oligonucleotide probe 7.
 XX
 KW Human; probe; ss; allele-specific; SNP; single nucleotide polymorphism;
 KW cerberus 1 homologue; cysteine knot superfamily; CER1; drug screening;
 KW developmental disorder; polymorphic site; CER1 haplotyping.
 XX
 OS Homo sapiens.
 XX
 PN WO200232929-A2.
 XX
 PD 25-APR-2002.
 XX
 PF 19-OCT-2001; 2001WO-US046100.
 XX
 PR 19-OCT-2000; 2000US-0241634P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Kazemi A, Shah N;
 XX
 DR WPI; 2002-435527/46.
 XX
 PT Novel genetic variants of Cerberus 1 (Xenopus laevis) Homolog (Cysteine
 PT Knot Superfamily) (CER1) isogenes, useful for improving efficiency and
 PT reliability in drug development for treating developmental disorders.
 XX
 PS Claim 14; Page 13; 75pp; English.
 XX
 CC The invention relates to the identification of 13 novel polymorphic sites
 CC in the human cerberus 1 (Xenopus laevis) homologue (cysteine knot
 CC superfamily) (CER1) gene. The invention also comprises the amino acid and
 CC coding sequence of CER1. The CER1 protein is useful for screening drugs
 CC that target CER1 - for the treatment of developmental disorders. The CER1
 CC coding sequence is useful in studying the expression of CER1 isogenes,
 CC for screening and testing of drugs targeted against CER1 protein, and in
 CC testing the efficacy of therapeutic agents for treating developmental
 CC disorders. The 13 novel polymorphic sites identified in the invention are
 CC useful for haplotyping the CER1 gene of an individual. The present DNA
 CC sequence represents a human CER1 gene allele-specific oligonucleotide
 CC probe

XX SQ Sequence 15 BP; 6 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
 Query Match 0.3%; Score 14.6; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4921 TTTAAATTTTCAA 4935
 DB |||||
 15 TTTAAATTTTCAA 1
 RESULT 88
 AAL42984/C
 ID AAL42984 standard; DNA; 15 BP.
 AC AAL42984;
 XX
 DT 08-AUG-2002 (first entry)
 XX
 DE Human cerberus 1 (CER1) gene allele-specific oligonucleotide primer 15.
 XX
 KW Human; PCR; allele-specific; SNP; single nucleotide polymorphism; ss;
 KW cerberus 1 homologue; cysteine knot superfamily; CER1; drug screening;
 KW developmental disorder; polymorphic site; CER1 haplotyping; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200232929-A2.
 XX
 PD 25-APR-2002.
 XX
 PF 19-OCT-2001; 2001WO-US046100.
 XX
 PR 19-OCT-2000; 2000US-0241634P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Kazemi A, Shah N;
 XX
 DR WPI; 2002-435527/46.
 XX
 PT Novel genetic variants of Cerberus 1 (Xenopus laevis) Homolog (Cysteine
 PT Knot Superfamily) (CER1) isogenes, useful for improving efficiency and
 PT reliability in drug development for treating developmental disorders.
 XX
 PS Claim 14; Page 13; 75pp; English.
 XX
 CC The invention relates to the identification of 13 novel polymorphic sites
 CC in the human cerberus 1 (Xenopus laevis) homologue (cysteine knot
 CC superfamily) (CER1) gene. The invention also comprises the amino acid and
 CC coding sequence of CER1. The CER1 protein is useful for screening drugs
 CC that target CER1 - for the treatment of developmental disorders. The CER1
 CC coding sequence is useful in studying the expression of CER1 isogenes,
 CC for screening and testing of drugs targeted against CER1 protein, and in
 CC testing the efficacy of therapeutic agents for treating developmental
 CC disorders. The 13 novel polymorphic sites identified in the invention are
 CC useful for haplotyping the CER1 gene of an individual. The present DNA
 CC sequence represents a human CER1 gene allele-specific oligonucleotide
 CC primer
 XX
 SQ Sequence 15 BP; 5 A; 0 C; 1 G; 8 T; 0 U; 1 Other;
 Query Match 0.3%; Score 14.6; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4921 TTTAAATTTTCAA 4935
 DB |||||
 15 TTTAAATTTTCAA 1
 RESULT 89

AD24994/c
 ID AAD24994 standard; DNA; 15 BP.
 XX
 AC AAD24994;
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human AANAT gene polymorphism detecting ASO primer #8.
 XX
 KM Human; genetic variant; arylalkylamine N-acetyltransferase; AANAT gene;
 KM haplotyping; genotyping; pineal gland disorder; melatonin synthesis;
 KM gene therapy; antisense therapy; allele specific oligonucleotide;
 KM ASO primer; polymorphism; ss.
 XX
 OS Homo sapiens.
 XX
 PN MO200187909-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 18-MAY-2001; 2001MO-US016279.
 XX
 PR 18-MAY-2000; 2000US-0205068P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Choi JY, Kazemi A, Nandabalan K;
 XX
 DR WPI; 2002-055682/07.
 XX
 PT New genetic variants of human arylalkylamine N-acetyltransferase (AANAT)
 PT gene for studying expression, function of the gene and expressing AANAT
 PT protein for use in screening for drugs to treat disorders of pineal
 PT gland.
 XX
 PS Claim 16; Page 13; 67pp; English.
 XX
 CC The patent discloses novel genetic variants of the arylalkylamine N-
 CC acetyltransferase (AANAT) gene. The invention also relates to
 CC compositions and methods for haplotyping and/or genotyping the AANAT
 CC gene. Polymorphic variants of AANAT protein are useful for screening for
 CC drugs targeting the polypeptide. AANAT polynucleotides are useful for
 CC studying the expression and function of AANAT and for expressing AANAT
 CC protein for use in screening for candidate drugs to treat diseases
 CC related to AANAT activity. The methods are used to develop diagnostic
 CC tests and therapeutic treatment for disorders of pineal gland that derive
 CC from defects in melatonin synthesis. It is useful for determining whether
 CC an individual has one of the haplotypes 1-4 or the haplotype pairs. The
 CC haplotyping method is useful to validate AANAT as a candidate target for
 CC treating a specific condition or disease predicted to be associated with
 CC AANAT activity. AANAT sequences of the invention are also used in gene
 CC therapy and antisense therapy. The present DNA sequence is an allele.
 CC specific oligonucleotide (ASO) primer which is used for detecting human
 CC AANAT gene polymorphisms
 XX
 SQ Sequence 15 BP; 1 A; 3 C; 5 G; 5 T; 0 U; 1 Other;
 XX
 QY Query Match 0.3%; Score 14.6; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1e+02;
 Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 XX
 DB 3442 TGACAGCACCACAGG 3456
 15 TRACAGCACCACAGG 1
 XX
 RESULT 90
 AAX81622/c
 ID AAX81622 standard; DNA; 21 BP.
 XX
 AC AAX81622;
 XX
 DT 26-AUG-1999 (first entry)

XX
 DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
 XX
 KM Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
 XX
 OS Synthetic.
 OS Erythrovirus.
 XX
 PN FR2771751-A1.
 XX
 PD 04-JUN-1999.
 XX
 PF 03-DEC-1997; 97FR-00015197.
 XX
 PR 03-DEC-1997; 97FR-00015197.
 XX
 PA (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
 XX
 PI Nguyen QT, Garbarg CA, Auguste V;
 XX
 DR WPI; 1999-349543/30.
 XX
 PT Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 XX
 PS Claim 3; Page 30; 80pp; French.
 XX
 CC AAX81588-X81630 represent PCR primers used to amplify erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential
 CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antipodes can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections
 XX
 SQ Sequence 21 BP; 10 A; 3 C; 0 G; 8 T; 0 U; 0 Other;
 XX
 QY Query Match 0.3%; Score 14.4; DB 1; Length 21;
 Best Local Similarity 93.8%; Pred. No. 2.2e+02;
 Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 XX
 DB 4383 TATTTTAAAAAATCT 4398
 21 TATTTTAAAAAATCT 6
 XX
 RESULT 91
 AAD45233/c
 ID AAD45233 standard; DNA; 15 BP.
 XX
 AC AAD45233;
 XX
 DT 27-DEC-2002 (first entry)
 XX
 DE Human PON-1 gene polymorphism detecting ASO probe #1.
 XX
 KM Human; paroxonase 1; PON1; single nucleotide polymorphism; transgenic;
 KM SNP; drug screening; organo-phosphorous metabolism; target validation;
 KM atherosclerosis; type II diabetes; gene therapy; antilipemic; probe;
 KM allele specific oligonucleotide; ASO; ss.
 XX
 OS Homo sapiens.
 XX
 PN MO200266680-A1.
 XX
 PD 29-AUG-2002.
 XX
 PF 06-DEC-2001; 2001MO-US046896.
 XX
 PR 16-FEB-2001; 2001MO-US005126.
 XX

XX The invention describes an isolated polynucleotide comprising a
 CC nucleotide sequence which is a polymorphic variant of a reference
 CC sequence for the aldehyde dehydrogenase 5 family, member A1 (succinate-
 CC semialdehyde dehydrogenase) (ALDH5A1) gene or its fragment. The
 CC polypeptide is useful for screening for drugs targeting it by contacting
 CC the ALDH5A1 polymorphic variant with a candidate agent and assaying for
 CC binding activity. The polypeptide and haplotypes are useful for
 CC identifying an association between a trait such as a clinical response to
 CC a drug targeting ALDH5A1 and a haplotype of ALDH5A1 gene. Transgenic animals
 CC are also useful for studying expression of the ALDH5A1 isogenes in vivo,
 CC for in vivo screening and testing of drugs against ALDH5A1 protein and
 CC for testing the efficacy of therapeutic agents and compounds for 4-
 CC hydroxybutyric aciduria and metabolic diseases in a biological system.
 CC Antibodies are useful for diagnostic and prognostic formats and
 CC therapeutic methods, for immunoprecipitating the polypeptide from
 CC solution, for detecting ALDH5A1 protein isoforms in biological samples,
 CC frozen tissue sections, for use in immunocytochemical,
 CC immunohistochemical and immunofluorescence techniques. The polynucleotide
 CC is useful for gene therapy and antisense gene therapy. This sequence is
 CC an allele specific oligonucleotide (ASO) primer used to detect
 CC polymorphisms in the ALDH5A1 gene described in the method of the
 CC invention

XX Sequence 15 BP; 3 A; 10 C; 0 G; 1 T; 0 U; 1 Other;

XX Query Match 0.3%; Score 13.6; DB 1; Length 15;
 XX Best Local Similarity 92.9%; Pred. No. 1.4e+02;
 XX Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2152 GGCGGAGCGGTGGG 2165
 DB 15 GGCGGAGCGGTGGG 2

RESULT 94
 AAX81647/c
 ID AAX81647 standard; DNA; 30 BP.
 AC AAX81647;
 DT 26-AUG-1999 (first entry)
 XX Probe used to isolate erythrovirus V9 nucleotide sequences.
 DE Erythrovirus V9; differential diagnosis; parvovirus; infection;
 KM erythrovirus screening; typing; immunoassay; probe; ss.
 XX
 OS Synthetic.
 OS Erythrovirus.
 XX
 PN FR2771751-A1.
 XX
 PD 04-JUN-1999.
 XX
 PF 03-DEC-1997; 97FR-00015197.
 XX
 PR 03-DEC-1997; 97FR-00015197.
 XX
 PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
 PI Nguyen QT, Garbarg CA, Auguste V;
 DR WPI; 1999-349543/30.
 XX
 XX Erythrovirus V9 and its nucleic acid sequences - can be used in the
 PT diagnosis of its infections.
 XX
 PS Claim 3; Page 37; 80pp; French.
 CC AAX81630-X81666 represent probes used to isolate erythrovirus V9
 CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
 CC polynucleotide sequences (AAX81580) can be used for differential

CC diagnosis of erythrovirus (parvovirus) infections by a combination of
 CC amplification and hybridisation assay. The probes can also be used to
 CC assess susceptibility to erythrovirus infection and for erythrovirus
 CC screening and typing. The antibodies can be used in immunoassays for
 CC diagnosis of erythrovirus V9 infections

XX Sequence 30 BP; 8 A; 4 C; 6 G; 12 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 13.2; DB 1; Length 30;
 XX Best Local Similarity 83.3%; Pred. No. 2.8e+02;
 XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3769 AATGTACACCTTTGTA 3786
 DB 30 AATGTACAAACTTTGTA 13

RESULT 95
 ABC44830
 ID ABC44830 standard; DNA; 13 BP.
 AC ABC44830;
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 44847 for detecting SNP TSC0013119.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 EN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 44847; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 13; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2411 TTTATGAAAAG 2423

PA (GENA-) GENAISSANCE PHARM INC.
 XX Anastrasio AE, Chew A, Choi JY, Denton RR, Nandabalan K, Parks KE;
 PI Stephens JC;
 XX WPI; 2002-682769/73.
 DR
 XX New genetic variants of human paraoxonase 1 (PON1) gene with
 PT polymorphisms, useful for treating disorders associated with PON1 isogene
 PT activity e.g. atherosclerosis or diabetes, or for screening drugs for
 PT treating these diseases.
 XX
 PS Claim 15, Page 15; 118pp; English.
 CC The invention relates to methods for haplotyping human paraoxonase 1
 CC (PON1) gene. It also relates to the single nucleotide polymorphisms (SNP)
 CC in PON-1 gene. Polymorphic variants of the PON1 gene are useful in
 CC studying the expression and function of PON1, and in expressing PON1
 CC proteins for use in screening candidate drugs to treat diseases
 CC associated with PON1 activity, e.g. disorders of lipid and organo-
 CC phosphorous metabolism such as atherosclerosis or type II diabetes. They
 CC are also used in gene therapy. Establishing PON1 haplotype or haplotype
 CC pair of an individual is useful for improving the efficiency and
 CC reliability of several steps including target validation, in the
 CC discovery and development of drugs for treating diseases associated with
 CC PON1 activity. Transgenic animals are useful for studying expression of
 CC the PON1 isogenes in vivo. The present sequence is an allele specific
 CC oligonucleotide (ASO) probe used to detect human PON-1 gene polymorphisms
 CC
 SQ Sequence 15 BP; 4 A; 3 C; 5 G; 2 T; 0 U; 1 Other;
 OY
 Query Match 0.3%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.4e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 4549 TCCTCATGCAGCTG 4562
 14 TCCTCAGCAGCTG 1
 RESULT 92
 ABA99286
 ID ABA99286 standard; DNA; 15 BP.
 AC ABA99286;
 XX
 DT 13-MAY-2002 (first entry)
 DE Human ALDH5 allele-specific oligonucleotide SEQ ID No 6.
 XX
 KW ALDH5, human; gene; polymorphism; haplotype; aldehyde dehydrogenase 5;
 KW binding affinity; drug targeting; alcoholism; alcohol-induced disorder;
 KW antialcoholic; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192279-A2.
 PD 06-DEC-2001.
 XX
 PF 29-MAY-2001; 2001WO-US017253.
 XX
 PR 26-MAY-2000; 2000US-0207508P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Duda A, Finkel K, Kazemi A, Messer C, Sanchis A;
 XX WPI; 2002-122054/16.
 DR
 XX New genetic variants with polymorphisms in the aldehyde dehydrogenase 5
 PT (ALDH5) gene, useful for studying the function of ALDH5, and for
 PT expressing ALDH5 protein which is useful in screening drugs for treating

PT ALDH5-related diseases.
 XX
 PS Claim 17; Page 75; 96pp; English.
 XX
 CC This invention describes a novel isolated genes and haplotypes of the
 CC human aldehyde dehydrogenase 5 (ALDH5) gene containing polymorphic sites.
 CC The polymorphic ALDH5 variant is useful in studying the effect of the
 CC variation on the biological activity of ALDH5 and on the binding affinity
 CC of candidate drugs targeting ALDH5 for the treatment of alcoholism and
 CC alcohol-induced disorders. Polynucleotides comprising a polymorphic gene
 CC variant or fragment may be used for therapeutic purposes. ALDH5 protein
 CC isoforms may be used in assays to measure the binding affinities of one
 CC or more candidate drugs targeting the ALDH5 protein. ALDH5 proteins may
 CC be used to generate antibodies. Haplotyping method can be used by
 CC scientists to validate ALDH5 as a candidate target for treating a
 CC specific condition or disease predicted to be associated with ALDH5
 CC activity, and in the design of clinical trials of candidate drugs for
 CC treating a specific condition or disease predicted to be associated with
 CC ALDH5 activity. Information on polymorphisms on the ALDH5 gene can be
 CC applied for studying the biological function of ALDH5 as well as in
 CC identifying drugs targeting this protein for the treatment of disorders
 CC related to its abnormal expression or function. The products of the
 CC invention have antialcoholic activity. This sequence represents a human
 CC ALDH5 allele-specific oligonucleotide described in the disclosure of the
 CC invention
 XX
 SQ Sequence 15 BP; 2 A; 1 C; 6 G; 5 T; 0 U; 1 Other;
 OY
 Query Match 0.3%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.4e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 494 ATTTTACTGCGCGG 507
 2 ATTTTATGTGCGCGG 15
 RESULT 93
 AAS99335/c
 ID AAS99335 standard; DNA; 15 BP.
 AC AAS99335;
 XX
 DT 12-MAR-2002 (first entry)
 DE Aldehyde dehydrogenase 5 family, member A1, oligonucleotide #28.
 XX
 KW Aldehyde dehydrogenase 5 family member A1; ALDH5A1;
 KW succinate-semialdehyde dehydrogenase; gene therapy; primer;
 KW antisense technology; allele specific oligonucleotide; ASO;
 KW 4-hydroxybutyric aciduria; metabolic disease; transgenic animal; ss.
 XX
 OS Synthetic.
 XX
 PN WO200190119-A2.
 PD 29-NOV-2001.
 XX
 PF 21-MAY-2001; 2001WO-US016558.
 XX
 PR 19-MAY-2000; 2000US-0205849P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Kiem SE, Koshy B, Tanguay DA;
 XX WPI; 2002-089912/12.
 DR
 XX New genetic variants of human aldehyde dehydrogenase 5 family, member A1,
 PT ALDH5A1 gene for treating metabolic diseases and for expressing ALDH5A1
 PT protein useful in identifying drugs to treat 4-hydroxybutyric aciduria.
 XX
 PS Claim 16; Page 14; 151pp; English.

Db	1	TTTTATGAAAAAG	13
RESULT 96			
ABC28197/c			
ID	ABC28197	standard; DNA; 13 BP.	
XX			
AC	ABC28197;		
XX			
DT	20-FEB-2002	(first entry)	
XX			
DE	Oligonucleotide SEQ ID NO 28214	for detecting SNP TSC0007986.	
XX			
XX	SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;		
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;		
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.		
OS	Homo sapiens.		
PN	WO200177384-A2.		
PD	18-OCT-2001.		
XX			
PF	06-APR-2001; 2001WO-1B000713.		
XX			
PR	07-APR-2000; 2000DE-01019173.		
XX			
PA	(EPIG-) EPIGENOMICS AG.		
PI	Olek A, Piepenbrock C, Berlin K;		
XX			
DR	WPI; 2001-657177/75.		
XX			
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is		
PT	designed to detect single-nucleotide polymorphisms and cytosine		
PT	methylation status.		
XX			
PS	Claim 1; SEQ ID NO 28214; 29pp + Sequence Listing; German.		
XX			
CC	This invention describes novel oligonucleotide primers or peptide nucleic		
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)		
CC	and cytosine methylation status in chemically pretreated genomic DNA. The		
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a		
CC	range of diseases including immune system, gastrointestinal, respiratory,		
CC	central nervous system, cardiovascular and metabolic disorders. The		
CC	oligomers are also used for detecting cell type differentiation. ABC000010		
CC	-ABC99989, ABR00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073		
CC	represent the oligomers described in the invention. NOTE: The sequence		
CC	data for this patent did not form part of the printed specification, but		
CC	was obtained in electronic format from WIPO at		
CC	ftp.wipo.int/pub/published_pct_sequences		
XX			
XX	Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;		
QY	Query Match	0.3%; Score 13; DB 1; Length 13;	
	Best Local Similarity	100.0%; Pred. No. 1.2e+02;	
	Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Db	1588 GTTGTGAGTGGTA 1600		
	13 GTTGTGAGTGGTA 1		
RESULT 97			
ABC55713			
ID	ABC55713	standard; DNA; 13 BP.	
XX			
AC	ABC55713;		
XX			
DT	21-FEB-2002	(first entry)	
XX			
DE	Oligonucleotide SEQ ID NO 55730	for detecting SNP TSC0015185.	

XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
PN	
XX	
PD	18-OCT-2001.
XX	
PE	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 55730; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. AB000010
CC	-AB099989, AB000010-AB099989, AB000010-AB099989 and AB000010-AB182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
	Query Match 0.3%; Score 13; DB 1; Length 13;
	Best Local Similarity 100.0%; Pred. No. 1.2e+02;
	Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	306 TACTACTTTTAA 318
DB	1 TACTACTTTTAA 13
RESULT 98	
ABC87118	
ID	ABC87118 standard; DNA; 13 BP.
XX	
AC	ABC87118;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 87135 for detecting SNP TSC0021905.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
PN	
PS	
PD	18-OCT-2001.
XX	
PE	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 55730; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. AB000010
CC	-AB099989, AB000010-AB099989, AB000010-AB099989 and AB000010-AB182073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;
	Query Match 0.3%; Score 13; DB 1; Length 13;
	Best Local Similarity 100.0%; Pred. No. 1.2e+02;
	Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	306 TACTACTTTTAA 318
DB	1 TACTACTTTTAA 13
RESULT 98	
ABC87118	
ID	ABC87118 standard; DNA; 13 BP.
XX	
AC	ABC87118;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 87135 for detecting SNP TSC0021905.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
PN	
PS	
PD	18-OCT-2001.
XX	
PE	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
XX	
PS	Claim 1; SEQ ID NO 55730; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC</	

PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 87135; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 1 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1193 AAAAAATTAATGCT 1205
DB 1 AAAAAATTAATGCT 13
XX
XX RESULT 99
ABC87968/c
ID ABC87968 standard; DNA; 13 BP.
XX
XX ABC87968;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 87985 for detecting SNP TSC0022114.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 87985; 29pp + Sequence Listing; German.

XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 0 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2875 AAAAAATTAATTAAT 2887
DB 13 AAAAAATTAATTAAT 1
XX
XX RESULT 100
ABF74977
ID ABF74977 standard; DNA; 13 BP.
XX
XX ABF74977;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 174974 for detecting SNP TSC0043498.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 174974; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

```
XX Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 3310 TTTCACCATTA 3322
DB 1 TTTCACCATTA 13
RESULT 101
ABH02517
ID ABH02517 standard; DNA; 13 BP.
AC ABH02517;
DT 22-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 202494 for detecting SNP TSC0049770.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 202494; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 9 A; 3 C; 0 G; 1 T; 0 U; 0 Other;
OY
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DB 1284 TAAAAAACACC 1296
DB 1 TAAAAAACACC 13
RESULT 102
```

```
ABF83464/c
ID ABF83464 standard; DNA; 13 BP.
XX
XX ABF83464;
AC
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 183461 for detecting SNP TSC0045298.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 183461; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4391 AAAATCTACAC 4403
DB 13 AAAATCTACAC 1
RESULT 103
ABH45580
ID ABH45580 standard; DNA; 13 BP.
AC ABH45580;
DT 22-FEB-2002 (first entry)
DE
XX
XX Oligonucleotide SEQ ID NO 245557 for detecting SNP TSC0059958.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 245557; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2409 AATTTATGAAAA 2421
DB 1 AATTTATGAAAA 13

RESULT 104
ABH61839
ID ABH61839 standard; DNA; 13 BP.
XX ABH61839;
XX AC
XX XX
XX XX
XX 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 261816 for detecting SNP TSC0063522.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
```

```
XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 261816; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 TTAACCTTAATT 686
DB 1 TTAACCTTAATT 13

RESULT 105
ABC93518/C
ID ABC93518 standard; DNA; 13 BP.
XX ABC93518;
XX AC
XX XX
XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 93535 for detecting SNP TSC0023374.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 93535; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
```


CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

Sequence 13 BP; 2 A; 0 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;

Matches 13; Conservative 0; Indels 0; Gaps 0;
Db 2874 AAAATATATAAAAA 2886
13 AAAATATATAAAAA 1

RESULT 106
ABF99196/c
ID ABF99196 standard; DNA; 13 BP.

XX ABF99196;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 139193 for detecting SNP TSC0034867.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 139193; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and

XX cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH2073

XX represent the oligomers described in the invention. NOTE: The sequence

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Query 3487 TAAATACCATAT 3499
13 TAAATACCATAT 1

RESULT 107
ABH17341
ID ABH17341 standard; DNA; 13 BP.

XX ABH17341;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 217318 for detecting SNP TSC0052834.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 217318; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and

XX cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH2073

XX represent the oligomers described in the invention. NOTE: The sequence

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;

Matches 13; Conservative 0; Indels 0; Gaps 0;
Query 2539 TAACTTTAAAC 2551
1 TAACTTTAAAC 13

RESULT 108

ABF96463/c

ID ABF96463 standard; DNA; 13 BP.

XX ABF96463;

DT 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 196460 for detecting SNP TSC0008585.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX MO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 196460; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX
XX Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred.No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 144 TTTAATGTTATAT 156
DB 13 TTTAATGTTATAT 1
RESULT 109
ABH03634/C
ID ABH03634 standard; DNA; 13 BP.
XX
XX ABH03634;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 203611 for detecting SNP TSC004989.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX MO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD

XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 203611; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
XX
XX Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred.No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2343 AAACCACTACCA 2355
DB 13 AAACCACTACCA 1
RESULT 110
ABH44073/C
ID ABH44073 standard; DNA; 13 BP.
XX
XX ABH44073;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 244050 for detecting SNP TSC0059546.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX MO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PT methylation status.
XX
XX Claim 1; SEQ ID NO 244050; 29bp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989, and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;
Matches 13; Conservative 0; Indels 0; Gaps 0;

Qy 1194 AAATAAATATGTA 1206
Db 13 AAATAAATATGTA 1

RESULT 111
ABC99979
ID ABC99979 standard; DNA; 13 BP.
XX
XX ABC99979;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 99996 for detecting SNP TSC0024859.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 99996; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 2 A; 10 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;
Matches 13; Conservative 0; Indels 0; Gaps 0;

Qy 4717 CCCACCGCCACC 4729
Db 1 CCCACCGCCACC 13

RESULT 112
ABC85489/C
ID ABC85489 standard; DNA; 13 BP.
XX
XX ABC85489;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 85506 for detecting SNP TSC0021486.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 85506; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;
Matches 13; Conservative 0; Indels 0; Gaps 0;

Qy 1206 AAATAAATATG 1218
Db 13 AAATAAATATG 1

```
RESULT 113
ABC61205/C
ID ABC61205 standard; DNA; 13 BP.
XX
AC ABC61205;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 61222 for detecting SNP TSC0016301.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI MPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
PS Claim 1; SEQ ID NO 61222; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 9 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 916 TGTGGAGGGGAG 928
XX |||||||
XX 13 TGTGGAGGGGAG 1
XX
RESULT 114
ABC38594
ID ABC38594 standard; DNA; 13 BP.
XX
AC ABC38594;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 38611 for detecting SNP TSC0011898.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI MPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
PS Claim 1; SEQ ID NO 38611; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 3760 TTTTATGAATG 3772
XX |||||||
XX 1 TTTTATGAATG 13
XX
RESULT 115
ABF83465
ID ABF83465 standard; DNA; 13 BP.
XX
AC ABF83465;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 183462 for detecting SNP TSC0045298.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
```

PA (EPIG-)EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 183462; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0.
OY 4391 AAAATCTACCCAC 4403
XX |||||
XX 1 AAAATCTACCCAC 13
Db
RESULT 116
ABC49034
ID ID ABC49034 standard; DNA; 13 BP.
XX
XX ABC49034;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 49051 for detecting SNP TSC0013913.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX W0200177384-A2.
PN
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 49051; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic

CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABR00010-ABR99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
Oy	Query Match 0.3%; Score 13; DB 1; Length 13; Best Local Similarity 100.0%; Pred. No. 1.2e+02; Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Dd	2857 AGATGAGCAATTG 2869 1 AGATGAGCAATTG 13
RESULT 117	
ID	ABH02516/C
XX	ABH02516 standard; DNA; 13 BP.
XX	ABH02516;
XX	22-FEB-2002 (first entry)
DE	Oligonucleotide SEQ ID NO 202493 for detecting SNP TSC0049770.
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
PN	WO200177384-A2.
PD	18-OCT-2001.
Pf	06-APR-2001; 2001WO-IB000713.
PR	07-APR-2000; 2000DB-01019173.
XX	(EPIG-) EPIGENOMICS AG.
PA	Olek A, Piepenbrock C, Berlin K,
Pt	WPi; 2001-657177/75.
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PS	Claim 1; SEQ ID NO 202493; 29pp + Sequence Listing; German.
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABR00010-ABR99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 1 A; 0 C; 3 G; 9 T; 0 U; 0 Other;

```

Query Match      0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1284 TAAAAAAACACC 1296
DB      13 TAAAAAAACACC 1

RESULT 118
ABF80047/c
ID ABF80047 standard; DNA; 13 BP.
AC ABF80047;
XX
XX ABF80047;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 180044 for detecting SNP TSC0044583.
DE
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 180044; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match      0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      3463 GTGTATGTTAGTG 3475
DB      13 GTGTATGTTAGTG 1

RESULT 119
ABH48162
ID ABH48162 standard; DNA; 13 BP.

```

```

XX ABH48162;
AC
XX 22-FEB-2002 (first entry).
XX
XX Oligonucleotide SEQ ID NO 248139 for detecting SNP TSC0060641.
DE
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 248139; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
Query Match      0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      143 GTTTATGTTATA 155
DB      1 GTTTATGTTATA 13

RESULT 120
ABH55808
ID ABH55808 standard; DNA; 13 BP.
AC ABH55808;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 255785 for detecting SNP TSC0062332.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX

```

PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX
 PR 06-APR-2001; 2001WO-IB000713.
 XX
 XX 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 255785; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 0 C; 0 G; 9 T; 0 U; 0 Other;
 Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 151 TTATATTTTAAAT 163
 DB 1 TTATATTTTAAAT 13
 RESULT 121
 ABC29747/c
 ID ABC29747 standard; DNA; 13 BP.
 XX
 AC ABC29747;
 XX
 XX 20-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 29764 for detecting SNP TSC0008996.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR

XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 29764; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 94 TTTGAATTTTGG 106
 DB 13 TTTGAATTTTGG 1
 RESULT 122
 ABC15877
 ID ABC15877 standard; DNA; 13 BP.
 XX
 AC ABC15877;
 XX
 XX 20-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 15884 for detecting SNP TSC0003503.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 15884; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4923 TAAATTTTCAAA 4935

Db 1 TAAATTTTCAAA 13

RESULT 123

ABF26254

ID ABF26254 standard; DNA; 13 BP.

XX ABF26254;

XX 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 126251 for detecting SNP TSC0031588.

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX MPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 126251; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2213 AATTAGAGAGTT 2225

Db 1 AATTAGAGAGTT 13

RESULT 124

ABH40445/c

ID ABH40445 standard; DNA; 13 BP.

XX ABH40445;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 240422 for detecting SNP TSC0058645.

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX MPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 240422; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2327 TTGTAGATTATGA 2339

Db 13 TTGTAGATTATGA 1

RESULT 125

ABH45581/c

ID ABH45581 standard; DNA; 13 BP.

XX ABH45581;

XX 22-FEB-2002 (first entry)

DE oligonucleotide SEQ ID NO 245558 for detecting SNP TSC0059958.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX MO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
DR
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 245558; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;
QY 2409 AATTTTATGAAA 2421
Db 13 AATTTTATGAAA 1
XX
RESULT 126
ABC87119/c
ID ABC87119 standard; DNA; 13 BP.
AC ABC87119;
XX
XX 21-FEB-2002 (first entry)
XX
DE oligonucleotide SEQ ID NO 87136 for detecting SNP TSC0021905.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX

XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
DR
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 87136; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
-ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 1 C; 0 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 0;
QY 1193 AAAATTAATAGT 1205
Db 13 AAAATTAATAGT 1
XX
RESULT 127
ABC88723
ID ABC88723 standard; DNA; 13 BP.
AC ABC88723;
XX
XX 21-FEB-2002 (first entry)
XX
DE oligonucleotide SEQ ID NO 88740 for detecting SNP TSC0022299.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
DR
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

PS Claim 1; SEQ ID NO 88740; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 6 A; 0 C; 0 G; 7 T; 0 U; 0 Other;
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 4383 TATTTTAAAAAT 4395
Db 1 TATTTTAAAAAT 13
RESULT 128
ABC88723/c
ID ABC88723 standard; DNA; 13 BP.
XX ABC88723;
AC
XX 21-FEB-2002 (first entry)
DT
XX
XX
DE Oligonucleotide SEQ ID NO 88740 for detecting SNP TSC0022299.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 88740; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 0 G; 7 T; 0 U; 0 Other;
Qy 4384 ATTTTAAAAATA 4396
Db 13 ATTTTAAAAATA 1
RESULT 129
ABF26255/c
ID ABF26255 standard; DNA; 13 BP.
XX ABF26255;
AC
XX 21-FEB-2002 (first entry)
DT
XX
XX
DE Oligonucleotide SEQ ID NO 126252 for detecting SNP TSC0031588.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 126252; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 5 A; 3 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2213 AATTAGAGAGCTT 2225
Db 13 AATTAGAGAGCTT 1

RESULT 130
ABF35252/c
ID ABF35252 standard; DNA; 13 BP.
XX
XX
AC ABF35252;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 135249 for detecting SNP TSC0033736.
XX
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX
PN W0200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 135249; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4389 TAAAAATCTACC 4401
DB 13 TAAAAATCTACC 1

RESULT 131
ABF96986
ID ABF96986 standard; DNA; 13 BP.
XX
XX
AC ABF96986;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 196983 for detecting SNP TSC0008717.
XX
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.
XX
XX
PN W0200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 196983; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TATTTAATATGT 647
DB 1 TATTTAATATGT 13

RESULT 132
ABF76958/c
ID ABF76958 standard; DNA; 13 BP.
XX
XX
AC ABF76958;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 176955 for detecting SNP TSC0043904.
XX
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX
PN W0200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX

PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 176955; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4374 CCCCTCAATATT 4386
DB 13 CCCCTCAATATT 1
XX
RESULT 133
ABH05853/C
XX ID ABH05853 standard; DNA; 13 BP.
XX
AC ABH05853;
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 205830 for detecting SNP TSC0050445.
XX
DE Oligonucleotide SEQ ID NO 205830 for detecting SNP TSC0050445.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 205830; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4415 ATTGGAGGTATTA 4427
DB 13 ATTGGAGGTATTA 1
XX
RESULT 134
ABF63756
XX ID ABF63756 standard; DNA; 13 BP.
XX
AC ABF63756;
XX
DT 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 163753 for detecting SNP TSC0041141.
XX
DE Oligonucleotide SEQ ID NO 163753 for detecting SNP TSC0041141.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 163753; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 1 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1186 ATTAAGAAATA 1198

DB 1 ATTAAGAAATA 13

RESULT 135

ABH43913/C

ID ABH43913 standard; DNA, 13 BP.

AC ABH43913;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 243890 for detecting SNP TSC0059498.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 243890; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI2073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 8 A; 1 C; 0 G; 4 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 13; DB 1; Length 13;

XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;

XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX QY 149 TGTATATTTTAA 161

XX DB 13 TGTATATTTTAA 1

XX RESULT 136

XX ABH62153/C

XX ID ABH62153 standard; DNA, 13 BP.

XX XX ABH62153;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 262130 for detecting SNP TSC0063598.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

XX designed to detect single-nucleotide polymorphisms and cytosine

XX methylation status.

XX Claim 1; SEQ ID NO 262130; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic

XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX and cytosine methylation status in chemically pretreated genomic DNA. The

XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX range of diseases including immune system, gastrointestinal, respiratory,

XX central nervous system, cardiovascular and metabolic disorders. The

XX oligomers are also used for detecting cell type differentiation. ABC00010

XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI2073

XX represent the oligomers described in the invention. NOTE: The sequence

XX data for this patent did not form part of the printed specification, but

XX was obtained in electronic format from WIPO at

XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 1 C; 0 G; 8 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 13; DB 1; Length 13;

XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;

XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX QY 4802 AGAATTAATTA 4814

XX DB 13 AGAATTAATTA 1

XX RESULT 137

XX ABH62479/C

XX ID ABH62479 standard; DNA, 13 BP.

XX AC ABH62479;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 262456 for detecting SNP TSC0063663.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 262456; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 QY Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred.No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 142 TGTTTAATGTTAT 154
 13 TGTTTAATGTTAT 1
 XX
 RESULT 138
 ABC49035/c
 ID ABC49035 standard; DNA; 13 BP.
 XX
 AC ABC49035;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 49052 for detecting SNP TSC0013913.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 49052; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
 XX
 QY Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred.No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 2857 AGATGAGAGATTG 2869
 13 AGATGAGAGATTG 1
 XX
 RESULT 139
 ABC01020/c
 ID ABC01020 standard; DNA; 13 BP.
 XX
 AC ABC01020;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 1011 for detecting SNP TSC0000334.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 1011; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2872 AAAAAATATATAA 2884

DB 13 AAAAAATATATAA 1

RESULT 140
ABC51623/c
ID ABC51623 standard; DNA; 13 BP.

XX ABC51623;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 51640 for detecting SNP TSC0014402.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1, SEQ ID NO 51640; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 159 TAAATTAATTGGA 171

|||||

DB 13 TAAATTAATTGGA 1

RESULT 141

ABC29746
ID ABC29746 standard; DNA; 13 BP.

XX ABC29746;

XX 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 29763 for detecting SNP TSC0008896.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIDENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1, SEQ ID NO 29763; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 94 TTGGAATTTTGG 106

DB 1 TTGGAATTTTGG 13

RESULT 142

ABC85488
ID ABC85488 standard; DNA; 13 BP.

XX ABC85488;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 85505 for detecting SNP TSC0021486.

SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.

WO200177384-A2.

18-OCT-2001.

06-APR-2001; 2001WO-IB000713.

07-APR-2000; 2000DE-01019173.

(EPIG-) EPIGENOMICS AG.

Olek A, Piepenbrock C, Berlin K;

WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 85505; 29pp + Sequence listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1206 AAAATTATTATG 1218
DB 1 AAAATTATTATG 13

RESULT 143
ABF22170/c

ID ABF22170 standard; DNA; 13 BP.

AC ABF22170;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 122167 for detecting SNP TSC0030535.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR

XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 122167; 29pp + Sequence listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4188 CTTACTCCCTTA 4200
DB 13 CTTACTCCCTTA 1

RESULT 144
ABF22171

ID ABF22171 standard; DNA; 13 BP.

AC ABF22171;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 122168 for detecting SNP TSC0030535.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 122168; 29pp + Sequence listing; German.

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4880 AAAATAAGCCTTAA 4896
|||||
Db 23 AAAATTTAAGCATTAA 7

RESULT 288
ABF42913
ID ABF42913 standard; DNA; 13 BP.
XX
AC ABF42913;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 142910 for detecting SNP TSC0035848.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PS 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 142910; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4925 AAAATTTCAAAA 4936
|||||
Db 2 AAAATTTCAAAA 13

RESULT 289
ABF42912/C
ID ABF42912 standard; DNA; 13 BP.
XX
AC ABF42912;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 142910 for detecting SNP TSC0035848.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PS 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 142909; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4925 AAAATTTCAAAA 4936
|||||
Db 12 AAAATTTCAAAA 1

RESULT 290
ABCT1205/C
ID ABCT1205 standard; DNA; 13 BP.
XX
AC ABCT1205;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 71222 for detecting SNP TSC0018455.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.

DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 142909 for detecting SNP TSC0035848.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PS 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 142909; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4925 AAAATTTCAAAA 4936
|||||
Db 12 AAAATTTCAAAA 1

RESULT 290
ABCT1205/C
ID ABCT1205 standard; DNA; 13 BP.
XX
AC ABCT1205;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 71222 for detecting SNP TSC0018455.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.

```

XX PS Example 2, Page 42; 148pp; English.
CC CC The present invention describes a method for detecting a human parvovirus
CC CC B19 infection in a biological sample. The method comprises reacting the
CC CC isolated parvovirus B19 nucleic acid with a first oligonucleotide
CC CC consisting of a first primer containing a complexing sequence
CC CC sufficiently complementary to the 3'-terminal portion of the RNA target
CC CC sequence to complex with. Also described: (1) amplifying a target
CC CC parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
CC CC of 47 700 base pair sequences (see AB259549 to AB259569, and AB259604 to
CC CC AB259629); (3) a polynucleotide comprising either of 2 4678 base pair
CC CC sequences (see AB259570 and AB259571); (4) an oligonucleotide primer
CC CC consisting of a promoter region recognised by a DNA-dependent RNA
CC CC polymerase operably linked to a human parvovirus B19-specific complexing
CC CC sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
CC CC parvovirus B19-specific hybridising sequence of 10-50 nucleotides linked
CC CC to an acridinium ester label; and (6) a diagnostic test kit comprising an
CC CC oligonucleotide primer of (4), and instructions for conducting the
CC CC diagnostic test. The method is useful for detecting parvovirus infection
CC CC in a biological sample, such as in blood products, to prevent
CC CC transmission of the virus through blood and plasma derivatives or by
CC CC close personal contact. AB259549 to AB259634 and AB257262 to AB257267
CC CC represent sequences used in the exemplification of the present invention
XX SQ Sequence 24 BP; 10 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      0.3%; Score 12.6; DB 1; Length 24;
Best Local Similarity 78.9%; Pred. No. 3.2e+02;
Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 560 AAGGCTATCATTCATCT 578
Db 20 AGGCTTTTCATTCATCT 2

RESULT 286
AAK57350/c
ID AAK57350 standard; DNA; 26 BP.
XX AC
XX AC AAK57350;
XX DT 22-JUN-1999 (first entry)
XX DE Parvovirus detecting oligonucleotide 3.
XX KM Detection; viral concentration; blood plasma; serum; PCR sensitivity;
XX KM extraction; amplification; detection; PCR primer; ss.
XX OS Synthetic.
XX OS Parvovirus.
XX PH
XX PH Key Location/Qualifiers
XX FT modified_base 1 /*tag= a
XX FT modified_base 26 /*tag= "5'-end modified by FAM group"
XX FT modified_base 26 /*tag= b
XX FT /*tag= "3'-end modified by TMRA group"
XX PN BP922771-A2.
XX PN 16-JUN-1999.
XX PD
XX PD 03-NOV-1998; 98EP-00120799.
XX PF
XX PF 28-NOV-1997; 97DE-01052898.
XX PR
XX PR (CENT-) CENTEON PHARMA GMBH.
XX PA
XX PA Weimer T, Groener A;
XX PI
XX PI MPI; 1999-329400/28.
XX DR

```

```

XX PS Process to detect high concentrations of virus in blood plasma or serum,
XX PS by restricting the sensitivity of PCR.
XX CC
XX CC Example 1; Page 7; 8pp; German.
XX CC
XX CC This invention describes a novel method for detection of high viral
XX CC concentrations in blood plasma or serum by restriction of PCR sensitivity
XX CC through suboptimal nucleic acid extraction, amplification and detection
XX CC conditions. The method described is used to detect high concentrations of
XX CC parvovirus in the blood plasma or serum of humans. The method detects
XX CC parvovirus DNA with a content in humans of greater than 106 to 107 genome
XX CC equivalents
XX SQ Sequence 26 BP; 5 A; 1 C; 10 G; 10 T; 0 U; 0 Other;

Query Match      0.2%; Score 12.4; DB 1; Length 26;
Best Local Similarity 72.7%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Oy 1802 ATGCCCTCCACCGAGATCTCCA 1823
Db 22 ATACCTTCATCCAGACACCA 1

RESULT 287
AAK81615/c
ID AAK81615 standard; DNA; 23 BP.
XX AC
XX AC AAK81615;
XX DT 26-AUG-1999 (first entry)
XX DE PCR primer used to amplify erythrovirus V9 nucleotide sequences.
XX KM Erythrovirus V9; differential diagnosis; parvovirus; infection;
XX KM erythrovirus screening; typing; immunoassay; PCR primer; ss.
XX OS Synthetic.
XX OS Erythrovirus.
XX PN FR2771751-A1.
XX PD 04-JUN-1999.
XX PF 03-DEC-1997; 97FR-00015197.
XX PR 03-DEC-1997; 97FR-00015197.
XX PA (ASSI-) ASSISTANCE PUBLIQUE HOPITALUX PARIS.
XX PI Nguyen QT, Garbary CA, Auguste V;
XX PI MPI; 1999-349543/30.
XX DR
XX DR Erythrovirus V9 and its nucleic acid sequences - can be used in the
XX PT diagnosis of its infections.
XX PS Claim 3; Page 28; 80pp; French.
XX CC
XX CC AAK81586-X81630 represent PCR primers used to amplify erythrovirus V9
XX CC polynucleotide sequences. Probes and primers derived from erythrovirus V9
XX CC polynucleotide sequences (AAK81580) can be used for differential
XX CC diagnosis of erythrovirus (parvovirus) infections by a combination of
XX CC amplification and hybridisation assay. The probes can also be used to
XX CC assess susceptibility to erythrovirus infection and for erythrovirus
XX CC screening and typing. The antibodies can be used in immunoassays for
XX CC diagnosis of erythrovirus V9 infections
XX SQ Sequence 23 BP; 7 A; 1 C; 2 G; 13 T; 0 U; 0 Other;

Query Match      0.2%; Score 12.2; DB 1; Length 23;
Best Local Similarity 82.4%; Pred. No. 3.4e+02;

```

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DB-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 258929; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and AB100010-AB12073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SO Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 2538 GTAATCTTAAAA 2550
 Db 13 RTAATCTTAAAA 1
 RESULT 284
 ABH59162
 ID ABH59162 standard; DNA; 13 BP.
 XX
 AC ABH59162;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 259139 for detecting SNP TSC0062961.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DB-01019173.
 XX

XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 PS Claim 1; SEQ ID NO 259139; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and AB100010-AB12073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SO Sequence 13 BP; 5 A; 0 C; 1 G; 6 T; 0 U; 1 Other;
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 3759 ATTTTATGAAT 3771
 Db 1 ATTTTATGAAT 13
 RESULT 285
 ABZ59580/C
 ID ABZ59580 standard; DNA; 24 BP.
 XX
 AC ABZ59580;
 XX
 DT 22-APR-2003 (first entry)
 XX
 DE Human parvovirus B19 VP2 PCR primer VP2-5 SEQ ID NO:38.
 XX
 KM Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma;
 KM PCR primer; ss.
 XX
 OS B19 virus.
 OS Synthetic.
 XX
 PN WO2003002753-A2.
 XX
 PD 09-JAN-2003.
 XX
 PF 28-JUN-2002; 2002WO-US020684.
 XX
 PR 28-JUN-2001; 2001US-0302077P.
 PR 19-MAR-2002; 2002US-0365956P.
 PR 29-MAR-2002; 2002US-0369224P.
 XX
 PA (CHIR) CHIRON CORP.
 XX
 PI Pichuanes S, Shyamala V;
 XX
 DR WPI; 2003-201510/19.
 XX
 PT Detecting a human parvovirus B19 infection in a biological sample to
 PT prevent viral transmission, comprises reacting a parvovirus B19 nucleic
 PT acid with a primer complementary to the 3'-terminal portion of the RNA
 PT target sequence.

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC

Sequence 13 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

4206 GAACCAACATA 4218
 :|||||
 13 RAACCAACAATA 1

RESULT 261

ABH10370
 ID ABH10370 standard; DNA; 13 BP.

ABH10370;

22-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 210347 for detecting SNP TSC0051369.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.

MO200177384-A2.

18-OCT-2001.

06-APR-2001; 2001WO-IB000713.

07-APR-2000; 2000DE-01019173.

(EPIG-) EPIGENOMICS AG.

Olek A, Piepenbrock C, Berlin K;

WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.

Claim 1; SEQ ID NO 210347; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 and cytosine methylation status in chemically pretreated genomic DNA. The
 oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 range of diseases including immune system, gastrointestinal, respiratory,
 central nervous system, cardiovascular and metabolic disorders. The
 oligomers are also used for detecting cell type differentiation. ABC00010
 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 represent the oligomers described in the invention. NOTE: The sequence
 data for this patent did not form part of the printed specification, but
 was obtained in electronic format from WIPO at
 ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

92 TTTTGAATTT 104
 |||||

DB 1 TTTTGAATTT 13

RESULT 262

ABH10370/c
 ID ABH10370 standard; DNA; 13 BP.

ABH10370;

22-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 210347 for detecting SNP TSC0051369.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.

MO200177384-A2.

18-OCT-2001.

06-APR-2001; 2001WO-IB000713.

07-APR-2000; 2000DE-01019173.

(EPIG-) EPIGENOMICS AG.

Olek A, Piepenbrock C, Berlin K;

WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
 designed to detect single-nucleotide polymorphisms and cytosine
 methylation status.

Claim 1; SEQ ID NO 210347; 29pp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic
 acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 and cytosine methylation status in chemically pretreated genomic DNA. The
 oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 range of diseases including immune system, gastrointestinal, respiratory,
 central nervous system, cardiovascular and metabolic disorders. The
 oligomers are also used for detecting cell type differentiation. ABC00010
 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 represent the oligomers described in the invention. NOTE: The sequence
 data for this patent did not form part of the printed specification, but
 was obtained in electronic format from WIPO at
 ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

4925 AAAATTTCAAAA 4937
 :|||||
 13 AAAATTTCAAAA 1

RESULT 263

ABH58952/c
 ID ABH58952 standard; DNA; 13 BP.

ABH58952;

22-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 258929 for detecting SNP TSC0062929.

PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 197490; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 CC Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
 XX
 SQ
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 XX
 OY 4381 AATATTTTAAAA 4393
 :|||||||
 Db 1 RATATTTTAAAA 13
 XX
 RESULT 279
 ABH00437
 ID ABH00437 standard; DNA; 13 BP.
 XX
 AC ABH00437;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 200414 for detecting SNP TSC0049317.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 200414; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 CC Sequence 13 BP; 7 A; 3 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 SQ
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 XX
 OY 2136 ACATATTAACAC 2148
 :|||||||
 Db 1 RCATATTAACAC 13
 XX
 RESULT 280
 ABH28094/C
 ID ABH28094 standard; DNA; 13 BP.
 XX
 AC ABH28094;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 228071 for detecting SNP TSC0055616.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 228071; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 152 TATATTTTAAATTT 164

DB 1 TATATTTTAAATTT 13

RESULT 276

ABC81994 standard; DNA; 13 BP.

AC ABC81994;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 82011 for detecting SNP TSC0020736.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 82011; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 0 C; 0 G; 7 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 155 ATTTTAATTTAAT 167

DB 1 ATTTTAATTTAAT 13

RESULT 277

ABF97492/c
ID ABF97492 standard; DNA; 13 BP.

XX ABF97492;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 197489 for detecting SNP TSC0007561.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 197489; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 4381 AATATTTTAAAA 4393

DB 13 AATATTTTAAAA 1

RESULT 278

ABF97493
ID ABF97493 standard; DNA; 13 BP.

AC ABF97493;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 197490 for detecting SNP TSC0007561.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PI Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PR methylation status.
XX
XX
PS Claim 1; SEQ ID NO 71149; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 3 G; 3 T; 0 U; 1 Other;
XX
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 1025 AATGGAATTACT 1037
DB 1 AATGGAATTAG 13
XX
XX
XX RESULT 274
ABC73638/c
ID ABC73638 standard; DNA; 13 BP.
XX
XX ABC73638;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 73655 for detecting SNP TSC0018971.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PR methylation status.
XX
XX
PS Claim 1; SEQ ID NO 73655; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 2 G; 4 T; 0 U; 1 Other;
XX
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 762 AATTCCTTAAT 774
DB 13 AATTCCTTAAT 1
XX
XX
XX RESULT 275
ABC27078
ID ABC27078 standard; DNA; 13 BP.
XX
XX ABC27078;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 27095 for detecting SNP TSC0007379.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PR methylation status.
XX
XX
PS Claim 1; SEQ ID NO 27095; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 0 G; 8 T; 0 U; 1 Other;
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;

```

RESULT 271
ABF95352
ID ABF95352 standard; DNA; 13 BP.
XX
AC ABF95352;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 195349 for detecting SNP TSC0048065.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 195349; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;
XX
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1486 ATTTAGTGTGTC 1498
DB 1 ATTTAGTGTGTC 13
XX
RESULT 272
ABF91346/c
ID ABF91346 standard; DNA; 13 BP.
XX
AC ABF91346;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 191343 for detecting SNP TSC0047085.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 191343; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 0 G; 9 T; 0 U; 1 Other;
XX
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
OY 2875 AAATATTAATAAT 2887
DB 13 RAATATTAATAAT 1
XX
RESULT 273
ABC71132
ID ABC71132 standard; DNA; 13 BP.
XX
AC ABC71132;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 71149 for detecting SNP TSC0018444.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX

```


PS Claim 1; SEQ ID NO 156839; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4382 ATATTTTTAAAA 4394
 Db :|||||
 13 RTATTTTAAAAA 1
 RESULT 269
 ABC46938/c
 ID ABC46938 standard; DNA; 13 BP.
 XX
 AC ABC46938;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 46935 for detecting SNP TSC0013517.
 XX
 SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPig-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 46955; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 0 G; 10 T; 0 U; 1 Other;
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 2874 AAAATTTTAAAA 2886
 Db :|||||
 13 RAAATTTTAAAAA 1
 RESULT 270
 ABF29045/c
 ID ABF29045 standard; DNA; 13 BP.
 XX
 AC ABF29045;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 129042 for detecting SNP TSC0032305.
 XX
 SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPig-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 129042; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 3298 TTTAAATTTGTTT 3310
 Db :|||||
 13 TTTAAATTTGTTT 1

DE Oligonucleotide SEQ ID NO 229500 for detecting SNP TSC0010567.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 229500; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;
SQ
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX 3300 TAAATTGTTTTT 3312
DB 13 TAAATTGTTTTT 1
XX
XX
XX RESULT 267
ABF56842
ID ABF56842 standard; DNA; 13 BP.
XX
XX AC ABF56842;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 156839 for detecting SNP TSC0039545.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX

XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 156839; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
SQ
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX 4385 TTTTAAAAATAC 4397
DB 1 TTTTAAAAATAT 13
XX
XX
XX RESULT 268
ABF56842/C
ID ABF56842 standard; DNA; 13 BP.
XX
XX AC ABF56842;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 156839 for detecting SNP TSC0039545.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 4924 AAAATTTCAAA 4936
 :|||||
 13 RAAATTTCAAA 1

RESULT 264

ABC09225 ID ABC09225 standard; DNA; 13 BP.

AC ABC09225;

DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 9216 for detecting SNP TSC0002449.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 9216; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1767 AAACACACATTT 1779
 :|||||
 1 RAACTACACATTT 13

RESULT 265

ABC09802 ID ABC09802 standard; DNA; 13 BP.

AC ABC09802;

DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 9793 for detecting SNP TSC0002547.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 9793; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2076 GTTAGTAGCGGTT 2088
 :|||||
 1 GTTAGTAGCGGTT 13

RESULT 266

ABH29523/C ID ABH29523 standard; DNA; 13 BP.

AC ABH29523;

DT 22-FEB-2002 (first entry)

PN WO200177384-A2.
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPig-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 228072; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 1 Other;
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4206 GAACCCAAACATA 4218
 DB 1 RAACCCAAACATA 13
 RESULT 262
 ABC71133/c
 ID ABC71133 standard; DNA; 13 BP.
 AC ABC71133;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 71150 for detecting SNP TSC0018444.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPig-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 71150; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 3 C; 0 G; 6 T; 0 U; 1 Other;
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1025 AATGGAATTAGT 1037
 DB 13 AATGGAATTAGT 1
 RESULT 263
 ABC71204/c
 ID ABC71204 standard; DNA; 13 BP.
 AC ABC71204;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 71221 for detecting SNP TSC0018455.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPig-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 71221; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 4384 ATTTTAAAAATA 4396
 : |||||
 1 RTTTTAAAAATA 13

RESULT 259
 ABC63769/c
 ID ABC63769 standard; DNA; 13 BP.
 XX
 AC ABC63769;
 XX
 DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 63786 for detecting SNP TSC0016840.
 XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX

XX MO200177384-A2.
 XX

XX 18-OCT-2001.
 XX

XX 06-APR-2001; 2001WO-IB000713.
 XX

XX 07-APR-2000; 2000DE-01019173.
 XX

XX (EPIC-) EPIGENOMICS AG.
 XX

XX Olek A, Piepenbrock C, Berlin K;
 XX

XX WPI; 2001-657177/75.
 XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

XX Claim 1; SEQ ID NO 63786; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC

XX Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
 SQ

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 4383 TATTTTAAAAAT 4395
 : |||||
 13 TATTTTAAAAAT 1

RESULT 260
 ABH00436/c
 ID ABH00436 standard; DNA; 13 BP.

XX ABH00436;
 AC
 XX
 DT 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 200413 for detecting SNP TSC0049317.
 XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX

XX MO200177384-A2.
 XX

XX 18-OCT-2001.
 XX

XX 06-APR-2001; 2001WO-IB000713.
 XX

XX 07-APR-2000; 2000DE-01019173.
 XX

XX (EPIC-) EPIGENOMICS AG.
 XX

XX Olek A, Piepenbrock C, Berlin K;
 XX

XX WPI; 2001-657177/75.
 XX

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

XX Claim 1; SEQ ID NO 200413; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC

XX Sequence 13 BP; 2 A; 0 C; 3 G; 7 T; 0 U; 1 Other;
 SQ

Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2136 ACATATTAACAAC 2148
 : |||||
 13 RCTATTAACAAC 1

RESULT 261
 ABH28095
 ID ABH28095 standard; DNA; 13 BP.
 XX

XX ABH28095;
 XX

XX 22-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 228072 for detecting SNP TSC0055616.
 XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX

PA (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 XX
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 195350; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1486 ATTTAGTGTC 1498
 DB 13 ATTTAGTGTC 1
 RESULT 257
 ID ABC46939 standard; DNA; 13 BP.
 AC ABC46939;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 46956 for detecting SNP TSC0013517.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 PR 07-APR-2000; 2000DE-01019173.
 PR
 XX
 PA (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 46956; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 10 A; 0 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 2874 AAAATATAAAAA 2886
 DB 1 AAAATATAAAAA 13
 RESULT 258
 ID ABC63769 standard; DNA; 13 BP.
 AC ABC63769;
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 63786 for detecting SNP TSC0016840.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 PN WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 PR 07-APR-2000; 2000DE-01019173.
 PR
 XX
 PA (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 XX
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 63786; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;

RESULT 254
 ABC71205
 ID ABC71205 standard; DNA; 13 BP.
 AC ABC71205;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 71222 for detecting SNP TSC0018455.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 71222; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 4924 AAAAATTTCAAA 4936
 :|||||
 1 RAAAAATTTCAAA 13
 Db
 RESULT 255
 ABC09803/c
 ID ABC09803 standard; DNA; 13 BP.
 AC ABC09803;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 9794 for detecting SNP TSC0002547.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 9794; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 2076 GTTAGTAGGGCTT 2088
 :|||||
 13 GTTAGTAGGGCTT 1
 Db
 RESULT 256
 ABF95353/c
 ID ABF95353 standard; DNA; 13 BP.
 AC ABF95353;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 195350 for detecting SNP TSC0048065.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PT methylation status.
PS Claim 1; SEQ ID NO 218905; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 4 A; 0 C; 0 G; 8 T; 0 U; 1 Other;
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 151 TTATATTTTAAAT 163
|||||
1 TTATATTTTAAAT 13

Db 1 TTATATTTTAAAT 13

RESULT 252
ABH47170/c
ID ABH47170 standard; DNA; 13 BP.
XX
XX ABH47170;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 247147 for detecting SNP TSC0060388.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 247147; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 0 C; 0 G; 5 T; 0 U; 1 Other;
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 632 GTTATTTTAAAT 644
:|||||
13 RTTATTTTAAAT 1

Db 13 RTTATTTTAAAT 1

RESULT 253
ABH58953
ID ABH58953 standard; DNA; 13 BP.
XX
XX ABH58953;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 258930 for detecting SNP TSC0062929.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 258930; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2538 GTATCTTAAAA 2550
:|||||
1 RTATCTTAAAA 13

DT 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 259122 for detecting SNP TSC0062956.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001, 2001WO-IB000713.
 XX
 XX 07-APR-2000, 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI, 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 259122; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SO Sequence 13 BP; 5 A; 1 C; 0 G; 6 T; 0 U; 1 Other;
 QY
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. NO. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 736 TTTATGAAAT 748
 13 TTTATGAAAT 1
 RESULT 250
 ID ABF09107 standard; DNA; 13 BP.
 XX
 XX ABF09107;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 109104 for detecting SNP TSC0027309.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.

XX
 XX 06-APR-2001, 2001WO-IB000713.
 XX
 XX 07-APR-2000, 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI, 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 109104; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SO Sequence 13 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 1 Other;
 QY
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. NO. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 3002 GAAATACCCCA 3014
 1 RAAATACCCCA 13
 RESULT 251
 ID ABH18928 standard; DNA; 13 BP.
 XX
 XX ABH18928;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 218905 for detecting SNP TSC0053241.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 XX WO200177384-A2.
 XX
 XX 18-OCT-2001.
 XX
 XX 06-APR-2001, 2001WO-IB000713.
 XX
 XX 07-APR-2000, 2000DE-01019173.
 XX
 XX (EPIG-) EPIGENOMICS AG.
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI, 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIDENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 156840; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 SQ Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4385 TTTTAAATAATAC 4397
 DB 13 TTTTAAATAATAY 1
 RESULT 245
 ABH10371
 ID ABH10371 standard; DNA; 13 BP.
 AC ABH10371;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 210348 for detecting SNP TSC0051369.
 XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIDENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI

XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 210348; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4925 AAAATTTCAAAA 4937
 DB 1 RAAATTTCAAAA 13
 RESULT 246
 ABH10371/C
 ID ABH10371 standard; DNA; 13 BP.
 AC ABH10371;
 XX 22-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 210348 for detecting SNP TSC0051369.
 XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 XX 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIDENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 210348; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

```
XX SQ Sequence 13 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 1 Other;
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1767 AACTACACATTT 1779
    :|||||
    13 RAACACACATTT 1
RESULT 242
ABF74749
ID ABE74749 standard; DNA; 13 BP.
XX
XX ABE74749;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 174746 for detecting SNP TSC0043465.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 174746; 29bp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;
SQ
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 4894 AATTAATTAATTC 4906
    :|||||
    1 RAATTAATTAATTC 13
RESULT 243
```

```
ABF56843
ID ABF56843 standard; DNA; 13 BP.
XX
XX AC ABF56843;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 156840 for detecting SNP TSC0039545.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 156840; 29bp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
SQ
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 4382 ATATTTTAAAAA 4394
    :|||||
    1 RTATTTTAAAAA 13
RESULT 244
ABF56843/C
ID ABF56843 standard; DNA; 13 BP.
XX
XX AC ABF56843;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 156840 for detecting SNP TSC0039545.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

PR 07-APR-2000; 2000DE-01019173.
XX
CC (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 247148; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 0 G; 7 T; 0 U; 1 Other;
XX
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
QY 632 GTTATTATTATA 644
DB :|||||
1 RTTATTATTATA 13
XX
RESULT 240
ABC27845
ID ABC27845 standard; DNA; 13 BP.
XX
AC ABC27845;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 27862 for detecting SNP TSC0007854.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPiG-) EPIGENOMICS AG.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 27862; 29pp + Sequence Listing; German.

XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;
XX
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
QY 742 GAAATTACTTAA 754
DB :|||||
1 RAAATTACTTAA 13
XX
RESULT 241
ABC09224/C
ID ABC09224 standard; DNA; 13 BP.
XX
AC ABC09224;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 9215 for detecting SNP TSC0002449.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPiG-) EPIGENOMICS AG.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 9215; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

```

Db      13 AAATTGTTT 1
RESULT 237
ABH17947
ID      ABH17947 standard; DNA; 13 BP.
XX
XX
AC      ABH17947;
XX
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 217924 for detecting SNP TSC0005381.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIDENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 217924; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 9 A; 2 C; 0 G; 1 T; 0 U; 1 Other;
XX
XX      Query Match
XX      Best Local Similarity 92.3%; Score 12.6; DB 1; Length 13;
XX      Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX      1283 GTAAAAAAACAC 1295
XX      :|||||
XX      1 RTAAAAAAACAC 13
XX
XX      RESULT 238
XX      ID      ABH18929 standard; DNA; 13 BP.
XX
XX      AC      ABH18929;
XX
XX      XX      22-FEB-2002 (first entry)
XX
XX      DE      Oligonucleotide SEQ ID NO 218906 for detecting SNP TSC005241.
XX

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIDENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 218906; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 8 A; 0 C; 0 G; 4 T; 0 U; 1 Other;
XX
XX      Query Match
XX      Best Local Similarity 92.3%; Score 12.6; DB 1; Length 13;
XX      Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX      151 TTATATTTTAAAT 163
XX      :|||||
XX      13 TTATATTTTAAAT 1
XX
XX      Db      13 TTATATTTTAAAT 1
XX
XX      RESULT 239
XX      ID      ABH47171 standard; DNA; 13 BP.
XX
XX      AC      ABH47171;
XX
XX      XX      22-FEB-2002 (first entry)
XX
XX      DE      Oligonucleotide SEQ ID NO 247148 for detecting SNP TSC0060388.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS Claim 1, SEQ ID NO 4093; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 0 G; 10 T; 0 U; 1 Other;
XX
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 2872 AAAAATATATAA 2884
DB :|||||
13 RAAAAATATAAA 1
RESULT 235
ABH58431
ID ABH58431 standard; DNA; 13 BP.
XX
XX ABH58431;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 258408 for detecting SNP TSC0062835.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1, SEQ ID NO 258408; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 0 G; 10 T; 0 U; 1 Other;

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1325 GAAACCAATTT 1337
DB :|||||
1 RAAACCAATTT 13
RESULT 236
ABH58431/C
ID ABH58431 standard; DNA; 13 BP.
XX
XX ABH58431;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 258408 for detecting SNP TSC0062835.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1, SEQ ID NO 258408; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 3301 AATTTGTTTTC 3313

```

AC ABC00871;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 862 for detecting SNP TSC0000294.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 862; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 10 A; 0 C; 0 G; 2 T; 0 U; 1 Other;
SQ
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY
XX 2873 AAAAATATATAAAA 2885
XX :|||||
XX 1 RAAAAATATATAAAA 13
DB
XX
XX RESULT 233
XX ABH62307/c
XX ID ABH62307 standard; DNA; 13 BP.
XX AC ABH62307;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 262284 for detecting SNP TSC0003624.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX

```

```

XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 262284; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 1 Other;
SQ
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY
XX 708 AGCAAAATATTTT 720
XX :|||||
XX 13 AGCAAAATATTTT 1
DB
XX
XX RESULT 234
XX ABC04102/c
XX ID ABC04102 standard; DNA; 13 BP.
XX AC ABC04102;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 4093 for detecting SNP TSC0001538.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX

```


CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 10 A; 0 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2872 AAAAAATATATAAA 2884
:|||||
1 RAAAAATATATAAA 13

Db

RESULT 230
ABH59144
ID ABH59144 standard; DNA; 13 BP.
XX
XX ABH59144;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 259121 for detecting SNP TSC0062956.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
XX Claim 1; SEQ ID NO 259121; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 6 A; 0 C; 1 G; 5 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 736 TTTATGAAAAAT 748
:|||||
1 TTTATGAAAAAT 13

Db

RESULT 231
ABC73639
ID ABC73639 standard; DNA; 13 BP.
XX
XX ABC73639;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 73656 for detecting SNP TSC0018971.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
XX Claim 1; SEQ ID NO 73656; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 2 C; 0 G; 6 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 762 AATTCCTTTAAAT 774
:|||||
1 AATTCCTTTAAAT 13

Db

RESULT 232
ABC00871
ID ABC00871 standard; DNA; 13 BP.
XX

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX MO200177384-A2.
 PN
 XX 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001MO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPiG-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 259140; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 6 A; 1 C; 0 G; 5 T; 0 U; 1 Other;
 QY
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 3759 ATTTTATGAAT 3771
 13 ATTTTATGAAT 1
 RESULT 228
 ABC27844/c
 ID ABC27844 standard; DNA; 13 BP.
 AC ABC27844;
 XX
 AC 20-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 27861 for detecting SNP TSC0007854.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS
 XX Homo sapiens.
 OS
 PN MO200177384-A2.
 PD 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001MO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPiG-) EPIGENOMICS AG.
 PA

XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 27861; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
 QY
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 742 GAATATTACTTAA 754
 13 RAATATTACTTAA 1
 RESULT 229
 ABC04103
 ID ABC04103 standard; DNA; 13 BP.
 AC ABC04103;
 XX
 AC 20-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 4094 for detecting SNP TSC0001538.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS
 XX Homo sapiens.
 OS
 PN MO200177384-A2.
 PD 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001MO-IB000713.
 PF
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX (EPiG-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 XX Claim 1; SEQ ID NO 4094; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;

Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3002 GAAAAATACCCCA 3014

DB 13 RAAAAATACCCCA 1

RESULT 225

ABF29044 ID ABF29044 standard; DNA; 13 BP.

AC ABF29044;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 129041 for detecting SNP TSC0032305.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 129041; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;

Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3298 TTTAAATTTGTTT 3310

DB 1 TTTAAATTTGTTT 13

RESULT 226

ABH47999/C ID ABH47999 standard; DNA; 13 BP.

XX ABH47999;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 247976 for detecting SNP TSC0060610.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 247976; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 1 C; 0 G; 4 T; 0 U; 1 Other;

Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;

Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 144 TTTAATTTATAT 156

DB 13 TTTAATTTATAT 1

RESULT 227

ABH59163/C ID ABH59163 standard; DNA; 13 BP.

XX ABH59163;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 259140 for detecting SNP TSC0062961.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 27096; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 0 C; 0 G; 4 T; 0 U; 1 Other;
XX
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 152 TATATTTTAAATTT 164
Db 13 TATATTTTAAATTT 1
XX
RESULT 223
ABC81995/c
ID ABC81995 standard; DNA; 13 BP.
XX
XX ABC81995;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 82012 for detecting SNP TSC0020736.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```

```

XX
XX Claim 1; SEQ ID NO 82012; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 0 C; 0 G; 5 T; 0 U; 1 Other;
XX
Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 155 ATTTTAAATTTAAT 167
Db 13 ATTTTAAATTTAAT 1
XX
RESULT 224
ABF09106/c
ID ABF09106 standard; DNA; 13 BP.
XX
XX ABF09106;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 109103 for detecting SNP TSC0027309.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 109103; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but

```

QY 144 TTTAATGTATAT 156
 DB 1 TTTAATGTATAT 13
 RESULT 220
 ABH58430
 ID ABH58430 standard; DNA; 13 BP.
 AC ABH58430;
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 258407 for detecting SNP TSC0062835.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 PI Homo sapiens.
 OS
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 258407; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;
 XX
 QY Query Match 0.3%; Score 12.6; DB 1; Length 13;
 XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 13301 AAATTGTTTTC 3313
 1 AAATTGTTTTC 13
 RESULT 221
 ABH58430/c
 ID ABH58430 standard; DNA; 13 BP.
 AC ABH58430;
 XX
 DT 22-FEB-2002 (first entry)

XX
 DE Oligonucleotide SEQ ID NO 258407 for detecting SNP TSC0062835.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 PI Homo sapiens.
 OS
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 258407; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;
 XX
 QY Query Match 0.3%; Score 12.6; DB 1; Length 13;
 XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 DB 13325 GAAAAACAATTT 1337
 13 RAAAAACAATTT 1
 RESULT 222
 ABC27079/c
 ID ABC27079 standard; DNA; 13 BP.
 AC ABC27079;
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 27096 for detecting SNP TSC0007379.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 PI Homo sapiens.
 OS
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 63785; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
 SQ
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4384 ATTTTAAAAATA 4396
 :|||||
 13 RTTTTAAAAATA 1
 Db
 RESULT 218
 ABF45890/c
 ID ABF45890 standard; DNA; 13 BP.
 XX
 XX ABF45890;
 AC
 XX
 XX 21-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 145887 for detecting SNP TSC0036753.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 145887; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;
 SQ
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 4080 GACAAACACTTA 4092
 :|||||
 13 RACAAACACTTA 1
 Db
 RESULT 219
 ABH47998
 ID ABH47998 standard; DNA; 13 BP.
 XX
 XX ABH47998;
 AC
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 XX Oligonucleotide SEQ ID NO 247975 for detecting SNP TSC0060610.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX
 XX 18-OCT-2001.
 PD
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 247975; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;
 SQ
 Query Match 0.3%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

ID ABC00870 standard; DNA; 13 BP.
XX
XX ABC00870;
AC
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 861 for detecting SNP TSC0000294.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 861; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 0 G; 10 T; 0 U; 1 Other;
SQ
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2873 AAAAATATATAAAA 2885
QY :|||||
:|||||
13 RAAAAATATAAAA 1
Db
XX
XX RESULT 216
XX ABC63768
XX ABC63768 standard; DNA; 13 BP.
XX
XX ABC63768;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 63785 for detecting SNP TSC0016840.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX
```

```

XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 63785; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 0 C; 0 G; 6 T; 0 U; 1 Other;
SQ
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
XX
XX 4383 TATTTTAAAT 4395
QY :|||||
:|||||
1 TATTTTAAAT 13
Db
XX
XX RESULT 217
XX ABC63768/c
XX ABC63768 standard; DNA; 13 BP.
XX
XX ABC63768;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 63785 for detecting SNP TSC0016840.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX
```

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 4 A; 0 C; 1 G; 7 T; 0 U; 1 Other;

XX

QY Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

XX

AB 4894 AATTAATTAATTC 4906
13 AATTAATTAATTC 1

XX

RESULT 213
ABF91347
ID ABF91347 standard; DNA; 13 BP.
XX
XX ABF91347;
AC
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 191344 for detecting SNP TSC0047085.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 191344; 29pp + Sequence Listing; German.
PS
XX
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 9 A; 0 C; 0 G; 3 T; 0 U; 1 Other;

XX

QY Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

XX

AB 2875 AATTAATTAAT 2887
1 AATTAATTAAT 13

XX

RESULT 214
ABH62306
ID ABH62306 standard; DNA; 13 BP.
XX
XX ABH62306;
AC
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 262283 for detecting SNP TSC0063624.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 262283; 29pp + Sequence Listing; German.
PS
XX
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 6 A; 0 C; 2 G; 4 T; 0 U; 1 Other;

XX

QY Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

XX

AB 708 AGAATAATTTT 720
1 AGAATAATTTT 13

XX

RESULT 215
ABC00870/C

KW Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KM smooth muscle cell; hyperproliferation; restenosis; cancer; c-myc;
KM coronary angioplasty; ss.
XX Homo sapiens.
OS
XX
XX WO9531541-A2.
XX
XX
XX 23-NOV-1995.
PD
XX
XX 18-MAY-1995; 95WO-US006368.
PF
XX
XX 18-MAY-1994; 94US-00245466.
PR
XX 13-JAN-1995; 95US-00373124.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Stinchcomb DT, Draper K, Mcswigen J, Jarvis T;
PI
XX WPI; 1996-010927/01.
DR
XX
XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myc,
PT for treating restenosis or cancer.
PS
XX Claim 1; Page 75; 128pp; English.
XX
XX The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myc sequence at the base position indicated in the descriptor
CC line. The c-myc sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myc sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
CC
SQ Sequence 17 BP; 8 A; 1 C; 0 G; 0 T; 8 U; 0 Other;
XX
XX
XX Query Match 0.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4384 ATTTTAAAAATA 4396
DB 17 ATTTTAAAAATA 5
XX
XX
XX RESULT 211
ABH17946/C
ID ABH17946 standard; DNA; 13 BP.
XX
XX
XX ABH17946;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 217923 for detecting SNP TSC0005381.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PS
XX

XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX
XX Olek A, Piepenbrock C, Berlin K;
PT
XX
XX WPI; 2001-657177/75.
DR
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1; SEQ ID NO 217923; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABP00010-ABP9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 2 G; 9 T; 0 U; 1 Other;
XX
XX
XX Query Match 0.3%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1283 GTAAAAAAACAC 1295
DB 13 RTAAAAAAACAC 1
XX
XX
XX RESULT 212
ABF74748/C
ID ABF74748 standard; DNA; 13 BP.
XX
XX
XX ABF74748;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 174745 for detecting SNP TSC0043465.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PS
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PT
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1; SEQ ID NO 174745; 29pp + Sequence Listing; German.
XX

Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2327 TTGTGATTATGA 2339
DB 1 TTGTGATTATGA 13

RESULT 208
ABH55809/c
ID ABH55809 standard; DNA; 13 BP.

XX AC ABH55809;

XX DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 255786 for detecting SNP TSC006232.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIC-) EPIDENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX PS Claim 1; SEQ ID NO 255786; 23bp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102072
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 9 A; 0 C; 0 G; 4 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 151 TTATATTTTAAAT 153
DB 13 TTATATTTTAAAT 1

RESULT 209
AAV48500/c
ID AAV48500 standard; DNA; 14 BP.
XX AC AAV48500;

XX DT 15-OCT-1998 (first entry)

XX DE p53 gene antisense oligonucleotide p53-16.

XX KW p53; antisense oligonucleotide; modulate; gene expression; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN EP856579-A1.

XX PD 05-AUG-1998.

XX PR 31-JAN-1997; 97EP-00101531.

XX PR 31-JAN-1997; 97EP-00101531.

XX PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.

XX PI Schlingensiefen K, Brysach W;

XX DR WPI; 1998-400910/35.

XX Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of residues
PT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
PT culture.

XX Claim 10; Fig 4a; 286pp; English.

XX AAV48485-564 represent antisense oligonucleotides directed against the
CC p53 gene. Of these, only oligonucleotides AAV48485-517 resulted in
CC effective downregulation of negative growth by p53 and increased cell
CC proliferation, while AAV48518-64 had little effect. The oligonucleotides
CC exemplify the invention. The specification describes oligonucleotides
CC that contain 8-30 nucleotides, which contain at most 8 nucleotides that
CC can each form three hydrogen bonds to cytosine; do not contain four
CC consecutive nucleotides able to form three H-bonds each to four
CC consecutive cytosines; do not contain two sequences of three consecutive
CC nucleotides each able to form three H-bonds to three consecutive
CC cytosines, and the ratio between residues able to form two H-bonds each
CC (2R) or three such bonds (3R) is given by 2R/3R = 0.33-0.72. The
CC oligonucleotides are used to modulate expression of genes, particularly
CC the genes for p53, E2F-2, JunB, JunD, TGF-beta 1 or beta 2 to control
CC proliferation of primary cell cultures (e.g. bone marrow stem, liver or
CC kidney cells, osteoclasts, osteoblasts and/or keratinocytes). The
CC oligonucleotides can also be used to analyse function of proteins (by
CC altering their expression or activity) and therapeutically, e.g. in cases
XX of cancer or (targeting TGF) for stimulating the immune system

XX Sequence 14 BP; 1 A; 1 C; 6 G; 6 T; 0 U; 0 Other;

XX Query Match 0.3%; Score 13; DB 1; Length 14;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3730 CCCAGAAAACCTA 3742
DB 14 CCCAGAAAACCTA 2

RESULT 210
AAT81447/c
ID AAT81447 standard; RNA; 17 BP.
XX AC AAT81447;

XX DT 07-DEC-1997 (first entry)

XX Human c-myc hammerhead ribozyme target sequence (nt. position 2526).
XX

PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 227647; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 2 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 4876 TGGAAAAATATATA 4888
Db 1 TGGAAAAATATATA 13
XX
RESULT 206
ABF83173
ID ABF83173 standard; DNA; 13 BP.
XX
XX ABF83173;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 183170 for detecting SNP TSC0045230.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 183170; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 2 G; 2 T; 0 U; 0 Other;

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 0 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 153 ATATTTTAAATTA 165
Db 1 ATATTTTAAATTA 13
XX
RESULT 207
ABH40444
ID ABH40444 standard; DNA; 13 BP.
XX
XX ABH40444;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 240421 for detecting SNP TSC0058645.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 240421; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.3%; Score 13; DB 1; Length 13;

RESULT 203
ABC51622
ID ABC51622 standard; DNA; 13 BP.
XX
XX ABC51622;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 51639 for detecting SNP TSC0014402.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 51639; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
QY 159 TAAATTAATTGA 171
DB 1 TAAATTAATTGA 13
XX
XX
RESULT 204
ABC61704
ID ABC61704 standard; DNA; 13 BP.
XX
XX ABC61704;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 61721 for detecting SNP TSC0016411.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 61721; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989, and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 11 A; 0 C; 0 G; 2 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
QY 2873 AAAAATATAAAA 2885
DB 1 AAAAATATAAAA 13
XX
XX
RESULT 205
ABH27670
ID ABH27670 standard; DNA; 13 BP.
XX
XX ABH27670;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 227647 for detecting SNP TSC0055515.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX

PS Claim 1; SEQ ID NO 205829; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4415 ATTGAGGTATT 4427
DB 1 ATTGAGGTATT 13
|||||
|
RESULT 201
ABF00054/c
ID ABF00054 standard; DNA; 13 BP.
XX
AC ABF00054;
XX
XX 22-FEB-2002 (first entry)
XX
DT Oligonucleotide SEQ ID NO 190051 for detecting SNP TSC0009718.
XX
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
OS
XX
PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PA Olek A, Piepenbrock C, Berlin K;
XX
PI
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 190051; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4379 CAAATTTTAA 4391
DB 13 CAAATTTTAA 1
|||||
|
RESULT 202
ABC01021
ID ABC01021 standard; DNA; 13 BP.
XX
AC ABC01021;
XX
XX 20-FEB-2002 (first entry)
XX
DT Oligonucleotide SEQ ID NO 1012 for detecting SNP TSC0000334.
XX
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
OS
XX
PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PA Olek A, Piepenbrock C, Berlin K;
XX
PI
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 1012; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 11 A; 0 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2872 AAAAAATATATA 2884
DB 1 AAAAAATATATA 13
|||||
|

DE Oligonucleotide SEQ ID NO 99995 for detecting SNP TSC0024859.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 99995; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 1 C; 10 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 4717 CCCACGCCGCCACC 4729
XX 13 CCCACGCCGCCACC 1
XX
XX RESULT 199
XX ABH18736/C
XX ID ABH18736 standard; DNA; 13 BP.
XX
XX ABH18736;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 218713 for detecting SNP TSC0053197.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX

XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 218713; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 2 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 4324 TTTTAAACTCAA 4336
XX 13 TTTTAAACTCAA 1
XX
XX RESULT 200
XX ABH05852
XX ID ABH05852 standard; DNA; 13 BP.
XX
XX ABH05852;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 205829 for detecting SNP TSC0050445.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SO Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4300 TAAATCCCTAAC 4312
 DB 13 TAAATCCCTAAC 1

RESULT 196
 ABF90055
 ID ABF90055 standard; DNA; 13 BP.
 AC ABF90055;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 190052 for detecting SNP TSC0009718.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 XX Claim 1; SEQ ID NO 190052; 29bp + Sequence Listing; German.
 PS
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 XX Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4379 CAAATTTTAA 4391
 DB 1 CAAATTTTAA 13

RESULT 197
 ABH43912
 ID ABH43912 standard; DNA; 13 BP.
 AC ABH43912;
 XX
 XX
 DT 22-FEB-2002 (first entry)
 XX
 XX Oligonucleotide SEQ ID NO 243889 for detecting SNP TSC0059498.
 DE
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200177384-A2.
 PN
 XX
 PD 18-OCT-2001.
 XX
 XX 06-APR-2001; 2001WO-IB000713.
 PF
 XX
 XX 07-APR-2000; 2000DE-01019173.
 PR
 XX
 XX (EPIC-) EPIGENOMICS AG.
 PA
 XX
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 XX WPI; 2001-657177/75.
 DR
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 XX Claim 1; SEQ ID NO 243889; 29bp + Sequence Listing; German.
 PS
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABP00010-ABP9989, ABH00010-ABH9989 and ABI00010-ABI2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 XX
 XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 149 TGTATATTTTAA 161
 DB 1 TGTATATTTTAA 13

RESULT 198
 ABC9978/c
 ID ABC9978 standard; DNA; 13 BP.
 AC ABC9978;
 XX
 XX
 DT 21-FEB-2002 (first entry)
 XX

```

EN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 219978; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 9 A; 2 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 3646 TTTTATGCTGTTA 3658
XX 13 TTTTATGCTGTTA 1
XX
XX RESULT 194
XX ABF96462
XX ID ABF96462 standard; DNA; 13 BP.
XX
XX ABF96462;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 196459 for detecting SNP TSC0008585.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```

```

XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 196459; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 144 TTTATGCTATAT 156
XX 1 TTTATGCTATAT 13
XX
XX RESULT 195
XX ABF54068/C
XX ID ABF54068 standard; DNA; 13 BP.
XX
XX ABF54068;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 154065 for detecting SNP TSC0000578.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 154065; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The

```


Query Match 0.3%; Score 13; DB 1; Length 13;
AC Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;
Matches 13; Conservative 0; Indels 0; Gaps 0;

QY 2411 TTTTATGAAAAAG 2423
DB 13 TTTTATGAAAAAG 1

RESULT 191
ABC53973/c
ID ABC53973 standard; DNA; 13 BP.
XX
XX ABC53973;
AC
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 53990 for detecting SNP TSC0014846.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 53990; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 6 A; 0 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
AC Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;
Matches 13; Conservative 0; Indels 0; Gaps 0;

QY 4381 AATATTTTAAAAA 4393
DB 13 AATATTTTAAAAA 1

RESULT 192
ABF42912
ID ABF42912 standard; DNA; 13 BP.

XX
AC ABF42912;
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 142909 for detecting SNP TSC0035848.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 142909; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
AC Best Local Similarity 100.0%; Pred. No. 1.2e+02; Mismatches 0; Gaps 0;
Matches 13; Conservative 0; Indels 0; Gaps 0;

QY 93 TTTTGAATTTTG 105
DB 1 TTTTGAATTTTG 13

RESULT 193
ABH20001/c
ID ABH20001 standard; DNA; 13 BP.
XX
XX ABH20001;
AC
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 219978 for detecting SNP TSC0053526.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX

PA (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 163754; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences

Seq Sequence 13 BP; 3 A; 1 C; 0 G; 9 T; 0 U; 0 Other;
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1186 ATTAAAGAAATA 1198
Db 13 ATTAAAGAAATA 1

RESULT 189
ABC93208
ID ABC93208 standard; DNA; 13 BP.
XX
XX ABC93208;
XX
XX 21-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 93225 for detecting SNP TSC0023296.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX OS
XX
XX WO200177384-A2.
XX
XX
XX 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 93225; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences

Seq Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 3647 TTTTATGTGTAG 3659
Db 1 TTTTATGTGTAG 13

RESULT 190
ABC44831/C
ID ABC44831 standard; DNA; 13 BP.
XX
XX ABC44831;
XX
XX 21-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 44848 for detecting SNP TSC0013119.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX OS
XX
XX WO200177384-A2.
XX
XX
XX 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
XX Claim 1; SEQ ID NO 44848; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences

Seq Sequence 13 BP; 5 A; 2 C; 0 G; 6 T; 0 U; 0 Other;

```
RESULT 186
ABF35253
ID ABF35253 standard; DNA; 13 BP.
XX
XX ABF35253;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 135250 for detecting SNP TSC0033736.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
PT
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1; SEQ ID NO 135250; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4389 TAAAAATACTACC 4401
DB 1 TAAAAATACTACC 13
AC
XX
XX ABF39197 standard; DNA; 13 BP.
ID ABF39197;
AC
XX
XX ABF39197;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 139194 for detecting SNP TSC0034867.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
```

```
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
PT
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX
XX Claim 1; SEQ ID NO 139194; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 3487 TAAATACCATAT 3499
DB 1 TAAATACCATAT 13
AC
XX
XX ABF63757;
ID ABF63757 standard; DNA; 13 BP.
XX
XX ABF63757;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 163754 for detecting SNP TSC0041141.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
```

PT methylation status.
XX
PS Claim 1; SEQ ID NO 75869; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABH00010-ABF9989, ABH00010-ABH9989 and ABH00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 632 GTTATTTAATTA 644
Db 1 GTTATTTAATTA 13

RESULT 184
ABC55712/c
ID ABC55712 standard; DNA; 13 BP.
XX
AC ABC55712;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 55729 for detecting SNP TSC0015185.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 55729; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABH00010-ABF9989, ABH00010-ABH9989 and ABH00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 306 TACTACTTTAA 318
Db 13 TACTACTTTAA 1

RESULT 185
ABC15876/c
ID ABC15876 standard; DNA; 13 BP.
XX
AC ABC15876;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 15883 for detecting SNP TSC0003503.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 15883; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABH00010-ABF9989, ABH00010-ABH9989 and ABH00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4923 TAAATTTCAAA 4935
Db 13 TAAATTTCAAA 1

DT 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 174973 for detecting SNP TSC0043498.
DE
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 174973; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 3310 TTCTCACCATT 3322
DB 13 TTCTCACCATT 1
XX
XX RESULT 182
XX ABF76959
XX ID ABF76959 standard; DNA; 13 BP.
XX
XX ABF76959;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 176956 for detecting SNP TSC0043904.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.

XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 176956; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 4374 CCCCTCAATATT 4386
DB 1 CCCCTCAATATT 13
XX
XX RESULT 183
XX ABC75852
XX ID ABC75852 standard; DNA; 13 BP.
XX
XX ABC75852;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 75869 for detecting SNP TSC0019439.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. AB000010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 0 C; 0 G; 6 T; 0 U; 0 Other;

Query Match
Best Local Similarity 0.3%; Score 13; DB 1; Length 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4383 TATTTTAAAT 4395
DB 13 TATTTTAAAT 1

RESULT 179
ABF42913/C
ID ABF42913 standard; DNA; 13 BP.

XX ABF42913;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 142910 for detecting SNP TSC0035848.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 142910; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. AB000010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

Query Match
Best Local Similarity 0.3%; Score 13; DB 1; Length 13;
Matches 13; Conservative 100.0%; Pred. No. 1.2e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 93 TTTTGAATTTTG 105
DB 13 TTTTGAATTTTG 1

RESULT 180

ABH18737
ID ABH18737 standard; DNA; 13 BP.

XX ABH18737;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 218714 for detecting SNP TSC0053197.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

XX Claim 1; SEQ ID NO 218714; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. AB000010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 2 C; 0 G; 5 T; 0 U; 0 Other;

Query Match
Best Local Similarity 0.3%; Score 13; DB 1; Length 13;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4324 TTTTAACTCAA 4336
DB 1 TTTTAACTCAA 13

RESULT 181

ABF74976/C
ID ABF74976 standard; DNA; 13 BP.

XX ABF74976;

```
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 75870; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred.No.1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY
XX 632 GTTTATTATATA 644
XX |||||
XX 13 GTTTATTATATA 1
Db
XX
XX RESULT 177
XX ABC8722
XX ID ABC8722 standard; DNA; 13 BP.
XX
XX ABC8722;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 86739 for detecting SNP TSC0022299.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
```

```
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 86739; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 0 C; 0 G; 6 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred.No.1.2e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY
XX 4384 ATTTTAAAAATA 4396
XX |||||
XX 1 ATTTTAAAAATA 13
Db
XX
XX RESULT 178
XX ABC8722/c
XX ID ABC8722 standard; DNA; 13 BP.
XX
XX ABC8722;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 86739 for detecting SNP TSC0022299.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 86739; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
```

ABC93519	
ID	ABC93519 standard; DNA; 13 BP.
XX	
AC	ABC93519;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 93536 for detecting SNP TSC0023374.
XX	
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
XX	
PD	18-OCT-2001.
XX	
PX	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIDENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WP1; 2001-657177//75.
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
XX	methylation status.
PS	Claim 1; SEQ ID NO 93536; 29bp + Sequence listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including, immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	fip.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 11 A; 0 C; 0 G; 2 T; 0 U; 0 Other;
Query Match	0.3%; Score 13; DB 1; Length 13;
Best Local Similarity	100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0	
DY	2874 AAAATTTAAAAA 2886
DB	1 AAAATTTAAAAA 13
RESULT 176	
ABC75853/c	
ID	ABC75853 standard; DNA; 13 BP.
XX	
AC	ABC75853;
XX	
DT	21-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 75870 for detecting SNP TSC0019439.
XX	
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.

PR 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 154066; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4300 TAAATCCCTAAC 4312
 DB 1 TAAATCCCTAAC 13
 RESULT 172
 ABF83172/c
 ID ABF83172 standard; DNA; 13 BP.
 XX ABF83172;
 AC 22-FEB-2002 (first entry)
 XX
 DT Oligonucleotide SEQ ID NO 183169 for detecting SNP TSC0045230.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIC-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 183169; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 8 A; 0 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 153 ATATTTTATTTA 165
 DB 13 ATATTTTATTTA 1
 RESULT 173
 ABH09679/c
 ID ABH09679 standard; DNA; 13 BP.
 XX ABH09679;
 AC 22-FEB-2002 (first entry)
 XX
 DT Oligonucleotide SEQ ID NO 209656 for detecting SNP TSC0051193.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 PN 18-OCT-2001.
 PD
 XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPIC-) EPIGENOMICS AG.
 XX
 PA Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 209656; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
PN	WO200177384-A2.
PD	18-OCT-2001.
PF	06-APR-2001; 2001WO-IB000713.
PR	07-APR-2000; 2000DE-01019173.
PA	(EPIG-) EPIGENOMICS AG.
PI	Olek A, Piepenbrock C, Berlin K;
DR	WPI; 2001-657177/75.
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
Pt	designed to detect single-nucleotide polymorphisms and cytosine
Pr	methylation status.
PS	Claim 1; SEQ ID NO 203612; 29pp + Sequence Listing; German.
XX	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
	Query Match 0.3%; Score 13; DB 1; Length 13;
	Best Local Similarity 100.0%; Pred. No. 1.2e+02;
	Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	2343 AAACCACTAACAA 2355
Dd	1 AAACCCTTACCAA 13
	RESULT 171
ID	ABF54069
AB	ABF54069 standard; DNA; 13 BP.
XX	ABF54069;
AC	
XX	21-FEB-2002 (first entry)
DT	
XX	Oligonucleotide SEQ ID NO 154066 for detecting SNP TSC0000578.
De	
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
Xx	Homo sapiens.
OS	
XX	WO200177384-A2.
PN	
PD	18-OCT-2001.
PF	06-APR-2001; 2001WO-IB000713.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 61221; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 916 TGTGAGGGGAG 928
DB 1 TGTGAGGGGAG 13

RESULT 167
ABC38595/c
ID ABC38595 standard; DNA; 13 BP.
XX
XX ABC38595;
XX
XX 20-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 38612 for detecting SNP TSC0011898.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 38612; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 9 G; 2 T; 0 U; 0 Other;

CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 3760 TTTTATGAAG 3772
DB 13 TTTTATGAAG 1

RESULT 168
ABC38904/c
ID ABC38904 standard; DNA; 13 BP.
XX
XX ABC38904;
XX
XX 20-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 38921 for detecting SNP TSC0011982.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 38921; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1652 TAACTTACCAT 1664

AC ABH61838;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 261815 for detecting SNP TSC0063522.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PS (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 261815; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SO Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;
 XX
 QY Query Match 0.3%; Score 13; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 674 TTAACTTAAATT 686
 13 TTAACTTAAATT 1
 RESULT 165
 ID ABC93209 standard; DNA; 13 BP.
 AC ABC93209;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 93226 for detecting SNP TSC0023296.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.

XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 93226; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SO Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 QY Query Match 0.3%; Score 13; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 3647 TTTTATGCTTTG 3659
 13 TTTTATGCTTAG 1
 RESULT 166
 ID ABC61204 standard; DNA; 13 BP.
 AC ABC61204;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 61221 for detecting SNP TSC0016301.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2539 TAGCTTAAAC 2551

DB 13 TAGCTTAAAC 1

RESULT 162

ABF93900 standard; DNA; 13 BP.

XX ABF93900;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 193897 for detecting SNP TSC0047679.

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX Claim 1; SEQ ID NO 193897; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 0 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4801 TAGAATTAATT 4813

DB 1 TAGAATTAATT 13

RESULT 163

ABH23867/C standard; DNA; 13 BP.

XX ABH23867;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 223844 for detecting SNP TSC0054506.

XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX Claim 1; SEQ ID NO 223844; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 1 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1202 TAGTAATTAATT 1214

DB 13 TAGTAATTAATT 1

RESULT 164

ABH61838/C standard; DNA; 13 BP.

XX

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 61722; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 0 C; 0 G; 11 T; 0 U; 0 Other;
 Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2873 AAAAATATAAAA 2885
 DB 13 AAAAATATAAAA 1
 RESULT 160
 ABC38905
 ID ABC38905 standard; DNA; 13 BP.
 AC ABC38905;
 DT 20-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 38922 for detecting SNP TSC0011982.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA

XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 38922; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 5 A; 3 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1652 TAACTTACCAT 1664
 DB 1 TAACTTACCAT 13
 RESULT 161
 ABH17340/C
 ID ABH17340 standard; DNA; 13 BP.
 AC ABH17340;
 DT 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 217317 for detecting SNP TSC0052834.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 217317; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 1 C; 0 G; 7 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4801 TAGAATATTAATT 4813

DB 13 TAGAATATTAATT 1

RESULT 157

ABC28196 ABC28196 standard; DNA; 13 BP.

XX ABC28196;

XX 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 28213 for detecting SNP TSC0007986.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 28213; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1588 GTTGTGAGTGTGTA 1600

DB 1 GTTGTGAGTGTGTA 13

RESULT 158

ABF08586 ABF08586 standard; DNA; 13 BP.

XX ABF08586;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 108583 for detecting SNP TSC0027160.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 108583; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1209 ATTATTATTTGCT 1221

DB 1 ATTATTATTTGCT 13

RESULT 159

ABC61705/C ABC61705 standard; DNA; 13 BP.

XX ABC61705;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 61722 for detecting SNP TSC0016411.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

PF 06-APR-2001; 2001WO-IB000713.
XX
PS 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
PA
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 262455; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 2 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 142 TGTTTAATGTTAT 154
DB 1 TGTTTAATGTTAT 13
XX
RESULT 155
ABF08587/C
ID ABF08587 standard; DNA; 13 BP.
XX
AC ABF08587;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 108584 for detecting SNP TSC0027160.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 108584; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1209 ATTATTATGTCG 1221
DB 13 ATTATTATGTCG 1
XX
RESULT 156
ABF93901/C
ID ABF93901 standard; DNA; 13 BP.
XX
AC ABF93901;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 193898 for detecting SNP TSC0047679.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 193898; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

QY 3463 GGTATGTTAGTG 3475
 DB 1 GGTATGTTAGTG 13
 RESULT 152
 ABH44072
 ID ABH44072 standard; DNA; 13 BP.
 AC ABH44072;
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 244049 for detecting SNP TSC0059546.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 CC Claim 1; SEQ ID NO 244049; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SO Sequence 13 BP; 9 A; 0 C; 1 G; 3 T; 0 U; 0 Other;
 QY Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1194 AATATAATAGTA 1206
 DB 1 AATATAATAGTA 13
 RESULT 153
 ABH62152
 ID ABH62152 standard; DNA; 13 BP.
 AC ABH62152;
 XX
 XX 22-FEB-2002 (first entry)

XX
 DE Oligonucleotide SEQ ID NO 262129 for detecting SNP TSC0063598.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PA (EPIG-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 CC
 CC Claim 1; SEQ ID NO 262129; 29pp + Sequence Listing; German.
 XX
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SO Sequence 13 BP; 8 A; 0 C; 1 G; 4 T; 0 U; 0 Other;
 QY Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DB 4802 AGAATATAATTA 4814
 DB 1 AGAATATAATTA 13
 RESULT 154
 ABH62478
 ID ABH62478 standard; DNA; 13 BP.
 AC ABH62478;
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 262455 for detecting SNP TSC0063663.
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 223843; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 0 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1202 TAGTAAATTAAT 1214
 |||||
 1. TAGTAAATTAAT 13

Db

RESULT 150
 ABH27671/C
 ID ABH27671 standard; DNA; 13 BP.

XX ABH27671;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 227648 for detecting SNP TSC005515.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

OS WO200177384-A2.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 227648; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 2 C; 0 G; 9 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4876 TCGAAAAATTAATA 4888
 |||||
 13 TCGAAAAATTAATA 1

Db

RESULT 151
 ABF80046
 ID ABF80046 standard; DNA; 13 BP.

XX ABF80046;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 180043 for detecting SNP TSC0044583.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

OS WO200177384-A2.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 180043; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

ID ABC53972 standard; DNA; 13 BP.
XX
AC ABC53972;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 53989 for detecting SNP TSC0014846.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 53989; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 0 C; 0 G; 6 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 4381 AATATTTTAAAA 4393
DB 1 AATATTTTAAAA 13
XX
XX RESULT 148
ABC87969
ID ABC87969 standard; DNA; 13 BP.
XX
XX ABC87969;
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 87986 for detecting SNP TSC0022114.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS

XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 87986; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 10 A; 0 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2875 AATATTAATAAT 2887
DB 1 AATATTAATAATAAT 13
XX
XX RESULT 149
ABH23866
ID ABH23866 standard; DNA; 13 BP.
XX
XX ABH23866;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 223843 for detecting SNP TSC0054506.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP, 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4188 CATACCTCCCTAA 4200
DB 1 CATACCTCCCTAA 13

RESULT 145

ABF96987/C
ID ABF96987 standard; DNA; 13 BP.

AC ABF96987;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 196984 for detecting SNP TSC0008717.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PT Claim 1, SEQ ID NO 196984; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SEQ Sequence 13 BP, 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 635 TATTATTAATGT 647
DB 13 TATTATTAATGT 1

RESULT 146

ABH09678
ID ABH09678 standard; DNA; 13 BP.

AC ABH09678;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 209655 for detecting SNP TSC0051193.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIG-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PT Claim 1, SEQ ID NO 209655; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 9 A; 0 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.3%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1198 AAAATAGTAAAT 1210
DB 1 AAAATAGTAAAT 13

RESULT 147

ABC53972

XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 71222; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, cardiovascular, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 TTTTGAATTTT 104
13 TTTTGAATTTT 2

RESULT 291
ABC71204
ID ABC71204 standard; DNA; 13 BP.
XX
XX ABC71204;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 71221 for detecting SNP TSC0018455.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
XX
XX Claim 1; SEQ ID NO 71221; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, cardiovascular, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;

Query Match 0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 TTTTGAATTTT 104
1 TTTTGAATTTT 12

Search completed: April 22, 2004, 06:33:04
Job time : 14 secs

THIS PAGE BLANK (USPTO)

PP 10-30 MRS

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 22, 2004, 06:34:40 ; Search time 1 Seconds
(without alignments)
3.791 Million cell updates/sec

Title: us-09-555-640-1
Perfect score: 5028
Sequence: 1 gacgtcacaggaatgacgt.....acgtcattctgtgacgtc 5028

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 0.5

Searched: 21 seqs, 377 residues

Total number of hits satisfying chosen parameters: 42

Minimum DB seq length: 10
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 24 summaries

Database : rni.seq*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	DB ID	Description
1	24.4	0.5	26	1 US-09-198-243-3
2	22	0.4	22	1 US-09-311-260-91
3	22	0.4	22	1 US-09-642-633A-1
4	21.4	0.4	23	1 US-09-245-248B-6
5	21	0.4	21	1 US-09-311-260-92
6	20	0.4	20	1 US-09-245-248B-10
7	20	0.4	20	1 US-09-642-633A-2
8	18.4	0.4	20	1 US-09-619-420A-2
9	15.4	0.3	17	1 US-08-390-850-588
10	15.4	0.3	17	1 US-08-373-124A-872
11	15.4	0.3	17	1 US-08-435-634-588
12	15.4	0.3	17	1 US-08-435-628-872
13	15.4	0.3	17	1 US-08-584-040-1770
14	15.4	0.3	17	1 US-08-584-040-4253
15	15.4	0.3	17	1 US-08-584-040-5823
16	15.4	0.3	17	1 US-09-371-772B-315
17	15.4	0.3	17	1 US-09-371-772B-2020
18	13	0.3	17	1 US-08-373-124B-872
19	13	0.3	17	1 US-08-435-628-872
20	12.4	0.2	26	1 US-09-198-243-3
21	12	0.2	12	1 US-08-765-340-159
22	12	0.2	12	1 US-09-772-315-1
23	12	0.2	13	1 US-09-772-315-7
24	12	0.2	13	1 US-09-367-513-4

ALIGNMENTS

RESULT 1
US-09-198-243-3
Sequence 3, Application US/09198243
Patent No. 618399

GENERAL INFORMATION:
APPLICANT: WEIMER, Thomas
APPLICANT: GROENER, Albrecht
TITLE OF INVENTION: Procedure for the detection of high virus concentrations in blood plasma and/or blood serum by means of the polymerase chain reaction
FILE REFERENCE: 06478.1419-00000
CURRENT APPLICATION NUMBER: US/09/198,243
CURRENT FILING DATE: 1998-11-24
EARLIER APPLICATION NUMBER: P 197 52 898.9
EARLIER FILING DATE: 1997-11-28
NUMBER OF SEQ ID NOS: 3
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 3
LENGTH: 26
TYPE: DNA
ORGANISM: Parvovirus B19
FEATURE:
OTHER INFORMATION:
NAME/KEY: modified_base
LOCATION: (1)
OTHER INFORMATION: FAM, carboxy fluorescein substitution
FEATURE:
NAME/KEY: modified_base
LOCATION: (26)
OTHER INFORMATION: TAMRA, carboxytetramethylrhodamine substitution
US-09-198-243-3

Query Match 0.5%; Score 24.4; DB 1; Length 26;
Best Local Similarity 96.2%; Pred. No. 1.3;
Matches 25; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1430 TGGTGTCTGGGATGAAGGCATTATT 1455
DB 1 TGGTGTCTGGGATGAAGGCATTATT 26

RESULT 2
US-09-311-260-91
Sequence 91, Application US/09311260
Patent No. 6214555
GENERAL INFORMATION:
APPLICANT: Leushner, James
APPLICANT: Hui, May
APPLICANT: Dunn, James M.
APPLICANT: LaCroix, Jean-Michel
TITLE OF INVENTION: METHOD, COMPOSITIONS AND KIT FOR DETECTION OF MICROORGANISMS AND BI-DIRECTIONAL SEQUENCING OF NUCLEIC ACID
TITLE OF INVENTION: POLYMERS
NUMBER OF SEQUENCES: 189
CORRESPONDENCE ADDRESS:
ADDRESSEE: Oppedahl & Larson LLP
STREET: P.O. Box 5270
CITY: Frisco
STATE: CO
COUNTRY: US
ZIP: 80443-5270
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: MS DOS
SOFTWARE: Word Perfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/311,260
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Larson, Marina T.
REGISTRATION NUMBER: 32,038

parkin640-1.rni

Thu Apr 22 06:52:32 2004

```

; REFERENCE/DOCKET NUMBER: VGEN.P-058-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (970) 668-2050
; TELEFAX: (970) 668-2082
; TELEX:
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; FRAGMENT TYPE: internal
; US-09-311-260-91

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2429 GGAACAGACTTAGCTTATTC 2450
DB 1 GGAACAGACTTAGCTTATTC 22

```

```

Query Match 0.4%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 2.6;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 3015 GCATGACTTCAGTTAACTGCA 3037
DB 1 GCATGACTTCAGTTAACTGCA 23

```

RESULT 5

```

US-09-311-260-92/c
; Sequence 92, Application US/09311260
; Patent No. 6214555
; GENERAL INFORMATION:

```

```

; APPLICANT: Leusner, James
; APPLICANT: Hui, May
; APPLICANT: Dunn, James M.
; APPLICANT: LaCroix, Jean-Michel
; TITLE OF INVENTION: METHOD, COMPOSITIONS AND KIT FOR DETECTION OF
; TITLE OF INVENTION: MICROORGANISMS AND BI-DIRECTIONAL SEQUENCING OF NUCLEIC ACID
; TITLE OF INVENTION: POLYMERS
; NUMBER OF SEQUENCES: 189
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson LLP
; STREET: P.O. Box 5270
; CITY: Frisco
; STATE: CO
; COUNTRY: US
; ZIP: 80443-5270

```

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage.
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/311,260
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Marina T.
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VGEN.P-058-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (970) 668-2050
; TELEFAX: (970) 668-2082
; TELEX:
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:

```

EP96 000012345
WD 0096:2345

```

; REFERENCE/DOCKET NUMBER: VGEN.P-058-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (970) 668-2050
; TELEFAX: (970) 668-2082
; TELEX:
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; FRAGMENT TYPE: internal
; US-09-311-260-91

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2429 GGAACAGACTTAGCTTATTC 2450
DB 1 GGAACAGACTTAGCTTATTC 22

```

```

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2429 GGAACAGACTTAGCTTATTC 2450
DB 1 GGAACAGACTTAGCTTATTC 22

```

RESULT 3

```

US-09-642-633A-1
; Sequence 1, Application US/09642633A
; Patent No. 6649339
; GENERAL INFORMATION:

```

```

; APPLICANT: Baxter Aktiengesellschaft
; APPLICANT: Zerlauth, Gerold
; APPLICANT: Gessner, Matthias
; APPLICANT: Koethnitzer, Karl
; APPLICANT: Gross, Patricia
; TITLE OF INVENTION: A Method for Producing a Quality Assured
; TITLE OF INVENTION: Biological Sample and Composition Containing the Same
; FILE REFERENCE: 236.00
; CURRENT APPLICATION NUMBER: US/09/642.633A
; CURRENT FILING DATE: 2000-08-18
; PRIOR APPLICATION NUMBER: A1443/99
; PRIOR FILING DATE: 1999-08-20
; PRIOR APPLICATION NUMBER: PCT/EP96/12345
; PRIOR FILING DATE: 1996-12-31
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO: 1
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
; US-09-642-633A-1

```

```

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2589 GACAGTTATCTGACCAACCCCA 2610
DB 1 GACAGTTATCTGACCAACCCCA 22

```

```

Query Match 0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2589 GACAGTTATCTGACCAACCCCA 2610
DB 1 GACAGTTATCTGACCAACCCCA 22

```

RESULT 4

```

US-09-245-248B-6
; Sequence 6, Application US/09245248B
; Patent No. 6395472
; GENERAL INFORMATION:

```

```

; APPLICANT: Abbott Laboratories
; APPLICANT: Leary, Thomas
; APPLICANT: Erker, James
; APPLICANT: Chalmers, Michelle

```



```
/ LENGTH: 21
/ TYPE: nucleic acid
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ HYPOTHETICAL: no
/ ANTI-SENSE: no
/ FRAGMENT TYPE: internal
/ US-09-311-260-92

Query Match          0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2667 CTAGTGAAGACTTACACAGC 2687
Db 21 CTAGTGAAGACTTACACAGC 1

RESULT 6
US-09-245-248B-10/c
/ Sequence 10, Application US/09245248B
/ Patent No. 6395472
/ GENERAL INFORMATION:
/ APPLICANT: Abbott Laboratories
/ APPLICANT: Leary, Thomas
/ APPLICANT: Erker, James
/ APPLICANT: Chalmers, Michelle
/ APPLICANT: Simons, John
/ APPLICANT: Birkenmeyer, Larry
/ APPLICANT: Muerhoff, Scott
/ APPLICANT: Pilot-Matias, Tami
/ APPLICANT: Desai, Suresh
/ APPLICANT: Mushahwar, Isa
/ TITLE OF INVENTION: METHODS OF UTILIZING THE TT VIRUS
/ FILE REFERENCE: 6461.US.01
/ CURRENT APPLICATION NUMBER: US/09/245,248B
/ CURRENT FILING DATE: 1999-02-05
/ NUMBER OF SEQ ID NOS: 71
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 10
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Homo sapien
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: (0)...(0)
/ OTHER INFORMATION: B19.2119-al primer
/ US-09-245-248B-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1992 CGGAAGCCCGAGTTTCTCTCCG 2011
Db 20 CGGAAGCCCGAGTTTCTCTCCG 1

RESULT 7
US-09-642-633A-2/c
/ Sequence 2, Application US/09642633A
/ Patent No. 6649339
/ GENERAL INFORMATION:
/ APPLICANT: Baxter Aktiengesellschaft
/ APPLICANT: Zerlauth, Gerold
/ APPLICANT: Gesner, Matthias
/ APPLICANT: Koettnitz, Karl
/ APPLICANT: Gross, Patricia
/ TITLE OF INVENTION: A Method for Producing a Quality Assured
/ TITLE OF INVENTION: Biological Sample and Composition Containing the Same
/ FILE REFERENCE: 236.00
/ CURRENT APPLICATION NUMBER: US/09/642, 633A

/ LENGTH: 21
/ TYPE: nucleic acid
/ STRANDEDNESS: double
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ HYPOTHETICAL: no
/ ANTI-SENSE: no
/ FRAGMENT TYPE: internal
/ US-09-311-260-92

Query Match          0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.4;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2667 CTAGTGAAGACTTACACAGC 2687
Db 21 CTAGTGAAGACTTACACAGC 1

RESULT 6
US-09-245-248B-10/c
/ Sequence 10, Application US/09245248B
/ Patent No. 6395472
/ GENERAL INFORMATION:
/ APPLICANT: Abbott Laboratories
/ APPLICANT: Leary, Thomas
/ APPLICANT: Erker, James
/ APPLICANT: Chalmers, Michelle
/ APPLICANT: Simons, John
/ APPLICANT: Birkenmeyer, Larry
/ APPLICANT: Muerhoff, Scott
/ APPLICANT: Pilot-Matias, Tami
/ APPLICANT: Desai, Suresh
/ APPLICANT: Mushahwar, Isa
/ TITLE OF INVENTION: METHODS OF UTILIZING THE TT VIRUS
/ FILE REFERENCE: 6461.US.01
/ CURRENT APPLICATION NUMBER: US/09/245,248B
/ CURRENT FILING DATE: 1999-02-05
/ NUMBER OF SEQ ID NOS: 71
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 10
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Homo sapien
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: (0)...(0)
/ OTHER INFORMATION: B19.2119-al primer
/ US-09-245-248B-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1992 CGGAAGCCCGAGTTTCTCTCCG 2011
Db 20 CGGAAGCCCGAGTTTCTCTCCG 1

RESULT 7
US-09-642-633A-2/c
/ Sequence 2, Application US/09642633A
/ Patent No. 6649339
/ GENERAL INFORMATION:
/ APPLICANT: Baxter Aktiengesellschaft
/ APPLICANT: Zerlauth, Gerold
/ APPLICANT: Gesner, Matthias
/ APPLICANT: Koettnitz, Karl
/ APPLICANT: Gross, Patricia
/ TITLE OF INVENTION: A Method for Producing a Quality Assured
/ TITLE OF INVENTION: Biological Sample and Composition Containing the Same
/ FILE REFERENCE: 236.00
/ CURRENT APPLICATION NUMBER: US/09/642, 633A

/ CURRENT FILING DATE: 2000-08-18
/ PRIOR APPLICATION NUMBER: A1443/99
/ PRIOR FILING DATE: 1999-08-20
/ PRIOR APPLICATION NUMBER: PCT/EP96/12345
/ PRIOR FILING DATE: 1996-12-31
/ NUMBER OF SEQ ID NOS: 3
/ SOFTWARE: FastSeq for Windows Version 3.0
/ SEQ ID NO 2
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: PCR primer
/ US-09-642-633A-2

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2682 ACAAGCCTGGCAAGTTAGC 2701
Db 20 ACAAGCCTGGCAAGTTAGC 1

RESULT 8
US-09-619-420A-2/c
/ Sequence 2, Application US/09619420A
/ Patent No. 6642033
/ GENERAL INFORMATION:
/ APPLICANT: LAZO, ARISTIDES
/ APPLICANT: ZHAO, XIAOJUAN
/ APPLICANT: TASSELLO, JODIE ANN
/ APPLICANT: GIBAJA, VERONICA
/ TITLE OF INVENTION: NUCLEIC ACIDS FOR DETECTING PARVOVIRUS AND METHODS OF
/ TITLE OF INVENTION: USING SAME
/ FILE REFERENCE: 18242-S03 US
/ CURRENT APPLICATION NUMBER: US/09/619,420A
/ CURRENT FILING DATE: 2000-07-19
/ PRIOR APPLICATION NUMBER: USSN 60/144,721
/ PRIOR FILING DATE: 1999-07-20
/ NUMBER OF SEQ ID NOS: 10
/ SOFTWARE: Patentin Ver. 2.0
/ SEQ ID NO 2
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: VINS-3R PRIMER
/ US-09-619-420A-2

Query Match          0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 5;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 414 AGATACTTCTGACTGGGAAC 433
Db 20 AGACACTTCTGACTGGGAAC 1

RESULT 9
US-08-390-850-588
/ Sequence 588, Application US/08390850
/ Patent No. 5612215
/ GENERAL INFORMATION:
/ APPLICANT: Draper, Kenneth G.
/ APPLICANT: Pavco, Pamela
/ APPLICANT: McSwiggen, James
/ APPLICANT: Gustofson, John
/ APPLICANT: Stinchcomb, Dan T.
/ TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
/ TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
/ NUMBER OF SEQUENCES: 1151
/ CORRESPONDENCE ADDRESS:
```

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/390,850
FILING DATE: February 17, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5612215ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 588:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-390-850-588

Query Match, 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 9.1;
Matches 13; Conservative 3; Mismatches 0; Indels 1; Gaps 0;

QY 2738 ATGAGCTACAGCTGG 2754
|||:|||||:
Db 1 AUAUGAGGUACAGCUGG 17

RESULT 10
US-08-373-124A-872
Sequence 872, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 872:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-872

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 9.1;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 4379 CAAATATTTTAAAT 4395
|||:|||||:
Db 1 CAUAUAUUUUAAAAU 17

RESULT 11
US-08-435-634-588
Sequence 588, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995

APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 588:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-588

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 9.1;
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 2738 AATGAGCTACAGCTGG 2754
||:||||:||||:||||
Db 1 A AUGAGGUACAACUGG 17

RESULT 12
US-08-435-628-872
Sequence 872, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 872:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-872

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 9.1;
Matches 9; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 4379 CAAATATTTTAAAT 4395
||:||||:||||:||||
Db 1 CAUAUAUUUUAAAAU 17

RESULT 13
US-08-584-040-1770
Sequence 1770, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1770:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 64.1%; Pred. No. 9.1;
Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

OY 2282 TGTTAACTGTGAAAAA 2298
DB 1 UGUUACUUGAAAAA 17

RESULT 14

US-08-584-040-4253/c
Sequence 4253, Application US/08584040
Patent No. 6346398

GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 4253:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-4253

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 9.1;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 703 ACCAAGGAAATATTT 719
DB 17 ACCTAAGGAAATATTT 1

RESULT 15

US-08-584-040-5823/c
Sequence 5823, Application US/08584040
Patent No. 6346398

GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
CONDITIONS RELATED TO LEVELS
OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 5823:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-5823

Query Match 0.3%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 9.1;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 703 ACCAAGGAAATATTT 719
DB 17 ACCTAAGGAAATATTT 1

RESULT 16

US-09-371-772B-315
Sequence 315, Application US/09371772B
Patent No. 6566127

GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel

; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MEHB00,876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 315
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; US-09-371-772B-315

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 64.7%; Pred. No. 9.1;
 Matches 11; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2282 TGTTAACTTGTAATAAAA 2298
 Db 1 UGUUACUUGAATAAAA 17

RESULT 17
 US-09-371-772B-2020/c
 ; Sequence 2020, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyne Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; FILE REFERENCE: MEHB00,876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2020
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; US-09-371-772B-2020

Query Match 0.3%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 9.1;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 703 ACCAAGGAAATATT 719
 Db 17 ACCTAAGGAAATATT 1

RESULT 18
 US-08-373-124A-872/c
 ; Sequence 872, Application US/08373124A
 ; Patent No. 5646042
 ; GENERAL INFORMATION:
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Draper, Kenneth
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Jarvis, Thale
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
 ; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
 ; TITLE OF INVENTION: CANCER USING RIBOZYMES

; NUMBER OF SEQUENCES: 2627
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/373,124A
 ; FILING DATE: January 13, 1995
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/245,466
 ; FILING DATE: May 18, 1994
 ; APPLICATION NUMBER: 08/192,943
 ; FILING DATE: February 7, 1994
 ; APPLICATION NUMBER: 07/987,132
 ; FILING DATE: December 7, 1992
 ; APPLICATION NUMBER: 07/936,422
 ; FILING DATE: August 26, 1992
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 209/035
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 872:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-373-124A-872
 Query Match 0.3%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 18;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 4384 ATTTTAAAAATA 4396
 Db 17 ATTTTAAAAATA 5
 RESULT 19
 US-08-435-628-872/c
 ; Sequence 872, Application US/08435628
 ; Patent No. 5817796
 ; GENERAL INFORMATION:
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Draper, Kenneth
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Jarvis, Thale
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
 ; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
 ; TITLE OF INVENTION: CANCER USING RIBOZYMES
 ; NUMBER OF SEQUENCES: 2627
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071

```

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 872:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-435-628-872

```

```

Query Match      0.3%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 18;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 4384 ATTTTAAAAATA 4396
Db 17 ATTTTAAAAATA 5

```

```

RESULT 20
US-09-198-243-3/c
; Sequence 3, Application US/09198243
; Patent No. 618399
; GENERAL INFORMATION:
; APPLICANT: WEIMER, Thomas
; APPLICANT: GROENER, Albrecht
; TITLE OF INVENTION: Procedure for the detection of high virus
; TITLE OF INVENTION: concentrations in blood plasma and/or blood serum by
; TITLE OF INVENTION: means of the polymerase chain reaction
; FILE REFERENCE: 06478.1419-00000
; CURRENT APPLICATION NUMBER: US/09/198,243
; CURRENT FILING DATE: 1998-11-24
; EARLIER APPLICATION NUMBER: P 197 52 898.9
; EARLIER FILING DATE: 1997-11-28
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 3
; LENGTH: 26
; TYPE: DNA
; ORGANISM: Parvovirus B19
; FEATURE:
; OTHER INFORMATION:
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: FAM, carboxy fluorescein substitution

```

```

; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (26)
; OTHER INFORMATION: TAMRA, carboxytetramethylrhodamine substitution
US-09-198-243-3

```

```

Query Match      0.2%; Score 12.4; DB 1; Length 26;
Best Local Similarity 72.7%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

```

```

QY 1802 ATGCCCTCCACCAGATCTCCA 1823
Db 22 ATACCTTCATCCGACCACCA 1

```

```

RESULT 21
US-08-765-340-159
; Sequence 159, Application US/08765340
; Patent No. 615092
; GENERAL INFORMATION:
; APPLICANT: UCHIDA, K.,
; APPLICANT: UCHIDA, T.,
; APPLICANT: TANAKA, Y.,
; APPLICANT: MATSUDA, Y.,
; APPLICANT: KONDO, S.,
; TITLE OF INVENTION: AN ANTISENSE NUCLEIC ACID
; NUMBER OF SEQUENCES: 185
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version
; SOFTWARE: #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/765,340
; FILING DATE: 23-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 145146/94
; FILING DATE: 27-JUN-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 311130/94
; FILING DATE: 21-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: SERUNIAN, LESLIE
; REGISTRATION NUMBER: 35,353
; REFERENCE/DOCKET NUMBER: 1452-4005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; INFORMATION FOR SEQ ID NO: 159:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "synthetic DNA"
;
; US-08-765-340-159

```

```

Query Match      0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 12; Conservative 0; Mismatches 0; Indels -0; Gaps 0;

```

```

QY 1582 ACATTGTGTGTG 1593

```

Db 1 ACATTGTGTG 12

RESULT 22

US-09-772-315-1/c

; Sequence 1, Application US/09772315

; Patent No. 6559125

; GENERAL INFORMATION:

; APPLICANT: DERVAN, Peter

; APPLICANT: WURTZ, Nicholas

; APPLICANT: CHANG, Aileen

; TITLE OF INVENTION: POLYAMIDE-ALKYLATOR CONJUGATES & RELATED PRODUCTS & METHODS

; FILE REFERENCE: GENESOF09/772315

; CURRENT APPLICATION NUMBER: US/09/772,315

; CURRENT FILING DATE: 2001-01-26

; NUMBER OF SEQ ID NOS: 25

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1

; LENGTH: 12

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc feature

; OTHER INFORMATION: Description of Artificial Sequence: Polyamide-Alkylator

; OTHER INFORMATION: Conjugate Target Sequence

US-09-772-315-1

Query Match 0.2%; Score 12; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 13;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 212 ATATAAGCAGCT 223

Db 12 ATATAAGCAGCT 1

RESULT 23

US-09-772-315-7/c

; Sequence 7, Application US/09772315

; Patent No. 6559125

; GENERAL INFORMATION:

; APPLICANT: DERVAN, Peter

; APPLICANT: WURTZ, Nicholas

; APPLICANT: CHANG, Aileen

; TITLE OF INVENTION: POLYAMIDE-ALKYLATOR CONJUGATES & RELATED PRODUCTS & METHODS

; FILE REFERENCE: GENESOF09/772315

; CURRENT APPLICATION NUMBER: US/09/772,315

; CURRENT FILING DATE: 2001-01-26

; NUMBER OF SEQ ID NOS: 25

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 7

; LENGTH: 13

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc feature

; OTHER INFORMATION: Description of Artificial Sequence: Polyamide-Alkylator

; OTHER INFORMATION: Conjugate Target Sequence

US-09-772-315-7

Query Match 0.2%; Score 12; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 214 ATAAAGCAGCTGC 225

Db 13 ATAAAGCAGCTGC 2

RESULT 24

US-09-367-513-4

; Sequence 4, Application US/09367513

; Patent No. 6660255

; GENERAL INFORMATION:

; APPLICANT: Gottesfeld, Joel M.

; APPLICANT: Dervan, Peter B.

; APPLICANT: Mosier, Donald E.

; APPLICANT: Baird, Eldon E.

; TITLE OF INVENTION: INHIBITION OF GENE TRANSCRIPTION BY

; TITLE OF INVENTION: POLYAMIDE DNA-BINDING LIGANDS

; FILE REFERENCE: 27801-20012.00

; CURRENT APPLICATION NUMBER: US/09/367,513

; CURRENT FILING DATE: 2000-04-25

; PRIOR APPLICATION NUMBER: US 60/038,384

; PRIOR FILING DATE: 1997-02-14

; PRIOR APPLICATION NUMBER: US 60/038,394

; PRIOR FILING DATE: 1997-02-14

; PRIOR APPLICATION NUMBER: US 60/(CIT2683)

; PRIOR FILING DATE: 1997-09-02

; PRIOR APPLICATION NUMBER: US 60/(CIT2684)

; PRIOR FILING DATE: 1997-09-10

; PRIOR APPLICATION NUMBER: US 08/853,022

; PRIOR FILING DATE: 1997-04-21

; PRIOR APPLICATION NUMBER: PCT/US97/12722

; PRIOR FILING DATE: 1997-07-21

; NUMBER OF SEQ ID NOS: 16

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 4

; LENGTH: 13

; TYPE: DNA

; ORGANISM: HIV

US-09-367-513-4

Query Match 0.2%; Score 12; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 212 ATATAAGCAGCT 223

Db 2 ATATAAGCAGCT 13

Search completed: April 22, 2004, 06:34:42

Job time: 1 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 22, 2004, 06:36:27 ; Search time 1 Seconds
(without alignments)
5.611 Million cell updates/sec

Title: us-09-555-640-1
Perfect score: 5028
Sequence: 1 gacgtcacaggaatgacgt.....acgtcatttcctgtgacgtc 5028

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 26 seqs, 558 residues

Total number of hits satisfying chosen parameters: 52

Minimum DB seq length: 10
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 26 summaries

Database : rnpb.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	27.4	0.5	29	1	US-10-231-843-14
2	27	0.5	28	1	US-10-231-843-1
3	27	0.5	28	1	US-10-231-843-22
4	25	0.5	25	1	US-10-231-843-17
5	23.4	0.5	25	1	US-10-231-843-15
6	23.4	0.5	25	1	US-10-231-843-37
7	22.4	0.4	24	1	US-10-187-253A-38
8	22	0.4	22	1	US-09-802-110B-91
9	22	0.4	22	1	US-10-231-843-18
10	22	0.4	22	1	US-10-231-843-28
11	21.4	0.4	23	1	US-09-815-656-6
12	21	0.4	21	1	US-09-802-110B-92
13	21	0.4	21	1	US-10-231-843-30
14	21	0.4	21	1	US-10-231-843-31
15	21	0.4	21	1	US-10-231-843-32
16	20	0.4	20	1	US-09-815-656-10
17	18.4	0.4	20	1	US-10-231-843-27
18	18.4	0.4	20	1	US-10-187-253A-37
19	18	0.4	18	1	US-10-231-843-39
20	18	0.4	18	1	US-10-231-843-40
21	17.4	0.3	19	1	US-10-187-253A-59
22	16.4	0.3	18	1	US-10-231-843-38
23	16	0.3	17	1	US-09-827-395A-840
24	16	0.3	17	1	US-09-827-395A-1020
25	16	0.3	17	1	US-10-430-882-840
26	16	0.3	17	1	US-10-430-882-1020

ALIGNMENTS

RESULT 1
US-10-231-843-14

; Sequence 14, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GP132-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-14

Query Match 0.5%; Score 27.4; DB 1; Length 29;
Best Local Similarity 96.6%; Pred. No. 2.9;
Matches 28; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2551 CTCTCCAGACCTATATAGTCATCATTTTC 2579
|||||
Db 1 CTCTCCAGACTTATATAGTCATCATTTTC 29

RESULT 2
US-10-231-843-1/c
; Sequence 1, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GP132-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 28
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-1

Query Match 0.5%; Score 27; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.9;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2786 AGGATTCATGACTTTAGGTATAGCCAA 2812
|||||
Db 28 AGGATTCATGACTTTAGGTATAGCCAA 2

RESULT 3
US-10-231-843-22
; Sequence 22, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita

```
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 22
; TYPE: DNA
; LENGTH: 28
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-22

Query Match          0.5%; Score 27; DB 1; Length 28;
Best Local Similarity 100.0%; Pred. No. 2.9;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2786 AGGATTGATGACCTTTAGGTATAGCCAA 2812
Db 1 AGGATTGATGACCTTTAGGTATAGCCAA 27
|||||

RESULT 4
US-10-231-843-17
; Sequence 17, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; TYPE: DNA
; LENGTH: 25
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-17

Query Match          0.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.7;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2589 GACAGTTATCTGACCAACCCCATGTC 2613
Db 1 GACAGTTATCTGACCAACCCCATGTC 25
|||||

RESULT 5
US-10-231-843-15
; Sequence 15, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843

; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; TYPE: DNA
; LENGTH: 25
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-15

Query Match          0.5%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 5.3;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2551 CTCTCCAGACTTATATAGTCATCAT 2575
Db 1 CTCTCCAGACTTATATAGTCATCAT 25
|||||

RESULT 6
US-10-231-843-37
; Sequence 37, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 37
; TYPE: DNA
; LENGTH: 25
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-37

Query Match          0.5%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 5.3;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2551 CTCTCCAGACTTATATAGTCATCAT 2575
Db 1 CTCTCCAGACTTATATAGTCATCAT 25
|||||

RESULT 7
US-10-187-253A-38
; Sequence 38, Application US/10187253A
; Publication No. US20030170612A1
; GENERAL INFORMATION:
; APPLICANT: Pichuanes, Sergio
; APPLICANT: Shyamala, Venkatakrishna
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
; FILE REFERENCE: CHIR-17194/03US / PPI7194.004
; CURRENT APPLICATION NUMBER: US/10/187,253A
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 38
; TYPE: DNA
; LENGTH: 24
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer VP2-5
US-10-187-253A-38

Query Match      0.4%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 6.2;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 4620 GACACGATATGAAAGCCTGAAG 4643
Db 1 GACATGGATATGAAAGCCTGAAG 24

RESULT 8
US-09-802-110B-91
; Sequence 91, Application US/09802110B
; Publication No. US20030082535A1
; GENERAL INFORMATION:
; APPLICANT: Leushner, James
; Hui, May
; Dunn, James M.
; LaCroix, Jean-Michel
; TITLE OF INVENTION: METHOD, COMPOSITIONS AND KIT FOR
; DETECTION AND IDENTIFICATION OF MICROORGANISMS
; NUMBER OF SEQUENCES: 189
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Oppedahl & Larson LLP
; STREET: PO Box 5068
; CITY: Dillon
; STATE: CO
; COUNTRY: US
; ZIP: 80435
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/802,110B
; FILING DATE: 07-Mar-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: <Unknown>
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Marina T.
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VGEN.P-058-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (970) 468-6600
; TELEFAX: (970) 468-0104
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; FRAGMENT TYPE: internal
; SEQUENCE DESCRIPTION: SEQ ID NO: 91:
US-09-802-110B-91

Query Match      0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 5.8;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2429 GGAACAGACTTAGAGCTTATTC 2450
Db 1 GGAACAGACTTAGAGCTTATTC 22
```

```
RESULT 9
US-10-231-843-18
; Sequence 18, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GP132-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-18

Query Match      0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 5.8;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2585 CATGGACAGTTATCTGACCACC 2606
Db 1 CATGGACAGTTATCTGACCACC 22

RESULT 10
US-10-231-843-28
; Sequence 28, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GP132-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-28

Query Match      0.4%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 5.8;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2660 GTATTATCTAGTGAAGACTTAC 2681
Db 1 GTATTATCTAGTGAAGACTTAC 22

RESULT 11
US-09-815-656-6
; Sequence 6, Application US/09815656
; Patent No. US20010041331A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; APPLICANT: Leary, Thomas
; APPLICANT: Erker, James
; APPLICANT: Chalmers, Michelle
; APPLICANT: Simons, John
; APPLICANT: Birkenmeyer, Larry
; APPLICANT: Muerthoff, Scott
; APPLICANT: Pilot-Matias, Tami
; APPLICANT: Desai, Suresh
; APPLICANT: Mushanwar, Isa
; TITLE OF INVENTION: METHODS OF UTILIZING THE TT VIRUS
; FILE REFERENCE: 6461.US.01
; CURRENT APPLICATION NUMBER: US/09/815,656
; CURRENT FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: 09/245,248
; PRIOR FILING DATE: 1999-02-05
; NUMBER OF SEQ ID NOS: 71
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (0)...(0)
; OTHER INFORMATION: B19-Reverse primer
; US-09-815-656-6

Query Match      0.4%; Score 21.4; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 7.2;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3015 GCATGACTTCAGTAACTCTGCA 3037
DB 1 GCATGACTTCAGTAACTCTGCA 23

RESULT 12
US-09-802-110B-92/c
; Sequence 92, Application US/09802110B
; Publication No. US20030082535A1
; GENERAL INFORMATION:
; APPLICANT: Leushner, James
; Hui, May
; Dunn, James M.
; LaCroix, Jean-Michel
; TITLE OF INVENTION: METHOD, COMPOSITIONS AND KIT FOR
; DETECTION AND IDENTIFICATION OF MICROORGANISMS
; NUMBER OF SEQUENCES: 189
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Opedahl & Larson LLP
; STREET: PO Box 5068
; CITY: Dillon
; STATE: CO
; COUNTRY: US
; ZIP: 80435
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: MS DOS
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/802,110B
; FILING DATE: 07-Mar-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: <Unknown>
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Larson, Marina T.
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: VGEN.P-058-2

```

```

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (970) 468-6600
; TELEFAX: (970) 468-0104
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: no
; FRAGMENT TYPE: internal
; SEQUENCE DESCRIPTION: SEQ ID NO: 92:
US-09-802-110B-92

Query Match      0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2667 CTAGTGAAGACTTACACAGC 2687
DB 1 CTAGTGAAGACTTACACAGC 1

RESULT 13
US-10-231-843-30
; Sequence 30, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 30
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-30

Query Match      0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2667 CTAGTGAAGACTTACACAGC 2687
DB 1 CTAGTGAAGACTTACACAGC 21

RESULT 14
US-10-231-843-31
; Sequence 31, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30

```

```
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 31
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-31

Query Match          0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2670 GTGAAGACTTACACAGCCTG 2690
Db 1 GTGAAGACTTACACAGCCTG 21

RESULT 15
US-10-231-843-32
; Sequence 32, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GP132-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 32
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-32

Query Match          0.4%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 6.6;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2657 GCAGTATTATCTAGTGAAGAC 2677
Db 1 GCAGTATTATCTAGTGAAGAC 21

RESULT 16
US-09-815-656-10/c
; Sequence 10, Application US/09815656
; Patent No. US20010041331A1
; GENERAL INFORMATION:
; APPLICANT: Abbott Laboratories
; APPLICANT: Leary, Thomas
; APPLICANT: Erker, James
; APPLICANT: Chalmers, Michelle
; APPLICANT: Simons, John
; APPLICANT: Birkenmeyer, Larry
; APPLICANT: Muerhoff, Scott
; APPLICANT: Pilot-Matias, Tami
; APPLICANT: Desai, Suresh
; APPLICANT: Mushahwar, Isa
; TITLE OF INVENTION: METHODS OF UTILIZING THE TT VIRUS
; FILE REFERENCE: 6461.US.O1
; CURRENT APPLICATION NUMBER: US/09/815,656

; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: 09/245,248
; PRIOR FILING DATE: 1999-02-05
; NUMBER OF SEQ ID NOS: 71
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapien
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (0)...(0)
; OTHER INFORMATION: B19.2119-al primer
US-09-815-656-10

Query Match          0.4%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1992 CGGAAGCCCGATTCTCTCG 2011
Db 20 CGGAAGCCCGATTCTCTCG 1

RESULT 17
US-10-231-843-27
; Sequence 27, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GP132-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: 60/316,691
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-27

Query Match          0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 11;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2593 GCCATGGACAGATTATCTGAC 2602
Db 1 GCCATGGACAGATTATCTGAC 20

RESULT 18
US-10-187-253A-37/c
; Sequence 37, Application US/10187253A
; Publication No. US20030170612A1
; GENERAL INFORMATION:
; APPLICANT: Pichuanter, Sergio
; APPLICANT: Shyamala, Venkatakrishna
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
; FILE REFERENCE: CHIR-17194/03US / PP17194.004
; CURRENT APPLICATION NUMBER: US/10/187,253A
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 37
; LENGTH: 20
```

```

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer VP-3
US-10-187-253A-37

Query Match          0.4%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 11;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3315 CACCATTAGAGTTTCAGCAC 3334
Db 20 CACCATTAGAGTTTCAGCAC 1
|||||
RESULT 19
US-10-231-843-39
; Sequence 39, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 39
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-39

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.8;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2670 GTGAAGACTTACACAGC 2687
Db 1 GTGAAGACTTACACAGC 18
|||||
RESULT 20
US-10-231-843-40
; Sequence 40, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-40

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.8;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2670 GTGAAGACTTACACAGC 2687
Db 1 GTGAAGACTTACACAGC 18
|||||
RESULT 20
US-10-231-843-40
; Sequence 40, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 40
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-40

Query Match          0.4%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.8;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2660 GTATTATCTAGTGAAGAC 2677
Db 1 GTATTATCTAGTGAAGAC 18
|||||
RESULT 21
US-10-187-253A-59/c
; Sequence 59, Application US/10187253A
; Publication No. US20030170612A1
; GENERAL INFORMATION:
; APPLICANT: Pichuanes, Sergio
; APPLICANT: Shyamala, Venkatakrishna
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
; FILE REFERENCE: CHIR-17194/03US / PP17194.004
; CURRENT APPLICATION NUMBER: US/10/187,253A
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 59
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer VSP2
US-10-187-253A-59

Query Match          0.3%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 12;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3316 ACCATTAGAGTTTCAGCAC 3334
Db 19 ACCTTTAGAGTTTCAGCAC 1
|||||
RESULT 22
US-10-231-843-38
; Sequence 38, Application US/10231843
; Publication No. US20030124578A1
; GENERAL INFORMATION:
; APPLICANT: Brentano, Steven T.
; APPLICANT: Batranina-Kaminsky, Margarita
; APPLICANT: Hasselkus-Light, Cynthia S.
; APPLICANT: Kolk, Daniel P.
; TITLE OF INVENTION: Assay for detection of human parvovirus B19 nucleic acid
; FILE REFERENCE: GPI32-02.UT
; CURRENT APPLICATION NUMBER: US/10/231,843
; CURRENT FILING DATE: 2002-08-30
; PRIOR FILING DATE: 2001-08-31
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 38
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic construct
US-10-231-843-38

Query Match          0.3%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 14;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2583 GCCATGCAGAGTTATCTG 2600
Db 1 GTCATGCAGAGTTATCTG 18
|||||
```

RESULT 23
 US-09-827-395A-840
 ; Sequence 840, Application US/09827395A
 ; Publication No. US20030113891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MEHB00-878-C (400/017)
 ; CURRENT APPLICATION NUMBER: US/09/827,395A
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 840
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-827-395A-840

 Query Match 0.3%; Score 16; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 14;
 Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

 QY 2767 TGCTGTGGACAGTGCT 2782
 :||:|||||:
 Db 1 UGCUGGACAGUGCU 16

 RESULT 24
 US-09-827-395A-1020
 ; Sequence 1020, Application US/09827395A
 ; Publication No. US20030113891A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MEHB00-878-C (400/017)
 ; CURRENT APPLICATION NUMBER: US/09/827,395A
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1020
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-827-395A-1020

 Query Match 0.3%; Score 16; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 14;
 Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

 QY 2767 TGCTGTGGACAGTGCT 2782
 :||:|||||:
 Db 2 UGCUGGACAGUGCU 17

 RESULT 25
 US-10-430-882-840
 ; Sequence 840, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MEHB00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; PRIOR FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1020
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-1020

 Query Match 0.3%; Score 16; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 14;
 Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

 QY 2767 TGCTGTGGACAGTGCT 2782
 :||:|||||:
 Db 1 UGCUGGACAGUGCU 16

 RESULT 26
 US-10-430-882-1020
 ; Sequence 1020, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MEHB00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; PRIOR FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1020
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-1020

 Query Match 0.3%; Score 16; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 14;
 Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

 QY 2767 TGCTGTGGACAGTGCT 2782
 :||:|||||:
 Db 1 UGCUGGACAGUGCU 16

; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MEHB00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; PRIOR FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 840
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-840

 Query Match 0.3%; Score 16; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 14;
 Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

 QY 2767 TGCTGTGGACAGTGCT 2782
 :||:|||||:
 Db 1 UGCUGGACAGUGCU 16

 RESULT 26
 US-10-430-882-1020
 ; Sequence 1020, Application US/10430882
 ; Publication No. US20030203870A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Lawrence Blatt
 ; APPLICANT: James McSwiggen
 ; APPLICANT: Bharat Chowhira
 ; APPLICANT: Peter Haerberli
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
 ; FILE REFERENCE: MEHB00-878-H (400/112)
 ; CURRENT APPLICATION NUMBER: US/10/430,882
 ; PRIOR FILING DATE: 2003-05-06
 ; PRIOR APPLICATION NUMBER: 09/827,395
 ; PRIOR FILING DATE: 2001-04-05
 ; PRIOR APPLICATION NUMBER: 09/780,533
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: PCT/US01/04273
 ; PRIOR FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/181,797
 ; PRIOR FILING DATE: 2000-02-11
 ; PRIOR APPLICATION NUMBER: PCT/US02/10512
 ; NUMBER OF SEQ ID NOS: 2617
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1020
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-430-882-1020

 Query Match 0.3%; Score 16; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 14;
 Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

 QY 2767 TGCTGTGGACAGTGCT 2782
 :||:|||||:
 Db 1 UGCUGGACAGUGCU 16

Qy 2767 TGCTGTGGACAGTGCT 2782
:|:|:|:|:|:|:|:|:|:
Db 2 UGCUGGACAGUGCU 17

Search completed: April 22, 2004, 06:36:29
Job time : 1 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 22, 2004, 06:38:30 ; Search time 0.001 Seconds
(without alignments)
1005.600 Million cell updates/sec

Title: us-09-555-640-1
Perfect score: 5028
Sequence: 1 gacgtcacggaatgacgt.....acgtatttcgtgacgtc 5028

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 9 seqs, 100 residues

Total number of hits satisfying chosen parameters: 18

Minimum DB seq length: 10
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 13 summaries

Database : rst.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	12	0.2	12	1	CF300273
2	12	0.2	12	1	CF331951
3	12	0.2	13	1	CF299938
C 4	10.4	0.2	13	1	CF299938
C 5	10	0.2	10	1	CF302524
C 6	10	0.2	11	1	CF299360
7	10	0.2	11	1	CF300559
8	10	0.2	11	1	CF543159
C 9	9.4	0.2	11	1	CF299360
C 10	9.4	0.2	12	1	CF300273
C 11	9.4	0.2	12	1	CF331951
C 12	9	0.2	10	1	CA795700
13	9	0.2	10	1	CF333615

ALIGNMENTS

RESULT 1
LOCUS CF300273 12 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--04-J19.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza sativa cDNA clone 7LEAF--04-J19, mRNA sequence.
ACCESSION CF300273
VERSION CF300273.1 GI:33672034
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE 1. (bases 1 to 12)
AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C.,

Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyonggi, Korea
Tel: 82 31 321 6193
Fax: 82 31 321 6355
Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source
1. .12
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF--04-J19"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/notes="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.85;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2872 AAAAAATATATAA 2883

Db 1 AAAAAATATATAA 12

RESULT 2

LOCUS CF331951 12 bp mRNA linear EST 18-AUG-2003
DEFINITION NACL--08-E07.g1 Rice callus plasmid cDNA library (NACL) Oryza sativa cDNA clone NACL--08-E07, mRNA sequence.
ACCESSION CF331951 GI:33812123
VERSION CF331951.1
KEYWORDS Oryza sativa
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE 1. (bases 1 to 12)
AUTHORS Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Kyonggi, Korea
Tel: 82 31 321 6193
Fax: 82 31 321 6355
Email: bhnahm@bio.com, bhnahm@bio.myongji.ac.kr.

FEATURES

source
1. .12
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="NACL--08-E07"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/notes="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

```

Query Match      0.2%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.85;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2874 AAAATATAAAA 2885
Db 1 AAAATATAAAA 12

RESULT 3
CF299938      13 bp mRNA linear EST 15-AUG-2003
LOCUS 7LEAF--04-C12.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
DEFINITION sativa cDNA clone 7LEAF--04-C12, mRNA sequence.
ACCESSION CF299938
VERSION CF299938.1 GI:33671699
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 13)
REFERENCE Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
AUTHORS Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
source
1..13
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF--04-C12"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match      0.2%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.6;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 523 TTATCTTTTTT 534
Db 12 TTATATTTTTT 1

RESULT 5
CF302524/c 10 bp mRNA linear EST 15-AUG-2003
LOCUS 7LEAF--08-B22.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
DEFINITION sativa cDNA clone 7LEAF--08-B22, mRNA sequence.
ACCESSION CF302524
VERSION CF302524.1 GI:33674285
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 10)
REFERENCE Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
AUTHORS Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
source
1..10
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF--08-B22"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match      0.2%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 0.78;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2872 AAAAATATAAA 2883
Db 2 AAAAATATAAA 13

RESULT 4
CF299938/c 13 bp mRNA linear EST 15-AUG-2003
LOCUS 7LEAF--04-C12.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
DEFINITION sativa cDNA clone 7LEAF--04-C12, mRNA sequence.
ACCESSION CF299938
VERSION CF299938.1 GI:33671699
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 13)

```

```

AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
Location/Qualifiers
1..13
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF--04-C12"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match      0.2%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 3.6;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 523 TTATCTTTTTT 534
Db 12 TTATATTTTTT 1

RESULT 5
CF302524/c 10 bp mRNA linear EST 15-AUG-2003
LOCUS 7LEAF--08-B22.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
DEFINITION sativa cDNA clone 7LEAF--08-B22, mRNA sequence.
ACCESSION CF302524
VERSION CF302524.1 GI:33674285
KEYWORDS EST.
SOURCE Oryza sativa
ORGANISM Oryza sativa
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 10)
REFERENCE Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
AUTHORS Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE Large-scale Sequencing Analysis of Rice ESTs
JOURNAL Unpublished (2003)
COMMENT Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bnhahm@bio.com, bnhahm@bio.myongji.ac.kr.

FEATURES
Location/Qualifiers
1..10
/organism="Oryza sativa"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:4530"
/clone="7LEAF--08-B22"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

```

```

RT-PCR.
Query Match      0.2%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 6;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 680 TTAATTTT 689
DB 10 TTAATTTT 1

RESULT 6
CF299360
LOCUS      11 bp mRNA linear EST 15-AUG-2003
DEFINITION 7LEAF--03-F15.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
sativa cDNA clone 7LEAF--03-F15, mRNA sequence.
ACCESSION  CF299360
VERSION     CF299360.1 GI:33671121
KEYWORDS   EST.
SOURCE     Oryza sativa
ORGANISM   Oryza sativa
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE  1 (bases 1 to 11)
AUTHORS   Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
TITLE     Large-scale Sequencing Analysis of Rice ESTs
JOURNAL   Unpublished (2003)
COMMENT   Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.

FEATURES
    source
    1..11
    Location/Qualifiers
        /organism="Oryza sativa"
        /mol_type="mRNA"
        /cultivar="Nackdong"
        /db_xref="taxon:4530"
        /clone="7LEAF--05-B09"
        /tissue_type="leaf"
        /dev_stage="7 days after germination"
        /lab_host="E.coli DH10B"
        /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
        /note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
        with oligoribonucleotides and then used as templates for
        RT-PCR."

Query Match      0.2%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 6;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4879 AAAAAATAAAA 4888
DB 2 AAAAAATAAAA 11

RESULT 8
CF543159
LOCUS      11 bp mRNA linear EST 22-SEP-2003
DEFINITION S014678-024-030-006-SP6 MP1Z-ADIS-024-leaf Beta vulgaris cDNA clone
024-030-006 5-PRIME, mRNA sequence.
ACCESSION  CF543159
VERSION     CF543159.1 GI:34891599
KEYWORDS   EST.
SOURCE     Beta vulgaris
ORGANISM   Beta vulgaris
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            Caryophyllales; Amaranthaceae; Beta.
REFERENCE  1 (bases 1 to 11)
AUTHORS   Herwig,R., Schulz,B., Weisshaar,B., Hennig,S., Steinfath,M.,
Drungowski,M., Stahl,D., Wruck,W., Menze,A., O'Brien,J., Lehrach,H.
and Radelof,U.
TITLE     Construction of a 'unigene' cDNA clone set by oligonucleotide
fingerprinting allows access to 25 000 potential sugar beet genes
JOURNAL   Plant J. 32 (5), 845-857 (2002)
MEDLINE    22362189
PUBMED     12472698
COMMENT   Contact: Weisshaar B
ADIS DNA core facility at MP1Z
Max-Planck-Institute for Plant Breeding Research
Carl-von-Linne Weg 10, 50829 Koeln, Germany
Fax: 00492215062851
Email: weisshaar@piz-koeln.mpg.de
Insert Length: 11 Std Error: 0.00
Plate: 30 row: 0 column: 06
Seq primer: SP6.

FEATURES
    source
    1..11
    Location/Qualifiers
        /organism="Beta vulgaris"
        /mol_type="mRNA"
        /cultivar="KWS2320 (double haploid, monogerm breeding
        line)"

```

/db_xref="GABI:936619"
 /db_xref="taxon:161934"
 /clone="024-030-006"
 /tissue_type="leaf"
 /lab_host="EMDH108"
 /clone_lib="MP1Z-ADIS-024-leaf"
 /note="Vector: pCMVSPORT6; Site 1: Sali; Site 2: NotI;
 cDNA library from sugar beet, library provided by KWS
 Kleinwanzlebener Saatgut AG Einbeck, Germany, contact:
 b.schulz@kws.de; cloning sites Sali-NotI, primer sites and
 orientation:
 SP6-Sali-CCACGGCTCG-Sprime-cDNA-polyA-CC-NotI-T7; Note:
 Sequencing granted in the context of the GABI-Beet
 project, local PI: Dr. Katharina Schneider, coordinator:
 Prof. Christian Jung; Sequence submission managed by
 RZPD/GABI-Primary database:http://gabi.rzpd.de"

Query Match 0.2%; Score 10; DB 1; Length 11;
 Best Local Similarity 100.0%; Pred. No. 6;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 234 ACACCTTCTT 243
 |||||
 Db 2 ACACCTTCTT 11

RESULT 9
 CF299360/c
 LOCUS 11 bp mRNA linear EST 15-AUG-2003
 DEFINITION 7LEAF--03-F15-g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
 sativa cDNA clone 7LEAF--03-F15, mRNA sequence.

ACCESSION CF299360
 VERSION CF299360.1 GI:33671121
 KEYWORDS EST.

SOURCE Oryza sativa

ORGANISM Oryza sativa
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzeae; Oryza.

REFERENCE 1 (bases 1 to 11)

AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
 Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
 TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)

COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 321 6193
 Fax: 82 31 321 6355
 Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES Location/Qualifiers

1..11
 /organism="Oryza sativa"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:4530"
 /clone="7LEAF--03-F15"
 /tissue_type="leaf"
 /dev_stage="7 days after germination"
 /lab_host="E.coli DH108"
 /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
 /notes="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
 with oligoribonucleotides and then used as templates for
 RT-PCR."

Query Match 0.2%; Score 9.4; DB 1; Length 11;
 Best Local Similarity 90.9%; Pred. No. 9.6;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 92 TTTTGAATT 102
 |||||
 Db 11 TTTTGAATT 1

RESULT 10
 CF300273/c

LOCUS 12 bp mRNA linear EST 15-AUG-2003
 DEFINITION 7LEAF--04-J19-g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
 sativa cDNA clone 7LEAF--04-J19, mRNA sequence.

ACCESSION CF300273
 VERSION CF300273.1 GI:33672034
 KEYWORDS EST.

SOURCE Oryza sativa

ORGANISM Oryza sativa
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzeae; Oryza.

REFERENCE 1 (bases 1 to 12)

AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
 Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
 TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)

COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea
 Tel: 82 31 321 6193
 Fax: 82 31 321 6355
 Email: bnhahm@gbio.com, bnhahm@bio.myongji.ac.kr.

FEATURES source

1..12
 /organism="Oryza sativa"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:4530"
 /clone="7LEAF--04-J19"
 /tissue_type="leaf"
 /dev_stage="7 days after germination"
 /lab_host="E.coli DH108"
 /clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
 /note="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped
 with oligoribonucleotides and then used as templates for
 RT-PCR."

Query Match 0.2%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 8.8;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 523 TTATATTTTT 533
 |||||
 Db 11 TTATATTTTT 1

RESULT 11

LOCUS 12 bp mRNA linear EST 18-AUG-2003
 DEFINITION NACL--08-E07-g1 Rice callus plasmid cDNA library (NACL) Oryza
 sativa cDNA clone NACL--08-E07, mRNA sequence.

ACCESSION CF331951
 VERSION CF331951.1 GI:33812123
 KEYWORDS EST.

SOURCE Oryza sativa

ORGANISM Oryza sativa
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzeae; Oryza.

REFERENCE 1 (bases 1 to 12)

AUTHORS Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
 Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
 TITLE Large-scale Sequencing Analysis of Rice ESTs
 JOURNAL Unpublished (2003)

COMMENT Contact: Nahm B.H.
 Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University
 Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.

FEATURES

source

Location/Qualifiers
 1. .12
 /organism="Oryza sativa"
 /mol_type="mRNA"
 /cultivar="Nackdong"
 /db_xref="taxon:4530"
 /clone="NACL-08-E07"
 /tissue_type="callus"
 /dev_stage="proliferated callus on 2N6 media for 30 days"
 /lab_host="E.coli DH10B"
 /clone_lib="Rice callus plasmid cDNA library (NACL)"
 /note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.2%; Score 9.4; DB 1; Length 12;
 Best Local Similarity 90.9%; Pred. No. 8.8;
 Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

CA795700 10 bp mRNA linear EST 05-DEC-2002
 Cac_BL_2724 Cac_BL (Bean and Leaf from Amelonardo type Cacao)
 Theobroma cacao cDNA clone Cac_BL_2724 5', mRNA sequence.

CA795700.1 GI:26052776
 EST.

Theobroma cacao (cacao)

LOCUS
 DEFINITION
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Malvales; Malvaceae; Byttnerioideae;
 Theobroma.

1 (bases 1 to 10)
 Jones, P.G., Allaway, D., Gilmour, D.M., Harris, C., Rankin, D.,
 Retzel, E.R. and Jones, C.A.
 Gene discovery and microarray analysis of cacao (Theobroma cacao
 L.) varieties

JOURNAL
 MEDLINE
 PUBMED
 COMMENT

Planta 216 (2), 255-264 (2002)
 22337596
 12447539
 Masterfoods
 Contact: Jones, Paul
 3d Dundee Road, Slough, Berkshire, UK, SL1 4LG
 Tel: +44 1664 416644
 Email: Paul.Jones@eu.effem.com
 Seq primer: T3.

FEATURES

source

Location/Qualifiers
 1. .10
 /organism="Theobroma cacao"
 /mol_type="mRNA"
 /strain="Amelonado type"
 /db_xref="taxon:3641"
 /clone="Cac BL 2724"
 /tissue_type="Mature leaf and mature bean"
 /cell_type="whole organ"
 /dev_stage="maturity"
 /lab_host="XL-1 Blue MRF"
 /clone_lib="Cac_BL (Bean and Leaf from Amelonardo type Cacao)"
 /note="Vector: pBK-CMV; Bean and leaf tissue from an Amelonado type Cacao tree."

Query Match 0.2%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 13;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 AGGGCGGA 199

Db 10 AGGGCGGA 2

RESULT 13

CF333615

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Oryza sativa

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
 of Bioscience and Bioinformatics, Myongji University

Yongin, Kyonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.

Location/Qualifiers

1. .10

/organism="Oryza sativa"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:4530"

/clone="JMT-02-J09"

/tissue_type="leaf"

/dev_stage="14 days after germination"

/lab_host="E.coli DH10B"

/clone_lib="AtJMT-overexpressing transgenic rice plasmid
 cDNA library (JMT)"/note="Vector: pCR4-TOPO; Site 1: EcoRI; Oligo-capped mRNA
 was reverse transcribed and then used for PCR. mRNA was
 prepared from Arabidopsis Jasmonate Carboxyl
 methyltransferase overexpression line."Query Match 0.2%; Score 9; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 13;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4036 GGACACTGA 4044

Db 1 GGACACTGA 9

Search completed: April 22, 2004, 06:38:31
 Job time : 1 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2004, 23:48:16 ; Search time 18804 Seconds
(without alignments)
11589.490 Million cell updates/sec

Title: US-09-555-640-1
Perfect score: 5028
Sequence: 1 gagctcacaggaaatgacgt.....acgtcatttcctgtgacgtc 5028

Scoring table: IDENTITY NUC
Gap 10.0, Gapext 1.0

Searched: 3470272 seqs, 21671516995 residues

Total number of hits satisfying chosen parameters: 6940544

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

GenEmbl.*

- 1: gb_ba.*
- 2: gb_htg.*
- 3: gb_in.*
- 4: gb_om.*
- 5: gb_ov.*
- 6: gb_pat.*
- 7: gb_ph.*
- 8: gb_pl.*
- 9: gb_pr.*
- 10: gb_ro.*
- 11: gb_sta.*
- 12: gb_sy.*
- 13: gb_un.*
- 14: gb_vi.*
- 15: em_ba.*
- 16: em_fun.*
- 17: em_hum.*
- 18: em_in.*
- 19: em_mu.*
- 20: em_om.*
- 21: em_or.*
- 22: em_ov.*
- 23: em_pat.*
- 24: em_ph.*
- 25: em_pl.*
- 26: em_ro.*
- 27: em_sta.*
- 28: em_un.*
- 29: em_vi.*
- 30: em_htg_hum.*
- 31: em_htg_inv.*
- 32: em_htg_other.*
- 33: em_htg_mus.*
- 34: em_htg_pln.*
- 35: em_htg_rod.*
- 36: em_htg_mam.*
- 37: em_htg_vrt.*
- 38: em_sy.*
- 39: em_htgo_hum.*
- 40: em_htgo_mus.*
- 41: em_htgo_other.*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	5028	100.0	5028	6	AX003421	Sequence
2	5028	100.0	5028	6	BD087037	Erythrovi
3	5028	100.0	5028	14	AJ249437	Human ery
4	4587.4	91.2	5017	14	AY083234	B19 virus
5	4119.2	81.9	4844	14	AY064475	Erythrovi
6	4117.6	81.9	4844	14	AY064476	Erythrovi
7	3941.8	78.4	4612	14	AY044266	B19 virus
8	3888.4	77.3	5156	14	PVB19NSVP	Z68146 Parvovirus
9	3875.6	77.1	5596	14	AY386330	B19 virus
10	3864.4	76.9	5594	14	AF162273	Erythrovi
11	3858.4	76.7	5255	14	PVBPPO	M24682 Human parvo
12	3839.8	76.4	5112	14	PVBPAU	M13178 Human parvo
13	3729	74.2	4803	14	AB030694	Erythrovi
14	3714.6	73.9	4803	14	AB030693	Erythrovi
15	3632.6	72.2	4531	14	PVB19X560	AB030693 Erythrovi
16	3629.4	72.2	4677	6	E09420	Z70560 Parvovirus
17	3621.2	72.0	4578	14	PVB19X528	E09420 Nucleotide
18	3605.2	71.7	4628	14	AB030673	Z70528 Parvovirus
19	3600.4	71.6	4538	14	AF113323	AB030673 Erythrovi
20	3573.8	71.1	4513	14	AY028237	AF113323 Erythrovi
21	3571.8	71.0	4514	14	PVB19X599	AY028237 B19 virus
22	3552	70.6	4466	14	AB126265	Z70599 Parvovirus
23	3550.4	70.6	4474	14	AB126270	AB126265 B19 virus
24	3544	70.5	4466	14	AB126262	AB126270 B19 virus
25	3544	70.5	4466	14	AB126263	AB126262 B19 virus
26	3542.4	70.5	4466	14	AB126264	AB126263 B19 virus
27	3539.2	70.4	4466	14	AB126266	AB126264 B19 virus
28	3536	70.3	4466	14	AB126269	AB126266 B19 virus
29	3531.2	70.2	4466	14	AB126267	AB126269 B19 virus
30	3531.2	70.2	4466	14	AB126268	AB126267 B19 virus
31	3528	70.2	4466	14	AB126266	AB126268 B19 virus
32	3420	68.0	4279	14	AF161226	AB126266 B19 virus
33	3397.6	67.6	4268	14	AF161225	AF161226 Erythrovi
34	3385.6	67.3	4265	14	AF161224	AF161225 Erythrovi
35	3377.2	67.2	4265	14	AF161223	AF161224 Erythrovi
36	3010.2	59.9	3737	14	AY028241	AF161223 Erythrovi
37	2343	46.6	2343	6	AX003505	AY028241 B19 virus
38	2343	46.6	2343	6	BD087119	AX003505 Sequence
39	2280.8	45.4	2805	14	AY028225	BD087119 Erythrovi
40	2218.8	44.1	2630	14	AY044268	AY028225 B19 virus
41	2013	40.0	2013	6	AX003501	AY044268 B19 virus
42	2013	40.0	2013	6	BD087117	AX003501 Sequence
43	1960	39.0	2537	14	AY028255	BD087117 Erythrovi
44	1942.8	38.6	2450	14	AY028234	AY028255 B19 virus
45	1914	38.1	2346	14	EBU38509	AY028234 B19 virus

ALIGNMENTS

RESULT 1	AX003421	Sequence 1	5028 bp	DNA	linear	PAT 07-SBP-2000
LOCUS	AX003421	Sequence 1	5028 bp	DNA	linear	PAT 07-SBP-2000
DEFINITION	AX003421	Sequence 1	5028 bp	DNA	linear	PAT 07-SBP-2000
ACCESSION	AX003421	Sequence 1	5028 bp	DNA	linear	PAT 07-SBP-2000
VERSION	AX003421.1	GI:9927225				
KEYWORDS						
SOURCE						
ORGANISM						
REFERENCE						
AUTHORS						
TITLE						
JOURNAL						

Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
1
Auguste, V., Garbarg-Chenon, A. and Nguyen, Q.T.
Erythrovirus and its applications
Patent: WO 9928439-A 1 10-JUN-1999;
ASSIST PUBL HOPITAUX DE PARIS (FR); AUGUSTE VERONIQUE (FR); GARBARG

CHENON ANTOINE (FR); NGUYEN QUANG TRI (FR)
FEATURES
source
1. 5028
/organism="B19 virus"
/mol_type="unassigned DNA"
/db_xref="taxon:10798"

ORIGIN

Query Match 100.0%; Score 5028; DB 6; Length 5028;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 5028; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GAGCTCACAGGAAATGACGTAACCTGTCGCGCATCTTGACCGGAAGTCCCGCTACCGGC 60
DB 1 GAGCTCACAGGAAATGACGTAACCTGTCGCGCATCTTGACCGGAAGTCCCGCTACCGGC 60
QY 61 GCGACCGCGGATCTGATTTGGTGTCTCTTTTGAATTTGGCGGCTTTTCCCG 120
DB 61 GCGACCGCGGATCTGATTTGGTGTCTCTTTTGAATTTGGCGGCTTTTCCCG 120
QY 121 CCTTATGCAATTAAGCGGCATCTTAACTGTTATATTTTAAATTTAAATTTGACAAACGCCT 180
DB 121 CCTTATGCAATTAAGCGGCATCTTAACTGTTATATTTTAAATTTAAATTTGACAAACGCCT 180
QY 181 AACGGTTACTAGGGCGGAGTTACGGCGGATATTAAGCAGCTGCGTTCCTCGACACTTT 240
DB 181 AACGGTTACTAGGGCGGAGTTACGGCGGATATTAAGCAGCTGCGTTCCTCGACACTTT 240
QY 241 CTTTCTGTTGCTTTTGAAGTGAACCTCACTGCTGCTCTTTGCTGCTTAAGTAACAGGT 300
DB 241 CTTTCTGTTGCTTTTGAAGTGAACCTCACTGCTGCTCTTTGCTGCTTAAGTAACAGGT 300
QY 301 ATTTATATACTAACTTTTAAATTAACATGAGCTATTTTCGGGCTGCTTTGACACATTTCC 360
DB 301 ATTTATATACTAACTTTTAAATTAACATGAGCTATTTTCGGGCTGCTTTGACACATTTCC 360
QY 361 TCTAACATTTCTGACCTGCTTAATGATTAATCTGCTGCTCTATGCTAGACTTAGATACT 420
DB 361 TCTAACATTTCTGACCTGCTTAATGATTAATCTGCTGCTCTATGCTAGACTTAGATACT 420
QY 421 TCTGACTGGGAACCACTAACCCATCTACAGATTAATGCAATTAATTTAAGCAGTGT 480
DB 421 TCTGACTGGGAACCACTAACCCATCTACAGATTAATGCAATTAATTTAAGCAGTGT 480
QY 481 GCTTCTAAACTTGAATTTTACTGGGGCGCTAGCAGGTTGCTATATCTTTTTCAGGTG 540
DB 481 GCTTCTAAACTTGAATTTTACTGGGGCGCTAGCAGGTTGCTATATCTTTTTCAGGTG 540
QY 541 GAATGTAAACAAATTTGAGGAAGGCTATCATATCCATGTAGTTATTTGGTCCAGGACTA 600
DB 541 GAATGTAAACAAATTTGAGGAAGGCTATCATATCCATGTAGTTATTTGGTCCAGGACTA 600
QY 601 AATGTAGAAACTTAACTGTGCGGTAGAGGTTTATTTTAAATGTTCTTTTACCATCTT 660
DB 601 AATGTAGAAACTTAACTGTGCGGTAGAGGTTTATTTTAAATGTTCTTTTACCATCTT 660
QY 661 GTAACCTGAAGTGTAACTTAAATTTTTCAGGGATGACTACCAAGGAAATATTTT 720
DB 661 GTAACCTGAAGTGTAACTTAAATTTTTCAGGGATGACTACCAAGGAAATATTTT 720
QY 721 AGAGATGAGACAGTTTATAGAAATTTACTTAAATGAAATTTTCCCTTTAAATGTTGTG 780
DB 721 AGAGATGAGACAGTTTATAGAAATTTACTTAAATGAAATTTTCCCTTTAAATGTTGTG 780
QY 781 TGGTGTGAACAAATTTGACGGGTATATAGACCTGTATTTCCGCTCTTTTCGGGGA 840
DB 781 TGGTGTGAACAAATTTGACGGGTATATAGACCTGTATTTCCGCTCTTTTCGGGGA 840
QY 841 GGAGCTTGTATGCTTAAAGACCCCGCATTTACTGCAATATACAGACAGTGTACTAATGAA 900
DB 841 GGAGCTTGTATGCTTAAAGACCCCGCATTTACTGCAATATACAGACAGTGTACTAATGAA 900
QY 901 ACTGGGGAGTCTAGCTGTGGGGGGAGATGTTGTGCCATTCGCTGGGAAGGAACAAA 960

DB 901 ACTGGGGAGTCTAGCTGTGGAGGGGAGATGTTGTGCCATTCGCTGGAAAAGGAAACAAA 960
QY 961 GCGGGTTAAAGTCTTCAAAACCATGTTAAATTTGGCTATGTGAAAAACAGAGTATTTACTGAA 1020
DB 961 GCGGGTTAAAGTCTTCAAAACCATGTTAAATTTGGCTATGTGAAAAACAGAGTATTTACTGAA 1020
QY 1021 GATTAATGGAATTTAGTGGATTTTAAACCAATATACCTTTATTAAGTAGCAGTCAAGTGGC 1080
DB 1021 GATTAATGGAATTTAGTGGATTTTAAACCAATATACCTTTATTAAGTAGCAGTCAAGTGGC 1080
QY 1081 AGCTTTCAAATTTCAAAGTCCCTTAAAGTTAGCTATTTATAAGCTACTAACTTAGTACCC 1140
DB 1081 AGCTTTCAAATTTCAAAGTCCCTTAAAGTTAGCTATTTATAAGCTACTAACTTAGTACCC 1140
QY 1141 ACTAGTACATCTCTGTTTACATTCAGACTTTTGACAGGTTTACTTGCATTTAAAGAAATAAA 1200
DB 1141 ACTAGTACATCTCTGTTTACATTCAGACTTTTGACAGGTTTACTTGCATTTAAAGAAATAAA 1200
QY 1201 ATAGTAAATTTATTTATTTGTCACAACTATGATCTCTTTTAGTGGGTCAACATGTGTTA 1260
DB 1201 ATAGTAAATTTATTTATTTGTCACAACTATGATCTCTCTTTTAGTGGGTCAACATGTGTTA 1260
QY 1261 AGGTGGAATTCACAAAAATTTGTTAAAAACACCCCTGTGTTTACGGGCCACCAAGT 1320
DB 1261 AGGTGGAATTCACAAAAATTTGTTAAAAACACCCCTGTGTTTACGGGCCACCAAGT 1320
QY 1321 ACTGAAAAACAAATTTGCGCAATGCTATGCTAAAACTGTACCAAGTGTATGGAATGGTG 1380
DB 1321 ACTGAAAAACAAATTTGCGCAATGCTATGCTAAAACTGTACCAAGTGTATGGAATGGTG 1380
QY 1381 AATTGGAATATGAAAACTTTTCCATTTAATGATGTAGCGGGGAAAAAGTTTGGTGTCTGG 1440
DB 1381 AATTGGAATATGAAAACTTTTCCATTTAATGATGTAGCGGGGAAAAAGTTTGGTGTCTGG 1440
QY 1441 GATGAAGCATTATTAAGTCCACTATTGTGAAGCTGCAAAAGCCATTTTAGTGTGCTCAG 1500
DB 1441 GATGAAGCATTATTAAGTCCACTATTGTGAAGCTGCAAAAGCCATTTTAGTGTGCTCAG 1500
QY 1501 CCAACAGGTTAGATCAGAAAAATGCGTGGCAGTGTGGCAGTGTGCGGTGTGCTGTGTT 1560
DB 1501 CCAACAGGTTAGATCAGAAAAATGCGTGGCAGTGTGGCAGTGTGCGGTGTGCTGTGTT 1560
QY 1561 ATAAACAGCAATGTGTGACATTTTGTCTGAGTGTATATACCACTACACTGTGAT 1620
DB 1561 ATAAACAGCAATGTGTGACATTTTGTCTGAGTGTATATACCACTACACTGTGAT 1620
QY 1621 GCTAAAGCCTTTAAAGGAAACGGATGTTAAAGCTAAACCTTTACCAATAGATGTAGCCCTGAC 1680
DB 1621 GCTAAAGCCTTTAAAGGAAACGGATGTTAAAGCTAAACCTTTACCAATAGATGTAGCCCTGAC 1680
QY 1681 ATGGGTTTACTTACAGAGGCTGATACAAATGGCTTAAGTGTGTTAATGTGCAAAAGC 1740
DB 1681 ATGGGTTTACTTACAGAGGCTGATACAAATGGCTTAAGTGTGTTAATGTGCAAAAGC 1740
QY 1741 TGGAGCCACTATGAAAACTGGGCAATTAACATTTGATTTCCCTGGGAATAAATGCA 1800
DB 1741 TGGAGCCACTATGAAAACTGGGCAATTAACATTTGATTTCCCTGGGAATAAATGCA 1800
QY 1801 GATGCCCTCCACCAGATCTCCAAACCAACCCCTATGTCAGACACACAGTATCAGCAGC 1860
DB 1801 GATGCCCTCCACCAGATCTCCAAACCAACCCCTATGTCAGACACACAGTATCAGCAGC 1860
QY 1861 AGTGGTGTGAAAGCTCTGAAGAACTCAGTGAAGAGCTTTTTCACCTCATCCTCCCA 1920
DB 1861 AGTGGTGTGAAAGCTCTGAAGAACTCAGTGAAGAGCTTTTTCACCTCATCCTCCCA 1920
QY 1921 GCGCCTGGAAACAGTGAACCCCGCTCTAGTACGCGCTTCCCGGGACAGTTCAGGA 1980
DB 1921 GCGCCTGGAAACAGTGAACCCCGCTCTAGTACGCGCTTCCCGGGACAGTTCAGGA 1980
QY 1981 GATATCTTCTCGGAAGCCAGTTTCTCCGAAGTGTAGCCCGCTGTGGGAGGAAGCT 2040

Db 1981 GAATCATTTGTCGGAAGCCAGCTTTCTCCGAAGTGTAGCCGGTCTGGGAGGAGCT 2040
Qy 2041 TTTTACAGCCGCTGTCGCGATCAGTTTCGTGAACCTGTTAGTAGGGGTGACTTTGTATGG 2100
Db 2041 TTTTACAGCCGCTGTCGCGATCAGTTTCGTGAACCTGTTAGTAGGGGTGACTTTGTATGG 2100
Qy 2101 GATGGTGTAGGGGATTCCTGTTGCTGTGTGGAACATATAAACAACAGTGGGGAGGG 2160
Db 2101 GATGGTGTAGGGGATTCCTGTTGCTGTGTGGAACATATAAACAACAGTGGGGAGGG 2160
Qy 2161 TTGGGGCTTTGCCCTCATCTGATTAATGTGGGAGCTTGGTATATATGATGGAATTTAGA 2220
Db 2161 TTGGGGCTTTGCCCTCATCTGATTAATGTGGGAGCTTGGTATATATGATGGAATTTAGA 2220
Qy 2221 GAGTTTACTCCAGACTTTAGTGGCTGCGATGTCAGTGTGATAGGAGCTCTTAACCCATTTCT 2280
Db 2221 GAGTTTACTCCAGACTTTAGTGGCTGCGATGTCAGTGTGATAGGAGCTCTTAACCCATTTCT 2280
Qy 2281 GTGTTAACTTGTAAAAATGTCTTACCTGTCTGGATTACAAAGTTTGTAGATTATGAG 2340
Db 2281 GTGTTAACTTGTAAAAATGTCTTACCTGTCTGGATTACAAAGTTTGTAGATTATGAG 2340
Qy 2341 TAAAAACACTAACAAATGTGGGAAGCAGTGAACAATTTGCCAGGACGTGTATAGCA 2400
Db 2341 TAAAAACACTAACAAATGTGGGAAGCAGTGAACAATTTGCCAGGACGTGTATAGCA 2400
Qy 2401 GTTTGTGCAATTTTATGAAAAAGCTACTGGAACAGACTTATCAAAATTTTAA 2460
Db 2401 GTTTGTGCAATTTTATGAAAAAGCTACTGGAACAGACTTATCAAAATTTTAA 2460
Qy 2461 AGACCAATTAACAATTTCTTTAGATAATCTTTTGAAGAACCCCTCTTTTATTTGACTT 2520
Db 2461 AGACCAATTAACAATTTCTTTAGATAATCTTTTGAAGAACCCCTCTTTTATTTGACTT 2520
Qy 2521 AGTTGCTCGCATTAAGTAATCTTAAACCTCTCCAGACCTATATAGTCAATTTTCA 2580
Db 2521 AGTTGCTCGCATTAAGTAATCTTAAACCTCTCCAGACCTATATAGTCAATTTTCA 2580
Qy 2581 GAGCCATGACAGTATCTGACCAACCCCTGCTTATCATCCAGTAAACAGTAGTGAGA 2640
Db 2581 GAGCCATGACAGTATCTGACCAACCCCTGCTTATCATCCAGTAAACAGTAGTGAGA 2640
Qy 2641 ACCTAGAGGAAAAATGACAGTATATCTAGTGAAGACTTACACAGCTGGGCAAGTTAG 2700
Db 2641 ACCTAGAGGAAAAATGACAGTATATCTAGTGAAGACTTACACAGCTGGGCAAGTTAG 2700
Qy 2701 CATACAATTTACCCGGTACTAATCTATGTTGGCCCTGCAATGAGTCAAGCTGGGCTCC 2760
Db 2701 CATACAATTTACCCGGTACTAATCTATGTTGGCCCTGCAATGAGTCAAGCTGGGCTCC 2760
Qy 2761 GCAGAATGCTGTGACAGTCTGCAAGGATTCATGACTTTAGGTATAGCCAAATTTGGCTAA 2820
Db 2761 GCAGAATGCTGTGACAGTCTGCAAGGATTCATGACTTTAGGTATAGCCAAATTTGGCTAA 2820
Qy 2821 GTTGGGAATAAATCCTTATACATTTGACCGGTAGCAGATGAAGAATTTGTAATAAATAT 2880
Db 2821 GTTGGGAATAAATCCTTATACATTTGACCGGTAGCAGATGAAGAATTTGTAATAAATAT 2880
Qy 2881 AAAAAATGAACAGGGTTTCAAGCAACAGCAGTAAAGATTACTTTTAAAGGTGC 2940
Db 2881 AAAAAATGAACAGGGTTTCAAGCAACAGCAGTAAAGATTACTTTTAAAGGTGC 2940
Qy 2941 AGCTGCCCTGTGGCCCATTTTCAAGGAAGTTTACCGGAAGTGCCTGACACGCTC 3000
Db 2941 AGCTGCCCTGTGGCCCATTTTCAAGGAAGTTTACCGGAAGTGCCTGACACGCTC 3000
Qy 3001 AGAAAAATACCCAGCATGACTTCAAGTAACTCTGCAAGAGCCAGCACTGGTCCAGCGG 3060
Db 3001 AGAAAAATACCCAGCATGACTTCAAGTAACTCTGCAAGAGCCAGCACTGGTCCAGCGG 3060
Qy 3061 GGGAGGTAGCAACCCCTACAAAAAGCATGTGAGTGAAGGGGCTACATTTACTGCTAATTC 3120
Db 3061 GGGAGGTAGCAACCCCTACAAAAAGCATGTGAGTGAAGGGGCTACATTTACTGCTAATTC 3120

Qy 3121 TGTAAACGTGTACATTTCTTAGGCAATTTTAAATTCATATGATCCAGAGCATCATTTATAA 3180
Db 3121 TGTAAACGTGTACATTTCTTAGGCAATTTTAAATTCATATGATCCAGAGCATCATTTATAA 3180
Qy 3181 AGTGTCTCTCCAGCAGCTAGTAGTGCACAAATGCTAGTGGGAAAGGCAAAAGTGTG 3240
Db 3181 AGTGTCTCTCCAGCAGCTAGTAGTGCACAAATGCTAGTGGGAAAGGCAAAAGTGTG 3240
Qy 3241 CACTATTAGTCCCAATTTATGGGGTACTCTACTCCGTGGAGATCTTAGATTTTAAATGCTTT 3300
Db 3241 CACTATTAGTCCCAATTTATGGGGTACTCTACTCCGTGGAGATCTTAGATTTTAAATGCTTT 3300
Qy 3301 AAATTTGTTTTTCTCAACATTAGAGTTTCAGCACTTAAATTTGAAAAATTTAGTATAGC 3360
Db 3301 AAATTTGTTTTTCTCAACATTAGAGTTTCAGCACTTAAATTTGAAAAATTTAGTATAGC 3360
Qy 3361 TCCAGATGCTTTAACTGTAACTATTTTCAGAAATTCCTGTAAAGATGTCCACAGCAAAAC 3420
Db 3361 TCCAGATGCTTTAACTGTAACTATTTTCAGAAATTCCTGTAAAGATGTCCACAGCAAAAC 3420
Qy 3421 AGGAGGAGTGTGCAAGTTACTGACAGCACCAAGACGCTTTGTGTATGTTAGTGGATCA 3480
Db 3421 AGGAGGAGTGTGCAAGTTACTGACAGCACCAAGACGCTTTGTGTATGTTAGTGGATCA 3480
Qy 3481 TGAGTATAAATACCCATATGCTAGTCTAGGTCAGGGACAAGACACACTAGTCCAGAACTGCC 3540
Db 3481 TGAGTATAAATACCCATATGCTAGTCTAGGTCAGGGACAAGACACACTAGTCCAGAACTGCC 3540
Qy 3541 CAATTTGGGTTTACTTTCCCTCCAGTATGCTTACTTAAACAGTAGTGAAGTAAACACACA 3600
Db 3541 CAATTTGGGTTTACTTTCCCTCCAGTATGCTTACTTAAACAGTAGTGAAGTAAACACACA 3600
Qy 3601 AGGAATTTTCAGGAGACAGCAAAAAATTTGGCTAGTGAAGAAATCAGCTTTTATGTTAGTA 3660
Db 3601 AGGAATTTTCAGGAGACAGCAAAAAATTTGGCTAGTGAAGAAATCAGCTTTTATGTTAGTA 3660
Qy 3661 GCACAGTTTCATTTGAACTTTTGGGTACAGGGGGATCTGCCACTATGCTCTCAAAATTTCC 3720
Db 3661 GCACAGTTTCATTTGAACTTTTGGGTACAGGGGGATCTGCCACTATGCTCTCAAAATTTCC 3720
Qy 3721 AGCTGTGCCCCAGAAACCTAGAGGCTGACGCAACATTTTATGAATGTACAAACC 3780
Db 3721 AGCTGTGCCCCAGAAACCTAGAGGCTGACGCAACATTTTATGAATGTACAAACC 3780
Qy 3781 TTTGTACGGTCTCTGTTTAGGGTACTTCACACATTTAGGAGGGACCCCTAAATTTAGATC 3840
Db 3781 TTTGTACGGTCTCTGTTTAGGGTACTTCACACATTTAGGAGGGACCCCTAAATTTAGATC 3840
Qy 3841 ATTGACACACAGAACCCAGCAATTCAGCCACAAAACTTTATGCTTGGGCCACTAATAA 3900
Db 3841 ATTGACACACAGAACCCAGCAATTCAGCCACAAAACTTTATGCTTGGGCCACTAATAA 3900
Qy 3901 TTCAGTGTCTCAAAAGAGGAGACAATTTCTAATACAGTGTCTGGAAGAGCCCTTACGGG 3960
Db 3901 TTCAGTGTCTCAAAAGAGGAGACAATTTCTAATACAGTGTCTGGAAGAGCCCTTACGGG 3960
Qy 3961 GCTTAGTACTGGCAGCTAGCCAAAACACACAGAAATTTTCCCTACGCCCGGCCAGTATCTCA 4020
Db 3961 GCTTAGTACTGGCAGCTAGCCAAAACACACAGAAATTTTCCCTACGCCCGGCCAGTATCTCA 4020
Qy 4021 GCCATACCATCTCTGGGACACTGATAAATATGTTACAGGAATAAATGCCATTTACATGG 4080
Db 4021 GCCATACCATCTCTGGGACACTGATAAATATGTTACAGGAATAAATGCCATTTACATGG 4080
Qy 4081 ACAACCACTTATGAAGATGTGAGGACAAGAGATTAAGAGGGGTAGGAAGATTTCC 4140
Db 4081 ACAACCACTTATGAAGATGTGAGGACAAGAGATTAAGAGGGGTAGGAAGATTTCC 4140
Qy 4141 AAATGAAGAAAGACAGCTTAAAGCAGTTTAAAGTCTTAAACATGCACACATCTTCCCTAA 4200
Db 4141 AAATGAAGAAAGACAGCTTAAAGCAGTTTAAAGTCTTAAACATGCACACATCTTCCCTAA 4200

QY 4201 TAAAGGAAACCCAAACAATTCAGAGCCCTCTTATGTTGGGCTCTGTTTG 4260
 Db TAAAGGAAACCCAAACAATTCAGAGCCCTCTTATGTTGGGCTCTGTTTG 4260
 QY 4261 GAACAGAGAGCTCTTCACTATCAAGTCAAGTCTGAGTAAATCCCTAACTTAGATGA 4320
 Db GAACAGAGAGCTCTTCACTATCAAGTCAAGTCTGAGTAAATCCCTAACTTAGATGA 4320
 QY 4321 CAGTTTAAACCTCAATTTGACAGCCCTAGGCGGGTGGGTTTGCATCAACCCCTCA 4380
 Db CAGTTTAAACCTCAATTTGACAGCCCTAGGCGGGTGGGTTTGCATCAACCCCTCA 4380
 QY 4381 AATATTTTAAATAATCTACCAAAAGTGGCCAAATGGAGTATTAATCCATGGGAAT 4440
 Db AATATTTTAAATAATCTACCAAAAGTGGCCAAATGGAGTATTAATCCATGGGAAT 4440
 QY 4441 TACTACTTTAGTTCAATATGCTGGGAATATGACAGTTACCATGACCTTTAAATTTGG 4500
 Db TACTACTTTAGTTCAATATGCTGGGAATATGACAGTTACCATGACCTTTAAATTTGG 4500
 QY 4501 ACCTCGAAGGCTACTGGAAGTGGAAATCCCGAGCTGGCGTTTATCCTCTCATGCGC 4560
 Db ACCTCGAAGGCTACTGGAAGTGGAAATCCCGAGCTGGCGTTTATCCTCTCATGCGC 4560
 QY 4561 TGGTCATTTACATATGCTATGATGACCCCAAGTACAGTCAAGTCAAGTCAAGTCAAG 4620
 Db TGGTCATTTACATATGCTATGATGACCCCAAGTACAGTCAAGTCAAGTCAAGTCAAG 4620
 QY 4621 ACAGGATATGAAAGCTGAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 4680
 Db ACAGGATATGAAAGCTGAAAGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGT 4680
 QY 4681 AACATTCGCCACCGTCTCAGCAGGAAACCGTCAACCCAGCCAGCTGTGCGGCCCA 4740
 Db AACATTCGCCACCGTCTCAGCAGGAAACCGTCAACCCAGCCAGCTGTGCGGCCCA 4740
 QY 4741 GATTATATGTCGCCCTCCCAATACCCGAGGCAACCATCTATAAAGATACAGAGCTG 4800
 Db GATTATATGTCGCCCTCCCAATACCCGAGGCAACCATCTATAAAGATACAGAGCTG 4800
 QY 4801 TAGAATAATAATTATTAATAGATATGAAACCAATGATTAAGTAAAGTATATGTA 4860
 Db TAGAATAATAATTATTAATAGATATGAAACCAATGATTAAGTAAAGTATATGTA 4860
 QY 4861 ATATGACACAGTTTGGAAAAATAAGCTTAAATAATAATTCATAGTGTATGTTTC 4920
 Db ATATGACACAGTTTGGAAAAATAAGCTTAAATAATAATTCATAGTGTATGTTTC 4920
 QY 4921 TTTAAAAATTTCAAAAAGAGACACCAATCAGATCCCGCGTGGCGCGGTTAGGCGG 4980
 Db TTTAAAAATTTCAAAAAGAGACACCAATCAGATCCCGCGTGGCGCGGTTAGGCGG 4980
 QY 4981 GACTTCGGTACAAGATGGCGGACAGTTACGTCATTTCTGTGAGCTC 5028
 Db GACTTCGGTACAAGATGGCGGACAGTTACGTCATTTCTGTGAGCTC 5028

RESULT 2
 BD087037
 LOCUS 5028 bp DNA linear PAT 27-AUG-2002
 DEFINITION Erythrovirus and application thereof.
 ACCESSION BD087037
 VERSION BD087037.1 GI:22632647
 KEYWORDS JP 2001525163-A/1.
 SOURCE Erythrovirus
 ORGANISM Erythrovirus
 REFERENCE 1 (bases 1 to 5028)
 AUTHORS Nguyen.Q.T., Garbarg, C.A. and Auguste, V.
 TITLE Erythrovirus and application thereof
 JOURNAL Patent: JP 2001525163-A 1 11-DEC-2001;
 ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
 COMMENT OS Erythrovirus

PN JP 2001525163-A/1
 PD 11-DEC-2001
 PF 03-DEC-1998 JP 2000523317
 PR 03-DEC-1997 FR 97/15197
 PI QUANG TRI NGUYEN CHENON ANTOINE GARBARG, VERONIQUE AUGUSTE PC
 C12N15/09, A61K39/12, A61K48/00, C07K14/015, C07K16/08, C12Q1/68, PC
 G01N33/53,
 PC C12N15/00
 CC Erythrovirus and application thereof
 FH Key Location/Qualifiers
 FT source 1..5028 /organism='Erythrovirus'.
 FEATURES
 source Location/Qualifiers
 i..5028 /organism='Erythrovirus'
 /mol_type='genomic DNA'
 /db_xref='taxon:40121'
 ORIGIN
 Query Match 100.0%; Score 5028; DB 6; Length 5028;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 5028; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GACGTCACAGGAAATGACGTAACTGTCGCCCATCTTGTACCGGAAGTCCCGCCTACCGGC 60
 Db 1 GACGTCACAGGAAATGACGTAACTGTCGCCCATCTTGTACCGGAAGTCCCGCCTACCGGC 60
 QY 61 GCGGACCGCGGCATCTGATTTGGTGTCTCTTTTGAATTTTGGGGGGCTTTTCCCG 120
 Db 61 GCGGACCGCGGCATCTGATTTGGTGTCTCTTTTGAATTTTGGGGGGCTTTTCCCG 120
 QY 121 CCTATGCAAAATAGCGGCCCATGTTTAAATGTTATATTTAAATTAATGGAACACGCT 180
 Db 121 CCTATGCAAAATAGCGGCCCATGTTTAAATGTTATATTTAAATTAATGGAACACGCT 180
 QY 181 AACGTTTACTAGGCGCGGAGTTACGGCGGTATATAAGCAGCTGCGTCCCTGACATTT 240
 Db 181 AACGTTTACTAGGCGCGGAGTTACGGCGGTATATAAGCAGCTGCGTCCCTGACATTT 240
 QY 241 CTTTTCCTGTTGCTTTTACCTGGAATCTCACTGCTGTTCTTTGCTGCTTAAGTAACAGGT 300
 Db 241 CTTTTCCTGTTGCTTTTACCTGGAATCTCACTGCTGTTCTTTGCTGCTTAAGTAACAGGT 300
 QY 301 ATTTATATTAATTTTAAATTTTAACTAATGATTAATGATTAATGATTAATGATTAATGAT 360
 Db 301 ATTTATATTAATTTTAAATTTTAACTAATGATTAATGATTAATGATTAATGATTAATGAT 360
 QY 361 TCTAACATTTCTGAGTGTGCTAATGATTAATGATTAATGATTAATGATTAATGATTAATGAT 420
 Db 361 TCTAACATTTCTGAGTGTGCTAATGATTAATGATTAATGATTAATGATTAATGATTAATGAT 420
 QY 421 TCTGACTGGGAACCACTTAACCCATCTTAACAGATTAATGGAATTAATGGAATTAATGGAAT 480
 Db 421 TCTGACTGGGAACCACTTAACCCATCTTAACAGATTAATGGAATTAATGGAATTAATGGAAT 480
 QY 481 GCTTCTAAACCTTGATTTTACTGGCGGCGCTAGCAGGTTGCTTATACCTTTTTCAGGTG 540
 Db 481 GCTTCTAAACCTTGATTTTACTGGCGGCGCTAGCAGGTTGCTTATACCTTTTTCAGGTG 540
 QY 541 GAATGTAACAAATTTGAGGAAGCTATCATATCCATGATTAATGGAATTAATGGAATTAATGGAAT 600
 Db 541 GAATGTAACAAATTTGAGGAAGCTATCATATCCATGATTAATGGAATTAATGGAATTAATGGAAT 600
 QY 601 AATGCTAGAAACTTAATCTGTCGCGAGAGGTTTATTTAAATGCTTTTACCATCTTT 660
 Db 601 AATGCTAGAAACTTAATCTGTCGCGAGAGGTTTATTTAAATGCTTTTACCATCTTT 660
 QY 661 GTAACGAAAGTGTAAACTTAAATTTTTCAGGAGTACCTACCAAGGAAATATTTT 720
 Db 661 GTAACGAAAGTGTAAACTTAAATTTTTCAGGAGTACCTACCAAGGAAATATTTT 720
 QY 721 AGAGATGGAGACAGTTTATACAAATTAATGGAATTAATGGAATTAATGGAATTAATGGAAT 780
 Db 721 AGAGATGGAGACAGTTTATACAAATTAATGGAATTAATGGAATTAATGGAATTAATGGAAT 780

Db 721 AGAGATGGAGGAGCGATTATAGAAAATTAATTAAGAAAATTCCTTTAAATGTTGTG 780
QY 781 TGGTGTGTAACAAATATGACGGGTATATAGACACCTGTATTTCCGCTCTCTTTTCGGCGA 840
Db 781 TGGTGTGTAACAAATATGACGGGTATATAGACACCTGTATTTCCGCTCTCTTTTCGGCGA 840
QY 841 GGAGCTTGTCATGCTAAAGACCCCGCATTAACGCAATTAACGCAATTAACGCAATTAACGCA 900
Db 841 GGAGCTTGTCATGCTAAAGACCCCGCATTAACGCAATTAACGCAATTAACGCAATTAACGCA 900
QY 901 ACTGGGGAGTCTAGCTGTGGAGGGGAGATGTTGTGCCATTCCTCGGAAGGGAACAAA 960
Db 901 ACTGGGGAGTCTAGCTGTGGAGGGGAGATGTTGTGCCATTCCTCGGAAGGGAACAAA 960
QY 961 GCGGGGTAAAGTTTCAAAACCATGTGTAATTTGGCTATGTGAAAACAGAGTATTTACTGAA 1020
Db 961 GCGGGGTAAAGTTTCAAAACCATGTGTAATTTGGCTATGTGAAAACAGAGTATTTACTGAA 1020
QY 1021 GATAAATGGAAATTTAGTGGATTTTAAACCAATATATCTTTAATTAAGTAGCAGTCAAGTGGC 1080
Db 1021 GATAAATGGAAATTTAGTGGATTTTAAACCAATATATCTTTAATTAAGTAGCAGTCAAGTGGC 1080
QY 1081 AGCTTTCAAAATTCAGAGTCCCTTAAAGTTAGCTATTTAATTAAGTACTAATTTAGTACCC 1140
Db 1081 AGCTTTCAAAATTCAGAGTCCCTTAAAGTTAGCTATTTAATTAAGTACTAATTTAGTACCC 1140
QY 1141 ACTAGTACATTTCTGTTTACATTCAGACTTTGAGCAGGTACTTTGCAATTAAGAAATAA 1200
Db 1141 ACTAGTACATTTCTGTTTACATTCAGACTTTGAGCAGGTACTTTGCAATTAAGAAATAA 1200
QY 1201 ATAGTAAATTTATTAATGTCGCAAACTATGATCTCTTTTATGAGGTCGCAATGTTA 1260
Db 1201 ATAGTAAATTTATTAATGTCGCAAACTATGATCTCTTTTATGAGGTCGCAATGTTA 1260
QY 1261 AGTGCATTTGACAAAATTTGCTTAAAGAAACACCTCTGCTGTTTACCGGCCACCAAGT 1320
Db 1261 AGTGCATTTGACAAAATTTGCTTAAAGAAACACCTCTGCTGTTTACCGGCCACCAAGT 1320
QY 1321 ACTGGAATAATGGAATTTGCAATTTGATGATGATGATGATGATGATGATGATGATGATG 1380
Db 1321 ACTGGAATAATGGAATTTGCAATTTGATGATGATGATGATGATGATGATGATGATGATG 1380
QY 1381 AATTGGAATAATGGAATTTGCAATTTGATGATGATGATGATGATGATGATGATGATGATG 1440
Db 1381 AATTGGAATAATGGAATTTGCAATTTGATGATGATGATGATGATGATGATGATGATGATG 1440
QY 1441 GATGAAGGCAATTTAAGTCCACTATTTGGAAGCTGCAAAAGCCATTTTATGATGATGATG 1500
Db 1441 GATGAAGGCAATTTAAGTCCACTATTTGGAAGCTGCAAAAGCCATTTTATGATGATGATG 1500
QY 1501 CCAACAGGCTAGATCAGAAAATGCGTGGCAGTGTGGCAGTGTGGCAGTGTGGCAGTGTGG 1560
Db 1501 CCAACAGGCTAGATCAGAAAATGCGTGGCAGTGTGGCAGTGTGGCAGTGTGGCAGTGTGG 1560
QY 1561 ATAAACAGCAATGGTGACATTAATTTGTTGAGTGGTAAATACCACCTACAACTGTGCAT 1620
Db 1561 ATAAACAGCAATGGTGACATTAATTTGTTGAGTGGTAAATACCACCTACAACTGTGCAT 1620
QY 1621 GCTTAAAGCCTTAAAGGACGATGATGATGATGATGATGATGATGATGATGATGATGATG 1680
Db 1621 GCTTAAAGCCTTAAAGGACGATGATGATGATGATGATGATGATGATGATGATGATGATG 1680
QY 1681 ATGGGTTTACTTACAGAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1740
Db 1681 ATGGGTTTACTTACAGAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1740
QY 1741 TGGAGCCACTATGAAAACCTGGCAATTAACCTACATTTGATTTCCCTGGAAATTAATGCA 1800
Db 1741 TGGAGCCACTATGAAAACCTGGCAATTAACCTACATTTGATTTCCCTGGAAATTAATGCA 1800
QY 1801 GATGCCCTCCACCGATCTCCAAACCCACCCCATTTGTCAGACACCCAGTATCAGCAGC 1860
Db 1801 GATGCCCTCCACCGATCTCCAAACCCACCCCATTTGTCAGACACCCAGTATCAGCAGC 1860

QY 1861 AGTGGTGTGAAGCTCTGAAGAACTCAGTGAAGCAGCTTTTCAACCTCATCACTCCA 1920
Db 1861 AGTGGTGTGAAGCTCTGAAGAACTCAGTGAAGCAGCTTTTCAACCTCATCACTCCA 1920
QY 1921 GGGGCTTGAAGCAGTGAAGAACTCAGTGAAGCAGCTTTTCAACCTCATCACTCCA 1980
Db 1921 GGGGCTTGAAGCAGTGAAGAACTCAGTGAAGCAGCTTTTCAACCTCATCACTCCA 1980
QY 1981 GAATCATTTGTGCGAAGCCAGCTTTCTCCGAGTGTAGCCGCTGCTGGGAGGAGCT 2040
Db 1981 GAATCATTTGTGCGAAGCCAGCTTTCTCCGAGTGTAGCCGCTGCTGGGAGGAGCT 2040
QY 2041 TTTTACACCCCTTTCGCGATCAGTTTCTGTAAGCTGTTAGTAGGGGTTGCACTTTGTATGG 2100
Db 2041 TTTTACACCCCTTTCGCGATCAGTTTCTGTAAGCTGTTAGTAGGGGTTGCACTTTGTATGG 2100
QY 2101 GATGGTGTGAGGGGATTTGCTGTTGCTGTGGAACATATAACACAGTGGGGAGGG 2160
Db 2101 GATGGTGTGAGGGGATTTGCTGTTGCTGTGGAACATATAACACAGTGGGGAGGG 2160
QY 2161 TTGGGCTTTGGCCTCATTTGATTAATGTGGGAGCTTTGGTATTAATGGATGGAAATTTAGA 2220
Db 2161 TTGGGCTTTGGCCTCATTTGATTAATGTGGGAGCTTTGGTATTAATGGATGGAAATTTAGA 2220
QY 2221 GAGTTTACTCCAGACTTTAGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2280
Db 2221 GAGTTTACTCCAGACTTTAGTGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2280
QY 2281 GTGTTAACTTTGAAAATTTGCTTACCTGCTGGAATTAACAAAGTTTGTAGATTTAGAG 2340
Db 2281 GTGTTAACTTTGAAAATTTGCTTACCTGCTGGAATTAACAAAGTTTGTAGATTTAGAG 2340
QY 2341 TAAACCACTAAACAAATGTTGGGAAAGCAGTGAACAAATTTGCCAGAGCTGTATTAAGCA 2400
Db 2341 TAAACCACTAAACAAATGTTGGGAAAGCAGTGAACAAATTTGCCAGAGCTGTATTAAGCA 2400
QY 2401 GTTGTGCAATTTTATGAAAAAGCTACTGGAACAGACTTTAGAGCTTTTCAAAATTTTAA 2460
Db 2401 GTTGTGCAATTTTATGAAAAAGCTACTGGAACAGACTTTAGAGCTTTTCAAAATTTTAA 2460
QY 2461 AGACCAATTAACAAATTTCTTTAGATTAATCTTTAGAAAACCTCTCTTTTATTTGACTT 2520
Db 2461 AGACCAATTAACAAATTTCTTTAGATTAATCTTTAGAAAACCTCTCTTTTATTTGACTT 2520
QY 2521 AGTTGCTCCCATTTAAAGTAATCTTAAACCTCTCCAGACCTATATAGTCACTATTTC 2580
Db 2521 AGTTGCTCCCATTTAAAGTAATCTTAAACCTCTCCAGACCTATATAGTCACTATTTC 2580
QY 2581 GAGCCATGACAGTTATCTGACCAACCCCATGCTTATCATCCAGTAAACAGTAGTGACAG 2640
Db 2581 GAGCCATGACAGTTATCTGACCAACCCCATGCTTATCATCCAGTAAACAGTAGTGACAG 2640
QY 2641 ACCTAGAGAGAAATGAGTATTAATCTAGTGAAGCTTTACACAGCTGGGCAAGTTAG 2700
Db 2641 ACCTAGAGAGAAATGAGTATTAATCTAGTGAAGCTTTACACAGCTGGGCAAGTTAG 2700
QY 2701 CATACAAATTTACCCGTTACTAACTATGTTGGGCTGGCAATGAGTACAGCTGGGCTCC 2760
Db 2701 CATACAAATTTACCCGTTACTAACTATGTTGGGCTGGCAATGAGTACAGCTGGGCTCC 2760
QY 2761 GCAGAAATGCTGGAGCAGTCTGCAAGGATTCATGACTTTAGGTAAGCAATTTGGCTAA 2820
Db 2761 GCAGAAATGCTGGAGCAGTCTGCAAGGATTCATGACTTTAGGTAAGCAATTTGGCTAA 2820
QY 2821 GTTGGAAATTAATCTTTATACACTTTGAGCGGTAGCAGATGAAGATTTGTTAAAAATAT 2880
Db 2821 GTTGGAAATTAATCTTTATACACTTTGAGCGGTAGCAGATGAAGATTTGTTAAAAATAT 2880
QY 2881 AAAAAATGAACAGGGTTTCAAGCAACAGCAGTAAAGATTTACTTTTAAAGGTGC 2940
Db 2881 AAAAAATGAACAGGGTTTCAAGCAACAGCAGTAAAGATTTACTTTTAAAGGTGC 2940

QY 2941 AGCTGCCCTGTGGCCCATTTTCAAGGAAGTTTACCGGAAGTGC CGCGGTACAACGCCCTC 3000
Db |||||
QY 2941 AGCTGCCCTGTGGCCCATTTTCAAGGAAGTTTACCGGAAGTGC CGCGGTACAACGCCCTC 3000
Db |||||
QY 3001 AGAAATATCCCGAGCATGATCTTCAAGTAACTCTGAGAAAGCCAGCACTGTGTCAGAGCGG 3060
Db |||||
QY 3001 AGAAATATCCCGAGCATGATCTTCAAGTAACTCTGAGAAAGCCAGCACTGTGTCAGAGCGG 3060
Db |||||
QY 3061 GGGAGGTAGCAACCCCTACAAAAGAGTGTGAGTGAAGGGCTACATTTACTGTCTGAATTC 3120
Db |||||
QY 3061 GGGAGGTAGCAACCCCTACAAAAGAGTGTGAGTGAAGGGCTACATTTACTGTCTGAATTC 3120
Db |||||
QY 3121 TGTAACTGTATCAATCTCTAGGCAATTTTAAATCCATATATCCAGAGCATCAATTATAA 3180
Db |||||
QY 3121 TGTAACTGTATCAATCTCTAGGCAATTTTAAATCCATATATCCAGAGCATCAATTATAA 3180
Db |||||
QY 3181 AGTGTCTCTCCAGAGCTAGTAGTGCACCAATCTAGTGGAAAGGCAAAAGTGTG 3240
Db |||||
QY 3181 AGTGTCTCTCCAGAGCTAGTAGTGCACCAATCTAGTGGAAAGGCAAAAGTGTG 3240
Db |||||
QY 3241 CACTATATAGTCCCATATATGGGTACTCTACTCCGTGGAGATCACTTAGATTTTAAATGCTTT 3300
Db |||||
QY 3241 CACTATATAGTCCCATATATGGGTACTCTACTCCGTGGAGATCACTTAGATTTTAAATGCTTT 3300
Db |||||
QY 3301 AAATTTGTTTTCTCACCATTAGAGTTTTCAGCACTTAATTTGAAAATTTATGTAGTATG 3360
Db |||||
QY 3301 AAATTTGTTTTCTCACCATTAGAGTTTTCAGCACTTAATTTGAAAATTTATGTAGTATG 3360
Db |||||
QY 3361 TCCAGATGCTTTAACTGTAACTATTTTCAAGAAATTTGCTTAAAGATGTCTACAGCAAAAC 3420
Db |||||
QY 3361 TCCAGATGCTTTAACTGTAACTATTTTCAAGAAATTTGCTTAAAGATGTCTACAGCAAAAC 3420
Db |||||
QY 3421 AGGAGGAGTGTGCAAGTTACTGACAGCAACAAGACGTTTGTATGTATGTAGTATGATCA 3480
Db |||||
QY 3421 AGGAGGAGTGTGCAAGTTACTGACAGCAACAAGACGTTTGTATGTATGTAGTATGATCA 3480
Db |||||
QY 3481 TGAGTATAAATPACCCATATATGTCTAGGTGAGGACAGACACTAGCTCCAGAACTGCC 3540
Db |||||
QY 3481 TGAGTATAAATPACCCATATATGTCTAGGTGAGGACAGACACTAGCTCCAGAACTGCC 3540
Db |||||
QY 3541 CATTTGGGTTTACTTTTCCCGCCAGATGCTTAACTAACTAGTGTGAAAGTAAACACACA 3600
Db |||||
QY 3541 CATTTGGGTTTACTTTTCCCGCCAGATGCTTAACTAACTAGTGTGAAAGTAAACACACA 3600
Db |||||
QY 3601 AGGAATTTACGAGACAGCAAAAATTTGGCTAGTGAAGATCACTTTTATGTATGTATG 3660
Db |||||
QY 3601 AGGAATTTACGAGACAGCAAAAATTTGGCTAGTGAAGATCACTTTTATGTATGTATG 3660
Db |||||
QY 3661 GCACAGTTCAATTTGAATCTTTGGGTAAGGGGATCTGCCATATGTCTCAAAATTTTCC 3720
Db |||||
QY 3661 GCACAGTTCAATTTGAATCTTTGGGTAAGGGGATCTGCCATATGTCTCAAAATTTTCC 3720
Db |||||
QY 3721 AGCTGTGCCCCCAGAAAACCTAGAGGCTGACGCAACATTTTATGAAATGTACAACCC 3780
Db |||||
QY 3721 AGCTGTGCCCCCAGAAAACCTAGAGGCTGACGCAACATTTTATGAAATGTACAACCC 3780
Db |||||
QY 3781 TTTGTACGGTCTCTGTTTAGGGTACCTGACACATTTAGAGGGGACCCCTAAATTTAGATC 3840
Db |||||
QY 3781 TTTGTACGGTCTCTGTTTAGGGTACCTGACACATTTAGAGGGGACCCCTAAATTTAGATC 3840
Db |||||
QY 3841 ATTGACACAGGAAGACCAAGTCTGACCAAACTTTATGCTGGGCCACTAATAA 3900
Db |||||
QY 3841 ATTGACACAGGAAGACCAAGTCTGACCAAACTTTATGCTGGGCCACTAATAA 3900
Db |||||
QY 3901 TTCAGTGTCTCAAAAGAGGAGACAATTTCTAATACAGGTGCTGGAAAAGCCCTTACGGG 3960
Db |||||
QY 3901 TTCAGTGTCTCAAAAGAGGAGACAATTTCTAATACAGGTGCTGGAAAAGCCCTTACGGG 3960
Db |||||
QY 3961 GCTTAGTACTGSCACTAGCAGCAACCAAGATTTTCCCTACGCCCGGGCCAGTATCTCA 4020
Db |||||
QY 3961 GCTTAGTACTGSCACTAGCAGCAACCAAGATTTTCCCTACGCCCGGGCCAGTATCTCA 4020
Db |||||
QY 4021 GCCATACCATCTGGGACACTGATAAATATGTTTACAGGAATTAATGCCATTTTCACATGG 4080

Db |||||
QY 4021 GCCATACCATCTGGGACACTGATAAATATGTTACAGGAATAAATGCCATTTTCATGG 4080
Db |||||
QY 4081 ACAAAACCACTTATGGAAATGCTGAGCAAAAAGATATCAGCAAGGGGTAGGAAGATTTC 4140
Db |||||
QY 4081 ACAAAACCACTTATGGAAATGCTGAGCAAAAAGATATCAGCAAGGGGTAGGAAGATTTC 4140
Db |||||
QY 4141 AAATGAAAAGAACACGCTTAAAGCAGTTTAAAGGCTCTTAACATGCAACATATCTCCCTAA 4200
Db |||||
QY 4141 AAATGAAAAGAACACGCTTAAAGCAGTTTAAAGGCTCTTAACATGCAACATATCTCCCTAA 4200
Db |||||
QY 4201 TAAAGGAAACCAACAATATACACAGCAAAATTCAGAGCCCTCTTATGGTGGGCTCTGTTG 4260
Db |||||
QY 4201 TAAAGGAAACCAACAATATACACAGCAAAATTCAGAGCCCTCTTATGGTGGGCTCTGTTG 4260
Db |||||
QY 4261 GAACAGAGAGCTCTTCACTATGAAGTCACTGTGGAGTAAATCCCTAACTTAGATGA 4320
Db |||||
QY 4261 GAACAGAGAGCTCTTCACTATGAAGTCACTGTGGAGTAAATCCCTAACTTAGATGA 4320
Db |||||
QY 4321 CAGTTTAAACCTCAATTTGACAGCCCTAGGCGGGTGGGGTTTGATCAACACCCCTCA 4380
Db |||||
QY 4321 CAGTTTAAACCTCAATTTGACAGCCCTAGGCGGGTGGGGTTTGATCAACACCCCTCA 4380
Db |||||
QY 4381 AATATTTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4440
Db |||||
QY 4381 AATATTTTAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4440
Db |||||
QY 4441 TACTACTTTAGTTTCAATATGCTGTGGGAAATTAATCAAGTGGGCAATTTGAGGTATTAAT 4500
Db |||||
QY 4441 TACTACTTTAGTTTCAATATGCTGTGGGAAATTAATCAAGTGGGCAATTTGAGGTATTAAT 4500
Db |||||
QY 4501 ACCTCGAAGGCTACTGGAAGTGGAAATCCCGAGCTGGCGTTTATCTCTCTCATGCGC 4560
Db |||||
QY 4501 ACCTCGAAGGCTACTGGAAGTGGAAATCCCGAGCTGGCGTTTATCTCTCTCATGCGC 4560
Db |||||
QY 4561 TGGTCATTTTACCATATGCTACTGTATGACCCCAAGCTGACAGTACAGATGCAAGCAACACAG 4620
Db |||||
QY 4561 TGGTCATTTTACCATATGCTACTGTATGACCCCAAGCTGACAGTACAGATGCAAGCAACAG 4620
Db |||||
QY 4621 ACACGGATATGAAAGGCTGGAAGTGTGGAATGTCGCAAAAGCCGTGTGACCCATTGTA 4680
Db |||||
QY 4621 ACACGGATATGAAAGGCTGGAAGTGTGGAATGTCGCAAAAGCCGTGTGACCCATTGTA 4680
Db |||||
QY 4681 AACATTTCCCGCCAGCTGTCTCAGCCAGGACCCGTGACCCCAAGCTGTGCGGCCCA 4740
Db |||||
QY 4681 AACATTTCCCGCCAGCTGTCTCAGCCAGGACCCGTGACCCCAAGCTGTGCGGCCCA 4740
Db |||||
QY 4741 GATTATATGTCGCCCTTCCAAATACCCGTAGGCAACCATCTATAAAAGATACAGACGCTG 4800
Db |||||
QY 4741 GATTATATGTCGCCCTTCCAAATACCCGTAGGCAACCATCTATAAAAGATACAGACGCTG 4800
Db |||||
QY 4801 TAGAATATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4860
Db |||||
QY 4801 TAGAATATAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4860
Db |||||
QY 4861 ATATGTACCAAGTTTGGAAAAATAAAAGCCCTTAAATTAATTAATTAATTAATTAATTAAT 4920
Db |||||
QY 4861 ATATGTACCAAGTTTGGAAAAATAAAAGCCCTTAAATTAATTAATTAATTAATTAATTAAT 4920
Db |||||
QY 4921 TTTTAAAAATTTTCAAAAGAGACCAATCAGATGCGCGCGGTGCGCGCGGTAGGCGG 4980
Db |||||
QY 4921 TTTTAAAAATTTTCAAAAGAGACCAATCAGATGCGCGCGGTGCGCGCGGTAGGCGG 4980
Db |||||
QY 4981 GACTTCCCGGTACAGATGGCGACAGTTTACGTCATTTTCTGTGACGTC 5028
Db |||||
QY 4981 GACTTCCCGGTACAGATGGCGACAGTTTACGTCATTTTCTGTGACGTC 5028
Db |||||

RESULT 3

HER249437

LOCUS

DEFINITION

Human erythrovirus V9, NS1, VP1, VP2, VP3, 7.5-KDa, X, 11-KDa genes.

ACCESSION

AJ249437

HER249437 5028 bp DNA linear VRL 30-SEP-2001

VERSION AJ249437.1 GI:15865306
KEYWORDS major capsid protein; minor capsid protein; nonstructural protein; NS1 protein; VP1 protein; VP2 protein; X protein.
SOURCE Human erythrovirus V9
ORGANISM Human erythrovirus V9
REFERENCE Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
1 Nguyen,Q.T.
AUTHORS Molecular cloning and sequencing of a novel human erythrovirus
TITLE genome: new species beside B19 in the genus Erythrovirus
JOURNAL Unpublished
AUTHORS 2 (bases 1 to 5028)
TITLE Nguyen,Q.T.
JOURNAL Direct Submission
AUTHORS Submitted (09-SEP-1999) Nguyen Q.T., Unite de Genetique et
TITLE Biochimie du Developpement, Institut Pasteur, 25 rue du Dr. Roux,
JOURNAL Paris 75 015, France
FEATURES Location/Qualifiers
source
1..5028
/organism="Human erythrovirus V9"
/viral
/mol_type="genomic DNA"
/strain="V9"
/specific_host="Homo sapiens"
/db_xref="taxon:72197"
/clone="PCD.V9.C22"
/note="AJ223617 corresponds to nt 2336-2681"
328..2343
/gene="NS1"
328..2343
/gene="NS1"
/function="nonstructural protein"
/codon_start=1
/product="NS1 protein"
/protein_id="CAC80618.1"
/db_xref="GI:15865307"
/db_xref="SPTREMBL:Q912B9"
/translation="MELFRGVLIHSNILDANDNWCMSMLDLDTSDWEPLTHSNRLM
A1YLSVASKLDTGTGGLAGCLYFFQVECNKEEGVHIHVITGGPLNARLNTVCVBG
LNNVLYHVLTSKVKLPLPGMTTKGYFRDGEORTENLYMKKIPLNVVWCNTIDGY
LITCSASFRGACVAKPRITANTDSATNETGESCGGDVVPFAGKTKAGLKFQT
MNNLCENVEFTEDKWLGVDFNQYILLSSSHSGSQIQSALKLAIYKATNLVPTSTFL
LHSDPEQVTKENKILLCNDYLLVQGVLRWDKCGCKNTLWFYGPSTGK
TNLWAIATKIVGVGMVNNENFPFNDVAGSLVWDEGIIKSTIVEAAKAILGGQP
TDQKMGKSVAVPGVNVITSGNDITFVSGNTTTHAKALKERMVKLNTIRCSPT
DMGLTEADVQQLTWCAQNSHYENMAINTFDPGINADALHPDLQTTPIVPTS
ISSGSESEELSESFPNLITPGANSETPRSSFPVPGTSSGESFVGSFVSSEVAA
SWEEAFYTLADQFRELVLGVDFVMDGVRLPVCCVEHINNNGGGLGLGLCPHCINVGAW
YNGWKFRFTPLVRCSCVHGASNPFSVLTKCKCAYLSGLQSFVDYE"
1796..2020
/gene="7.5-kDa"
1796..2020
/gene="7.5-kDa"
/function="nonstructural protein"
/codon_start=1
/product="7.5-kDa protein"
/protein_id="CAC80619.1"
/db_xref="GI:15865308"
/db_xref="SPTREMBL:Q910P6"
/translation="MQMPTQISKPPPLSQTPVSAVVVVKLNKSVKAAFTSTSLQAP
GVTKPRALVRSPGFPVQENHLSAQFPKKW"
2336..4681
/gene="VP1"
2336..4681
/gene="VP1"
/function="minor capsid protein"
/codon_start=1
/product="VP1 protein"
/protein_id="CAC80620.1"
/db_xref="GI:15865309"
/db_xref="GOA:Q912B8"
/db_xref="SPTREMBL:Q912B8"
/translation="MSKTTNKWSSSDKFAQDVYKQFVQFYEKATGTDLLELIQLKDH

YNI LNDNPLENPSSLFDLVARIKSNLKNSPDLYSHHFQSHQSLSDHPHALSSNSAE
PRGENAVLSSDLHKPGVSIQLPCTNYVPGNELQAGPPQNAVDSAAIHDHFRYSOL
AKLGNPYTHWTVADEELLKNIKNETGFQAQVKDYFTLKGAAPVAHFQSLPEVPA
YNASEKPSMTSVNSAEASTGAGGGSNPTKSMWSEGATFTANSTCTTFSROFLPYD
PEHYKPSPAASCHNAGKEAKVCTTISPIMGYSTPWRYLDFNALNLFPSLEPQHL
IENYGSIAADALTITISIAVADVTDTGGGVQVDTSTTGRCLMLVDHIEKTYPIVLGQ
GQDTLAPBLPIWVFPQYAYLTGVEVNTQGISGSKLASSEAFVLEHSSFBELLG
TGSATMSYKFPAPPENLEYSQHFEYMPNPLYGRSLGVPDPTLGGDPKFRSLTHEDH
AIOQNFMPGLINSVTKGDSNNTGAKALTGLSTGTSQNTSLRPGSPQVYHH
WDTQVVTGINAISHGQTTYGNARDEKYOQGVGRFPNKEOLKQLGLNMHTYFPNKG
TQOYTDQLERPLWGSVNRRLHYESQLMSKIPNLDDSPFTQFPAALGSGHLPQPPQ
IFKLIPSGPIGKSGITTLVQYAVGIMVTMTFKLGPRAKATGRWNPQPGVTPPH
AAGHLPIVLYDPTATDAKQHRHRYGKEPEELWTAKS RVHL"
2586..2831
/gene="X"
2586..2831
/gene="X"
/codon_start=1
/product="X protein"
/protein_id="CAC80621.1"
/db_xref="GI:15865310"
/db_xref="SPTREMBL:Q910M7"
/translation="MDSYLTTPMPYHPVTVVONLEEKMOYLYLVKTYTSLGLKLYNPV
ITMLGLAWSYKLGRLRLWTVLQGFMTLIGIANWLSWE"
3017..4681
/gene="VP2"
3017..4681
/gene="VP2"
/function="major capsid protein"
/codon_start=1
/product="VP2 protein"
/protein_id="CAC80622.1"
/db_xref="GI:15865311"
/db_xref="GOA:Q912B7"
/db_xref="SPTREMBL:Q912B7"
/translation="MISVNSAEASTGAGGGSNPTKSMWSEGATFTANSTCTTFSROF
LIPDPEHYKVSFPAASCHNAGKEAKVCTTISPIMGYSTPWRYLDFNALNLFPSPL
EFQHLIENYGSIAADALTITISIAVADVTDTGGGVQVDTSTTGRCLMLVDHIEKYP
VYLGQDTLAPBLPIWVFPQYAYLTGVEVNTQGISGSKLASSEAFVLEHSS
FELLGSGASMSYKFPAPPENLEYSQHFEYMPNPLYGRSLGVPDPTLGGDPKFRSL
THEDHAIQPNFMPGLINSVTKGDSNNTGAKALTGLSTGTSQNTSLRPGSPV
QYHMDTQVVTGINAISHGQTTYGNARDEKYOQGVGRFPNKEOLKQLGLNMHTY
FPNKGTQYTDQLERPLWGSVNRRLHYESQLMSKIPNLDDSPFTQFPAALGSGH
OPPQIFKLIPQSGPIGKSGITTLVQYAVGIMVTMTFKLGPRAKATGRWNPQPG
VYPPHAGHLPVLYDPTATDAKQHRHRYGKEPEELWTAKS RVHL"
4575..4886
/gene="11-kDa"
4575..4886
/gene="11-kDa"
/function="nonstructural protein"
/codon_start=1
/product="11-kDa protein"
/protein_id="CAC80623.1"
/db_xref="GI:15865312"
/db_xref="SPTREMBL:Q912B6"
/translation="MYCMTPOLQMSNTTDTDMKSLKNCGLPKFVCTHCKHSPCPQP
GTVTHRPVPPRLYVPPPIPRQPSIKDTEAVEYKLLTRYEQHIVIRMLRLCNWYTSLE
K"
K"
ORIGIN
Query Match 100.0%; Score 5028; DB 14; Length 5028;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 5028; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 GACGTCACAGGAATGACGTAACCTGCGCCATCTTGACCGGAAGTCCCGCTACCGGC 60
Db 1 GAGGTGACAGGAATGACGTAACCTGCGCCATCTTGACCGGAAGTCCCGCTACCGGC 60
Qy 61 GCGGACCGCGGCATCTGATTTGGTGTCTCTTTTGAATAATTTGCGGGCTTTTCCCG 120
Db 61 GCGGACCGCGGCATCTGATTTGGTGTCTCTTTTGAATAATTTGCGGGCTTTTCCCG 120
Qy 121 CCTATGCAATAAGCGGCCATGTTTAATGTTATATTTTAATTTAATTTGGAACAACGCT 180

[illegible]

Db	1201	ATAGTAAAAATTAATTATTGTGTCAAAAATAATGATCCTCTTTTGTAGTGGGTCAACATGTGTGA	1261
Qy	1261	AGGTGGATTGACAAAAATGTGTAAAAAAACACCTGTGGTTTTCACGGCCACCAAGT	1320
Db	1261	AGGTGGATTGACAAAAATGTGTAAAAAAACACCTGTGGTTTTCACGGCCACCAAGT	1320
Qy	1321	ACTGAAAAACAAATTTTGGCAATGGCTATTGTCTAAAACTGTACAGTGTATGGAATGGTG	1380
Db	1321	ACTGAAAAACAAATTTTGGCAATGGCTATTGTCTAAAACTGTACAGTGTATGGAATGGTG	1380
Qy	1381	AAATGGGAATATGAAAACTTTCCATTTAAATGATGTAGCGGGGAAAAAGTTTGGTGTCTGG	1440
Db	1381	AAATGGGAATATGAAAACTTTCCATTTAAATGATGTAGCGGGGAAAAAGTTTGGTGTCTGG	1440
Qy	1441	GATGAAGGCATTATTAAGTCCACTATTGTGTGGAAGTGTCAAAAGCCATTTTAGTGTGTCTAG	1500
Db	1441	GATGAAGGCATTATTAAGTCCACTATTGTGTGGAAGTGTCAAAAGCCATTTTAGTGTGTCTAG	1500
Qy	1501	CCAACCCAGGTAGATCAGAAAAATCGGTGGCAGTGTGGCAGTGCCTGGTGTGGTGTGGTT	1560
Db	1501	CCAACCCAGGTAGATCAGAAAAATCGGTGGCAGTGTGGCAGTGCCTGGTGTGGTGTGGTT	1560
Qy	1561	ATAACCCAGCAATGTGTGACATTACATTTGTTGTGAGTGTGTAATACCACTACAACGTGTGCAT	1620
Db	1561	ATAACCCAGCAATGTGTGACATTACATTTGTTGTGAGTGTGTAATACCACTACAACGTGTGCAT	1620
Qy	1621	GCTAAAGCCTTAAAGGAACGGATGTGTAAGACTTAACTTTACCAATAGATGTAGCCCTGAC	1680
Db	1621	GCTAAAGCCTTAAAGGAACGGATGTGTAAGACTTAACTTTACCAATAGATGTAGCCCTGAC	1680
Qy	1681	ATGGGTTTTACTTACAGAGGCTGATGTACAACTAGCTAACTTGGTGTGTAATGCACAAAGC	1740
Db	1681	ATGGGTTTTACTTACAGAGGCTGATGTACAACTAGCTAACTTGGTGTGTAATGCACAAAGC	1740
Qy	1741	TGGAGCCACTATGAAAACTGGGCAATAAACTACACATTTGATTTCCCTGGAAATAATGCA	1800
Db	1741	TGGAGCCACTATGAAAACTGGGCAATAAACTACACATTTGATTTCCCTGGAAATAATGCA	1800
Qy	1801	GATGCCCTCCACCAGATCTCCAAACGACCCCATTTGTCGCAGACACAGTATCAGCAGC	1860
Db	1801	GATGCCCTCCACCAGATCTCCAAACGACCCCATTTGTCGCAGACACAGTATCAGCAGC	1860
Qy	1861	AGTGGTGGTGAAGACTCTGAAAGAACTCAGTGAAGCAGCTTTTTCAACCTCATCACTCCA	1920
Db	1861	AGTGGTGGTGAAGACTCTGAAAGAACTCAGTGAAGCAGCTTTTTCAACCTCATCACTCCA	1920
Qy	1921	GGCGCTTGGACAGTGAACCCCGCGCTCTAGTACGCCCGTCCCGGGACCAAGTTCAGGA	1980
Db	1921	GGCGCTTGGACAGTGAACCCCGCGCTCTAGTACGCCCGTCCCGGGACCAAGTTCAGGA	1980
Qy	1981	GAATCATTTTCTCGGAAGCCAGTTTCTCCGAAGTGGTAGCCGCTGTGGGAGGAAGCT	2040
Db	1981	GAATCATTTTCTCGGAAGCCAGTTTCTCCGAAGTGGTAGCCGCTGTGGGAGGAAGCT	2040
Qy	2041	TTTTACAGCGCGTTGCCGATCAGTTTCTGTGTGTAACCTGTTAGTAGGGGTTGACTTTGATGG	2100
Db	2041	TTTTACAGCGCGTTGCCGATCAGTTTCTGTGTGTAACCTGTTAGTAGGGGTTGACTTTGATGG	2100
Qy	2101	GATGCTGTGAGGGATTGGCTGTTTCTGTGTGGAACATATAACCAAGTGTGGGAGGG	2160
Db	2101	GATGCTGTGAGGGATTGGCTGTTTCTGTGTGGAACATATAACCAAGTGTGGGAGGG	2160
Qy	2161	TTGGGGCTTTGCCCTCATTTGATTAATGTGGGAGCTTGGTATAATGGATGGAATTTAGA	2220
Db	2161	TTGGGGCTTTGCCCTCATTTGATTAATGTGGGAGCTTGGTATAATGGATGGAATTTAGA	2220
Qy	2221	GAGTTTACTCCACATTTAGTCGCTGACGTGTGATGTAGGAGCCTTAAACCACTTTTCT	2280
Db	2221	GAGTTTACTCCACATTTAGTCGCTGACGTGTGATGTAGGAGCCTTAAACCACTTTTCT	2280
Qy	2281	GTGTTAACTGTAAAAAATGTGTTACTCTGTCTGGAATTAACAAAGTTTTGTAGATTATGAG	2340
Db	2281	GTGTTAACTGTAAAAAATGTGTTACTCTGTCTGGAATTAACAAAGTTTTGTAGATTATGAG	2340

2341 TAAAAACACTAACAAATGGTGGAAAGCAGTGACAAATTTGCCAGGACGTGTATAAGCA 2400
2341 TAAAAACACTAACAAATGGTGGAAAGCAGTGACAAATTTGCCAGGACGTGTATAAGCA 2400
2401 GTTGTGCAATTTTATGAAAGACTACTGGAACAGACTTATTCAAATTTTAA 2460
2401 GTTGTGCAATTTTATGAAAGACTACTGGAACAGACTTATTCAAATTTTAA 2460
2461 AGACCAATTACAACTTCTTTAGATAATCTTTAGAAACCCCTCTCTTTATTTGACTT 2520
2461 AGACCAATTACAACTTCTTTAGATAATCTTTAGAAACCCCTCTCTTTATTTGACTT 2520
2521 AGTTGCTCGCAATTAAGAATCTTAAAACTCTCCAGACCTATATAGTCATCATTTTCA 2580
2521 AGTTGCTCGCAATTAAGAATCTTAAAACTCTCCAGACCTATATAGTCATCATTTTCA 2580
2581 GAGCCATGACAGTTATCTGACACCCCTGCTTATCATCCAGTAACAGTAGTCAGA 2640
2581 GAGCCATGACAGTTATCTGACACCCCTGCTTATCATCCAGTAACAGTAGTCAGA 2640
2641 ACCTAGAGGAAATGCGAGTATATCTAGTGAAGACTTACAAAGCCTGGGCAAGTTAG 2700
2641 ACCTAGAGGAAATGCGAGTATATCTAGTGAAGACTTACAAAGCCTGGGCAAGTTAG 2700
2701 CATACAAATTACCCGGTACTAACTATGTTGGGCCCTGGCAATGAGCTACAAGCTGGGCTCC 2760
2701 CATACAAATTACCCGGTACTAACTATGTTGGGCCCTGGCAATGAGCTACAAGCTGGGCTCC 2760
2761 GCGAATGCTGGACAGTCTGCAAGGATTCATGACTTTAGTATAGCCAAATTTGGCTAA 2820
2761 GCGAATGCTGGACAGTCTGCAAGGATTCATGACTTTAGTATAGCCAAATTTGGCTAA 2820
2821 GTTGGCAATAAATCCTTTATACATTTGAGCGGTAGCAGATGAGAAATTTGTTAAAAATAT 2880
2821 GTTGGCAATAAATCCTTTATACATTTGAGCGGTAGCAGATGAGAAATTTGTTAAAAATAT 2880
2881 AAAAAATGAACAGGGTTTCAAGCACAAAGCAGTAAAGATTACTTTTAAAGGTGC 2940
2881 AAAAAATGAACAGGGTTTCAAGCACAAAGCAGTAAAGATTACTTTTAAAGGTGC 2940
2941 AGTGCCTCTGGGCCATTTTCAAGGAGTTTACCGAAGTGCCTGGCTGACAAAGCTC 3000
2941 AGTGCCTCTGGGCCATTTTCAAGGAGTTTACCGAAGTGCCTGGCTGACAAAGCTC 3000
3001 AGAAAATACCCAGCATGACTTCAAGTAACTCTGAGAGCCAGCACTGGTGCAGCGG 3060
3001 AGAAAATACCCAGCATGACTTCAAGTAACTCTGAGAGCCAGCACTGGTGCAGCGG 3060
3061 GCGAGGTAGCAACCTTACAAAAAGCATGTGGAGTGAAGGGCTTACTCTCTAATTC 3120
3061 GCGAGGTAGCAACCTTACAAAAAGCATGTGGAGTGAAGGGCTTACTTACTCTAATTC 3120
3121 TGTAAAGGTGATACCTCTAGGCAATTTTAAATTCATATGATCCAGAGCATCATTTAA 3180
3121 TGTAAAGGTGATACCTCTAGGCAATTTTAAATTCATATGATCCAGAGCATCATTTAA 3180
3181 AGTGTCTCTCCAGCAGCTAGTAGTCCCAATGCTAGTGGAGAGGCAAGGTG 3240
3181 AGTGTCTCTCCAGCAGCTAGTAGTCCCAATGCTAGTGGAGAGGCAAGGTG 3240
3241 CACTATTAGTCCCATTTATGGGTACTCTACTCCGTGGAGATCTTAGATTTTAAATGCTTT 3300
3241 CACTATTAGTCCCATTTATGGGTACTCTACTCCGTGGAGATCTTAGATTTTAAATGCTTT 3300
3301 AAATTTGTTTTCTACCAATAGAGTTTCAAGCTTAAATTTGAAAAATTTAGTATAGC 3360
3301 AAATTTGTTTTCTACCAATAGAGTTTCAAGCTTAAATTTGAAAAATTTAGTATAGC 3360
3361 TCCAGATGCTTTAACTGTAATTTTCAAGAAATTTGTTAAAGATGTACAGACAAAC 3420
3361 TCCAGATGCTTTAACTGTAATTTTCAAGAAATTTGTTAAAGATGTACAGACAAAC 3420

3421 AGGAGAGGTGTGCAAGTTTACTGACAGCACCAAGAGCGTTTGTGTATGTTAGTGATCA 3480
3421 AGGAGAGGTGTGCAAGTTTACTGACAGCACCAAGAGCGTTTGTGTATGTTAGTGATCA 3480
3481 TGAGTATAAATACCCATATGCTAGTCTAGGACAGGACAAAGACACACTAGCTCCAGACTGCC 3540
3481 TGAGTATAAATACCCATATGCTAGTCTAGGACAGGACAAAGACACACTAGCTCCAGACTGCC 3540
3541 CATTTGGGTTTACTTTTCCCGCCAGTATGCTTTTAAACAGTAGGTGAAGTAAACACACA 3600
3541 CATTTGGGTTTACTTTTCCCGCCAGTATGCTTTTAAACAGTAGGTGAAGTAAACACACA 3600
3601 AGGAATTTGAGAGACAGCAAAAAATTTGCTAGTGAAGAAATCAGCTTTTATGTTAGTAGA 3660
3601 AGGAATTTGAGAGACAGCAAAAAATTTGCTAGTGAAGAAATCAGCTTTTATGTTAGTAGA 3660
3661 GCACAGTTCAATTTGAACTTTTGGGTACAGGGGATCTGCCACTATGCTCTACAAATTTCC 3720
3661 GCACAGTTCAATTTGAACTTTTGGGTACAGGGGATCTGCCACTATGCTCTACAAATTTCC 3720
3721 AGCTGTGCCCCCAGAAAACTTAGAAGCTGACAGCCAAACATTTTATGAAATGTACAAACC 3780
3721 AGCTGTGCCCCCAGAAAACTTAGAAGCTGACAGCCAAACATTTTATGAAATGTACAAACC 3780
3781 TTTGTACGGTCTCTCGTTTATAGGGTACCTGACACATTTAGGAGGACCCCTAAATTTAGATC 3840
3781 TTTGTACGGTCTCTCGTTTATAGGGTACCTGACACATTTAGGAGGACCCCTAAATTTAGATC 3840
3841 ATTGACACAGGAGACCAAGCAATTTGAGCCACAAATTTTATGCTGGGCGCACTAATAA 3900
3841 ATTGACACAGGAGACCAAGCAATTTGAGCCACAAATTTTATGCTGGGCGCACTAATAA 3900
3901 TTTGAGTGTCTTCAAAAGAGGAGACAAATTTCTAATACAGTGTCTGGAAGAGCCCTTACGGG 3960
3901 TTTGAGTGTCTTCAAAAGAGGAGACAAATTTCTAATACAGTGTCTGGAAGAGCCCTTACGGG 3960
3961 GCTTGTACTGCGACTAGCCAAACACAGAAATTTCCCTACGCCCCGGGCGCACTATCTCA 4020
3961 GCTTGTACTGCGACTAGCCAAACACAGAAATTTCCCTACGCCCCGGGCGCACTATCTCA 4020
4021 GGCATACCATCACTGGGACACTGATAAATATGTTACAGGAATAAATGCCATTTTCAATGG 4080
4021 GGCATACCATCACTGGGACACTGATAAATATGTTACAGGAATAAATGCCATTTTCAATGG 4080
4081 ACAACCACTTATGAAATGCTGAGGACAAAGAGTATCAGCAAGGGGTAGGAAGATTTCC 4140
4081 ACAACCACTTATGAAATGCTGAGGACAAAGAGTATCAGCAAGGGGTAGGAAGATTTCC 4140
4141 AAATGAAAAGAACAGCTTTAAGCAGTTTAAAGGTCTTAAACATGACACATCTTCCCTAA 4200
4141 AAATGAAAAGAACAGCTTTAAGCAGTTTAAAGGTCTTAAACATGACACATCTTCCCTAA 4200
4201 TAAAGAACCCCAACATACACAGCAAAATTTGAAAGGTCTTATGCTGGGCTCTGTTG 4260
4201 TAAAGAACCCCAACATACACAGCAAAATTTGAAAGGTCTTATGCTGGGCTCTGTTG 4260
4261 GAAACAGAGCTCTTCACTATGAAAGTCAAGTGTGAGGTAAATCCCTAACTTAGATGA 4320
4261 GAAACAGAGCTCTTCACTATGAAAGTCAAGTGTGAGGTAAATCCCTAACTTAGATGA 4320
4321 CAGTTTTAAAACTCAATTTGACGCCCTAGGCGGGTGGGTTGTCATCAACACCCCTCA 4380
4321 CAGTTTTAAAACTCAATTTGACGCCCTAGGCGGGTGGGTTGTCATCAACACCCCTCA 4380
4381 AATTTTTTAAAAATACCAAGTGGGCAATTTGAGGTATTTAAATCCATGGGAAT 4440
4381 AATTTTTTAAAAATACCAAGTGGGCAATTTGAGGTATTTAAATCCATGGGAAT 4440
4441 TACTACTTTAGTTCAATATGCTGTGGGAATATGACAGTTTACCATGACCTTTAAATTTGGG 4500
4441 TACTACTTTAGTTCAATATGCTGTGGGAATATGACAGTTTACCATGACCTTTAAATTTGGG 4500
4501 ACCTCGAAAGGCTACTGGAAGGTGGAAATCCCGAGCCTGGCGTTTATCTCTCTCATGAGC 4560

```
Db 4501 ACCTCGAAGGCTACTGGAAGGTGGAATCCCGACGCTGCGTATCTCTCATGAGC 4560
Qy 4561 TGGTCATTTACCATATGCTACTGTATGATGACCCACAGCTACAGTCAAGCAACACACAG 4620
Db 4561 TGGTCATTTACCATATGCTACTGTATGATGACCCACAGCTACAGTCAAGCAACACACAG 4620
Qy 4621 ACACGGATATGAAAGCCTGAAGAAATGTGAGCTGCGCAAAAGCGGTGACACCATGTA 4680
Db 4621 ACACGGATATGAAAGCCTGAAGAAATGTGAGCTGCGCAAAAGCGGTGACACCATGTA 4680
Qy 4681 AACATTCGCCACCGTCTCCTCAGCCAGCAACCGTCAACCCACCGCCACCTGTCGCGCCCA 4740
Db 4681 AACATTCGCCACCGTCTCCTCAGCCAGCAACCGTCAACCCACCGCCACCTGTCGCGCCCA 4740
Qy 4741 GATTATATGTCGCCCTCCATATACCCCGTAGGCAACCATCTATAAGATACAGAGCTG 4800
Db 4741 GATTATATGTCGCCCTCCATATACCCCGTAGGCAACCATCTATAAGATACAGAGCTG 4800
Qy 4801 TAGAATAATAATTATTAACATAGATATGAAACAAATGTAATAGAACTAAGATTATGTA 4860
Db 4801 TAGAATAATAATTATTAACATAGATATGAAACAAATGTAATAGAACTAAGATTATGTA 4860
Qy 4861 ATATGTACACAGTTTGGAAAATAAAGCCTTAATAATAATTCATAGTGTATGTTTC 4920
Db 4861 ATATGTACACAGTTTGGAAAATAAAGCCTTAATAATAATTCATAGTGTATGTTTC 4920
Qy 4921 TTTAAAAATTTCAAAAAGAGACACCAATCAGATCGCGCGTCCGCCCGGTAGCGGG 4980
Db 4921 TTTAAAAATTTCAAAAAGAGACACCAATCAGATCGCGCGTCCGCCCGGTAGCGGG 4980
Qy 4981 GACTTCGGTACAGATGCGGAGAGTACGTCAATTCCTGTGACGTC 5028
Db 4981 GACTTCGGTACAGATGCGGAGAGTACGTCAATTCCTGTGACGTC 5028

RESULT 4
AY083234
LOCUS
DEFINITION
B19 virus isolate D91.1 NS1, 7.5 kDa protein, VP1, X-9 kDa protein,
VP2, and 11 kDa protein genes, complete cds.
ACCESSION
AY083234
VERSION
AY083234.1
KEYWORDS
GI:22535302
SOURCE
B19 virus
ORGANISM
B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 (bases 1 to 5017)
Servant,A., Laperche,S., Lallemand,F., Marinho,V., De Saint
Maur,G., Meritet,J.F. and Garbarg-Chenon,A.
Genetic Diversity within Human Erythroviruses: Identification of
Three Genotypes
J. Virol. 76 (18), 9124-9134 (2002)
12186896
REFERENCE
2 (bases 1 to 5017)
Servant,A., Laperche,S., Lallemand,F., Marinho,V., De Saint
Maur,G., Meritet,J.F. and Garbarg-Chenon,A.
Direct Submission
Submitted (11-MAR-2002) Laboratoire de Virologie, Hopital Trousseau
(EA2391, UFR Saint-Antoine), 26 Avenue du Dr. Arnold Netter, Paris
75012, France
LOCATION/Qualifiers
1..5017
/organism="B19 virus"
/mol_type="genomic DNA"
/isolate="D91.1"
/db_xref="taxon:10798"
/note="genotype: 3"
323..2338
/codon_start=1
/product="NS1"
/protein_id="AAL91012.1"
/db_xref="GI:22535303"

CDS
891.2%; Score 4587.4; DB 14; Length 5017;
Best Local Similarity 94.8%; Pred. No. 0;
Matches 4755; Conservative 0; Mismatches 261; Indels 1; Gaps 1;

ORIGIN
PRLYVPPVPSQPSVKTDVAVEYKLLTRYEQHVIRMLRLCNMYTNLEK"

/translation="MELFRGVLIHSSNILDNCANDNWCMSLDLDTSDWBLPLTNSRLM
AIIYSVASKLDFTCGGLAGCIYFFQVECNKEFEGYHIVHVGCPGLNARLNTVCVBG
LFNNVLYLTKETVTKLPGMTTKTKYFRDGEQFIENYLMKKIPLNVVVCVTNIDGY
IDTCISAPRRGACAKPRITANTDNVTSETGESSCGGDVVPAGKGTAKGLFQPT
MYNLCENRFTEDKWLVDNOYTLSSSHSGSQIQSALKAIYKATNLVPTSTFEL
LWSDPEQVTCIKDNKLVLLCONVDPLLVGQHLVLDKRCRKNITLFWFYGPSTGK
TNLAIAKTVPVYGVNWNENPFNDVAGSLVWDEGIITKSTVEAAKILGGQK
TRVDKMRGSVAVPGVPVVTISNGDITFVNSGNTTTHAKALERMVKNLFTVDCSP
DNGLTLEADVOQWLTCNAQSNWYHNAINYTFDGINADALHPDLQTTTIVDPTS
ISSGSESESSSESSFFNLITPGAWNSETPRSTPVPCTSSGSGFVSGPVSEVVA
SWERAFYPLADQPRELLVGVDPVWDVGRGLPVCCVEHNSGGSLGLCPHCINVGAW
YNGKFRSEFTPLVRCSCHVGNASFPVLTCKKAYLSGLQSFVDYE"
1797..2015
/codon_start=1
/product="7.5 kDa protein"
/protein_id="AAL91015.1"
/db_xref="GI:22535306"
/translation="MPSQTQSKPPPLSQTPVSAVVVKALKNSVAAAFSTSSLOAPGT
VKPRALVPSQPVQENHLSAQFPFK"
2331..4676
/codon_start=1
/product="VP1"
/protein_id="AAL91013.1"
/db_xref="GI:22535304"
/translation="MSKTTDRWESNDTFAQDVYKQVQFYEKVTGTDLLELIQILKOH
YNSIDNPLENPSLFDLIVARKSNKSPDIYSHHFSQSHQOLSDHPHALSSNSSTE
PRGENAVLUSDLHKPGQVSMOLPTGTVNGNELQAGPQNVDAARLHDPFYSOL
AKGLNPFYTHLVADDELLKNIKNETGFAQAVKDYFTLKGAAPVAFHQSGLSEVPA
YNASEKPSMTSVNSAASGAGGGSNPTKSMWSEGAFTTANSVCTTFCFSQFLIPYD
PEHYKVPFPAASASGAGGAGKAVCTTIPMGYSTPWRLDNLALNFFSLBEFHL
IENYTSAPDALVTISEIAVKDVTDKTGGOVDTSTGELCMVDHEYKYPVLQ
QODTLAPELPIWVFPQYALTVGEVNTQVSGDSKLAESAFTVLEHSSFQLLG
TGSATMSYKFPAPPENLECGSOHFTEMINPLYSRLGVDPDTLGGDPKFSLSLTHEDH
AIQONFMGPPLINSVSTGEGDTSNTGKALGLSTGTSTQSTISLRPGVPSQFHH
WTDKYVGINAISHGQTTYGNAEDKEYQGVGRFNEKEQLKQGLNMHTYFPNGK
TQOYTDQIERPLMVGSVNNRRALHYSOLSKIPNLDSPKTPKQFALGGWGLHOPPO
IFLKLPSQSGPIGGIKSMGITTVQYAVGIMVTMTFKLGRKATGRWNPPQGYVPH
AAGHLPVLYDPTATDAKQHRHGYEKEPEELWATAKSRVHPL"
2581..2826
/codon_start=1
/product="X-9 kDa protein"
/protein_id="AAL91017.1"
/db_xref="GI:22535308"
/translation="MDSYLTTPMPYHPVTVVQNLKQYVLMKTYTSLGKLCNYPV
LTMLGLAMSYKLGRLRLMTVLQGFMTLIGIANWLSWE"
3012..4676
/codon_start=1
/product="VP2"
/protein_id="AAL91014.1"
/db_xref="GI:22535305"
/translation="MTSVNSAEASTGAGGGSNPTKSMWSEGAFTTANSVCTFESQF
LIPVDPHHYKVPFPAASASGAGGAGKAVCTTIPMGYSTPWRLDNLALNFFSPL
EFQHLNENYSIAPDALVTISEIAVKDVTDKTGGOVDTSTGRLCMVDHEYKYP
YVLGGQDTLAPELPIWVFPQYALTVGEVNTQVSGDSKLAESAFTVLEHSS
FQLLGTGSATMSYKFPAPPENLECGSOHFTEMINPLYSRLGVDPDTLGGDPKFSLSL
THEDHAIQONFMGPPLINSVSTGEGDTSNTGKALGLSTGTSTQSTISLRPGVPS
QPYHHWDTKYVGINAISHGQTTYGNAEDKEYQGVGRFNEKEQLKQGLNMHTY
FPNGKTOYTDQIERPLMVGSVNNRRALHYSOLSKIPNLDSPKTPKQFALGGWGLH
OPPOELKLPSQSGPIGGIKSMGITTVQYAVGIMVTMTFKLGRKATGRWNPPQ
YVFPFHAAGHLPVLYDPTATDAKQHRHGYEKEPEELWATAKSRVHPL"
4597..4891
/codon_start=1
/product="11 kDa protein"
/protein_id="AAL91016.1"
/db_xref="GI:22535307"
/translation="MQSNSTDDTKMSKNCGLPKAVCTHCKHSPPCPKGTVTHRPVP
PRLYVPPVPSQPSVKTDVAVEYKLLTRYEQHVIRMLRLCNMYTNLEK"
```


Db 2161 GCTTTGCTCCTCAATGATTAATTAATGCGAGCTTGGTATTAATGATGGAATTTAGAGATT 2220
QY 2226 TACTCAGACTTAGTCGCTGAGTTGTATGATGAGGCTCTAACCCATTTCTGTGTT 2285
Db 2221 TACTCAGACTTAGTCGCTGAGTTGTATGATGAGGCTCTAACCCATTTCTGTGTT 2280
QY 2286 AACTTTGTAATAATGCTGCTTACTCTGTGGAATTAATAAGTTTGTAGATTATGAGTAAA 2345
Db 2281 AACTTTGTAATAATGCTTACTCTGTGGAATTAATAAGTTTGTAGATTATGAGTAAA 2340
QY 2346 CCACTAAACAAATGCTGGGAAGCAGTGCACAAATTTGCCAGAGCTGTATGAAGCAGTTTG 2405
Db 2341 CCACTGACAGATGCTGGGAAGTAAATGACAAATTTGCCAGAGCTGTATGAAGCAATTTG 2400
QY 2406 TCAATTTTATGAAAAGCTACTGGAACAGACTTAGAGCTTATTAATAAGTAAACAC 2465
Db 2401 TACAATTTTATGAAAAGCTACTGGAACAGACTTAGAGCTTATTAATAAGTAAACATC 2460
QY 2466 ATTACACAAATTTCTTTAGATTAATCTTTAGAAAACCTCTCTTTTATTTGACTTAGTTG 2525
Db 2461 ATTATACAAATTTCTTTAGATTAATCTTTAGAAAACCTCTCTTTTATTTGACTTAGTTG 2520
QY 2526 CTCGCATTAAGAAGTAATCTTAAAACTCTCCAGACCTATATAGTCATCAATTTTCAGAGCC 2585
Db 2521 CTCGCATTAAGAAGTAATCTTAAAACTCTCCAGACCTATATAGTCATCAATTTTCAGAGCC 2580
QY 2586 ATGGACAGTTATCTGACACACCCCATGCTTATCATCCAGTAAACAGTAGTCAGAAACCTA 2645
Db 2581 ATGGACAGTTATCTGACACACCCCATGCTTATCATCCAGTAAACAGTAGTCAGAAACCTA 2640
QY 2646 GAGGAGAAAATGCAATTAATCTAGTGAAGACTTACACAGCTGTGAGCTGCGGCAATGAC 2705
Db 2641 GAGGAGAAAATGCAATTAATCTAGTGAAGACTTACACAGCTGTGAGCTGCGGCAATGAC 2700
QY 2706 AATTACCGGTACTAATCTGTTGGCTGCGCAATGAGCTACAGCTGCGGCTCCGACAG 2765
Db 2701 AACTACCGGTACTAATCTGTTGGCTGCGCAATGAGCTACAGCTGCGGCTCCGACAG 2760
QY 2766 ATGCTGTGGACAGTGTGCAAGATTCATGACTTTAGGTATAGCCAAATTTGGCTAAGTTGG 2825
Db 2761 ATGCTGTGGACAGTGTGCAAGATTCATGACTTTAGGTATAGCCAAATTTGGCTAAGTTGG 2820
QY 2826 GAATAAATCTTTATACATTTGACGCTGACAGATGAAGATTTGTTAAAAATATAAAAA 2885
Db 2821 GAATAAATCTTTATACATTTGACGCTGACAGATGAAGATTTGTTAAAAATATAAAAA 2880
QY 2886 ATGAAACAGGTTTCAAGCACAGCAGTAAAGATTTACTTTTAAAGGTGACGCTG 2945
Db 2881 ATGAAACAGGTTTCAAGCACAGCAGTAAAGATTTACTTTTAAAGGTGACGCTG 2940
QY 2946 CCCTGTGGCCCAATTTTCAAGGAAGTTTACCGGAAGTGCCTGACAGCTGCTGTCAGGCGGGGAG 3065
Db 2941 CCCTGTGGCCCAATTTTCAAGGAAGTTTACCGGAAGTGCCTGACAGCTGCTGTCAGGCGGGGAG 3060
QY 3066 ATATACCCAGCATGACTTCAGTTAACTCTGCAAGAGCCAGCACTGCTGTCAGGCGGGGAG 3125
Db 3061 ATATACCCAGCATGACTTCAGTTAACTCTGCAAGAGCCAGCACTGCTGTCAGGCGGGGAG 3120
QY 3126 CTTGTACATCTCTAGGCAATTTTAAATTCATATGATCCAGAGCATCATTTATAAGTGT 3185
Db 3121 CATGCACATCTCTAGGCAATTTTAAATTCATATGATCCAGAGCATCATTTATAAGTGT 3180
QY 3186 TCTCTCCAGCAGTGTAGTGCACCAATGCTAGTGGGAAAGAGGCAAAAGTGTGCACTA 3245
Db 3181 TTTCTCCAGCAGCAGTGTAGTGCACCAATGCTAGTGGGAAAGAGGCAAAAGTGTGCACTA 3240
QY 3246 TTAGTCCCATTTAGGGGTACTCTACTCCGTGGAGATCTAGATTTTAAATGCTTTAAAT 3305
Db 3241 TTAGTCCCATTTAGGGGTACTCTACTCCGTGGAGATCTAGATTTTAAATGCTTTAAAT 3300

QY 3306 TGTTTTCTCACCATTAGAGTTTTCAGCACTTAATTTGAAATTTATGTTAGTATAGCTCCAG 3365
Db 3301 TGTTTTCTCACCATTAGAGTTTTCAGCACTTAATTTGAAATTTATGTTAGTATAGCTCCAG 3360
QY 3366 ATGCTTTTAACTCTAACTATTTTTCAGAAATTTGCTGTTAAAGATGTTACAGACAAAACAGGAG 3425
Db 3361 ATGCTTTTAACTCTAACTATTTTTCAGAAATTTGCTGTTAAAGATGTTACAGACAAAACAGGAG 3420
QY 3426 GAGGTGTGAAGTTTACTGACAGCACACAGGACGTTTGTGTATGTTAGTGGATCATGAT 3485
Db 3421 GAGGTGTGAAGTTTACTGACAGCACACAGGACGTTTGTGTATGTTAGTGGATCATGAT 3480
QY 3486 ATAAATACCCATATGTTGCTAGAGTCAAGGACAAAGACACACTAGCTCCAGAACTGCCCATT 3545
Db 3481 ATAAATACCCATATGTTGCTAGAGTCAAGGACAAAGACACACTAGCTCCAGAACTGCCCATT 3540
QY 3546 GGGTTTACTTTTCCCTCCAGTATGCTTACTTAAACAGTAGGTGAAGTAAACACACAGGAG 3605
Db 3541 GGGTTTACTTTTCCCTCCAGTATGCTTACTTAAACAGTAGGTGAAGTAAACACACAGGAG 3600
QY 3606 TTTTCAAGGACAGCAAGCAAAATTTGGCTAGTGAAGATCAGCTTTTATGTTAGGACACA 3665
Db 3601 TTTTCAAGGACAGCAAGCAAAATTTGGCTAGTGAAGATCAGCTTTTATGTTAGGACACA 3660
QY 3666 GTTTCATTTTAACTTTTGGGTACAGGGGATCTGCCATATGCTCCTCAAAATTTCCAGCTG 3725
Db 3661 GCTTCTTTTAACTTTTGGGTACAGGGGATCTGCCATATGCTCCTCAAAATTTCCAGCTG 3720
QY 3726 TGCCCCAGAAAACCTTGAAGGCTGACAGGCTTGAAGATCAGCTTTTATGTTAGGACACA 3785
Db 3721 TGCCCCAGAAAACCTTGAAGGCTGACAGGCTTGAAGATCAGCTTTTATGTTAGGACACA 3780
QY 3786 ACGGTTCTGTTTGGGTACCTGACACATTTAGAGGGGACCCCTAAATTTAGATCAATGA 3845
Db 3781 ACGGTTCTGTTTGGGTACCTGACACATTTAGAGGGGACCCCTAAATTTAGATCAATGA 3840
QY 3846 CACACAGAGACACGCAATTTAGGACCAACAACTTTTATGCTGGGCACTAATAAATTCAG 3905
Db 3841 CACACAGAGACACGCAATTTAGGACCAACAACTTTTATGCTGGGCACTAATAAATTCAG 3900
QY 3906 TGTCTACAAAGAGAGAGACAATTTCTAATAAGTGTGGAAGGCGCTTACCGGGCTTA 3965
Db 3901 TGTCTACAAAGAGAGAGACAATTTCTAATAAGTGTGGAAGGCGCTTACCGGGCTTA 3960
QY 3966 GTACTGCACTAGCAAAACACAGCAATTTCCCTAGCCCCGGGCGGCACTATCTAGCCAT 4025
Db 3961 GTACTGCACTAGCAAAACACAGCAATTTCCCTAGCCCCGGGCGGCACTATCTAGCCAT 4020
QY 4026 ACCATCACTGGGACACTGATTAATAATTTTACAGGAATAAATGCCATTTACATGGACAAA 4085
Db 4021 ACCATCACTGGGACACTGATTAATAATTTTACAGGAATAAATGCCATTTACATGGACAAA 4080
QY 4086 CCATTTATGGAATGCTGAGGACAAAGATGATCAGCAAGGGGTAGGAAGATTTCCAAATG 4145
Db 4081 CCATTTATGGAATGCTGAGGACAAAGATGATCAGCAAGGGGTAGGAAGATTTCCAAATG 4140
QY 4146 AAAAAGAACAGCTTAAAGCAGTTTACAGGCTTAAACATGACACATCTTCCCTTAATAAG 4205
Db 4141 AAAAAGAACAGCTTAAAGCAGTTTACAGGCTTAAACATGACACATCTTCCCTTAATAAG 4200
QY 4206 GAACCCAAACATACAGACCCAAATTTGAAGGACCTTTAATGTTGGGCTCTGTGTGGAACA 4265
Db 4201 GAACCCAAACATACAGACCCAAATTTGAAGGACCTTTAATGTTGGGCTCTGTGTGGAACA 4260
QY 4266 GAAGAGCTCTTCACTATGAAAGTGTGAGTGAAGTAAATCCCTAACTAGATGACGTT 4325
Db 4261 GAAGAGCTCTTCACTATGAAAGTGTGAGTGAAGTAAATCCCTAACTAGATGACGTT 4320
QY 4326 TTAATACTCAATTTGAGGCTTACAGGCTTACAGGCTTGGGCTTGCATCAACCCCTCCAAATAT 4385
Db 4321 TTAATACTCAATTTGAGGCTTACAGGCTTACAGGCTTGGGCTTGCATCAACCCCTCCAAATAT 4380

QY 334 CTATTTGGGGTGTCTTGACATTTCCCTTAACATCTCGAGCTGTCTAATGATAACTGG 393
Db |||||
QY 241 CTATTTAGGGTGTGTGCATATTTCTCTAACATTTTAGACTGTCTAATGATAACTGG 300
Db |||||
QY 394 TGGTCTCTATGCTAGACTTAGATTAATCTGAGCTGGGAACCACTAACTCTCTAACAGA 453
Db |||||
QY 301 TGGTCTCTATGCTGGATTTAGATTAATCTGAGCTGGGAACCACTAACTCTCTAACAGA 360
Db |||||
QY 454 TTAATGGCAATATATTTAAGCAGTGTCTCTTAACCTTGATTTTACTGGGGGCCGCTA 513
Db |||||
QY 361 CTATGGCAATATATTTAAGTAATGTCTCTTAACCTGGATTTTACTGGGGGCCGCTG 420
Db |||||
QY 514 GCAGGTGCTTATACTTTTTCAGGTGGAATGTAACTAACTTTGAGGAAGGCTATCATC 573
Db |||||
QY 421 CGGGTGTCTTATATCTTTTTCAGGTGGAATGTAACTAACTTTGAGGAAGGCTACCATTT 480
Db |||||
QY 574 CATGTAGTTATTTGGTGTCCAGGACTAATGCTAGAACTTAATCTGTGCGTAGAAGGT 633
Db |||||
QY 481 CATGTAGTTATTTGGTGTCCAGGACTTAACTGTAGAACTTAACTGTGTGTAGAGGC 540
Db |||||
QY 634 TTAATTAATATTTCTTTTACCATCTTTGTAAGTGAAGTGTAACTTTAACTTTAACTTTTGCCA 693
Db |||||
QY 541 TTGTTTAATATTTGCTTTTACCACCTGTAAATGAAGTGTAACTGAATTTTGTGCCA 600
Db |||||
QY 694 GGGATGACTACCAAGGAATATTTTAGAGTGGAGAGCAGTTTATAGAAAATTACTTA 753
Db |||||
QY 601 GGAATGACTACAAAGGAAGATATTTTAGAGTGGAGAGCAGTTTATAGAAAATTACTTA 660
Db |||||
QY 754 ATGAAAAAATTTCTTTTAAATGTTGTGTGTGTAACTGAACAAATATTCAGCGGTATATAGAC 813
Db |||||
QY 661 ATGAAAAAATTTCTTTTAAATGTTGTGTGTGTAACTGAACAAATATTCAGCGGTATATAGAC 720
Db |||||
QY 814 ACCTGTAATTTCCGCTCTTTTGGCGAGGAGTGTGTCTGCTAAAGAGCCCGCATTTACT 873
Db |||||
QY 721 ACCTGTAATTTCTGCATCTTTTAGACGAGGAGTGTGCTGCTAAAGAGCCCGCATTTACT 780
Db |||||
QY 874 GCAATAACAGACAGTGTCTAATGAATGAATCTGGGAGTCTAGCTGTGGAGGGGAGATGT 933
Db |||||
QY 781 ACAAACAGACACTGTAAATATGAAGAGGGGAATCAAGCTGTGGAGGGGAGATGTG 840
Db |||||
QY 934 GTGCCATTTGCTGGAAAGGAAACAAAGCGGGGTAAAGTTTCAACACCATGTAAATTTGG 993
Db |||||
QY 841 GTGCCATTTGCTGGAAAGGAAACAAAGCGAGGCTTAAAGTTTCAACCAATGTAAATTTGG 900
Db |||||
QY 994 CTATGTGAAACAGAGTATTTACTGAAGATAATGAATAGTGAATTTTAAACCAATAT 1053
Db |||||
QY 901 CTATGTGAAACAGAGTATTTACTGAAGATAATGAAGTGTAGTGAATTTTAAATCAGTAT 960
Db |||||
QY 1054 ACTTTATTAAGTAGCAGTCACAGTGGCAGCTTTCAAAATCAAGTGCCTTAAAGTTAGCT 1113
Db |||||
QY 961 ACATTAATTAAGCAGTAGTCATAGTGGAGTTTTCAATACAAAGTGCATTAAGCTAGCT 1020
Db |||||
QY 1114 ATTTATAAGCTACTAATCTAGTACCCAGTACATCTCTGTTACATTCAGACTTTTCAG 1173
Db |||||
QY 1021 ATTTATAAGCTACTAATCTAGTACCCAGTACATCTCTGTTACATTCAGACTTTTCAG 1080
Db |||||
QY 1174 CAGGTACTTGCATTAAGAAAAATAAATAGTAAATATTTATTTCTGTCGCAAACTATGAT 1233
Db |||||
QY 1081 CAGGTACTTGCATTAAGAAAAATAAATAGTAAATATTTATTTATGTCAGAAATTTATGAT 1140
Db |||||
QY 1234 CCTCTTTTAGTGGGTCAACATGTTTAAAGTGGATTTGACAAAAATGTGTAAGAAAAAC 1293
Db |||||
QY 1141 CCTCTTTTAGTGGGTCAACATGTTTAAAGTGGATTTGACAAAAATGTGTAAGAAAAAC 1200
Db |||||
QY 1294 ACCCTGTGTTTACGGGCGCAAGTACTGGAAAAATAAATTTGGCAATGGCTATTGCT 1353
Db |||||
QY 1201 ACCCTGTGTTTACGGGCGCAAGTACTGGAAAAATAAATTTGGCAATGGCTATTGCT 1260
Db |||||
QY 1354 AAACTGTACCAAGTGTATGGAATGTGAATGAATGAATGAATGAATGAATGAATGAATGAAT 1413
Db |||||
QY 1261 AAACTGTCCAGTGTATGGCATGTTAAATGGAATGAATGAATGAATGAATGAATGAATGAAT 1320
Db |||||
QY 1414 GTAGCGGGAAAGTTTGGTGTCTGGGATGAGGCATTTAAGTCCACTATTGTGGAA 1473
Db |||||

Db |||||
QY 1321 GTAGCGGGAAAAAGTTTGGTGGTCTGGATGAAGCATTTAATTAAGTCCACTATTGTGGAA 1380
Db |||||
QY 1474 GCTGCAAAAGCCATTTTAGTGTGTCAGCCAAACAGGGTAGATCAGAAAAATGCTGGCAGT 1533
Db |||||
QY 1381 GCTGCAAAAGCCATTTTAGTGTGTCAGCCAAACAGGGTAGATCAGAAAAATGCTGGCAGT 1440
Db |||||
QY 1534 GTGGCAGTCCCGGTGTGCTGTGTTTAAACAGCAATGGTGACATTAATTAATTTGTTGTG 1593
Db |||||
QY 1441 GTGGCAGTCCCGGTGTGCTGTGTTTAAACAGCAATGGTGACATTAATTAATTTGTTGTG 1500
Db |||||
QY 1594 AGTGGTAAATACCACTACAACTGTGATGCTTAAGGCTTAAAGGAACGGATGTAAGCTTA 1653
Db |||||
QY 1501 AGTGGTAAATACCACTACAACTGTGATGCTTAAGGCTTAAAGGAACGGATGTAAGCTTA 1560
Db |||||
QY 1654 AACTTTACCATTAAGATGTAGCCCTGACATGGGTACTTTACAGAGGCTGTAGTACAA 1713
Db |||||
QY 1561 AACTTTACCATTAAGATGTAGCCCTGACATGGGTACTTTACAGAGGCTGTAGTACAGCA 1620
Db |||||
QY 1714 TGGCTAACTTGGTGTAAATGCAAAAGCTGGAGCCACTATGAAAACTGGGCAATAAATAC 1773
Db |||||
QY 1621 TGGCTAACTTGGTGTAAATGCAAAAGCTGGAGCCACTATGAAAACTGGGCAATAAATAC 1680
Db |||||
QY 1774 ACATTTGATTTCCCTGGAAATAAATGTCAGATGCCCTCCACCCAGATCTCCTAAACCC 1833
Db |||||
QY 1681 AGTGTGATTTCCCTGGAAATAAATGTCAGATGCCCTCCACCCAGATCTCCTAAACCC 1740
Db |||||
QY 1834 ATGTGCCAGACACAGTATCAGCAGCAGTGTGTTGAGAACTCTGAGAACTCAGTGAA 1893
Db |||||
QY 1741 ATGTGCCAGACACAGTATCAGCAGCAGTGTGTTGAGAACTCTGAGAACTCAGTGAA 1800
Db |||||
QY 1894 AGCAGCTTTTCAACCTCANTCACTCCAGGCGCTGGAAACAGTGAACCCCGCGCTCTAGT 1953
Db |||||
QY 1801 AGCAGCTTTTCAACCTCANTCACTCCAGGCGCTGGAAACAGTGAACCCCGCGCTCTAGT 1860
Db |||||
QY 1954 ACGCCGCTCCCGGAGCCAGTTCAGGAGAACTCAATTTGCGGAAGCCAGATTTCTCCGAA 2013
Db |||||
QY 1861 ACGCCGCTCCCGGAGCCAGTTCAGGAGAACTCAATTTGCGGAAGCCAGATTTCTCCGAA 1920
Db |||||
QY 2014 GTGGTACCGGCTGTGGGAGAAAGCTTTTACAGCGGCTTGGCGATCAGTTTCGTGAA 2073
Db |||||
QY 1921 GTGGTACCGGCTGTGGGAGAAAGCTTTTACAGCGGCTTGGCGATCAGTTTCGTGAA 1980
Db |||||
QY 2074 CTGTAGTAGGGTGTGACTTTGTATGGATGTGTGAGGGATTTGCTGTTGCTGTGTG 2133
Db |||||
QY 1981 CTGTAGTAGGGTGTGACTTTGTGAGATGTGTGAGGGATTTGCTGTTGCTGTGTGTG 2040
Db |||||
QY 2134 GAACATATAAACAGTGGGGAGGTTGGGCTTTGCGCTCAITGTATTAATGTGGGA 2193
Db |||||
QY 2041 CAGCATATAATAATAGTGGGGAGGTTAGGCTTTGTCTCAITGTATTAATGTGGGA 2100
Db |||||
QY 2194 GCTTGGTATAATGGATGGAATTTAGAGAGTTTTACTCCAGACTTAGTGCCTGAGTTGT 2253
Db |||||
QY 2101 GCTTGGTATAATGGATGGAATTTTCTGGAATTTTACTCCAGATTTGTAGCGTGCAGTGC 2160
Db |||||
QY 2254 CATGTAGGAGCTCTAACCCATTTCTGTGTTAACTTTGTAAAAAATGTGCTTACCTGTCT 2313
Db |||||
QY 2161 CATGTAGGAGCTCTAACCCATTTCTGTGTTAACTTTGCTGCAAAATAATGTGCTTACTGTCT 2220
Db |||||
QY 2314 GGATTAACAGTTTTCTAGATTAATGATTAACCACTAACAATGTGTGGGAAGCAGTGA 2373
Db |||||
QY 2221 GGATTAACAGTTTTCTAGATTAATGATTAACCACTAACAATGTGTGGGAAGCAGTGA 2280
Db |||||
QY 2374 CAAATTTGCCAGGAGCTGTATAAGCAGTTTGTGCAATTTTATGAAAAAGCTACTGGAAC 2433
Db |||||
QY 2281 TAAATTTGTAGGAGCTGTATAAGCAATTTGTAGAAATTTTATGAAAAAGTACTGAGAC 2340
Db |||||
QY 2434 AGACTTAGAGCTTATTAATTTTAAAGACCACTTAACATTTCTTTAGATAAATCCCTTT 2493
Db |||||
QY 2341 AGACTTAGAGCTTATTAATTTTAAAGATCAATTAATATTTCTTTAGATAAATCCCTTT 2400
Db |||||
QY 2494 AGAAAAACCCCTCTCTTTTATTTGACTTAGTGTGCTGCATTAAGATTAATCTTTAAACCTC 2553
Db |||||

Db 2401 AGAAACCCTCTTCCCTGTTGACCTTAGTTGCTGCTGTAATTAAGAATACTTAAAGACAC 2460
Qy 2554 TCAGACCTATATAGTCACTATTTTCAGAGCCATGACAGATTAATCTGACACCCCCCATGC 2613
Db 2461 TCAGACCTATATAGTCACTATTTTCAGAGCCATGACAGATTAATCTGACACCCCCCATGC 2520
Qy 2614 CTTATCATCCAGTAAACAGTAGTCAGAACCTAGAGGAGAAATGCAAGTATTATCTAGTGA 2673
Db 2521 CTTATCACCAGTAGAGCAGTCATACAGAACCTAGAGGAGAGATGCAAGTATTATCTAGTGA 2580
Qy 2674 AGACTTTACACAAGCCTGGGCAAGTTAGCATACAAATTAACCGGCTACTAACTATGCTGGGC 2733
Db 2581 AGACTTTACACAAGCCTGGGCAAGTTAGCATACAACTACCCGGCTACTAACTATGCTGGCC 2640
Qy 2734 TGSCAATAGACTACAAGCTGGGCTCCGCGAGAAATGCTGTGGACAGTGTGCAAGGATTC 2793
Db 2641 TGSCAATAGACTACAAGCTGGGCTCCGCGCAAGTGTGTGGACAGTGTGCAAGGATTC 2700
Qy 2794 TGACTTTAGGTATAGGCAATGGCTAAGTTGGGAATAAATCTTATACACATTTGAGCGGT 2853
Db 2701 TGACTTTAGGTATAGGCAATGGCTAAGCTGGGAATAAATCTTATCTATCTGAGCTGT 2760
Qy 2854 AGCAGATGAAGATTTGTTAAATAATATAAATAATGAACAGGCTTTCAAGCACAACAGT 2913
Db 2761 AGCAGATGAAGACTGTTAAATAATATAAATAATGAACAGGCTTTCAAGCACAACAGT 2820
Qy 2914 AAAAGATTACTTTTAAAGGTGAGCTGCGCTGCTGGCCATTTTCAAGGAAAGTTT 2973
Db 2821 AAAAGATTACTTTTAAAGGTGAGCTGCGCTGCTGGCCATTTTCAAGGAAAGTTT 2880
Qy 2974 ACCGAAGTGCCTGCTACAAACCCCTCAGAAAATACCCAGCATGACTTTAGTTAACTC 3033
Db 2881 GCGGAAGTTCCCGCATACAAACCCCTCAGAAAATACCCAGCATGACTTTAGTTAACTC 2940
Qy 3034 TGCAAGCCAGCAGTGTGCGAGCGGGAGGTAGCAACCTTACAAAAGCATGAGGAG 3093
Db 2941 TGCAAGCCAGCAGTGTGCGAGCGGGAGGAGCATGATCTGTCAAAGCATGAGGAG 3000
Qy 3094 TGAAGGGGCTACATTTACTGCTAAATCTGTAACTGTACATTTCTTAGGCAATTTTAAAT 3153
Db 3001 TGAGGGCGCACTTTTACTGCAACTCTGTAACTGTACATTTTCCAGACAGTTTAAAT 3060
Qy 3154 TCATATATATCCAGAGCATCAATTAAGTGTCTCTCCAGAGCTAGTAGTGCACAA 3213
Db 3061 CCATATAGCCAGAGCAGCGTTATAAGTGTCTTCTCCGCGAGCTAGTAGTGCATAA 3120
Qy 3214 TGCTAGTGGGAAGGCAAAAGTGTGCACTATTTAGTCCCATTTAGGGGTACTTACTCC 3273
Db 3121 TGCCAGTGGGAAGGCAAAAGTGTGCACTATTTAGTCCCATTTAGGGGTACTTCAACGCC 3180
Qy 3274 GTGGAGATCTTAGATTTTAAATGCTTTAAATTTGTTTCTCACCATTAGAGTTTCAGCA 3333
Db 3181 ATGGAGATCTTAGATTTTAAATGCTTTAAATTTTCTACCTTTAGAAATTTCAACA 3240
Qy 3334 CTTAAATGAAAATATGTTAGTATAGTCCAGATGCTTTAACTGTAACTATTTTCAGAAAT 3393
Db 3241 TTTAAATGAAAATATGTTAGTATAGTCCAGATGCTTTAACTGTAACTATTTTCAGAAAT 3300
Qy 3394 TGCTGTAAAGATGTACAGACAAACAGGAGGAGGTGCAAGTTACTGACAGCACCAC 3453
Db 3301 TGCTGTAAAGATGTACAGACAAACAGGAGGAGGTGCAAGTTACTGACAGTACTAC 3360
Qy 3454 AGGACGTTTGTGTATGTTAGTGGATCATGAGTATAAATACCCATATGCTAGGTCAGGG 3513
Db 3361 AGGGCGTTTATGATGTTAGTATGATGATGATGATGATGATGATGATGATGATGATGATG 3420
Qy 3514 ACAAGACACTAGCTCCAGAACTGCGCAATTTGGGTTTACTTTCCCGCCAGTATGCTTA 3573
Db 3421 ACAGGATACCTTAGCCCGCAAACTGCTTATTTGGTGTACTTTCCCGCCCTCAATATGCTTA 3480
Qy 3574 CTTAAAGTATGTTAGTAAACACACAGGAAATTTAGGAGACAGCAAAAATTTGCTAG 3633
Db 3481 TTTAAACCGGGAGATGTAAACACACAGGAAATTTTCAAGGGAGCAGTAAAGAGCTAGCAAG 3540

Qy 3634 TCAAGAAATCAGCTTTTATAGTGTAGACACAGTTCATTTTGAACCTTTTGGGTACAGGGG 3693
Db 3541 TCAAGAAATCAGCATTTTATAGTGTAGGAAACACAGTTCATTTGAACCTTTTGGGTACAGGGG 3600
Qy 3694 ATCTGCCATATGCTCTACAAATTTCCAGCTGTGCCCCAGAAACCTAGAAAGGCTGCAG 3753
Db 3601 CTCTGCCATATGCTCTATAAAATTTCCACAGTGTGCCCCAGAAACCTTTGGAGGTTGTAG 3660
Qy 3754 CCAACATTTTATGAAATGTACAAACCTTTGTACGGTTCTCGTTTGTAGGGGTACTGACAC 3813
Db 3661 CCAACATTTTATGAAATGTACAAACCTTTGTATGGTCTCGTTTGTAGGGGTACTGACAC 3720
Qy 3814 ATTAGAGGGGACCTTAATTTAGATCAATGACACAGAAACCTAGCAATTCAGCCACA 3873
Db 3721 ACTAGGGGGGACCTTAATTTAGATCAATTAACCTACGAAGATCATGCAATTCAGCCACA 3780
Qy 3874 AAACCTTTATGCTGGGCCACTTAATTAATTCAGTGTCTACCAAGAGGAGACAAATTTCTAA 3933
Db 3781 AAACCTTTATGCTGGGCCACTTAATTAATTCAGTGTCTACCAAGAGGAGACAAATTTCTAA 3840
Qy 3934 TACAGTGTCTGAAAGGCCCTTTACGGGGCTTAGTACTGTCACCTAGCAAAAACACAGAAAT 3993
Db 3841 TACAGGGCGGGAAGGCCCTTTACGGGGCTTAGTACTGTCACCTAGTCAAAAGACCAAGAT 3900
Qy 3994 TTCCCTTACGCCCGGGCCAGTATCTCAGCCATACCAATCACTGGGACACTGATATAATATGT 4053
Db 3901 ATCCCTTGCGCCAGGACCAAGTGTCTCAGCCATACCACTAGTGGGACACTGATAAGTATGT 3960
Qy 4054 TACAGGAATAATGCCATTTTCACTAGGACAAACCACTTATGGAATGCTTGAGGACAAAGA 4113
Db 3961 CACAGGAATAATGCTTATTTTCACTAGGACAAACCACTTATGGAATGCTTGAGGACAAAGA 4020
Qy 4114 GTATCAGCAAGGGGTAGGAAGATTTTCCAAATGAAAGAAACAGCTTAAGCAGTTACAAGG 4173
Db 4021 GTATCAGCAAGGGGTAGGAAGATTTTCCAAATGAAAGAAACAGCTTAAGCAGTTACAAGG 4080
Qy 4174 TCTTAACATGCAACATCTTCCCTTAATAAGGAACCCCAACATAACAGACCAAAATTTGA 4233
Db 4081 CCTAAACATTCACACATCTTTTCCAAACAAAGGAACCCCAACATAACAGATCAAAATTTGA 4140
Qy 4234 AGCCCTCTTATGTTGGGCTCTGTTTGGAAACAGAGAGCTCTTCACTATGAAGTCAAGT 4293
Db 4141 AGCCCTCTTATGTTGGGCTCTGTTTGGAAACAGAGAGCTCTTCACTATGAAGTCAAGT 4200
Qy 4294 GTGGAGTAAATCCCTTAACTTAGATGACAGTTTTAAACCTCAATTTGACAGCCCTAGGCG 4353
Db 4201 GTGGAGTAAATCCCTTAACTTAGATGACAGTTTTAAACCTCAATTTGACAGCCCTAGGCG 4260
Qy 4354 GTGGGTTTTGCAATCAACCCCTCAAAATATTTTAAATAATTAACCAAGTGGGCC 4413
Db 4261 GTGGGTTTTTACATCAACCACTCTCAAAATATTTTAAATAATTAACCAAGTGGGCC 4320
Qy 4414 AATTGAGGATTAATAATCACTGGGAATTTACTACTTTAGTTTCAATATGCTGTGGGAATAT 4473
Db 4321 AATTGAGGATTAATAATCACTGGGAATTTACTACTTTAGTTTCAATATGCTGTGGGAATAT 4380
Qy 4474 GACAGTTACCATGACCTTTAAATTTGGGACCTCGAAAGGCTACTGGAAGGTGGAATCCCCA 4533
Db 4381 GACAGTTACTATGACATTTAAATTTGGGACCTCGTAAGGCTACTGTTAGGTGGGAATCCACA 4440
Qy 4534 GCCTGGGTTTTTCTCTCTCATGCACTGGTCAATTTTCAATATGCTATGTAAGACCCAC 4593
Db 4441 GCCTGGGTTTTTCTCTCTCATGCACTGGTCAATTTTCAATATGCTATGTAAGACCCAC 4500
Qy 4594 AGCTACAGATGCAAGCAACACACAGACCGATATGAAGCCCTGAAGATTTGGAC 4653
Db 4501 AGCTACAGATGCAAGCAACACACAGACCGATATGAAGCCCTGAAGATTTGGAC 4560
Qy 4654 TGCCAAAAGCCGTGTGACCCCACTTTGAAACATTTCCCAACCGTGTCTCAGCCAGGAACCG 4713
Db 4561 TGCCAAAAGCCGTGTGACCCCACTTTGAAACATTTCCCAACCGTGTCTCAGCCAGGAACCG 4620

Db 2821 AAAAGATTACTTTTAAAGGTGCGAGTGGCCCTGTGGCCCAATTTTCAAGGAAGTTT 2880

Qy 2974 ACCGGAAGTGGCCGCTACACGCTCAGAAAATAATCCAGCATGACTTTCAGTTAACTC 3033

Db 2881 GCGGGAAGTTCGCGCATACAAAGCTCAGAAAGTACCCAAAGCATGACTTTCAGTTAACTC 2940

Qy 3034 TGCAGAACGACGACTGCTGAGCGGGGAGGTAGCAACCCCTACAAAAGCATGTGGAG 3093

Db 2941 TGCAGAACGACGACTGCTGAGCGGGGAGGTAGCAACCCCTACAAAAGCATGTGGAG 3000

Qy 3094 TGAAGGGGCTTACTTACTGCTAACTTCTGTAACGCTGACATTTCTTAGGCAATTTTAAAT 3153

Db 3001 TGAGGGGCGCCACTTTTACTGCGCAACTCTGTAACCTGTGACATTTTTCAGACAGTTTTTAAAT 3060

Qy 3154 TCCATATGATCCAGAGCATCAITATAAAGTGTCTCTCCAGCAGCTAGTAGCTGCCACAA 3213

Db 3061 CCCATATGACCCAGAGCACCATTAATAAGTGTCTCTCCAGCAGCTAGTAGCTGCCATAA 3120

Qy 3214 TGCTAGTGGAAAGAGCAAAAGTGTGCACTATTTAGTCCCAATATAGGGGTACTCTACTCC 3273

Db 3121 TGCAGTGGAAAGAGCAAAAGTGTGCACTATTTAGTCCCAATATAGGGGTACTCTACTCC 3180

Qy 3274 GTGAGATACTTAGATTTTAAATGCTTTAAATTTGTTTCTCACCANTTAGAGTTTCAGCA 3333

Db 3181 ATGGAGATCTTAGACTTTTAAGCTTTTAACCTTAATTTTTCACCTTTTGAATTTTCAACA 3240

Qy 3334 CTTAAATGAAAATTTATGGTAGTATAGCTCCAGATGCTTTAACTGTAACTATTTTCAGAAAT 3393

Db 3241 TTTAAATGAAAATTTATGGTAGTATAGCTCCAGATGCTTTAACTGTAACTATTTTCAGAAAT 3300

Qy 3394 TGCCTGTAAGAGTGTACACAGCAAAACAGGAGAGGTGTGCAAGTTTACTGACAGCACAC 3453

Db 3301 TGCCTGTAAGAGTGTACACAGCAAAACAGGAGAGGTGTGCAAGTTTACTGACAGTACTAC 3360

Qy 3454 AGGACGCTTTGTATGTTAGTGTGATCATGAGTATATAATCCCATATGCTCTAGGTACAGG 3513

Db 3361 AGGCGCTTTATGCTATGATGATCATGAGTACAGTATCCATATGTTTAGGTACAGG 3420

Qy 3514 ACNAGACACTAGTCTCAGAACTGCCCAATTTGGGTTTACTTTTCCCCCGCAGTATGCTTTA 3573

Db 3421 ACAGGATACCTTAGCCGCCAGAACTGCTATTTGGGTGTACTTTTCCCCCTCAATATGCTTA 3480

Qy 3574 CTTAAACAGTAGGTGAAGTAAACACACAGGAATTTTCAGGAGACACCAAAATTTGGCTAG 3633

Db 3481 TTTAACCGTGGAGATGTAAACACACAGGGAATTTTCAGGAGACAGTAAAGAGCTAGCAAG 3540

Qy 3634 TGAAGATCAGCTTTTATGTTGTAGACACAGTTTCATTTGAACTTTTGGGTACAGGGGG 3693

Db 3541 TGAAGATCAGCATTTTATGTTTGGAAACACAGTTTCATTTGAACTTTTGGGTACAGGTGG 3600

Qy 3694 ATCTGCCACTATGCTCAAAATTTCCAGCTGTGCCCGCAGAAACCTTAGAAGGTGCGAG 3753

Db 3601 CTCCTGCCACTATGCTCAAAATTTCCAGCTGTGCCCGCAGAAACCTTAGAAGGTGCTAG 3660

Qy 3754 CCAACATTTTATGAAATGTACAACTTTGTAGCTGTCTCTGTTAGGGGTACCTGACAC 3813

Db 3661 CCAACATTTTATGAAATGTACAACTTTGTAGCTGTCTCTGTTAGGGGTACCTGACAC 3720

Qy 3814 ATTAGGAGGGGACCTTAATTTTATGATCATGTGACACAGGAAGACCAAGCAATTTTCAGCCACA 3873

Db 3721 ACTAGGGGGGGACCTTAATTTTATGATCATGTGACACAGGAAGACCAAGCAATTTTCAGCCACA 3780

Qy 3874 AAACCTTTTATGCTGGGCGCACTTAATTTTATGATCATGTGACACAGGAAGACCAAGCAATTTTCAG 3933

Db 3781 AAACCTTTTATGCTGGGCGCACTTAATTTTATGATCATGTGACACAGGAAGACCAAGCAATTTTCAG 3840

Qy 3934 TACAGGTGCTGAAAGCCCTTACGGGCTTAGTACTGGCACTAGCCACTAGCCAAACACAGCAAT 3993

Db 3841 TACAGGTGCTGAAAGCCCTTACGGGCTTAGTACTGGCACTAGCCACTAGCCAAACACAGCAAT 3900

Qy 3994 TTCCCTAGCCCGGCGGCGAGTATCTCAGCCATACCATCCTGGGACACTGATAATATGT 4053

Db 3901 ATCCCTGCGCCGACGAGTGTCTCAGCCATACCATCCTGGGACACTGATAATATGT 3960

Qy 4054 TACAGGAATAAATGCCATTTTACATGGACAAACCACTTATGGAATGCTGAGGACAAAGA 4113

Db 3961 CACAGGAATAAATGCTATTTTACACGGACAAACCACTTATGGAATGCTGAGGACAAAGA 4020

Qy 4114 GTATCAGCAAGGGGTAGGAAGATTTTCCAAATGAAAAGAAACAGCTTAAAGCAGTTCAAGG 4173

Db 4021 GTATCAGCAAGGGGTAGGAAGATTTTCCAAATGAAAAGAAAGCACTTAAACAGTTTCAAGG 4080

Qy 4174 TCTTAACTATGACACATACCTTCCCTTAATAAAGAAACCCAACTACACAGACCAATTTGA 4233

Db 4081 CCTAAACATTTACATACCTTCCCAAAACAAAGAAACCCAACTACACAGATCAAAATTTGA 4140

Qy 4234 AGCCCTCTTATGCTGGGCTCTGTTTGGAAACAGAGAGCTTCTTCACTATGAAGTCAGCT 4293

Db 4141 AGCCCTCTTATGCTGGGCTCTGTTTGGAAACAGAGAGCTTCTTCACTATGAAGTCAGCT 4200

Qy 4294 GTGGAGTAAATCCCTAACTTAGATGACAGTGTAAAACTCAATTTGAGCCCTTAGGGGG 4353

Db 4201 GTGGAGTAAATCCCTAACTTAGATGACAGTGTAAAACTCAATTTGAGCCCTTAGGGGG 4260

Qy 4354 GTGGGTTTGCATCAACCAACCCCTCAATATTTTAAAAATACCTTACCAAAAGTGGGCC 4413

Db 4261 GTGGGTTTGCATCAACCAACCCCTCAATATTTTAAAAATACCTTACCAAAAGTGGGCC 4320

Qy 4414 AATTGGAGGTATTAATCCATGGGAATTTACTTCTTCAATATGCTGTGGGNAATAT 4473

Db 4321 AATTGGGAGTATTAATCCATGGGAATTTACTTCTTCAATATGCTGTGGGNAATAT 4380

Qy 4474 GACAGTTACCATGACCTTTAAATTTGGGACCTCGAAAGCTTACTGGAAGGTGGAATCCCCA 4533

Db 4381 GACAGTTACCATGACCTTTAAATTTGGGACCTCGTAAAGCTTACTGGAAGGTGGAATCCACA 4440

Qy 4534 GCCTGGCGTTTATCCTCTCATGCTGAGTGTGCTTACCATATGATCTGTATGACCCAC 4593

Db 4441 GCCTGGAGTGTATCCTCTCATGCTGAGTGTGCTTACCATATGATCTGTATGACCCCTAC 4500

Qy 4594 AGCTACAGATCAAAAGCAACACACAGACAGCGATATGAAAGCTTGAAGAAATTTGGTAC 4653

Db 4501 AGCTACAGATCAAAAGCAACACACAGACAGCGATATGAAAGCTTGAAGAAATTTGGTAC 4560

Qy 4654 TGCACAAAGCGGTGTGACCCCACTTTGTAAACATTCCTCCACCGTCTCAGCCAGGAACCG 4713

Db 4561 TGCACAAAGCGGTGTGACCCCACTTTGTAAACATTCCTCCACCGTCTCAGCCAGGAACCG 4620

Qy 4714 TCACCCACCGCCACCTGTGCGCCAGATTTATATGTGCCCTCCCAATACCCCGTAGGC 4773

Db 4621 TAAACCAACCGTCTCCTGTGACCCAGATTTATATGTGCCCTCCCAATACCCCGTAGGC 4680

Qy 4774 AACCATCTATAAAGATACAGACGCTGTAGAATAAATTTATTAACCTAGATATCAACAAC 4833

Db 4681 AACCGCTTGTAAAGATACAAATGCTGTAGAATAAATTTATTAACCTAGATATCAACAAC 4740

Qy 4834 ATGTAAATAGATGCTAAGATTTATTAATATGTATACACAGTTTGGAAAAATAAAGCCTT 4893

Db 4741 ATGTAAATAGATGCTTATGATTTGTATATATATACAAATTTGGAAAAATAAATAACTT 4800

Qy 4894 AAATAAATAATTCATAGTGTATGCTTCTTTAAAAATTTTCAAAA 4937

Db 4801 AAATAAATAATTCATAGTGTATGCTTCTTTAAAAATTTTAAAAA 4844

RESULT 7
AY044266
LOCUS
DEFINITION B19 virus isolate LaLi non-structural protein NS1 (NS1) gene, complete cds; and minor virus capsid protein VP1 (VP1) and major virus capsid protein VP2 (VP2) genes, partial cds.
ACCESSION AY044266
VERSION AY044266.1
KEYWORDS GI:15421202
SOURCE B19 virus
ORGANISM B19 virus

Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
1 (bases 1 to 4612)
Hokynar,K., Soderlund-Venermo,M., Pesonen,M., Ranki,A.,
Kiviluoto,O., Partio,E.K. and Hedman,K.
A new parvovirus genotype persistent in human skin
Virology 302 (2), 224-228 (2002)
22329669
MEDLINE
PUBMED
12441066
2 (bases 1 to 4612)
Hokynar,K., Soderlund-Venermo,M., Ranki,A. and Hedman,K.
Direct Submission
TITLE
Submitted (09-JUL-2001) Dept. of Virology, Univ. of Helsinki, POB
21 (Haartmaninkatu 3), Helsinki 00014, Finland
FEATURES
Location/Qualifiers
1. .4612
/organism="B19 virus"
/mol_type="genomic DNA"
/isolate="Lali"
/db_xref="taxon:10798"
/note="similar to the sequence deposited in GenBank
Accession Number M13178
genotype: K71"
285. .2300
/gene="NS1"
285. .2300
/gene="NS1"
/note="multifunctional"
/codon_start=1
/product="non-structural protein NS1"
/protein_id="AAK95570.1"
/db_xref="GI:15421203"
/translation="MELFRGLHISNILDANDNWCMSMLDLDTSDBEPLTHSNRLM
AIVLSNVASKLDTFGPGLAGCLYFFQVGCNKFEGYIHVVIIGPGINARNLTVCEG
LFNNLVHLVNGNKLFLPGLMGTGKYFRDGEQFTEYLMKKIPLNVVVCVNTIDGY
IDICIASFRGACHAKPRI SANTITVANNEAGESCGGVDVVPFAGKGTAGLKEQT
MNSDFRQVTCIKENKVLDFNQITLSSHSQSFOI QSKALAIATKALNLPSTFPL
TNLMAIAKTPVYGVNWNENPFNDVAGSLVWDEGIIKSTTVEAAKAILGQGP
TRVDQMRGSVAVGPVVTITNSGDIITFVSGNTTTHAKALKERMKLNFTRGSP
DMGLLEADVOQMLWCNAQWNHYENWAI NYTFDPGINADALHPDLQTVPIVADTS
VSSGGSESELSSEFFNLITPGANNSETPSPTVPGTSSGESVGSFVSSEVAA
SWEAEFTPLADQFRELIVGVDVWVGRLPVCCVQHINSGGGLGCLPHCINVGAM
YNGWKREFTPLDVRCSCHVGASNPFSVLTKCKCAYLSGLQSPVDYE"
2293. .>4612
/gene="VP1"
2293. .>4612
/gene="VP1"
/note="structural protein"
/codon_start=1
/product="minor virus capsid protein VP1"
/protein_id="AAK95571.1"
/db_xref="GI:15421204"
/translation="MSKESKWESEDDKRAKDVYKQVVEFYKVVCTDLELIQDKH
YNSLDNPLENPSLDFLVAIKSNLKDSPDLXSHFQSHQSLSDPHALSSSSITE
PRGENAVLSEEDLHKQGVSIQLPGTNYGPNELQAGPPQSAVDSAAKHIDFVRSOL
AKLGINPTWDBELKNIKNETQFAQVKDYFTLKGAAAPVAHFQGSLEPYPA
YNASEKYPVSNSAEASTGAGGSGNPVKMSSEGAFTANSVTCFSRQPLIYD
PEHYKVFSPPAASSCHNASKAEKVCVTISPIMGYSTPWRVLDNFALNLFESPLEFOHL
IENYGIAPDALVITISEIAVKDVTDKTGGGVQVDTSTTGRCLMLVDHYEYKYPVLQ
QDTLAPELFIPVFPFQYALTVGDNVTQISGDSKKLASBESAFVLEHSFELLG
TGSATMYKFPVPVPPENLEGSCQHFYEMNPLYGSRVLPVDTLGGDPKFRSLTBEDH
AIQPNFMPGPNLVNSVTKEGDTNTGAGKATLGLSTGTSQSTRISLRPGVSPYHH
WDTKVVTGINALSHGQTTVYNAEDKEYQGVGRFNEKEQLKQLGNIHTYFNKQ
TQOYTDQIERPLMVGSVNNRRALHYESQLWSKIPNLDSDSKFTQFAALGGMGLHPPQ
IFKLILPQSGPIGGIKSMGITTLVQYAVGIMVTMTFKLGRKATGRWNPQGVPPH
AAGLHPVLYDPTATDAKQHRHGYEKPEBLWT"
2974. .>4612
/gene="VP2"
2974. .>4612
/gene="VP2"
/note="structural protein"
/codon_start=1
/product="major virus capsid protein VP2"

/protein_id="AAK95572.1"
/db_xref="GI:15421205"
/translation="MTSVNSAEASTGAGGSGNPVKMSSEGAFTANSVTCFRQF
LIPYDPEHYKVFSPPAASSCHNASKAEKVCVTISPIMGYSTPWRVLDNFALNLFESPL
EFOHLIENYGIAPDALVITISEIAVKDVTDKTGGGVQVDTSTTGRCLMLVDHYEYKYP
YVLGQQTDLAPELFIPVFPFQYALTVGDNVTQISGDSKKLASBESAFVLEHS
FELLGTGGSATMSPFPVPPENLEGSCQHFYEMNPLYGSRVLPVDTLGGDPKFRSL
THEDHAIQPNFMPGPNLVNSVTKEGDTNTGAGKATLGLSTGTSQSTRISLRPGVGS
QPNKHTQOYTDQIERPLMVGSVNNRRALHYESQLWSKIPNLDSDSKFTQFAALGGMGLH
OPPOIFLKLILPQSGPIGGIKSMGITTLVQYAVGIMVTMTFKLGRKATGRWNPQGV
VYPPHAAAGLHPVLYDPTATDAKQHRHGYEKPEBLWT"
ORIGIN
Query Match 78.4%; Score 3941.8; DB 14; Length 4612;
Best Local Similarity 91.0%; Pred. No. 0;
Matches 4200; Conservative 0; Mismatches 412; Indels 1; Gaps 1;
QY 43 GAAGTCCCGCTACCGGCGGCGACCGGCGCATCTGATTTGGTGTCTCTTTTGAAT 102
DB 1 GAAGTCCCGCTACCGGCGGCGACCGGCGCATCTGATTTGGTGTCTCTCTTTTGAAT 59
QY 103 TTGGCGGGCTTTTCCCGCTTATGCAATAAGCGCCCATGTTTAAATGTTTAAAT 162
DB 60 TCGCGGGCTTTTCCCGCTTATGCAATAAGCGCCCATGTTTAAATGTTTAAAT 119
QY 163 TTAAATGGACAAACCGCTAAACGGTTACTAGGCGCGGAGTTACGGCGGTATATAACGAGC 222
DB 120 TTGATTTGGACAAACCGCTAAACGGTTTATGCGGAGTTACGATGTTATATAACGAG 179
QY 223 TCGGTTCCCTGACACCTTTCTTTCTGGTGTCTTTTGAACCTGCACTTGTCTGTTCTTT 282
DB 180 TGAATTTCTGACAACTTTCTTTCTGGTGTCTTTTACTGGGAATAAATCTGCTGTTATTT 239
QY 283 GCCTGTAGTAAACAGGTATTTTACTAACTTTTAAATTTTAACTAACTGAGGTATTTCCG 342
DB 240 GCGTCTAAATTAACAGGTATTTTATACTAACTTTTAAATTTTAACTAACTGAGGTATTTAG 299
QY 343 GGTGTCTTCCACATTTCTCTCAACATTTCTGACTGTGCTAAATGATAAATCTGCTGCTCT 402
DB 300 GGTGTGTGCTATTTCTCTCAACATTTTAGACTGGCTTAATGATAAATCTGCTGCTCT 359
QY 403 ATGCTAGACTTAGATACTTCTGACTGGGAACCACTAAACCATTTCTAAACAGATTAATGGCA 462
DB 360 ATGCTGATTTAGATACTTCTGACTGGGAACCACTAACTCACTCTAAACAGATTAATGGCA 419
QY 463 ATATATTTAAAGCAGTGTGCTTTCTAACTTTGATTTTACTGGGCGCGCTAGCAGGTGCG 522
DB 420 ATATATTTAAAGTAAATGTTGCTTTCTAACTTAGATTTTACTGGGCGCGCTAGCAGGTGCG 479
QY 523 TTATATCTTTTTCAGGTGGAATGTAAACAAATTTGAGGAAGGCTATCATATCATGTAGTT 582
DB 480 TTATATTTTTCAGGTGGAATGTAAACAAATTTGAGGAAGGCTATCATATCATGTAGTT 539
QY 583 ATTGTGTGTCAGGACTAAATGCTAGAACTTAACTGTGTGCGTAGAAGTTTATTTAAT 642
DB 540 ATTGTGTGTCAGGACTTAAATGCTAGAACTTAACTGTGTGCGTAGAAGTTTATTTAAT 599
QY 643 AATGTTCTTTTACATCTGTTACTGAACTGTTTAACTTTAAATTTTTCGAGGAGTACT 702
DB 600 AATGTTCTTTTACATCTGTTACTGAACTGTTTAACTTTAAATTTTTCGAGGAGTACT 659
QY 703 ACCAAGGAAATATTTTAGAGATGAGAGAGTATTTATAGAAATTTACTTAAATGAAAAA 762
DB 660 ACTAGGGAAGATTTTATAGATGGAGAACAGTTTATAGAAATTTACTTAAATGAAAAA 719
QY 763 ATTCTCTTTAAATGTTGT 822
DB 720 ATTCTCTTTAAATGTTGT 779
QY 823 TCGGCTCTTTTCGCGGAGGAGCTTGTCTATGCTATAAAGACCCCGGCTTACTGCAATACA 882
DB 780 TCTGCTATCTTTTAGACGAGGAGCTTGCCTATGCTATAAAGACCCCGGCTTACTGCAATACA 839

QY	883	GACAGTGTCTAATGAACTGGGAGTCTAGCTGTGGAGGGGAGATGTTGTGCCATTC	942
Db	840	GACACTGTTAATAATGAAGCCGGGAATCAAGCTGTGGAGGGGAGATGTTGTGCCATTC	899
QY	943	GCTGAAAGGGAACAAAGCGGGGTAAAGTTTCAAAACCATGGTAAATTCGCTATGTGAA	1002
Db	900	GCAGAAAGGGAACAAAGCGGGGTAAAGTTTCAAAACCATGGTAAATTCGCTATGTGAA	959
QY	1003	AACAGATATTCTAGAGATAAATGAATAGTGAATTTAAACCAATATATCTTTATTA	1062
Db	960	AACAGATGTTTCTAGAGACAAATGAAGTTAGTGAAATTTCAATCAATATATCAATTA	1019
QY	1063	AGTAGAGTCAAGTGGCAGCTTTCAAAATCAAAAGTCCCTTAAAGTTAGCTATTTATTA	1122
Db	1020	AGCAGTAGTCATAGTGGAGTTTCAATCAAAAGTCAATTAAGCTAGCTATTTATTA	1079
QY	1123	GCTACTAACTTAGTACCCTAGTACATCTCTGTGTTCAATTCAGACTTTGAGCAGGTACT	1182
Db	1080	GCTACTAACTTAGTACCCTAGTACATCTCTGTGTTCAATTCAGACTTTGAGCAGGTACT	1139
QY	1183	TGCATTAAAGAAATAAAATAGTAAATTAATTTGTTGTCAAAACCTATGATCTCTTTTA	1242
Db	1140	TGCATTAAAGAAATAAAATAGTAAATTAATTTGTTGTCAAAACCTATGATCTCTTTTA	1199
QY	1243	GTGGGTCAACATGTTTAAAGTGGATTGACAAAAAATGTGGTAAAAAAACACCTGTGG	1302
Db	1200	GTGGGTCAACATGTTTAAAGTGGATTGACAAAAAATGTGGTAAAAAAACACCTGTGG	1259
QY	1303	TTTTACGGGCCACCAAGTACTGCAAAAACAAATTTGGCAATGCTATTCGTAACCTGTA	1362
Db	1260	TTTTACGGGCCACCAAGTACTGCAAAAACAAATTTGGCAATGCTATTCGTAACCTGTA	1319
QY	1363	CCAGTGTATGGAATGTGTAATGGAATAATGAAAACTTTCCATTTAATGATGTAGCGGG	1422
Db	1320	CCAGTGTATGGAATGTGTAATGGAATAATGAAAACTTTCCATTTAATGATGTAGCGGG	1379
QY	1423	AAAAGTTTGGTGTCTGGGATGAAGCAATTAATTAAGTCCAATTTGTGGAAGCTGCAAAA	1482
Db	1380	AAAAGTTTGGTGTCTGGGATGAAGCAATTAATTAAGTCCAATTTGTGGAAGCTGCAAAA	1439
QY	1483	GCCATTTTAGTGTGCTCAGCCAAACCGGTAGATCAGAAAATCGGTGGCAGTGGCAGTG	1542
Db	1440	GCCATTTTAGTGTGCTCAGCCAAACCGGTAGATCAGAAAATCGGTGGCAGTGGCAGTG	1499
QY	1543	CCGGTGTGCTGTGTTTAAACCAAGCAATGTGACATTAATTTGTTGTGAGTGGTAAT	1602
Db	1500	CCTGTGTGCTGTGTTTAAACCAAGCAATGTGACATTAATTTGTTGTGAGTGGTAAT	1559
QY	1603	ACCACCTACAACTGTGATGCTAAAGCCTTAAAGGAAGGATGGTAAAGCTAACTTTTACC	1662
Db	1560	ACCACCTACAACTGTGATGCTAAAGCCTTAAAGGAAGGATGGTAAAGCTAACTTTTACC	1619
QY	1663	ATAAGATGTAGCCCTGACATGGGTTTACTTTACAGAGGCTGTATCAACCAATGGCTAACT	1722
Db	1620	ATAAGATGTAGCCCTGACATGGGTTTACTTTACAGAGGCTGTATCAACCAATGGCTAACT	1679
QY	1723	TGGTGTAAATGCAAAAGCTGGAGCCACTATGAAAATCTGGGCAATAAATCAACATTTGAT	1782
Db	1680	TGGTGTAAATGCAAAAGCTGGAGCCACTATGAAAATCTGGGCAATAAATCAACATTTGAT	1739
QY	1783	TTCCCTGGAAATAATGACAGTCCCTCCACCCAGATCTCCAAACCAACCCCAATTTGTCCA	1842
Db	1740	TTCCCTGGAAATAATGACAGTCCCTCCACCCAGATCTCCAAACCAACCCCAATTTGTCCA	1799
QY	1843	GACACAGTATCAGCAGCAGTGGTGTGAAAGCTCTGAAAGCACTCAGTGAAGCAGCTTTT	1902
Db	1800	GACACAGTATCAGCAGCAGTGGTGTGAAAGCTCTGAAAGCACTCAGTGAAGCAGCTTTT	1859
QY	1903	TTCAACCTCATCATCTCCAGCGCCCTGGAAACAGTGAACCCCGCGCTCTAGTACGCCCGTC	1962
Db	1860	TTCAACCTCATCATCTCCAGCGCCCTGGAAACAGTGAACCCCGCGCTCTAGTACGCCCGTC	1919

QY	1963	CCGGGACAGTTTCAGGAGAAATCATTTGTGCGAAGCCAGTTTCTCCGAAAGTGGTAGCC	2022
Db	1920	CCGGGACAGTTTCAGGAGAAATCATTTGTGCGAAGCCAGTTTCTCCGAAAGTGGTAGCC	1979
QY	2023	GGGTCTGTGGAGGAGAGCTTTTACACGCGCTTTCGCGATCAGTTTCTGCGAACTGTTAGTA	2082
Db	1980	GGGTCTGTGGAGGAGAGCTTTTACACTCACTTCAGACCAAGTTTCTGCGAACTGTTAGTT	2039
QY	2083	GGGTTGACTTTGTATGGGATGGTGTGAGGGGATTCCTGTTTGTGTGTGTGGAACATATA	2142
Db	2040	GGGTTGACTTTGTATGGGATGGTGTGAGGGGATTCCTGTTTGTGTGTGTGAGCAGATAT	2099
QY	2143	AACAACAGTGGGGAGGGTTCGGGCTTTCCTCAATGTATTAATGTGGAGCTTTGGTAT	2202
Db	2100	AATAATAGTGGGGAGGGTTCGGGCTTTCCTCAATGTATTAATGTGGAGCTTTGGTAT	2159
QY	2203	AATGGATGGAATTTAGAGAGTTTACTCCAGACTTTAGTGGCTGCGCTGCGATGTGATGAGA	2262
Db	2160	AATGGATGGAATTTAGAGAGTTTACTCCAGACTTTAGTGGCTGCGCTGCGATGTGAGA	2219
QY	2263	GCCTCTAACCCATTTTCTGTGTAACTTTGTAATAAATGTGCTTACTGTCTGGATTAACA	2322
Db	2220	GCCTCTAACCCATTTTCTGTGTAACTTTGTAATAAATGTGCTTACTGTCTGGATTAACA	2279
QY	2323	AGTTTGTAGATTATGAGTAAAAACCACTAAACAAATGGTGGGAAAGCACTGCAAAATTTGC	2382
Db	2280	AGTTTGTAGATTATGAGTAAAAAGTGTAAATGGTGGGAAAGTGAATTAATTTGC	2339
QY	2383	CCAGGACGTGTATTAAGCAGTTTGTGCAATTTTATGAAAAAGCTACTGGAAACAGACTTAGA	2442
Db	2340	TAAGGATGTATTAAGCAATTTGTAGAAATTTTATAAAAAAGTTACTGGGACAGACTTAGA	2399
QY	2443	GCTTATTTCAAAATTTTAAAGACCAATTAACAATTTCTTTAGATAATCTTTAGAAAAACC	2502
Db	2400	GCTTATTTCAAAATTTTAAAGACCAATTAACAATTTCTTTAGATAATCTTTAGAAAAACC	2459
QY	2503	CTCTTTTATTTGACTTTAGTTGCTCGCATTTAAAGTAATCTTTAAAGTAATCTTCAGACCT	2562
Db	2460	ATCTTCCCTGTTGACTTTAGTTGCTCGTATTTAAAGTAATCTTTAAAGTAATCTTCAGACCT	2519
QY	2563	ATATAGTCACTATTTTACAGCCATGACAGTATCTGACCAACCCCACTGCTTATCATC	2622
Db	2520	ATATAGTCACTATTTTCAAAAGTCAAGCAGTATCTGACCAACCCCACTGCTTATCATC	2579
QY	2623	CAGTAAACAGTAGTGTGAGAACCTAGAGGAGAAATGCAATTTATCTAGTGAAGCTTACA	2682
Db	2580	CAGTAAACAGTAGTGTGAGAACCTAGAGGAGAAATGCAATTTATCTAGTGAAGCTTACA	2639
QY	2683	CAAGCTGGGCAAGTTAGCATACAATTAACCGGTPACTAACTATGTTGGGCTGGCAATGA	2742
Db	2640	CAAGCTGGGCAAGTTAGCATACAATTAACCGGTPACTAACTATGTTGGGCTGGCAATGA	2699
QY	2743	GCTAACAGCTGGGCTCGCAGAAATGCTGTGGAAGTGTGCAAGGATTCATGCTTTAG	2802
Db	2700	GCTAACAGCTGGGCTCGCAGAAATGCTGTGGAAGTGTGCAAGGATTCATGCTTTAG	2759
QY	2803	GTAATGCAATTTGGCTAAAGTTGGGAATAAATCTTTATACACTTTGGACGGTAGCAGATGA	2862
Db	2760	GTAATGCAATTTGGCTAAAGTTGGGAATAAACCCTATCTCTAGTGTAGCAGATGA	2819
QY	2863	AGAAATTTTAAATAAATAAATAAAGAAACAGGGTTTCAAGCAACAGCAGTAAAGATTA	2922
Db	2820	AGAAATTTTAAATAAATAAATAAAGAAACAGGGTTTCAAGCAACAGCAGTAAAGATTA	2879
QY	2923	CTTTTACTTTTAAAGGTGACGCTCCCTGTGGCCCAATTTTCAAGGAAGTTTACCGGAAGT	2982
Db	2880	CTTTTACTTTTAAAGGTGACGCTCCCTGTGGCCCAATTTTCAAGGAAGTTTACCGGAAGT	2939
QY	2983	GCCCGGTACAAACGCTCAGAAAAATACCCAGCAGTACTTCAAGTTAACTCTGCGAAGC	3042
Db	2940	TCCCGCATCAACGCTCAGAAAAAGTACCCAGCAGTACTTCAAGTTAACTCTGCGAAGC	2999
QY	3043	CAGCACTGGTGCAGGGGGGAGGTAGCAACCCCTCAAAAAAGCATGTGGAGTGAAGGGC	3102

Db	3000	 CAGCAC	 TGGTGC	 AGCATG	 TGGAGT	 GAGGGG	 CAGGGG	 GGGGGC	3059																					
Qy	3103	TACATTT	TACTGCT	TAATTT	CTGTAA	CGTGTA	CAATTT	CTCTAGG	CAATTT	TAATTT	CCATATGA	3162																		
Db	3060	CACTTT	TACTG	CCCAAT	CTGTAA	CACTTT	CTCAG	CAGATG	TTTAA	TTTAA	TTTCCATATGA	3119																		
Qy	3163	TCCAG	AGCATC	ATTAT	AAAGT	TTTCT	CTC	CAGCAG	CTAGT	AGTGC	CACAATG	CTAGTGG	3222																	
Db	3120	CCCAG	AGCAC	CCATT	ACAAG	TGTTTT	CT	CCGCG	AGCT	TAGT	AGTGC	CAATTAATGCC	AGTGG	3179																
Qy	3223	GAAGA	GGCAAA	AGTG	GCAC	TATTA	GT	CCCAT	TAT	TGGGG	TACT	CT	TACT	CCGTGG	AGATA	3282														
Db	3180	AAAAG	GGCAAA	AGGT	TTTGC	ACTAT	T	AGT	CCCAT	TAAT	GGGCT	TACT	CA	CAC	CAC	ATGG	AGATA	3239												
Qy	3283	CTTAG	ATTT	TAAT	CTTT	TAAT	TTT	TCT	CAC	CAAT	TAGAG	TTT	CAG	CAC	CTT	AA	TTGA	3342												
Db	3240	CTTAG	ACTTT	TAAT	AGCTTT	TAAT	TTT	TCT	CAC	CTTT	TAGA	TTT	C	CA	CA	TTT	AA	TTGA	3299											
Qy	3343	AAAT	TAT	GGT	AGT	ATAG	CT	CCAG	TGCT	TTAA	CT	TAA	CT	ATTT	C	GA	AA	TT	CTGT	TA	3402									
Db	3300	AAAT	TAT	GG	AA	GTAT	AG	CCCT	GT	AT	AA	CT	GT	T	AA	CC	AT	AT	CAG	AG	AT	TGCT	GT	TA	3359					
Qy	3403	AGAT	GT	CA	CA	GA	CA	AAAA	CAG	AG	AG	GT	GT	GC	AA	GT	T	ACT	GA	CA	CA	CC	CA	CA	GA	CA	GT	TTT	3462	
Db	3360	AGA	CGTT	TAC	GA	CA	CA	AAAA	CAG	AG	AG	GGG	GT	GC	AG	GT	T	ACT	GA	CA	GT	ACT	GA	CA	GG	GG	GG	TTT	3419	
Qy	3463	GTG	TAT	CT	GT	AGT	GC	AT	CAT	AGT	ATA	AA	T	AC	CC	AT	T	GT	CT	AG	GT	CAG	GG	CA	CA	GA	CAC	3522		
Db	3420	ATG	CA	T	GT	T	AGT	AT	CAT	GA	GT	ACA	AGT	AC	CC	AT	T	GT	T	AG	GT	CAG	GG	CA	GG	AT	AT	3479		
Qy	3523	ACT	AG	CT	CC	CA	AA	CT	GT	GGG	TTT	ACT	TTT	CCCC	CCCC	CAG	TAT	GC	TT	T	ACT	TT	AA	CAGT	3582					
Db	3480	CTT	AG	CCCC	CA	GA	CT	GC	CT	ATTT	GGG	TG	TACT	TTT	CCCC	CT	CA	T	AT	GC	TT	TT	TA	CAGT	3539					
Qy	3583	AGT	GA	AGT	TA	AA	CA	CA	AA	GGAA	TTT	CA	GA	GA	CAG	CA	AAAA	TT	TG	CT	AGT	GA	GA	AT	3642					
Db	3540	GGG	AG	AT	GT	TA	AA	CA	CA	AGG	AA	TTT	CA	GA	GA	CAGT	AAAA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	3599	
Qy	3643	AGC	TTT	TAT	GT	GT	TAG	AG	CA	CA	GT	TT	CA	TT	T	GA	CT	TT	T	CG	GT	TAC	AGG	GG	AT	CT	CC	CA	3702	
Db	3600	AGC	AT	TT	TAT	GT	TTT	T	GA	AA	CA	CA	GT	TT	CA	TT	T	GA	AA	CT	GT	T	AG	GT	CAG	GT	CT	CC	CA	3659
Qy	3703	TAT	GT	CT	CA	AAA	TTT	CC	AG	CT	GT	GG	CCCC	CC	CA	AAAA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	3762
Db	3660	TA	GT	CT	TA	AA	TTT	CCA	CA	AG	CT	GG	CC	CC	CA	AAAA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	AA	3719
Qy	3763	TTAT	GA	AA	AT	GT	ACA	CC	CTT	TG	T	AC	GGT	TT	CT	CG	TT	T	AG	GG	GT	AC	CT	GA	CA	CA	TT	AG	AG	3822
Db	3720	TTAT	GA	AA	AT	GT	ACA	CC	CTT	TG	T	AC	GGT	TT	CT	CG	TT	T	AG	GG	GT	AC	CT	GA	CA	CA	TT	AG	AG	3779
Qy	3823	GGAC																												

LFNNVLYHLVENVKLPFLPGMTTKGKPRDGEQFIENVLMKKIPLNVVWCVNIDGY
IDTCIATFRGACHAKPRIITTAINDTSSDAGESSCTGAEVPPNGKGTAKSIKQI
MNNLCENRVFTEDKWLVDENQYTLTSSSHSGSQIQSALKALILYKATNLPVPTSTEL
LHTDFQVNCIKDKIKVLLLCQNDPLLVGHQVHLWIDKKCKKNTLWFYGPSTGK
TNLAMAIAKSPVPGMNVNENPFNDVAGSLVWDEGIIKSTIVEAAKAILGGOP
TRVDQMRGSAVPGVPPVITVTSNGDITFVSGNTTIVHAKALKERVMKLNFTVRCSF
DMGLUTADVQWLTWCNAQSDWHDYENWAINVTFDFPCINADALHPDLQTPPIVTDNIS
ISSGGSESELESSESFNLIPTGAMNTEPRSSPIPTSGSSGVSGSPVSSVRAA
SWEEAFYPLADQFRELVLGVVDYVWVGRLPVCCVQHINNSGGGLGCHPCINVGAM
YNGWFRFBPTDPLVRCSCHVGASNFPVSLTKCKAYLSGLQSFVDYE"
2401..4746
/codon_start=1
/product="capsid proteins vp"
/protein_id="CAA92270.1"
/db_xref="GI:1103617"
/db_xref="GOA:O85117"
/db_xref="SPTREMBL:O85117"

CDS

/translation="MSKESGKWESDDKFAKAVIQQVFEYKVTGDTLLELIQILKDH
YNSILDNPLENPSFLDLVARIKNLNKNSPLYSHPHQSHQSLSDHPHALSSSSSHAE
PRGEDAVLSSDHLKPGQVQLPNTNNGVGNELQAGPQSAVDSARLHDPYRSL
AKLGINPTHTWADBEILLKNIKNETGFQAVVNDYFTLKGAAAPVAHFQGSIPYPA
YNASEKPSMTSVASAEATGAGGSGNPVKSMMSEGAFTSANSVTCFTSRQPLIIPYD
PEHYKVPSPAASCHNAGKEAKVCTISPTMGVSTPRWYLDNFALNLPSPLEFQHL
IENYGSIPADLTWTISIAVKQVDTKGTGGVQVDTSTIGRLCMLVDHEYKYPYVIGQ
GQDTLAPLPTVWVPPQYAYLVTDVNTQISGSKLASSESAFVLEHSSFOLLG
TGSTATMSKYPFPVPPENLEGCQSHFYEMNPLYGSLRGVDPDTLGGDPKFRSLTHEDH
ALQFQNFMPGLVNSVSTKGSQNTGAGKALTLSTGTSQNTRIQLRPGVPSQPVYH
WDTKYVYTGNAISHGQTYTGNADKEYQGVGRFNEKEOLQOLGNWHYFPPNKG
TQOYTDQIERPLMGVNNRRALHYESQLSKIPNLDDSPKTOPALGNGWGLHQPDPQ
IFLKLIPQSGPIGGIKSMGITLVOVAVGIMVTMTFKLGPRAKATGRWNPQGVVPPH
AAGHLPVLYDPTADAKQHRHGYEKPBEELWAKSRVHPL"

ORIGIN

Query Match 77.3%; Score 3888.4; DB 14; Length 5156;
Best Local Similarity 86.2%; Pred. No. 0;
Matches 4340; Conservative 0; Mismatches 686; Indels 10; Gaps 3;
1 GACGTACAGGAATGACGTAACTGTCGGCATCTGTACCGGAAGTCCGCTACCGGC 60
59 GACGTACAGGAATGACGTAACTGTCGGCATCTGTACCGGAAGTCCGCTACCGGC 118
61 GCGACCGCGGCATCTGATTGCTCTCTTTTGAATTTGCGGGCTTTTCCGC 120
119 GCGACCGCGGCATCTGATTGCTCTCTCTTTTGAATTTGCGGGCTTTTCCGC 177
121 CCTTATCAATTAAGCGGCATCTTAAATGTTATATTTAAATTAATGACAAACGCT 180
178 CCTTATCAATGCGGCGCATCTTAAATGTTATATTTAAATTTGCTCAGTTTGT 237
181 AACGGTTACTAGGGCGGAGTTACGG-----GCGGTATATAAGCAGCTCGCTTCCCT 232
238 AACGGTTAAATGCGGCGGAGCTAGCGGGGACTACAGTATATATAGCAGCACTGCGC 297
233 GACACTTCTTCTCGGTGCTTTGACTGGAACCTCACTGCTGTTCTTTGCTGCTTAAG 292
298 CAGCTCTTCTTCTCGGTGCTTTTCTCGGACTTCTTCTGCTGTTTCTTCTGAGCTAAC 357
293 TAAACAGTTATATATCTTAACTTTAACTTAACTAATGAGCTATTTGCGGTGCTTTCG 352
358 TAAACAGTTATATATCTTAACTTTAACTTAACTAATGAGCTATTTGAGGGGTGCTTC 417
353 ACATTTCTCTAACATTTCTGACTGCTGCTAATGATAAATGCTGGTGTCTCTATGCTAGCT 412
418 AAGTTTCTTCTAATGTTCTGAGCTGCTGCTTAAAGATAAATGAGCTATTTAGGGGTG 477
413 TAGATACTTCTGACTGGGAACCACTAACCCATCTTAACAGATTAATGGCAATATATTAA 472
478 TAGACACTTCTGACTGGGAACCACTAACCTAATGAGCTAATGGCAATATATTAA 537
473 GCAGTGTGCTTCTAACTGATTTTACTGCGGGGCGGCTAGCAGGTGCTTATACCTTTT 532
538 GCAGTGTGCTTCTAAGCTTGAATTTTACCGGGGCGGCTAGCAGGTGCTTATCTTTT 597

1678 DB CTGTACATGCTAAAGCCTTAAAGAGCGCATGCTGTAAGTTAAACTTTTACTGTAAAGTGCA 1737
1673 QY GCCTTGACATGGGTTTACTTTACAGAGCGCTGATGTACAACTAACTGCTTAACTTGGTGTAAATG 1732
1738 DB GCCTTGACATGGGTTTACTTAAAGAGCGCTGATGTACAACTAACTGCTTAACTTGGTGTAAATG 1737
1733 QY CACAAAGCTGGAGCCACTATGAAGAACTGGGCAATAAACTACACATTTGATTTCCCTGGAA 1792
1798 DB CACAAAGCTGGAGCCACTATGAAGAACTGGGCAATAAACTACACATTTGATTTCCCTGGAA 1857
1793 QY TAAATGAGATGCGCTCCACCCAGATCTCCAAAGCAGCCCGCTTGTCCAGACACACAGTA 1852
1858 DB TTAATGAGATGCGCTCCACCCAGATCTCCAAAGCAGCCCGCTTGTCCAGACACACAGTA 1917
1853 QY TCAGCAGCAGTGGTGGTGAAGCTCTGAAGAACTCAGTGAAGCAGCTTTTTCACACTCA 1912
1918 DB TCAGCAGCAGTGGTGGTGAAGCTCTGAAGAACTCAGTGAAGCAGCTTTTTCACACTCA 1977
1913 QY TCACCTCAGCGCGCTGGAAACAGTGAACCCCGCGCTCTAGTACGCGCGCTCCCGGGACCA 1972
1978 DB TCACCCAGCGCGCTGGAAACAGTGAACCCCGCGCTCTAGTACGCGCGCTCCCGGGACCA 2037
1973 QY GTTCAGAGAAATCATTTGTGCGAAGCCAGTTTCTCCGAAAGTGGTAGCGCGCTGTGGG 2032
2038 DB GTTCAGAGAAATCATTTGTGCGAAGCCAGTTTCTCCGAAAGTGGTAGCGCGCTGTGGG 2097
2033 QY AGCAAGCTTTTACAGCGCGCTTGGCGATCAGTTCGTAAGCTTGTAGTGGGTTGACT 2092
2098 DB AGCAAGCTTTTACAGCGCGCTTGGCGATCAGTTCGTAAGCTTGTAGTGGGTTGACT 2157
2093 QY TTCTATGGGATGCTGTGAGCGGATTTGCTCTTTGCTGTGTGGAACTATATAACACAGTG 2152
2158 DB ATGCTGGGAGCGTGTAAAGGGTTTACCTGTGTGTGTGGCAATATTAACATAGTG 2217
2153 QY GGGAGGGTTGGGCTTTGGCCCTCAATGTATTAATGTGGAGCTTGGTATATGAATGGA 2212
2218 DB GGGAGGGTTGGGCTTTGGCCCTCAATGTATTAATGTGGAGCTTGGTATATGAATGGA 2277
2213 QY AATTTAGAGATTTACTCCAGACTAGTGGCGCTGAGTGTCTGATGTAGGAGCTCTTAAC 2272
2278 DB AATTTAGAGATTTACTCCAGACTAGTGGCGCTGAGTGTCTGATGTAGGAGCTCTTAAC 2337
2273 QY CATTTTCTGTGTAACTGTGTAATAAATGCTCTTACCTGTCTGATGTACAAAGTTTGTAG 2332
2338 DB CCTTTTCTGTGTAACTGTGTAATAAATGCTCTTACCTGTCTGATGTACAAAGCTTGTAG 2397
2333 QY ATTATGAGTAAACCACTAAACAAATGGTGGGAAAGCAGTGAACAAATTTGCCAGGCGTG 2392
2398 DB ATTATGAGTAAACCACTAAACAAATGGTGGGAAAGCAGTGAACAAATTTGCCAGGCGTG 2457
2393 QY TATAAGCAGTTTGTGCAATTTTATGAAGAACTGCTGGAACAGCTTAGGCTTATTTCAA 2452
2458 DB TATCAGCAATTTGTGGAAATTTTATGAAGAACTGCTGGAACAGCTTAGGCTTATTTCAA 2517
2453 QY AATTTAAAGACCAATTAACAACTTTCTTTAGATAAATCTTTAGAAAACCCCTCTCTTTA 2512
2518 DB ATATTAAGAGATCATTAATAATTTCTTTAGATAAATCTTTAGAAAACCCCTCTCTTTG 2577
2513 QY TTTGACTTGTGCTGCATTAAGAAATGTAATCTTAAAGAACTCTCCAGACCTATATAGTCAT 2572
2578 DB TTTGACTTGTGCTGCATTAAGAAATGTAATCTTAAAGAACTCTCCAGACCTATATAGTCAT 2637
2573 QY CATTTTCAGAGCCATGGACAGTTATCTGACCAACCCCGCTTATCATCCAGTAACAGT 2632
2638 DB CATTTTCAGAGCCATGGACAGTTATCTGACCAACCCCGCTTATCATCCAGTAACAGT 2697
2633 QY AGTGCAGAACTAGAGAGAAATGCAATATCTAGTGAAGCTTACACAGACCTGGG 2692
2698 DB CATGCAGAACTAGAGAGAAATGCAATATCTAGTGAAGCTTACACAGACCTGGG 2757
2693 QY CAAAGTTAGCATACAATTTACCCGCTACTAATATGTTGGGCTGGCAATGAGCTTACAAGCT 2752

2758 DB CAAAGTTAGCATACAACTACCCGCTACTAACTATGTTGGCGCTGGCAATGAGCTTACAAGCT 2817
2753 QY GGGCGCTCCCGCAAGATGCTGTGACAGTGTCTGCAAGGATTCATGACTTTTAGGTATAGCCAA 2812
2818 DB GGGCGCTCCCGCAAGATGCTGTGACAGTGTCTGCAAGGATTCATGACTTTTAGGTATAGCCAA 2877
2813 QY TTTGGCTAAGTTTGGGAATAAATCCTTATACAAATTTGGAACGGTAGCAGATGAAGATTTGTTA 2872
2878 DB CTGGCTAAGTTTGGGAATAAATCCTTATACAAATTTGGAACGGTAGCAGATGAAGATTTTAA 2937
2873 QY AAAAAATATAAAAAATGAAGCTGGGTTTCAAGCAAGTAGTAGTAAAGACTTACTTTACTTTA 2932
2938 DB AAAAAATATAAAAAATGAAGCTGGGTTTCAAGCAAGTAGTAGTAAAGACTTACTTTACTTTA 2997
2933 QY AAGGTGACAGCTGCGCGCTGCGGCTTCAAGGAAGTTTACCGGAAGTTCGCGCGCTAC 2992
2998 DB AAGGTGACAGCTGCGCGCTGCGGCTTCAAGGAAGTTTTCGCGGAAGTTCCCGCTTAC 3057
2993 QY AACGCTTCAGAAAAATACCCAGCATGCTTCAAGTTAACTCTGCAAGACGACACTGGT 3052
3058 DB AACGCTTCAGAAAAATACCCAGCATGCTTCAAGTTAACTCTGCAAGACGACACTGGT 3117
3053 QY GCAGCGGGGGAGGTAGCAACCTACAAAAAGCATGTGAGTGAAGGGGCTACTTTACT 3112
3118 DB GCAGCGGGGGAGGTAGCAACCTACAAAAAGCATGTGAGTGAAGGGGCTACTTTACT 3177
3113 QY GCTAATTTCTGAACGTGTACTTCTAGGCAATTTTAAATTCATATGATCCAGAGCAT 3172
3178 DB GCAACTCTGTAACTGTGTACATTTTCCAGACAGTTTTAAATTTCCATATGACCCAGAGCAC 3237
3173 QY CATTTATAAAGTGTCTCTCAGCAGCTAGTGTGCAACATGCTAGTGGGAAAGAGGCA 3232
3238 DB CATTTATAAGTGTGTCTCTCAGCAGCAAGTGTGCAACATGCTAGTGGGAAAGAGGCA 3297
3233 QY AAGGTGACACTATTTAGTCCCATTTAGGGGTACTCTACTCGTGGAGACTTTAGATTTT 3292
3298 DB AAGGTGTGACCACTTAGTCCCATTAATGGGATACTCAACCCCACTGGAGATTTTAGATTTT 3357
3293 QY AATGCTTTAAATTTGTTTCTTCACTTATGAGTGTTCAGCACTTAACTGAAATTTATGTT 3352
3358 DB AATGCTTTAAATTTTATTTTCTTCACTTATGAGTGTTCAGCACTTAACTGAAATTTATGGA 3417
3353 QY AGTATAGCTCCAGATGCTTTTAACTGTGTAATTTTCAGAAATTTGCTGTAAAAGATGTACA 3412
3418 DB AGTATAGCTCCAGATGCTTTTAACTGTGTAATTTTCAGAAATTTGCTGTAAAAGATGTACA 3477
3413 QY GACAAAAAGGAGGAGGTGTGCAAGTACTGACAGCACACAGGAGCTTTGTATGTTA 3472
3478 DB GACAAAAAGTGGAGGGGGGTGCAAGTACTGACAGCACACAGGAGCTTTGTATGTTA 3537
3473 QY GTGGATCATGAGTATATAATACCCATATGTGTAGGTGACGGGCAACACACACTAGCTCCA 3532
3538 DB GTAGACCATGAATACAGTATCCCATATGTGTAGGGCAAGGTCAAGATACTTTAGGCCCA 3597
3533 QY GAACCTGCCCATTTGGGTTTACTTTCCCGCTTACTTTTCAATATGCTTACTTAAACAGTAGGAGATGTC 3592
3598 DB GAACCTGCCCATTTGGGTTTACTTTCCCGCTTACTTTTCAATATGCTTACTTAAACAGTAGGAGATGTC 3657
3593 QY AACACAAAGGAATTTTCAGGAGACAGCAAAAAATTTGGGCTAGTGAAGAAATCAGCTTTTAT 3652
3658 DB AACACAAAGGAATTTTCAGGAGACAGCAAAAAATTTAGCAAGTGAAGAAATCAGCTTTTAT 3717
3653 QY GTGTTAGACACAGTTCATTTGAACTTTTGGGTACAGGGGATCTCCCACTATGCTCTAC 3712
3718 DB GTTTTGGAAACAGTTCATTTGAGCTTTTAGGTACAGGAGGTACAGCAACTATGCTTAT 3777
3713 QY AATTTTCCAGCTGTGCCCCCAGAAAACTTAGAAGGCTGACAGCCAACTTTTATGAAATG 3772
3778 DB AAGTTTCTCCAGTGGCCCCCAGAAAAATTTAGAGGGCTGACGACCACTTTTATGAAATG 3837
3773 QY TACAAACCTTTGTACGGTCTCGTTAGGGGTACTGACACATTAGAGGGGAGCCCTAAA 3832
3838 DB TACAAATCCCTTATACGGATCCCGCTTAGGGGTTTCTTGACACATTAGAGGAGTGACCCAAA 3897

```
Qy 3833 TTTAGATCATTTGACACACGAAGACACGCAATTCAGCCACAAATCTTATGCTGGGCCA 3892
Db 3898 TTTAGATCTTTAACACATGAGACCATGCAATTCAGCCCAAAATCTTATGCTGGGCCA 3957
Qy 3893 CTAAATAAATCAGTGCTCTACCAAGAGGAGAGCAATTTCTAATACAGAGTGTCTGGAAGGCC 3952
Db 3958 CTAGTAAATCAGTGCTCTACCAAGAGGAGGAGAGCAATTTCTAATACAGAGTGTCTGGAAGGCC 4017
Qy 3953 CTTACGGGCTTAGTACTAGGCACTAGCCAAACACAGAAATTTCCCTACGCCCGCGGCCA 4012
Db 4018 TTAACAGGCTTAGGACAGAGTACCTCTCAAAACACTAGAAATATCTTACGCCCTGGGCCA 4077
Qy 4013 GTATCTCAGCCATACCATCAGCTGGGACACTGATAAATATGTTACAGGATTAATGCCATT 4072
Db 4078 GTGTCTCAGCCGTACCCAGCTGGGACAGAGTAATATGTCACAGGATAAATGCCATT 4137
Qy 4073 TCACATGGACAAACACTTTGGAATGCTGAGGACAAAGAGTATCAGCAAGGGGTAGGA 4132
Db 4138 TCTCATGGTCAACACTTTATGTTAAGCTGAAGACAAAGAGTATCAGCAAGGAGTGGT 4197
Qy 4133 AGATTTCCAAATGAAAGAAACAGCTTAAGCAGTTTACAGGTCTTAACATGCACACATAC 4192
Db 4198 AGATTTCCAAATGAAAGAAACAGCTTAAGCAGTTTACAGGTCTTAACATGCACACATAC 4257
Qy 4193 TTCCCTAATAAGAACCCAAACATACACAGACCAAAATTTGAACGCCCTCTTATGGTGGGC 4252
Db 4258 TTTCCCAATAAGGAACCCAGCAATATACAGATCAAAATTTGAGCGCCCTTAATGGTGGGT 4317
Qy 4253 TCTGTTTGGAAACAGAGAGCTCTTCACTATGTAAGTACAGCTGGGAGTAAATCCCTAAC 4312
Db 4318 TCTGTATGAACAGAGAGCCCTTCACTATGAAGCCGCTGTGGAGTAAATTTCCAAAT 4377
Qy 4313 TTAGATGACAGTTTAAATCTCAATTTGACGCCCTAGCGGGTGGGTTTGCAATCAACCA 4372
Db 4378 TTAGATGACAGTTTAAATCTCAATTTGACGCCCTAGCGGGTGGGTTTGCAATCAACCA 4437
Qy 4373 CCCCCTCAATATTTTAAATAATACCAACAGTGGGCCAATTTGGAGTATTAATCC 4432
Db 4438 CCTCTCAATATTTTAAATAATTTACCAACAGTGGGCCAATTTGGAGTATTAATCA 4497
Qy 4433 ATGGGAATTAATCTTCTAGTTTCAATATGCTGTGGGAATATGACAGTACCATGACCTTT 4492
Db 4498 ATGGGAATTAATCTTCTAGTTTCAATATGCTGTGGGAATATGACAGTACCATGACCTTT 4557
Qy 4493 AAATTTGGACCTCGAAGGCTACTGGAAGTGAATCCCGAGCTGGCGTTTATCCTCT 4552
Db 4558 AAATTTGGCTCCCGTAAAGCTACGGGACCGTGGGAATCTCAACCTGGAGTATATCCCGC 4617
Qy 4553 CATGCACTGGTCAATTTACCATATGCTGTGCTGTGACCCACAGCTACAGATGCAAGCAA 4612
Db 4618 CACGCAAGCTCAATTTACCATATGCTGTGCTGTGACCCACAGCTACAGATGCAAGCAA 4677
Qy 4613 CACCACAGACAGGATGAAAGCTGAAGATTTGTGGAAGTGCACAAAGCGGTGTGCAC 4672
Db 4678 CACCACAGACAGGATGAAAGCTGAAGATTTGTGGAAGTGCACAAAGCGGTGTGCAC 4737
Qy 4673 CCATTTAAACATTTCCCAACCGTGTCTCAGCGCAGGAACCGTCAACCGCCCGCCACCTGT 4732
Db 4738 CCATTTAAACATTTCCCAACCGTGTCTCAGCGCAGGATGCGTAACTAAACCGCCCGCCAGT 4797
Qy 4733 GCGGCCCAATATATGTCGCCCTTCCCAATACCCCGTAGGCAACCATCTATAAAGATAC 4792
Db 4798 ACCACCAAGCTGTACCTGCCCTTCCCAATACCCCGTAGGCAACCATCTATAAAGATAC 4857
Qy 4793 AGACGCTGTAGATATAAATTAATTAAGTATGATGACCAACATGTAATTAAGATGCTAAG 4852
Db 4858 AGACAATGTAGATTTAAGTACTTAACCGATATGACCAACATGTAATTAAGATGCTAAG 4917
Qy 4853 ATTATGTAATGTACCAAGTTTGGAAAAATAAAGCCTTTAAATAAATTAATTCATAGTG 4912
Db 4918 ATTGTGTAATGTATCAAAATTTAGAAAAATAAACAATTTCTGTGGTTAAAAAATTAATG 4977
```

```
Qy 4913 TATGGTTCTTTAAAAATTTCAAAAGAGACACCAATCAGATGCGCGGTGCGCGCGC 4972
Db 4978 T-TGTTGCGCTTTAAAAATTTAAAGAGACACCAATCAGATGCGCGGTGCGCGCGC 5036
Qy 4973 GTAGGCGGAGCTTCCGGTACAAGATGCGGACAGTTACGTTCTTCTGTGAGCTC 5028
Db 5037 GTAGGCGGAGCTTCCGGTACAAGATGCGGACCAATTAAGTCTTCTGTGAGCTC 5092

RESULT 9
AY386330
LOCUS B19 virus isolate J35, 5596 bp DNA linear VRL 08-OCT-2003
DEFINITION AY386330
ACCESSION AY386330
VERSION AY386330.1 GI:37499708
KEYWORDS
SOURCE B19 virus
ORGANISM B19 virus
VIRUSES; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE 1 (bases 1 to 5596)
AUTHORS Zhi,N., Zadori,Z., Brown,K.E. and Tijssen,P.
TITLE Construction and Sequencing of an Infectious Clone of the Human
JOURNAL Parvovirus, B19
REFERENCE 2 (bases 1 to 5596)
AUTHORS Brown,K.E., Zhi,N., Zadori,Z. and Tijssen,P.
TITLE Direct Submission
JOURNAL Submitted (09-SEP-2003) Hematology Branch, National Heart Lung and
Blood Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA
FEATURES
source
1. 5596
/organism="B19 virus"
/mol_type="genomic DNA"
/isolate="J35"
/db_xref="taxon:10798"
616..2631
/gene="NS"
616..2631
/gene="NS"
/codon_start=1
/product="non-structural protein NS1"
/protein_id="AAQ91878.1"
/db_xref="GI:37499709"
/translat="MELFRGLQVSSNVLDCCANDWVCSLLDLDTSDEPLTHNRLM
AYLSVSVASKLILDTGGPLAGCLYFQAECKNKEEGYTHIHVVGGLNPRNLTVCEG
LENNLYHVFENVKLFPLGKTFKDFQGFENYLMKKIPLNVVWCVNTIDGY
IDTICATFRGACHAKPRITTAINDTSSDAGESSTGAEVVPFNGKTKASIKQT
MWNLCENRVFTEDKWKVDFNQYTYLLSSSHSGSQIQSALKAIYKATNLVPTSTFL
LHTDFQVNCIKDKIVKLLCONYDPLLVGQHLVKWIDKCGKNTLWFYGPSTGK
TNLAMAIAKSVFVYGMVNNNPNFNDVAGSLVWVWDEGIIKSTIVEAKAILGGOP
TRYDQMRGSAVPGVPVITSGNDITFVSGNTTTTTHAKALKERMVKLNTVRCSP
DMGLLTDADVQOQLTWCAAGSDHVENAINTTFFPFGNADALHPDLQTTPIVDTDS
ISSGSESEELSESFPNLITPGAWNTETPRSTPIPGTSSGSEFVSGSPVSEVAA
SHEEAYTPEADQFRELIVGVDYVMDVGVGLVPCVCCQHHNNSSGGGLGCPHCINVGAW
YNGWKRREFTPDLVRCSCHVGSNPFSLVLTCKKAYLSGLQSFVDYE"
2084..2308
/codon_start=1
/product="7.5 kDa protein"
/protein_id="AAQ91882.1"
/db_xref="GI:37499713"
/translat="MQMESTQTSKPPQLSOTFPVSAVVVKALKNSVKAFLTSSPQAP
GTIKRALVVRPSPGVPQENHLSAQPPLK"
2624..4969
/gene="VP1"
2624..4969
/gene="VP1"
/notes="minor capsid protein"
/codon_start=1
/product="capsid protein 1"
/protein_id="AAQ91879.1"
/db_xref="GI:37499710"
/translat="MSKESGKWESDDDEFAKAVYQQFVFVEYKVTGDTLELIQTLKDH
YNI SLDNPLENPSSLFDLVARIKNLKNPSDLYSHHFQSHQLSDHPSHSSSHAE
```


PRECEDAVILSLEDLHRPQGVSVQLPGCTNVTVGPNELQAGPQSAVDSAAIRLHDPFRYSQL
AKUGINPTHTWVDBEELKNTKNETGQAVXVMDTGLTGKGAANAVFAHQSGVPEPVA
YNASEKPYMTSVNSNEASTGAGGSGSNVKSMEGATSAVSTCFGRQLIPYD
IENYGVKFSAPVASSCHNAGEAKVCTISPTMGVSTPMRWLDFNALMFPSEFQHL
IENYGVSPADALTVISLAVQVDTGTGGVQVDTSTGRLCLMDVHEYKVPYVLQG
GODTLAPELIWIYVEPPLVYGVGTVDNTPGLSGDSKSLAEESEFVPLVHBSHSEQLLQ
TGCTATVSVKFPENPELVGSGHVEYMTNPLIAGSGVDPTDGLGDPKFSRITREDH
ALIQONPMGCPVLNVSTKEGSDSSNTGACKALTGLSTGTSQNTRLSILRPGVSPQVPHH
WDTDKTVGLINLHGQTVITGNAEDKTYQQGVGRPNFEKQLQOLGJINMHTVFPNKG
TOQYTDIIBERLWGSVNMNRALHEYBSQMSIENLDDSTQPOALGGLWGLHPQPPQ
IFLKLIPQSVGTGGIKSMGIITLVYGVYIMTVTWTGPRKATGRWNPQGVGYPPH
AAGHLVPLVDPYDTADOKHRRHGVGEKPEELWATAKSRVHL"

CDS

gene

CDS

```

/genes="Vf2"
/notes="major capsid protein"
/codon_start=1
/product="capsid protein 2"
/protein_id="AAQ91880.1"
/db_xref="GI:37499711"
/translation="MTSVNSAASASTGAGGGSNPVKSMSEGATFSANSVTCFSRQF
LIPDPEHHYKVFSAATTSNCSNAGSEAKVCTTIPGMYSTPNRYIDFNALNLPFSP
EFOHLLTNEYSAPALATVITSEAKVDQTDSTGGQVDTSTTGRCLMDVDEHYKYP
VYLGQCGDTPALPELIPVFPPOYALVTVGVNTQVIGSGDSKKLASBPASVYLVHSS
FOLLGNGGTAATWSYKEPVPVPEPVPENLPGCSQHFPEVWQVGLYSGRLGDTGLGDDPKFSRL
THEDHAIQONFMWPGELVNSVSTGKEDSNSTGACKALTGSTGTSQNTRLSLRPGPV
QPVHHQWTDKYQIEGLMASHGQTTVGNABDKYEQWGRFPNEKEQLKQLQGLNMTH
FKNQYDQDQYQDTEPLMVSQSVWNNRLYQSGQKQIPNLDDSPFKTQFAALGGWGLH
QPPQPLFKLILQSQSGIGIKSMGTTTLLVQAVGIMTVMTFKLGRPKATGRWNPPQG
VYPPAAGHLPYLVDPDTATDAKQHRRHGVEKPEBELTAKSRVHPL"
4890..5174
/codon_start=1
/product="11 kDa protein"
/protein_id="AAQ91881.1"
/db_xref="GI:37499712"
/translation="MQNNTTDMKLSKCGQKPAVCTCHKSPGPCPCGVCTKRPVP
PPRLYLPPIPIRQPNQTDIDNVEPKYLRVEOHWIMRLRLCNMYQNLEK"

```

ORIGIN

Query Match	77.1%	Score	3875.6	DB	14	Length	5596	
Best Local Similarity	86.0%	Pred. No.	0					
Matches 4332	Conservative	0	Mismatches	694	Indels	10	Gaps	3

QY	1	GAGCTCACAGGAATGACGTAACTGTCCGCCATCTTGTACCGAAGTCCCGCTACCGGC	60
DB	282	GAGCTCACAGGAATGACGTAAATGTCCGCCATCTTGTACCGAAGTCCCGCTACCGGC	341
QY	61	GGCGACCGCGGCATCTGATTTGGTGCTCTCTTTTGAATTTTGGCGGCGCTTTTCCCG	120
DB	342	GGCGACCGCGGCATCTGATTTGGTGCTCTC-ATTTAAATTTTACGCGGCTTTTCCCG	400
QY	121	CCTTATGCAAAATGAAGCGGCCATGTTTAATGTTATATTTAAATTTAATTGAGACAAACGCCT	180
DB	401	CCTTATGCAAAATGGGACGCCATTTAAGTGTTTACTATTAATTTATTTGTCAGTTTTGT	460
QY	181	AACGGTTTACTAGGGCGGAGTTACGG-----GCGGTATATAAGCAGCTCGGTTCCCT	232
DB	461	AACGGTTAAATGGGCGGAGGTAGGCGGGACTACAGTATATATAGCACAGCACTGCCG	520
QY	233	GACACTTCTTTCTGGTTGCTTTTGACTGGAACCTCACTTGCTGTTCTTTTGGCCTGCTAAG	292
DB	521	CAGCTCTTCTTCTCGGCTGCTTTTTCCTGGACTTCTTGCTGTTTGTGTTGTGAGCTAAC	580
QY	293	TAAACAGGTAATTTATATCTAACTTTTAAATTTACTAACATGAGGCTATTTTCGGGGTGCTTGC	352

QY	1433	TGGTCTGGGATGAAGGCATTATTAAGTCCACTATTGTGGAGCTGCAGAAAGCCATTITAG	1492
Db	1721	TGGTCTGGGATGAAGGTATTATTAAGTCTACAAATGTAGAAAGCTGCAGAAAGCCATTITAG	1780
QY	1493	GTGGTCAGCCAAACAGAGGTAGATCAGAAATGCGTGGCAGTGGCCAGTCCCGGTGTC	1552
Db	1781	CGGGCAACCCAGGAGGTAGATCAAAAGATGCGTGGAGGTAGCTGTCCTGGAGTAC	1840
QY	1553	CTGTGGTTATAAACAGCAATGGTGCACATTATTTGTGTGGTGTGGTGAATACCACTACAA	1612
Db	1841	CTGTGGTTATTAACAGCAATGGTGCACATTATTTGTGTGGTGTGGTGAATACCACTACAA	1900
QY	1613	CTGTGCATGCTPAAAGCCTTAAAGCAACGGATGTTAAAGCTTAACTTTACCATTAAGATGTA	1672
Db	1901	CTGTACATGCTPAAAGCCTTAAAGCAACGGATGTTAAAGCTTAACTTTACCATTAAGATGTA	1960
QY	1673	GCCCTGCATGCTTAAAGCCTTAAAGCAACGGATGTTAAAGCTTAACTTTACCATTAAGATGTA	1732
Db	1961	GCCCTGCATGCTTAAAGCCTTAAAGCAACGGATGTTAAAGCTTAACTTTACCATTAAGATGTA	2020
QY	1733	CACAAAGCTGAGCCACTATGAAGCACTGGCAATTAAGCTTAACTTTACCATTAAGATGTA	1792
Db	2021	CACAAAGCTGAGCCACTATGAAGCACTGGCAATTAAGCTTAACTTTACCATTAAGATGTA	2080
QY	1793	TAAATGAGATGCTCCACCCAGATCTCAAAACCCACCCCAATGTCACAGACACCACTCA	1852
Db	2081	TAAATGAGATGCTCCACCCAGATCTCAAAACCCACCCCAATGTCACAGACACCACTCA	2140
QY	1853	TCAGCAGCAGTGTGTGAAGCTCTGAAGCACTGGCAATTAAGCTTAACTTTACCATTAAGATGTA	1912
Db	2141	TCAGCAGCAGTGTGTGAAGCTCTGAAGCACTGGCAATTAAGCTTAACTTTACCATTAAGATGTA	2200
QY	1913	TCACTCCAGCGCTGGAACAGTGAACCCCGCTCTAGTACGCCGCTCCCGGAGCA	1972
Db	2201	TCACTCCAGCGCTGGAACAGTGAACCCCGCTCTAGTACGCCGCTCCCGGAGCA	2260
QY	1973	GTTTCAGAGATCATTTTGTGGAGGCCAGTTTCTCCGAGGTGTAGCGGCTGTGGG	2032
Db	2261	GTTTCAGAGATCATTTTGTGGAGGCCAGTTTCTCCGAGGTGTAGCGGCTGTGGG	2320
QY	2033	AGGAAGCTTTTACCGCGCTTGGCGATCGATTTCTCCGAGGTGTAGCGGCTGTGGG	2092
Db	2321	AGGAAGCTTTTACCGCGCTTGGCGATCGATTTCTCCGAGGTGTAGCGGCTGTGGG	2380
QY	2093	TGTATGGAGTGTGTAGGGGATTTGCTGTTGTGTGTGGAAATATAAACAACAGTG	2152
Db	2381	ATGTGTGGAGCGGTGAAGGGTTTACCTGTGTGTGTGGAAATATAAACAACAGTG	2440
QY	2153	GGGGAGGTGTGGGCTTGGCTCATTTGTATGTGGAGCTTGGTATTAATGGATGGA	2212
Db	2441	GGGGAGGTGTGGGCTTGGCTCATTTGTATGTGGAGCTTGGTATTAATGGATGGA	2500
QY	2213	AATTTAGAGATTTACTCCAGACTTGTGCGCTGCAATTTGTATGTAGGAGCTCTAAC	2272
Db	2501	AATTTAGAGATTTACTCCAGACTTGTGCGCTGCAATTTGTATGTAGGAGCTCTAAC	2560
QY	2273	CAATTTCTGTGTAACTGTGAAAGTGTGCTTACCTGTGTGGATTAAGAGTTTGTAG	2332
Db	2561	CAATTTCTGTGTAACTGTGAAAGTGTGCTTACCTGTGTGGATTAAGAGTTTGTAG	2620
QY	2333	ATTATGAGTAAACCACTAACAATGGTGGGAAAGCAGTGAACAATTTGCCAGGACGTG	2392
Db	2621	ATTATGAGTAAACCACTAACAATGGTGGGAAAGCAGTGAACAATTTGCCAGGACGTG	2680
QY	2393	TATAAGCAGTGTGTGCAATTTTATGAAAGCTTCTGGAACAGACTTACAGCTTATTCAA	2452
Db	2681	TATAAGCAGTGTGTGCAATTTTATGAAAGCTTCTGGAACAGACTTACAGCTTATTCAA	2740
QY	2453	ATTTTAAAGCACTTACCAATTTCTTTAGATATCTTTAGAAACCCCTCTCTTTTA	2512
Db	2741	ATTTTAAAGCACTTATTAATATTTCTTTAGATATCTTTAGAAACCCCTCTCTCTG	2800

QY	2513	TTTGACTTGTGCTCGCATTAAGTAATCTTAAAGACTCTCCAGACCTATATAGTCAAT	2572
Db	2801	TTTGACTTGTGCTCGCATTAAGTAATCTTAAAGACTCTCCAGACCTATATAGTCAAT	2860
QY	2573	CATTTTCAGAGCCATGGACAGTATCTGACACCCCATGCTTATCATCCAGTACAGT	2632
Db	2861	CATTTTCAGAGCCATGGACAGTATCTGACACCCCATGCTTATCATCCAGTACAGT	2920
QY	2633	AGTGCAAGACCTAGAGGAGAAATGCAATTTATCTAGTGAAGACTTACACAAGCCTGGG	2692
Db	2921	CATGCAAGACCTAGAGGAGAAATGCAATTTATCTAGTGAAGACTTACACAAGCCTGGG	2980
QY	2693	CAAGTTAGCATCAATTTACCCGGTACTTAACATTTGTTGGCCTGGCAATGAGCTACAAGCT	2752
Db	2981	CAAGTTAGCATCAATTTACCCGGTACTTAACATTTGTTGGCCTGGCAATGAGCTACAAGCT	3040
QY	2753	GGGCTCCGCAAGATGCTGTGGACAGTCTGCAAGGATTCATGACTTTAGGTATAGCCAA	2812
Db	3041	GGGCTCCGCAAGATGCTGTGGACAGTCTGCAAGGATTCATGACTTTAGGTATAGCCAA	3100
QY	2813	TTGGCTAAGTTGGGAATTAATCTTTATACATTTGGAAGCTGAGTGAAGAAATTTGTA	2872
Db	3101	CTGGCTAAGTTGGGAATTAATCTTTATACATTTGGAAGCTGAGTGAAGAAATTTGTA	3160
QY	2873	AAAAATATAAAATGAAACAGGTTTCAAGCAGCAGTGAAGAAATTTGTA	2932
Db	3161	AAAAATATAAAATGAAACAGGTTTCAAGCAGCAGTGAAGAAATTTGTA	3220
QY	2933	AAAGTGCAGCTGCCCTGTGGCCCATTTTCAAGGAAGTTTCCGGAAGTTCGCCCTTAC	2992
Db	3221	AAAGTGCAGCTGCCCTGTGGCCCATTTTCAAGGAAGTTCGCCCTTAC	3280
QY	2993	AACGCTCAGAAATATACCCAGCATGACTTCAAGCAGTGAAGAAATTTGTA	3052
Db	3281	AACGCTCAGAAATATACCCAGCATGACTTCAAGCAGTGAAGAAATTTGTA	3340
QY	3053	GCAGCGGGGAGGTAGCAACCTTACAAAGAGTGTGGAGTGAAGGGGCTACATTTACT	3112
Db	3341	GCAGCGGGGAGGTAGCAACCTTACAAAGAGTGTGGAGTGAAGGGGCTACATTTACT	3400
QY	3113	GCTAATCTGTAAAGTGTACATTTCTAGGCAATTTTAAATTCATATGATPCCAGAGCAT	3172
Db	3401	GCTAATCTGTGTGACTTGTACATTTTCTAGCAGTGTAAATTCATATGATPCCAGAGCAT	3460
QY	3173	CATTATAAGTGTCTCTCCAGCAGTGTAGCTGCCACATGCTAGTGGGAAAGAGCA	3232
Db	3461	CATTATAAGTGTCTCTCCAGCAGTGTAGCTGCCACATGCTAGTGGGAAAGAGCA	3520
QY	3233	AAAGTGTGCACTATTAGTCCCATTTATGGGGTACTCTACTCCGTGGAGATACTTATAGATTTT	3292
Db	3521	AAAGTGTGCACTATTAGTCCCATTTATGGGGTACTCTACTCCGTGGAGATACTTATAGATTTT	3580
QY	3293	AATGCTTTAAATTTGTTTCTCAACATTTAGAGTTTCAGCACTTAATTTGAAATTTATGGT	3352
Db	3581	AATGCTTTAAATTTGTTTCTCAACATTTAGAGTTTCAGCACTTAATTTGAAATTTATGGT	3640
QY	3353	AGTATAGCTCCAGATGCTTTAACTGTAATTTTCAAGATTTGCTGTAAAGATGTACA	3412
Db	3641	AGTATAGCTCCAGATGCTTTAACTGTAATTTTCAAGATTTGCTGTAAAGATGTACA	3700
QY	3413	GACAAACAGGAGGAGTGTGCAAGTTTACTGACAGCAACCAAGGAGCTTTGTGTATGTTA	3472
Db	3701	GACAAACAGGAGGAGTGTGCAAGTTTACTGACAGCAACCAAGGAGCTTTGTGTATGTTA	3760
QY	3473	GTGGATCATGATTAATACCATATGCTAGTGTAGGAGCAAGACACACTAGCTCCA	3532
Db	3761	GTGGATCATGATTAATACCATATGCTAGTGTAGGAGCAAGACACACTAGCTCCA	3820
QY	3533	GAATGCTGCAATTTGGGTTTACTTTCCCGCCAGTGTGCTTACTTAAACAGTGTAGTGA	3592
Db	3821	GAATGCTGCAATTTGGGTTTACTTTCCCGCCAGTGTGCTTACTTAAACAGTGTAGTGA	3880
QY	3593	AACACAGGAATTTTCAGGAGACAGCAAAATTTGGCTAGTGAAGAAATCTTTTAT	3652


```
Db 3881 |||||AACACACAGGAATTTCTGGAGACGCAAAATTTAGCAAGTGAAGAAATCAGCATTTTAT 3940
QY 3653 GTCTTAGAGCACAGTTTCATTGAACTTTTGGGTACAGGGGATCTGCCACTATGTCTTAC 3712
Db 3941 GTTTTGGACACAGTTCTTTTTCAGCTTTTAGGTACAGGAGGTACACCACTATGTCTTAT 4000
QY 3713 AAATTTCCAGCTGTGCCCCAGAAAAACCTAGAAAGCTGCAGCACAATTTTATGAATG 3772
Db 4001 AAGTTTCTCCAGTGCCTCCAGAAAAATTTAGAGGCTGCAGTCAACACATTTTATGAGATG 4060
QY 3773 TACAACCTTTGTACGGTCTCTGTTAGGGGTACCTGACACATTTAGAGGGGACCTTAA 3832
Db 4061 TACAATCCCTTATACGGATCCCGCTTAGGGGTTCTTGACACATTTAGGAGGTGACCCAAA 4120
QY 3833 TTTAGATCATTTGACACAGGAACACGCAATTCAGCCACAAATTTTATGCCCTGGGCCA 3892
Db 4121 TTTAGATCTTTAACAATGACATGAGACCATGCAATTCAGCCCCAATCTCATGCCAGGCCA 4180
QY 3893 CTAAATAATTCAGTGTCTACCAAGAGGAGACAATTTCTAATACAGGTGCTGGAAGGCC 3952
Db 4181 CTAGTAAACTCAGTGTCTACAAAGGAGGAGACAGCTCTAATACTGGAGCTGGGAAGCC 4240
QY 3953 CTTACGGGCTTAGTACTGCACTAGCCAAACACCAAGATTTCCCTACGCCCGCGGCCA 4012
Db 4241 TTAACAGGGCTTAGCACAGGTACTCTCAAAACACTAGAAATATCTTACGCCCGGGGCCA 4300
QY 4013 GTATCTCAGCATPACCATCACTGGGACACTGATAAATATGTTACAGGAATAAATGCCATT 4072
Db 4301 GTGTCTCAGCGTACCACCACTGGGACACAGATAAATATGTTACAGGAATAAATGCTATT 4360
QY 4073 TCATATGACAAACCACTTATGAAATGCTGAGGACAAAGAGTATCAGCAAGGGGTAGGA 4132
Db 4361 TCTCATGTCAGACCACTTATGTAACGCTGAAGACAAAGAGTATCAGCAAGGGGTGGT 4420
QY 4133 AGATTTCCAAATGAAAAAGAACAGCTTAAAGCATTACAGTCTTAAACATGACACATAC 4192
Db 4421 AGATTTCCAAATGAAAAAGAACAGCTTAAACAGTTACAGGGTTTAAACATGACACCTAC 4480
QY 4193 TTCCCTTAATAAGGAACCAACAAATACACAGACCAAAATGAACGCTCTTATGGTGGC 4252
Db 4481 TTTCCCAATAAAGGAACCCAGCAATATACAGATCAAAATGAGCGCCCTTAATGGTGGT 4540
QY 4253 TCTGTTTGGACAAAGAGAGCTTCTACTATGAAGTACAGCTGTGGAGTAAATCCCTAAC 4312
Db 4541 TCTGTATGAAACAGAGAGCCCTTCACTATGAAGCCAGCTGTGGAGTAAATTCCAAT 4600
QY 4313 TTAGATGACAGTTTAAACTCAATTTGACCCCTAGCGGGTGGGGTTTGATCAACCA 4372
Db 4601 TTAGATGACAGTTTAAACTCAATTTGACCCCTTAGAGGATGGGGTTTGATCAGCCA 4660
QY 4373 CCCCCTCAAAATTTTAAATACTACCAAAAGTGGGCCAATTCGAGGTATTAATCC 4432
Db 4661 CTTCTCAAAATTTTAAATAATTTACCAAAAGTGGGCCAATTCGAGGTATTAATCA 4720
QY 4433 ATGGGAATTACTACTTTAGTTCAATATGCTGTGGGAATTAATGACAGTACCATGACCTTT 4492
Db 4721 ATGGGAATTACTACTTTAGTTCAATATGCTGTGGGAATTAATGACAGTACCATGACATTT 4780
QY 4493 AAATTTGGGACCTCGAAAGGCTACTGGAAGTGAATTCCTCAGCGCTGGCGTTTATCTCCT 4552
Db 4781 AAATTTGGGACCTCGTAAAGCTACGGGACCGTGAATCTCAACCTGGAGTATATCCCGG 4840
QY 4553 CATGACGTGCTCATTTACCATATGCTGTATGACCCACAGCTACAGATGCAAGCA 4612
Db 4841 CAGCAGCAGGTGCTTTTACCATATGCTATATGACCTTACAGCTACAGATGCAAAACA 4900
QY 4613 CACACAGACACGGATATGAAAGCTGGAAGATTTGGAAGTCTCCCAAGCCGTGTGCAC 4672
Db 4901 CACACAGACATGATATGAAAGCTGGAAGATTTGGAAGCCTCAAGCCGTGTGCAC 4960
QY 4673 CCATTTGAAATTTCCCGACCGTGTCTCAGCCAGGAACCGTCAACCCACCGCCCACTGT 4732
|||||
```

```
Db 4961 CCAATTGTAACACTCCCAACCGTGCCCTCAGCCAGGATCGGTAACATAACGCCCACT 5020
QY 4733 GCCGCCAGATATATGTGCCCCCTCCCAATACCCCGTAGCAACCACTCTATATAAGATAC 4792
Db 5021 ACCACCCAGCTGTACCTGCCCTCTCTATACCTATAGACAGCCTAACACAAAGATAT 5080
QY 4793 AGACGCTGTAGAAATATAATTAATCTAGATATGAACAAATGTAATTAAGATGCTAAG 4852
Db 5081 AGACAATGTAGAAATTAAGTATTTAACCCAGATGAACAAATGTTATTAGAAATGTTAAG 5140
QY 4853 ATTATGTAATGTACACAAAGTTTGAAGAAATAAAGCCTTAAATAAATAATTCATAGTG 4912
Db 5141 ATTGTGTAATGTATCAAAATTTAGAAATAAAGCTTTGTTGTTGTTGTTGTTGTTGTTG 5200
QY 4913 TATGTTCTTTAAAAATTTCAAAAAAGACACCAATCAGATGCCCGCGTCCGCCCG 4972
Db 5201 T-TGTTGCGCTTTAAAAATTTAAAGAGACACCAATCAGATGCCCGCGTCCGCCCG 5259
QY 4973 GTAGCGGACCTTCGGGTACAAAGTGGCGGACAGTTACGTCAATTTCTCTGTAGCTC 5028
Db 5260 GTAGCGGACCTTCGGGTACAAAGTGGCGGACAAATTACGTCAATTTCTCTGTAGCTC 5315

RESULT 10
AF162273
LOCUS Erythrovirus B19 strain HV, complete genome.
DEFINITION AF162273
ACCESSION AF162273
VERSION AF162273.1 GI:5670171
KEYWORDS
SOURCE
ORGANISM B19 virus
Virus; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE 1 (bases 1 to 5594)
AUTHORS Gallinella, G. and Venturoli, S.
TITLE B19 Genome Sequence and Structure Analysis
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 5594)
AUTHORS Gallinella, G. and Venturoli, S.
TITLE Direct Submission
JOURNAL Submitted (23-JUN-1999) Clinical and Experimental Medicine -
Division of Microbiology, University of Bologna, Via Massarenti, 9,
Bologna I-40138, Italy
FEATURES
source
1..5594
/organism="B19 virus"
/mol_type="genomic DNA"
/strain="HV"
/db_xref="taxon:10798"
1..382
/note="5' hairpin; left ITR; flop sequence orientation"
615..2630
/gene="ns"
615..2630
/gene="ns"
/codon_start=1
/product="non-structural protein"
/protein_id="AAD4613.1"
/db_xref="GI:5670172"
/translation="MELFRGLVQSVNLDCAANDNWCSLDLDLDTSDWELPLTHNRLM
AIVLSSVASKLDFTGGPLAGCLYFFQVCKNFEQYHIVVIGGGLNPNRLTVCVGG
LFPNVLHLVTENVKLPGLMGTGKYPDGEQFIENLMKKIPLNVVCMVTNIDGY
IDTCLSATFRGACHAKPRIITTAINDTSSDAGESSTGAEVVPVINGKTKASIKFOT
MYNLCENRVFTEDKWLVDVFNQYTLTSSSSSGSPQIQSALKLAIYKATNLVPTSTPL
LHTEFQVNCIKDKILVKLLCQNTDPLLVGHVLDKIDKKCKKNTILFYGFPSGK
TNLMAIAIKSPVYGVNWNENPFNDVAGSLVWDEGIIKSTIVEAKAILGGQ
TRVDMKRGSAVPGVPVITNSGDIITFVSGNTTTTHAKALKERVMKLNFTVRCSP
DMLGLTEADVOQLTWCAQSDHYENWAINYTFDPPGINADALHPLDCTPLVDTGS
ISSGSESEELSESSFNLTTPGAWNTETPESSTPICTSSGESPVGSSSEVVA
SHEEAFYPLADOFRELLVGVYVWVGRGLPVCCVQHINNNGGGLGLCPHCLNVGAM
YNGWKFRTFDPDLVRCSCHVGNPNFSLVLTCKKAYLSGLQSFVDYE"
2623..4968
gene
CDS
```


Db 1780 GCGGCAACCCACAGGGTAGATCAAAAATGCGTGAAGTAGCTGCGCTGGAGTAC 1839
QY 1553 CTGTGGTTATAACAGCAATGGTGCACATTATCTGTGGTGGTGAATPACCACTACAA 1612
Db 1840 CTGTGGTTATAACAGCAATGGTGCACATTATCTGTGGTGGTGAATPACCACTACAA 1899
QY 1613 CTGTGCATGTAAAGCCTTAAAGGAAACGAGTGTAAAGCTAAATCTTACATGAAGATGA 1672
Db 1900 CTGTACATGTAAAGCCTTAAAGGAAACGAGTGTAAAGCTTAAATCTTACTGTGAAGATGA 1959
QY 1673 GCCTGCATGGTGTACTTACAGAGGCTGATGTACAAATGGCTAACTTGTGTGAATG 1732
Db 1960 GCCTGCATGGTGTACTTACAGAGGCTGATGTACAAAGAGGCTTACATGGTGTAAAG 2019
QY 1733 CACAAAGCTGGAGCCACTATGAATACTGGGCAATAAATACTACACATTTGATTTCCCTGGAA 1792
Db 2020 CACAAAGCTGGAGCCACTATGAATACTGGGCAATAAATACTACACATTTGATTTCCCTGGAA 2079
QY 1793 TAAATGCAGATGCCCTCCACCCAGATCTCCAAACCAACCCCAATGTGCCAGACACCACTA 1852
Db 2080 TTAATGCAGATGCCCTCCACCCAGATCTCCAAACCAACCCCAATGTGTACAGACACCACTA 2139
QY 1853 TCAGCAGCAGTGTGTGAAGCTCTGAAGAACTCTAGTGAAGCAGCTTTTTCACCTCA 1912
Db 2140 TCAGCAGCAGTGTGTGAAGCTCTGAAGAACTCTAGTGAAGCAGCTTTTTCACCTCA 2199
QY 1913 TCACCTCAGGCGCTGGAAACAGTGAACCCCGCTCTAGTACGCCCGCTCCCGGAGCCA 1972
Db 2200 TCACCCAGGCGCTGGAAACAGTGAACCCCGCTCTAGTACGCCCGCTCCCGGAGCCA 2259
QY 1973 GTTCAGGAGATCAATTTGTGCGAAGCCAGCTTTCTCCGAAAGTGTAGCGCGCTCGTGGG 2032
Db 2260 GTTCAGGAGATCAATTTGTGCGAAGCTCAGTTTCTCCGAAAGTGTAGCTGCTGTGGG 2319
QY 2033 AGAAAGCTTTTACAGCCGCTTCCGATCAGTTTCTGTAACCTGTAGTAGGGGTTGACT 2092
Db 2320 AGAAAGCTTTTACAGCCGCTTCCGATCAGTTTCTGTAACCTGTAGTTGGGGTTGACT 2379
QY 2093 TTGTATGGAGTGTGTGAGGGGATTTGCTGTTGCTGTGTGGAACATATAAACAACAGTG 2152
Db 2380 ATGTGTGGAGCGGTGAAGGGGTTTACCTGTGTGTGTGTGGAACATATAAACAACAGTG 2439
QY 2153 GGGAGGGTTGGGCTTTGCGCTCATTTGATTAATGTGGAGCTTGGTATAATGGATGA 2212
Db 2440 GGGAGGGTTGGGCTTTGCGCTCATTTGATTAATGTGGAGCTTGGTATAATGGATGA 2499
QY 2213 AATTTAGAGTTTACTCCAGACTTATGTGCGCTGCGATGTGTATGTAGGAGCCTCTAAC 2272
Db 2500 AATTTAGAGTTTACTCCAGACTTATGTGCGCTGCGATGTGTATGTAGGAGCCTCTAAC 2559
QY 2273 CATTTTCTGTGTTAACTTTGTAATAATGCTGTTTACCTGCTGCTGATTTACAAAGTTTGTAG 2332
Db 2560 CCTTTTCTGTGCTAACTGCTGAAATAATGCTGTTTACCTGCTGCTGATTTGAAAGCTTTGTAG 2619
QY 2333 ATTTAGTAAACCACTAAACAAATGGTGGAAAGCAGTGAACAAATTTGCCAGGACGTG 2392
Db 2620 ATTTAGTAAACCACTAAACAAATGGTGGAAAGTGAATGAATTTTGTAAAGCTGTG 2679
QY 2393 TATAAGCAGTTTGTGCAATTTTATGAATAAGCTACTGGAAACAGACTTAGAGCTTATTCAA 2452
Db 2680 TATCAGCAATTTGTGGAAATTTTATGAATAAGCTTACTGGAAACAGACTTAGAGCTTATTCAA 2739
QY 2453 ATTTTAAAGACCACTTACAACTTTCTTTAGATAATCTTTTGAACCCCTCTCTTTTA 2512
Db 2740 ATTTTAAAGACCACTTACAACTTTCTTTAGATAATCTTTTGAACCCCTCTCTCTG 2799
QY 2513 TTTGACTTGTGCTCGCTAAAGAGTAATCTTAAACCACTCTCCAGACCTTATAGTCAAT 2572
Db 2800 TTTGACTTGTGCTCGCTAAAGAGTAATCTTAAACCACTCTCCAGACCTTATAGTCAAT 2859
QY 2573 CATTTTACAGCCATGAGCAGTTTATCTGACCAACCCCAAGCTTTATCTCCAGTAAACAGT 2632

Db 2860 CATTTTCAAAGTCATGGACAGTTATCTGACACACCCCATCTATCATCCAGTAGAGT 2919
QY 2633 AGTGCAAGAACCTAGAGGAGAAAATGAGTATTTATCTAGTGAAGCTTACACAAAGCCTGGG 2692
Db 2920 CATGCAAGAACCTAGAGGAGAAAATGAGTATTTATCTAGTGAAGCTTACACAAAGCCTGGG 2979
QY 2693 CAAAGTTAGCATACAAATTTACCCGCTACTAATATGTTGGGCTTGGCAATGAGCTACAAGCT 2752
Db 2980 CAAAGTTAGCGTACAATACCCGCTACTAATATGTTGGGCTTGGCAATGAGCTACAAGCT 3039
QY 2753 GGGCTCTCCAGATGCTGCTGACAGCTGCTGCAAGGATTCATGACTTTAGGTATAGCCAA 2812
Db 3040 GGGCTCTCCAGATGCTGCTGACAGCTGCTGCAAGGATTCATGACTTTAGGTATAGCCAA 3099
QY 2813 TTGGCTAAAGTTGGGAAATAATCTTATACACATTTGACCGGTAGCAGATGAAGATTTGTTA 2872
Db 3100 CTGGCTAAAGTTGGGAAATAATCCATATCTCATTTGGACTGTAGCAGTGAAGCTTTTA 3159
QY 2873 AAAAATATAAAAATGAAAACAGGGTTTCAAGCAACAGCAGTAAAGATTTACTTTTACTTTA 2932
Db 3160 AAAAATATAAAAATGAAAACAGGGTTTCAAGCAACAGTAAAGATTTACTTTTACTTTA 3219
QY 2933 AAAGGTGACGCTGCCCTGCTGGCCCAATTTTCAAGGAGTTTACCCGAAAGTCCCGCTTAC 2992
Db 3220 AAAGGTGACGCTGCCCTGCTGGCCCAATTTTCAAGGAGTTTACCCGAAAGTCCCGCTTAC 3279
QY 2993 AACGCTCAGAAAAATPACCCAGCAGTACTTCAAGTTAACTCTGCAAGAACGACACTGGT 3052
Db 3280 AACGCTCAGAAAAATPACCCAGCAGTACTTCAAGTTAACTCTGCAAGAACGACACTGGT 3339
QY 3053 GCAGGCGGGAGGTAGCAACCCCTCAAAAAGCATGTGAGTGAAAGGGCTACATTTACT 3112
Db 3340 GCAGGAGGGGTGGCGATTAATCTCTGCAAAAAGCATGTGAGTGAGGGGGCCACTTTTAGT 3399
QY 3113 GCTAATTTCTGAACGTTGATCACTTCTAGGCAATTTTAAATTCATATGATCCAGAGCAT 3172
Db 3400 GCCAATCTGTAACTTTGATCACTTTTCCAGCAGTTTAAATTTCTTATGACCCAGAGCAC 3459
QY 3173 CATTTAAAGTGTCTCTCCAGCAGCTAGTCTGCAACATGCTAGTGGGAAAGAGGCA 3232
Db 3460 CATTTAAAGTGTCTCTCCAGCAGCAGCTGCAACATGCTAGTGGAAAGAGGCA 3519
QY 3233 AAAGTGTGCACTTATAGTCCCATTTAGGGTACTCTACTCTCGTGGAGATCTTTAGATTTT 3292
Db 3520 AAAGTTTGCACAATTTAGTCCCATTAATGGGATACTCAACCCCATGGAGATATTTAGATTTT 3579
QY 3293 AATGCTTTAAATTTGTTTCTCACTTATGAGTTTTCAGCACTTAAATGAAATTTAGT 3352
Db 3580 AATGCTTTAAATTTTATTTTTCACCTTTTAGAGTTTTCAGCAGCTTAAATGAAATTTAGGA 3639
QY 3353 AGTATAGCTCCAGATGCTTTAACTGTAACTATTTCAAGAAATGCTGTAAAAGATGTCA 3412
Db 3640 AGTATAGCTCCAGATGCTTTAACTGTAACTATTTCAAGAAATGCTGTAAAAGATGTCA 3699
QY 3413 GACAAACAGGAGGGTGTCAAGTTACTGACAGCAACACAGGAGCTTTGTGTATGTTA 3472
Db 3700 GACAAACAGGAGGGTGTCAAGTTACTGACAGCACTACAGGGGCGCTATCCATGTTA 3759
QY 3473 GTGGATCATGAGTATATAATACCATATGTGTAGGTGAGGACAGACACACTAGTCCA 3532
Db 3760 GTAGACCATGAAATCAAGTACCNTATGTGTAGGACAAAGGTGAGGATTTTAGGCCCCA 3819
QY 3533 GAACTGCCCATTTGGGTTTACTTTTCCCGCCAGTATGCTTTACTTAAACAGTAGGTGAAGTA 3592
Db 3820 GAACTTCTTATTTGGGTATCTTTTCCCGCTCAATATGCTTTACTTAAACAGTAGGATGTT 3879
QY 3593 AACACAAAGGAATTTAGGAGACAGCAAAAATTTGGCTAGTGAAGATTCAGCTTTTAT 3652
Db 3880 AACACAAAGGAATCTCTGGAGACAGCAAAAATTTAGCAAGTGAAGATTCAGCTTTTAT 3939
QY 3653 GTGTTAGACACAGTTTCAATTTGAACTTTTGGGTGACAGGGGATCTGCCACTATGCTCTAC 3712
Db 3940 GTTTTGGAAACAGATTTCTTTTTCAGCTTTTGGGTGACAGGAGGTACAGCAACTATGCTTAT 3999

QY 3713 AATTTCCAGCTGTGCCCCAGAAAACCTAGAGGCTGCAGCCACATTTTATCAATG 3772
 Db |||||
 QY 4000 AAGTTTCTCCAGTGCCCCAGAAAATTTAGAGGGCTGCAGTCAACACTTTATGAATG 4059
 Db |||||
 QY 3773 TACAACCCCTTTGACCGTTCTCGTTTACGGGTACCTGACACATTTAGGAGGAGCCCTAAA 3832
 Db |||||
 QY 4060 TACAATCCCTTTACGGATCCCGCTTAGGGTTCTGACACATTTAGGAGGTGACCCAAA 4119
 Db |||||
 QY 3833 TTTAGATCAATGACACAGAACGACCAAGCAATTTACGCCACAAAATTTATGCTGGGCCA 3892
 Db |||||
 QY 4120 TTTAGATCTTTACATGACATGACACATGCAATTTACAGCCCCAAAATTTATGCCAGGCCA 4179
 Db |||||
 QY 3893 CTAATAAATTCAGTGTCTACCAAGAGGAGACACATTTCTAATACAGGTGCTCGGAAAGCC 3952
 Db |||||
 QY 4180 CTAGTAAATCTAGTGTCTACAAAGAGGAGGAGACAGCTCTAATATCTGGAGCTGGAAAGCC 4239
 Db |||||
 QY 3953 CTTACGGGCTTAGTACTGGCACTAGCCAAACACAGAAATTTCCCTACGCCCGGGCCA 4012
 Db |||||
 QY 4240 TTAACAGGCTTTAGCACAGGCACTCTCAAAACACTAGAAATATCTTACGCCCTGGGCCA 4299
 Db |||||
 QY 4013 GPATCTAGCCATACCATCACTGGGACACTGATAAATATGTTACAGGAATAAATGCCATT 4072
 Db |||||
 QY 4300 GTGTACAGCCATACCACTACCTGGGACACAGATTAATGTTCCAGGAATAAATGCCATT 4359
 Db |||||
 QY 4073 TCACATGACAAACCACTTATGGAATGCTGAGGACAAAGAGTATCAGCAAGGGGTAGGA 4132
 Db |||||
 QY 4360 TCTCATGTGTCAGACCACTTATGTAAGCTGAAGACAAAGAGTATCAGCAAGGAGTGGGT 4419
 Db |||||
 QY 4133 AGATTTCCAAATGAAAAGAACACCTTAAGCAGTTTACAGGTCTTAACATGACACATAC 4192
 Db |||||
 QY 4420 AGATTTCCAAATGAAAAGAACACCTTAAGCAGTTTACAGGTCTTAACATGACACATAC 4479
 Db |||||
 QY 4193 TTCCCTTAATAAGAACCCCAACATACACAGACCAAAATTTGAACGCCCTCTTATGGTGGGC 4252
 Db |||||
 QY 4480 TTCCCAATAAAGAACCCAGCAATATACAGATCAAAATTTGAGCGCCCTAATGTTGGGT 4539
 Db |||||
 QY 4253 TCTGTTTGGAAACAGACAGCTCTCACTATGAAGTCAGCTGTGGAGTAAATTCCTAAC 4312
 Db |||||
 QY 4540 TCTGTATGGAAACAGAGGCCCTTCACTATGAAGCCAGCTGTGGAGTAAATTCCTAAC 4599
 Db |||||
 QY 4313 TTAGATGACAGTTTAAACCTCAATTTGACGCCCTAGCGGGTGGGTTTGCATCAACCA 4372
 Db |||||
 QY 4600 TTAGATGACAGTTTAAACCTCAATTTGACGCCCTAGCGGGTGGGTTTGCATCAACCA 4659
 Db |||||
 QY 4373 CCCCCTCAAAATATTTTAAATTAATACACAAAGTGGGCCAATTTGGAGTTTAAATTC 4432
 Db |||||
 QY 4660 CCTCTCAAAATATTTTAAATTAATTAACCAAAAGTGGGCCAATTTGGAGTTTAAATTC 4719
 Db |||||
 QY 4433 ATGGGAATTAATCTTTAGTTCAATATGCTGTGGGAATTAATGACAGTTTACCATGACCTTT 4492
 Db |||||
 QY 4720 ATGGGAATTAATCTTTAGTTCAATATGCTGTGGGAATTAATGACAGTTTACCATGACCTTT 4779
 Db |||||
 QY 4493 AAATTTGGGACCTCGAAGGCTACTGGAAGTGGGAATTCGCCCTGGGTTTATCCTCCT 4552
 Db |||||
 QY 4780 AAATTTGGGACCTCGAAGGCTACTGGAAGTGGGAATTCGCCCTGGGTTTATCCTCCT 4839
 Db |||||
 QY 4553 CATGACGTGGTCAITTTACCATATGCTGTATGATGACCCACAGCTACAGATGCAAGCA 4612
 Db |||||
 QY 4840 CACGACGACAGGTCAITTTACCATATGCTGTATGATGACCCACAGCTACAGATGCAAGCA 4899
 Db |||||
 QY 4613 CACCAAGACACAGATATGAAGCCTGAAGATTTGGAGCTGCCAAAGCCGTGTGCAC 4672
 Db |||||
 QY 4900 CACCAAGACATGATGCAAGAAAGCTGAAGATTTGGAGCTGCCAAAGCCGTGTGCAC 4959
 Db |||||
 QY 4673 CCATTTGAAACATTTCCCAACCGTGTCTTCAGCCAGGACCGTTCACCCACCGCCACCTGT 4732
 Db |||||
 QY 4960 CCATTTGAAACATTTCCCAACCGTGTCTTCAGCCAGGATGCGTAACCTAAACGCCCCACGT 5019
 Db |||||
 QY 4733 GCCGCCAGATATATGTCGCCCTTCCCAATACCCCGTAGGCAACCACTTATAAAGATAC 4792
 Db |||||
 QY 5020 ACCACCCAGATGATCTTCGCCCTTCTGTACCTTATAGACAGCTTAACCAAGATAT 5079
 Db |||||

QY 4793 AGACGCTGTAGATATAAATTTAATTAATAGATATGAACAACATGTAAATAGATGCTAAG 4852
 Db |||||
 QY 5080 AGACATGTAGATTTAAGTACTTAAACCAAGATATGAACAACATGTATTAGAAATGTTAAG 5139
 Db |||||
 QY 4853 ATTATGTAATATGACACAAAGTTTGGAAAAATAAAGCCCTTAAATAAATAATTCATAGTG 4912
 Db |||||
 QY 5140 ATTGTGTAATATGATCAAAATTTAGAAAAATAAACAATTTGTTGTTGTTTAAAAAATTAG 5199
 Db |||||
 QY 4913 TATGGTTCCTTTAAAAATTTCAAAAAGACACACCAAAATCAGATGCCGCGTGCAGCGG 4972
 Db |||||
 QY 5200 T-TGTTGCCCTTTAAAAATTTAAAAAGAGACACCAAAATCAGATGCCGCGTGCAGCGG 5258
 Db |||||
 QY 4973 GTAGCGGACCTTCGGGTACAAGATGGCGGACAGTTACGTCAATTTCTCTGTGACGTC 5028
 Db |||||
 QY 5259 GTAGCGGACCTTCGGGTACAAGATGGCGGACATTAAGTCAATTTCTCTGTGACGTC 5314
 Db |||||

RESULT 11
 PVPBRO
 LOCUS
 DEFINITION Human parvovirus B19-Wi promoter region, partial genome.
 ACCESSION M24682
 VERSION M24682.1 GI:333411
 KEYWORDS repeat region.
 SOURCE B19 virus
 ORGANISM B19 virus
 Viruses; ssDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
 REFERENCE 1 (bases 1 to 5255)
 AUTHORS Blundell M.C., Beard, C. and Astell, C.R.
 TITLE In vitro identification of a B19 parvovirus promoter
 JOURNAL Virology 157 (2): 534-538 (1987)
 MEDLINE 87151152
 PUBMED 3824909
 COMMENT
 Original source text: Parvovirus B19-Wi (Augusta isolate) DNA clones pYT[101.102], isolated from asymptomatic human blood serum. Draft entry and computer-readable sequence for [1] kindly submitted by C.Astell, 05-MAY-1989.

FEATURES
 source
 1..5255
 /organism="B19 virus"
 /mol_type="genomic DNA"
 /db_xref="taxon:10798"
 repeat_region 7..203
 /note="left terminal repeat"
 mRNA 351..>5255
 /product="ORF mRNA"
 repeat_region 5034..5249
 /note="right inverted terminal repeat"
 ORIGIN 1134 bp upstream of SpeI site.
 Query Match 76.7%; Score 3858.4; DB 14; Length 5255;
 Best Local Similarity 85.9%; Pred. No. 0;
 Matches 4328; Conservative 0; Mismatches 696; Indels 12; Gaps 4;
 QY 1 GAGTCACAGGAATGACGTAACTGTCCGCCACTTGTACCGCACTTGTACCGGAAGTCCCGCTACCGGC 60
 Db |||||
 QY 96 GACGTACAGGAATGACGTAACTGTCCGCCACTTGTACCGCACTTGTACCGGAAGTCCCGCTACCGGC 155
 Db |||||
 QY 61 GCGCCCGCGGCACCTGATTTGGTGTCTCTTTTGAATTTTGGCGGCTTTTTCGG 120
 Db |||||
 QY 156 GCGCCCGCGGCACCTGATTTGGTGTCTTCTTTAAATTTTAGCGGCTTTTTCGG 214
 Db |||||
 QY 121 CTTATGCAAAATGACGGCCATGTTTAATGTTATATTTTAAATTTATTTGGAACAAAGCCT 180
 Db |||||
 QY 215 CTTATGCAAAATGACGGCCATTTTAAAGTGTTTTACATATAATTTTATTTGTCAGTTTGT 274
 Db |||||
 QY 181 AACGGTTACTAGGGGGGAGTTACGG-----GCGGTATATAAGCAGCTGCTTCCCT 232
 Db |||||
 QY 275 AACGGTTAAATGCGCGGAGCGTAGCGGGGACTACAGTATATATAGCAGGCACTGCGC 334
 Db |||||
 QY 233 GACACTTTCTTTTCTGGTGTCTTTTGAAGTGAAGTCACTTGTCTCTTTTCTGCTTAAG 292
 Db |||||
 QY 335 CAGCTCTTTCTTCTGGGCTGCTTTTCTCTGGACTTCTTCTGCTGTTTCTTTGTGAGCTAAC 394
 Db |||||

Db 2555 ATATTAAGAGATCATTTATATATATTTCTTTAGATCATCCCTAGAAAAACCACTCTCTCTG 2614
QY TTTGACTTGTAGTCTCGCATTTAAAGTAACTTTAAACCTCTCCAGACTATATAGTCAT 2572
Db 2615 TTTAACTTGTAGTCTCGCATTTAAAGTAACTTTAAACCTCTCCAGACTATATAGTCAT 2674
QY CATTTTCAGAGCCATGGACAGTTATCTGACCAACCCCTGCTTATCATCCAGTAAACAGT 2632
Db 2675 CATTTTCAGAGCCATGGACAGTTATCTGACCAACCCCTGCTTATCATCCAGTAGCAGT 2734
QY AGTCAGAGCCATGGAGGAAATCCAGTATTTCTAGTGAAGCTTTACACAGCCCTGGG 2692
Db 2735 CATGAGAGCCATGGAGGAAATCCAGTATTTCTAGTGAAGCTTTACACAGCCCTGGG 2794
QY CAAGTTAGCATCAATTAACCCGGTACTAACTATGTTGGGCTGCAATGAGCTACAAGCT 2752
Db 2795 CAAGTTAGCATCAATTAACCCGGTACTAACTATGTTGGGCTGCAATGAGCTACAAGCT 2854
QY GGGCCCTCCGAGATGCTGTGGACAGTGTGCAAGGATTCATGACTTTAGGTATAGCCAA 2812
Db 2855 GGGCCCTCCGAGATGCTGTGGACAGTGTGCAAGGATTCATGACTTTAGGTATAGCCAA 2914
QY TTGGCTAAGTTGGGAATAAATCCCTTATACATTTGGAGGCTGAGAGTAAAGATTTT 2872
Db 2915 CTGGCTAAGTTGGGAATAAATCCCTTATACATTTGGAGGCTGAGAGTAAAGATTTT 2974
QY AAAATATATAAATAAGAAACAGGTTTCAAGCAACAGCAGTAAAGATTTTACTTTTA 2932
Db 2975 AAAATATATAAATAAGAAACAGGTTTCAAGCAACAGCAGTAAAGATTTTACTTTTA 3034
QY AAAGTGCAGCTGCCCTGCGCCATTTTCAAGCAACAGCAGTAAAGATTTTACTTTTA 2992
Db 3035 AAAGTGCAGCTGCCCTGCGCCATTTTCAAGCAACAGCAGTAAAGATTTTACTTTTA 3094
QY AACCCCTCAGAAAAATACCCAGCATGACTTCAAGTAACTCTGCAAGCAGCAGCTGTG 3052
Db 3095 AACCCCTCAGAAAAATACCCAGCATGACTTCAAGTAACTCTGCAAGCAGCAGCTGTG 3154
QY GCAGCGGGGGGTAGCAACCTTACAAAGCATGTGGAGTGAAGGGCTCATTTTACT 3112
Db 3155 GCAGCGGGGGGTAGCAACCTTACAAAGCATGTGGAGTGAAGGGCTCATTTTACT 3214
QY GCTAATCTGTAAACGTGTACATTTCTAGGCAATTTTAAATTCCTATGATCCAGCAT 3172
Db 3215 GCCAATCTGTACTGTACATTTTCCAGCAGTTTTAAATTCCTATGATCCAGCAT 3274
QY CATTTAAGTGTCTCTCAGCAGCTGTAGTGCACAAATGCTAGTGGGAAAGAGCA 3232
Db 3275 CATTTAAGTGTGTCTCTCAGCAGCTGTAGTGCACAAATGCTAGTGGGAAAGAGCA 3334
QY AAAGTGTGCATTTAGTCCCATTTATGGGTTACTCTACTCCGTCGAGATCTTATGAT 3292
Db 3335 AAGTTTGCACCATTTAGTCCCATTTATGGGTTACTCTACTCCGTCGAGATCTTATGAT 3394
QY AATGCTTTAAATTTGTTTCTCACCATTTAGGTTTCTAGCAGCTTAAATTTAAATTTATG 3352
Db 3395 AATGCTTTAAATTTGTTTCTCACCATTTAGGTTTCTAGCAGCTTAAATTTAAATTTATG 3454
QY AGTATAGCTCCAGATGCTTTAACTGTAACTATTTTCAAGAAATGCTGTAAAGATGT 3412
Db 3455 AGTATAGCTCCAGATGCTTTAACTGTAACTATTTTCAAGAAATGCTGTAAAGATGT 3514
QY GACAAAAACGAGAGGAGTGTGCAAGTTACTGACAGCAGCAGGAGCTTTGATGATGTA 3472
Db 3515 GACAAAAACGAGAGGAGGAGTGTGCAAGTTACTGACAGCAGCAGGAGCTTTGATGATGTA 3574
QY GTGGATCATGATGATTAATACCATATGCTAGTGTAGGAGCAAGACACATAGCTCCA 3532
Db 3575 GTAGACCATGATGATTAATACCATATGCTAGTGTAGGAGCAAGGAGTCACTTTAGCCCA 3634
QY GAACTGCCCATTTGGGTTTACTTTTCCCGCCCGCATGCTTAAACAGTAGGTGAGTA 3592

Db 3635 GAACTTCTTATTTGGGTATATCTTTCCCTCAATATGCTTACTTAACAGTGGGAGATGTC 3694
QY AACACACAAAGGAATTTTCAGAGCAGACAAAAAATTTGGCTAGTGAAGAAATCAGCTTTTAT 3652
Db 3695 AACACACAAAGGAATTTTCAGAGCAGACAAAAAATTTAGCAAGTGAAGAAATCAGCTTTTAT 3754
QY GTGTTAGACACAGATTTTCAATTTGAACCTTTTGGGTACAGGGGGATCTGCCACTATGCTTAC 3712
Db 3755 GTTTTGGAAACACAGATTTTCCCTTTTCAAGCTTTTGGTACAGGAGGTACAGCAACTATGCTTAT 3814
QY AAATTTCCAGCTGTGCCCCCAGAAAAACCTAGAAAGCTGAGCCAAATTTTATGAATG 3772
Db 3815 AAGTTTCTCCAGTGTGCCCCCAGAAAAATTTAGAGGCTGCAAGTCAACACTTTTATGAATG 3874
QY TACAACCTTTTGTACGGTTTCTGTTTGGGTACAGGGGGATCTGCCACTATGCTTAC 3772
Db 3875 TACAATCTTTTATACAGGATCCGCTTGGGTTCCTGACACTAGGAGGTGACCCAAA 3934
QY TTTAGATCATTTGACACAGAGACCAACCAATTTAGCCCAAACTTTATGCCAGGGCCA 3892
Db 3935 TTTAGATCATTTGACACAGAGACCAACCAATTTAGCCCAAACTTTATGCCAGGGCCA 3994
QY CTATAAATTTCACTGTCTACCAAGAGAGAGACCAATTTAGCCCAAACTTTATGCCAGGGCCA 3952
Db 3995 CTAGTAAATTTCACTGTCTACCAAGAGAGAGACCAATTTAGCCCAAACTTTATGCCAGGGCCA 4054
QY CTAGCGGCTTTAGTGTGCACTAGCCAAACCAACCAAGTATTTCCCTACGCCCCGGGCCA 4012
Db 4055 TTAACAGGCTTTAGCAGAGTACCTCTCAAAACACTAGATATCTTTAGCCCTTGGGCCA 4114
QY GTATCTCAGCCATACCATCTGCGGACACTGATATAATTTGTTACAGAAATAATGCCATT 4072
Db 4115 GTGCTCAGCCATACCATCTGCGGACACTGATATAATTTGTTACAGAAATAATGCCATT 4174
QY TCACATGGAACAAACCTTTATGGAATGCTGAGGACAAAGATATCAGCAAGGGGTAGGA 4132
Db 4175 TCTCATGCTCAAACTTATGTTTAACTGTTAACTGAGACAAAGATATCAGCAAGGGGTAGGA 4234
QY AGATTTCCAAATGAAGAAAGACAGCTTTAAGAGTTTAACTGATTAACATGCAACATAC 4192
Db 4235 AGATTTCCAAATGAAGAAAGACAGCTTTAAGAGTTTAACTGATTAACATGCAACATAC 4294
QY TTTCCCTAATAAGGAACCCCAACATACACAGACCAAAATGCAAGCTTTTATGTTGGG 4252
Db 4295 TTTCCCAATAAGGAACCCCAACATACACAGACCAAAATGCAAGCTTTTATGTTGGG 4354
QY TCTGTTTGAACAGAGAGCTCTTCACTATGAAGTCAAGTGTGAGTAAATTTCCCTAAC 4312
Db 4355 TCTGTTTGAACAGAGAGAGCTCTTCACTATGAAGTCAAGTGTGAGTAAATTTCCCTAAC 4414
QY TTAGATGACAGTTTAAAACCTCAATTTGAGCCCTAGGCGGGTGGGTTTGCATCAACCA 4372
Db 4415 TTAGATGACAGTTTAAAACCTCAATTTGAGCCCTAGGCGGGTGGGTTTGCATCAACCA 4474
QY CCCCCTCAATATTTTAAAATATTAACCAAGTGGGCCAAATTTGGAGGTATTAATCC 4432
Db 4475 CCCCCTCAATATTTTAAAATATTAACCAAGTGGGCCAAATTTGGAGGTATTAATCC 4534
QY ATGGGAATTTACTTACTTCAATATGCTGTGGGAATTAATGACAGTTACCATGACCTTT 4492
Db 4535 ATGGGAATTTACTTACTTCAATATGCTGTGGGAATTAATGACAGTTACCATGACCTTT 4594
QY AAATTTGGGACCTTGAAGGCTTACTGGAAGGTGGAATTTCCAGCTGGGGTTTATCCTCT 4552
Db 4595 AAATTTGGGACCTTGAAGGCTTACTGGAAGGTGGAATTTCCAGCTGGGGTTTATCCTCT 4654
QY CATGAGCTGTGCTCAATTTACCATATGCTGTGGAATTAATGACAGTTACCATGACCTTT 4612
Db 4655 CAGCAGCAGGCTCAATTTACCATATGCTGTGGAATTAATGACAGTTACCATGACCTTT 4714
QY CACCAACAGATGATGAAAGGCTGAAAGTTGTGGAATTTGTGGAATTTGTGGAATTTGTG 4672
Db 4715 CACCAACAGATGATGAAAGGCTGAAAGTTGTGGAATTTGTGGAATTTGTGGAATTTGTG 4774

Db 581 ||||| GCAGTGTGCTTCTAAGCTTGACTTTACCGGGGGCCACTAGCAGGGTGTGTACTTTT 640
QY 533 ||||| TTCAAGTGAATGTAACAAATTTGAGGAGGCTATCATATCCATAGATTATTTGGTGTGTC 592
Db 641 ||||| TTCNAGTAGAATGTAACAAATTTGAGGAGGCTATCATATTTCAATGTGTACTGGGGGC 700
QY 593 ||||| CAGGACTAAATGCTAGAACTTAACTTAACTGTGTGCTAGAGAGGTTTATTTAATAATGTTCTTT 652
Db 701 ||||| CAGGGTTAAACCCAGAAACCTTACAGTGTGTGTAGAGGGTTATTTAATAATGTTACTTT 760
QY 653 ||||| ACCATCTGTACTGAAGTGTAACTTAACTTAAATTTTCCAGGAGTACTACCAAGGAA 712
Db 761 ||||| ATCACTCTGTAACTGAAGTGTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAA 772
QY 713 ||||| AATAATTTAGAGATGGAGAGGAGTTTATAGAAATTTTAACTTAACTTAACTTAACTTAA 820
Db 821 ||||| AATACTTTAGAGATGGAGAGGAGTTTATAGAAATTTTAACTTAACTTAACTTAACTTAA 880
QY 773 ||||| ATGTTGTGTGTGTGTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTT 832
Db 881 ||||| ATGTTGTGTGTGTGTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTT 940
QY 833 ||||| TTCGGCAGGAGCTTGTCACTTAAAGACCCCGCATTTACTGCAATATACAGACAGTGCTA 892
Db 941 ||||| TTAGAGGGGAGCTTGCATGCCAGAAACCCCGCATTTACACAGCCATTAATGATACTA 1000
QY 893 ||||| CTAAATGAACCTGGGGAGTCTAGCTGTGGAGGGGAGATGTTGTGCCATTCGCTGGAAAGG 952
Db 1001 ||||| GTAGTGTGTGTGTGTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTT 1060
QY 953 ||||| GAACAAAGCGGGTTTAAAGTTTCAACCAATGTTAACTTAACTTAACTTAACTTAACTTAACTT 1012
Db 1061 ||||| GAATAAGCTAGCATTAAGTTTCAACTATGTTAACTTAACTTAACTTAACTTAACTTAACTT 1120
QY 1013 ||||| TTACTGAAGATAAATGAATTAAGTGTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAA 1132
Db 1121 ||||| TTACAGAGGATAGTGGAACTAGTTGACTTTAACTTAACTTAACTTAACTTAACTTAACTTAA 1180
QY 1073 ||||| ACAGTGGCAGCTTCAAACTCAAGTGTCTTAAAGTGTAACTTAACTTAACTTAACTTAACTTAA 1132
Db 1181 ||||| ACAGTGGAGTGTTCAAATTCAAAGTGTCACTTAACTTAACTTAACTTAACTTAACTTAACTTAA 1240
QY 1133 ||||| TAGTACCCTAGTACATTTCTGTACATTTCAAGTGTCACTTAACTTAACTTAACTTAACTTAACTT 1192
Db 1241 ||||| TAGTGCTACTAGCACATTTTATGCTACAGACTTTCAGCAGGTTATGTGTATTAAG 1300
QY 1193 ||||| ABAATAAATAGTAAATTTATTTGTGCAAACTATGATCCTCTTTTGTGGGTCAAC 1252
Db 1301 ||||| ACAATAAATTTGTAAATTTGTACTTTGTCAAACTATGACCCCTTATGTGGGGCAGC 1360
QY 1253 ||||| ATGTGTTAAGGTGATTTGACAAATTTGTTAAAGTGTGTAAGAAACACCCCTGTGGTTTACGGGC 1312
Db 1361 ||||| ATGTGTTAAGGTGATTTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAG 1420
QY 1313 ||||| CACCAAGTACTGGAAAACTTGGCAATTTGGCAATTTGGCAATTTGGCAATTTGGCAATTTGGCAAT 1372
Db 1421 ||||| CGCCAGTACAGGAAAACTTGGCAATTTGGCAATTTGGCAATTTGGCAATTTGGCAATTTGGCAAT 1480
QY 1373 ||||| GAATGTGAATTTGGAATTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGT 1432
Db 1481 ||||| GCATGTTTAACTGGAATTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGT 1540
QY 1433 ||||| TGGTCTGGGATGAAGGCTATTTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAG 1492
Db 1541 ||||| TGGTCTGGGATGAAGGCTATTTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAGTGTGTAAG 1600
QY 1493 ||||| GTGGTCAAGCAGGCTAGTACAGAAATTTGGGAGTGTGGGAGTGTGGGAGTGTGGGAGTGTGGGAG 1552
Db 1601 ||||| GGGGCAACCCACAGGCTAGTACAGAAATTTGGGAGTGTGGGAGTGTGGGAGTGTGGGAGTGTGGGAG 1660
QY 1553 ||||| CTGTGGTTTAAACAGCAATGCTGACATTTTACATTTTGTGTGAGTGTGTAAGTGTGTAAGTGTGTAAG 1612

Db 1661 ||||| CTGTGGTTTAAACAGCAATGTTGACATTTCTTGTGTAAAGCGGAACACTACAACA 1720
QY 1613 ||||| CTGTGCTGTAAAGCTTAAAGGAACGGATGGTAAAGCTTAACTTTACATAAGATGTA 1672
Db 1721 ||||| CTGTACATGCTAAAGCTTAAAGAGCGCATGTAAGATTTAACTTTACTGTAAAGTGA 1780
QY 1673 ||||| GCCTGACATGGGTTTACTTACAGAGGCTGTACAACTATGGCTTAACTTGGTGTAAAG 1732
Db 1781 ||||| GCCTGACATGGGTTTACTTAAACAGAGGCTGTACAACTATGGCTTAACTTGGTGTAAAG 1840
QY 1733 ||||| CACAAAGCTGGAGCCACTATGAAACTGGGCAATTAACATTAATTTGATTTCCCTGGAA 1792
Db 1841 ||||| CACAAAGCTGGAGCCACTATGAAACTGGGCAATTAACATTAATTTGATTTCCCTGGAA 1900
QY 1793 ||||| TAAATGACAGTCCCTCCACCCAGACTCTCAAAACCAACCCCAATTTGTCACAGACACGTA 1852
Db 1901 ||||| TTAATGACAGTCCCTCCACCCAGACTCTCAAAACCAACCCCAATTTGTCACAGACACGTA 1960
QY 1853 ||||| TCAGCAGCAGTGGTGTGAAAGCTCTGAAGAACTCAGTGAAGAGCTTTTTCACCTCA 1912
Db 1961 ||||| TCAGCAGCAGTGGTGTGAAAGCTCTGAAGAACTCAGTGAAGAGCTTTTTCACCTCA 2020
QY 1913 ||||| TCACCTCCAGGCGCTGGAAACAGTGAACCCCGCGCTAGTACCGCGTCCCGGGAGCA 1972
Db 2021 ||||| TCACCCAGGCGCTGGAAACAGTGAACCCCGCGCTAGTACCGCGTCCCGGGAGCA 2080
QY 1973 ||||| GTTACAGGAATCATTTGTGGAAGCCAGTTTCTCCGAAGTGTAGCCCGCTCGTGGG 2032
Db 2081 ||||| GTTACAGGAATCATTTGTGGAAGCCAGTTTCTCCGAAGTGTAGCTCGTGGG 2140
QY 2033 ||||| AGGAAGCTTTTACACCGCGCTTCCCGATCAGTTTGTGTGAACTTTTGTAGTGGGTTGACT 2092
Db 2141 ||||| AAGAAGCTTTTACACACTTTTGGCAGACCACTTGTGAACTTTTGTAGTGGGTTGACT 2200
QY 2093 ||||| TTGTATGGATGGTGTGAGGGGATTTGCTGTGTGTGAACTATTAATGTGGAGCTTGGTATAATGGATGGA 2212
Db 2201 ||||| ATGTGTGGACGGTGAAGGGTTTACCTGTGTGTGTGTGTGCAACATTTTAACTAGT 2260
QY 2153 ||||| GGGGAGGTTGGGCTTTTGGCCTCATTTGTATTAATGTGGAGCTTGGTATAATGGATGGA 2212
Db 2261 ||||| GGGGAGGTTGGGCTTTTGGCCTCATTTGTATTAATGTGGAGCTTGGTATAATGGATGGA 2320
QY 2213 ||||| AATTTAGAGGTTTACTTCCAGACTTGTGCGCTGTGCACTTGTATGTAGGAGCTTCTAAAC 2272
Db 2321 ||||| AATTTAGAGGTTTACTTCCAGACTTGTGCGCTGTGCACTTGTATGTAGGAGCTTCTAAAC 2380
QY 2273 ||||| CATTTTCTGTGTAACTTTGTAAGGCTTCTTACCTGTGTGATTAACAAAGTTTGTAG 2332
Db 2381 ||||| CTTTCTGTGTAACTTTGTAAGGCTTCTTACCTGTGTGATTAACAAAGTTTGTAG 2440
QY 2333 ||||| ATTATGAGTAAACCTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAA 2392
Db 2441 ||||| ATTATGAGTAAACCTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAA 2500
QY 2393 ||||| TATAAGCAGTTTGTGCAATTTTATGAAAAAGCTTCTGGAACAGACTTGTAGAGCTTATTCAA 2452
Db 2501 ||||| TATCAGCAATTTTGTGCAATTTTATGAAAAAGCTTCTGGAACAGACTTGTAGAGCTTATTCAA 2560
QY 2453 ||||| ATTTTAAAGACCATTTACCAATTTTCTTGTAGATTAATCTTTTGTAGAAAAACCTTCTTCTTTA 2512
Db 2561 ||||| ATATTAAAGATCATTTATTAATTTCTTTTGTAGATTAATCTTTTGTAGAAAAACCTTCTTCTTTA 2620
QY 2513 ||||| TTTGACTTGTGTGCTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAA 2572
Db 2621 ||||| TTTGACTTGTGTGCTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAACTTAA 2680
QY 2573 ||||| CATTTTTCAGAGCCATGAGTATCTGACCAACCCCGATGCTTATCATPCCAGTAACT 2632
Db 2681 ||||| CATTTTTCAGAGCCATGAGTATCTGACCAACCCCGATGCTTATCATPCCAGTAACT 2740
QY 2633 ||||| AGTCAGAACTTAGAGGAGAAATGCAGTATTTATCTAGTGAAGCTTACACAGCTGGG 2692
Db 2741 ||||| CATGCAGAACTTAGAGGAGAAATGCAGTATTTATCTAGTGAAGCTTACACAGCTGGG 2800

QY 2693 CAAGTTAGCATACAATTAACCCGGTACTAACTATGTTGGGCTGGCAATGAGCTACAAGCT 2752
DB |||||
2801 CAAGTTAGCGTACAACATACCCGGTACTAATGTTGGGCTGGCAATGAGCTACAAGCT 2860
QY 2753 GGCGCTCCGGAGAAATGCTGTGGACAGTGTGCAAGGATTCATGACTTTAGGTATAGCCAA 2812
DB |||||
2861 GGCGCCCGCAAAATGCTGTGACAGTGTGCAAGGATTCATGACTTTAGGTATAGCCAA 2920
QY 2813 TTGGCTAAAGTTGGGAATAAATCCTTATACATTTGGACGGTACAGATGAAGATTTGTTA 2872
DB |||||
2921 CTGGCTAAAGTTGGGAATAAATCCTTATACATTTGGACGGTACAGATGAAGAGCTTTTA 2980
QY 2873 AAAAAATATAAAAAATGAAACAGGGTTTCAAGCAACAGTAAAGATTAATTTACTTTTA 2932
DB |||||
2981 AAAAAATATAAAAAATGAAACAGGGTTTCAAGCAACAGTAAAGATTAATTTACTTTTA 3040
QY 2933 AAAGGTGACGCTGCCCTGTGGGCCAATTTTCAAGGAAGTTTACCGGAAGTGGCCGGGTAC 2992
DB |||||
3041 AAAGGTGACGCTGCCCTGTGGGCCAATTTTCAAGGAAGTTTACCGGAAGTGGCCGGTAC 3100
QY 2993 AACGCTCAGAAAAATACCCAGCATGACTTCAAGTTAACTCTGCAGAACCCAGCATGCT 3052
DB |||||
3101 AACGCTCAGAAAAATACCCAGCATGACTTCAAGTTAACTCTGCAGAACCCAGCATGCT 3160
QY 3053 GCAGGCGGGGAGGTAGCAACCCCTACAAAAAGCATGTGGAGTGAAGGGGCTACATTTACT 3112
DB |||||
3161 GCAGGAGGGGGGCGAGTAATCTGTGTAAGCAATGTGGAGTGAAGGGGCGCATTTTACT 3220
QY 3113 GCTAATTCGTAAAGTGTACATTTCTGAGGCAATTTTAAATCCATATGATCCAGAGCAT 3172
DB |||||
3221 GCTAATTCGTAAAGTGTACATTTCTGAGGCAATTTTAAATCCATATGATCCAGAGCAT 3280
QY 3173 CATTAATAAGTGTCTCTCCAGCAGTGTAGTGTCCACAACTCTAGTGGGAAGAGGCA 3232
DB |||||
3281 CATTAATAAGTGTCTCTCCAGCAGTGTAGTGTCCACAACTCTAGTGGGAAGAGGCA 3340
QY 3233 AAAGTGTGCACTAATAGTCCCATTTATGGGGTACTCTACTCCGTGGAGATCTTTAGATTTT 3292
DB |||||
3341 AAGGTTGACCAATCAGTCCCATTAATGGGATCTCAACCCATGGAGATATTTAGATTTT 3400
QY 3293 AATGCTTTAAATTTGTTTTCTCACCATTAGAGTTTCAGCAGCTTAATGAAATATAGT 3352
DB |||||
3401 AATGCTTTAAATTTATTTTTTTTCCACCTTTAGAGTTTCAGCAGCTTAATGAAATATAG 3460
QY 3353 AGTATAGCTCCAGATGCTTTAACTGTAACTATTTTCAGAAATGCTGTAAAGATGTACA 3412
DB |||||
3461 AGTATAGCTCCAGATGCTTTAACTGTAACTATTTTCAGAAATGCTGTAAAGATGTACA 3520
QY 3413 GACAAAAAGGAGGAGTGTGCAAGTTTACTGACAGCACCAAGGAGCTTTGTGTATGTTA 3472
DB |||||
3521 GACAAAAAGGAGGAGTGTGCAAGTTTACTGACAGCACCAAGGAGCTTTGTGTATGTTA 3580
QY 3473 GTGGATCATGAGTATAAATACCATATGCTAGGTGAGGACAGACACACTAGCTCCA 3532
DB |||||
3581 GTAGACCATGAATACAAAGTACCCTATATGTTAGGGCAAGGTCAAGGATCTTTAGCCCA 3640
QY 3533 GAAGTCCCAATTTGGGTTTACTTTTCCCGGAGTATGCTTTTAAAGATGTAGTGAAGTA 3592
DB |||||
3641 GAAGTCCCAATTTGGGTTTACTTTTCCCGGAGTATGCTTTTAAAGATGTAGTGAAGTA 3700
QY 3593 AACACACAAAGGAATTTTCAGGAGACAGCAAAAAATTTGGCTAGTGAAGATTCAGCTTTTAT 3652
DB |||||
3701 AACACACAAAGGAATTTTCAGGAGACAGCAAAAAATTTGGCTAGTGAAGATTCAGCTTTTAT 3760
QY 3653 GTGTTAGACACAGTTTCAATTTGAATTTTGGGTACAGGGGATGCTGCCCATATGCTCTAC 3712
DB |||||
3761 GTTTTGGAAACACAGTTCTTTTACGCTTTTAAAGTACAGGAGTACAGCATCTATGCTTAT 3820
QY 3713 AAATTTCCAGCTGTGCCCGGAGAAACCTAGAGGGTGTGAGGCAACATTTTATGAATG 3772
DB |||||
3821 AAGTTTCTCCAGTGTGCCCGGAGAAATTTTAAAGGGGTGCGAGTCAACACTTTTATGAATG 3880

QY 3773 TACAACCCCTTTGTACGGTTCTCGTTTATGGGGTACCTGACACATTTAGGAGGGGACCCCTAAA 3832
DB |||||
3881 TACAATCCCTTTATACGGATCCCGCTTAGGGTTCTCTGACACATTTAGGAGGTGACCCAAA 3940
QY 3833 TTTAGATCATTTGACACACAGAACACCGCAATTTGAGCCACAAAATTTTATGCTTGGGCCA 3892
DB |||||
3941 TTTAGATCTTTTAAACATGAAGACCATGCAATTTGAGCCCAAAATTTGATGCCAGGGCCA 4000
QY 3893 CTAATAAAATTTCAAGTGTCTACCAAGAGAGAGACAAATTTCTAATACAGGTGCTGGAAGAAGCC 3952
DB |||||
4001 CTAGTAAATCTCAGTGTCTACAAAGGAGGAGACAGCTCTAATACTGGAGCTGGAAGAAGCC 4060
QY 3953 CTTACGGGCTTTAGTACTGGCACTAGCCAAAACACAGAAATTTCCCTACGCCCGGGGCCA 4012
DB |||||
4061 TTTAACAGGCTTTAGCACAGGTACTCTCTCAAAAACACTAGAAATATCTTTACGCCCTGGGCCA 4120
QY 4013 GTATCTCAGCCATACCATCCTGGGACACTGATAAATATGTTTACAGGAATAAATGCAAT 4072
DB |||||
4121 GTGCTCTCAGCCATACCCACACTGGGACACAGATAAATATGTCACAGGAATAAATGCAAT 4180
QY 4073 TCACATGGACAAACCACTTTATGAAATGCTGAGGACAAAAGAGTATCAGCAAGGGGTAGGA 4132
DB |||||
4181 TCTCATGCTCAGACCACTTTATGTAACGCTGAAGACAAAAGAGTATCAGCAAGGAGTGGGT 4240
QY 4133 AGATTTTCCAAATGAAAAAGAACAGCTTAAAGCAGTTTAAAGGCTTTAAACATGCAACATAC 4192
DB |||||
4241 AGATTTTCCAAATGAAAAAGAACAGCTTAAAGCAGTTTAAAGGCTTTAAACATGCAACATAC 4300
QY 4193 TTCCCTTAATAAAGGAACCCCAACATACACAGAACCAAAATTTGAAGCCCTCTTTATGTTGGGC 4252
DB |||||
4301 TTTCCCAATAAAGGAACCCCAAGCAATATACAGATCAAAATTTGAGCGCCCTCTTAATGTTGGGT 4360
QY 4253 TCTGTTTGAACACAGAGAGCTCTTCACTATGAAAGTCACTGTGGAGTAAATCCCTTAAC 4312
DB |||||
4361 TCTGTATGGAACAGAGAGCCCTTCACTATGAAAGCCAGCTGTGGAGTAAATTTCCAAAT 4420
QY 4313 TTAGATGACAGTTTTAAAACTCAATTTGAGCGCTTAGGGGGTGGGTTTGATCAACCA 4372
DB |||||
4421 TTAGATGACAGTTTTAAAACTCAATTTGAGCGCTTAGGGAGGATGGGTTTGATCAACCA 4480
QY 4373 CCCCCTCAAAATTTTAAAAATATACACAAAGTGGGCAATTTGGAGGTATTAATCC 4432
DB |||||
4481 CCTCTCTCAAAATTTTAAAAATATATACCAAAAGTGGGCAATTTGGAGGTATTAATCA 4540
QY 4433 ATGGGAATTTACTACTTTTAGTTCAAATATGCTGTGGGAATAATGACAGTACCATGACCTTT 4492
DB |||||
4541 ATGGGAATTTACTACTTTTAGTTCAGTATGCTGTGGGAATTTAGACATTAATGACATTT 4600
QY 4493 AAATTTGGGACCTCGAAAGGCTACTGGAAGGTGGAATCCCGAGCTGGCGTTTATCTCTCT 4552
DB |||||
4601 AAATTTGGGACCTCGGTAAGCTACGGGACGGTGGAAATCTCAACCTGGAGTATATCCCG 4660
QY 4553 CATGACGTGTGTCATTTTACCATATGTAATGATGAGCCCAAGCTACAGATGCAAGAACAA 4612
DB |||||
4661 CACGACGACAGGTCAATTTTACCATATGTAATGATGAGCCCAAGCTACAGATGCAAGAACAA 4720
QY 4613 CACCAACAGACAGGATATGAAAGCTGGAAGTGTGGAGCTGCAAGGAGCGGTGGTGCAC 4672
DB |||||
4721 CACCAACAGACAGGATATGAAAGCTGGAAGTGTGGAGCTGCAAGGAGCGGTGGTGCAC 4780
QY 4673 CCATTTGTAACATTTCCCAACCGTGTCTCAGCCAGGAACCGTCACCCAGCGCCACCTGT 4732
DB |||||
4781 CCATTTGTAACATTTCCCAACCGTGTCTCAGCCAGGAACCGTCACCCAGCGCCACCTGT 4840
QY 4733 GGCGCCAGATTTATGTTGCCCTCTCAATATACCCCGTAGGCAACCATCTATATAAGATAC 4792
DB |||||
4841 ACCACCCAGATGTTACTGCTGCCCTCTCTGTACTATATAGACAGCCCTTAACACAAAGATAT 4900
QY 4793 AGACGCTGTAGATATAAATTTAATTAAGTATGAAACCAATGTAATTTAGATGCTTAAG 4852
DB |||||
4901 AGACAAATGTAGAAATTTTAAAGTACTTAAACCAATGTAATGTAATTTAGATGTTAAG 4960
QY 4853 ATTATGTAATGTATACACAAAGTTTGGAAAAATAAAGGCTTAAATAAATAATTCATAGTG 4912

```

/gene="VP1"
/codon_start=1
/product="capsid protein vp1"
/protein_id="BAA90292.1"
/db_xref="GI:6759338"
/translation="MNSKESGKWSDDKFAKAVYQQVFVEFYKVTGTDLELIQLKDH
YNSLDHLEPNSSLSFDLVARIKNNKNSPNLYSHHFQSHGQLSDHPHALSSSSHAE
PRGENVADELHKPQSVQVLPKNTYVGFNGLQAGPQPSAVDSAAIRIHDPRVSQL
AKLGINTPYHTWTVADDELLKNIKNETGFAQVVKDYETLKGAAAPVAHFQGGSLPEVA
YNASEKPSMTSVNSARASTGAGGSGNPKMSGSGATFTANSVTCITSRFOLPIPYD
PEHYKVPSPAASSCHASKEAKVCTIISIMGISTPWRYLDNFNALNLFFSFLFQHL
LENTGSAPDALVTWISZAYAVDKTGGQVQVTDSTGLRCLMLVDHEYKPYVILQG
QODILAEPLWTFPPQYALVTGDVNTGGISGDSKGLASBESAPYVLEHSFQVILQG
TGGTATWSPFPPVNSPENTREGCSQHIFYEMNPLYGSRGLGVPDTLGGDKPRFSLTHEDH
AQIQNPMFGLPNSVETKEDGSNTGAGKALTGLSTGTSQNTRIISLRPGPVQSPYHH
WDTKYVTGINALSHGQVTCGNABDEKYYQQGVGRPNKEKQLKQLGLNMHTYFPNKG
TQOYTDQIERPLMWGSVNNRRALHYESQKIPNLDDSEFKTQFAALGQVGLHQPQPPQ
IFKLIPQSGPIGGIKSMGITLIVQYAVGLMTVTMTFKLGPRTKGRMNPQGVYPPH
AAGLHPVLVDPTATDAKQHRHGYEKPEBELMTAKSRVHPL"
3061..4725
/gene="vp2"
CDS
3061..4725
/gene="VP2"
/codon_start=1
/product="capsid protein vp2"
/protein_id="BAA90293.1"
/db_xref="GI:6759339"
/translation="MTSVNSAEASTCAGGGGSPAKSNMWSSEGATFTANSVTCITFSRQF
LIYPDEHYKVPSPAASSCHASKEAKVCTIISIMGISTPWRYLDNFNALNLFFSPL
EFQHLLENTGSAPDALVTWISZAYAVDKTGGQVQVTDSTGLRCLMLVDHEYKYP
YVLGQODTLAEPLWTFPPQYALVTGDVNTGGISGDSKGLASBESAPYVLEHSF
FOLLGQDITKATWSYEPFPPVNPENLSCSHQFYEMNPLYGSRGLGVPDTLGGDKPRFSL
THEGHALQPNFMFGLPNSVETKEDGSNTGAGKALTGLSTGTSQNTRIISLRPGPV
QPHWMDTKYVTGINALSHGQVTCGNABDEKYYQQGVGRPNKEKQLKQLGLNMHTY
FPNKGQYTDQIERPLMWGSVNNRRALHYESQKIPNLDDSEFKTQFAALGQVGLH
QPQOIFKLIPQSGPIGGIKSMGITLIVQYAVGLMTVTMTFKLGPRTKGRMNPQGV
VYPPHAAGHLPVLDPTATDAKQHRHGYEKPEBELMTAKSRVHPL"

ORIGIN
Query Match 74.2%; Score 3729; DB 14; Length 4803;
Best Local Similarity 86.7%; Pred. No. 0;
Matches 4133; Conservative 0; Mismatches 625; Indels 9; Gaps 2;

Qy 1 GAGCTCACAGGAATGACGTAACCTCTCGCCACTCTTGACCGGAAGTCCGCCCTACCGGC 60
Db 38 GAGCTCACAGGAATGACGTAATTCGCGCACTCTTGACCGGAAGTCCGCCCTACCGGC 97

Qy 61 GCGCACC GCGGCATCTGATTTGGTGTCTCTTTTTCAAATTTTGGCGGGCTTTTCCCG 120
Db 98 GCGCACC GCGGCATCTGATTTGGTGTCTTC-TTTTAAATTTTAGCGGGCTTTTCCCG 156

Qy 121 CTTTATGCAATTAAGCGGCATGTTTAAATGTTATTTTAAATTAATGACAAACGCCT 180
Db 157 CTTTATGCAATTGGCAGCCATTTTAAAGTGTTTTACTTTTAAATTTTATTGGCCAGTTTGT 216

Qy 181 AAGCGTTACTAGGCGCGAGTTACGG-----GCGGTATATAAGCAGCTGCGTCCCT 232
Db 217 AACGGTTAAATGGCGGAGCGTGGCGGGGAATACAGTATATATAGCAGGCACTGCCG 276

Qy 233 GACACTTTCTTTCTGGTGTCTTTTGACTGGACTACTTGTCTGTTCTTTGCCCTGCTAAG 292
Db 277 GAGCTCTTCTTCTGGGCTGCTTTTTTCTGGACTTTTCTTGTCTGTTTTTGTGAGCTAAC 336

Qy 293 TAAACAGGTATTTACTAACTTTTAAATTTACTAACTGAGCTATTTCCGGGTGCTTCG 352
Db 337 TAAACAGGTATTTACTACTTTGTTTACATACTAACATGAGCTATTTAGGGGTGCTTC 396

Qy 353 ACATTTCTCTCAACATTTCTGCACTGTGCTTAAATGATAACTGGTGGTCTCTATGCTAGCT 412
Db 397 AAGTTTCTCTTAATGTTTCTGCACTGTGCTAACGATAACTGGTGGTCTCTTACTGGATT 456

Qy 413 TAGATACTTCTGACTGGGAACCACTAACCCATTTCTAACAGNTAATGCAATATATTAA 472

```

Db 457 TAGACACTTCTGACTGGGACCACTAACTCATACTAAAGACCTAATGGCAATATACCTTAA 516
Qy 473 GCAGTGTGCTCTCAAACTTGATTTTAACTGGGGGGCCGTAGCAGAGTTGCTTATACCTTTT 532
Db 517 GCAGTGTGGCTTCTAAGCTTGACTTTTACCGGGGGCCGTAGCAGGGTGTCTGTACTTTT 576
Qy 533 TTCAAGTGGATGTAACTAAATTTGAGGAAGGCTATCATATCCATGTAGTTATTTGGTGC 592
Db 577 TTCAAGTGAAGTGAACAAATTTGAAGAGGCTATCATATTCATGTGGTTATTTGGGGGGC 636
Qy 593 CAGGACTAAATGCTAGAACTTAACCTGTGTGCGTAGAAGGTTTATTTAATAATGTTCTTT 652
Db 637 CAGGGTAAACCCAGAACTTCAAGTGTGTAGAGGGTTTATTTAATAATGTAATTT 696
Qy 653 ACCATCTGTAACTGAAGGTGTTAACTTAAATTTTGGCAGGATGACTACCAAGGAA 712
Db 697 ATCACCTTGTAACTGAATGTAAAGCTAAATTTTGGCAGGAATGACTACAAAGGCA 756
Qy 713 AATATTTTAGAGATGAGAGCAGTTTATAGAAATTTACTTTATGAAAAAATTCCTTTAA 772
Db 757 AATACCTTTAGAGATGAGAGCAGTTTATAGAAATTTACTTTAATAAGAAAAATACCTTTAA 816
Qy 773 ATGTTGTGTGTGTGTAACAAATTTAGCGGGTATATAGACACTGTATTTCCGCTCTT 832
Db 817 ATGTTGTGTGTGTGTAACAAATTTAGTGTATATAGATACCTGTATTTCTGCTACTT 876
Qy 833 TTCCGCGAGGAGCTTGTCTATGCTTAAAGAGCCCGCATTTACTGCAAAATACAGACAGTGCTA 892
Db 877 TTAGAAGGGAGCTTCCCATGCCAAGAACCCCGCATTTACCGCAGCATTAATATGATACTA 936
Qy 893 CTAAATGAATCTGGGAGTCTAGCTGTGGAGGGGAGATGTTGTGCCATTCGCTGGAAAG 952
Db 937 GTAGTGATCCGGGGAGTCTAGCGGTACAGGGGCAGAGGTTGTGCCATTTAATGGGAAG 996
Qy 953 GAACAAAGCGGGTTAAAGTTTCAACCAATGCTTAATTTGGCTATGTGAAACAGAGTAT 1012
Db 997 GAACAAAGCTAGCAATAAGTTTCAAACTATGTTAACTGTTGTGTGAAACAGAGTGT 1056
Qy 1013 TTACTGAAGATAAATAGTGGATTTTAAACCAATATATCTTTAATAGTAGCAGTC 1072
Db 1057 TTACAGAGNTAGTGGAACTAGTTGACTTTAAACCAAGTACACTTTACTAAGCAGTAGTC 1116
Qy 1073 ACAGTGGCAGCTTTCAAAATTTCAAAAGTCCCTTAAAGTTAGCTATTTAATAAGCTACTA 1132
Db 1117 ACAGTGGAAAGTTTCAAAATTTCAAAAGTCCCTAATAAATAGCAATTTAATAAGCACTAAT 1176
Qy 1133 TAGTACCCACTAGTACATTTCTGTACATTTACACTTTGAGCAGGTTACTTTGCATTTAAAG 1192
Db 1177 TGTGCTCTACTAGCACTTTTATTTATGATACAGACTTTGAGCAGGTTATGTGTATTTAAAG 1236
Qy 1193 AAAATAAAATAGTAAATTTATTTGTTGTCAAAACCTATGATCTCTTTTAGTGGGTCAAC 1252
Db 1237 ACATAAAATTTGTAATTTGTTACTTTGTGTCAAAACCTATGACCCCTATTTGGTGGGCGC 1296
Qy 1253 ATGTGTTAAGTGGATGTGCAAAAAATTTGTTGTTAAAAAACAACCCCTGTGTTTACCGGC 1312
Db 1297 ATGTGTTAAGTGGATGTGCAAAAAATTTGTTGTTAAAAAACAACCTGTGTTTATGGGC 1356
Qy 1313 CACCAAGTACTGCAAAAAAATAATTTGGCAATGCTATTGCTAAACCTGTACCAAGTGTATG 1372
Db 1357 CGCAAGTACAGAAAAAACAACCTTGGCAATGCTTGGCAATGCTTGGCAATGCTTGGCAATG 1416
Qy 1373 GAATGTTGAATTTGGAATTAATGAAAACTTTCCATTTAATGATGTAGCGGGGAAAGTTTGG 1432
Db 1417 GCATGTTAATCTGGAATTAATGAAAACTTTCCATTTAATGATGTAGCAGGAAAGCTTGG 1476
Qy 1433 TGTCTGGGATGAAGGCAATTTAAGTCCAATTTGTGGAGCTGCAAAAGCCATTTTATG 1492
Db 1477 TGTCTGGGATGAAGGCAATTTAAGTCCAATTTGTAGAAGCTGCAAAAGCCATTTTATG 1536
Qy 1493 GTGGTCAGCCCAACAGGATGATACAGAAAAATGCTGCGCAGTGTGGCAGTGTCCCGGTGTC 1552
Db 1537 GCGGGCAACCCACAGGGTAGATCAAAAAATGCGGTGGAAGTGTAGCTGTGCTGCGGTAGATC 1596

Qy 1553 CTGTGGTTATTAACAGCAATATGTGTGACATTTATTTGTTGTGTGAGTGGTAATACCACTACAA 1612
Db 1597 CTGTGGTTATTAACAGCAATATGTGTGACATTTATTTGTTGTGTGAGTGGTAATACCACTACAA 1656
Qy 1613 CTGTGCATGCTAAAGCCTTTAAAGGAACGATGTAAGCTTAAAGCTTTTACCATAAGATGTA 1672
Db 1657 CTGTGCATGCTAAAGCCTTTAAAGGAACGATGTAAGCTTTTAAAGCTTTTACTGTAAATGCA 1716
Qy 1673 GGCCTGACATGGGTTTACTTTACAGAGGCTGTATGTAACAACATGGCTTAACTTTGGTGTAAATG 1732
Db 1717 GGCCTGACATGGGTTTACTTAAACAGAGGCTGTATGTAACAACATGGCTTAACTTTGGTGTAAATG 1776
Qy 1733 CACAAAGCTGGAGGCCATATGAAAACTGGGGAATTAACCTTAACTTTTACTGTAAATGCA 1792
Db 1777 CACAAAGCTGGAGGCCATATGAAAACTGGGGAATTAACCTTAACTTTTACTGTAAATGCA 1836
Qy 1793 TAAATGCAGATGCCCTCCACCCAGATCTCCAAACCAACCCCAATTTGTACAGACACCACTA 1852
Db 1837 TAAATGCAGATGCCCTCCACCCAGATCTCCAAACCAACCCCAATTTGTACAGACACCACTA 1896
Qy 1853 TCAGCAGCAGTGGTGTGAAAGCTCTGAAGAACTCAAGTGAAGCAGCTTTTCAAGCTCA 1912
Db 1897 TCAGCAGCAGTGGTGTGAAAGCTCTGAAGAACTCAAGTGAAGCAGCTTTTAACTCA 1956
Qy 1913 TCATCTCCAGGCGCTGGAAACAGTGAACCCCGCTCTAGTAGCGCCGCTCCCGGGAACA 1972
Db 1957 TCATCTCCAGGCGCTGGAAACAGTGAACCCCGCTCTAGTAGCGCCGCTCCCGGGAACA 2016
Qy 1973 GTTCAGGAGAACTTTGTGCGAAGCTCAGTTTCCCGAAGCTGTAGTGCATCGTGG 2032
Db 2017 GTTCAGGAGAACTTTGTGCGAAGCTCAGTTTCCCGAAGCTGTAGTGCATCGTGG 2076
Qy 2033 AGAAGCTTTTACACGCGCTTGGCGATCGATGCTGTAACCTGTTAGTAGGCTTTGACT 2092
Db 2077 AGAAGCTTTTACACACCTTTGGCAGACAGTTTCTGTGACCTGTTAGTTGGGTTGAT 2136
Qy 2093 TTGTATGGGATGGTGTAGGGGATTCCTGTTGTTGTTGTGTGGAACATATAACCAAGT 2152
Db 2137 ATGTGTGGGACGGTGTAGGGGTTTACCTGTGTGTTGTGTGCAACATATAACCAAGT 2196
Qy 2153 GGGAGGGTGGGGCTTTGCCCTCATTTGTTAATGTTGGAGCTTGGTATATGATGGA 2212
Db 2197 GGGAGGGTGGGGCTTTGCCCTCATTTGTTAATGTTGGAGCTTGGTATATGATGGA 2256
Qy 2213 AATTTAGAGAGTTTACTCCAGACTTGTGCGCTGCAAGTTGTATGTAGCAGAGCTCTAACC 2272
Db 2257 AATTTAGAGAGTTTACTCCAGACTTGTGCGCTGCAAGTTGTATGTAGCAGAGCTCTAACC 2316
Qy 2273 CATTTTCTGTGTTAACTTGTAAAAAATGTTGCTTAACTGCTGCTGATTTACAAAGTTTGTAG 2332
Db 2317 CATTTTCTGTGTTAACTTGTAAAAAATGTTGCTTAACTGCTGCTGATTTGCAAGCTTTGTAG 2376
Qy 2333 ATTTAGAGTAAACCACTAAACAAATGTTGGGGAAGCAGTGAACAAATTTGCCAGGAGCTG 2392
Db 2377 ATTTAGAGTAAACCACTAAACAAATGTTGGGGAAGCAGTGAACAAATTTGCCAGGAGCTG 2436
Qy 2393 TATAAGCAGTTGTGCAATTTTATGAAAAAGCTTACGGAACAGACTTTAGAGCTTTATCAA 2452
Db 2437 TATAAGCAGTTGTGCAATTTTATGAAAAAGCTTACGGAACAGACTTTAGAGCTTTATCAA 2496
Qy 2453 ATTTTAAAAAGACCACTTACAACTTTCTTTAGATAAATCTTTTAGAAAAACCCCTCTCTTTA 2512
Db 2497 ATTTTAAAAAGACCACTTACAACTTTCTTTAGATAAATCTTTTAGAAAAACCCCTCTCTTG 2556
Qy 2513 TTTGACTTGTGCTGCAATTTAAAAAGTAACTTTAAAACTCTCCAGACCTATATAGTCA 2572
Db 2557 TTTGACTTGTGCTGCAATTTAAAAAGTAACTTTAAAACTCTCCAGACCTATATAGTCA 2616
Qy 2573 CATTTTACAGGCAATGAGCAGTTTATCTGACCAACCCCGCTTATCATCCAGTAACAGT 2632
Db 2617 CATTTTACAGGCAATGAGCAGTTTATCTGACCAACCCCGCTTATCATCCAGTAACAGT 2676

QY	2633	AGTGCAAGAACCTAGAGGAGAAATTCAGTATTATCTAGTGAAGACTTACACAAGCCTGGG	2692
DB	2677	CATGCAAGAACCTAGAGGAGAAATTCAGTATTATCTAGTGAAGACTTACACAAGCCTGGG	2736
QY	2693	CAAGTTAGCATACAAATTACCCGGTACTAACTATGTTGGGCCTGGCAATGAGCTACAGCT	2752
DB	2737	CAAGTTAGCGTACAACCTACCCGGTACTAACTATGTTGGGCCTGGCAATGAGCTACAGCT	2796
QY	2753	GGGCCTCGCGAAGTCTGTGCGACAGTCTGCAAGCAATTCATGACTTTAGGTATAGCCAA	2812
DB	2797	GGGCCTCGCGAAGTCTGTGCGACAGTCTGCAAGCAATTCATGACTTTAGGTATAGCCAA	2856
QY	2813	TTGGCTAGTTGGGAATAAATCCCTTATACACATTGGACGCTAGCAGATGAAGATCTGTTA	2872
DB	2857	CTGGCTAAGTTGGGAATAAATCCCTTATACACATTGGACGCTAGCAGATGAAGATCTGTTA	2916
QY	2873	AAAAATATAAAAAATGAAACAGAGTTTCAAGCACAGCAGTAAAGATTTACTTTACTTTTA	2932
DB	2917	AAAAATATAAAAAATGAAACAGAGTTTCAAGCACAGCAGTAAAGATTTACTTTACTTTTA	2976
QY	2933	AAAGGTGAGTGCCTCTGTGGCCCAATTTTCAAGGAAGTTTACCGGAAGTTCGCCGGCTTAC	2992
DB	2977	AAAGGTGAGTGCCTCTGTGGCCCAATTTTCAAGGAAGTTCGCCGGCTTAC	3036
QY	2993	AACGCTCTCAGAAAAATACCCAGCAGTACTTCAGTTAACTCTGCAGAACGACACTGCT	3052
DB	3037	AACGCTCTCAGAAAAATACCCAGCAGTACTTCAGTTAACTCTGCAGAACGACACTGCT	3096
QY	3053	GCAGGGGGGAGGTAGCAACCTTCAAAAAAGCATGTGGAGTGAAGGGGCTACATTACT	3112
DB	3097	GCAGGGGGGAGGTAGCAACCTTCAAAAAAGCATGTGGAGTGAAGGGGCTACATTACT	3156
QY	3113	GCTAAATCTGTAACGTGTACATCTCTAGGCAATTTTAAATTCATATGACAGAGCAT	3172
DB	3157	GCCAACTCTGTAACCTGTAACATTTTCAGACAGTTTTTAAATTCATATGACAGAGCAC	3216
QY	3173	CATTATAAGTGTCTCTCAGCAGCTAGTAGTGCCACAATGCTAGTGGGAAGAGGCCA	3232
DB	3217	CATTATAAGTGTGTCTCTCAGCAGCTAGTAGTGCCACAATGCTAGTGGGAAGAGGCCA	3276
QY	3233	AAAGTGTGCACCTATTAGTTCGCCATTTAGGGGTACTCTCTCGTGAGATCTTAGATTTT	3292
DB	3277	AAGGTTGCACCATTTAGTTCGCCATTTAGGGGTACTCTCTCGTGAGATCTTAGATTTT	3336
QY	3293	AATGCTTTAAATTTGTTTTCTCACCATTAGAGTTTCAGCACTTAATTTGAAATTAATGGT	3352
DB	3337	AATGCTTTAAATTTGTTTTCTCACCATTAGAGTTTCAGCACTTAATTTGAAATTAATGGA	3396
QY	3353	AGTATAGCTCAGATGCTTTAACTGTAACTATTTCAGAAATTCGTGTAAAGATGTCA	3412
DB	3397	AGTATAGCTCCTGATGCTTTAACTGTAACTATTTCAGAAATTCGTGTAAAGATGTCA	3456
QY	3413	GACAAAACAGAGGAGGTGTGCAAGTTACTGACAGCACACAGGACGTTTGTGTATGTTA	3472
DB	3457	GACAAAACAGAGGAGGTGTGCAAGTTACTGACAGCACACAGGACGTTTGTGTATGTTA	3516
QY	3473	GTGATCATGAGTATAAATACCCATATGTGCTAGGTGAGGACAAGACACACTAGCTCCA	3532
DB	3517	GTGACCATGATTAACAGTACCCATATGTGTTAGGCAAGTTCAGGATCTTTAGCCCCA	3576
QY	3533	GAACTGCCATTTGGGTTTACTTTCCCGCCCAAGTATGCTTACCTTTACAGTGGTAGTA	3592
DB	3577	GAACTTTCCATTTGGGTATCTTTCCCGCCCAAGTATGCTTACCTTTACAGTGGTAGTA	3636
QY	3593	AACACAAAGGAATTCAGGAGACAGCAAAATTTGGCTAGTGAAGATTCAGCTTTTTAT	3652
DB	3637	AACACAAAGGAATCTCTGGAGACAGCAAAATTTAGCAAGTGAAGATTCAGCTTTTTAT	3696
QY	3653	GTGTTAGACACAGTTTCAATTTGAACTTTTGGGTACAGGGGATCTGCCACTATGCTTAC	3712
DB	3697	GTTTTGGAACACAGTTTCTTTTTCAGCTTTTAGGTACAGGAGTACAGCAACTATGCTTAT	3756
QY	3713	AAATTTCCAGTGTGCCCCCAGAAAAACCTAGAGGCTGCAGGCCAACTTTTTATGAATG	3772

AB030693
LOCUS
DEFINITION
Erythrovirus B19 genes for non-structural protein VP1, capsid protein VP2, isolate:Mi.
ACCESSION
AB030693
VERSION
AB030693.1 GI:6759332
KEYWORDS
VP1; VP2; NS1; capsid protein VP2; capsid protein VP1;
non-structural protein NS1.
SOURCE
B19 virus
ORGANISM
B19 virus
Virus: sDNA viruses; Parvoviridae; Parvovirinae; Erythrovirus.
REFERENCE
1 (sites)
Ishii,K.K., Munakata,Y., Funato,T., Fu,Y., Koseki,N., Sugamura,K.
and Sasaki,T.
TITLE
Sequence of human parvovirus B19 isolates from patients with
rheumatoid arthritis
Unpublished
2 (bases 1 to 4803)
Ishii,K.K.
Direct Submission
Submitted (29-JUL-1999) Keiko K Ishii, Tohoku University School of
Medicine, Department of Molecular Diagnostics; 1-1 Seiryomachi,
Aoba-ku, Sendai, Miyagi 980-8574, Japan
(E-mail:ishii-k@mail.cc.tohoku.ac.jp, Tel:81-22-717-7373,
Fax:81-22-717-7390)
FEATURES
source
Location/Qualifiers
1..4803
/organism="B19 virus"
/mol_type="genomic DNA"
/isolate="Mi"
/db_xref="taxon:10798"
/map="65-4867"
/tissue_type="bone marrow"
/note="an isolate obtained from a patient with rheumatoid
arthritis"
35..371
/notes="p6 promoter"
372..2387
/genes="NS1"
372..2387
/genes="NS1"
/codon_start=1
/product="non-structural protein NS1"
/protein_id="BAA90288.1"
/db_xref="GI:6759333"
/translation="MELFRGLVQVSSNVLDCCANDNWCISLLDLDTSDEPLTHNRLM
AIYLSVASKLDFGTGLAGCLYFFQVCKEPEGYHIHVIWGGELNPNLTVCEG
LFNNVLIHLVNVKRLPFGMTKGIYFRDGEQFIENYIMRKIPILNVWCVTNIDGY
IDTCISATFRGACHAKPRITAAINDTSSDAGESSTGAEVVFPNGKGTAKSIKFTQ
MNVLCENRVFTEDKWLDPNQYITLLSSHSGSFQISALKLAIYKATNLVPTSTFL
LHTDFQVWCIKDKIKVLLCONYDPLVQGVHLRWIDKCGKNTLWYFGPPSTGK
TNLMAIAKSPVYGVNWNNEFPNDVAGSLVVDGIIKSTIVEAKAILGGQP
TRVDOKRGSVAVPGVPVITNSGNDITFVVSNGTITTVHAKALKERWKLNTVRCSP
DMGLLEADVQWMLWCNAQSDHYENWAINYTFDPGINADRLDLQTLPLVDTIS
ISSSGEESSELESSEFNLTIPGAWNTPTSSPTPGTSGESFVSGSPVSEVVA
SWEEAFYPLADQFRELLVGVYDVGVRGLPVCCQVHINNNGGLGLCPHCINVGAW
YNGWKREFPDLVRCSCHVGASNPESVLTCKKCAVLSGLQSFVDE"
2380..4725
/genes="VP1"
2380..4725
/genes="VP1"
/codon_start=1
/product="capsid protein VP1"
/protein_id="BAA90289.1"
/db_xref="GI:6759334"
/translation="MSKSGKMWESDDKFAKAVYQQFVFEYKVTGDTLELIQILKH
YNIISLDNPLENSLFDLVARIKNLKNPSDLYSHRFQSHGQLSDHPHALSSSSHAE
PRGENAVLSSEDLHKPQVSVQLPGNTYVGPNELOQPPQSAVSAARIHDFRYGQL
AKLGINPYHTWVADDELLKNIKNETGFOAVVVDYFLTKGAAAPVAHFQGLPEVPA
YNASEKVPSTMSAEASTAGGGSNPVKSMWSEGAFTFSASVTCFSGROLIPYD
PEHYKVFSPAASSCHNAGKEAKVCTISPIMGYSTPWRYLDPNALNLPSLEFQHL
IENYGSIAIDPALVTISEIAVKDVTGGGVQVDTUSTLCMLVDHBYIKYPIVUG
GQDTLAPELFIWYFFPQVAYLTVGDVNTQGISGDSKSLASESFAVLEHSSFQLLG

TCGTATMSYKPPPPENLEGCSQHFYEMYNPLYGSRLGVDPDLGLDGPFRSLTHEDH
ATQPNFMPGLVNSVTKGDSNTGAKALTGLSTGTSQNTSLRSLRPGVSPQVYHH
WDTQYVTVGINAISHGQTYGNAEDKEYQGVGRFNEKEQLKQLQGLNHYFPNKG
TQOYTDQIERPLMWGSVMNRALHYESOLWSKIPNLDDSFKTQFALGCGWLHQPPO
IFKLILPOSPIGGIKSMGTLTVOYAVGIMTVMTFKLGRKATGRWNPQGVYPPH
AAGHLPVLYDPTATDAKQHHBHYEKEPELWAKSRVHPL"
3061..4725
/gene="VP2"
3061..4725
/gene="VP2"
/codon_start=1
/product="capsid protein VP2"
/protein_id="BAA90290.1"
/db_xref="GI:6759335"
/translation="MTSVNSAEASTAGGGSNPVKSMWSEGAFTFSANSVTCFSRQF
LIPYDPEHHYKVFSPASCHNAGKEAKVCTISPIMGYSTPWRYLDFLNLFFPPL
BFOHLIENYGIAPDALVTIIEIAVKDVTGGGVQVDTSTYGLDNLVDEHYKVP
VYLGOGDTLAPELPIWYFFPQVAYLTVGDVNTQGISGDSKSLASESFAVLEHSS
FOLLGTGATMSYKPPPPENLEGCSQHFYEMYNPLYGSRLGVDPDLGLDGPFRSL
THEDHAIQPNFMPGLVNSVTKGDSNTGAKALTGLSTGTSQNTSLRSLRPGVSP
QYHHWDTKYVTVGINAISHGQTYGNAEDKEYQGVGRFNEKEQLKQLQGLNHY
FPNKGTYQYTDQIERPLMWGSVMNRALHYESOLWSKIPNLDDSFKTQFALGCGWLH
QPPQIFELKILPOSPIGGIKSMGTLTVOYAVGIMTVMTFKLGRKATGRWNPQGV
VYPPHAAGHLPVLYDPTATDAKQHHBHYEKEPELWAKSRVHPL"
ORIGIN
Query Match 73.9%; Score 3714.6; DB 14; Length 4803;
Best Local Similarity 86.5%; Pred. No. 0;
Matches 4124; Conservative 0; Mismatches 634; Indels 9; Gaps 2;
QY 1 GAGGTACAGGAAATGACGTATCTGTCGCCCATCTTGTACCGGAAGTCCCGCTACCGGC 60
DB 38 GAGGTACAGGAAATGACGTATCTGTCGCCCATCTTGTACCGGAAGTCCCGCTACCGGC 97
QY 61 GCGACCGCGGCATCTGATTTGGTGTCTTCTTTTGAATTTTGGCGGGCTTTTCCCG 120
DB 98 GCGACCGCGGCATCTGATTTGGTGTCTTCTTTTGAATTTTGGCGGGCTTTTCCCG 156
QY 121 CCTTATGCAATAAGCGGCATCTTGTATGTTATATTTTAAATTTTAAATGCAACAGCCT 180
DB 157 CCTTATGCAATAAGCGGCATCTTGTATGTTATATTTTAAATTTTAAATGTTGT 216
QY 181 AACGGTTACTAGCGCGGAGTAGCGG-----GCGGTATATAAGCAGCTGCGTCCCT 232
DB 217 AACGGTTAAATGCGCGGAGTAGCGGCGGACTACAGTATATATAGCAGCACTGCCG 276
QY 233 GACATCTTCTTCTTGGTGTCTTGTGACGTGGAACCTACCTGCTGTTCTTTCCTGCTAG 292
DB 277 CAGCTCTTCTTCTTGGGCTGCTTTTCTGACATTTCTTCTGCTGTTTGTGAGCTAAC 336
QY 293 TAACAGTATTTATATACTAATTTTAAATTTTAAATGAGGCTATTTCCGGGGTGTCTTGC 352
DB 337 TAACAGTATTTATATACTTCTTAACTATTAACATGAGGCTATTTAGAGGGTGTCTT 396
QY 353 ACATTTCTCTAACATTTCTGAGCTGTGCTTAATGATAAATCTGTTGGTGTCTCTATGCTAG 412
DB 397 AAGTTTCTTCTAATGTTCTTGGACTGTGCTAAACGATAAATCTGTTGCTCTTCTTACTG 456
QY 413 TAGATACTTCTGACTGGGAACCACTAAACCAATTTCTTAACAGATTAATGAGCAATATATA 472
DB 457 TAGACACTTCTGACTGGGAACCACTAAACCACTAATCACTAACAGACTAATGAGCAATATA 516
QY 473 GCAGTGTCTTCTTAACTTTGATTTTCTGCGGGGCGCGCTAGCAGGCTTGTCTATCTTTT 532
DB 517 GCAGTGTGCTTCTTAAGCTTGTACTTTTACCGGGGGCCACTAGCAGGGTGTCTTCTTCT 576
QY 533 TTACAGTGGAAATGTAACAAATTTGAGGAAGGCTATCATATCCATGCTAGTTATTTGGTGC 592
DB 577 TTCAAGTGAATGTAACAAATTTGAAGAAGGCTATCATATTCATGCTGTTTATTTGGGGGC 636
QY 593 CAGGACTAATGCTAGAAATCTTAACTGTGCTGCTAGAAAGGTTTATTTAATAATGTTCTTT 652
DB 637 CAGGGTTAAACCCAGAAACCTTTACAGTGTGTGTAGAGGGGTTTATTTAATAATGTTCTTT 696

QY	653	ACCACTTGTAACTGAAAGTGTAAACCTTAAATTTTGGCAGGATGACTACAAAGGAA	712
Db	697	ATCACCTTGTAACTGAAAGTGTAAAGCTTAAATTTTGGCAGGATGACTACAAAGGCA	756
QY	713	AATATTTTAGAGATGGAGAGCACTTTATAGAAATTTACTTAATGAAATTTTCTTTAA	772
Db	757	AATATTTTAGAGATGGAGAGCACTTTATAGAAATTTACTTAATGAAATTTTCTTTAA	816
QY	773	ATGTTGTGTGTGTGTAAACAAATTTATGAGGGGTATATGACACCTTGTATTTCCGCTCTT	832
Db	817	ATGTTGTGTGTGTGTAAACAAATTTATGAGGGGTATATGACACCTTGTATTTCCGCTCTT	876
QY	833	TTCCGGCAGAGCTTGTCTATGCTTAAAGACCCCGCATTTACTGCAATACACAGCAGTCTA	892
Db	877	TTAGAAGGGGAGCTTCCCATGCCAAGAAACCCCGCATTTACCGCAGCAATTAATGATCTA	936
QY	893	CTAATGAAACTCGGGAGTCTAGCTGTGGAGGGGAGATGTTGTGCCATTCCTCGTGAAGG	952
Db	937	GTAGTGTCTGGGAGTCTAGCGCAGAGGGGAGAGTGTGCGCATTTAATGGGAAGG	996
QY	953	GAACAAAGCGGGTAAAGTTTCAAAACCATGCTGTAATTTGGCTATGTGAAACAGAGTAT	1012
Db	997	GAACTAAGGCTAGCATAAAGTTTCAAACTATGTGTAACTGGTGTGTGAAACAGAGTGT	1056
QY	1013	TTACTGGAAGATAAATGGAATTTAGTGGATTTTAAACCAATATPCTTTTAAAGTAGCAGTC	1072
Db	1057	TTACAGAGATAAGTGGAACTAGTGTGACTTTTAAACCAAGTACACTTTACTAAGCAGTAGTC	1116
QY	1073	ACAGTGGCAGCTTTCAAAATTCAAAGTGTCTTAAAGTTAGCTATTTATTAAGCTACTAAT	1132
Db	1117	ACAGTGGAGTTTTCAAAATTCAAAGTGTCTTAAAGTTAGCTATTTATTAAGCTACTAAT	1176
QY	1133	TAGTACCACCTAGTACATTTCTGTTCATTCAGACTTTGAGCAGGTACTTGTCAATTAAG	1192
Db	1177	TAGTGCCTACTAGCACATTTTATTCATACAGACTTTGAGCAGGTATGCTGTATTAAG	1236
QY	1193	AAAAATAAATAGTAAAAATTTATTTGTCCAAACTATGATCTCTTTAGTGGGTCAAC	1252
Db	1237	ACAATAAATTTGTAAATTTGTACTTTGTCAAACCTATGATCTCTTTAGTGGGTCAAC	1296
QY	1253	ATGTTTAAAGGTGATGACAAATAATGTTGGTAAAAAACAACCTGTGTTTAAAGGGC	1312
Db	1297	ATGTTTAAAGGTGATGACAAATAATGTTGGTAAAAAACAACCTGTGTTTAAAGGGC	1356
QY	1313	CACCAAGTACTGCAAAAAACAAATTTGCAATGCTTATTCCTAAACTGTACAGGTATG	1372
Db	1357	CGCCAAAGTACAGGAAACAAACTTGGCAATGGCCATTTGCTAAAAAGTGTTCAGTATATG	1416
QY	1373	GAATGGTGAATGGAAATAATGAAACCTTTCCATTTAATGATGTAGCGGGAAGTTTGG	1432
Db	1417	GCATGGTTAACTGGAATAATGAAACCTTTCCATTTAATGATGTAGCGGGAAGTTTGG	1476
QY	1433	TGCTCTGGGATGAAGCATTATTAAGTCCACTTATTTGTGGAAGCTGCAAAAGCCATTTAG	1492
Db	1477	TGCTCTGGGATGAAGTATTTAAGTCTCAATTTGTAGAAGCTGCAAAAGCCATTTAG	1536
QY	1493	GTGGTCAGCCAAACCAAGGTAGATCAGAAATGCGTGGCAGTGTGGCAGTGGCCGTGTC	1552
Db	1537	GGGGGCAACCCACAGGTAGATCAAAATGCGTGGGAGTGTAGCTGTGCTGGAGTAC	1596
QY	1553	CTGTGGTTATACCAAGCAATGCTGACATTAATTTGTTGGAGTGGTAAATACCACTACAA	1612
Db	1597	CTGTGGTTATACCAAGCAATGCTGACATTAATTTGTTGGAGTGGTAAATACCACTACAA	1656
QY	1613	CTGTGCATGCTAAAGCCTTAAAGGAACGATGTTAAAGCTTAACTTTACCATTAAGATGA	1672
Db	1657	CTGTACATGCTAAAGCCTTAAAGGAACGATGTTAAAGCTTAACTTTACCATTAAGATGA	1716
QY	1673	GCCCTGACATGGGTTTACTTACAGAGGCTGATGTACAACTGGCTAACTTGGTGTAAATG	1732
Db	1717	GCCCTGACATGGGTTTACTTACAGAGGCTGATGTACAACTGGCTAACTTGGTGTAAATG	1776

QY	1733	CACAAAGCTGAGCCACTATGAAAACCTGGCAATAAACTACACATTTGATTTCCCTGGAA	1792
Db	1777	CACAAAGCTGAGCCACTATGAAAACCTGGCAATAAACTACACATTTGATTTCCCTGGAA	1836
QY	1793	TAAATGAGATGCGCTCCACCCAGATCTCCAAACCAACCCCATTTGTCACAGACACAGTA	1852
Db	1837	TAAATGAGATGCGCTCCACCCAGATCTCCAAACCAACCCCATTTGTCACAGACACAGTA	1896
QY	1853	TCAGCAGCAGTGTGTGGAAGCTCTGAAGAACTCAGTGAAGAGCAGCTTTTCAACCTCA	1912
Db	1897	TCAGCAGCAGTGTGTGGAAGCTCTGAAGAACTCAGTGAAGAGCAGCTTTTCAACCTCA	1956
QY	1913	TCACTCCAGCGCTGGAAACAGTGAACCCCGCTCTAGTACGCCGCTCCCGGGACCA	1972
Db	1957	TCACCACCGCGCTGGAAACAGTGAACCCCGCTCTAGTACGCCGCTCCCGGGACCA	2016
QY	1973	GTTTCAGGGAATCATTTTGTGGAGCCAGTTTCTCCGAAAGTTGTAGCTGATCGTGG	2032
Db	2017	GTTTCAGGGAATCATTTTGTGGAGCCAGTTTCTCCGAAAGTTGTAGCTGATCGTGG	2076
QY	2033	AGGAAGCTTTTACACGCGCTTGTGGAGCCAGTTTCTCCGAAAGTTGTAGCTGATCGTGG	2092
Db	2077	AGGAAGCTTTTACACACACTTTGGAGCCAGTTTCTCCGAAAGTTGTAGCTGATCGTGG	2136
QY	2093	TTGTATGGAGTGTGTGAGGGATGCTGCTGTTGCTGTGGAAACATATAAACAACAGTG	2152
Db	2137	ATGTGTGGAGCGGTGTAAAGGGTTTACCTGTGTGTGTGTGCAACATATTAACATAGTG	2196
QY	2153	GGGAGAGGTTGGGCTTTGCCCTCATTTGTAATTAATGTTGGAGCTTGTATAATGGATGGA	2212
Db	2197	GGGAGAGGTTGGGCTTTGCCCTCATTTGTAATTAATGTTGGAGCTTGTATAATGGATGGA	2256
QY	2213	AATTTAGAGTTPACTCCAGACTTAGTGGCTGCGCTGAGTGTCTCATGTAGGAGCTCTAAC	2272
Db	2257	AATTTAGAGTTPACTCCAGACTTAGTGGCTGCGCTGAGTGTCTCATGTAGGAGCTCTAAC	2316
QY	2273	CATTTCTGTGTAACTGTGTAATAATGCTTACCTGTCTGATTAACAAAGTTTGTAG	2332
Db	2317	CTTTTCTGTGTAACTGTGTAATAATGCTTACCTGTCTGATTAACAAAGTTTGTAG	2376
QY	2333	ATTATAGTAAAAACCACTAACAAATGTTGGAAAGCAGTGACAAATTTGCCAGGACGTG	2392
Db	2377	ATTATAGTAAAAACCACTAACAAATGTTGGAAAGCAGTGATGATTAATTTCTAAGCTGTG	2436
QY	2393	TATAAGCAGTTTGTCAATTTTATGAAAAGCTACTGGAACAGACTTAGAGCTTATTCAA	2452
Db	2437	TATCAGCAATTTGTGGAATTTTATGAAAAGCTACTGGAACAGACTTAGAGCTTATTCAA	2496
QY	2453	ATTTTAAAGACCATTAACCAATTTCTTTAGATAATCTTTTAGAAAACCCCTCTCTTTA	2512
Db	2497	ATATTAAAGATCATTTATTAATTTCTTTAGATAATCTTTTAGAAAACCCCTCTCTCTG	2556
QY	2513	TTTGACTTGTGCTCGCATTAATAAGTAAATCTTAAAAAATCTCTCCAGACTATAGTCAAT	2572
Db	2557	TTTGACTTGTGCTCGCATTAATAAGTAAATCTTAAAAAATCTCTCCAGACTATAGTCAAT	2616
QY	2573	CATTTTTCAGAGCCATGGAAGTATCTGACCAACCCCGCTTATCATCAGTAAACAGT	2632
Db	2617	CATTTTTCAGAGCCATGGAAGTATCTGACCAACCCCGCTTATCATCAGTAAACAGT	2676
QY	2633	AGTCAGAACCTTAGAGGAGAAATGCAATTTATCTAGTGAAGACTTACAAAGCTTGGG	2692
Db	2677	CATGAGAACCTTAGAGGAGAAATGCAATTTATCTAGTGAAGACTTACAAAGCTTGGG	2736
QY	2693	CAAGTTAGCATACAAATACCGGTACTAACTATGTTGGGCTTGGCAATGAGCTACAAGCT	2752
Db	2737	CAAGTTAGCTACAATACCGGTACTAACTATGTTGGGCTTGGCAATGAGCTACAAGCT	2796
QY	2753	GGGCTTCGCAAGATGCTGTGGAAGTGTGCAAGGATTCATGACTTTAGCTATAGCCAA	2812
Db	2797	GGGCTTCGCAAGATGCTGTGGAAGTGTGCAAGGATTCATGACTTTAGCTATAGCCAA	2856
QY	2813	TTGGCTAAGTTGGGAATAAATCCTTTATACACATTTGGACGGTAGCAGATGAAGAATTGTTA	2872

Db 2857 CTGGCTAAGTTGGGAATAATCATATATCTCATTTGGACTGTAGCAGTGAAGACTTTTA 2916
Qy 2873 AAAAAATATAAAAAATGAACAGAGGTTTCAAGCACAAGCAGTAGTAAAGATTACTTTTACTTTA 2932
Db 2917 AAAAAATATAAAAAATGAACAGAGGTTTCAAGCACAAGCAGTAGTAAAGATTACTTTTACTTTA 2976
Qy 2933 AAAGGTGACAGTCCCTGCTGGCCCAATTTTCAAGGAAGTTTACCGGAAGTGCCTGGGTAC 2992
Db 2977 AAAGGTGACAGTCCCTGCTGGCCCAATTTTCAAGGAAGTTTTCGCGGAAGTTTCCCGCTTAC 3036
Qy 2993 AAGCCTCAGAAAAATACCCAGCAGTACTTCAGTTTAACTCTGCAAGCAGCAGCTGGT 3052
Db 3037 AAGCCTCAGAAAAATACCCAGCAGTACTTCAGTTTAACTCTGCAAGCAGCAGCTGGT 3096
Qy 3053 GCAGCGGGGGAGGTAGCAACCTCAAAAAAGCATGTGGAGTGAAGGGGCTACATTTACT 3112
Db 3097 GCAGGAGGGGGGAGTAACTCTGTCAAAAGCATGTGGAGTGAAGGGGCTACATTTACT 3156
Qy 3113 GCTAATCTGTAAAGTGTACTCTCTAGGCAATTTTAAATTCATATATGATCCAGAGAT 3172
Db 3157 GCCAATCTGTAACTGTATCTTCCAGACAGTCTTAAATTCATATGACCCAGAGCAC 3216
Qy 3173 CATTATAAGTGTCTCTCCAGCAGTACTGTGCTGCCACAATGCTAGTGGGAAGAGGCA 3232
Db 3217 CATTATAAGTGTCTCTCCAGCAGTACTGTGCTGCCACAATGCTAGTGGGAAGAGGCA 3276
Qy 3233 AAAGTGTGACATTAATAGTCCCATTAATGGGTACTCTACTCCGTTGGAGATCTTAGATTTT 3292
Db 3277 AAGTTTGCACCATTAATAGTCCCATTAATGGGTACTCAACCCCATGGAGATTTTAGATTTT 3336
Qy 3293 AATGCTTTAAATTTGTTTTCTCAACATTAGAGTTTTCAGCAGTAAATGAAATTAATGT 3352
Db 3337 AATGCTTTAAATTTTATTTTCACTTTAGAGTTTTCAGCAGTAAATGAAATTAATGA 3396
Qy 3353 AGTATAGTCCAGATCTTTAACTGTAACTTTTCAAGAAATGCTGTAAAGATGTACA 3412
Db 3397 AGTATAGTCCAGATCTTTAACTGTAACTTTTCAAGAAATGCTGTAAAGATGTACA 3456
Qy 3413 GACAAAAAGGAGGAGTGTGAAGTTACTGTACAGCACCACAGGAGCTTTGTGTATGTTA 3472
Db 3457 GACAAAACTGGAGGGGGGTACAGTTACTGTACAGCAGCTACAGGGGCTTATGCAATTTA 3516
Qy 3473 GTGGATCATAGTATATAATACCATATGTCTAGGTACAGGGAACAAGACACACTAGCTCCA 3532
Db 3517 GTAGACCATGAATACAAATACCATATGTGTAGGGCAAGGTCAAGATACTTTAGCCCCA 3576
Qy 3533 GAATGCCCATTTGGGTTTACTTTTCCCTCCAGTATGCTTAAACAGTAGTGAAGTA 3592
Db 3577 GAATCTTCTATTGGGTATCTTTTCCCTCCATATGCTTAAACAGTAGGAGATGTT 3636
Qy 3593 AACACACAAAGGAATTTACAGAGACAGCAAAAAATTTGGCTAGTGAAGATCAAGCTTTTAT 3652
Db 3637 AACACACAAAGGTATTTCTGGAGACAGCAAAAAATTTAGCAAGTGAAGATCAAGCAATTTAT 3696
Qy 3653 GTGTTAGACACAGTTTCAATTTGAACTTTTGGGTACAGGGGGTCTGCCACTATGCTCTAC 3712
Db 3697 GTTTTGGACACAGTTCTTTTCACTTTTAGGTACAGGAGGTACAGCAACTATGCTCTAT 3756
Qy 3713 AAATTTCCAGCTGTGCCCCCAGAAAACTTAGAAGGCTGAGGCCAACATTTTATGAAGTG 3772
Db 3757 AAGTTTCTCTCCAGTGGCCCCCAGAAAAATTTAGAGGGCTGAGTCAACATTTTATGAAGTG 3816
Qy 3773 TACAACCTTTGTACGGTTCTGTTTGGGTACCTGTACACATTTAGGAGGGGACCCCTAAA 3832
Db 3817 TACAATCCCTTTATACGGATCCCGCTTAGGGTTCTGTACACATTTAGGAGGTGACCCAAA 3876
Qy 3833 TTTAGATCATTTGACACACAGAACACAGCAATTTAGCCTCAAAAACTTTATGCTGGGCCA 3892
Db 3877 TTTAGATCTTTAACACATGAAGACCATGCAATTTAGCCCCCAAACTTTATGACGGGCCA 3936
Qy 3893 CTAATAAATTCAGTGTCTACCAAGAGAGACAAATTTCTAATACAGGTGCTGGAAGGCC 3952

Db 3937 CTAGTAAACTCAGTGTCTCAAAAGGAGGAGACAGCTCTAATACTGGAGCTGGAAGGCC 3996
Qy 3953 CTTACGGGGCTTTAGTACTGGCACTAGCCAAAAACACAGAAATTTCCCTACGCCCGGGCCA 4012
Db 3997 TTAACAGGACTTTAGCACAGGTACTCTCAAAACACTAGAAATATCTTTACGCCCTGGGCCA 4056
Qy 4013 GTATCTCAGCATACCATCAGTGGGACACTGATAAATATGTTACAGGAATAAATGCAAT 4072
Db 4057 GTGTCTCAGCCATACCACTGGGACACAGATAAATATGTCACAGGAATAAATGCAAT 4116
Qy 4073 TCACATGGACAAACCACTTATGGAATCTGAGGACAAAGAGTATCAGCAAGGGGTAGGA 4132
Db 4117 TCTCATGTGTCAGACCACTTATGTTAAGCTGAAGACAAAGAGTATCAGCAGGAGTGGGT 4176
Qy 4133 AGATTTCCAAATGAAAAAGAACAGCTTAAAGAGTCTTAAGAGTCTTAACATGCAACATAC 4192
Db 4177 AGATTTCCAAATGAAAAAGAACAGCTTAAAGAGTCTTAAGAGTCTTAACATGCAACATAC 4236
Qy 4193 TTCCCTTAATAAGGAACCCCAAAATACACAGACCAAAATGAAGCCCTCTTATGGTGGC 4252
Db 4237 TTTCCCAATTAAGGAACCCCAAGCAATATACAGATCAAAATGAGCGCCCTTAATGGTGGGT 4296
Qy 4253 TCTGTTTGGACACAGAGAGTCTCTCACTATGAAAGTCAGCTGTGGAGTAAAAATCCCTAAC 4312
Db 4297 TCTGTATGGAACAGAGAGCCCTTCACTATGAAGCCAGCTGTGGAGTAAAAATCCAAAT 4356
Qy 4313 TTAGATGACAGTTTTAAAACTCAATTTGAGCGCTAGCGGGTGGGGTTTGATCAACCA 4372
Db 4357 TTAGATGACAGTTTTAAAACTCAATTTGAGCGCTAGCGGGTGGGGTTTGATCAACCA 4416
Qy 4373 CCCCCTCAAAATTTTAAAAATATCAACAAAGTGGGCCAAATTTGGAGGTATTAATCC 4432
Db 4417 CCTCTCAAAATTTTGAATAATATTAACCAAAAGTGGGCCAAATTTGGAGGTATTAATCA 4476
Qy 4433 ATGGGAATTTACTACTTTAGTTCAATATGCTGTGGGAATATGACAGTTTACCAGCTTT 4492
Db 4477 ATGGGAATTTACTACTTTAGTTCAATATGCTGTGGGAATTTATGACAGTTTACCAGCTTT 4536
Qy 4493 AAATTTGGGACCTTCGAAAGGCTACTGGAAGTGGAAATCCCGAGCTGGCGTTTATCTCCT 4552
Db 4537 AAATTTGGGACCTTCGTAAGCTAGCGGACGTTGGAAATCTCACTGAGTATATCCCCG 4596
Qy 4553 CATGACGTGTGTCATTTTACCATAATGATCTGTATGACCCCAAGCTACAGATGAAGCA 4612
Db 4597 CACGACGAGGTCAATTTTACCATATGATATATGATACCCCAAGCTACAGATGAAGCA 4656
Qy 4613 CACACACAGCAGGATATGAAGGCTGAGAAATTTGTGCACTGCCAAAGGCGTGTGCAC 4672
Db 4657 CACACACAGCAGGATATGAAGGCTGAGAAATTTGTGCACTGCCAAAGGCGTGTGCAC 4716
Qy 4673 CCATTTGTAACATTTCCCGAGCTGCTCAGCGGAGAACCGTCAACCCAGCGCCACCTGT 4732
Db 4717 CCATTTGTAACATTTCCCGAGCTGCTCAGCGGAGAACCGTCAACCCAGCGCCACCTGT 4776
Qy 4733 GCCGCCACAGATTTATGTCCTCCCTCC 4759
Db 4777 ACCACCCAGCTGTACTGCCCCCTCC 4803

RESULT 15
PVB19X560
LOCUS
DEFINITION
Parvovirus B19 DNA, patient I/1, genome position 413-5044.
ACCESSION
Z70560
VERSION
Z70560.1
KEYWORDS
GI:1262041
SOURCE
B19 virus
ORGANISM
B19 virus
REFERENCE
1
Hemauer, A., Von Pöblitzki, A., Giegler, A., Cassinotti, P., Siegl, G.,
Wolff, H. and Modrow, S.
AUTHORS
XXXSequence variability among different parvovirus B19 isolates
TITLE

QY 1745 GCACATATGAAAACTGGGCAATATACTACACATTTGATTTCCCTGGAATAAATGACAGATG 1804
DB 1441 ACCACTATGAAAACTGGGCAATATACTACACATTTGATTTCCCTGGAATAAATGACAGATG 1500
QY 1805 CCTCCACCCAGATCTCCAAACCAACCCCAATGTCCTCCAGACACCACTATCAGCAGCAGTG 1864
DB 1501 CCTCCACCCAGACCTCCAAACCAACCCCAATGTCACAGACACCACTATCAGCAGCAGTG 1560
QY 1865 GTGGTGAAGCTCTGAAGAACTCAGTGAAGCAGCTTTTTCAACCTCATCACTCCAGGGG 1924
DB 1561 GTGGTGAAGCTCTGAAGAACTCAGTGAAGCAGCTTTTTCAACCTCATCACTCCAGGGG 1620
QY 1925 CTTGGAACAGTGAAACCCCGCGCTCTAGTACGCGCGTCCCGGGACCACTTCAGGAGAAAT 1984
DB 1621 CTTGGAACAGTGAAACCCCGCGCTCTAGTACGCGCGTCCCGGGACCACTTCAGGAGAAAT 1680
QY 1985 CATTTCTCGGAAGCCAGTTTCTCCGAAAGTGTAGCGCGTCTGGGAGGAGCTTTTT 2044
DB 1681 CATTTGGCGGAAGCCAGTTTCTCCGAAAGTGTAGCGCGTCTGGGAGGAGCTTTTT 1740
QY 2045 ACACGCGCTTGGCGGATCAGTTTCTGTAACCTGTTAGTGGGTTGACTTTGTATGGGATG 2104
DB 1741 ACACACCTTTGGCAGACCACTTCTGTAACCTGTTAGTGGGTTGACTTTGTATGGGATG 1800
QY 2105 GTGTGAGGGATGTCCTGTTGCTGTGTGGAAACATATAAACAACAGTGGGGGAGGTTGG 2164
DB 1801 GTGTGAGGGGTTTACCTGTGTGTGTGCAACATATAAACAACAGTGGGGGAGGCTTG 1860
QY 2165 GCTTTGCCCTCATCTATTAATGTGGGAGCTGTGTATAGTGGAAATTTAGAGCT 2224
DB 1861 GACTTTGTCCCCATTTGCAATTAATGTAGGGGCTTGGTATATAGTGGAAATTTGAGAAAT 1920
QY 2225 TTACTCCAGACTTGTGCGCTGAGTTGTCTAGTAGGAGCTCTAACCCATTTCTGTGT 2284
DB 1921 TTACCCCAATTTGGTGGGATGTAGTGGCACTGTGGGAGCTTCTATCCCTTTCTGTGC 1980
QY 2285 TAACTTTGTAATAATGCTTACCTGCTGGATTTACAAAGTTTGTAGATTATGAGTAA 2344
DB 1981 TAACTTGCATAAATGCTTACCTGCTGGATTTACAAAGTTTGTAGATTATGAGTAA 2040
QY 2345 ACCACTTAACAAATGTGGGAAAGCAGTACAAATTTGCCAGGACGTGTATGAGCAATTT 2404
DB 2041 GAAAGTGGCAATGTGGGAAAGTGTATGATAAATTTGCTAAGCTGTGTATGAGCAATTT 2100
QY 2405 GTGCAATTTTATGAAAGCTACTGGAACAGACTTGTAGAGCTTATTCAAATTTTAAAGAC 2464
DB 2101 GTGGAATTTTATGAAAGCTTACTGGAACAGACTTGTAGAGCTTATTCAAATTTTAAAGAT 2160
QY 2465 CATTAACAATTTCTTTAGATAATCTTTAGAAACCCCTCTCTTTTATTTGACTTTAGTT 2524
DB 2161 CATTAATAATTTCTTTAGATAATCTTTAGAAACCCCTCTCTCTTTGACTTTAGTT 2220
QY 2525 GCTCCGATTAAGTAATCTTAAAACTCTCCAGCTATATAGTATCATTTTTCAGAGC 2584
DB 2221 GCTCGATTTAAATAATCACTTAAAACTCTCCAGCTATATAGTATCATTTTTCAAAGT 2280
QY 2585 CATGACAGTATCTGACCAACCCCACTGCTTATCATCCAGTAAACAGTGTGAGCAACCT 2644
DB 2281 CATGACAGTATCTGACCAACCCCACTGCTTATCATCCAGTAAACAGTGTGAGCAACCT 2340
QY 2645 AGAGGAGAAATGACGATTAATCTAGTGAAGACTTACAAAGCTGGGCAAGTTAGCATATA 2704
DB 2341 AGAGGAGAAATGACGATTAATCTAGTGAAGACTTACAAAGCTGGGCAAGTTAGCATATA 2400
QY 2705 CAATTAACCGGTACTCAACTATGTTGGGCTTGGCAATGAGCTCAAGCTGGGCTCCGAG 2764
DB 2401 CAATTAACCGGTACTCAACTATGTTGGGCTTGGCAATGAGCTCAAGCTGGGCTCCGAG 2460
QY 2765 AATGCTGTGACAGTCTCAAGGATTTATGACTTTTGTAGTATAGCAATTTGCTAGTTG 2824
DB 2461 AGTGTCTGTGACAGTCTCAAGGATTTATGACTTTTGTAGTATAGCAATTTGCTAGTTG 2520

QY 2825 GGAATAAATCCTTATATACACATTTGGACGGTAGCAGATGAAGAAATTTGTTAAAAATATAAAA 2884
DB 2521 GGAATAAATCCTTATATATACATTTGGACGGTAGCAGATGAAGAAATTTGTTAAAAATATAAAA 2580
QY 2885 AATGAAACAGGGTTCACAGCAACAGTAAAGATTAATTTTAAAGGTGAGCT 2944
DB 2581 AATGAAACAGGGTTCACAGCAACAGTAAAGATTAATTTTAAAGGTGAGCT 2640
QY 2945 GCCCTGTGGCCCATTTTCAAGGAAATTTTACCGGAGTCCCGCGTACCAACGCTTCAGAA 3004
DB 2641 GCCCTGTGGCCCATTTTCAAGGAAATTTTACCGGAGTTCCTCCGCTTACCAACGCTTCAGAA 2700
QY 3005 AAATACCCAGCATGATCTTCAAGTAACTCTGCAAGAACCCAGCACTGGTGAGCGGGGGA 3064
DB 2701 AAATACCCAGCATGATCTTCAAGTAACTCTGCAAGAACCCAGCACTGGTGAGCGGGG 2760
QY 3065 GTTAGCAACCTTACAAAGACATGTGGAGTGAAGGGGCTACATTTACTGCTAATCTCTGA 3124
DB 2761 GGCAGTAACTCTGTCAAAGCAATGTGGAGTGAAGGGGCTACATTTACTGCTAATCTCTGA 2820
QY 3125 AGTGTACATTTCTTAGGCAATTTTAAATTCATATGATCCAGAGCATCAITTTATAAAGTG 3184
DB 2821 ACTTGCACATTTTCCAGACAGTTTTTAAATTCATATGACCCAGAGCACCATTTAAGGTG 2880
QY 3185 TTCTCTCCAGCAGCTAGTAGTGCCACAATGCTAGTGGGAAAGAGGCAAAAGTGTGACT 3244
DB 2881 TTTTCTCCCGCAGCAGTAGTGCCACAATGCTAGTGGGAAAGAGGCAAAAGTGTGACT 2940
QY 3245 ATTAGTCCCATTTAGGGTACTCTACTCGTGGAGTACTAGTATTTTAAATGCTTTAAAT 3304
DB 2941 ATTAGTCCCATTTAGGGTACTCTACTCGTGGAGTACTAGTATTTTAAATGCTTTAAAT 3000
QY 3305 TTGTTTTCTCAACCATTTAGAGTTTTCAGCACTTTTAAATTTGAAATTTATGGTAGTAGTCCA 3364
DB 3001 TTATTTTTTTCACCTTTAGAGTTTTCAGCACTTTTAAATTTGAAATTTATGGTAGTAGTCCA 3060
QY 3365 GATGCTTTAACTGTAACTATTTTCAAGAAATGCTGTAAAGATGTGCACAGCAAAACAGGA 3424
DB 3061 GATGCTTTAACTGTAACTATTTCAAGAAATGCTGTAAAGATGTGCACAGCAAAACAGGA 3120
QY 3425 GGAGTGTGCAAGTTTACTGCACAGCACCACAGACCTTTTGTGTATGTTAGTGTGATCATGAG 3484
DB 3121 GGGGGGGTACAGGTTTACTGCACAGCACCACAGACCTTTTGTGTATGTTAGTGTGATCATGAG 3180
QY 3485 TATAAATACCCATATGTTGTAGTGCAGGACCAAGACACACTAGCTCCAGAACTGCCCAAT 3544
DB 3181 TACAAGTACCCATATGTTGTAGGCAAGGTAGGATACCTTTAGCCCAAGAACTTCTCTAT 3240
QY 3545 TGGGTTTACTTTTCCCGCCAGTATGCTTAAACAGTAGGTGAAGTAAACACAAAGGA 3604
DB 3241 TGGGTATATCTTTTCCCGCCCAATATGCTTAAACAGTAGGTGAAGTAAACACAAAGGA 3300
QY 3605 ATTTCCAGGAGCAGCAAAATTTGGCTAGTGAAGATCAGCTTTTATGTTGTAGAGCAC 3664
DB 3301 ATTTCCAGGAGCAGCAAAATTTGGCTAGTGAAGATCAGCTTTTATGTTGTAGAGCAC 3360
QY 3665 AGTTCATTTGAACTTTTGGGTACAGGGGATCTGCCACTATGCTCTACAAATTTTCCAGCT 3724
DB 3361 AGTTCATTTGAACTTTTGGGTACAGGGGATCTGCCACTATGCTCTACAAATTTTCCAGCT 3420
QY 3725 GTGCCCCAGAAAACCTTAGAGGCTGCAGCCCAACATTTTTTATGAAATGTACAAACCTTTG 3784
DB 3421 GTGCCCCAGAAAACCTTAGAGGCTGCAGCCCAACATTTTTTATGAAATGTACAAACCTTTA 3480
QY 3785 TACGCTTCTGTTTGGGTTAGGCTGACACATTTAGGAGGAGCCCTAAATTTTATGATCATTTG 3844
DB 3481 TACGCTTCTGTTTGGGTTAGGCTGACACATTTAGGAGGAGCCCTAAATTTTATGATCATTTG 3540
QY 3845 ACACAGGAGACCAAGCAATTTAGGAGGAGCCCTAAATTTTATGATCATTTG 3904
DB 3541 ACACAGGAGACCAAGCAATTTAGGAGGAGCCCTAAATTTTATGATCATTTG 3600
QY 3905 GTGTCTCAAGAGAGGAGCAATTTCTAATACAGGTGTGGAAGAGCCCTTTACGGGGCTT 3964

Job time : 18829 secs

Dd		3601	G G T C T A C A A G G A G G A G A C A G C T T A A T A C T G G A G C T G G A A G C C T T A C A G G C T T	3660
Qy		3965	A G T A G T G C A C T A G C A A A A C C A G A N T T C C T A C G C C G G G C G G C A G T A T C T C A G C C A	4024
Dd		3661	A G C A C A G T A C C T C T C A A A C A C T A G A T A T C C T A C G C C C T G G G A C A G T G T C T C A G C C A	3720
Qy		4025	T A C C A T C A C T G G G A C A C T G A T A A T A T G T T C A G G A T A A A T G C A T T C C A T G C A A	4084
Dd		3721	T A C C A C A C T G G G A C A C A G A T A C T A T G T C A C A G G A T A C A T G C A T T C T A G T C A G	3780
Qy		4085	A C C A C T T A T G G A A T G C T G A G C A A A G A G T A T C A G C A C A T A C T T C C A T G G C T T C A A T	4144
Dd		3781	A C C A C T T A T G G T A A C C T G A G C A A A G G T A T C A G A G G T G G T A G T T C C A A T	3840
Qy		4145	G A A A A G A C A G C T T A G C A G T T A C A G G T C T T A A C A T G C A C A C A T A C T T C C A T A A A	4204
Dd		3841	G A A A A G A C A G C T A A A C A G T T A C A G G T T T A A C A T G C A C A C A C T A C T T C C A T A A A	3900
Qy		4205	G G A C C O A A C A A T A C A C A G A C C A A T G A G C C C C T T A T G T G G C T C T T T G G A C	4264
Dd		3901	G G A C C G A C A A T A C A G A T C A A T G A G C C C C C T T A T G T G G T T G G C T C T T T G G A C	3960
Qy		4265	A G A A G A G C T T C A C T A C A A G T C A G T G G A G T A A A T C C T A A C T T A G A T G A C A G T	4324
Dd		3961	A G A G A G C C T T C A T A A A G C C G C T G G A G A G T G G G T T G C A T C A C C A C C T C C T C A A T A	4080
Qy		4325	T T T A A A C T C A N T T G C A G C C T A G G C G G T G G G T T G C A T C A C C A C C C C T C A A T A	4384
Dd		4021	T T T A A A C T C A G T T T G C A G C C T T A G A G A G T G G G T T G C A T C A C C A C C T C C T C A A T A	4444
Qy		4385	T T T T A A A A T A C T A C A C A A G T G G C C A N T G H A G T T T A A N T C A N T G G G A A T T A C T	4444
Dd		4081	T T T T T A A A A T A T A C A C A A G T G G C C A N T T G A G G T T T A A A T C A N T G G G A A T T A C T	4140
Qy		4445	A C T T T A G T T C A N T G T G G G A T A T G A C A G T T A C A G C T T T A A N T G G G A C C T	4504
Dd		4141	A C C T T A G T T C A G T A T G C G T G G G A T T A T G A C A G T A C T A T G A C A N T T A A N T T G G G C C	4200
Qy		4505	C G A A G G C T A C T G A A G G T G G A T C C C A G C T G G G T T A T C C T C T C A N T G C A G T G T	4564
Dd		4201	C G T A A G C T A C G G A C G T G G A T C C T C A C T G A G T A T C C C C G C A C G C A G C G T	4260
Qy		4565	C A T T T C A C A T A C T G T A T G A C C C C A C G T A C A G T A C A G T A C A G T A C A G T A C A G T	4624
Dd		4261	C A T T T C A C A T A T G A T A T G A C C C C A C G T A C A G T A C A G T A C A G T A C A G T A C A G T	4320
Qy		4625	G G A T A G A A G C C T G A A G A T T G G A C T G C A A A A G C G T G C A C C A C C A T T G A A C A	4684
Dd		4321	G G A T A G A A G C C T G A A G A T T G G A C A C C A A A G C G T G C A C C A C C A T T G A A C A	4380
Qy		4685	T T C C C A C C G T C T C A G C C A G G A C G T C A C C C G C C A C C T G T G C C C C C A G T	4744
Dd		4381	C T C C C A C C G C C T C A G C A G A G T G G T A C T T A A C G C C A C C A C C A C C C A G T	4440
Qy		4745	A T A T G T G C C C T C C A T A C C C G T A G G C A C C A C C T T A T A A A A G A T A C A G C G T G A	4804
Dd		4441	G T A C T G G C C C T C T G T A C C T A T A A G A G A T A C A G C G T G A	4500
Qy		4805	A T A T A A T T A T A C A	

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 20, 2004, 20:36:51 ; Search time 1743 Seconds
(without alignments)
12254.699 Million cell updates/sec

Title: US-09-555-640-1

Perfect score: 5028
Sequence: 1 gacgtcacaggaatgacgt.....acgtcatctccctgtgacgtc 5028

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 3373863 seqs, 2124099041 residues

Total number of hits satisfying chosen parameters: 6747726

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

N_Geneseq_29Jan04:*
1: geneseqn1980s:*
2: geneseqn1990s:*
3: geneseqn2000s:*
4: geneseqn2001as:*
5: geneseqn2001bs:*
6: geneseqn2002s:*
7: geneseqn2003as:*
8: geneseqn2003bs:*
9: geneseqn2003cs:*
10: geneseqn2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	5027	100.0	5028	2	AAx81580
2	3629.4	72.2	4677	2	AAx81580 Genomic D
3	3627.6	72.1	4678	8	ABz59570 Human par
4	3626	72.1	4678	8	ABz59571 Human par
5	2343	46.6	2343	2	AAx81583
6	2013	40.0	2013	2	AAx81581
7	1912.6	38.0	2380	8	ABz59573 Human par
8	1911	38.0	2380	8	ABz59576 Human par
9	1868	37.2	2600	2	AAx81586
10	1662	33.1	1662	2	AAx81586
11	1585.6	31.5	2016	4	AAA91321
12	1585.6	31.5	2016	6	AAx81580
13	1585.6	31.5	2016	6	AAx81580
14	1585.6	31.5	2016	6	AAx81580
15	1585.6	31.5	2016	7	ABx96680
16	1585.6	31.5	2016	7	ABx96680
17	1584	31.5	2016	6	AAx81580
18	1579.6	31.4	2049	8	ABz59572
19	1578	31.4	2049	8	ABz59575
20	1576	31.3	2016	4	AAA91320
21	1576	31.3	2016	6	AAx81580
22	1576	31.3	2016	6	AAx81580
23	1576	31.3	2016	7	ABx96679

24	1576	31.3	2016	7	ABx96534	ABx96534 DNA encod
25	1576	31.3	2016	7	ACC69255	ACC69255 B19 virus
26	1574.4	31.3	2016	6	AAx81580	AAx81580 B19 virus
27	1327.2	26.4	1699	8	ABz59574	ABz59574 Human par
28	1327.2	26.4	1699	8	ABz59577	ABz59577 Human par
29	1319.4	26.2	2271	3	AAx81580	AAx81580 Adeno-as8
30	725	14.4	725	2	AAx81584	AAx81584 Probe use
31	681	13.5	681	2	AAx81584	AAx81584 Erythrovi
32	664	13.2	670	2	AAx81584	AAx81584 Probe use
33	582	11.6	678	6	ABK33258	Abk33258 B19 human
34	568.8	11.3	700	8	ABz59560	ABz59560 Human par
35	568.8	11.3	700	8	ABz59562	ABz59562 Human par
36	567.2	11.3	700	8	ABz59606	ABz59606 Human par
37	567.2	11.3	700	8	ABz59607	ABz59607 Human par
38	567.2	11.3	700	8	ABz59610	ABz59610 Human par
39	567.2	11.3	700	8	ABz59612	ABz59612 Human par
40	567.2	11.3	700	8	ABz59627	ABz59627 Human par
41	567.2	11.3	700	8	ABz59611	ABz59611 Human par
42	567.2	11.3	700	8	ABz59616	ABz59616 Human par
43	567.2	11.3	700	8	ABz59561	ABz59561 Human par
44	567.2	11.3	700	8	ABz59615	ABz59615 Human par
45	567.2	11.3	700	8	ABz59609	ABz59609 Human par

ALIGNMENTS

RESULT 1	AAx81580	AAx81580 standard; DNA; 5028 BP.
XX	XX	
AC	AAx81580;	
XX	XX	
DT	26-AUG-1999	(first entry)
XX	XX	
DE	Genomic DNA sequence of erythrovirus V9.	
XX	XX	
KW	Erythrovirus V9; differential diagnosis; parvovirus; infection;	
KM	erythrovirus screening; typing; immunoassay; ss.	
XX	XX	
OS	Erythrovirus.	
XX	XX	
EH	Key	Location/Qualifiers
FT	misc_feature	4891
FT		/tag= a
FT		/note= "this base represents a nucleotide missing from
FT		the sequence given in the specification. It is included
FT		to maintain the nucleotide numbering given in the
XX	XX	specification for this sequence"
XX	XX	
XX	FR2771751-A1.	
XX	XX	
PD	04-JUN-1999.	
XX	XX	
PF	03-DEC-1997;	97RR-00015197.
XX	XX	
PR	03-DEC-1997;	97RR-00015197.
XX	XX	
PA	(ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.	
XX	XX	
PI	Nguyen QT, Garbarg CA, Auguste V;	
XX	XX	
DR	WPI, 1999-349543/30.	
XX	XX	
PT	Erythrovirus V9 and its nucleic acid sequences - can be used in the	
XX	diagnosis of its infections.	
XX	XX	
PS	Claim 1; Page 19-21; 80pp; French.	
XX	XX	
CC	The present sequence represents the genomic sequence of erythrovirus V9.	
CC	Probes and primers derived from erythrovirus V9 polynucleotide sequences	
CC	(AAx81580) can be used for differential diagnosis of erythrovirus	
CC	(parovirus) infections by a combination of amplification and	

CC hybridisation assay. The probes can also be used to assess susceptibility
 CC to erythrovirus infection and for erythrovirus screening and typing. The
 CC antibodies can be used in immunoassays for diagnosis of erythrovirus V9
 CC infections
 XX

Sequence 5028 BP; 1528 A; 1010 C; 1106 G; 1383 T; 0 U; 1 Other;

Query Match 100.0%; Score 5027; DB 2; Length 5028;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 5027; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 1 GACGTCACGGAATGACGTAACTGTCCGCCATCTTGTACCGGAAGTCCCGCTACCGGC 60
DB 1 GACGTCACGGAATGACGTAACTGTCCGCCATCTTGTACCGGAAGTCCCGCTACCGGC 60
QY 61 GCGGACCGGCGGATCTGATTTGGTCTCTCTTTTGAATTTGGCGGCTTTTCCCG 120
DB 61 GCGGACCGGCGGATCTGATTTGGTCTCTCTTTTGAATTTGGCGGCTTTTCCCG 120
QY 121 CCTTATGCAAAATAGCGGCCCATGTTAAATGTTAATTTTAAATTGAACAAACGCT 180
DB 121 CCTTATGCAAAATAGCGGCCCATGTTAATGTTAATTTTAAATTGAACAAACGCT 180
QY 181 AACGCTTCTAGGCGGCGAGTTAAGCGCGTATATAGCAAGCTGCTCCCTGACACTT 240
DB 181 AACGCTTCTAGGCGGCGAGTTAAGCGCGTATATAGCAAGCTGCTCCCTGACACTT 240
QY 241 CTTTCTGCTGCTTTTGACTGAACTCACTTGGCTGTTTGGCTGTAAGTAAAGCT 300
DB 241 CTTTCTGCTGCTTTTGACTGAACTCACTTGGCTGTTTGGCTGTAAGTAAAGCT 300
QY 301 ATTATATCTAATCTTTAATTTACTTACATGAGAGCTATTTGGGGTGTCTTGCACATTTCC 360
DB 301 ATTATATCTAATCTTTAATTTACTTACATGAGAGCTATTTGGGGTGTCTTGCACATTTCC 360
QY 361 TCTAACATCTGAGCTGCTAATGATATACGTGGGTGCTCTATGCTAGACTTATGATACT 420
DB 361 TCTAACATCTGAGCTGCTAATGATATACGTGGGTGCTCTATGCTAGACTTATGATACT 420
QY 421 TCTGACCTGGGAAACCACTAACCCATCTTACAGATTAATGCAATATATTTAACACATGTT 480
DB 421 TCTGACCTGGGAAACCACTAACCCATCTTACAGATTAATGCAATATATTTAACACATGTT 480
QY 481 GCTTCTAACTGATTTTAACTGGGGGCGGCTAGCAGGTGCTTAACTTTTTCAGGTG 540
DB 481 GCTTCTAACTGATTTTAACTGGGGGCGGCTAGCAGGTGCTTAACTTTTTCAGGTG 540
QY 541 GAATGTAAACAATTTGAGGAAGCTATCATATCATATGATGTTATGTTGGTCCAGAGCTA 600
DB 541 GAATGTAAACAATTTGAGGAAGCTATCATATCATATGATGTTATGTTGGTCCAGAGCTA 600
QY 601 AATGCTAGAACTTAATCTGTGCTGAGGAAGTTTATTTAATATGTTCTTTAACATCTT 660
DB 601 AATGCTAGAACTTAATCTGTGCTGAGGAAGTTTATTTAATATGTTCTTTAACATCTT 660
QY 661 GTAATGAAAGTGTAACTTAATTTTGGCAGGAGTACACAAAGGAAATATTTT 720
DB 661 GTAATGAAAGTGTAACTTAATTTTGGCAGGAGTACACAAAGGAAATATTTT 720
QY 721 AGGAGAGGAGAGAGTTTATGAAATTAATTAATGAAATTAATTTCTTTAATGTTGG 780
DB 721 AGGAGAGGAGAGAGTTTATGAAATTAATTAATGAAATTAATTTCTTTAATGTTGG 780
QY 781 TGGTGTGTAACAAATTTAGACGGGTATATGACACCTGATTTCCGCTTTTGGGGA 840
DB 781 TGGTGTGTAACAAATTTAGACGGGTATATGACACCTGATTTCCGCTTTTGGGGA 840
QY 841 GGAAGCTTGTATGCTAAAGAACCCCGCATTTACGAAATATACAGAGTCTACTAATGAA 900
DB 841 GGAAGCTTGTATGCTAAAGAACCCCGCATTTACGAAATATACAGAGTCTACTAATGAA 900
QY 901 ACTGGGAGATCTAGCTGTGAGGAGGAGATGTTGGCCATTTGCTGGAAGGAAACAAA 960
DB 901 ACTGGGAGATCTAGCTGTGAGGAGGAGATGTTGGCCATTTGCTGGAAGGAAACAAA 960

```

```

DB 901 ACTGGGAGATCTAGCTGTGAGGAGGAGATGTTGGCCATTTGCTGGAAGGAAACAAA 960
QY 961 GCGGGGTTAAAGTTTCAACCAAGTAAATGGCTATGAGAAACAGAGATTTACTGAA 1020
DB 961 GCGGGGTTAAAGTTTCAACCAAGTAAATGGCTATGAGAAACAGAGATTTACTGAA 1020
QY 1021 GATTAATGAAATTAAGTGAATTTTAAACAAATACTTTAATTAAGTACAGTACAGTGC 1080
DB 1021 GATTAATGAAATTAAGTGAATTTTAAACAAATACTTTAATTAAGTACAGTACAGTGC 1080
QY 1081 AGCTTCAATTTAAAGTGTCTTAAAGTATTAATTAAGTAACTTAACTTAAGTACC 1140
DB 1081 AGCTTCAATTTAAAGTGTCTTAAAGTATTAATTAAGTAACTTAACTTAAGTACC 1140
QY 1141 ACTAGTACATCTTGTGTAATCAGACTTGTGAGCAGGTACTGTGATTAAGAAATAA 1200
DB 1141 ACTAGTACATCTTGTGTAATCAGACTTGTGAGCAGGTACTGTGATTAAGAAATAA 1200
QY 1201 ATATGTAATTAATTAATGTTGTCAAACTATGATCCCTTTTATGAGGTCAACATGTTA 1260
DB 1201 ATATGTAATTAATTAATGTTGTCAAACTATGATCCCTTTTATGAGGTCAACATGTTA 1260
QY 1261 AGGTGATTTGACAAAATATGTTTAAATTAATTAATTAATTAATTAATTAATTAAT 1320
DB 1261 AGGTGATTTGACAAAATATGTTTAAATTAATTAATTAATTAATTAATTAATTAAT 1320
QY 1321 ACTGAAAACAAATTTGGCAATGCTATGCTAAACCTGATACAGTATGAAATGTTG 1380
DB 1321 ACTGAAAACAAATTTGGCAATGCTATGCTAAACCTGATACAGTATGAAATGTTG 1380
QY 1381 AATGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1440
DB 1381 AATGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1440
QY 1441 GATGAAGCATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1500
DB 1441 GATGAAGCATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1500
QY 1501 CCAACCAAGGTAATGATCAAAAATGCTGTGCAAGTGTGCAAGTGTGCTGTGTT 1560
DB 1501 CCAACCAAGGTAATGATCAAAAATGCTGTGCAAGTGTGCAAGTGTGCTGTGTT 1560
QY 1561 ATTAACAGCAATGTTGATCAATTAATTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 1620
DB 1561 ATTAACAGCAATGTTGATCAATTAATTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 1620
QY 1621 GCTAAAGCTTAAAGGAACGAGTGTAAAGCTTAACTTAACATTAAGATGAGCCCTGAC 1680
DB 1621 GCTAAAGCTTAAAGGAACGAGTGTAAAGCTTAACTTAACATTAAGATGAGCCCTGAC 1680
QY 1681 ATGGGTTTACTTACAGAGGCTGATGTAACAANTGCTAATGCTGTTGTTATGCAAAAGC 1740
DB 1681 ATGGGTTTACTTACAGAGGCTGATGTAACAANTGCTAATGCTGTTGTTATGCAAAAGC 1740
QY 1741 TGAAGCACTATGAAAACCTGGGCAATTAATTAACATTTGTTCCCTGGAATTAATGCA 1800
DB 1741 TGAAGCACTATGAAAACCTGGGCAATTAATTAACATTTGTTCCCTGGAATTAATGCA 1800
QY 1801 GATGCTCCACACCCAGATCTCCCAACCAACCCCATTTGTTCCCAACCAACAGTATCAGCAGC 1860
DB 1801 GATGCTCCACACCCAGATCTCCCAACCAACCCCATTTGTTCCCAACCAACAGTATCAGCAGC 1860
QY 1861 AGTGTGTGTAAGGCTCTGAAAGACTCAAGTAAAGAGCTTTTCAACTCAATCACTCA 1920
DB 1861 AGTGTGTGTAAGGCTCTGAAAGACTCAAGTAAAGAGCTTTTCAACTCAATCACTCA 1920
QY 1921 GGGGCTTGAACAGTGAACCCCGGCTTAAAGTACGCTCCCGGGAACAAGTTCAAGA 1980
DB 1921 GGGGCTTGAACAGTGAACCCCGGCTTAAAGTACGCTCCCGGGAACAAGTTCAAGA 1980
QY 1981 GAATCAATTTGTGGAAGCCAGTTTCTCCGAAGTGTGAGCGGCTGTTGGGAGGAAGCT 2040
DB 1981 GAATCAATTTGTGGAAGCCAGTTTCTCCGAAGTGTGAGCGGCTGTTGGGAGGAAGCT 2040

```

QY 2041 TTTTACACGCGCTGCGCATGATTTCGGAACGTGTAGAGGGGTGACTTGTATGG 2100
Db 2041 TTTTACACGCGCTGCGCATGATTTCGGAACGTGTAGAGGGGTGACTTGTATGG 2100
QY 2101 GATGTGTAGAGGGGATTCCTGTTTGTGTGTGGAACATATAAACAAGTGGGAGGG 2160
Db 2101 GATGTGTAGAGGGGATTCCTGTTTGTGTGTGGAACATATAAACAAGTGGGAGGG 2160
QY 2161 TTGGGGCTTTGCCCTCATGTGTATTAATGTGGAGCTTGGTAATATGGAATTTAGA 2220
Db 2161 TTGGGGCTTTGCCCTCATGTGTATTAATGTGGAGCTTGGTAATATGGAATTTAGA 2220
QY 2221 GAGTTTACTCCAGACTTATAGTGGCTGAGTGTGATGTAGAGGCTCTAACCCATTTCT 2280
Db 2221 GAGTTTACTCCAGACTTATAGTGGCTGAGTGTGATGTAGAGGCTCTAACCCATTTCT 2280
QY 2281 GTGTAACTTGTAAAAAATGTGCTTACCTGTCTGATTAACAAGTTTGTATATAG 2340
Db 2281 GTGTAACTTGTAAAAAATGTGCTTACCTGTCTGATTAACAAGTTTGTATATAG 2340
QY 2341 TAAACCACTAACAAATGTGGGAAAGCAGTGAACAATTTGCCAGAGCGTGTATAAGCA 2400
Db 2341 TAAACCACTAACAAATGTGGGAAAGCAGTGAACAATTTGCCAGAGCGTGTATAAGCA 2400
QY 2401 GTTTGTGCAATTTTATGAAAAAAGCTATGGAACAGACTTATAGCTTATTAATTTAA 2460
Db 2401 GTTTGTGCAATTTTATGAAAAAAGCTATGGAACAGACTTATAGCTTATTAATTTAA 2460
QY 2461 AGACCAATTAACAATTTCTTATAGTATATCTTTAGAAAAACCCCTCTTATTTGACTT 2520
Db 2461 AGACCAATTAACAATTTCTTATAGTATATCTTTAGAAAAACCCCTCTTATTTGACTT 2520
QY 2521 AGTTGCTGCAATTAAGTATCTTTAAAACTCTCCAGACCTATATAGTATCAATTTCA 2580
Db 2521 AGTTGCTGCAATTAAGTATCTTTAAAACTCTCCAGACCTATATAGTATCAATTTCA 2580
QY 2581 GAGCCATGACATATATGTGACCAACCCCTGCTTATCATCCAGTAAAGTATGTGAGA 2640
Db 2581 GAGCCATGACATATATGTGACCAACCCCTGCTTATCATCCAGTAAAGTATGTGAGA 2640
QY 2641 ACCTAAGAGAGAAATGACATATATGTGAGAAAGCTTACACAAGCTGGGCAAGTTAG 2700
Db 2641 ACCTAAGAGAGAAATGACATATATGTGAGAAAGCTTACACAAGCTGGGCAAGTTAG 2700
QY 2701 CATACATTAACCCGGTATCTAATATGTGGCCCTGGCAATGAGCTAACAAGCTGGCTCC 2760
Db 2701 CATACATTAACCCGGTATCTAATATGTGGCCCTGGCAATGAGCTAACAAGCTGGCTCC 2760
QY 2761 GCGAATGCTGTGTGACAGTGTGCAAGAGATTCATGACTTTAGTATAGCAATTTGGCTTA 2820
Db 2761 GCGAATGCTGTGTGACAGTGTGCAAGAGATTCATGACTTTAGTATAGCAATTTGGCTTA 2820
QY 2821 GTTGGGGAATTAATCTTATACATTTGACATGTGACGATGAGATTTGTTAAAAATAT 2880
Db 2821 GTTGGGGAATTAATCTTATACATTTGACATGTGACGATGAGATTTGTTAAAAATAT 2880
QY 2881 AAAAATGAAAAGGGTTTCAAGCAACAAGAGTAAAGATTACTTTAATTAAAAAGTGC 2940
Db 2881 AAAAATGAAAAGGGTTTCAAGCAACAAGAGTAAAGATTACTTTAATTAAAAAGTGC 2940
QY 2941 AGCTGCCCTGTGGCCCATTTTCAAGAAAGTTTACGGAGAGTGCCTGGTACAACGCTTC 3000
Db 2941 AGCTGCCCTGTGGCCCATTTTCAAGAAAGTTTACGGAGAGTGCCTGGTACAACGCTTC 3000
QY 3001 AGAAAAATACCCAGAGATGACTTCAAGTTAACTCTGAGAAAGCAGCACTGTGTCAAGCGG 3060
Db 3001 AGAAAAATACCCAGAGATGACTTCAAGTTAACTCTGAGAAAGCAGCACTGTGTCAAGCGG 3060
QY 3061 GGGAGGTAGCAACCTTACAAAAAGCATGTGTGAGGAGGCTTACATTTTCTGTATTTT 3120
Db 3061 GGGAGGTAGCAACCTTACAAAAAGCATGTGTGAGGAGGCTTACATTTTCTGTATTTT 3120

QY 3121 TGTAACTGTATACCTCTAGAGCAATTTTAAATTCATATGATCCAGAGCATTAATA 3180
Db 3121 TGTAACTGTATACCTCTAGAGCAATTTTAAATTCATATGATCCAGAGCATTAATA 3180
QY 3181 AGTGTCTCTCCAGCAGCTAGTATGCTGCAAAATGTACTGTGGAAAGAGCAAAAGTGTG 3240
Db 3181 AGTGTCTCTCCAGCAGCTAGTATGCTGCAAAATGTACTGTGGAAAGAGCAAAAGTGTG 3240
QY 3241 CACTATTAAGTCCCATTAATGGGGTACTTACTCCGTGGAATATCTTATGATTTTAAATGCTTT 3300
Db 3241 CACTATTAAGTCCCATTAATGGGGTACTTACTCCGTGGAATATCTTATGATTTTAAATGCTTT 3300
QY 3301 AAATTTGTTTCTACCAATTAAGTGTAGAGCACTTAATTTGAAAAATTAATGTATAGC 3360
Db 3301 AAATTTGTTTCTACCAATTAAGTGTAGAGCACTTAATTTGAAAAATTAATGTATAGC 3360
QY 3361 TCCAGATGCTTAACTGTATCTAATTTCAAAAATGTGTAAAGATGTCAACAGCAAAAC 3420
Db 3361 TCCAGATGCTTAACTGTATCTAATTTCAAAAATGTGTAAAGATGTCAACAGCAAAAC 3420
QY 3421 AGAGAGAGGTGTGCAAGTTACTGACAGCACACAGAGAGCTTGTGTATGTATGATCA 3480
Db 3421 AGAGAGAGGTGTGCAAGTTACTGACAGCACACAGAGAGCTTGTGTATGTATGATCA 3480
QY 3481 TGAGTAAATATCCCATATGTGTAGGTGAGGAGCAAGACACATGATCTCCAGAACTGCC 3540
Db 3481 TGAGTAAATATCCCATATGTGTAGGTGAGGAGCAAGACACATGATCTCCAGAACTGCC 3540
QY 3541 CATTTGGTTTACTTTTCCCCCAGATATCTTACTTAAAGTATGTAAGTAAACACACA 3600
Db 3541 CATTTGGTTTACTTTTCCCCCAGATATCTTACTTAAAGTATGTAAGTAAACACACA 3600
QY 3601 AGGAATTTGAGAGACAGCAAAATTTGCTGTAGTAAAGATCACTTTTATGTGTAGA 3660
Db 3601 AGGAATTTGAGAGACAGCAAAATTTGCTGTAGTAAAGATCACTTTTATGTGTAGA 3660
QY 3661 GCAAGTTCATTTGAACTTTTGGGTACAGGGGAGTGTGCACTATGTCTTACAAATTTCC 3720
Db 3661 GCAAGTTCATTTGAACTTTTGGGTACAGGGGAGTGTGCACTATGTCTTACAAATTTCC 3720
QY 3721 AGCTGTGCCCCAGAAAACCTTAGAAGGCTGACGCCAATTTTATGAAATGTACAACC 3780
Db 3721 AGCTGTGCCCCAGAAAACCTTAGAAGGCTGACGCCAATTTTATGAAATGTACAACC 3780
QY 3781 TTTGTACGGTTCCTTTAGGGGTACTCTGACATTTAGAGAGGAGCCCTTAATTTAGATC 3840
Db 3781 TTTGTACGGTTCCTTTAGGGGTACTCTGACATTTAGAGAGGAGCCCTTAATTTAGATC 3840
QY 3841 ATTGACACAGAAAGACAGCAATTCAGGCCAATAATGCTTATGCTGGGCCACTAATTA 3900
Db 3841 ATTGACACAGAAAGACAGCAATTCAGGCCAATAATGCTTATGCTGGGCCACTAATTA 3900
QY 3901 TTCAGTGTCTACCAAAAGAGAGCAATTCATATACAGGTGCTGAAAAGCCCTTAACGGG 3960
Db 3901 TTCAGTGTCTACCAAAAGAGAGCAATTCATATACAGGTGCTGAAAAGCCCTTAACGGG 3960
QY 3961 GCTTACTGTGCACTAGCCAAAACACAGAAATTTCCCTACAGCCCGGGCCAGTATCTCA 4020
Db 3961 GCTTACTGTGCACTAGCCAAAACACAGAAATTTCCCTACAGCCCGGGCCAGTATCTCA 4020
QY 4021 GCCATACCATCTGGGACATCTAATATGTTAAGGAATTAATGCCATTTCAACATGG 4080
Db 4021 GCCATACCATCTGGGACATCTAATATGTTAAGGAATTAATGCCATTTCAACATGG 4080
QY 4081 ACAAAACCACTTATGAAAATGTGTGAGCAAAAGATATCAGCAAGGGGTAGGAAGATTTCC 4140
Db 4081 ACAAAACCACTTATGAAAATGTGTGAGCAAAAGATATCAGCAAGGGGTAGGAAGATTTCC 4140
QY 4141 AAATGAAAAAGAACAGCTTAAAGCATGTTACAGAGTCTTAAATGACACATATCTTCCCTTA 4200
Db 4141 AAATGAAAAAGAACAGCTTAAAGCATGTTACAGAGTCTTAAATGACACATATCTTCCCTTA 4200
QY 4201 TAAAGAACCCCAACATATACAGAACCAATTAAGCCCTCTTATATGTGGGCTCTGTGG 4260

```

Db      4201 TAAAGAACCCACATATACAGACCAATTGAGCCCTCTTATGAGGAGCTGCTGTTG 4260
Qy      4261 GAACAGAAAGAGCTTCTCACTATGAAAGTCACTGTGAGTAAATCCCTTAATTGATGA 4320
Db      4261 GAACAGAAAGAGCTTCTCACTATGAAAGTCACTGTGAGTAAATCCCTTAATTGATGA 4320
Qy      4321 CAGTTTAAAGCTCAATTTGAGAGCCCTAGAGGGGAGGGTGTGATCAACCAACCCCTCA 4380
Db      4321 CAGTTTAAAGCTCAATTTGAGAGCCCTAGAGGGGAGGGTGTGATCAACCAACCCCTCA 4380
Qy      4381 AATATTTTAAATTTCTACCAAGATGGGCAATTTGAGAGTATTAATCAATGGGAT 4440
Db      4381 AATATTTTAAATTTCTACCAAGATGGGCAATTTGAGAGTATTAATCAATGGGAT 4440
Qy      4441 TACTACTTATGTTCAATTTGCTGGGAAATATGACATTAACATGACCTTTAAATTTGG 4500
Db      4441 TACTACTTATGTTCAATTTGCTGGGAAATATGACATTAACATGACCTTTAAATTTGG 4500
Qy      4501 ACCTGAAAGGCTACTGGAAGGTGGAATCCCAAGCTGGGCTTATCTCTCATGAGC 4560
Db      4501 ACCTGAAAGGCTACTGGAAGGTGGAATCCCAAGCTGGGCTTATCTCTCATGAGC 4560
Qy      4561 TGTGATTATACCATATGATGATGACCCCAAGCTACAGATGCAAGCAACACACAG 4620
Db      4561 TGTGATTATACCATATGATGATGACCCCAAGCTACAGATGCAAGCAACACACAG 4620
Qy      4621 ACAGGATATGAAAGAGCTGGAAGATTTGTGAGTGGCAAGAGCGTGTGACCCATTTGA 4680
Db      4621 ACAGGATATGAAAGAGCTGGAAGATTTGTGAGTGGCAAGAGCGTGTGACCCATTTGA 4680
Qy      4681 AACATTTCCCAACCGTCTCTGAGGAGGACCGTCCACCGCCACCTGTGGCCCA 4740
Db      4681 AACATTTCCCAACCGTCTCTGAGGAGGACCGTCCACCGCCACCTGTGGCCCA 4740
Qy      4741 GATTATATGTCCTCCCTCAATACCCGATGAGGACCATATTAAGATATGACAGCTG 4800
Db      4741 GATTATATGTCCTCCCTCAATACCCGATGAGGACCATATTAAGATATGACAGCTG 4800
Qy      4801 TAGAATTTAAATTTTATGATGATGATGACCAATGATTAAGATGATTAATGTA 4860
Db      4801 TAGAATTTAAATTTTATGATGATGATGACCAATGATTAAGATGATTAATGTA 4860
Qy      4861 ATATGTCACAGTTTGGAAATTAAGGCTTAATTAATTTTATGATGATGATG 4920
Db      4861 ATATGTCACAGTTTGGAAATTAAGGCTTAATTAATTTTATGATGATGATG 4920
Qy      4921 TTTTAAATTTTCAAAAGAGACCAATCAGATGCGGCGGCTGAGGCGG 4980
Db      4921 TTTTAAATTTTCAAAAGAGACCAATCAGATGCGGCGGCTGAGGCGG 4980
Qy      4981 GACTTCGGTACAAAGATGGGCACTTACGTCATTTCTGTGACGTC 5028
Db      4981 GACTTCGGTACAAAGATGGGCACTTACGTCATTTCTGTGACGTC 5028

```

RESULT 2
AAT49535
ID AAT49535 standard; DNA; 4677 BP.

XX AAT49535;

DT 27-AUG-2003 (revised)
DT 26-FEB-1997 (first entry)

XX Human parvovirus genome fragment.

KW Human, parvovirus genome; structural gene; VP-1; VP2; arthritis;
KW non-structural protein; NS; diagnosis; vaccine; parvoviral disease;
KW erythroblastemia; abortion; universal fetal hydrops; liver disease;
KW haemorrhagic fever; rheumatism; detection; IgG antibody; ds.

OS B19 virus.

```

XX Key Location/Qualifiers
FH CDS 222..2237
FT /tag= c
FT /product= "NS_protein"
FT CDS 2230..4575
FT /tag= a
FT /product= "VP1"
FT CDS 2911..4575
FT /tag= b
FT /product= "VP2"
XX JP07147986-A.
XX 13-JUN-1995.
XX 24-SEP-1992; 92JP-00281017.
XX 24-SEP-1992; 92JP-00281017.
XX (BLED) DENKI KAGAKU KOGYO KK.
XX (DENK-) DENKA SEIKEN KK.
XX WP1; 1995-242756/32.
XX P-PSDB; AAM08986, AAM08987, AAM08988.
XX Human parvovirus gene coding for a polypeptide - useful for developing
XX vaccines against parvoviral diseases such as erythroblastemia,
XX haemorrhagic fever, etc.
XX Claim 1; Page 2-5; 38pp; English.
XX
XX This sequence represents a fragment of the human parvovirus genome which
XX encodes the parvovirus structural genes VP-1 and VP2, and the non-
XX structural protein, NS. This coding sequence may be used for the
XX diagnosis and development of vaccines for parvoviral diseases including
XX erythroblastemia, abortion, universal fetal hydrops, liver diseases,
XX haemorrhagic fever, arthritis and rheumatism. The VP-1 and VP-2 proteins
XX may be used to detect parvovirus IgG antibodies. (Updated on 27-AUG-2003
XX to correct OS field.)
XX
XX Sequence 4677 BP; 1430 A; 931 C; 1030 G; 1277 T; 0 U; 9 other;
XX
XX Query Match 72.2%; Score 3629.4; DB 2; Length 4677;
XX Best Local Similarity 86.1%; Pred. No. 0;
XX Matches 4023; Conservative 7; Mismatches 633; Indels 8; Gaps 1;
XX
Qy 115 TTCCCGCTTATGCAATTAAGCGGCATGTTATGTTATATTTTAAATTGACAA 174
Db 1 TTCCCGCTTATGCAATTAAGCGGCATGTTATGTTATATTTTAAATTGACAA 174
Qy 175 ACGCTAACGTTACTAGGGGCGGAGTTACG-----GCGATATTAAGACGCTGG 226
Db 61 TTTTGTACGCTTAAATGAGCGGAGGCTAGGCGGAGCTACAGATTAATTAAGCGCA 120
Qy 227 TTCCCTACACTTTCTTTCTGCTGTTGCTTTGACTGAATCACTGCTGTTCTTGGCT 286
Db 121 CTGCGGAGGCTTTCTTCTGCTGCTTTTCCGAGCTTTCTGCTGTTTGTGTA 180
Qy 287 GCTAAGTAAGAGTATTTATCTAATTTAATTTAATTAATTAATTAATTTGCGGGT 346
Db 181 GCTAAGTAAGAGTATTTATCTAATTTAATTTAATTTAATTTAATTTAATTTGCGGG 240
Qy 347 TCTGCACTTTCTCTCAACTTCTGAGCTGCTGATGATGATGATGATGATGCTATGC 406
Db 241 TTCTTCAAGTTTCTTCAATTTCTGAGCTGCTGATGATGATGATGATGATGCTATGC 300
Qy 407 TAACTTAAATTTGATTTGATGCTGGAACCACTAATCAATTTCAACATTAATGCAATAT 466
Db 301 TGAATTTAAGCACTTTGATGCTGGAACCACTAATCAATTTCAACATTAATGCAATAT 360
Qy 467 ATTAAGCAGTGTGCTTAAATTAATTTAATTTAATTTAATTTAATTTAATTTGCTAT 526

```


Db 361 ACTTAAGCAGTGTGCTTCAAGCTTACCTTACCCGGGGGCCACTAGCAGGGTGTGT 420
Qy 527 ACTTTTTCAGGTGGAATGTAAACAAATTGAGAGAGCTATCATTCAGATGTATATG 586
Db 421 ACTTTTTCAGAGTGAATGTAAACAAATTGAGAGAGCTATCATTCAGATGTATATG 480
Qy 587 GTGTGTCAGAGCTAAATGTAGAAACTTAACTGTGTGCTAGAGAGGTTTATTATATG 646
Db 481 GGGGGCCAGGGTTAAATCCAGAAACCTCACTGTGTGTGAGAGGGTTTATTATATG 540
Qy 647 TTCTTACCATCTTGTACTGAAAGTGTAACTTAAATTTTTCAGAGGATACATCA 706
Db 541 TACTTTATCACTGTATACGAAATGTAAAGCTTAAATTTTTCAGAGGATACATCA 600
Qy 707 AAGGAAATTTTAAAGATGAGAGAGAGCTTTATAGAAATTTACTTAAATGAAAAATTC 766
Db 601 AAGGCAAAATCTTAAAGATGAGAGAGAGCTTTATAGAAATCTATTAATGAAAAATAC 660
Qy 767 CTTTAATGTGTGTGTGTGTAAACAAATATGTACGGGTATATAGACCTGTATTTCCG 826
Db 661 CTTTAAATGTGTATGTGTGTGTATTAATGTATATATATATATATATATATTTCTG 720
Qy 827 CCTTTTTCGGCAGAGAGCTTGTATGTCTTAAAGACCCCGCATTACTGCAATACAGCA 886
Db 721 CTACTTTTGAAGGGAGCTTGCATGCAAGAAACCCGCAATTAACAAGCATTAATG 780
Qy 887 GTCTCTATATGAATCTGGGAGCTTACGTGTGTGAGAGGGGAGATGTGTGCTGCTG 946
Db 781 AATCTGT 840
Qy 947 GAAAGGAAACAAAGCGGGGTAAAGTTTCAACCATGTAAATTTGGCTATGTGAAACA 1006
Db 841 GGAAGAGAACTAAGGCTAGATTAAGTTTCAACCATGTAAATTTGGCTATGTGAAACA 900
Qy 1007 GAGTATTTACTAGAGATTAATGTAAATGTAGATTTTAAACCAATTAATTTTAAATA 1066
Db 901 GAGTGTTTACAGAGATTAAGTGAATCTAGTTGACTTTAACAGTACCTTTAAGCA 960
Qy 1067 GCAGTCAAGTGGCAGCTTTCAAAATTCAGAGTCCCTTAAAGTTAGCTATTTAAAGCTA 1126
Db 961 GTAGTCAAGTGGAGATTTTCAAAATTCAGAGTCACTTAAAGCTATTTAAAGCTA 1020
Qy 1127 CTAACTTAAACCACTAGTACATCTTGTGTACATTCAGACTTTGAGCAGGTTAGCTGCA 1186
Db 1021 CTAAATTTAGCTCTAGCAGCAATTTTATTTAGATACAGCTTTGAGCAGGTTATGTGTA 1080
Qy 1187 TTAAGAAATTAATTAATTAATTAATTTATTTGTGTCAAAACTATGATCTCTTTAGTGG 1246
Db 1081 TTAAGCAATTAATTAATTTGTTAAATTTGTTACTTTGTCAAACTATGACCCCTATTTGGTGG 1140
Qy 1247 GTCAACATGTGTTAAGTGTATGACAAATAATGTGTAAAAAACAACCTGTGTGTTT 1306
Db 1141 GGCAGCATGTGTAAAGTGTATGATTAATAATGTGTCAAAAAAATATACCTGTGTGTTT 1200
Qy 1307 ACGGGCCACCAAGTACTGAGAAAAACAATTTGGCAATGGCTATTTGCTAAACGTATCCAG 1366
Db 1201 ATGGGCGCGCAATACAGAAAAACAATTTGGCAATGGCTATTTGCTAAACGTATCCAG 1260
Qy 1367 TGTATGAAATGTGTAATGTGAATATGAAATCTTCCATTTAAATGATGTAGCGGGGAAA 1426
Db 1261 TATATGGCAATGTGTAATGTGAATATGAAATCTTCCATTTAAATGATGTAGCGGGAAA 1320
Qy 1427 GTTTGT 1486
Db 1321 GCTTGT 1380
Qy 1487 TTTTAAAGT 1546
Db 1381 TTTTAAAGT 1440
Qy 1547 GT 1606
Db 1441 GAGTATCTGT 1500

Qy 1607 CTACAACTGTGATGCTTAAAGCTTTAAAGCAACGATGTAAAGCTTAACTTACATTA 1666
Db 1501 CAACAACTGTGATGCTTAAAGCTTTAAAGCAACGATGTAAAGCTTAACTTACATTA 1560
Qy 1667 GATGAGCCCTGACATGAGGTTTACTTACAGAGGCTGATGTACAAACATGCTACTTGGT 1726
Db 1561 GATGAGCCCTGACATGAGGTTTACTTACAGAGGCTGATGTACAAACATGCTACTTGGT 1620
Qy 1727 GTATATCAAAAGCTGTGAGCCATATGAAATCTGGGCAATTAATCACTTTGATTTCC 1786
Db 1621 GTATATCAAAAGCTGTGAGCCATATGAAATCTGGGCAATTAATCACTTTGATTTCC 1680
Qy 1787 CTGGAATTAATGAGATGCGCTCCACCAAGATCTCCAAACCAACCCCATTTGTCAGACA 1846
Db 1681 CTGGAATTAATGAGATGCGCTCCACCAAGATCTCCAAACCAACCCCATTTGTCAGACA 1740
Qy 1847 CCAGTATCAGCAGCAGTGTGTGTGAAAGCTGTGAAAGCTCACTGTAAGAGAGCTTTTCA 1906
Db 1741 CCAGTATCAGCAGCAGTGTGTGTGAAAGCTGTGAAAGCTCACTGTAAGAGAGCTTTTCA 1800
Qy 1907 ACTCATCTCCAGGCGCTGTGAAACATGTAAACCCCGGCTTACTAGCGCCGCTCCCG 1966
Db 1801 ACTCATCTCCAGGCGCTGTGAAACATGTAAACCCCGGCTTACTAGCGCCGCTCCCG 1860
Qy 1967 GAGCCAGTTCAGAGAAATCATTTGTGGAAGCCCAAGTTCTCCGAAGTGTAGCGCGCT 2026
Db 1861 GAGCCAGTTCAGAGAAATCATTTGTGGAAGCCCAAGTTCTCCGAAGTGTAGCGCGCT 1920
Qy 2027 CGTGGAGAGAGCTTTTACACGCGCTGCGCATGATTCGTGTAAGCTTTAGTAGGGG 2086
Db 1921 CGTGGAGAGAGCTTTTACACGCGCTGCGCATGATTCGTGTAAGCTTTAGTAGGGG 1980
Qy 2087 TTGACTTTGTATGTGATGTGTGAGGGGATGCTGTGTGTGTGTGTGTGTGTGTGTGT 2146
Db 1981 TTGATATGT 2040
Qy 2147 ACAGTGGGAGAGGCTTGGGCTTGGCTCATTTGTATTAATGTGGAAGCTGTGTATTAATG 2206
Db 2041 ATATGGGGAGAGGCTTGGGCTTGGCTCATTTGTATTAATGTGGAAGCTGTGTATTAATG 2100
Qy 2207 GATGAAATTTAGAGAGTTTACTCCAGACTTATGTGCGCTGACGTGTATGTAGTAGAGCT 2266
Db 2101 GATGAAATTTAGAGAGTTTACTCCAGACTTATGTGCGCTGACGTGTATGTAGTAGAGCT 2160
Qy 2267 CTAAACCAATTTCTGTGTACTTGTAAATATGTGCTTACTGTGTGTATCAAAATGTT 2326
Db 2161 CTAAATCCCTTTCTGTGTACTTGTAAATATGTGCTTACTGTGTGTATCAAAATGTT 2220
Qy 2327 TTGTATATTAATGTAAACCACTAACAAATGTGTGGAAGAGAGTACAAATTTGCCAG 2386
Db 2221 TTGTATATTAATGTAAAGAGAGTGTGCAATGTGTGGAAGAGATTAATTTGCTAAA 2280
Qy 2387 GACGTATTAAGAGATTTGTGCAATTTTATGAAAAAGCTACTGGAACAGACTTAGAGCTT 2446
Db 2281 GCTGKTATACAGAAATTTGTGAATTTTATGAAAAAGCTACTGGAACAGACTTAGAGCTT 2340
Qy 2447 ATTCAATTTTAAAGACATTAACAATTTCTTAAATATCTTTTAAAGAAACCCCTCT 2506
Db 2341 ATTCAATTTTAAAGACATTAATTAATTTCTTAAATATCTTTTAAAGAAACCCCTCT 2400
Qy 2507 TCTTTATTTGACTTATGTGTGTGCAATTAAGTAATCTTAAAGAACTGTCAAGCTATAT 2566
Db 2401 TCTTGTTTTACTTATGT 2460
Qy 2567 AGTCATCATTTTCAAGCAGTGTATGTGACCAACCCCATCTTATCATCATG 2626
Db 2461 AGTCATCATTTTCAAGCAGTGTATGTGACCAACCCCATCTTATCATCATG 2520
Qy 2627 AACAGTATGTGAGAACCTTGAAGAGAAATGCAATTTATCTAGTAAGACTTACAAAG 2686
Db 2521 AACAGTATGTGAGAACCTTGAAGAGAAATGCAATTTATCTAGTAAGACTTACAAAG 2580

QY	2687	CCGTGGGCAAGTTAGATACATTAACCCGGTACTACTATGTTGGCCTTGGCAATGAGCTA	2748
Db	2581	CTGTGGGCAAGTTAGGTGACAACTAACCCGGTACTACTATGTTGGCCTGTATATGAGTTA	2640
QY	2747	CAAGCTGGGCGCTCGCAGAAATGCTGTGGACAGTGTGGCAAGGATTCATGACTTTAGTAT	2806
Db	2641	CAAGCTGGGCGCGCGCAAAAGTGTGTGACAGTGTGGCAAGGATTCATGACTTTAGTAT	2700
QY	2807	AGCCAAATGGGTAGTGGGATPAATCCTTATACACATTGGACGGTAGCAGATGAGAA	2866
Db	2701	AGCCAAATGGGTAGTGGGATPAATTCATATACATTGACCTGTAGCAGATGAGAG	2760
QY	2867	TTGTAAAAAATAAAAAATGAAACAGGGTTTCAAGCAACAGCTAAAGATTACTTT	2926
Db	2761	CTTTAAAAAATAAAAAATGAAATCTGGGTTTCAAGCAACAGTAAAAAGACTTACTTT	2820
QY	2927	ACTTTAAAGAGTGCAGTGCCTCCCTGTGGCCATTTTTCAGAGAAAGTTTACCGAAGTCCC	2986
Db	2821	ACTTTAAAGAGTGCAGTGCCTCCCTGTGGCCCAATTTTTCAGAGAAAGTTTCCGGAAGTTCCC	2880
QY	2987	GGGTACCAACCCCTCAGAAAAATACCCCAACAGTACTTCAATTAATCTGTGCAAAAGCAGC	3046
Db	2881	GCTTACCAAGCCCTCAGAAAAATACCCCAACAGTACTTCAATTAATCTGTGCAAAAGCAGC	2940
QY	3047	ACTGTGTGACGCGGGGAGTAGCAACCCATCAAAAAGCATGTGAGTAGAAGGGGCTACA	3106
Db	2941	ACTGTGTGACGAGAGGGGGGAGTAGATCCTGTCAAAAGCATGTGAGTAGAAGGGGCTACT	3000
QY	3107	TTTACTGCTAATTTCTGTAAACGTATCAATTTCTCTAGGCAATTTTAAATTCATATATCA	3166
Db	3001	TTTATGTCCACCTGTGTATCTGTATCAATTTTCTCAGACAGTTTTAAATTCATATATGCCA	3060
QY	3167	GAGCATCATTAAPAAAGTGTCTCTTCAGACAGTGTAGTGTGCCAACATGTCTATGTGGAAA	3226
Db	3061	GAGCACCATTAAPAAAGTGTCTCTCCGCAACAGATGTGTGCCAACATGTGCATGTGGAAA	3120
QY	3227	GAGGCAAAAGTGTGACATTAAGTCCCATTAATGGGGTACTCTACTCGGTGAGATATCTTA	3286
Db	3121	GAGGCAAAAGTGTGACATTAAGTCCCATTAATGGGGTACTCTACTCGGTGAGATATCTTA	3180
QY	3287	GATTTTAAATGCTTAAATTTGTTTTCTCAACATTAAGTTTCAAGCACTTAAATTTGAAAT	3346
Db	3181	GATTTTAAATGCTTAAATTTTATTTTCTCACTTTAGAGTTTCAGACTTAAATTTGAAAT	3240
QY	3347	TATGTATGATATAGCTCCAGATGCTTTAACTGTATACATTTTCAGAAATTCGTGTAAGAT	3406
Db	3241	TATGAAACATATAGCTCTGATGTCTTAACTGTATACCATTCAGAAATTCGTGTAAGAT	3300
QY	3407	GTCACAGACAAAACAGAGAGAGTGTGACAGTACTGACAGCACACAGGAAGTTTGTGT	3466
Db	3301	GTTACAGACAAAACCTGAGGGGGGTACAGTTTACTGACAGCATTCAGGGGCGCTTATGC	3360
QY	3467	ATGTTAAGTGAATCATGATGATTAATAATCCCATATGTCTTGTGTGACAGGACAAACACACTA	3526
Db	3361	ATGTTAAGTGAATCATGATGATTAATAATCCCATATGTGTTTGGGCAAGGTACAGAAATCTTTA	3420
QY	3527	GCTTCAGAACTGCCCATTTTGGTTTACTTCTTCCCGCCAGTATGCTTACTTAAACAGTATGT	3586
Db	3421	GCCCCAAGATCTCTTATTTGGGTATCTTTCCCGCCCATATGCTTACTTAAACAGTATGGA	3480
QY	3587	GAAGTAAACACACAGGAATTTTACAGAGACAGCAAAAAATTTGGCTATGAGAAATCACT	3646
Db	3481	GATTTTAAACACACAGGAATTTCTTGAGACAGCAAAAAATTTAGCAATGAGAAATTCAGCA	3540
QY	3647	TTTTTATGTGTTAGACAGTTCATTTGAACTTTTGGGTACAGGGGGATCTGTCCATATG	3706
Db	3541	TTTTTATGTGTGTGACACAGTTCTTTTCTTAAAGTTTATGATACAGAGGTATCAGCAACTATG	3600
QY	3707	TCCACCAAAATTTCCAGCTGTGCCCGCAGAAAACCTAGAAAGCTGTACAGCAAACTTTTAT	3766
Db	3601	TCTTTATAGTTTCTCTCAAGTGTCCCCAAGAAAATTTAGAGGGGCTGTCAATCAACTTTTAT	3660
QY	3767	GAAATGTACAACTTTGTATGAGTCTCTGTGTTTAAAGGGTAACTGTACAACTTATGAGAGGGGAC	3826

Db	3661	GAAATGTACATCCCTTATACGATCCCGTTAGGGGTCCTCGACACATTGAGAGGTGAC	3720
Qy	3827	CTTAATTTAGATCATTTGACACGAGAACAAGCAATTCAGCCACAATACTTTATGGCT	3886
Db	3721	CCAAATTTAGATCTTTTACATGAAGACATTCGATTCAGGCCCAAACTTCATGCA	3780
Qy	3887	GGGCGCACTAATTAATTCAGTGTCTACCAAGAAGAGACAAATCTTAATACAGGTGCGA	3946
Db	3781	GGGCGCACTAATTAATTCAGTGTCTACCAAGAAGAGAGACAGCTCTTAATACAGAGCTGGA	3840
Qy	3947	AAAGCCCTTAACGGGCGCTTAGTACCTGACCTACCCAAAACACAGAAATTTCCCTAGGCC	4006
Db	3841	AAAGCCCTTAACAGGCGCTTAGTACAGGATCTCGCAAAACATGAATATCTTACGSCCT	3900
Qy	4007	GGGCGCATATCTCAGCGCATACATCACTGAGGACATCTGATTAATATGTTAONAGATAAT	4066
Db	3901	GGGCGCATATCTCAGCGCATACATCACTGAGGACACAGATAATATGTTCACAGGAATTAAT	3960
Qy	4067	GCCATTTTCATGTCACAAACCACTTATGAAATGTGAGCAACAAGATTCAGCAAGG	4126
Db	3961	GCCATTTTCATGTCACAAACCACTTATGTAACGTGAAACAAAGATTCAGCAAGG	4020
Qy	4127	GTAGGAAGATTCCTCAATGAAAAAAGAGCTTAAAGCTTAAAGCTTAAATCATGCAAC	4186
Db	4021	GTGGGTAATTCCTCAATGAAAAAAGAGCTTAAAGCTTAAAGCTTAAATCATGCAAC	4080
Qy	4187	ACATTAATTCCTCAATGAAAAAGAACCCAAACATACACAGACCAATTCGACGCTCTTATG	4246
Db	4081	ACCTATTTTCCTCAATGAAAAAGAACCCAGCAATACATGATCAATTTAGGCGCCCTTAATG	4140
Qy	4247	GTGGGCTCTGTTTGGACAGAAAGAGCTTCACATGATAAAGTCACTGTGAGATAAATC	4306
Db	4141	GTGGGCTCTGTTTGGACAGAAAGAGCTTCCTCAATGATAAAGCTGAGATAAATC	4200
Qy	4307	CCCTAATTTGATGACAGTTTAAAACTCAATTGACAGCCCTAGCGGCTGAGGTTTGAT	4366
Db	4201	CCAAATTTGATGACAGTTTAAAACTCAATTGACAGCTTGAAGAGATGGGTTTGAT	4260
Qy	4367	CAGCAACCCCTCAAAATTTTAAAAATCTACACCAAAAGTGGGCAATTGAGAGTAT	4426
Db	4261	CAGCAACCTCTCAAAATTTTAAAAATTTTCAACCAAAAGTGGGCAATTGAGAGTAT	4320
Qy	4427	AAATCAATGGAATTAATCTAATTTAGTCAATATGCTGTGGGAATATGACAGTTACATG	4486
Db	4321	AAATCAATGGAATTAATCTAATTTAGTCAATATGCTGTGGGAATATGACAGTTACATG	4380
Qy	4487	ACCTTAAATTTGGAGCTCGAAGAGCTACGTGAAGGTGAATCCCACTCGGCTTAT	4546
Db	4381	ACATTTAAATTTGGGGCCCTCTAAAGCTACGGAGCGTGGAAATCTCAACTCGGAGTAT	4440
Qy	4547	CCCTCAATGAGCTGTGCTTTTACATATGTATCTGTATGACCCACAGCTACAGATGCA	4606
Db	4441	CCCTCAATGAGCTGTGCTTTTACATATGTATCTGTATGACCCACAGCTATGATGCA	4500
Qy	4607	AAGCAACACACAGACAGATATGAAAAAGCTGAAGAATGTGGAATGCGCAAAAGCGT	4666
Db	4501	AAACAAACACACAGACAGATATGAAAAAGCTGAAGAATGTGGAATGCGCAAAAGCGT	4560
Qy	4667	GTGACACCAATTTGAAAATTTCCCAACCGTGTCTACGCAAGAAACGTCAACCAACGCCCC	4726
Db	4561	GTGACACCAATTTGAAAATTTCCCAACCGTGTCTACGCAAGAAACGTCAATTAAGCCCC	4620
Qy	4727	ACCTGTGCGCGCCAGATTAATGATGCTCCCTCAATACCCCGTATGGAAGAAC	4777
Db	4621	ACCAATTAACCAACCAAGCTGTAACCTGCCCTCTGTATCTTAATGACAGCC	4671

[illegible]

```

Db      3421  |CCCCAGAACTTCGATTTGGGTAATCTTCCCTCAATACGCTTACTTAACAGTAGAG 3480
Qy      3588  |AAGTAAACACAGAAATTTTCAGAGACACGCAAAAATTTGGCTAGTGAAGATCACTT 3647
Db      3481  |ATGTAAACACAGAAATTTTCAGAGACAGCAAAAATTTGGCAAGTGAAGATCACTT 3540
Qy      3648  |TTTATGTGTAGAGACAGATTTCAATTTGAACTTTGGGTACAGGGGGAGTGGCCATAT 3707
Db      3541  |TTTATGTGTGTAGAGACAGATTTCTTTTCAAGCTTTTATAGTACAGAGGTACAGCA 3600
Qy      3708  |CCTACAAATTTCCAGCTGTGCCCCAGAAAACTTGAAGGCTGACCAATTTTATG 3767
Db      3601  |CTTATAGTTCTTCAGTGGCCCCAGAAAAATTAGAGGGGTGACATCACTTTATG 3660
Qy      3768  |AATATGACAACTCTTTGTAGGTTCTGTTTAAAGGGTACTGACACATTTAGAGGAG 3827
Db      3661  |AATATGACAACTCTTTGTAGGTTCTGTTTAAAGGGTACTGACACATTTAGAGGAG 3720
Qy      3828  |CTAATTTAGTATGACACAGAGACACAGCAATTTAGCCCAAACTTTATGCTG 3887
Db      3721  |CAAAATTTAGTATTTTACACATGAGACCAATGCAATTCAGCCCAAACTTTATG 3780
Qy      3888  |GGCCACTAATTAATTCAGTGTCTTACCAAGAGAGACAAATTTATATACAGTGTGAA 3947
Db      3781  |GGCCACTAATTAATTCAGTGTCTTACCAAGAGAGACAACTCTAGTACTGAGCTGAA 3840
Qy      3948  |AAGCCCTTACGAGGCTTATGATCTGACCTAGCCAAACACAGAAATTTCCCTAG 4007
Db      3841  |AAGCCCTTACGAGGCTTATGATCTGACCTAGCCAAACACAGAAATTTCCCTAG 3900
Qy      4008  |GGCCAGTATCTCAGCCATACATCACTGAGACCTGATTAATTTATGATGAAATTA 4067
Db      3901  |GGCCAGTATCTCAGCCATACATCACTGAGACCTGATTAATTTATGATGAAATTA 3960
Qy      4068  |CCATTTCACTGACAAACCACTTATGAAATGCTGAGACCAAGATATCAGCAAGGG 4127
Db      3961  |CCATTTCACTGACAAACCACTTATGAAATGCTGAGACCAAGATATCAGCAAGGG 4020
Qy      4128  |TAGGAAGATTTCAATGAAGAAAGACAGCTTAAAGCTTAAAGCTTAAAGCTTAA 4187
Db      4021  |TAGGAAGATTTCAATGAAGAAAGACAGCTTAAAGCTTAAAGCTTAAAGCTTAA 4080
Qy      4188  |CATACTTCCCTAATTAAGAAACCAATACACAGCAAAATTTGAAGGCTTATG 4247
Db      4081  |CTACTTCCCTAATTAAGAAACCAATACACAGCAAAATTTGAAGGCTTATG 4140
Qy      4248  |TGGGCTCTGTTTGAAGACAGAGCTTCACTATGAAAGTCAAGCTGTGAGTAAAT 4307
Db      4141  |TGGGCTCTGTTTGAAGACAGAGCTTCACTATGAAAGTCAAGCTGTGAGTAAAT 4200
Qy      4308  |CTACTTATGATGACAGTTTAAACCTCAATTTGACGCTTAAAGGCTGAGGTTG 4367
Db      4201  |CAATTTATGATGACAGTTTAAACCTCAATTTGACGCTTAAAGGCTGAGGTTG 4260
Qy      4368  |AACCACCCCTCAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTT 4427
Db      4261  |AGCCACCTCTCAATTTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTTT 4320
Qy      4428  |AATCCATGGGAATTAATCTATTTAGTTCAATATGCTGAGGAATTAATGACAT 4487
Db      4321  |AATCCATGGGAATTAATCTATTTAGTTCAATATGCTGAGGAATTAATGACAT 4380
Qy      4488  |CCTTAAATTTGGAAGCTGGAAGGCTTCTGGAAGGTTTCCCAAGCTGAGGTTT 4547
Db      4381  |CATTTAAATTTGGGAGCTGGAAGGCTTCTGGAAGGTTTCCCAAGCTGAGGTTT 4440
Qy      4548  |CTCTCATGAGAGCTGCTATTTTACATATGATCTGATGACCCCAAGCTTACAG 4607
Db      4441  |CCCCGACGAGAGCTGCTATTTTACATATGATCTGATGACCCCAAGCTTACAG 4500
Qy      4608  |AGCAACACGACAGAGCTGATGAAAGCTGGAAGATTTGGAAGCTGCAAAAGG 4667

```

```

Db      4501  |AACAACACACAGACATGATATGAAAAAGCCTGAAGATTTGTGACAGACCAAAAG 4560
Qy      4668  |TGACACCATTTGTAACATTTCCCAAGCTGTCTCAGCAGAGAACCCGACCCG 4727
Db      4561  |TGACACCATTTGTAACATTTCCCAAGCTGTCTCAGCAGAGAGTGTAACTTAA 4620
Qy      4728  |CCTGTGCGCCGACATTAATATGTCCTCCCAATACCCCGTGAAGC 4777
Db      4621  |CCAGTACACACGACGCTGACTGCCCCCTCTATCTATTAAGACAGCC 4670

RESULT 4
ABZ59571
ID  ABZ59571 standard; DNA; 4678 BP.
XX
AC  ABZ59571;
XX
DT  27-OCT-2003 (revised)
DT  22-APR-2003 (first entry)
XX
DE  Human parvovirus B19 clone #2-B6 DNA SEQ ID NO:23.
XX
XX  Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma;
XX  gene; ds.
XX
OS  B19 virus.
XX
PN  WO2003002753-A2.
XX
PD  09-JAN-2003.
XX
PF  28-JUN-2002; 2002MO-US020684.
XX
XX  28-JUN-2001; 2001US-0302077P.
XX  19-MAR-2002; 2002US-0365956P.
XX  29-MAR-2002; 2002US-0369224P.
XX
PA  (CHIR ) CHIRON CORP.
XX
PI  Pichnantes S, Shyamala V;
XX
DR  WPI; 2003-201510/19.
XX
PT  Detecting a human parvovirus B19 infection in a biological sample to
PT  prevent viral transmission, comprises reacting a parvovirus B19 nucleic
PT  acid with a primer complementary to the 3'-terminal portion of the RNA
PT  target sequence.
XX
PS  Claim 70; Fig 4A-C; 148pp; English.
XX
XX
XX  The present invention describes a method for detecting a human parvovirus
XX  B19 infection in a biological sample. The method comprises reacting the
XX  isolated parvovirus B19 nucleic acid with a first oligonucleotide
XX  consisting of a first primer containing a complexing sequence
XX  sufficiently complementary to the 3'-terminal portion of the RNA target
XX  sequence to complex with. Also described: (1) amplifying a target
XX  parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
XX  of 47 700 base pair sequences (see ABZ59549 to ABZ59563, and ABZ59604 to
XX  ABZ59629); (3) a polynucleotide comprising either of 2 4678 base pair
XX  sequences (see ABZ59570 and ABZ59571); (4) an oligonucleotide primer
XX  consisting of a promoter region recognised by a DNA-dependent RNA
XX  polymerase operably linked to a human parvovirus B19-specific complexing
XX  sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
XX  parvovirus B19-specific hybridising sequence of 10-50 nucleotides linked
XX  to an acridinium ester label; and (6) a diagnostic test kit comprising an
XX  oligonucleotide primer of (4), and instructions for conducting the
XX  diagnostic test. The method is useful for detecting parvovirus infection
XX  in a biological sample, such as in blood products, to prevent
XX  transmission of the virus through blood and plasma derivatives or by
XX  close personal contact. ABZ59549 to ABZ59634 and ABZ5762 to ABZ57267
XX  represent sequences used in the exemplification of the present invention.
XX  (Updated on 27-Oct-2003 to standardise OS field)

```

[illegible]

2208 ATGGAATTTAGAGTTTACTCCAGACTTATGCGCTGCGAGTTGATGATGAGAGCTC 2267
2101 ATGGAATTTGAGAAATTTACCCAGATTGGTGCATGTAGCCATGTGGAGCTTC 2160
2268 TAAACCATTTTCTGTGTTAACTGTAAAAAATGTCTTACCTGTCTGGAATTAACAAGTTT 2327
2161 TAAATCCCTTTTCTGTCTTAACTGTCAAAAAATGTCTTACCTGTCTGGAATTAACAAGTTT 2220
2328 TGTAGATTATGAGTAAACCACTTAACAATGTGGGAAAGCAGATGAACAATTTGCCAGG 2387
2221 TGTAGATTATGAGTAAAGAAAGTGGCAAAATGTGGGAAAGTGAATTAATTTGCTAAG 2280
2388 ACGTGTAAAGCACTTTGTGCAATTTTATGAAAAGCTACTGAAACAGACTTGAAGCTTA 2447
2281 CTGTGTATCAGCAATTTGTGGAATTTTATGAAAAGTTTACTGAAACAGACTTGAAGCTTA 2340
2448 TTCAAAATTTTAAAGACATTACAACTTTCTTATGATTAATCTTTAGAAAACCCCTCTT 2507
2341 TTCAAAATTTTAAAGACATTATTAATTTCTTATGATTAATCCCTAGAAAACCCATCTT 2400
2508 CTTTATTTTGACTTATGCTGCTGCACTTAAAGTATCTTAAAAAATCTTCCAGACTATTA 2567
2401 CTTTGTGTGACTTATGCTGCTGCTGCTTAAATAAATCTTAAAAAATCTTCCAGACTTATTA 2460
2568 GTCAATCTTTTCAAGGCACTGAACTGATATCTGACCAACCCCATGCTTATCATCAGTA 2627
2461 GTCAATCTTTTCAAGGCACTGAACTGATATCTGACCAACCCCATGCTTATCATCAGTA 2560
2628 ACAGTATGAGAACTTATGAGAGAAATGCAATTTATCTATGAAAGACTTATCAACAGC 2687
2521 GCAATCTGAGAACTTATGAGAGAAATGCAATTTATCTATGAAAGACTTATCAACAGC 2580
2688 CTGGGCAAGTTAGATATCAATTAACCCGGTACTAATGTTGGGCTCTGGCAATGAGCTAC 2747
2581 CTGGGCAAGTTAGATATCAATTAACCCGGTACTAATGTTGGGCTCTGGCAATGAGCTAC 2640
2748 AAGCTGGGCTCTGGCAAGTTAGATATCAATTAACCCGGTACTAATGTTGGGCTCTGGCAATGAGCTAC 2807
2641 AAGCTGGGCTCTGGCAAGTTAGATATCAATTAACCCGGTACTAATGTTGGGCTCTGGCAATGAGCTAC 2700
2808 GCCAATTTGCTAAGTTGGGAAATTAATCTTATACAACTTGGACGGTACAGATGAAAGAT 2867
2701 GCCAATTTGCTAAGTTGGGAAATTAATCTTATACAACTTGGACGGTACAGATGAAAGAT 2760
2868 TGTAAAAAATATTAATAATGAAACAGGTTTCAAGCAACAGCTAAAGATTAATCTTTA 2927
2761 TTTTAAAAAATATTAATAATGAAACAGGTTTCAAGCAACAGCTAAAGATTAATCTTTA 2820
2928 CTTTAAAAAGGAGCTGCCCCCTGTGGCCCACTTTTCAAGGAAAGTTTACCGGAAGTCCCG 2987
2821 CTTTAAAAAGGAGCTGCCCCCTGTGGCCCACTTTTCAAGGAAAGTTTACCGGAAGTCCCG 2880
2988 CGTAAACGCTCTGAGAAAATACCCCAAGATGACTTCAAGTTAACTCTGCAAGAACGCA 3047
2881 CTTAAACGCTCTGAGAAAATACCCCAAGATGACTTCAAGTTAACTCTGCAAGAACGCA 2940
3048 CTGTGTGAGGCGGGGAGGATGCAACCTTACAAAAGATGTGGAGTGAAGGGCTTCAAT 3107
2941 CTGTGTGAGGAGGGGGGAGGATGATCTGTGAAAACATGTGAGTGAAGGGGGCTCACTT 3000
3108 TTATGCTTAATTTCTATACGTTGATCTTCTAGCAATTTTAAATTTCAATATGATCAG 3167
3001 TTATGCTTAATTTCTATACGTTGATCTTCTAGCAATTTTAAATTTCAATATGATCAG 3060
3168 AGCATCTTAAATGAAGTGTCTCTGCAAGCACTATGAGCTGCAACATGCTAGTGGAAAG 3227
3061 AGCATCTTAAATGAAGTGTGTCTCTGCAAGCACTATGAGCTGCAACATGCTAGTGGAAAG 3120
3228 AGGCAAAAGTGTGACTATTTAGTCCCATTAATGGGATCTACTCTCGTGGAGATTAAG 3287
3121 AGGCAAAAGTGTGACTATTTAGTCCCATTAATGGGATCTCAACCCCATGAGATTAATTTAG 3180
3288 ATTTAATGCTTAAATTTGTTTCTCAACATTAAGATTTCAAGCACTTAATGAATTT 3347

3181 ATTTATGCTTAAATTTATTTTTCACCTTTAGGTTTGACACTTAATGAATTT 3240
3348 ATGTATGATATGCTCCAGATGCTTTTAACTGTAACTATTTCAAAAATTTGCTTAAAGATG 3407
3241 ATGAAATATGATCTGATGCTTTTAACTGTAACTATTTCAAAAATTTGCTTAAAGATG 3300
3408 TCAAGCAAAACAGGAGGAGTGTGCAAGTTACTGACAGCAACAGAGCTTTGTGTA 3467
3301 TTACAAACAAATCTGAGGGGGGGGTGAGTTTCTGACAGCACTACAGGCGCTTATGCA 3360
3468 TGTATGATCATGATATTAATTAACCATATGTGCTAGGTGAGGACAAAGACACTAG 3527
3361 TGTATGATCATGATATTAATTAACCATATGTGCTAGGTGAGGACAAAGATCTTAG 3420
3528 CTCCAGATCTGCCATTTTGGGTTTACTTTTCCCCCGAGTATGCTTACTTAACTAGTGTG 3587
3421 CCCAGAACTTCTAATTTGGGTATCTTTTCCCTCAATACGCTTACTTAACTAGTGTGAG 3480
3588 AAGTAAACACAAAGGAATTTGAGAGACAGCAAAAATTTGGCTAGTGAAGATCAGCTT 3647
3481 ATGTTAACACAAAGGAATTTGAGAGACAGCAAAAATTTGGCAAGTGAAGATCAGCAT 3540
3648 TTTATGTTTGAAGACAGTTCATTTGAATTTTGGGTACAGGGGGAATCTGCACTATGT 3707
3541 TTTATGTTTGAAGACAGTTCATTTGAATTTTGGGTACAGGGGGAATCTGCACTATGT 3600
3708 CTTACAAATTTCCAGCTGTGCCCCCAAGAACTTAAAGGCTGACGCAACTTTTATG 3767
3601 CTTATTAAGTTTCTCCAGTGCCCCCAAGAAATTTAAAGGGCTCAGTCAACACTTTTATG 3660
3768 AATATGACAACTTTGTAAGGTTCTGTTTAAAGGGTACCTGACACTTAAAGGGGAGC 3827
3661 AATATGACAACTTTGTAAGGTTCTGTTTAAAGGGTACCTGACACTTAAAGGGGAGC 3720
3828 CTTAATTTAGATCATTTGACACAGAAAGACCAATTCAGCCACAAACTTTATGCTG 3887
3721 CAATAATTTAGATCATTTTAAACAGAAAGACCAATTCAGCCACAAACTTTATGCTG 3780
3888 GGCACATTAATTAATTCAGTGTCTTACCAAGAAAGAGCAATTTTATACAGTGTGGA 3947
3781 GGCACATTAATTAATTCAGTGTCTTACCAAGAAAGAGCAATTTTATACAGTGTGGA 3840
3948 AAGCCCTTAAGGGGCTTATGATGAGTGGCACTAGCCAAACACAGAAATTTCCCTAGGCCG 4007
3841 AAGCCCTTAAGGGGCTTATGATGAGTGGCACTAGCCAAACACAGAAATTTCCCTAGGCCG 3900
4008 GGCACATCTCAGCATACATCACTGAGCACTGATTAATTTGTTACAGAAATTAATG 4067
3901 GGCACATCTCAGCATACATCACTGAGCACTGATTAATTTGTTACAGAAATTAATG 3960
4068 CCAATTCACATGACAAACCACTTATGAAATGCTGAGCAAAAGATATGACAGAGGG 4127
3961 CCAATTCACATGACAAACCACTTATGAAATGCTGAGCAAAAGATATGACAGAGAG 4020
4128 TAGGAATTTTCAAAATGAAAGAAAGCACTTAAAGCAAGTTAAAGGCTTAAATGACA 4187
4021 TGGGTGATTTTCAAAATGAAAGAAAGCACTTAAAGCAAGTTAAAGGCTTAAATGACA 4080
4188 CATATCTCCCTAATTAAGAAACCAACATTAACAGCAACAAATTTGAACGCTCTTATG 4247
4081 CTATCTTTCCATTAAGAAAGAAACCAACATTAACAGCAACAAATTTGAACGCTCTTATG 4140
4141 TGGGTCTGTGTTGAACAGAAAGCTTTCATATGAAAGTCAAGTGTGAGTGAATTC 4200
4308 CTAATCTAATGACAGTTTAAATCAATTTGACAGCCCTAAGGCGGGTGGGTTTGATC 4367
4201 CAATTTAGTACAGTTTAAATCACTAGTTTGAAGCTTGAAGAGTGGGGTTTGATC 4260
4368 AACACCCCTCAATATTTTAAAAATCACTACAAAGTGGGCCAATTTGAAGTATTA 4427

```

Db      4261 AGCCACTCTCTCAATATTTTAAAAATATTACACAAAGTGGCCAAATTGAGATTTA 4320
Qy      4428 AATCCATGGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 4487
Db      4321 AATCAATGGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 4380
Qy      4488 CCTTAATTTGGGACCTTCGAAAGGCTTAATGAAAGTGAATCCCGAGCTGGGCTTATC 4547
Db      4381 CATTTAAATTTGGGCCCCCGTAAAGCTACGGGAGGTGAATCTCAACCTGAGGTATTC 4440
Qy      4548 CTCCTCATGAGCTGCTCATTTTACCAATTAATTAATTAATTAATTAATTAATTAATTAAT 4607
Db      4441 CCCCAGACGACAGAGCTCATTTTACCAATTAATTAATTAATTAATTAATTAATTAATTAAT 4500
Qy      4608 AGCAACACACACACACACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4667
Db      4501 AACCAACACACACACACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4560
Qy      4668 TGACCCATTTGTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4727
Db      4561 TGACCCATTTGTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4620
Qy      4728 CCTGTGCCCCCGAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4777
Db      4621 CCAGTACACACACACACATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4670

```

RESULT 5

AA81583
ID AA81583 standard; DNA; 2343 BP.

AA81583;

26-AUG-1999 (first entry)

Erythrovirus V9 DNA sequence encoding VP1 protein.

Erythrovirus V9; differential diagnosis; parvovirus; infection;
erythrovirus screening; typing; immunosay; VP1 protein; ss.

Erythrovirus.

FR2771751-A1.

04-JUN-1999.

03-DEC-1997; 97FR-00015197.

03-DEC-1997; 97FR-00015197.

(ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

Nguyen QT, Garbarg CA, Auguste V,

WPI; 1999-349543/30.

P-PSDB; AAY23227.

Erythrovirus V9 and its nucleic acid sequences - can be used in the
diagnosis of its infections.

Claim 3; Page 48-50; 80pp; French.

The present sequence is derived from nucleotides 2336-4678 of AA81580,
and encodes an erythrovirus V9 protein. Probes and primers derived from
erythrovirus V9 polynucleotide sequences (AA81580) can be used for
differential diagnosis of erythrovirus (parvovirus) infections by a
combination of amplification and hybridization assay. The probes can also
be used to assess susceptibility to erythrovirus infection and for
erythrovirus screening and typing. The antibodies can be used in
immunosays for diagnosis of erythrovirus V9 infections

Sequence 2343 BP; 752 A; 498 C; 489 G; 604 T; 0 U; 0 Other;

Query Match 46.6%; Score 2343; DB 2; Length 2343;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2343; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy      2336 ATGAGTAAACCACTTAACAAATGTTGGAAAGAGTGAACAAATTTGCCAGAGCTGTAT 2395
Db      1 ATGAGTAAACCACTTAACAAATGTTGGAAAGAGTGAACAAATTTGCCAGAGCTGTAT 60
Qy      2396 AAGCAGTTTGTCAATTTTATGAAAAAGCTACGAGAACAGACTTAAGCTTATTCAAAT 2455
Db      61 AAGCAGTTTGTCAATTTTATGAAAAAGCTACGAGAACAGACTTAAGCTTATTCAAAT 120
Qy      2456 TTTAAAGACATTAACAAATTTCTTAGATTAATCTTTAGAAAAACCCCTCTTATTT 2515
Db      121 TTTAAAGACATTAACAAATTTCTTAGATTAATCTTTAGAAAAACCCCTCTTATTT 180
Qy      2516 GACTTAGTCTGCACTTAAAGTATCTTAAAGTATCTTAAAGTATCTTAAAGTATCTTAAAG 2575
Db      181 GACTTAGTCTGCACTTAAAGTATCTTAAAGTATCTTAAAGTATCTTAAAGTATCTTAAAG 240
Qy      2576 TTTCAAGCCATGACAGTTATCTGACCAACCCCATGCTTATCATCACTTAAGTATCT 2635
Db      241 TTTCAAGCCATGACAGTTATCTGACCAACCCCATGCTTATCATCACTTAAGTATCT 300
Qy      2636 GCAGAACTTAGAGAGAAAAATGAGTATTAATTAAGTAAAGCTTACACAGCTGGGCA 2695
Db      301 GCAGAACTTAGAGAGAAAAATGAGTATTAATTAAGTAAAGCTTACACAGCTGGGCA 360
Qy      2696 GTTAGCATCAATTTACCGGCTACTAATGTTGGCCCTGGCAATGAGCTTCAAGCTGGG 2755
Db      361 GTTAGCATCAATTTACCGGCTACTAATGTTGGCCCTGGCAATGAGCTTCAAGCTGGG 420
Qy      2756 CCTCCGAGAAATGCTGTGACAGTCTGCAAGATTCATGACTTATGATAGCAATTTG 2815
Db      421 CCTCCGAGAAATGCTGTGACAGTCTGCAAGATTCATGACTTATGATAGCAATTTG 480
Qy      2816 GCTAAGTTGGGAATTAATCTTATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2875
Db      481 GCTAAGTTGGGAATTAATCTTATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 540
Qy      2876 AATATTAATAAATGAACAGGCTTTCAGACACACAGTAAAGATTAATTAATTAATTAAT 2935
Db      541 AATATTAATAAATGAACAGGCTTTCAGACACACAGTAAAGATTAATTAATTAATTAAT 600
Qy      2936 GGTGAGCTGCCCCCTGTGCCCCCATTTTCAGAGAACTTACCGAAGTCCCGGTACAC 2995
Db      601 GGTGAGCTGCCCCCTGTGCCCCCATTTTCAGAGAACTTACCGAAGTCCCGGTACAC 660
Qy      2996 GCTTCAGAAAAATACCCAGCATGACTTCACTTACCTGCAAGAGCGACACTGGTGA 3055
Db      661 GCTTCAGAAAAATACCCAGCATGACTTCACTTACCTGCAAGAGCGACACTGGTGA 720
Qy      3056 GCGGGGAGGTAGCAACCTTAACAAAAAGCATGTGAGTGAAGGGCTACATTTACTGCT 3115
Db      721 GCGGGGAGGTAGCAACCTTAACAAAAAGCATGTGAGTGAAGGGCTACATTTACTGCT 780
Qy      3116 AATTCGTAAAGTACATTTCTAGGCAATTTTAAATCAATTAATTAATTAATTAATTAAT 3175
Db      781 AATTCGTAAAGTACATTTCTAGGCAATTTTAAATCAATTAATTAATTAATTAATTAAT 840
Qy      3176 TATTAAGTGTCTTCAGAGCTAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 3235
Db      841 TATTAAGTGTCTTCAGAGCTAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 900
Qy      3236 GTGAGCATTTATGCTCCATTAATGAGGTACTTCTCCGTGAGATTAATTAATTAAT 3295
Db      901 GTGAGCATTTATGCTCCATTAATGAGGTACTTCTCCGTGAGATTAATTAATTAATTAAT 960
Qy      3296 GCTTAAATTTGTTTTTCAACATTAAGTTCAGACTTAATTAATTAATTAATTAATTAAT 3355
Db      961 GCTTAAATTTGTTTTTCAACATTAAGTTCAGACTTAATTAATTAATTAATTAATTAAT 1020
Qy      3356 ATAGCTCCAGATGCTTAACTGAATTTTCAAGAAATGCTGTAAAGATGTACAGAC 3415

```



```

Db 1021 ATAGCTCAATGCTTTAACTGTAATCTATTCAGAAATGTGCTGTAAGAAATGTCAGAC 1080
Qy 3416 AAAACAGAGAGAGGTGTGCAAGTTACTGACAGCACCAAGAGCCTTGTGTATGTATGTG 3475
Db 1081 AAAACAGAGAGAGGTGTGCAAGTTACTGACAGCACCAAGAGCCTTGTGTATGTATGTG 1140
Qy 3476 GATCATGATTAATATCCATATGTGTAGTGTAGAGGAGCAAGACACTAGCTCCAGAA 3535
Db 1141 GATCATGATTAATATCCATATGTGTAGTGTAGAGGAGCAAGACACTAGCTCCAGAA 1200
Qy 3536 CTGCCCATTGTGGTTTACTTTCCTCCCAAGATGCTTACTTAACATGAGTGAAGTAAC 3595
Db 1201 CTGCCCATTGTGGTTTACTTTCCTCCCAAGATGCTTACTTAACATGAGTGAAGTAAC 1260
Qy 3596 ACACAGGAATTTTCAGAGACAGCAAAAATTTGCTGTAGAGATGAGCTTTTATGTG 3655
Db 1261 ACACAGGAATTTTCAGAGACAGCAAAAATTTGCTGTAGAGATGAGCTTTTATGTG 1320
Qy 3656 TTGAGACAGCTTCAATTTGAATTTGGGTACAGGGGGAGCTGCACTATGCTTACAA 3715
Db 1321 TTGAGACAGCTTCAATTTGAATTTGGGTACAGGGGGAGCTGCACTATGCTTACAA 1380
Qy 3716 TTTCAGCTGTGCCCCCAGAAAACCTTAGAAGCTGACCAACATTTTATGAATGTAC 3775
Db 1381 TTTCAGCTGTGCCCCCAGAAAACCTTAGAAGCTGACCAACATTTTATGAATGTAC 1440
Qy 3776 AACCTTTGTACGGTTCCTGTTTAGGGGTACTGACACATTTAGAGGGAGCCTTAAATTT 3835
Db 1441 AACCTTTGTACGGTTCCTGTTTAGGGGTACTGACACATTTAGAGGGAGCCTTAAATTT 1500
Qy 3836 AGATCATGACACAGAGACCAAGCAATTCAGCCACAAAACCTTATGCTGGGCCCTA 3895
Db 1501 AGATCATGACACAGAGACCAAGCAATTCAGCCACAAAACCTTATGCTGGGCCCTA 1560
Qy 3896 ATAAATTCAGTGTCTACCAAGAGAGAGACATTTCTAATACAGTGTGAAAAAGCCCTT 3955
Db 1561 ATAAATTCAGTGTCTACCAAGAGAGAGACATTTCTAATACAGTGTGAAAAAGCCCTT 1620
Qy 3956 ACGGGGCTTACTGCTGCACTAGCCAAAACACAGAAATTTCCCTACGCCCCGGGCCAGTA 4015
Db 1621 ACGGGGCTTACTGCTGCACTAGCCAAAACACAGAAATTTCCCTACGCCCCGGGCCAGTA 1680
Qy 4016 TCTCAGCATACATCACTGAGACCTGATTAATATGTGTACAGAAATTAATGCTCATTTCA 4075
Db 1681 TCTCAGCATACATCACTGAGACCTGATTAATATGTGTACAGAAATTAATGCTCATTTCA 1740
Qy 4076 CATGACAAACCACTTATGAAATGTGAGAGCAAAAGATATCGAAAGGGGTAGAAAGA 4135
Db 1741 CATGACAAACCACTTATGAAATGTGAGAGCAAAAGATATCGAAAGGGGTAGAAAGA 1800
Qy 4136 TTTCCAATGAAAAAGAACAGCTTAAAGCTTAAACAGTCAATGACACATACTTC 4195
Db 1801 TTTCCAATGAAAAAGAACAGCTTAAAGCTTAAACAGTCAATGACACATACTTC 1860
Qy 4196 CTTAATTAAGAAACCCCAATACACAGACCAATTAAGCCCTCTTATGTGTGGCTCT 4255
Db 1861 CTTAATTAAGAAACCCCAATACACAGACCAATTAAGCCCTCTTATGTGTGGCTCT 1920
Qy 4256 GTTTGGAACAGAGAGCTTCTCACTATGAAAGTCAAGCTGTGAGTAATATCCCTAATTA 4315
Db 1921 GTTTGGAACAGAGAGCTTCTCACTATGAAAGTCAAGCTGTGAGTAATATCCCTAATTA 1980
Qy 4316 GATGACAGTTTAAATCTCAATTTGACGCTTACGCGGTGTGGGTTTGCATCAACACC 4375
Db 1981 GATGACAGTTTAAATCTCAATTTGACGCTTACGCGGTGTGGGTTTGCATCAACACC 2040
Qy 4376 CTTCAATTAATTTTAAAAATCTACCAAAAGTGGGCCAATTTGAGATTAATCCATG 4435
Db 2041 CTTCAATTAATTTTAAAAATCTACCAAAAGTGGGCCAATTTGAGATTAATCCATG 2100
Qy 4436 GGAATTACTTATGTTCAATATGCTGTGGGAATTAATGACATGACCTTTAAA 4495

```

```

Db 2101 GGAATTACTTATGTTCAATATGCTGTGGGAATATGACAGTACCATGACCTTTAAA 2160
Qy 4496 TTGGACCTTGAAAGGCTACTGAAAGTGAATCCCAAGCTGTGGCTTTATCTCTTCAT 4555
Db 2161 TTGGACCTTGAAAGGCTACTGAAAGTGAATCCCAAGCTGTGGCTTTATCTCTTCAT 2220
Qy 4556 GCAGCTGTCTATTACATATGATGTATGATGACCCCAAGCTACAGATGAAAGCAACAC 4615
Db 2221 GCAGCTGTCTATTACATATGATGTATGATGACCCCAAGCTACAGATGAAAGCAACAC 2280
Qy 4616 CACAGACACGATATGAAAAAGCCTGAAAGATTTGTGAGCTGCAAAAAGCCGTGTGACCA 4675
Db 2281 CACAGACACGATATGAAAAAGCCTGAAAGATTTGTGAGCTGCAAAAAGCCGTGTGACCA 2340
Qy 4676 TTG 4678
Db 2341 TTG 2343

```

RESULT 6

AAK81581

ID AAK81581 standard; DNA; 2013 BP.

AAK81581;

26-AUG-1999 (first entry)

Erythrovirus V9 DNA sequence encoding NS1 protein.

Erythrovirus V9; differential diagnosis; parvovirus; infection;

Erythrovirus screening; typing; immunoassay; NS1 protein; ss.

Erythrovirus.

FR2771751-A1.

04-JUN-1999.

03-DEC-1997; 97FR-00015197.

03-DEC-1997; 97FR-00015197.

(ASST-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.

Nguyen QT, Garbary CA, Auguste V;

WPI; 1999-349543/30.

P-PSDB; AAY23225.

Erythrovirus V9 and its nucleic acid sequences - can be used in the diagnosis of its infections.

Claim 3; Page 42-45; 80pp; French.

The present sequence is derived from nucleotides 328-2340 of AAK81580, and encodes an erythrovirus V9 protein. Probes and primers derived from erythrovirus V9 polynucleotide sequences (AAK81580) can be used for differential diagnosis of erythrovirus (parvovirus) infections by a combination of amplification and hybridisation assay. The probes can also be used to assess susceptibility to erythrovirus infection and for erythrovirus screening and typing. The antibodies can be used in immunoassays for diagnosis of erythrovirus V9 infections

Sequence 2013 BP; 591 A; 355 C; 480 G; 587 T; 0 U; 0 Other;

Query Match 40.0%; Score 2013; DB 2; Length 2013;

Best Local Similarity 100.0%; Pred. No. 0; Mismatches 0; Gaps 0;

328 ATGAGCTAATTTGGGGGTGCTTGCACATTTCTTCAACATTTGACATGCTGTAAATGAT 387
 1 ATGAGCTAATTTGGGGGTGCTTGCACATTTCTTCAACATTTGACATGCTGTAAATGAT 60

QY 388 AACGCGGAGCTCTAAGCAGCTAGTAACTCTGACGTGGAAACAACCACTTCT 447
 DB 61 AACTGGTGGTCTCTAAGCTAGTAACTCTGACGTGGAAACAACCACTTCT 120
 QY 448 AACAGTTAATGCAATATATTAAGCAGTGTGCTCTAAACCTGATTTACTGGGGG 507
 DB 121 AACAGTTAATGCAATATATTAAGCAGTGTGCTCTAAACCTGATTTACTGGGGG 180
 QY 508 CCGCTAGCAGTGTGCTCTAATCTTTTTCAGGTGAATGTAACAATTTGAGGAAGCTAT 567
 DB 181 CCGCTAGCAGTGTGCTCTAATCTTTTTCAGGTGAATGTAACAATTTGAGGAAGCTAT 240
 QY 568 CATATCCATGTAATGTTGTTGTCAGACATAATGTAAGAACTTAACCTGATGCTA 627
 DB 241 CATATCCATGTAATGTTGTTGTCAGACATAATGTAAGAACTTAACCTGATGCTA 300
 QY 628 GAAGGTTAATTAATGTTCTTACCACTTGTAACTGAAGTGTAACTTAATTT 687
 DB 301 GAAGGTTAATTAATGTTCTTACCACTTGTAACTGAAGTGTAACTTAATTT 360
 QY 688 TTGCGCAGGATGACTACCAAGAAATATTTAGAGATGAGAGAGTTTATAGAAAT 747
 DB 361 TTGCGCAGGATGACTACCAAGAAATATTTAGAGATGAGAGAGTTTATAGAAAT 420
 QY 748 TACTTAATGAAAAAATCTCTTAATGTTGTTGTTGTAACAATTTGACCGGAT 807
 DB 421 TACTTAATGAAAAAATCTCTTAATGTTGTTGTTGTAACAATTTGACCGGAT 480
 QY 808 ATGACACCTGTAATTCCTGCTTCTTTCGCGAGAGAGCTTGCAGCTTAAGAACCCCGC 867
 DB 481 ATGACACCTGTAATTCCTGCTTCTTTCGCGAGAGAGCTTGCAGCTTAAGAACCCCGC 540
 QY 868 ATTACTGCAAAATCAGACAGTGTCTAATGAACTGGGAGCTTACGTGTGAGGGGGA 927
 DB 541 ATTACTGCAAAATCAGACAGTGTCTAATGAACTGGGAGCTTACGTGTGAGGGGGA 600
 QY 928 GATGTTGCTCATTGCTGGAAGGAAACAAGCGGGTTAAAGTTTCAACATGTA 987
 DB 601 GATGTTGCTCATTGCTGGAAGGAAACAAGCGGGTTAAAGTTTCAACATGTA 660
 QY 988 AATGCGTATGTAACAGAGTATTTCTGAATTAATGAAATTAAGTGAATTTTAC 1047
 DB 661 AATGCGTATGTAACAGAGTATTTCTGAATTAATGAAATTAAGTGAATTTTAC 720
 QY 1048 CAATTAATCTTTAATGAGCAGTCAAGTGCAGCTTCAATTAATGAAATGCTTTAAG 1107
 DB 721 CAATTAATCTTTAATGAGCAGTCAAGTGCAGCTTCAATTAATGAAATGCTTTAAG 780
 QY 1108 TTAGCTATTTAATGAGTAACTTAAGTAACTTCACTTCTTGTATCAATTCAGAC 1167
 DB 781 TTAGCTATTTAATGAGTAACTTAAGTAACTTCACTTCTTGTATCAATTCAGAC 840
 QY 1168 TTGAGCAGGTTACTTGCATTAAGAAATTAATGTAATTAATTTATTTGTCAAAAC 1227
 DB 841 TTGAGCAGGTTACTTGCATTAAGAAATTAATGTAATTAATTTATTTGTCAAAAC 900
 QY 1228 TATGATCTCTTTTAAAGGTCACACATGTTTAAAGTGAATGACAAAAATGTGTAA 1287
 DB 901 TATGATCTCTTTTAAAGGTCACACATGTTTAAAGTGAATGACAAAAATGTGTAA 960
 QY 1288 AAAAACCCTTGTTTAAAGGTCACACCAAGTACTGAAAAAACAATTTGGCAATGCT 1347
 DB 961 AAAAACCCTTGTTTAAAGGTCACACCAAGTACTGAAAAAACAATTTGGCAATGCT 1020
 QY 1348 ATTGCTAAACCTGACAGTGAATGAAATGTAATGAAATGAAATCTTTCATTT 1407
 DB 1021 ATTGCTAAACCTGACAGTGAATGAAATGTAATGAAATGAAATCTTTCATTT 1080
 QY 1408 AATGATGACCGGGAAAAAGTTGTTGCTGAGGATGAAAGCATTTAAGTCACTAT 1467
 DB 1081 AATGATGACCGGGAAAAAGTTGTTGCTGAGGATGAAAGCATTTAAGTCACTAT 1440
 QY 1468 GTGGAAGCTGCAAAAGCATTTTAAAGTGTGACCAACAGGTTAGTCAAAAAATGCT 1527

DB 1141 GTGGAAGCTGCAAAAGCATTTTAAAGTGTGACGCAACAGGTTAATGAAAAATGCT 1200
 QY 1528 GCGAGTGTGAGAGGCGCGGTGTCCTGTGTATTAACAGCAATGTGACATTAATTT 1587
 DB 1201 GCGAGTGTGAGAGGCGCGGTGTCCTGTGTATTAACAGCAATGTGACATTAATTT 1260
 QY 1588 GTTGTAGTGTATTAATCACTAACAATGTCATGTAAGGCTTAAGAAAGGATGTA 1647
 DB 1261 GTTGTAGTGTATTAATCACTAACAATGTCATGTAAGGCTTAAGAAAGGATGTA 1320
 QY 1648 AAGCTAACTTTACCAATTAATGATGACCTGTGATGTTTAACTTAAGAGGCTGATGTA 1707
 DB 1321 AAGCTAACTTTACCAATTAATGATGACCTGTGATGTTTAACTTAAGAGGCTGATGTA 1380
 QY 1708 CAACATGCTTAACTTGTGTATGACAAACCTGAGCACTAAGAAATCTGGAATA 1767
 DB 1381 CAACATGCTTAACTTGTGTATGACAAACCTGAGCACTAAGAAATCTGGAATA 1440
 QY 1768 AACTACATTTGATTCCTGGAATTAATGCAATGCTTCCACCAAGATCTCCAAAC 1827
 DB 1441 AACTACATTTGATTCCTGGAATTAATGCAATGCTTCCACCAAGATCTCCAAAC 1500
 QY 1828 ACCCCATTTGCCAGACACAGTATCAGCAGAGTGTGTGAATCTGGAATACTC 1887
 DB 1501 ACCCCATTTGCCAGACACAGTATCAGCAGAGTGTGTGAATCTGGAATACTC 1560
 QY 1888 AGTGAAGCAGCTTTTCACTCACTCACTCAGGCGCTGGAACAGTGAACCCCGCG 1947
 DB 1561 AGTGAAGCAGCTTTTCACTCACTCACTCAGGCGCTGGAACAGTGAACCCCGCG 1620
 QY 1948 TCTAATGAGCCGCTGCCGAGACAGTTCAGAGAAATCATTTGCGGAAGCCCAATTC 2007
 DB 1621 TCTAATGAGCCGCTGCCGAGACAGTTCAGAGAAATCATTTGCGGAAGCCCAATTC 1680
 QY 2008 TCCGAAGTGTAGGCGGCTGTGAGAGAACTTTTACACGCGCTTCCCATAGTTT 2067
 DB 1681 TCCGAAGTGTAGGCGGCTGTGAGAGAACTTTTACACGCGCTTCCCATAGTTT 1740
 QY 2068 CGTGAATCTTTAATGAGGTTGACTTGTATGAGAGTGTGAGAGGATTTGCTGTTGC 2127
 DB 1741 CGTGAATCTTTAATGAGGTTGACTTGTATGAGAGTGTGAGAGGATTTGCTGTTGC 1800
 QY 2128 TGTGTGAACATTAATTAACAACAGTGGGAGAGGTTTGCCTCATTTATTAAT 2187
 DB 1801 TGTGTGAACATTAATTAACAACAGTGGGAGAGGTTTGCCTCATTTATTAAT 1860
 QY 2188 GTGGAGCTTGTATTAATGATGAAATTTAGAGATTTACTCCAGACTTATGTCGCTGC 2247
 DB 1861 GTGGAGCTTGTATTAATGATGAAATTTAGAGATTTACTCCAGACTTATGTCGCTGC 1920
 QY 2248 AGTTGTCATGAGAGGCTTCAACCACTTTTGTGTAACTTGTAAATAATGTCTTAC 2307
 DB 1921 AGTTGTCATGAGAGGCTTCAACCACTTTTGTGTAACTTGTAAATAATGTCTTAC 1980
 QY 2308 CTGTCTGATTAACAAGTTTGTAGATTATGAG 2340
 DB 1981 CTGTCTGATTAACAAGTTTGTAGATTATGAG 2013

RESULT 7
 ABZ59573
 ID ABZ59573 standard; DNA; 2380 BP.
 AC ABZ59573;
 XX
 AC 27-OCT-2003 (revised)
 DT 22-APR-2003 (first entry)
 XX
 DE Human parvovirus B19 clone B1-VPI DNA sequence SEQ ID NO.26.
 XX
 KW Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma; gene; ds.

XX B19 virus.
OS MO2003002753-A2.
XX
XX 09-JAN-2003.
XX
XX 28-JUN-2002; 2002MO-US020684.
XX
XX 28-JUN-2001; 2001US-0302077P.
XX 19-MAR-2002; 2002US-0365956P.
XX 29-MAR-2002; 2002US-0369224P.
XX
XX (CHIR) CHIRON CORP.
XX
XX Pichantes S, Shyamala V;
XX MPI; 2003-201510/19.
XX P-PSDB; ABP57263.
XX
XX Detecting a human parvovirus B19 infection in a biological sample to
XX prevent viral transmission, comprises reacting a parvovirus B19 nucleic
XX acid with a primer complementary to the 3'-terminal portion of the RNA
XX target sequence.
XX
XX Example 4; Fig 6A; 148bp; English.
XX
XX The present invention describes a method for detecting a human parvovirus
XX B19 infection in a biological sample. The method comprises reacting the
XX isolated parvovirus B19 nucleic acid with a first oligonucleotide
XX consisting of a first primer containing a complexing sequence
XX sufficiently complementary to the 3'-terminal portion of the RNA target
XX sequence to complex with. Also described: (1) amplifying a target
XX parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
XX of 47 700 base pair sequences (see ABZ59549 to ABZ59569, and ABZ59604 to
XX ABZ59629); (3) a polynucleotide comprising either of 2,4678 base pair
XX sequences (see ABZ59570 and ABZ59571); (4) an oligonucleotide primer
XX consisting of a promoter region recognised by a DNA-dependent RNA
XX polymerase operably linked to a human parvovirus B19-specific complexing
XX sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
XX parvovirus B19-specific hybridising sequence of 10-50 nucleotides linked
XX to an acridinium ester label; and (6) a diagnostic test kit comprising an
XX oligonucleotide primer of (4), and instructions for conducting the
XX diagnostic test. The method is useful for detecting parvovirus infection
XX in a biological sample, such as in blood products, to prevent
XX transmission of the virus through blood and plasma derivatives or by
XX close personal contact. ABZ59549 to ABZ59634 and ABP57262 to ABP57267
XX represent sequences used in the exemplification of the present invention.
XX (Updated on 27-OCT-2003 to standardise OS field)
XX
XX Sequence 2380 BP; 765 A; 498 C; 500 G; 617 T; 0 U; 0 Other;
XX
XX Query Match 38.0%; Score 1912.6; DB 8; Length 2380;
XX Best Local Similarity 88.3%; Pred. No. 0;
XX Matches 2077; Conservative 0; Mismatches 274; Indels 0; Gaps 0;
XX
XX 2331 AGATTGAGTAAACCACTTAACCAATGTGGGAAAGCAAGTATGCTTAAGCTTATTC 2450
XX 18 ACMAATGAGTAAAGAAAGTGGCAATGTGGGAAAGTGAATTAATTGCTTAAGCTG 77
XX 2391 TGTATAGAGCACTTGTGCAATTTTATGAAAGTACTGAGACAGCTTAAGCTTATTC 2450
XX 78 TGTATAGCAATTTGTGGAATTTTATGAAAGTACTGAGACAGCTTAAGCTTATTC 137
XX 2451 AAAATTTAAAGACATTACCAATCTTTAGATTAATCTTTAGAAACCCCTCTTCTT 2510
XX 138 AAAATTTAAAGACATTATTAATTTCTTTAGATTAATCTTTAGAAACCCATCTCTT 197
XX 2511 TATTGAGTAAAGTGTGCGATTAAGTAAATCTTTAAACCTTCCAGACTTATATGTC 2570
XX 198 TGTTTGCTTAAGTGTGCTGTAATTAATAAATTAACCTTTAAACCTTATATATGTC 257
XX 2571 ATCATTTTCAAGCAGTGAAGTATCTGACCAACCCCATGCTTATCATCAAGTAA 2630

DB 258 ATCATTTTCAAGTGAAGCAAGTATCTGACCAACCCCATGCTTATCATCAAGTAA 317
XX 2631 GTATGCAAGCACTTAAGAGGAAATGCAATTAATCTTGTGAAGCTTAACAAGCTG 2690
XX 318 GTCTATGCAAGCACTTAAGAGGAAATGCAATTAATCTTGTGAAGCTTAACAAGCTG 377
XX 2691 GGCAGTGAAGCAATTAACCCGTAATTAATCTTGTGAAGCTTAACAAGCTG 2750
XX 378 GGCAGTGAAGCAATTAACCCGTAATTAATCTTGTGAAGCTTAACAAGCTG 437
XX 2751 CTGGGCTTCGCAAGTGTGTCGACAGTGTGCAAGATTCATGACTTTAGGTATAGCC 2810
XX 438 CTGGGCTTCGCAAGTGTGTCGACAGTGTGCAAGATTCATGACTTTAGGTATAGCC 497
XX 2811 AATTGCTTAAGTGAAGTAAATTAATCTTATACATTTGACAGTGAAGTGAAGTATGT 2870
XX 498 AACTGCTTAAGTGAAGTAAATTAATTAATCTTATGACAGTGAAGTGAAGTATGT 557
XX 2871 TAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2930
XX 558 TAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 617
XX 2931 TAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 2990
XX 618 TAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 677
XX 2991 ACAAGCTTCAGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 3050
XX 678 ACAAGCTTCAGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 737
XX 3051 GTGCAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 3110
XX 738 GTGCAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 797
XX 3111 CTGCTAATTTCTGTAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 3170
XX 798 GTGCAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 857
XX 3171 ATCATTTTCAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 3230
XX 858 ACCATTAATTAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 917
XX 3231 CAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 3290
XX 918 CAAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 977
XX 3291 TTAATGCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 3350
XX 978 TTAATGCTTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1037
XX 3351 GTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 3410
XX 1038 GAAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1097
XX 3411 CAGACAAACAG 3470
XX 1098 CAGACAAACAG 1157
XX 3471 TAGTGAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 3530
XX 1158 TAGTGAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1217
XX 3531 CAGAACTGCTTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 3590
XX 1218 CAGAACTGCTTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1277
XX 3591 TAAACACAG 3650
XX 1278 TTAACACAG 1337
XX 3651 ATGTGTTAAGCAG 3710

Db 1338 ATGTTTGAACAAGCTTTCTTTCAGCTTTTAGTACAGAGTACAGCACTATGCTT 1397
 Qy 3711 ACAATTTCCAGCTGTGCCCCGAGAAACCTTGAAGGCTGACGCCAACATTTTATGAA 3770
 Db 1398 ATAGTTTCTCCAGTGTGCCCCGAGAAATTTAGAGGGCTGACAGCTTTTATGAA 1457
 Qy 3771 TGTACAACTTTTGAAGGCTTCTGTTTGGGGTACCTGACACCTTAGAGGGACCTTA 3830
 Db 1458 TGTACAACTTTTGAAGGCTTCTGTTTGGGGTACCTGACACCTTAGAGGGACCTTA 3830
 Qy 3831 AATTGATCATTTGACAGAGAGACAGCAATTCATTAACAGGCTGCTGAAAG 3950
 Db 1518 AATTGATCATTTGACAGAGAGACAGCAATTCATTAACAGGCTGCTGAAAG 3950
 Qy 3891 CACTATTAATTCAGTGTCTACCAAGAGAGACCAATTCATTAACAGGCTGCTGAAAG 3950
 Db 1578 CACTATTAATTCAGTGTCTACCAAGAGAGACCAATTCATTAACAGGCTGCTGAAAG 3950
 Qy 3951 CCTTACAGGGGCTTGTAGTCTGAGCTAGCCCAACACAGAAATTTCCCTACGGCCGGG 4010
 Db 1638 CCTTACAGGGGCTTGTAGTCTGAGCTAGCCCAACACAGAAATTCCTTACGGCCGGG 1697
 Qy 4011 CAGTATTCAGCCATACCATCATCTGAGACATGTAATTTGTTACAGAAATTAATGCA 4070
 Db 1698 CAGTATTCAGCCATACCATCATCTGAGACATGTAATTTGTTACAGAAATTAATGCA 4070
 Qy 4071 TTTACATGACCAACCACTTATGGAATCTGAGACCAAGATATGCAAGGGGTAG 4130
 Db 1758 TTTCTCATGTGACACCACTTATGGAATCTGAGACCAAGATATGCAAGGGGTAG 4130
 Qy 4131 GAAGATTTCCAAATGAAAGAAAGACAGCTTATGAGATTAACAGTCTTAACTGACACAT 4190
 Db 1818 GAAGATTTCCAAATGAAAGAAAGACAGCTTATGAGATTAACAGTCTTAACTGACACAT 4190
 Qy 4191 ACTTCCCTATTAAGAGACCCCAATACAGACCAATTAAGACCCCTTATGAGTGG 4250
 Db 1878 ACTTCCCTATTAAGAGACCCCAATACAGACCAATTAAGACCCCTTATGAGTGG 4250
 Qy 4251 GCTCTGTTTGAACAGAGAGCTCTTCACTATGAAGTCACTGTGAGTAAATCCCTTA 4310
 Db 1938 GCTCTGTTTGAACAGAGAGCTCTTCACTATGAAGTCACTGTGAGTAAATCCCTTA 4310
 Qy 4311 ACTTATGATGACAGTTTAAACTCAATTTGACAGCCCTTACGGGGTGGTTCATCAAC 4370
 Db 1998 ACTTATGATGACAGTTTAAACTCAATTTGACAGCCCTTACGGGGTGGTTCATCAAC 4370
 Qy 4371 CACCCCTCAAAATTTTAAATACTACTACCAAAAGTGGGCAATTTGAGGGTATTAAT 4430
 Db 2058 CACCCCTCAAAATTTTAAATACTACTACCAAAAGTGGGCAATTTGAGGGTATTAAT 4430
 Qy 4431 CCATGGAATTAATTAATTTAGTCAATGCTGTGGAATATGACAGTTACATGACCT 4490
 Db 2118 CCATGGAATTAATTAATTTAGTCAATGCTGTGGAATATGACAGTTACATGACCT 4490
 Qy 4491 TTAATTTGGAATCTGGAAGGCTACTGGAAGTGTGAATCCCAAGCTACAGTCAAGC 4550
 Db 2178 TTAATTTGGAATCTGGAAGGCTACTGGAAGTGTGAATCCCAAGCTACAGTCAAGC 4550
 Qy 4551 CTATGAGCTGTGCTATTTACATGCTATGTAATGACCCCAAGCTACAGTCAAGC 4610
 Db 2238 CTATGAGCTGTGCTATTTACATGCTATGTAATGACCCCAAGCTACAGTCAAGC 4610
 Qy 4611 AAGACCAAGACAGGATATGAAAGCTGAGAAATTTGAGCTGCAAAAGCCGTGTGC 4670
 Db 2298 AAGACCAAGACAGGATATGAAAGCTGAGAAATTTGAGCTGCAAAAGCCGTGTGC 4670
 Qy 4671 ACCCATTTGTA 4681
 Db 2358 ACCCATTTGTA 2368

RESULT 8
 AB259576

ID AB259576 standard; DNA; 2380 BP.
 AC AB259576;
 DT 27-OCT-2003 (revised)
 DT 22-APR-2003 (first entry)
 DE Human parvovirus B19 clone B6-VPI DNA sequence SEQ ID NO:32.
 KW Human parvovirus B19; parvovirus B19; infection; virus; blood; plasma;
 KW gene; ds.
 OS B19 virus.
 PN MO2003002753-A2.
 PD 09-JAN-2003.
 PF 28-JUN-2002; 2002MO-US020684.
 PR 28-JUN-2001; 2001JUS-0302077P.
 PR 19-MAR-2002; 2002JUS-0365956P.
 PR 29-MAR-2002; 2002JUS-0369224P.
 PA (CHIR) CHIRON CORP.
 PI Pichantes S, Shyamala V;
 DR WPI; 2003-201510/19.
 DR P-FSD; ABP57266.
 PT Detecting a human parvovirus B19 infection in a biological sample to
 PT prevent viral transmission, comprises reacting a parvovirus B19 nucleic
 PT acid with a primer complementary to the 3'-terminal portion of the RNA
 PS target sequence.
 PS Example 4; Fig 9A; 148pp; English.
 XX The present invention describes a method for detecting a human parvovirus
 CC B19 infection in a biological sample. The method comprises reacting the
 CC isolated parvovirus B19 nucleic acid with a first oligonucleotide
 CC consisting of a first primer containing a complexing sequence
 CC sufficiently complementary to the 3'-terminal portion of the RNA target
 CC sequence to complex with. Also described: (1) amplifying a target
 CC parvovirus B19 nucleotide sequence; (2) a polynucleotide comprising one
 CC of 47 700 base pair sequences (see AB259549 to AB259569, and AB259604 to
 CC AB259629); (3) a polynucleotide comprising either of 2 4678 base pair
 CC sequences (see AB259570 and AB259571); (4) an oligonucleotide primer
 CC consisting of a promoter region recognised by a DNA-dependent RNA
 CC polymerase operably linked to a human parvovirus B19-specific complexing
 CC sequence of 10-75 nucleotides; (5) an oligonucleotide probe comprising a
 CC parvovirus B19-specific hybridising sequence of 10-50 nucleotides linked
 CC to an acridinium ester label; and (6) a diagnostic test kit comprising a
 CC oligonucleotide primer of (4), and instructions for conducting the
 CC in a biological sample, such as in blood products, to prevent
 CC transmission of the virus through blood and plasma derivatives or by
 CC close personal contact. AB259549 to AB259634 and AB257262 to AB257267
 CC represent sequences used in the exemplification of the present invention.
 CC (Updated on 27-OCT-2003 to standardise OS field)
 SQ Sequence 2380 BP; 767 A; 499 C; 498 G; 616 T; 0 U; 0 Other;
 XX
 Query Match 38.0%; Score 1911; DB 8; Length 2380;
 Best Local Similarity 88.3%; Pred. No. 0;
 Matches 2076; Conservative 0; Mismatches 275; Indels 0; Gaps 0;
 Qy 2331 AGATTATGATTAACCACTAACAATTTGTTGGAAGACAGTACAAATTTGCCAGAGCG 2390
 Db 18 ACAAAATGATTAAGAAAGTGGCAAAATGTTGGGAAAGTATGATTAATTTGCTAAAGCTG 77
 Qy 2391 TGTATAGCAGTTTGTGCAATTTTATGAAAGCTACTGGAACAGACTTAAGCTTATTC 2450

Db TGTATCAGCAATTTGGAATTTTATGAAAAGTTACTGAGACAGACTTAGACTTAATTC 137
QY 2451 AAATTTTAAAGACATTAACAATTTCTTAGATATCTTTAGAAAACCCCTCTTCT 2510
Db 138 AAATTTTAAAGACATTAATAATTTCTTAGATATTTCCCTAGAAAACCCCTCTTCT 197
QY 2511 TATTTGACTAGTGTCTGCAATTTAAAGTATCTTAAAACTCTCCAGACTTATAGTC 2570
Db 198 TGTTTGACTAGTGTCTGCAATTTAAAGTATCTTAAAACTCTCCAGACTTATAGTC 257
QY 2571 ATCATTTTCAGACCATGAGACAGTTATCTGACACCCCCATGCTTATCATCCAGTACA 2630
Db 258 ATCATTTTCAGACCATGAGACAGTTATCTGACACCCCCATGCTTATCATCCAGTACA 317
QY 2631 GTAGTGCAGAACTTAGAGAGAAAATGCAATTTATCTAGTGAAGATTTACAGAGCTG 2690
Db 318 GTATGCTGAGAACTTAGAGAGAAAATGCAATTTATCTAGTGAAGATTTACAGAGCTG 377
QY 2691 GGCAGATTAGCATATACATTAACCGGTACTAATGTTGGGCTGGGCAATGAGTACAG 2750
Db 378 GGCAGATTAGCATATACATTAACCGGTACTAATGTTGGGCTGGGCAATGAGTACAG 437
QY 2751 CTGGGCTCGCAGAAATGCTGTGACAGTCTGCAAGATTTCAATGCTTAGGTATAGCC 2810
Db 438 CTGGGCTCGCAGAAATGCTGTGACAGTCTGCAAGATTTCAATGCTTAGGTATAGCC 497
QY 2811 AATTGCTAAGTTGGGAATTAATCTTATACATTTGACGCTGACGATGAAAGATTTGT 2870
Db 498 AACTGCTAAGTTGGGAATTAATCTTATACATTTGACGCTGACGATGAAAGATTTGT 557
QY 2871 TAAAAATATAAAAATGAACAGGGTTTCAAGACAAGAGTAAAGATTAATCTTATCTT 2930
Db 558 TAAAAATATAAAAATGAACAGGGTTTCAAGACAAGAGTAAAGATTAATCTTATCTT 617
QY 2931 TAAAGGTGAGCTGCTGCTGTGAGCCCATTTTCAAGAGTTTACCGGAAGTGGCCGCT 2990
Db 618 TAAAGGTGAGCTGCTGCTGTGAGCCCATTTTCAAGAGTTTACCGGAAGTGGCCGCT 677
QY 2991 ACAAGCTCTAGAAAAATATACCCAGCATGATCTTCAAGTAACTCTGCAAGAGCCAGCATG 3050
Db 678 ACAAGCTCTAGAAAAATATACCCAGCATGATCTTCAAGTAACTCTGCAAGAGCCAGCATG 737
QY 3051 GTGAGGCTGGGAGGTAGGACACCCCTCAAAAAAGCATGTGAGTGAAGGGCTTACATTTA 3110
Db 738 GTGAGGAGGGGGGGGGGAGTATCTGTGAAAAGCATGTGAGTGAAGGGGGCCATTTTA 797
QY 3111 CTGCTAATCTGTACGCTGTACATTTCTTAGGCAATTTTAAATTCATATGATCCAGAGC 3170
Db 798 GTGCTCAATCTGTACGCTGTACATTTTCCAGACATTTTAAATTCATATGACCCAGAGC 857
QY 3171 ATCATTTTAAAGTGTCTCTCCAGAGCTAGTGTGCTCCAGATGCTAGTGGGAAAAGG 3230
Db 858 ACCATTTTAAAGTGTCTCTCCAGAGCTAGTGTGCTCCAGATGCTAGTGGGAAAAGG 917
QY 3231 CAAAAGGTGACATTAATGCTCCATTAATGAGGTTACTACTGCTGGGAGATTAATTAAT 3290
Db 918 CAAAAGTTTGCACCATTAATGCTCCATTAATGAGGATCTACACCCATGAGATTAATTAAT 977
QY 3291 TTAATGCTTAAATTTGTTTTTCTCACCATTAATGAGTTTCAAGCTTAATTAATTAATG 3350
Db 978 TTAATGCTTAAATTTTATTTTCTTCACTTAGAGTTTCAAGCTTAATTAATTAATG 1037
QY 3351 GTAGTATAGCTCCAGATGCTTAACTGTAATTTCAAGAAATGCTGTAAAGATGCA 3410
Db 1038 GAAGTATAGCTCCAGATGCTTAACTGTAATTTCAAGAAATGCTGTAAAGATGCA 1097
QY 3411 CAGACAAAAGAGGAGGTGCAAGTTACTGACACACCAAGAGCTTTGTATAGT 3470
Db 1098 CAAACAAAAGTGAAGGGGGGGGGGAGTACTGACACACCAAGAGGGGCTTATGATGT 1157
QY 3471 TAGTGATCATGAGTATTAATCCCATATGTGCTAGGTCAAGGACAAAGACACTAGCTC 3530
Db 1158 TAGTGACCATGATATATATATATCCCATATGTGTTAGGGCAAGGTCAAGATATCTTACCC 1217

QY 3531 CAGACGCCCCATTTGGGTTTACTTTCCGCCAGTATGCTTACTTAAACAGTATGTAAG 3590
Db 1218 CAGACCTCTCTAATTTGGGATTAATTTTCCCTCAATACGCTTACTTAACGATGAGATG 1277
QY 3591 TAAACACAGAGAAATTTAGAGAGACAGCAAAAAATTTGCTAGTGAAGATCAGCTTTT 3650
Db 1278 TTAACACAGAGAAATTTGAGAGACAGCAAAAAATTTGCAAGTGAAGATCAGCATTTT 1337
QY 3651 ATGTGTTAGACACAGTTCAATTTGAACTTTTGGGATCAGGGGATCTGCCATATGCTCT 3710
Db 1338 ATGTGTTAGACACAGTTCTTTTCACTTTTATGATCAGAGAGTACAGCAACTATGTCTT 1397
QY 3711 ACAATTTCCAGCTGAGCCCCCAGAAAACCTTAGAAGGCTGACGCAACTTTTATGAAA 3770
Db 1398 ATAGTTTCTCTCAGTCCCCCAGAAAATTTTAGAGGCTGCACTCACTTTTATGAAA 1457
QY 3771 TGTACAACTCTTTGTAAGGTTCTGTTTAGGGGTACTGACATTTAGAGAGGGACCTTA 3830
Db 1458 TGTACAACTCTTTAGAGATCCCGTTAGGGGTTCTGACATTTAGAGAGGTGACCCAA 1517
QY 3831 AATTAGATCATTTAGACACAGAAACCAAGCAATTTAGCCACAAACTTTATGCTGGGC 3890
Db 1518 AATTAGATCTTTAACAATGAAACCATGCAATTCAGCCCAAACTTCATGCGAGGC 1577
QY 3891 CACTAATTAATTCAGTGTCTACCAAGAGAGAGCAATCTAATTAACAGTGTGAGAAAAG 3950
Db 1578 CACTAGTAACTCAGTGTCTACCAAGAGAGAGCACTCTAATCTGAGAGCTGAGAAAAG 1637
QY 3951 CCCTTAGGGGCTTAGTACTGACCTAGCCAAACACAGAAATTTCTTACGCCCGGGC 4010
Db 1638 CTTTAAAGGCTTTAGACAGGTACCTCTCAAAACCTGAAATATCTTACGCCCTGGGC 1697
QY 4011 CAGTATCTCAGCCATACCATCTGAGACCTGATTAATATGTTTACAGAAATTAATGCCA 4070
Db 1698 CAGTGTCTCAGCCGATACCACTGAGACCAAGATTAATATGTCACAGGATTAATGCCA 1757
QY 4071 TTTTCAATGAGCAACACTTATGAAATGCTGAGACAAAGGTATCAGCAAGGGGTAG 4130
Db 1758 TTTTCAATGAGCAACACTTATGAAATGCTGAGACAAAGGTATCAGCAAGGGGTAG 1817
QY 4131 GAAGATTTCCAAATGAAAAAGAACAGCTTAAGCAGTTACAGAGTCTTAACTATCACACAT 4190
Db 1818 GTAGATTTCCAAATGAAAAAGAACAGCTTAAGCAGTTACAGAGTCTTAACTATCACACCT 1877
QY 4191 ACTTCCCTAATTAAGAAACCCAAATTAACAGACAAATTTGAACGCTCTTATGCTGG 4250
Db 1878 ACTTCCCAATTAAGAAACCCAGCAATTAACAGATCAAAATTTGAGCGCCCTAATGCTGG 1937
QY 4251 GCTCTGTTTGAACAGAAAGCTCTTCACTATGAAGTCAAGTGTGAGTAAATCCCTTA 4310
Db 1938 GTTCTGATGAAACAGAAAGCTCTTCACTATGAAGTCAAGTGTGAGTAAATCCCTTA 1997
QY 4311 ACTTAGATGACAGTTTAAAACTCAATTTGACAGCCCTAGCGGGGTGCTTCACTAAC 4370
Db 1998 ATTTAGATGACAGTTTAAAACTCAATTTGACAGCTTAAAGAGATGGGTTTCATAGC 2057
QY 4371 CACCCCTCAATATTTTAAAAATATCAACAAAGTGGCCAAATTTGAGGTATTAAT 4430
Db 2058 CACCTCTCAATATTTCTTAAAAATATTAACAAAGTGGGCCAAATTTGAGGTATTAAT 2117
QY 4431 CCAATGGAATTAATTAATTTAGTTCAATATGCTGTGGAATTAATGACAGTAAACATGACCT 4490
Db 2118 CCAATGGAATTAATTAATTTAGTTCAATATGCTGTGGAATTAATGACAGTAAACATGACCT 2177
QY 4491 TTAATTTGGGACCTCGAAAAGGCTACTGAAAGTGAATCCCGAGCTGCGTTATCTCTC 4550
Db 2178 TTAATTTGGGCCCCCTTAAAGCTAACGGGACGGTGAATCTCAACTGAGATGTATCCC 2237
QY 4551 CTCATCAGCTGTCTATTAACATATGTACTGTATGACCCCAAGCTTACAGATGCAAGC 4610
Db 2238 CGCAGCAGAGGTCTTTTACATATGTACTATATGACCCCAAGCTTACAGATGCAAGC 2297

QY 593 CAGACTAAATGCTAGAACTTAAGTGTGCTGAGAGGTTTATTAATATGTTCTT 652
 DB 701 CAGGGTTAAACCCAGAAACCTTAACAGTGTGTGAGGGGTTATTAATAATGTAATTT 760
 QY 653 ACCATCTTGAATCTGAAAGTGTAACTTAATTTTTCAGAGGATGACTACCAAGAA 712
 DB 761 ATACCTTGTGAATGAAATGTGAATTTTTCAGAGGATGACTACCAAGAA 820
 QY 713 AATATTTAAGATGAGAGAGTTTATAGAAATTTAATTAATGAATAAATCTTTAA 772
 DB 821 AATATTTAAGATGAGAGAGTTTATAGAAATTTAATTAATGAATAAATCTTTAA 880
 QY 773 ATGTGTGTGTGTGTAAATAATTTGACGGATATATGACACCTGTATTTCCGCTCT 832
 DB 881 ATGTGTGTGTGTGTAAATAATTTGATGATATATATGATATCTGTATTTCTGTACTT 940
 QY 833 TTGGGCGAGAGCTTGTCTATGCTTAAAGACCCGCAATTTCTGCAATATACAGAGTCTA 892
 DB 941 TTGAAAGGGGAGCTTGTCTATGCTTAAAGACCCGCAATTTCTGCAATATATGATCTA 1000
 QY 893 CTAAATGAATCTGGGAGTCTAGCTGTGAGGGGAGATGTTTGCCATTTGCTGGAAAG 952
 DB 1001 GTATGATGTCTGGAGTCTAGCGGCAAGGGGAGAGTTGTGCCATTTAATGGGAAAG 1060
 QY 953 GAACAAAGCGGGGTTAAAGTTTCAAAACATGTGAATTTGCTATGTGAAGACAGATAT 1012
 DB 1061 GAATTAAGCTAGATTAAGTTTCAAACTATGTGAATTTGCTATGTGAAGACAGATGT 1120
 QY 1013 TTAATGAATTAATGAAATTTAGTATTTTAAACAATATCTTTATTAATGAGAGTC 1072
 DB 1121 TTACAGAGATTAAGTGAATCTAGTTTAACTTAACAGTACACTTTACTAAGAGTATGC 1180
 QY 1073 ACAGTGCACCTTCAATCAATCAAGTGCCTTAAGTTAGCTATTTAATGAAGTACTACT 1132
 DB 1181 ACAGTGAATTTTCAATCAATCAAGTGCCTTAAGTTAGCTATTTAATGAAGTACTACT 1240
 QY 1133 TAGTACCCTAGTACATCTCTGTGTACATTCAGACTTGTGAGAGGTTACTTGAATTAAG 1192
 DB 1241 TAGTGCCTTACAGACATTTTATTTGCAATACAGCTTGTGAGAGGTTATGTATTAAG 1300
 QY 1193 AAAATTAATTAATTAATTAATTTATTTGTGTCAAACTATGATCCTTTTATGAGTCAAC 1252
 DB 1301 ACATATAATTTGTAAATTTGTACTTTGTCAAACTATGATCCTTTTATGAGTCAAC 1360
 QY 1253 ATGTGTTAAGTGTATGACAAAATATGTGTAAATAAATCAACCTGTGTGTATTAAGGCG 1312
 DB 1361 ATGTGTTAAGTGTATGATTAATAATGTGTAAATAAATCAACCTGTGTGTATTAAGGCG 1420
 QY 1313 CACCAATGACTGAAATTAATTTGCAATGCTATTTGCTAAATCTGTACAGTATATG 1372
 DB 1421 CGCCAGTACAGAAATTAATTTGCAATGCTATTTGCTAAATCTGTACAGTATATG 1480
 QY 1373 GAATGTGAATTTGCAATTAATGAATCTTTCAATTTAAATGATGAGCGGGAATTTTGG 1432
 DB 1481 GCATGTGAATTTGCAATTAATGAATCTTTCAATTTAAATGATGAGCGGGAATTTTGG 1540
 QY 1433 TGGTCTGGGATGAGGATTTAATGCTCACTATTTGTGGAAGCTGCAAAAGCCATTTTAA 1492
 DB 1541 TGGTCTGGGATGAGGATTTAATGCTCACTATTTGTGGAAGCTGCAAAAGCCATTTTAA 1600
 QY 1493 GTGGTCAAGCAACCAAGGATGATCAGAAATGCTGTGAGGAGTGTGGCGGCTGTGC 1552
 DB 1601 GCGGGCAACCCACCAAGGATGATCAGAAATGCTGTGAGGAGTGTGGCGGCTGTGC 1660
 QY 1553 CTGTGTATTAATCAAGCAATGTGACATTAATTTGTGTGAGTGTAAATCACTTAA 1612
 DB 1661 CTGTGTATTAATCAAGCAATGTGACATTAATTTGTGTGAGGGAACCTTAACTAA 1720
 QY 1613 CTGTGTATTAATCAAGCAATGTGAGGATGATGATGATGATGATGATGATGATGATGAT 1672
 DB 1721 CTGTGTATTAATCAAGCAATGTGAGGATGATGATGATGATGATGATGATGATGATGAT 1780
 QY 1673 GCCCTGACATGGGTTTACTTACAGAGGCTGATGTACAAATGCTTAACTTGTGTATG 1732

DB 1781 GCCCTGACATGGGTTTACTTAAACAGAGGCTGATGTACAAAGTGGCTTACATGTGTATG 1840
 QY 1733 CACAAAGCTGAGACCTATATGAAATCTGGGCAATTAATCTACATTTGATTTCCCTGAA 1792
 DB 1841 CACAAAGCTGAGACCTATATGAAATCTGGGCAATTAATCTACATTTGATTTCCCTGAA 1900
 QY 1793 TAAATGAGATGCTCTCCACCCAGATCTCCAAACCAACCCCATTTGTCCAGACAGTA 1852
 DB 1901 TTAATGAGATGCTCTCCACCCAGATCTCCAAACCAACCCCATTTGTCCAGACAGTA 1960
 QY 1853 TCAGACAGATGCTGTGAAAGCTTGAAGAACTCAGTGAAGACAGCTTTTCAACTCA 1912
 DB 1961 TCAGACAGATGCTGTGAAAGCTTGAAGAACTCAGTGAAGACAGCTTTTCAACTCA 2020
 QY 1913 TCACCTCAGGCGCTGAAACAGTGAACCCCGGCTCTAGTACGCCGCTCCCGGAGCA 1972
 DB 2021 TCACCCAGGCGCTGAAACAGTGAACCCCGGCTCTAGTACGCCGCTCCCGGAGCA 2080
 QY 1973 GTTCAGAGAACTATTTGTGGAAGCCAGTTTCTCCGAAGTGTAGCCGCTGTGGG 2032
 DB 2081 GTTCAGAGAACTATTTGTGGAAGCCAGTTTCTCCGAAGTGTAGCCGCTGTGGG 2140
 QY 2033 AGGAAGCTTTTTCACAGCCGCTTGCAGATCAGTTTCTGTAATCTTATAGAGGGTTGACT 2092
 DB 2141 AAGAGGCTTTCTACACACCTTTGGCAGACAGTTTCTGTGAATCTTATAGTTGGGGTTGATT 2200
 QY 2093 TTGTATGAGATGCTGTGAGAGGATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2152
 DB 2201 ATGTGTGAGAGGCTGTGAGAGGATGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2260
 QY 2153 GGGGAGGCTTGGGCTTGGCTCATTTGTATTAATGAGGAGCTGTGTATTAATGATGGA 2212
 DB 2261 GGGGAGGCTTGGGCTTGGCTCATTTGTATTAATGAGGAGCTGTGTATTAATGATGGA 2320
 QY 2213 AATTTAGAGATTTTCTCCAGCTTGTGAGTGTGCTGACAGTTGTCAATGAGAGCTTAAAC 2272
 DB 2321 AATTTAGAGATTTTCTCCAGCTTGTGAGTGTGCTGACAGTTGTCAATGAGAGCTTAAAC 2380
 QY 2273 CATTTTCTGTGTAACTTGTAAATAATGTGCTTACTGTGTGTGTGTGTGTGTGTGTGTGT 2332
 DB 2381 CATTTCCTGTGTAACTTGTAAATAATGTGCTTACTGTGTGTGTGTGTGTGTGTGTGTGT 2440
 QY 2333 ATATGAGTAAACCTAACTAAATGTGTGGAAGAGTGAACAATTTGCCAGAGCTG 2392
 DB 2441 ATATGAGTAAACCTAACTAAATGTGTGGAAGAGTGAACAATTTGCCAGAGCTG 2500
 QY 2393 TATAGAGTGTGTGCAATTTTATGAAATAGTACTGGAACAGACTTAAAGCTTATTA 2452
 DB 2501 TATAGAGTGTGTGCAATTTTATGAAATAGTACTGGAACAGACTTAAAGCTTATTA 2560
 QY 2453 ATTTTAAAGACATTAACCAATTTCTTTATGATTAATCC 2490
 DB 2561 ATTTTAAAGACATTAATATATTTCTTTATGATTAATCC 2598
 RESULT 10
 AAX81586
 ID AAX81586 standard; DNA; 1662 BP.
 XX AAX81586;
 DT 26-AUG-1999 (first entry)
 XX
 XX Erythrovirus v9 DNA sequence encoding VP2 protein.
 DE Erythrovirus v9; differential diagnosis; parvovirus; infection;
 XX Erythrovirus screening; typing; immunoassay; VP2 protein; ss.
 KM Erythrovirus.
 OS
 XX
 XX PR2771751-A1.
 XX
 XX

RESULT 11
 ID AAA91321
 AC AAA91321 standard; DNA; 2016 BP.
 XX AAA91321;
 AC
 DT 11-SEP-2003 (revised)
 DT 19-JUN-2001 (first entry)
 XX
 DE Orf1 protein coding sequence.
 XX
 KM Fusion nucleic acid library; Rep protein; tumour cell; apoptosis;
 KM nucleic acid modification enzyme; cell death; decreased cell growth;
 KM protein-protein interaction detection; cell division; cancer therapy;
 KM protein drug discovery; pharmacogenetics; orf1 protein; ds.
 XX
 OS B19 virus.
 FH
 FT Key
 FT CDS 1. 2016
 /tag= a
 /product= "orf1 protein"
 XX
 PN MO20014539-A2.
 PD 01-MAR-2001.
 XX
 PF 18-AUG-2000; 2000MO-US022906.
 XX
 PR 20-AUG-1999; 99US-0150004P.
 PR 02-JUN-2000; 2000US-0209130P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
 PI
 XX
 PI
 XX
 DR WPI: 2001-218443/22.
 DR P-PDB; AAY97731.
 XX
 PT New library of fusion nucleic acids each encoding a Rep protein
 PT recognized by a nucleic acid modification enzyme and a candidate protein,
 PT useful for detecting protein-protein interactions, protein drug discovery
 PT or pharmacogenetics.
 PT
 XX
 PS Disclosure; Fig 44; 106pp; English.
 XX
 CC This sequence encodes the Erythrovirus B19 orf1 protein. The invention
 CC relates to a library of fusion nucleic acids, each encoding a Rep
 CC protein, a candidate protein, a presentation structure, a targeting
 CC sequence, or a label. The Rep protein is a nucleic acid modification
 CC enzyme. The random or directed libraries (including the cDNA libraries)
 CC can be introduced into any tumour cell, and peptides identified which by
 CC themselves induce apoptosis, cell death, loss of cell division or
 CC decreased cell growth. The methods and compositions may also be used to
 CC detect protein-protein interactions, protein drug discovery, particularly
 CC for protein drugs that interact with targets on cell surfaces, to
 CC discover DNA or nucleic acid binding proteins, using nucleic acids as
 CC targets, to screen for nucleic acid modification enzymes with decreased
 CC toxicity for the host cells, to identify or generate Rep proteins with
 CC decreased toxicity, improved enzyme attachment sequences for use in
 CC expression vectors and in pharmacogenetic studies. The method is useful
 CC in cancer therapy and in killing tumour cells. The methods can be
 CC combined with other cancer therapeutics (drugs or radiation) to sensitize
 CC cells and thus induce rapid and specific apoptosis, cell death, loss of
 CC cell division or decreased cell growth after exposure to a secondary
 CC agent. (Updated on 11-SEP-2003 to standardise OS field)
 CC
 XX
 SQ Sequence 2016 BP; 607 A; 361 C; 479 G; 569 T; 0 U; 0 Other;

Query Match 31.5%; Score 1585.6; DB 4; Length 2016;
 Best Local Similarity 86.7%; Pred. No. 0;
 Matches 1747; Conservative 0; Mismatches 269; Indels 0; Gaps 0;

Qy	328	ATGAGCTATTTCGGGGTGTCTTGACATTTCCCTTAACATTTCTGACCTGCTAATGAT	387
Db	1	ATGAGCTATTTCGAGGGGCTTCAAGTTTCTTCTAATGTTCTGACCTGCTAAGAT	60
Qy	388	AACTGGTGTGCTCTAATGCTAGACTTAAGATCTTCTGACTGGGAACCACTAACCATTCT	447
Db	61	AACTGGTGTGCTCTTACTGATGATTTAGACACTTCTGACTGGGAACCACTAACCATTCT	120
Qy	448	AACAGATTAATGGCAATATTTTAAGCAGTGTGCTTCTTAACCTGATTTACTGGGGGG	507
Db	121	AACAGACTAATGCAATATTTTAAGCAGTGTGCTTCTTAACCTGATTTACTGGGGGG	180
Qy	508	CGCTGACAGGTTGCTTAATCTTTTTCAGGTGAATGTAACAATTTGAGAAGCTAT	567
Db	181	CGACTAGCAGGGTCTTGTACTTCTTTTCAAGTGAATGTAACAATTTGAGAAGCTAT	240
Qy	568	CATATCCATGTACTTAATGCTGTCAGACCTAATATGCTAGAACTTAACCTGCTGCGTA	627
Db	241	CATATTCATGTGTTAATGCGGGGCCAGGGTTAAACCCAGAAACCTCATATGTGTGTA	300
Qy	628	GAAGGTTTATTAATAATGTTCTTTACATCTTGTAACTGAAGTGTAACTTAATTT	687
Db	301	GAGGGGTTATTAATAATGTTCTTTACATCTTGTAACTGAAGTGTAACTTAATTT	360
Qy	688	TTGCCAGGATGACTCAAAAGGAATATTTTAGATGAGAGCAGTTTATGAAT	747
Db	361	TTGCCAGGAATGACTCAAAAGGAATATTTTAGATGAGAGCAGTTTATGAAT	420
Qy	748	TACTTAATGAAAAAATTCCTTTAAATGTTGTGTGTGTAACTAATATTTGACGGGTAT	807
Db	421	TATTTAATAAAAAAATTCCTTTAAATGTTGTGTGTGTAACTAATATTTGATGATAT	480
Qy	808	ATAGACACTGTATTTCCGCTCTTTTCCGCGAGAGCTTGTATGCTAAAGACCCCGC	867
Db	481	ATAGATACCTGTATTTCTGCTACTTTTGAAGGGAGCTTGCATGCAAGAAACCCCGC	540
Qy	868	ATTACTGCAAAATCAGACAGTGTCTAATAATGAATCGGGAGCTGAGGGGGA	927
Db	541	ATTACACAGCCCTTAATATGATTAAGTGAATGCTGGAGAGCTTACCGGCAAGGGCA	600
Qy	928	GATGTTGTCCATTCCTGGAAGGAACAAGCGGGGTTAAAGTTTCAACCATGTA	987
Db	601	GAGTTGTGCCATTTTATGGAAGGGAACTAAGGCTAGCAATAAGTTTCAACCATGTA	660
Qy	988	AATTGCTATGTGAAGACAGATTTTACTGAAGATTAATGAATTAATGATTTTAACT	1047
Db	661	AACGTGTGTGTGAAGACAGATTTTACTGAAGATTAATGAATTAATGATTTTAACT	720
Qy	1048	CATATTAATTTAATGATGACATCAAGTGGAGCTTCAATTCGAAGTCCCTTAAG	1107
Db	721	CAGTACCTTTACTTAAGCAGTATCAAGTGAAGTTTCAATTCGAAGTCACTAATA	780
Qy	1108	TTAGCTATTATTAAGCTACTTAATTAATGACATGACATTTCTGTTTACATTTGAC	1167
Db	781	CTAGCAATTTATTAAGCACTAATTTAGTCCCTAGTACGACATTTTATGCAATGAGAC	840
Qy	1168	TTTGAAGGTTACTTGCAATTAAGAAATTAATTAATTAATTAATTAATTAATTAATTAAT	1227
Db	841	TTTGAAGGTTACTTGCAATTAAGAAATTAATTAATTAATTAATTAATTAATTAATTAAT	900
Qy	1228	TATGATCCTCTTTAGTGGGTCAACATGCTTAAGTGAATTAAGTGAATTAAGTGAATTAAG	1287
Db	901	TATGATCCTCTTTAGTGGGTCAACATGCTTAAGTGAATTAAGTGAATTAAGTGAATTAAG	960
Qy	1288	AAAAACACCTGTGTTTACGGGCCAACAGTACTGAAAAACAATTTGGCAATGGCT	1347
Db	961	AAAAATACCTGTGTTTATGCGGCCCAAGTACAGAAAAACAATTTGGCAATGGCC	1020
Qy	1348	ATTGCTAAAACTGACAGTGTATGGAATGTGAATTTGGAATATGAAAACTTTCCATTT	1407
Db	1021	ATTGCTAAAAAGTGTCCAGTATGTGCAATGTTTAAATTTGAATATGAAAACTTTCCATTT	1080
Qy	1408	AATGATGTAGCGGGAAAAAGTTTGTGTGTGTGGAATGAAGCATTTAATGTCACATAT	1467


```

Db      181 CCAATGACAGGCTGCTTGTACTTTTCAAGTAGAATGTAACTAAATTTGAGAGGCTAT 240
Qy      568 CATATCATGTAGTATTATGTCAGGACTAAATGCTAGAACTTAACGTGTGCTA 627
Db      241 CATATCATGTATGTTATGTCAGGCTGAGGCTTAAACCCAGAAACCTCACTATGTGTGA 300
Qy      628 GAAGTTTATTTATATATGTTCTTATCAATCTGTAACTGAAAGTGTAACTTAAATTT 687
Db      301 GAGGGGTATTTATATATATGTAATCTTATCACTGTATCTGAAATGTGAAGCTTAAATTT 360
Qy      688 TTGCGAGGAGTACTACCAAGAGAAATATTTTATGAGATGAGAGCACTTTATGAAAT 747
Db      361 TTGCGAGGATGACTACCAAGAGAAATCTTTATGAGATGAGAGCACTTTATGAAAT 420
Qy      748 TACTTATGAGAAATTTCTTTTAAATGTTGTGTGTGTATCAATATTTAGCGGTAT 807
Db      421 TATTTATATATATATATATCTTTTAAATGTTGTGTGTATCAATATTTATGATAT 480
Qy      808 ATAGACACTGTATTTTCCGCTCTTTTCCGCGAGAGACTTGTCAATGCTTAAAGACCCGC 867
Db      481 ATAGATACCTGTATTTCTGCTACTTTTGAAGGGGACTTGCATGCGCAAGAAACCCGC 540
Qy      868 ATTACTGCAAAATACAGACAGTGTACTAATGAAATGAGGAGTCTAGCTGTGAGAGGGA 927
Db      541 ATTACCAAGACCAATTAATGATTAAGTGTAGTGTCTGAGGAGTCTAGCGGCAAGGGGA 600
Qy      928 GATGTTGTGCTATTTGCTGGAAGAGGAACTAAAGCGGGGTTAAAGTTTCAACATGTGA 987
Db      601 GAGGTGTGCTATTTATGGAAGAGGAACTAAGGCTGCAATTAAGTTTCAACATGTGA 660
Qy      988 AATTGCTATGTGAAACAGAGTATTTACTGAGATTAATGAAATTAATGATGATTTTAA 1047
Db      661 AACTGTGTGTGAAACAGAGTATTTACTGAGATTAATGAAATTAATGATGATTTTAA 720
Qy      1048 CAATATATCTTTATTAAGTACAGTCAAGTGGCACTTTCAATTAAGTGCCTTAAAG 1107
Db      721 CAGTACACTTTACTAAGCAGATGACAGTGGAAATTTCAATTAAGTGCCTTAAAG 780
Qy      1108 TTATGCTATTTATTAAGTACTTAATGTAACCACTGTAATCTTCTTTGTAATCAAG 1167
Db      781 CTAGCAATTTATTAAGCACTTAATTAAGTGTCTACTAGCACTTTTATGCAATACAG 840
Qy      1168 TTGAGCAGGTTACTTGTGCTTAAAGAAATTAATTAATTAATTAATGTCCTTAAAG 1227
Db      841 TTGAGCAGGTTATGTTATTAAGCAATTAATTAATTAATTAATGTCCTTAAAG 900
Qy      1228 TATGATCTCTTTTATGAGGTCAACATGTGTAAAGTGAATGCAAAAAATGTGTAA 1287
Db      901 TATGACCCCTTATGAGGTGAGGAGCATGTGTAAAGTGAATGCAAAAAATGTGTAA 960
Qy      1288 AAAAACAACCTGTGTGTTTACGGGCACTGAGTGTGAAAAACAATTTGCAATGCT 1347
Db      961 AAAAACAACCTGTGTGTTTATGAGGCTGCAAGTGTGAAAAACAATTTGCAATGCT 1020
Qy      1348 ATTGCTTAAATCTGATCAAGTGTATGAAATGTGAATGAAATTAATGCAATTT 1407
Db      1021 ATTGCTTAAATCTGATCAAGTGTATGCAATGTAATGTAATGAAATTAATGCAATTT 1080
Qy      1408 AATGATGTAGCGGAGAAATGTTGTGTCTGAGATGAGCAATTTAATGCTCACTAT 1467
Db      1081 AATGATGTAGCGGAGAAATGTTGTGTCTGAGATGAGCAATTTAATGCTCACTAT 1140
Qy      1468 GTGGAAGCTGCAAAAGCAATTTTATGTTGTCAGCAACGAGGTATGCAAAAAATGCT 1527
Db      1141 GTGGAAGCTGCAAAAGCAATTTTATGAGGCTGCAACGAGGTATGCAAAAAATGCT 1200
Qy      1528 GGCAGTGTGCAAGTCCCGGCTGTGTGCTGTGTTTAACTGCAAGCAATGCTCACTAT 1587
Db      1201 GGCAGTGTACTGTGCTGTGAGTACTGTGTGTATTAACGAGATGTGCAATTTCTTT 1260
Qy      1588 GTTGTGATGTGTATTAACCTACTAACAATGTGTCAATGCTTAAAGCAAGCATGTGA 1647
Db      1261 GTTGTGATGTGGAACACTAACAACAATGTGTCAATGCTTAAAGCAAGCATGTGA 1320

```

```

Qy      1648 AAGCTAACTTTTACATTAAGATGTAGCCCTGACATGAGGTTTACTTACAGAGGCTATGTA 1707
Db      1321 AAGTTAACTTTTACTGTATAGATCAAGCCCTGACATGAGGTTTACTTACAGAGGCTATGTA 1380
Qy      1708 CAACAAATGCTAACTTGTGTATATGCAACAAGCTGAGGCCATATGAAAACTGGGCAATA 1767
Db      1381 CAACAGTGTATCATATGTGTATATGCAACAAGCTGGGACACATATGAAAACTGGGCAATA 1440
Qy      1768 AACTTACATTTTATTTTCTGTGATTAATGCAATATGTCCTTCAACCAATCTTCAAAAC 1827
Db      1441 AACTTACATTTTATTTTCTGTGATTAATGCAATATGTCCTTCAACCAATCTTCAAAAC 1500
Qy      1828 ACCCCATGTTCCAGACACCACTATCAGAGAGTGTGTGTAAGGCTCTGAAGAACTC 1887
Db      1501 ACCCCATGTTCTACAGACACCACTATCAGAGAGTGTGTGTAAGGCTCTGAAGAACTC 1560
Qy      1888 AGTGAAGCAGCTTTTTCACCTCATCACTCCAGGCGCTGGAACAGTGAACCCCGCGC 1947
Db      1561 AGTGAAGCAGCTTTTTCACCTCATCACTCCAGGCGCTGGAACAGTGAACCCCGCGC 1620
Qy      1948 TCTAGTACGCCGCTCCCGGACCAAGTTTCAAGGAATCATTTGTGGAAGCCAGTTTC 2007
Db      1621 TCTAGTACGCCGCTCCCGGACCAAGTTTCAAGGAATCATTTGTGGAAGCCAGTTTC 1680
Qy      2008 TCCGAGTGTAGCCGCTCCTGAGGAGAACTTTTACACGCGCGCTTGCCGATCAAGTTT 2067
Db      1681 TCCGAGTGTAGCTCCTCATCTGTGAGGAGAAAGCTTTTACACACTTTTGGAGACAGTTT 1740
Qy      2068 CGTGAACCTGTATAGAGGCTTGTATGTGAGATGTGTGAGAGGATGCTGTGTTGC 2127
Db      1741 CGTGAACCTGTATAGAGGCTTGTATGTGTGAGATGTGTGAGAGGATGCTGTGTTGC 1800
Qy      2128 TGTGTGAACATATTAACAACAGTGTGAGGCTTGTGAGGCTTGTGAGGCTTGTGAGGCT 2187
Db      1801 TGTGTGAACATATTAACAACAGTGTGAGGCTTGTGAGGCTTGTGAGGCTTGTGAGGCT 1860
Qy      2188 GTGAGAGCTTGTGTATATGATGAGAAATTTAGAGAGTTTATCTCAGACTAGTGGCGTGC 2247
Db      1861 GTGAGAGCTTGTGTATATGATGAGAAATTTAGAGAGTTTATCTCAGACTAGTGGCGTGC 1920
Qy      2248 AGTTGTATGTAGAGAGCTTCAACCACTTTCTGTGTAACTTGTAAAAATGTGCTTAC 2307
Db      1921 AGCTGCATGTGAGAGCTTCTATCCCTTTCTGTGTAACTTGTAAAAATGTGCTTAC 1980
Qy      2308 CTGTCTGATTAACAAGTTTGTATATATGAGTAA 2343
Db      1981 CTGTCTGATTAACAAGCTTGTATATATGAGTAA 2016

```

```

RESULT 13
AAd4611
ID AAd4611 standard; DNA; 2016 BP.
XX
XX AAd4611;
AC 29-AUG-2003 (revised)
DT 13-DEC-2002 (first entry)
DE B19 virus B19 orf1 DNA.
XX
XX Prokaryotic library; candidate protein; nucleic acid modification; NAM;
XX enzyme attachment sequence; EAS; clinical pharmacology; chemical sensor;
XX enzymology; cosmetic research; toxic; environmental safety assessment;
XX nutrient biology; coat protein; gene; ds.
OS B19 virus.
XX
XX Key Location/Qualifiers
XX CDS 1..2016
XX FT /tag= a
XX FT /product= "B19 orf1 protein"
XX

```


DB 1441 AACCTACCTTTGATTTCCCTGGAAATTAATGACAGATCCCTCCAGCCCAAGCTTCAGAAC 1500
 QY 1828 ACCCCCTATTTCCAGACACACAGATATCAGACAGAGTGTGTGTAAGACTCTGAAGAACTC 1887
 DB 1501 ACCCCATTTGTCAACAGACACAGATATCAGACAGAGTGTGTGTAAGACTCTGAAGAACTC 1560
 QY 1888 AGTGAAGAGCTTTTCAACCTCATCATCTCCAGGCGCTGGAAACAGTGAACCCCGCGC 1947
 DB 1561 AGTGAAGAGCTTTTCTTAACCTCATCATCCCGGCGCTGGAAACAGTGAACCCCGCGC 1620
 QY 1948 TCTAGTACGCGCCCTCCCGGAGACAGTTCAGAGAAATCATTTGTCCGAGCCCAAGTTCC 2007
 DB 1621 TCTAGTACGCGCCATCCCGGAGACAGTTCAGAGAAATCATTTGTCCGAGCCCAAGTTCC 1680
 QY 2008 TCCGAAGTGTAGCCCGCTGTGTGGAGAGAACTTTTACACGCCCGCTCCGATCACTTT 2067
 DB 1681 TCCGAAGTGTAGCTGCATGTGTGGAGAGAACTTTTACACACCTTTGGCAGACCAAGTTT 1740
 QY 2068 CGTGAACCTGTAGAGGGGTGACTTTGTATGGGATGTGTGAGGGGATTCCTGTTGC 2127
 DB 1741 CGTGAACCTGTAGAGGGGTGACTTTGTATGGGATGTGTGAGGGGATTCCTGTTGT 1800
 QY 2128 TGTGTGACATATTAACAACAGTGGGGAGGGGTGGCGCTTGCCTCATTTGATTAAT 2187
 DB 1801 TGTGTGACATATTAACAATAGTGGGGAGGGCTTGGGACCTTTGCCCATTTGATTAAT 1660
 QY 2188 GTGGAGAGCTTGTATTAATGATGAGAAATTTAGAGAGTTTACTCCAGACTTATGTCGCTGC 2247
 DB 1861 GTAGGGGCTTGTATTAATGATGAGAAATTTAGAGAGTTTACTCCAGACTTATGTCGCTGT 1920
 QY 2248 AGTTGTATGATGAGAGCTTCAACCCATTTTCTGTATTAATGTAATAATGTGCTTAC 2307
 DB 1921 AGCTGCCATGTGGAGCTTCAATCCCTTTCTGTCTAACCTGGCAAAAATGTGCTTAC 1980
 QY 2308 CTGTCTGATTAACAAGTTTGTAGATTAGATTA 2343
 DB 1981 CTGTCTGATTAACAAGCTTGTAGATTAGATTA 2016
 RESULT 14
 ABX96680
 ID ABX96680 standard; DNA; 2016 BP.
 AC ABX96680;
 XX 27-OCT-2003 (revised)
 DT 14-MAY-2003 (first entry)
 XX
 DE Nonstructural protein sequence from Erythrovirus B19, DNA.
 XX
 KW Rep protein; ds; gene; capture probe; expression vector;
 KW nucleic acid protein conjugate; NAP; enzyme attachment sequence; EAS;
 KW biochip; gene expression profiling; mutation detection; Rep68; Rep78;
 KW nonstructural protein; NS1; major coat protein; U94.
 XX
 OS B19 virus.
 XX
 PN US2002172968-A1.
 XX
 PD 21-NOV-2002.
 XX
 PF 19-FEB-2002; 2002US-00080376.
 XX
 PR 22-FEB-2001; 2001US-00792630.
 XX
 PA (LIUH/) LIU H.
 PA (DAHI/) DAHIYAT B I.
 PA (LIHM/) LI M.
 XX
 PI Liu H, Dahiyat BI, Li M;
 XX WPI; 2003-310986/30.

DR P-PSDB; ABU64876.
 XX
 PT New composition comprising a substrate consisting of an array of capture
 PT probes hybridized to an expression vector or to a nucleic acid protein
 PT conjugate, useful for diagnostic test, gene expression profiling or
 PT mutation detection.
 XX
 PS Disclosure; Fig 44; 125pp; English.
 XX
 CC The invention relates to a composition comprising a substrate comprising
 CC an array of capture probes hybridized to an expression vector or to a
 CC nucleic acid protein conjugate. The capture probes are hybridized to an
 CC expression vector or to a nucleic acid protein (NAP) conjugate. The
 CC vector comprises: (a) a fusion nucleic acid; (b) a capture sequence; and
 CC (c) an enzyme attachment sequence (EAS). The NAP conjugate comprises: (a)
 CC a fusion polypeptide; and (b) an expression vector. The fusion nucleic
 CC acid comprises a nucleic acid encoding the NAP enzyme or candidate
 CC protein. The fusion polypeptide comprises a Rep and candidate protein.
 CC The EAS and NAP enzyme are covalently attached. Also included are
 CC detecting the presence of a target analyte in a sample, making biochips,
 CC and making NAP conjugates. The composition is useful for diagnostic
 CC applications, gene expression profiling or mutation detection. The
 CC present sequence encodes a viral Rep (or related protein e.g. Rep68,
 CC Rep78, nonstructural protein, NS1, major coat protein or U94 protein) for
 CC use in the composition of the invention. (Updated on 27-OCT-2003 to
 CC standardise OS field)
 XX
 SQ Sequence 2016 BP; 607 A; 361 C; 479 G; 569 T; 0 U; 0 Other;
 Query Match 31.5%; Score 1585.6; DB 7; Length 2016;
 Best Local Similarity 86.7%; Pred. No. 0;
 Matches 1747; Conservative 0; Mismatches 269; Indels 0; Gaps 0;
 QY 328 ATGAGACTATTTGGGGGTGCTTGCACATTTCTCTTACATTTGCACTGTGCTAATGAT 387
 DB 1 ATGAGACTATTTAGAGGGGTGCTTCAAGTTCTTTCAATGTTCTGAGCTGTCAAGAT 60
 QY 388 AACTGTGTGCTCTATGCTATGAGACTTATGAGACTTATGAGAGCAACCACTAACCTTCT 447
 DB 61 AACTGTGTGCTCTTATGAGACTTATGAGACTTATGAGACTTATGAGAGCAACCACTAACCT 120
 QY 448 AACGATTAATGAGCAATATATTAAGCAGTGTGCTTCAATCTTATTTATGAGGGGG 507
 DB 121 AACGATTAATGAGCAATATATTAAGCAGTGTGCTTCAATCTTATTTATGAGGGGG 180
 QY 508 CCGCTAGCAGGTTGCTTATACCTTTTTCAGTGTGAATGAACAAATTTGAGAAAGCTAT 567
 DB 181 CCACTAGCAGGGGTGCTTATCTTTTTCAGTGTGAATGAACAAATTTGAGAAAGCTAT 240
 QY 568 CATATCAGTATGATTTATGTTGTGCTCCAGACTAAATGCTGAACCTTAATCTGTGTGTA 627
 DB 241 CATATCAGTATGATTTATGTTGTGCTCCAGACTAAATGCTGAACCTTAATCTGTGTGTA 300
 QY 628 GAAGGTTATTTATATATGTTCTTACCATCTTGAATGAAGTTTAACTTAATTT 687
 DB 301 GAAGGTTATTTATATATGTTCTTACCATCTTGAATGAAGTTTAACTTAATTT 360
 QY 688 TTGCAAGGATGACTACCAAGAAATATTTTGAAGATGAGAGCAGTTTATAGAAAT 747
 DB 361 TTGCAAGGATGACTACCAAGAAATATTTTGAAGATGAGAGCAGTTTATAGAAAT 420
 QY 748 TACTTAATGAAAAAATCTCTTAATGTTGTGTGTGTATCAATATATGAGCGGTAT 807
 DB 421 TACTTAATGAAAAAATCTCTTAATGTTGTGTGTGTATCAATATATGAGCGGTAT 480
 QY 808 ATAGACACCTGTATTTCCGCTCTTTTGGCGAGAGCTTGCATGCTAAAGACCCCGC 867
 DB 481 ATAGATACCTGTATTTCTGTACTTTTGAAGGGAGCTTGCATGCTAAAGACCCCGC 540
 QY 868 ATTACTGCAATATCAGACAGTGTCTACTAATGAATCGGGAGTCTAGCTGTGAGAGGGGA 927
 DB 541 ATTACCAAGCCATTAATGATTACTAGTAGAGTGTGGGAGTGTAGCGGCAAGGGGCA 600

QY 928 GATGTTGGCCATTCGCTGGAAGGAAACAAAGCGGGTTAAGTTCAACACATGCTA 987
 DB 601 GAGGTGTGGCCATTTAATGGGAAGGAACTAAGGCTAGACATTAAGTTCAACATATGCTA 987
 QY 988 AATGGCTATGTAAGGAAACAGATATTTTCTGAAGATAATGGAATTAATGGAATTTTAC 1047
 DB 661 AACTGTTGTGTGAAACAGAGTGTTCACAGAGATTAAGTGAATCAATGTTGACTTTAC 1047
 QY 1048 CAATATCTTTATTAATGAGAGTCAACAGTGGCAGCTTTCAAAATTCAGATGCTTTAAG 1107
 DB 721 CAGTACATTTAATGAGAGTCAACAGTGGCAGCTTTCAAAATTCAGATGCTTTAAG 1107
 QY 1108 TTAGCTATTTAATGAGAGTCAACAGTGGCAGCTTTCAAAATTCAGATGCTTTAAG 1167
 DB 781 CTAGCAATTTAATGAGAGTCAACAGTGGCAGCTTTCAAAATTCAGATGCTTTAAG 1167
 QY 1168 TTGAGAGAGTGTACTTCAATTAAGAAATTAATTAATTAATTTATTTGCTCAAAAC 1227
 DB 841 TTGAGAGAGTGTACTTCAATTAAGAAATTAATTAATTAATTTATTTGCTCAAAAC 1227
 QY 1228 TATGATCTCTTTTATGAGGTCACATGTTAAGTGTGATGACAAAATTTGCTCAAAAC 1287
 DB 901 TATGATCTCTTTTATGAGGTCACATGTTAAGTGTGATGACAAAATTTGCTCAAAAC 1287
 QY 1288 AAAAACAACCTGTGTTTACGGGCAACAGTACAGTGAAGAAACAAATTTGCTCAAAAC 1347
 DB 961 AAAAACAACCTGTGTTTACGGGCAACAGTACAGTGAAGAAACAAATTTGCTCAAAAC 1347
 QY 1348 ATTGCTAAACCTGTACAGTGTATGATGATGATGATGATGATGATGATGATGATGATGAT 1407
 DB 1021 ATTGCTAAACCTGTACAGTGTATGATGATGATGATGATGATGATGATGATGATGATGAT 1407
 QY 1408 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1467
 DB 1081 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1467
 QY 1468 GTGGAAGCTGCAAAAGCAATTTAGTGTGTGATGATGATGATGATGATGATGATGATGAT 1527
 DB 1141 GTGGAAGCTGCAAAAGCAATTTAGTGTGTGATGATGATGATGATGATGATGATGATGAT 1527
 QY 1528 GGCAGTGTGAGAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1587
 DB 1201 GGCAGTGTGAGAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1587
 QY 1588 GTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1647
 DB 1261 GTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1647
 QY 1648 AAGCTAAACCTTACATTAAGATGATGATGATGATGATGATGATGATGATGATGATGAT 1707
 DB 1321 AAGCTAAACCTTACATTAAGATGATGATGATGATGATGATGATGATGATGATGATGAT 1707
 QY 1708 CAACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1767
 DB 1381 CAACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1767
 QY 1768 AACTACATTTATTTTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACT 1827
 DB 1441 AACTACATTTATTTTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACT 1827
 QY 1828 ACCCCATGTTTCCAGACACAGTATCAGACAGTGTGATGATGATGATGATGATGATGATGAT 1887
 DB 1501 ACCCCATGTTTCCAGACACAGTATCAGACAGTGTGATGATGATGATGATGATGATGATGAT 1887
 QY 1888 AGTGAAGAGAGCTTTTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACT 1947
 DB 1561 AGTGAAGAGAGCTTTTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACTCACT 1947
 QY 1948 TTTAGTACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2007
 DB 1621 TTTAGTACGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2007
 QY 2008 TCCGAAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2067

DB 1681 TCCGAAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1740
 QY 2068 GGTGAACCTGTTAGTATGAGGCTGATCTTTGATGAGGATGATGAGGATGATGAGGATGATGAG 2127
 DB 1741 GGTGAACCTGTTAGTATGAGGCTGATCTTTGATGAGGATGATGAGGATGATGAGGATGATGAG 2127
 QY 2128 TGTGTGAACTATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2187
 DB 1801 TGTGTGAACTATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2187
 QY 2188 GTGGAGCTGTGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2247
 DB 1861 GTGGAGCTGTGTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2247
 QY 2248 AGTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2307
 DB 1921 AGTTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2307
 QY 2308 CTGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2363
 DB 1981 CTGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 2363

RESULT 15

ABX96535
ID ABX96535 standard; DNA; 2016 BP.

AC ABX96535;

AC 27-OCT-2003 (revised)

DT 14-MAY-2003 (first entry)

DE DNA encoding an Erythrovirus open reading frame 1, orf1.

KW Gene; ds; biochip; capture probe; nucleic acid modification enzyme; NAM;
 KM enzyme attachment sequence; EMS; single-nucleotide polymorphism; SNP;
 XX protein-protein interaction.

OS B19 virus.

PN US2002168640-A1.

PD 14-NOV-2002.

PF 22-FEB-2001; 2001US-00792630.

PR 22-FEB-2001; 2001US-00792630.

PA (LIMM/) LI M.

PA (DAHI/) DAHIYAT B I.

PI LI M, Dahiayat B I.

DR WPI: 2003-298722/29.

DR P-PSDB; AB064771.

PT Biochip composition useful for creating protein biochips for detecting
 target analyte in a sample, has substrate having array of capture probes
 hybridized to nucleic acid/protein conjugate.

PS Disclosure; Fig 44; 123pp; English.

CC The invention discloses a biochip composition comprising a substrate
 CC having an array of capture probes, which are hybridized to a nucleic acid
 CC (NA)/protein (NAP) conjugate containing a fusion polypeptide, comprising
 CC a NA modification (NAM) enzyme and a candidate protein, and an expression
 CC vector, comprising a NA encoding NAM enzyme and a candidate protein
 CC fusion, a capture sequence and enzyme attachment sequence (EAS). The
 CC biochip composition is useful for detecting the presence of a target
 CC analyte in a sample, by contacting the sample with a biochip comprising
 CC the compositions under conditions where target analytes can bind to at
 CC least one of the candidate proteins to form an assay complex and

CC detecting the presence of target analyte on the substrate. The target
CC analyte is labelled with a fluorescent label and the method further
CC comprises adding a labelled soluble binding ligand to the assay complex.
CC The biochip compositions are useful for creating protein biochips which
CC are useful in diagnosing (detecting the presence of specific target
CC analytes), screening (looking for target analytes that bind to specific
CC proteins) and single-nucleotide polymorphism (SNP) analysis. The bioassay
CC chips are used in assays to determine protein-protein interactions. The
CC target analyte can be nucleic acid, drug, drug analogues or products. The
CC biochip compositions allow rapid and facile creation of protein biochips.
CC The sequences presented in ABX96514-ABX96536 are the DNAs encoding the
CC proteins disclosed in the invention. (Updated on 27-OCT-2003 to
CC standardise OS field)

XX Sequence 2016 BP; 607 A; 361 C; 479 G; 569 T; 0 U; 0 Other;

Query Match 31.5%; Score 1585.6; DB 7; Length 2016;

Best Local Similarity 86.7%; Pred. No. 0; Mismatches 269; Indels 0; Gaps 0;

Matches 1747; Conservative 0; Mismatches 269; Indels 0; Gaps 0;

QY 328 ATGAGCTATTTGGGGGTCTTGCACATTTCCCTTAACATTCGTGACCTGCTAATGAT 387
DB 1 ATGAGCTATTTAGAGGGGTCTTCAAGTTCTTAATGTTCTGACCTGCTAATGAT 60
QY 388 AACTGGTGTCTCTATGCTAGATTAATCTGACTGAGGAAACCACTAACCCATTC 447
DB 61 AACTGGTGTCTCTATGCTAGATTAATCTGACTGAGGAAACCACTAACCCATTC 120
QY 448 AACAGATTAATGCAATATATTTAAGCAGTGTGCTTCTAATCTGATTTTACGCGGG 507
DB 121 AACAGATTAATGCAATATATTTAAGCAGTGTGCTTCTAAGCTTGTACCTTACCGGGGG 180
QY 508 CCGGTAGCAGGTGCTTATATCTTTTTCAGGTGGAATGTAACAATTTGAGAGGCTAT 567
DB 181 CCACTAGCAGGTGCTTATATCTTTTTCAGGTGGAATGTAACAATTTGAGAGGCTAT 240
QY 568 CATATCATGTATGTTATGTTGTCGAGGACTAAATCTGAAATTAACCTGATGCTGTA 627
DB 241 CATATCATGTATGTTATGTTGTCGAGGACTAAATCTGAAATTAACCTGATGCTGTA 300
QY 628 GAAAGTTATTTAATAATGTTCTTTTACCATCTGTAACCTGAAATGTTAAATTT 687
DB 301 GAAAGTTATTTAATAATGTTCTTTTACCATCTGTAACCTGAAATGTTAAATTT 360
QY 688 TTGCGCAGGATGACTACCAAGGAAATTTTGAATGAGAGGAGCTTTATGAAAT 747
DB 361 TTGCGCAGGATGACTACCAAGGAAATTTTGAATGAGAGGAGCTTTATGAAAT 420
QY 748 TACTTATGAAAAAATTCCTTTAATGTTGTGAGTGAACAAATATTGACGGGTAT 807
DB 421 TACTTATGAAAAAATTCCTTTAATGTTGTGAGTGAACAAATATTGACGGGTAT 480
QY 808 ATAGACACTGTATTTCCGCTCTTTTCCGCGAGAGACTGTCTGCTAAAGACCCGCG 867
DB 481 ATAGACACTGTATTTCCGCTCTTTTCCGCGAGAGACTGTCTGCTAAAGACCCGCG 540
QY 868 ATTAGCTCAATATACAGCAGTGTCTAATGAAATCTGGGAGTGTACTGTGAGGGGGA 927
DB 541 ATTAGCTCAATATACAGCAGTGTCTAATGAAATCTGGGAGTGTACTGTGAGGGGGA 600
QY 928 GATGTTGTGCAATTCGCTGGAAGGGAACAAAGCGGGTTAAAGTTCAACACATGTA 987
DB 601 GATGTTGTGCAATTCGCTGGAAGGGAACAAAGCGGGTTAAAGTTCAACACATGTA 660
QY 988 AATGCTATGTGAAAAAGAGATATTTACTGAAGATTAATGAAATTAAGTGAATTTTAC 1047
DB 661 AATGCTATGTGAAAAAGAGATATTTACTGAAGATTAATGAAATTAAGTGAATTTTAC 720
QY 1048 CAATATATCTTTATTAAGTAGCAGTCAAGTGGCAGCTTTCAAAATTCAGAGCTTAAAG 1107
DB 721 CAATATATCTTTATTAAGTAGCAGTCAAGTGGCAGCTTTCAAAATTCAGAGCTTAAAG 780
QY 1108 TTAGCTATTTATAAGCTACTAATCTAGTACCCACTAGTACATTCCTGTATACATTGAC 1167

DB 781 CTAGCAATTTATAAGCACTAATTTAGTCCCTAGACACATTTTATGCTATACAGAC 840
QY 1168 TTGAGCAGGTATCTTGCAATTAAGAAATTAATAGTAAATTTATTTGTCGAAAAC 1227
DB 841 TTGAGCAGGTATCTTGCAATTAAGAAATTAATAGTAAATTTATTTGTCGAAAAC 900
QY 1228 TATGATCTCTTTTAAAGGTCGAACATGTTAAGGTCGATGACAAAAATGCTGTA 1287
DB 901 TATGATCTCTTTTAAAGGTCGAACATGTTAAGGTCGATGACAAAAATGCTGTA 960
QY 1288 AAAAACCCTGTGTTTAAAGGTCGAACATGTTAAGGTCGATGACAAAAATGCTGTA 1347
DB 961 AAAAACCCTGTGTTTAAAGGTCGAACATGTTAAGGTCGATGACAAAAATGCTGTA 1020
QY 1348 ATGCTTAAACCTGATCAATGTAATGGAATGGAATTTGGAATTTTCCATTT 1407
DB 1021 ATGCTTAAACCTGATCAATGTAATGGAATGGAATTTGGAATTTTCCATTT 1080
QY 1408 AATGATGTCGCGGGAAGTTGATGTCGAGGATGGAAGGCTATTTAAGTCACTATT 1467
DB 1081 AATGATGTCGCGGGAAGTTGATGTCGAGGATGGAAGGCTATTTAAGTCACTATT 1140
QY 1468 GTGGAAGCTGCAAAAGCAATTTTAAAGGTCGACCAACAGGTCGATGCAAGAAATGCGT 1527
DB 1141 GTGGAAGCTGCAAAAGCAATTTTAAAGGTCGACCAACAGGTCGATGCAAGAAATGCGT 1200
QY 1528 GGCAGTGTGCAAGTCCCGGTGTGCTGTGTTATTAACAGCAATGTCATTTACATTT 1587
DB 1201 GGCAGTGTGCAAGTCCCGGTGTGCTGTGTTATTAACAGCAATGTCATTTACATTT 1260
QY 1588 GTTGTAGGTCGATTAACCACTAATGTCGATGTCGATTAAGGCTTAAAGGAGCGATGTA 1647
DB 1261 GTTGTAGGTCGATTAACCACTAATGTCGATGTCGATTAAGGCTTAAAGGAGCGATGTA 1320
QY 1648 AACTTAATCTTTACCAATGATGATGATGATGATGATGATGATGATGATGATGATGTA 1707
DB 1321 AACTTAATCTTTACCAATGATGATGATGATGATGATGATGATGATGATGATGATGTA 1380
QY 1708 CAACATGCTTAATCTGTGTTAATGCAAAAGTGTGAGGCACTATGAAATCTGGCAATA 1767
DB 1381 CAACATGCTTAATCTGTGTTAATGCAAAAGTGTGAGGCACTATGAAATCTGGCAATA 1440
QY 1768 AACTTAATCTTTAATTTCCGTGAATTAATGAGATGATGATGATGATGATGATGATGATGTA 1827
DB 1441 AACTTAATCTTTAATTTCCGTGAATTAATGAGATGATGATGATGATGATGATGATGATGTA 1500
QY 1828 ACCCCATTTGCCAGACCACTATCAGCAGCAGTGTGTAAGGCTTGAAGAACTC 1887
DB 1501 ACCCCATTTGCCAGACCACTATCAGCAGCAGTGTGTAAGGCTTGAAGAACTC 1560
QY 1888 AGTGAAGCAGCTTTTCAACCTCATCATCTCCAGCGCTGGAACAGTGAACCCGCGC 1947
DB 1561 AGTGAAGCAGCTTTTCAACCTCATCATCTCCAGCGCTGGAACAGTGAACCCGCGC 1620
QY 1948 TCTAGTACGCGCTCCCGGAGCACTTCAAGGAAATCAATTTGCGGAAGCCAGTTTC 2007
DB 1621 TCTAGTACGCGCTCCCGGAGCACTTCAAGGAAATCAATTTGCGGAAGCCAGTTTC 1680
QY 2008 TCCGAAGTGTGATCCGCTGTGAGGAGAAAGCTTTTCAACGCGCTTGCATCACTTT 2067
DB 1681 TCCGAAGTGTGATCCGCTGTGAGGAGAAAGCTTTTCAACGCGCTTGCATCACTTT 1740
QY 1741 CGTGAACCTGTATGTTGAGGCTGTATGTTGTTGAGGAGGCTTTTCACTGTGTGT 1800
DB 2128 TGTGTGAACATTAATAACAGTGTGAGGAGGCTTGTGAGGAGGCTTGTGAGGAGGCTTGT 2187
QY 1801 TGTGTGAACATTAATAACAGTGTGAGGAGGCTTGTGAGGAGGCTTGTGAGGAGGCTTGT 1860
DB 2188 GTGGAAGCTTGTATATGATGATGATGATGATGATGATGATGATGATGATGATGATGTA 2247

Db 1861 GTAGGGGCTTGTATATAGATGGAATTCGAGATTACCCGAGATTGGTGGGT 1920
 Qy 2248 AGTTGTCATGTAGAGCCCTCTAACCATTCTGTGTTACTTGTAAAAATGCTTAC 2307
 Db 1921 AGCTGCCAATGTGGAGCTTCTAATCCCTTCTGTGCTAACCTGCAAAAATGTCTTAC 1980
 Qy 2308 CTGTCTGATTAACAAGTTTGTAGATTATGAGTAA 2343
 Db 1981 CTGTCTGATTCAAAAGCTTGTAGATTATGAGTAA 2016

Search completed: April 21, 2004, 07:14:42
 Job time : 1756 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 21, 2004, 05:04:07 ; Search time 315 Seconds
(without alignments)

8858.073 Million cell updates/sec

Title: US-09-555-640-1

Perfect score: 5028
Sequence: 1 gacgcacaggaatgacgt.....acgtatcttcctgtgacgac 5028

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 682709 seqs, 277475446 residues

Total number of hits satisfying chosen parameters: 1365418

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database :

Issued Patents NA: *
1: /cgn2_6/prodata/2/ina/5A_COMB.seq: *
2: /cgn2_6/prodata/2/ina/5B_COMB.seq: *
3: /cgn2_6/prodata/2/ina/6A_COMB.seq: *
4: /cgn2_6/prodata/2/ina/6B_COMB.seq: *
5: /cgn2_6/prodata/2/ina/PCUS_COMB.seq: *
6: /cgn2_6/prodata/2/ina/backfile1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1319.4	26.2	2271	4 US-09-438-268-3	Sequence 3, Appl1
2	146.6	2.9	201	3 US-08-905-124-1	Sequence 1, Appl1
3	107.4	2.1	4680	1 US-08-254-358-1	Sequence 1, Appl1
4	107.4	2.1	4680	1 US-08-475-391-1	Sequence 1, Appl1
5	107.4	2.1	4680	2 US-08-709-609-1	Sequence 1, Appl1
6	107.4	2.1	4680	5 PCT-US95-07178-1	Sequence 1, Appl1
7	107.4	2.1	4910	2 US-08-331-384-2	Sequence 2, Appl1
8	107.4	2.1	4910	2 US-08-836-087-2	Sequence 2, Appl1
9	107.4	2.1	4910	3 US-09-246-320-2	Sequence 2, Appl1
10	107.4	2.1	4910	4 US-09-546-738-2	Sequence 2, Appl1
11	107.4	2.1	7214	4 US-09-438-268-1	Sequence 1, Appl1
12	107.4	2.1	7557	4 US-09-770-315-3	Sequence 3, Appl1
13	107.4	2.1	8151	4 US-09-438-268-2	Sequence 2, Appl1
14	107.4	2.1	8179	4 US-09-438-268-5	Sequence 2, Appl1
15	107.4	2.1	8698	4 US-09-770-315-2	Sequence 2, Appl1
16	98.2	2.0	939	4 US-09-532-594B-12	Sequence 12, Appl1
17	98.2	2.0	1197	4 US-09-532-594B-13	Sequence 13, Appl1
18	98.2	2.0	1611	4 US-09-532-594B-14	Sequence 14, Appl1
19	98.2	2.0	1872	4 US-09-532-594B-3	Sequence 3, Appl1
20	98.2	2.0	1872	4 US-09-532-594B-15	Sequence 15, Appl1
21	98.2	2.0	4767	4 US-09-532-594B-1	Sequence 1, Appl1
22	90.2	1.8	5049	1 US-08-336-345-1	Sequence 1, Appl1
23	90.2	1.8	5049	1 US-08-336-345-2	Sequence 2, Appl1
24	90.2	1.8	5049	2 US-08-647-655-1	Sequence 1, Appl1
25	90.2	1.8	5049	2 US-08-647-655-2	Sequence 2, Appl1
26	86	1.7	225	1 US-07-789-917A-2	Sequence 2, Appl1
27	86	1.7	225	3 US-07-982-193-2	Sequence 2, Appl1

28	60.8	1.2	993	1 US-08-364-081-2	Sequence 2, Appl1
29	60.8	1.2	993	1 US-08-630-552-2	Sequence 2, Appl1
30	60.8	1.2	993	5 PCT-US95-16558-2	Sequence 2, Appl1
31	48.4	1.0	1617	4 US-09-532-594B-19	Sequence 19, Appl1
32	48.4	1.0	1800	4 US-09-532-594B-17	Sequence 17, Appl1
33	48.4	1.0	2208	4 US-09-532-594B-5	Sequence 5, Appl1
34	46	0.9	832	4 US-09-621-976-15639	Sequence 2813, Ap
35	44.4	0.9	505	4 US-09-621-976-15639	Sequence 15639, A
36	44	0.9	11049	4 US-10-204-708-22	Sequence 22, Appl1
37	43.2	0.9	7218	1 US-08-232-463-14	Sequence 14, Appl1
38	43	0.9	399	4 US-09-621-976-8976	Sequence 8976, Ap
39	43	0.9	4185	4 US-09-417-485D-7	Sequence 7, Appl1
40	43	0.9	10640	4 US-09-417-485D-5	Sequence 5, Appl1
41	42.8	0.9	8093	4 US-10-204-708-31	Sequence 31, Appl1
42	42.6	0.8	1664976	4 US-08-916-421B-1	Sequence 1, Appl1
43	42	0.8	1360	3 US-09-177-431-9	Sequence 9, Appl1
44	41.2	0.8	19233	4 US-10-204-708-46	Sequence 46, Appl1
45	41	0.8	640681	4 US-09-790-988-1	Sequence 1, Appl1

ALIGNMENTS

RESULT 1					
US-09-438-268-3					
Sequence 3, Application US/09438268					
Patent No. 6491907					
GENERAL INFORMATION:					
APPLICANT: Rabinowitz, Joseph E.					
APPLICANT: Samulevitz, Richard J.					
APPLICANT: Xiao, Weidong					
TITLE OF INVENTION: VIRUS VECTORS AND METHOD OF MAKING AND ADMINISTERING					
TITLE OF INVENTION: THE SAME					
FILE REFERENCE: 5470-186					
CURRENT APPLICATION NUMBER: US/09/438,268					
EARLIER FILING DATE: 1999-11-10					
EARLIER APPLICATION NUMBER: 60/107,840					
EARLIER FILING DATE: 1998-11-10					
EARLIER APPLICATION NUMBER: 60/123,651					
EARLIER FILING DATE: 1999-03-10					
NUMBER OF SEQ ID NOS: 59					
SOFTWARE: Patentin Ver. 2.0					
SEQ ID NO 3					
LENGTH: 2271					
TYPE: DNA					
ORGANISM: Virus					
US-09-438-268-3					
Query Match					
Best Local Similarity 87.0%; Pred. No. 0;					
Matches 1449; Conservative 0; Mismatches 216; Indels 0; Gaps 0;					
QY	3017	ATGACTTCACTTACTCTGAGAGCCAGACCTGTGACGCGGGAGGTAGCAACCT	3076		
DB	607	ATGACTTCACTTACTCTGAGAGCCAGACCTGTGACGCGGGAGGTAGCAACCT	666		
QY	3077	ACAAAAGCATGTGGAGTGAAGGGCTACATTTACTGCTTAATTCGTAAAGTGTACATTC	3136		
DB	667	GTCAAAAGCATGTGGAGTGAAGGGCTACATTTACTGCTTAATTCGTAAAGTGTACATTC	726		
QY	3137	TCTAGGCAATTTTATTCATATGATTCAGACATCATATTAAGTGTCTCTCCAGCA	3196		
DB	727	TCTAGGCAATTTTATTCATATGATTCAGACATCATATTAAGTGTCTCTCCAGCA	786		
QY	3197	GCTAGTACCTGACCAATGTCTAGTGGAAAAGGCAAAAGTGTGCACTATTAGTCCATT	3256		
DB	787	GCGAGTACCTGACCAATGTCTAGTGGAAAAGGCAAAAGTGTGCACTATTAGTCCATT	846		
QY	3257	ATGGGATCTCTATCTCCGAGATCTAGATTTTAATGCTTAATTTGTTTCTCA	3316		
DB	847	ATGGGATCTCTATCTCCGAGATCTAGATTTTAATGCTTAATTTGTTTCTCA	906		
QY	3317	CCATTAGAGTTTCAGACATTAATTTGAATAATGTAGTATAGCTCCAGATGCTTAACT	3376		

Db	907	CCCTTAGAGCTTCAGCACTTAATTAAATAATGAAATGAAATAGCTCCTGATGCTTTAACT	966
Oy	3377	GTAACTAATTTCAGAAATTGCTGTAAAAAGATGTCAAGACAATAACAGAGAGAGGTGGCA	343
Db	967	GTAAACCAATACAGAAATTGCTGTAAAGATGTTCAGACAAACTGAGGGGGGTACAG	102
Oy	3437	GTTAACGTACAGACACACAGAGAGCTTGCTGTATGTTAGTGATCATGAGTAATAATCCCA	349
Db	1027	GTTACTGACAGCACTACAGGGGGCCTATGCAATGTTATGTAAACATGAAATCAAGTACCCA	108
Oy	3497	TATGTCTAGGTCAAGGACAAAGACACATAGCTCAGAACTGGCCAAATTGGGGTTTCTTT	355
Db	1087	TATGTGTAGGGCAAGGTCAAGATATCTTTAGCCCAAGACTTCTATTGGGTATATCTTT	114
Oy	3557	CCCCCCAGTATGCTTACTTAACAGTGTGGAAGTAAACACACAGAAATTTCAAGAGAC	361
Db	1147	CCCCCTCAATATGCTTACTTAACAGTGTGGAAGTAAACACACAGAAATTTCTGAGAC	120
Oy	3617	AGCAAAAAATTTGGCTAGTGAAGATCAGCTTTTATATGTTGTAGAGACAGTTCAATTGAA	367
Db	1207	AGCAAAAAATTTAGCAAGTGAAGATTAAGCATTTTATATGTTTGGAAACAGGTTCTTTTACG	126
Oy	3677	CTTTTGGGTACAGGGGGATCTGCCACTATGTCCCAAAATTTCAAGCTGTGGCCCCAGAA	373
Db	1267	CTTTTATGTACAGAGAGGTACAGCAACTATGTCTTTATATGTTTCTGTCAAGTGGCCCCA	132
Oy	3737	AACTAGAAAGGTCTGACGCCAACTTTTATATGAAATGTAAACCTTTGTATGGTTCTGCT	379
Db	1327	AAATTAGAGGGCTGCAAGTCAACCTTTTATGAAATGTAAACCTTTATAGGATATCCCG	138
Oy	3797	TTTATGGGTACCTGACACATTTAGAGGGGACCTTAAATTTAGATCAATTGACACAGAAAG	385
Db	1387	TTTATGGGTCTGACACATTTAGAGGGGTGACCCAAATTTAGATCTTTTAAACATGAAAG	144
Oy	3857	CACGCAATTCAGGCAAAAACTTTATGCTGGGCCCACTAATAATTCAGTGTCTAACAA	391
Db	1447	CATGCAATTCAGGCCCAAACTTCATGTCAGGGGCCCACTAATACTCATGTCTTAAAG	150
Oy	3917	GAAAGGACAAATCTTAATCAGGTGCTGAAAAAGCCCTTACGGGGCTTATGATCGGCACT	397
Db	1507	GAGGGAGCAGCTCTAATCTGGAAGCTGAAAAAGCTTAAACAGGCTTTAGACAGATACC	156
Oy	3977	AGCAGAAAACACAGAAATTTCCCTAGGCCCCGGGCCAGATCTCAAGCAATCACTACG	403
Db	1567	TCTCAAAATACATGAATATCTTAAGCCCTGAGGCCAAGTCTCAAGCATCACCACTGG	162
Oy	4037	GACACTGATAAATATGTTACAGAAATAATGCCATTTCACTGGAACAAACACTTTATGA	409
Db	1627	GACACAGATAATATATGTACAGAAATAATGCCATTTCTATGTCAAGCACTTAATGTT	168
Oy	4097	AATGCTGAGGACAAAGAGTATCACAGAGGGTAGAGAAATTTCCAAATGAAAAAGACAG	415
Db	1687	AACGTGAAGACAAAGATATCACAGAGAGTGGTGAATTTCCAAATGAAAAAGACAG	174
Oy	4157	CTTAAAGCAATTACAGGCTTTAATCATCACAATCTCTCTAATAAGAAACCCAGAA	421
Db	1747	CTTAAAGCAATTACAGGGTTTAAATCATCACAATCTCTCTAATAAGAAACCCAGAA	180
Oy	4217	TACACAGACAAATTTGAAAGCCCTTATATGTTGGGCTCTGTTGGAACAAAGAGCTTT	427
Db	1807	TATACAGATCAAAATTTAGGCGCCCTTAAATGTTGGGTTCTGTATGGAACAGAAAGCCCTT	186
Oy	4277	CACATATAAAGTCAAGCTGTGAGATAAATCCCTAATCTTGATGACAGTTTAAATCTCAA	433
Db	1867	CACATATAAAGCCAGCTGTGAGATAAATTTCCAAATTTAGATGACAGTTTAAATCTCAG	192
Oy	4337	TTTGCACCCCTAGGCGGGGTGGGTTGCAATCAACCCCTCAATATTTTAAATAATA	439
Db	1927	TTTGCACCCCTTAGAGAGATGGGGTTTGCATACGCCACTCTCAATATTTTAAATAATA	198
Oy	4397	CTACCAAAATGGGGCAATTGAGGATTAATCAATGAGAAATTAATCAATTTAGTTCAA	445

Db	1987	TTACCAAAAGTGGGCCAATTGGAGGTATTAAATCAATGGGAATTACTACTTAGTTCAG	2046
Qy	4457	TATGCTGTGGGAATAATGACATTACATGACCTTTAAATTGGGACCTGGAAAGCTACT	4516
Db	2047	TATGCGGTGGGAATTATGACAGTAACTATTGACATTTAAATTGGGCCCCGTAAGACTACG	2106
Qy	4517	GGAAAGTGGAAATCCCCACGCTGGGGTTATCTCTCATGACGTGTCATTTAACCATAT	4576
Db	2107	GGACCGTGGAAATTCCTCAACTCTGGAGTATATCCCCGACGAGAGGTCATTTCACATAT	2166
Qy	4577	GTACGTGTGACCCCAACAGCTACAGATGCAAAAGCAACACACAGACACACGATATGAAAG	4636
Db	2167	GTACTATGTAGCCCCACAGCTACAGATGCAAAACAAACACACACATGTGATTGAAAAG	2226
Qy	4637	CCTGAGAGATTGTGACTGCTGCCAAAAGCGGTGACACCATTTGTA	4681
Db	2227	CCTAAGAGATTGTGACAGCGCAAAAGCCGTGTGACACCATTTGTA	2271

RESULT 2
MS-08-90

```

1 Sequence 1, Application US/08905124
2 Patent No. 6074825
3
4 GENERAL INFORMATION:
5 APPLICANT: Rundell, Clark A.
6 APPLICANT: Vary, Calvin P.H.
7 TITLE OF INVENTION: STABLE ENCAPSULATED REFERENCE
8 TITLE OF INVENTION: NUCLEIC ACID AND METHOD OF MAKING
9 NUMBER OF SEQUENCES: 5
10 CORRESPONDENCE ADDRESS:
11 ADDRESSEE: Wood, Herion & Evans, L.L.P.
12 STREET: 2700 Carew Tower
13 CITY: Cincinnati
14 STATE: OH
15
16 COUNTRY: USA
17 ZIP: 45202-2917
18
19 COMPUTER READABLE FORM:
20 MEDIUM TYPE: Diskette
21 COMPUTER: IBM Compatible
22 OPERATING SYSTEM: DOS
23 SOFTWARE: FAST-SEO for Windows DEMONSTRATION Version 2.0D
24 CURRENT APPLICATION DATA:
25 APPLICATION NUMBER: US/08/905.124
26 FILING DATE: 31-JUL-1997
27 CLASSIFICATION: 435
28 PRIOR APPLICATION DATA:
29 APPLICATION NUMBER:
30 FILING DATE:
31 ATTORNEY/AGENT INFORMATION:
32 NAME: Fred Donald F
33 REGISTRATION NUMBER: 21,190
34 REFERENCE/DOCKET NUMBER: CASI-02
35 TELECOMMUNICATION INFORMATION:
36 TELEPHONE: 513-241-2324
37 TELEFAX: 513-421-7269
38
39 TELEX:
40 INFORMATION FOR SEQ ID NO: 1:
41 SEQUENCE CHARACTERISTICS:
42 LENGTH: 201 base pairs
43 TYPE: nucleic acid
44 STRANDEDNESS: single
45 TOPOLOGY: linear
46 MOLECULE TYPE: Genomic DNA
47 HYPOTHEICAL: NO
48 ANTI-SENSE: NO
49 ORIGINAL SOURCE:
50 ORGANISM: parvovirus B19
51 STRAIN: B19
52
53 US-08-905-124-1

```

Query Match	2.9%	Score 146.6	DB 3	Length 201
Best Local Similarity	83.1%	Pred. No. 2.9e-29		
Matches 167; Conservative	0	Mismatches 34	Indels 0	Gaps 0

QY 3667 TTCAATTGAACCTTTGGGTACAGGGGANTGCGCACTATGCTTACAAATTTCCAGCTGT 3726
 Db 1 TTCTTTTACGCTTTTAGTGTACAGAGGTACAGATCATATGCTTTAAAGTTTCTCCAGT 60
 QY 3727 GCGCCCAAGAAACCTAGAGGCTGACGCCAATTTTATGAATGTACAACTTTGTA 3786
 Db 61 GCGCCCAAGAAATTTAGAGGGCTGACAGTCAACCTTTTATGAATGTACAACTTTGTA 120
 QY 3787 CGGTCTCGTTTAGGGTACTTGAACATTTAGAGGGAGCCCTTAAATTTAGATCATTTGAC 3846
 Db 121 CGATCCCGGTGGGGTCTTCTGACACATTTAGAGGGAGCCCAAAATTTAGATCTTTAAC 180
 QY 3847 ACAGAGAACACGCAATTC 3867
 Db 181 ACATGAGACCATGCAATTC 201

RESULT 3

US-08-254-358-1
 ; Sequence 1, Application US/08254358
 ; Patent No. 568785
 ; GENERAL INFORMATION:
 ; APPLICANT: Johnson, Philip R.
 ; TITLE OF INVENTION: Adeno-Associated Virus Materials and
 ; TITLE OF INVENTION: Methods
 ; NUMBER OF SEQUENCES: 3
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
 ; STREET: 6300 Sears Tower, 233 S. Wacker Drive
 ; CITY: Chicago
 ; STATE: Illinois
 ; COUNTRY: USA
 ; ZIP: 60606
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent in Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/254,358
 ; FILING DATE:
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: No. 568785and, Greta E.
 ; REGISTRATION NUMBER: 35,302
 ; REFERENCE/DOCKET NUMBER: 31975
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (312) 474-6300
 ; TELEFAX: (312) 474-0448
 ; TELEX: 25-3856
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 4680 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; US-08-254-358-1

Query Match 2.1%; Score 107.4; DB 1; Length 4680;
 Best Local Similarity 49.4%; Pred. No. 3.8e-18;
 Matches 279; Conservative 0; Mismatches 286; Indels 0; Gaps 0;

QY 1172 AGAGGTTACTGATTAAAGAAATTAAGTAATTAATTTGTGTCAAAATCTATG 1231
 Db 1183 AGCCCGTGAGAGCAATTTCCAGCATCGAATTTTAATTTGGAACCTAAACGGTACG 1242
 QY 1232 ATGCTCTTTAGTGGGCAACATGTGTTAAGTGTGATTCACAAAATGTGTAAATAA 1291
 Db 1243 ATCCCAATATGCGGCTTCCGTCTTTGTGGATGGCCACGAAAAGTTGGCAAGGGA 1302
 QY 1292 ACACCCGTGTGTTTACGGGCAACAGTACTGAAAAAACAATTTGGCAATGGCTATTG 1351

Db 1303 ACACCATCTGGCTGTGTTGGCCCTGCAACTACCGGGAAGCAACATCGCGAGGCCATAG 1362
 QY 1352 CTAAACCTGACCAAGTATGAAATGGTAATTTGAAATATGAAAATCTTCCATTAAATG 1411
 Db 1363 CCACACTGTGCTTCTTAAGGGTGGCTAACTGACCAATGGAATCTTCCCTTCAAG 1422
 QY 1412 ATGTACCGGGGAAAGATTGTGTGCTGGGATGAAAGCAATTAATTAATGTCATATTGTG 1471
 Db 1423 ACTGTGTCAAGATGTGTATGTGTGGAGAGGAGGAAGATGACCCGCAAGTGTG 1482
 QY 1472 AACCTCAAAAGCAATTTAGTGTGTCAAGCAACAGGTATGATCAAAAATCGTGGCA 1531
 Db 1483 AGTCGCCAAAGCATTTCTGAGAGGAAGAGTGGCGCTGACCAAAAATGCAATGCTT 1542
 QY 1532 GTGTGCAAGTGGCCCGGTGCTGTGTGTATTAACCAAGCAATGTGATTAATTTGTTG 1591
 Db 1543 CGGCCCAATGACCCGATCTCCGTATGTATCTTCAACCAACATATGTGCGCTGA 1602
 QY 1592 TGAGTGTATATACCACTAACAAGTGTGATCTTAAAGCTTAAAGAGATGTAAAG 1651
 Db 1603 TTGACGGAGACTCAAGACCTTGAACACAGAGCCGTTGCAAGACCGATTTCAAT 1662
 QY 1652 TAAACTTTACATAGATGATGACCTGACATGGTTTACTTACAGAGCTGATGTACAAC 1711
 Db 1663 TTGAATCAACCGCGCTGTGATCATGACTTTGGAAAGTCAACCAAGAGGAAGTCAAG 1722
 QY 1712 AATGCTTAATGTGTATGACA 1736
 Db 1723 ACTTTTCCGTGGGCAAGATCA 1747

RESULT 4

US-08-475-391-1
 ; Sequence 1, Application US/08475391
 ; Patent No. 5786211
 ; GENERAL INFORMATION:
 ; APPLICANT: Johnson, Philip R.
 ; TITLE OF INVENTION: Adeno-Associated Virus Materials and
 ; TITLE OF INVENTION: Methods
 ; NUMBER OF SEQUENCES: 3
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
 ; STREET: 6300 Sears Tower, 233 S. Wacker Drive
 ; CITY: Chicago
 ; STATE: Illinois
 ; COUNTRY: USA
 ; ZIP: 60606
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent in Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/475,391
 ; FILING DATE: 07-JUN-1995
 ; CLASSIFICATION: 435
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/254,358
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: No. 5786211and, Greta E.
 ; REGISTRATION NUMBER: 35,302
 ; REFERENCE/DOCKET NUMBER: 31975
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (312) 474-6300
 ; TELEFAX: (312) 474-0448
 ; TELEX: 25-3856
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 4680 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single

STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.2
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/07178
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Noland, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 31975
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 4680 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US95-07178-1

Query Match	2.1%	Score 107.4	DB 5	Length 4680
Best Local Similarity	49.4%	Pred. No. 3.8e-18		
Matches 279	Conservative 0	Mismatches 286	Indels 0	Gaps 0

Qy	1172	AGCAGGTACTTGCACTTAAGAAAATAAATAGTAAATTTATTTATGTGCMAAACCTATG	1231
Db	1183	AGCCCGTGGAGGACATTTCCAGCAATCCGATTTTATTAATTTTGGACCTAAACGGGTACG	1242
Qy	1232	ATCCCTCTTTTAGTGGGTCAACATGTGTTAAGGTGATTTGACMAAAATATGTGTAATAAAA	1291
Db	1243	ATCCCAATATAGCGGCTTCCGCTTTCTGGGATGGGCCAGAAAAAGTTCCGCAAGAGGA	1302
Qy	1292	ACACCTGTGTTTAAACGGGCCCAACAGTACTGAAAAACAATTTGGCAATGGCTATGTG	1351
Db	1303	ACACCAATCTGGCTGTTTGGGCGTGCACCTAACGGGAAACCAATCGCGAGGCGCTATG	1362
Qy	1352	CTAAACCTGTACCACTGTATGTGAATGTGTGAATTTGAATATTAATAAATCTTTCATTATG	1411
Db	1363	CCCAACACTGTCCCTTTCTACCGGTGCGTAAACCTGAACTAGAACATTTTCCCTTCAACG	1422
Qy	1412	ATGTAGCGGGGAAAAAGTTTGGTGTCTGGAGTGAAGGCAATTTAATGCTACTATTTGG	1471
Db	1423	ACTGTGTGACAAAGTGTGATCTGTGGAGAGAGGGAGAGTGAACCGCCAAAGTCTGTGG	1482
Qy	1472	AAGCTGCAAAAGCCATTTTAAAGTGTCAAGCCAACCAAGGATGATCAGAAAAATGCGTGGCA	1531
Db	1483	AGTCGGCCAAAGCCATTTCTCGAGGAGAACGAAGTGCGGGTGGACCAAAAAATGCAAGTCTT	1542
Qy	1532	GTGTGGCAGTGCCTCGGTGTGCTGTGTGTTATPACCAAGATGTGACATTACATTTGTTG	1591
Db	1543	CGGCCAGATAGACCCGATCCCGGTGATGCTCACCTCCAACCAACATGTGCGCCGTGA	1602
Qy	1592	TGAGTGTGAATACCACTCAACCTGTGCATGCTAAAGCCCTTAAAGGAACGAGTGTGAAGC	1651
Db	1603	TTGACGGGAACTCAACGAACCTTGCAAACACGACACCGTTGCAAACCGGAGTGTCAAT	1662
Qy	1652	TAAACTTTACATATAGATGTAGCCCTGCACATGGTTTACTTACAGAGGCTGATGTACAAC	1711
Db	1663	TTGAACCTACCCGCGGTCTGGATATATGACTTTTGGGAAGGTCCACCAAGCAGAGAGTCAAG	1722
Qy	1712	ATATGGCTAATTTGGTGTATATGCACA	1736

Db 1723 ACTTTTTCGGTGGCAAGGATCA 1747

RESULT 7
US-08-331-384-2/c

GENERAL INFORMATION:

APPLICANT: Willeson, James M.
APPLICANT: Kelley, William M.

APPLICANT: Fisher, Krishna J.

TITLE OF INVENTION: Hybrid Ac

TITLE OF INVENTION: of use thereof
NUMBER OF SEQUENCES: 2

CORRESPONDENCE ADDRESS:

ADDRESSEE: Howson at

STREET: Spring House
CITY: Spring House

STATE: Pennsylvania

COUNTRY: USA

ZIP: 19477

```

; COMPUTER READABLE FORM
;
MEDIUM TYPE: FLOPPY

```

COMPUTER: IBM

OPERATING S

```

; SOFTWARE: PatentIn K
;
; TRIPENT APPLICATION DATA

```

CONSENT FEEDBACK DATA:
APPLICATION NUMBER: US/0

FILING DATE: _____ ;

CLASSIFICATION: 435

! MIJUNKBEI INFORMATION:
! NAME: Bak, Mary E.

REGISTRATION NUMBER: 31,215

REFERENCE/DOCKET NUMBER: UPNG1149052

TELEPHONE:

TELEFAX: 21

INFORMATION FOR SEQ ID NO: 2

SEQUENCE CHARACTERISTICS:
LENGTH: 4910 base pairs

TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: unknown
MOLECULE TYPE: CDNA

US-08-331-384-2

Query Match	2.1%;
Best Local Similarity	49.4%;

Best local similarity 45.4
Matches 279; Conservative

QY 1172 AGCAGTTACTTGCAT

Db 1654 AGCCCGTGGAGGAC

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

QY 1232 ATCCTCTTTA

1594-77

Query Match	2.1%;	Score 107.4;	DB 2;	Length 4910;
Best Local Similarity	49.4%;	Pred. No. 3.9e-18;		
Matches 279;	Conservative 0;	Mismatches 286;	Indels 0;	Gaps 0;

Qy	1172	AGCAGGTTACTGATTTAAAGAAAATTAATATGTAATATTTATGTGCTCAAACTATG	1231
Db	1554	AGCCCCGAGAGACATTTCCAGCAATCGGATTTATATAATTTTGGAACTAAACGGGTACG	1599
Qy	1232	ATCCTCTTTTAGTGGGTCAACATGTGTTAAGTGGATTTGACAAAAATGTGCTAATAAAAA	1291
Db	1594	ATCCCCAATATGCGGCTTCCGTCTTTCTGGGATGGGCCACGAAAAAGTTCCGCAAGAGA	1539
Qy	1292	ACACCCGTGGTATTACGGGCGACCAAGTACTGAAAAACAAATTGGCAATGGCTATTG	1351
Db	1534	ACACCACTGGCTGTTTGGGCTGTCAACTACCGGGAAGACCAACATCGCGGAGGCCATAG	1475
Qy	1352	CTAATACCTGTACCACTGTATGGAATGTGAATTGGAATATGAAAACTTTCCATTATATG	1411
Db	1474	CCCAACCTGGCCCTCTTACGGGTCCTAACTGACCAATGAGAACTTTCCCTTCAACG	1415
Qy	1412	ATGTAAGCGGGAAAAGTTTGTTGGTCTGGGATGTAAGCATTAATTAAGTCCACTATGTTGG	1471
Db	1414	ACTGTGTCCACAGATGTGTATCTGTGTGGAGGAGGAGGAAGTACCCGCCAAGTCTGTGG	1355
Qy	1472	AAGCTGCAAAAGCCATTTTAGTGTGTAGCCCAACCAAGGTATGATCAGAAAATGCGTGGCA	1531
Db	1354	AGTCGGCCAAAGCATTTCTGGAGGAGCAAGGTCCCGCTGGACCAAGAAATGCAAGTCTT	1295

QY 1532 GTGTGGCAGTCCCGGTGCTGTGTTATACAGCAATGTGACATTATTTGTG 1591
Db 1294 CGGGCCAGATAGACCCCACTCCCGTATCTCACAACCAACATGTGCCCCGTGA 1235
QY 1592 TGAAGTGAATACCACTACCACTGTGCTAAAGCTTAAAGAAAGGATGTAAGC 1651
Db 1234 TTGACGGGAACTCAACGACTTCAACACACGACGCGTTGCAAGACCGGATGTTCAAT 1175
QY 1652 TAAACTTACCAATGAATGTAGCCCTGACATGGGTTTACTAGAGAGCTGATGTACAC 1711
Db 1174 TTGAACCTACCCCGCTGTGATCATGACTTTGGAAAGGTACCAAGAGAACTCAAG 1115
QY 1712 AATGCTAACTTGTGTATGACACA 1736
Db 1114 ACTTTTCCGGTGGCAAGATCA 1090

RESULT 8

US-08-836-087-2/c
Sequence 2, Application US/08836087
Patent No. 5871982
GENERAL INFORMATION:
APPLICANT: Trustees of University of Pennsylvania
APPLICANT: Wilson, James M.
APPLICANT: Kelley, William M.
APPLICANT: Fisher, Krishna J.
TITLE OF INVENTION: Hybrid Adenovirus-AAV Vector and
TITLE OF INVENTION: Methods of Use Thereof
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: Howson and Howson
STREET: Spring House Corporate Cntr, PO Box 457
CITY: Spring House
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/836,087
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/331,384
FILING DATE: 28-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: GNVN.007PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-540-9200
TELEFAX: 215-540-5818
INFORMATION FOR SEQ. ID NO.: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 4910 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: unknown
MOLECULE TYPE: cDNA
US-08-836-087-2

Query Match 2.1%; Score 107.4; DB 2; Length 4910;
Best Local Similarity 49.4%; Pred. No. 3.9e-18;
Matches 279; Conservative 0; Mismatches 286; Indels 0; Gaps 0;

QY 1172 AGCAGGTTACTTGATTAAGAAATAGTAATATTATTATGTCACAAACTATG 1231
Db 1654 AGCCCGTGAAGACATTCACGAATCGATTATTAATTTTGAACCTAAACGGGTAG 1595

QY 1232 ATCTCTTTTATGNGGGTCAACATGTGTAAAGTGAATTGACAAAAATGTGTAAAAA 1291
Db 1594 ATCCCAATATGCGGCTTCCTCTTCTGTGGATGGGCCAGAAAAAGTTCCGCAAGAGA 1535
QY 1292 ACACCCCTGTGTTTACGGGGCCACCAAGTACTGAAAAAATTTGGCAATGGCTATG 1351
Db 1534 ACACATCTGGCTGTGTGGGGCTGCAATACGGGGAAGACCAACATCGGGAGCGCATG 1475
QY 1352 CTAAACTGTACCACTGTATGGAATGTGAATTTGAAATATGAAAATTTCATTATG 1411
Db 1474 CCACACTGTGCTTCTACGGGTGTGTAACCTGACCAATAGAACTTCCCTTCAAG 1415
QY 1412 ATGTACGGGGAAGAAATTTGTGTGTGCTGGAGTGAAGGCAATTATAGTCACTATTGTG 1471
Db 1414 ACTGTGTCAACATG 1355
QY 1472 AAGCTCAAAAGCCATTTTAAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGCA 1531
Db 1354 AGTGGCCAAAGCCATTTCTGGAGGAAGCAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1295
QY 1532 GTGTGCACTGCCCGGTGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1591
Db 1294 CGGCCAGATTAAGCCGACTCCCGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1235
QY 1592 TGAAGTGAATACCACTACCACTGTGCTAAAGCTTAAAGAAAGGATGTAAGC 1651
Db 1234 TTGACGGGAACTCAACGACTTCAACACACGACGCGTTGCAAGCGGATGTTCAAT 1175
QY 1652 TAACTTACCAATGAATGTAGCCCTGACATGGGTTTACTAGAGCTGATGTACAC 1711
Db 1174 TTGAACCTACCCCGCTGTGATCATGACTTTGGAAAGGTACCAAGAGAACTCAAG 1115
QY 1712 AATGCTAACTTGTGTATGACACA 1736
Db 1114 ACTTTTCCGGTGGCAAGATCA 1090

RESULT 9

US-09-246-320-2/c
Sequence 2, Application US/09246320
Patent No. 6251677
GENERAL INFORMATION:
APPLICANT: Trustees of University of Pennsylvania
APPLICANT: Wilson, James M.
APPLICANT: Kelley, William M.
APPLICANT: Fisher, Krishna J.
TITLE OF INVENTION: Hybrid Adenovirus-AAV Vector and
TITLE OF INVENTION: Methods of Use Thereof
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: Howson and Howson
STREET: Spring House Corporate Cntr, PO Box 457
CITY: Spring House
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/246,320
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/836,087
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: GNVN.007PCT
TELECOMMUNICATION INFORMATION:

Db 1114 ACTTTTCCGGTGGCAAGATCA 1090

RESULT 11

US-09-438-268-1/c
; Sequence 1, Application US/09438268
; Patent No. 6491907
; GENERAL INFORMATION:
; APPLICANT: Rabinowitz, Joseph E.
; APPLICANT: Samueli, Richard J
; APPLICANT: Xiao, Weidong
; TITLE OF INVENTION: VIRUS VECTORS AND METHOD OF MAKING AND ADMINISTERING
; TITLE OF INVENTION: THE SAME
; FILE REFERENCE: 5470-186
; CURRENT APPLICATION NUMBER: US/09/438,268
; CURRENT FILING DATE: 1999-11-10
; EARLIER APPLICATION NUMBER: 60/107,840
; EARLIER FILING DATE: 1998-11-10
; EARLIER APPLICATION NUMBER: 60/123,651
; EARLIER FILING DATE: 1999-03-10
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 1
; LENGTH: 7214
; TYPE: DNA
; ORGANISM: Virus
US-09-438-268-1

Query Match 2.1%; Score 107.4; DB 4; Length 7214;
Best Local Similarity 49.4%; Pred. No. 4.8e-18;
Matches 279; Conservative 0; Mismatches 286; Indels 0; Gaps 0;

Qy 1172 AGCAGGTACTTGATTAAGAAAATAAATAGTAAATTTATTTGTGCAAAACTATG 1231
Db 4009 AGCCCGTGAGAGACATTTCCAGCATCGATTTATAAATTTGGAACTAAAGGGTAGC 3950
Qy 1232 ATCCCTTTTAGTGGGTCAACATGTGTAAGTGATTTGACAAAATAATGTGTAAATAA 1291
Db 3949 ATCCCAATATGCGGCTTCCTGCTTTTGAGATGGCCAGAAAATTTGGCAAGAGA 3890
Qy 1292 ACAACCTGTGTTTACGGGCCAACAGTACTGAAAAACAATTTGGCAATGGCTATTG 1351
Db 3889 ACACCACTGCTGTGTTGGGCTGCACTACCGGGAAGACCAACATGCGGAGGCCATAG 3830
Qy 1352 CTAAAACTGTACCAAGTATGATGATGTAATGGAATTAATGAAAATTTCCATTATG 1411
Db 3829 CCACACTGTGCTCTTCTACGGGTGCGTAAACTGACCAATGAACTTTCCCTTCAAG 3770
Qy 1412 ATGTAGCGGGAAAAGTTTGTGTGCTGGATGAGGCAATTATTAAGTCACTATTGTG 1471
Db 3769 ACTGTGTGCAAGATGTGATCTGTGTGGAGAGAGGGAAGATGACCCCAAGTGTGG 3710
Qy 1472 AAGGTGAAAAGCCATTTTAGTGTGTCAGCCAACAGGGTATGATCAGAAAATGCGTGCA 1531
Db 3709 AGTCGCGCAAGCCATTCGCGAGAGAACAAAGTCCGCGTGCACAGAAATGCAAGTCT 3650
Qy 1532 GTGTGGAGTGGCCCGGTGTGCTGTGTTTAAACACCAANTGTGATTAACATTGTG 1591
Db 3649 CGGCGCAAGATGAGCCGATCTCCGTGTGCTGATCTTCAACCAACCAATGCGCCGTGA 3590
Qy 1592 TGAAGTAAATACCACTACCACTGTGATGCTAAAGCCTTAAAGGAAGATGTGTAAGC 1651
Db 3589 TTGACGGGAATCAAGACCTTGAACACCAAGCGCGTTGCAAGAGCGGATGTCAAT 3550
Qy 1652 TAAACTTTACATTAAGTGTAGCCTTGAACATGGGTTTACTTACAGAGCGTGTATCAAC 1711
Db 3529 TTGAATCTCAACCGCGCTGTGATCATGCTTTGGGAAGTCAACCAAGAGTCAAG 3470
Qy 1712 AATGGCTAATCTGTGTAATGACA 1736
Db 3469 ACTTTTCCGGTGGCAAGATCA 3445

RESULT 12

US-09-770-315-3
; Sequence 3, Application US/09770315
; Patent No. 6429001
; GENERAL INFORMATION:
; APPLICANT: Chiron Corporation
; TITLE OF INVENTION: Recombinant AAV Packaging Systems
; FILE REFERENCE: 20263-501
; CURRENT APPLICATION NUMBER: US/09/770,315
; CURRENT FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: US 60/178,536
; PRIOR FILING DATE: 2000-01-26
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 3
; LENGTH: 7557
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: recombinant DNA
US-09-770-315-3

Query Match 2.1%; Score 107.4; DB 4; Length 7557;
Best Local Similarity 49.4%; Pred. No. 4.9e-18;
Matches 279; Conservative 0; Mismatches 286; Indels 0; Gaps 0;

Qy 1172 AGCAGGTACTTGATTAAGAAAATAAATAGTAAATTTATTTGTGCAAAACTATG 1231
Db 1211 AGCCCGTGAGAGACATTTCCAGCATCGATTTATAAATTTGGAACTAAAGGGTAGC 1270
Qy 1232 ATCCCTTTTAGTGGGTCAACATGTGTAAGTGATTTGACAAAATAATGTGTAAATAA 1291
Db 1271 ATCCCAATATGCGGCTTCCTGCTTTTGAGATGGCCAGAAAATTTGGCAAGAGA 1330
Qy 1292 ACAACCTGTGTTTACGGGCCAACAGTACTGAAAAACAATTTGGCAATGGCTATTG 1351
Db 1331 ACACCACTGCTGTGTTGGGCTGCACTACCGGGAAGACCAACATGCGGAGGCCATAG 1390
Qy 1352 CTAAAACTGTACCAAGTATGATGATGTAATGGAATTAATGAAAATTTCCATTATG 1411
Db 1391 CCACACTGTGCTCTTCTACGGGTGCGTAAACTGACCAATGAACTTTCCCTTCAAG 1450
Qy 1412 ATGTAGCGGGAAAAGTTTGTGTGCTGGATGAGGCAATTATTAAGTCACTATTGTG 1471
Db 1451 ACTGTGTGCAAGATGTGATCTGTGTGGAGAGGGAAGATGACCCCAAGTGTGG 1510
Qy 1472 AAGGTGAAAAGCCATTTTAGTGTGTCAGCCAACAGGGTATGATCAGAAAATGCGTGCA 1531
Db 1511 AGTCGCGCAAGCCATTCGCGAGAGAACAAAGTCCGCGTGCACAGAAATGCAAGTCT 1570
Qy 1532 GTGTGGAGTGGCCCGGTGTGCTGTGTTTAAACCAAGATGTGATTAACATTGTG 1591
Db 1571 CGGCGCAAGATGAGCCGATCTCCGTGTGCTGATCTTCAACCAACATGTGCGCGTGA 1630
Qy 1592 TGAAGTAAATACCACTACCACTGTGATGCTAAAGCCTTAAAGGAAGATGTGTAAGC 1651
Db 1631 TTGACGGGAATCAAGACCTTGAACACCAAGCGCGTTGCAAGAGCGGATGTCAAT 1690
Qy 1652 TAAACTTTACATTAAGTGTAGCCTTGAACATGGGTTTACTTACAGAGCGTGTATCAAC 1711
Db 1691 TTGAATCTCAACCGCGCTGTGATCATGCTTTGGGAAGTCAACCAAGAGTCAAG 1750
Qy 1712 AATGGCTAATCTGTGTAATGACA 1736
Db 1751 ACTTTTCCGGTGGCAAGATCA 1775

RESULT 13

US-09-438-268-2
; Sequence 2, Application US/09438268
; Patent No. 6491907
; GENERAL INFORMATION:
; APPLICANT: Rabinowitz, Joseph E.

Qy	1172	AGCAGGTACTGTGATTAAAGAAAAATAAAATAGTAAATTTATATGTGTCAAACTATG	1233
Db	1113	AGCCCGTGGAGACATTTCCAGCAATCGGATTTATAAAAATTTTGGAACTAAACGGGTACG	1172
Qy	1232	ATCTCTTTTATAGTGGGTCAACATGTGTTTAGGTGGATTGACAAAAATATGTGTAAAAAA	1291
Db	1173	ATCCCCAATATACGGCTTCCGTCCTTTCTGGGATGGGCCACAGAAAAAGTTCCGCAAGAGGA	1232
Qy	1292	ACACCCGTGTGTTTACGGGCCACCAAGTACTGCAAAAACAAAATTTGGCAATGGCTATTG	1351
Db	1233	ACACCACTGTGGCTTTTGGGGCTGTGCATACCGGGAGAACCAACATCGCGAGGCCATATG	1292
Qy	1352	CTAAACCTGTACAGTGTATGGAATGTGGAATTTGGAAATATGAAACCTTCATTTATATG	1411
Db	1293	CCCACTGTGCCCTTTCTACGGGTGCGTAACTGGACCAATGAGAACTTTCCCTTCAACG	1352
Qy	1412	ATGTAGCGGGGAAAAAGTTTGGTGTCTGGGATGAAAGCATTTATTAAGTCACTATTGTGG	1472
Db	1353	ACTGTGTGCAACAAGTGGTGTATCTGTGTGGAGAGGGGGAAGATGACCGCCAAAGTCTGTG	1412
Qy	1472	AAGCTGCAAAAGCCATTTTAGGTGTCAGCCAACCAAGGTTGATGAGAAAAATGCGTGCA	1531
Db	1413	AGTGGGCCAAAGCCATTTCTCGAGGAGAACCAAGTGTGCGGTGGACCAAGAAATGCAAGTCTT	1472
Qy	1532	GTGTGGCAGTCCCGGTGTGTGCTGTGTGTATTAACAGAAATGTGTACATTATTTGTTG	1591
Db	1473	CGGCCCCAGATAGACCCGACTCCCGGTGATGTGTCACTTCACAAACCAACATGTGTGCGCGTGA	1532
Qy	1592	TGAATGTGTAATACCACTTACAACCTGTGCATGTCTTAAAGCCTTAAAGGAACGATGTGTAAGC	1651
Db	1533	TTGACGGGGAATCAACACACTTTGCAGAACCAAGCAGCCGTTTGCAGAGACCGGATGTTCAAT	1592
Qy	1652	TAAACTTTACCAATAGATGATAGCCCTGACATGGGTTTATCTTACAGAGGCTGATGTACAAC	1711
Db	1593	TTTGAACTCACCGCGCTGTGATCATGACTTTGGGAAGTGTACCAACGACAGAAATGTCAAG	1652
Qy	1712	AATGTGTAATCTTGTGTATATGCAAC	1736
Db	1653	ACTTTTTCGGGTGGCAAAAGGATCA	1677

```

; TITLE OF INVENTION: THE SAME
; FILE REFERENCE: 5470-186
; CURRENT APPLICATION NUMBER: US/09/438,268
; CURRENT FILING DATE: 1999-11-10
; EARLIER APPLICATION NUMBER: 60/107,840
; EARLIER FILING DATE: 1998-11-10
; EARLIER APPLICATION NUMBER: 60/123,651
; EARLIER FILING DATE: 1999-03-10
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 8179
; TYPE: DNA
; ORGANISM: Virus
US-09-438-268-5

Query Match      2.1%; Score 107.4; DB 4; Length 8179;
Best Local Similarity 49.4%; Pred. No. 5.2e-18;
Matches 279; Conservative 0; Mismatches 286; Indels 0; Gaps 0;

Qy 1172 AGCAGTTACTTGTCATTAAGAAATAAATAGTAAATATTATTTGTGTCAAAACTATG 12311
Db 1113 AGCCCGTGAGAGACATTTCCAGCAACATCGATTTTAAATTTTGCACATAACGGGTACG 11727
Qy 1232 ATCCTCTTTAAGTGGGTCACACATGTGTAAAGTGAGATGACAAATAATGTGTAAATAA 1291
Db 1173 ATCCCAATATGCGCGCTCCGTCTTCTTGGAATGGGCGACGAAAAAGTTTCGCAAGAGA 12322
Qy 1292 ACACCCGTGTGTTTAAACGGGCGACCAAGTACTGGAAAAACAATTTGGCAATGCTATTG 1351
Db 1233 ACACCATCTGCTGTCTTTGGGCTCTGCACATACCGGAAAGACCAACATCGCGAGGCCATAG 1292
Qy 1352 CTAAACCTGTACCAAGTGTATGAAATGTGTGAATTTGAAATTAAGAAACTTTTCATTATG 1411
Db 1293 CCCACACTGTGCCCCCTTCTACCGGGTGCGTAAACTGTGACCAATGAGAACTTTCCTTCAAG 1352
Qy 1412 ATGTAGCGGGGAAAAAGTTTGTGTGTCTGGGATGAAGCATTTATTAAGTCCACTATTGTG 14711
Db 1353 ACTGTGTGCAACAAGATGTGATCTGTGTGGAGAGGAGGAAAGATGACCGCCAAAGTCTGTG 1412
Qy 1472 AAGCTGCAAAAAGCATTTTAAAGTGTGTCAGGCCAACAGGATGATCAGAAAAATGCGTGCA 1531
Db 1413 AGTGTGCGCAAAAGCATTTCTCGAGAGAAAGCAAGGTGCGCGTGACCAAGAAATGCAAGTCT 14727
Qy 1532 GTGTGGCAGTGCCCGGTGTGCTCTGTGTGTTAAACAGCAATGTGTGATTAATTTGTTG 1591
Db 1473 CGGCGCAGATTAAGACCGGACTCCGTGTATGTCTCAACACCAACATGTGCGCCGTGA 15322
Qy 1592 TGAAGTGTAAATACCATACTAACAATGTGTGATCTTAAGCCTTAAAGAAACGATGTAAAC 1651
Db 1533 TTGACGGGAACTCAACACACTTTCGAAACACCAAGCAGCGGTGCAAGACCGGATGTTCAAT 15922
Qy 1652 TAAACTTACCATTAAGATGAAGCCCTGACAGATGGGTTTACTTACGAGAGGTGATGAAC 17111
Db 1593 TTGAATCTACCCCGCGTGTGAATATGATCTTTGGAAAGTGTACCAAGCAGAGAGTCAAG 16522
Qy 1712 AATGGCTAATCTGTGTAAATGCA 1736
Db 1653 ACTTTTCCGGTGGGCAAAAGATCA 1677

RESULT 15
US-09-770-315-2
; Sequence 2, Application US/09770315
; Patent No. 6423001
; GENERAL INFORMATION:
; APPLICANT: Chiron Corporation
; TITLE OF INVENTION: Recombinant AAV Packaging Systems
; FILE REFERENCE: 20263-501
; CURRENT APPLICATION NUMBER: US/09/770,315
; CURRENT FILING DATE: 2001-01-26
; PRIOR APPLICATION NUMBER: US 60/178,536
; PRIOR FILING DATE: 2000-01-26

```

```

; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 8698
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: recombinant DNA
US-09-770-315-2

```

```

Query Match      2.1%; Score 107.4; DB 4; Length 8698;
Best Local Similarity 49.4%; Pred. No. 5.3e-18;
Matches 279; Conservative 0; Mismatches 286; Indels 0; Gaps 0;

```

```

QY 1172 AGCAGTTACTTCATTAAAGAAATATAAATAGTAATAATTAATTATTTGTCTCAAACTATG 1231
DB 1183 AGCCCGTGAGGACATTTCCAGCAATCGATTTATTAATTTTGGAACTAAACGGGTACG 1242
QY 1232 ATGCTCTTTAGTGGGTCAACATGTGTAGGTGATGACAAAAAATGTGTAAAAAA 1291
DB 1243 ATCCCAATATGCGGCTTCGCTTCTGTGGATGGCCACGAAAAAGTTCCGCAAGAGGA 1302
QY 1292 ACAACCTGTGTTTACGGGCAACAAGTACGAAAAAATTTGGCAATGCTATTG 1351
DB 1303 ACACCATCTGGCTGTTTGGGCTCGCAACTACCGGAAAGACCAACATCGGAGGCGCATG 1362
QY 1352 CTAAACTGTACAGTATGGAATGTGAATTTGGAATATGAAAACTTCCATTTAATG 1411
DB 1363 CCCACACTGTGCCCTTCTACGGGTGCTGAATGGAACCAATGAACTTTCCCTTCAACG 1422
QY 1412 ATGTAGCGGGGAAAGTTTGTGTGTCTGGGATGAAAGCATTAATTAGTCACTAATTGTG 1471
DB 1423 ACTGTGTGACAAAGATGTGATCTGTGTGGAGAGGGAAGATGACCGCCAAAGGTGCTGG 1482
QY 1472 AAGCTGCAAAAGCCATTTTAGTGTCTAGCCACACGAGGTAGATCAGAAAAATGCGTGGCA 1531
DB 1483 AGTCGGCCAAAGCCATTCTCGAGGAACAAAGTGTGCGGTGACCAAAATGCAAGTCTT 1542
QY 1532 GTGTGGCAGTGCCTCGGTGTCTGTGTATTAACCAAGCATGTGACATTACATTTGTG 1591
DB 1543 CGGCCCAATGACCCGACTCCCGTGTGATCTGACCTCCAAACCAACATGTGCGCGTGA 1602
QY 1592 TGAAGTAAATACCACTTACACTGTGCAATGCTAAAGCCTTAAAGGAAGGATGTAAAGC 1651
DB 1603 TTGACGGGAACCTCAACGACCTTGGAACACGACGACCGCTTGCAAGACCGATGTCAAA 1662
QY 1652 TAACTTTACATAAGATGATAGCCCTGACATGSGTTTACTTACAGAGGCTGATGTACAAC 1711
DB 1663 TTGAATCTACCCGCGCTGTGATCATGCTTTGGGAAGTCAACCAAGCAGGAAGTCAAG 1722
QY 1712 AATGCTAACTTGTGTATATGACA 1736
DB 1723 ACTTTTCCGTTGGCAAGATCA 1747

```

Search completed: April 21, 2004, 15:49:40
Job time : 322 secs

Qy	288	CTAAGTAAAGGATTTATTAACCTTTAAATTTACTAACAAGGAGCTATTTGGGGTCT	347
Db	181	CTAAGTAAAGGATTTATTAACCTTTAAATTTACTAACAAGGAGCTATTTGGGGTCT	240
Qy	348	CTTGCACATTTCTCTAAACATTTGCGACCTGCTAATGATTAAGTGTGCTTAAAGCT	407
Db	241	GGTTAAAGTTTCTTCTAAATGTTCTGAGCTGCTAAGATTAAGTGTGCTTAAAGCT	300
Qy	408	AGAATTAAATCTTCTGACCTGGGAAACCTTAACCTTAACAGATTAAGGCAATTA	467
Db	301	GGATTTAAAGCTTCTGACCTGGGAAACCTTAACCTTAACAGATTAAGGCAATTA	360
Qy	468	TTTAAGGAGTGTGCTTCTTAACCTTTAACTGCGGGGCGCTTAAGAGTGTGCTTA	527
Db	361	CTTAAGGAGTGTGCTTCTTAACCTTTAACTGCGGGGCGCTTAAGAGTGTGCTTA	420
Qy	528	CTTTTTCAGAGTGAATGTAACAATTGAGGAGGCTATCAATTCATGATTAAGTATGG	587
Db	421	CTTTTTCAGAGTGAATGTAACAATTGAGGAGGCTATCAATTCATGATTAAGTATGG	480
Qy	588	TGGTCCAGGACTAATATCTTAAGAACTTAACTGTGTGCGTAGAAGGTTTAAATTAATG	647
Db	481	GGGGCCAGGTTTAAACCCAGAAACCTCAAGTGTGTGAGAGGGCTTAAATTAATG	540
Qy	648	TCCTTACCATCTTGTAACTGAAGTGTAACTTAAATTTTGGCAGGAGATGACTACAA	707
Db	541	ACTTTATCACTTGTAACTGAAGTGTAACTTAAATTTTGGCAGGAGATGACTACAA	600
Qy	708	AGGAAATATTTTAAAGATGAGAGAGAGCTTTAAAGAAATTAAGTAAAGAAATATTC	767
Db	601	AGGAAATATTTTAAAGATGAGAGAGAGCTTTAAAGAAATTAAGTAAAGAAATATTC	660
Qy	768	TTTAAATGTTGTGTGTGTGTAAACAATTGAGAGGATTAATACCTGTATTTCCG	827
Db	661	TTTAAATGTTGTGTGTGTGTAAACAATTGAGAGGATTAATACCTGTATTTCCG	720
Qy	828	CTCTTTTGGCAGGAGCTTGTCAATGCTTAAAGAAACCCCGCATTAAGCAATACAGACAG	887
Db	721	TACTTTTAAAGAGGAGCTTGTCAATGCTTAAAGAAACCCCGCATTAAGCAATACAGACAG	780
Qy	888	TGCTAAATGAAGCTGGGAGTCTAAGTGTGAGGGGAGATTTGTGCTATTTGCTGG	947
Db	781	TACTAAATGAAGCTGGGAGTCTAAGTGTGAGGGGAGATTTGTGCTATTTGCTGG	840
Qy	948	AAAGGGAACAAGGCGGCTTAAAGTTCAACCATGATTAATTTGCTATGTAAGAAACAG	1007
Db	841	GAAGGGAACAAGGCGGCTTAAAGTTCAACCATGATTAATTTGCTATGTAAGAAACAG	900
Qy	1008	AGTATTTAACTGAAGTAAATGAATTAAGTGAATTTAAACCAATATCTTTATTAAGTAA	1067
Db	901	AGTATTTAACTGAAGTAAATGAATTAAGTGAATTTAAACCAATATCTTTATTAAGTAA	960
Qy	1068	CAGTACAGTGGCAGCTTTCAAATTCAAAGTGCCTTAAAGTTAGCTATTTAAAGCTAC	1127
Db	961	TAGTACAGTGGCAGCTTTCAAATTCAAAGTGCCTTAAAGTTAGCTATTTAAAGCTAC	1020
Qy	1128	TAACTTAAGTAAACCTAAGTCAATCTTGTATCACTTGAAGCTTTGAGAGCTTACAT	1187
Db	1021	TAACTTAAGTAAACCTAAGTCAATCTTGTATCACTTGAAGCTTTGAGAGCTTACAT	1080
Qy	1188	TAAAGAAAAATTAATTAATTTATTTGTGTCAAACTATGATCTCTTTTAAAGTGG	1247
Db	1081	TAAAGAAAAATTAATTAATTTATTTGTGTCAAACTATGATCTCTTTTAAAGTGG	1140
Qy	1248	TCAACATGTGTAAAGTGAATGACAAAAATGATGATTAAGTAAACACCTGTGTGTTTA	1307
Db	1141	GCAGCATGTGTAAAGTGAATGACAAAAATGATGATTAAGTAAACACCTGTGTGTTTA	1200
Qy	1308	CGGCGCAACCAATGTAAGTGAACCAATTTGCAATGCTATTTGCTAAATCTGAACAGT	1367
Db	1201	TGGCGCGCAACCAATGTAAGTGAACCAATTTGCAATGCTATTTGCTAAATCTGAACAGT	1260

Qy	1368	GTATGAAATGAGGATTTGGAATTAATGAATCTTTCCATTTAAATGATGACGGGAAAAG	1427
Db	1261	ATATGGAATGATTTAACTGGAATTAATGAATCTTTCCATTTAAATGATGACGGGAAAAG	1320
Qy	1428	TTTGTGTGTCTGGGATGAAGGCAATTTAAATGCTCAATATTTGGAAGCTGCAAAAGCAT	1487
Db	1321	CTTGTGTGTCTGGGATGAAGGCAATTTAAATGCTCAATATTTGGAAGCTGCAAAAGCAT	1380
Qy	1488	TTTAAATGATGAGGCAACCAAGGATTAATGAATATGCTGTGCAATGTTGCAAGTCCG	1547
Db	1381	TTTAAATGATGAGGCAACCAAGGATTAATGAATATGCTGTGCAATGTTGCAAGTCCG	1440
Qy	1548	TGTGCTGTGTGTTTAAACCAAGATGATCAATTTGTGTGATGTTGATTAATCAAC	1607
Db	1441	AGTACTGTGTGTTTAAACCAAGATGATCAATTTGTGTGATGTTGATTAATCAAC	1500
Qy	1608	TAAACATGATGCTTAAAGGCTTAAAGGAAAGGATGATTAAGTAAAGCTTAAACATTAAG	1667
Db	1501	AAACATGATGCTTAAAGGCTTAAAGGAAAGGATGATTAAGTAAAGCTTAAACATTAAG	1560
Qy	1668	ATGTAAGCTTGAATGAGGTTTAACTTAAGAGGCTGATTAACAAGGCTTAACTTGGT	1727
Db	1561	ATGTAAGCTTGAATGAGGTTTAACTTAAGAGGCTGATTAACAAGGCTTAACTTGGT	1620
Qy	1728	TAAATGCAAAAGCTGAGGCAATTAAGAACTGCGCAATTAACATTAATTTCCG	1787
Db	1621	TAAATGCAAAAGCTGAGGCAATTAAGAACTGCGCAATTAACATTAATTTCCG	1680
Qy	1788	TGGAATTAATGCAAGATGCTTCAACCCAGATCTGCAACCAACCCCATTTGTCCAGACAC	1847
Db	1681	TGGAATTAATGCAAGATGCTTCAACCCAGATCTGCAACCAACCCCATTTGTCCAGACAC	1740
Qy	1848	CAGTATCAACAGATGATGATTAAGTCTGGAAGATCTGAGAACTGAGTAAAGCCTTTTGA	1907
Db	1741	CAGTATCAACAGATGATGATTAAGTCTGGAAGATCTGAGAACTGAGTAAAGCCTTTTGA	1800
Qy	1908	CCTCATCACTCAAGGCTTGAACCAATGAAACCCCGGCTGATGAGGCGGCTGCTGG	1967
Db	1801	CCTCATCACTCAAGGCTTGAACCAATGAAACCCCGGCTGATGAGGCGGCTGCTGG	1860
Qy	1968	GACCAATTCAGAGATTAATTTGTGGAAGCCGATTTCTTCCGAATGATGAGCGGCTC	2027
Db	1861	GACCAATTCAGAGATTAATTTGTGGAAGCCGATTTCTTCCGAATGATGAGCGGCTC	1920
Qy	2028	GTGGAGGAACTTTTAAACGCGCTTGCATCAATGTTGTGTAACCTTTAAAGTGGGCT	2087
Db	1921	GTGGAGGAACTTTTAAACGCGCTTGCATCAATGTTGTGTAACCTTTAAAGTGGGCT	1980
Qy	2088	TGAATTTGATGAGGATGATGAGGAGATTTGCTGTTGTGTGTGGAACATTAATTAACA	2147
Db	1981	TGAATTTGATGAGGATGATGAGGAGATTTGCTGTTGTGTGTGGAACATTAATTAACA	2040
Qy	2148	CAGTGGGAGGCTTGGGCTTTGCTCAATGTTAAATGATGAGGATTTGATTAAGTGG	2207
Db	2041	TAGTGGGAGGCTTGGGCTTTGCTCAATGTTAAATGATGAGGATTTGATTAAGTGG	2100
Qy			

Db 2341 TTCAATATTAAGAATCATTTATTAATTTCTTTAGTAAATCCCTGAGAAACCCATCCT 2400
 Qy 2508 CTTTATTTGACCTTATGCTGCGATTAATTAAGTAACTTAAATACTCCAGACCTATTA 2567
 Db 2401 CTTTGTGTAAGTTGCTGTAATTAATACTTAAATCTCCAGACTTAATA 2460
 Qy 2568 GTGATCATTTTCAGAGCAGTGAAGTATCTGACCAACCCCAAGCCTTATCATCCAGTA 2627
 Db 2461 GTGATCATTTTCAGAGCAGTGAAGTATCTGACCAACCCCAAGCCTTATCATCCAGTA 2520
 Qy 2628 ACAGTATGAGAACTTGAAGAGAAATCAGTATATCTAGTGAAGACTTACACAAAGC 2687
 Db 2521 GAGTATGAGAACTTGAAGAGAAATCAGTATATCTAGTGAAGACTTACACAAAGC 2580
 Qy 2688 CTGGGCAAGTACATCAATTAACCGGTACTAATTTGTTGGGCGCTGGCAATGAGTAC 2747
 Db 2581 CTGGGCAAGTACATCAATTAACCGGTACTAATTTGTTGGGCGCTGGCAATGAGTAC 2640
 Qy 2748 AAGCTGGGCGCTGGCAAGTACATCAATTTGTTGGGCGCTGGCAATGAGTAC 2807
 Db 2641 AAGCTGGGCGCTGGCAAGTACATCAATTTGTTGGGCGCTGGCAATGAGTAC 2700
 Qy 2808 GCCAATTTGCTAAGTTGGGAATTAATCTTATACATTTGAGACGTAGACAGTAAAGAT 2867
 Db 2701 GCCAATTTGCTAAGTTGGGAATTAATCTTATACATTTGAGACGTAGACAGTAAAGAT 2760
 Qy 2868 TGTATAAATAATTAATAATAAGAAACAGGGTTTCAAGCAAGCAAGTAAAGTAACTTTA 2927
 Db 2761 TGTATAAATAATTAATAATAAGAAACAGGGTTTCAAGCAAGCAAGTAAAGTAACTTTA 2820
 Qy 2928 CTTTAAAGGTGAGCTGGCGCTGGGCGAATTTTCAAGGAAGTTTACGGAAAGTGGCCG 2987
 Db 2821 CTTTAAAGGTGAGCTGGCGCTGGGCGAATTTTCAAGGAAGTTTACGGAAAGTGGCCG 2880
 Qy 2988 CGTACAACGCTCAGAAATAATCCCGACATGACTTCAAGTAACTTCAAGAAACCGACA 3047
 Db 2881 CTTACAACGCTCAGAAATAATCCCGACATGACTTCAAGTAACTTCAAGAAACCGACA 2940
 Qy 3048 CTGGTGACGGCGGGGAGTGAACCTTACAAATAAGCAAGTGAAGTGAAGGGCTTACAT 3107
 Db 2941 CTGGTGACGGCGGGGAGTGAACCTTACAAATAAGCAAGTGAAGTGAAGGGGGCTTAC 3000
 Qy 3108 TTACGTGATATCTGTAAGGTATCAATCTTCAAGCAATTTTAACTTCAATGATCAG 3167
 Db 3001 TTACGTGATATCTGTAAGGTATCTTCAAGCAATTTTAACTTCAATGATCAG 3060
 Qy 3168 AGCATCATTAAGTGTCTCTCCAGCAGTATGAGTCCCAATGATGAGGAAAG 3227
 Db 3061 AGCATCATTAAGTGTCTCTCCAGCAGTATGAGTCCCAATGATGAGGAAAG 3120
 Qy 3228 AGGCAAAAGTGAATTAATGATCCCAATTAAGGGTACTCTCCGTGAGATCTTAC 3287
 Db 3121 AGGCAAAAGTGAATTAATGATCCCAATTAAGGGTACTCTCCGTGAGATCTTAC 3180
 Qy 3288 ATTATTAAGTTTAAATTTGTTTCTCAGCAATGAGTTTCAAGCAATTAAGTAAAT 3347
 Db 3181 ATTATTAAGTTTAAATTTGTTTCTCAGCAATGAGTTTCAAGCAATTAAGTAAAT 3240
 Qy 3348 ATGATGATATGATCCAGATGCTTTAACTGTAATCTATTTCAAGAAATGCTGTAAGATG 3407
 Db 3241 ATGATGATATGATCCAGATGCTTTAACTGTAATCTATTTCAAGAAATGCTGTAAGATG 3300
 Qy 3408 TCAACAGCAAAACAGAGAGGTGTCAGATTAAGTGAACAGCAAGAGCTTTGTGA 3467
 Db 3301 TCAACAGCAAAACAGAGAGGTGTCAGATTAAGTGAACAGCAAGAGCTTTGTGA 3360
 Qy 3468 TGTATGATGATCAATGATATTAATCAATATGATGATGATGATGATGATGATGATGATG 3527
 Db 3361 TGTATGATGATCAATGATATTAATCAATATGATGATGATGATGATGATGATGATGATG 3420
 Qy 3528 CTCAGAACTGCCAATTTGGGTTTACTTTCCCGCCAGATATGCTTAACTTAAAGTATG 3587

Db 3421 CCCAGAACTTCCATTTTGGGTATTAATTTCCCTCAATACGCTTACTTAACAGTAGAG 3480
 Qy 3588 AAGTAAACACAGAGAAATTTAGAGAGAGCAAGAAATAATGGCTAGGAAGATCAGCTT 3647
 Db 3481 ATGTAACACAGAGAAATTTCTGAGACAGCAAAATAATGGCAAGTGAAGATCAGCAT 3540
 Qy 3648 TTTATGTTTGAAGACAGTTCATTTGAATCTTTGGGTATCAGGGGATCTGCCATATGT 3707
 Db 3541 TTTATGTTTGAAGACAGTTCATTTGAATCTTTGAGTATCAGAGGATGACAGCAATATGT 3600
 Qy 3708 CTTACAAATTTCCAGCTGTCGCCCAAGAACTTGAAGGCTGACCAATTTTATG 3767
 Db 3601 CTTATTAAGTTTCTCCAGTGCCCGCAAGAAATTTAGAGGCTGACCAATTTATG 3660
 Qy 3768 AATATGAACCCCTTATGAGTTCGTTTCTGTTAGGGGTACTGACATTTAGAGGGAGC 3827
 Db 3661 AATATGAACCCCTTATGAGTTCGTTTCTGTTAGGGGTACTGACATTTAGAGGGAGC 3720
 Qy 3828 CTTAATTTAGATCATTTGACACAGAGAACCAAGCAATTCAGCCCAAACTTTATGCTG 3887
 Db 3721 CAATAATTTAGATCATTTGACACAGAGAACCAAGCAATTCAGCCCAAACTTTATGCTG 3780
 Qy 3888 GGCACATTAATTAATTAATGATGTTCAAGAAAGAGAGCAATTTCTTAATCAGGTGCTGA 3947
 Db 3781 GGCACATTAATTAATTAATGATGTTCAAGAAAGAGAGAGCAATTTCTTAATCAGGTGCTGA 3840
 Qy 3948 AAGCCCTTACGGGGCTTAATGATGAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 4007
 Db 3841 AAGCCCTTACGGGGCTTAATGATGAGTGAAGTGAAGTGAAGTGAAGTGAAGTGAAG 3900
 Qy 4008 GGCAGATCTGACCATACATCACTGAGGACATGTAATATGTTTACAGAAATAATG 4067
 Db 3901 GGCAGATCTGACCATACATCACTGAGGACATGTAATATGTTTACAGAAATAATG 3960
 Qy 4068 CCAATTTCAATGACAAACCACTTAATGAATGCTGAAGCAAGATATGACAAAGG 4127
 Db 3961 CCAATTTCAATGACAAACCACTTAATGAATGCTGAAGCAAGATATGACAAAGG 4020
 Qy 4128 TAGGAATTTTCAATGAATGAATGAATGAATGAATGAATGAATGAATGAATGAATGA 4187
 Db 4021 TAGGAATTTTCAATGAATGAATGAATGAATGAATGAATGAATGAATGAATGAATGA 4080
 Qy 4188 CATACCTTCCCTAATTAAGGAACCAACCAATACACAGCAATTTGAACGCTCTTATG 4247
 Db 4081 CATACCTTCCCTAATTAAGGAACCAACCAATACACAGCAATTTGAACGCTCTTATG 4140
 Qy 4248 TGGGCTCTGTTGGAACAGAAAGCTTCTCAATGAAGTCAAGCTGAGTGAATTC 4307
 Db 4141 TGGGCTCTGTTGGAACAGAAAGCTTCTCAATGAAGTCAAGCTGAGTGAATTC 4200
 Qy 4308 CTAACTTAATGACATGTTTAAATCAATTTGCAAGCCCTTAAAGCGGTGGGTGGATC 4367
 Db 4201 CAAATTTAGATGACATGTTTAAATCAATTTGCAAGCCCTTAAAGCGGTGGGTGGATC 4260
 Qy 4368 AACCAACCCCTCAATATTTTAAATTAATCAACCAAGTGGGCAATTTGAGGTATTA 4427
 Db 4261 AACCAACCCCTCAATATTTTAAATTAATCAACCAAGTGGGCAATTTGAGGTATTA 4320
 Qy 4428 AATCAATGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4487
 Db 4321 AATCAATGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4380
 Qy 4488 CTTTAAATTTGGAACCTCGAAAGGCTTGAAGGTGGAATTTCCCAAGCTGAGGTTATC 4547
 Db 4381 CATTTAATTTGGAACCTCGAAAGGCTTGAAGGTGGAATTTCCCAAGCTGAGGTTATC 4440
 Qy 4548 CTCCTATGAGCTGAGTCAATTTTCAATATGATCTGATGACCCCAAGTACAGATGCA 4607
 Db 4441 CCCCAGACGAGAGGTCAATTTTCAATATGATCTGATGACCCCAAGTACAGATGCA 4500
 Qy 4608 AGCAACACACAGACAGATATGAAGCTTGAAGATTTGGAATGCTGCCAAAGCCGTG 4667
 Db 4501 AACCAACACACAGACAGATATGAAGCTTGAAGATTTGGAATGCTGCCAAAGCCGTG 4560

Qy 4668 TGACCCATGTAACATTCCTCCACCGGTCTCTACAGCAGAAACGCTACCCAGCCCA 4727
Db 4661 TGACCCATGTAACATTCCTCCACCGGTCTCTACAGCAGAAACGCTACCCAGCCCA 4620
Qy 4728 CCGTGGCCGCGCAGATTAATATGAGCCCTCCCAATATCCCGTACGCAACC 4777
Db 4621 CCAGTACCAACCCAGACGTATACCGCCCTCTCTATACCTATTAAGACACC 4670

RESULT 2
US-10-187-253A-23
Sequence 23. Application US/10187253A
Publication No. US20030170612A1
GENERAL INFORMATION:
APPLICANT: Shyamala, Venkatakrishna
APPLICANT: Pichanthes, Sergio
TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
FILE REFERENCE: CHIR-17194/03US / PP17194.004
CURRENT APPLICATION NUMBER: US/10/187,253A
NUMBER OF SEQ ID NOS: 92
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 23
LENGTH: 4678
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: 4.7 kbp PCR fragment
US-10-187-253A-23

Query Match 72.1%; Score 3626; DB 15; Length 4678;
Best Local Similarity 86.2%; Pred. No. 0;
Matches 4026; Conservative 0; Mismatches 635; Indels 9; Gaps 1;

Qy 117 CCGGCTTATGCAATTAAGCGGCGCATGTTAATGTTATTTAATTTAATGCAAC 176
Db 1 CCGGCTTATGCAATTAAGCGGCGCATGTTAATGTTATTTAATTTAATGCAAC 176
Qy 177 GCTTACGCTTACTAGGCGCGGAGTTAGCGCGGTATTAAGACCTGCG-----T 227
Db 61 TTGTAACGGTTAAATGCGCGGAGCTAGGAGACATACAGTATATATACAGACACT 120
Qy 228 TCCCGACACTTTCTTTCTGCTGCTTTTATGCTGAACTCACTGCTGCTTTCGCTG 287
Db 121 GCGGAGCTCTTTCTTTCTGCTGCTTTTCTGCTGCTTCTGCTGCTTCTGCTGCTG 180
Qy 288 CTAACTAACAGGATTTTATCTAATCTTTAATTTAATTTAATGAGCTATTTGCGGTGT 347
Db 181 CTAACTAACAGGATTTTATCTAATCTTTAATTTAATTTAATGAGCTATTTGAGGGGT 240
Qy 348 CTGACACTTCTCTTAACTTCTGACTGTGCTAACTGATTAATGATGCTGCTGCTGCT 407
Db 241 GCTTCAAGTCTCTTAACTTCTGACTGTGCTAACTGATTAATGATGCTGCTGCTGCT 300
Qy 408 AGACTTAACTTCTGACTGTGCTAACTGATTAATGATGCTGCTGCTGCTGCTGCT 467
Db 301 GGAATTTAGACACTTCTGACTGTGCTAACTGATTAATGATGCTGCTGCTGCTGCT 360
Qy 468 TTTAAGAGGTTGCTTCTTAACTTCTGACTGTGCTAACTGATTAATGATGCTGCTGCT 527
Db 361 CTTAAGAGGTTGCTTCTTAACTTCTGACTGTGCTAACTGATTAATGATGCTGCTGCT 420
Qy 528 CTTTCTTCAAGTGAATGTAACAAATTTGAGGAAGGCTATCATTCATGCTGCTGCTGCT 587
Db 421 CTTTCTTCAAGTGAATGTAACAAATTTGAGGAAGGCTATCATTCATGCTGCTGCTGCT 480
Qy 588 TGGTCCAGACTAATGCTAGAACTTACTGTGCTGCTAGAAAGTATTTAATTAATGCT 647
Db 481 GGGGCGAGGTTAAACCCAGAACTCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 540
Qy 648 TCTTTACATCTTGTAACTGAAAGTGAATTTTGTGCGAGGATGACTACAA 707

Db 541 ACTTTATGACCTTTGATCTGAAATCTGAACCTTAAATTTTGTGCGAGATGACTCAAA 600
Qy 708 AGGAAATTTTATGAGATGAGAGCAGTTTATGAAATTTTACTTAAATGAAAAATTC 767
Db 601 AGGAAATTTTATGAGATGAGAGCAGTTTATGAAATTTTACTTAAATGAAAAATTC 660
Qy 768 TTTAAATGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 827
Db 661 TTTAAATGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 720
Qy 828 CTTTCTTCAAGTGAATGTAACAAATTTGAGGAAGGCTATCATTCATGCTGCTGCTGCT 887
Db 721 TACTTTGAGGAAGGACTTGGCCATCCAGAAACCCCTCATCAGCAAGCCATTAAGA 780
Qy 888 TGTACTTAATGAAATCTGGGAGCTGCTGCTGAGGAGGAGATGTTGCTGCTGCTGCTG 947
Db 781 TACTAGTACTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 840
Qy 948 AAAGGAGCAAAAGCGGCTTAAAGTTTCAACCATGTTAATTTGCTATGTAAGAAACAG 1007
Db 841 GAAGGAGCAAAAGCGGCTTAAAGTTTCAACCATGTTAATTTGCTATGTAAGAAACAG 900
Qy 1008 AGTATTTACTGAGATTAATGAAATTTAGTGAATTTTACCAATTAATTTATTAAGTAG 1067
Db 901 AGTATTTACTGAGATTAATGAAATTTAGTGAATTTTACCAATTAATTTATTAAGTAG 960
Qy 1068 CAGTCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1127
Db 961 TACTGACAGTGAATTTTCAAAATTTCAAAAGTCACTAAACTGACATTTTAAAGCAAC 1020
Qy 1128 TAATTAAGTCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1187
Db 1021 TAATTAAGTCACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1080
Qy 1188 TAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1247
Db 1081 TAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1140
Qy 1248 TCAATGATGTTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTA 1307
Db 1141 GCACTGATGTTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTA 1260
Qy 1308 CCGGCGCAAGTATCTGGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTA 1367
Db 1201 TGAACCGCGCAAGTATCTGGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGA 1260
Qy 1368 GTATGAAATGTTAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGA 1427
Db 1261 ATATGCAATGTTAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGA 1320
Qy 1428 TTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1487
Db 1321 CTTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1380
Qy 1488 TTTAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1547
Db 1381 TTTAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1440
Qy 1548 TGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1607
Db 1441 AGTACCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1500
Qy 1608 TACAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1667
Db 1501 AACAACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1560
Qy 1668 ATGTAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1727
Db 1561 ATGTAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1620
Qy 1728 TATATGCAAAAGCTGAGCACTATGAAATCTGAGCAATTAATTTTCC 1787

Db 1621 TAATGCAAAAGCTGGGACCACTATGAAAACTGGGCAATAAACAATTGATTTCCC 1680
Qy 1788 TGGAAATTAATGCAATGCTCCCTCCACCCAGATCTCCAAACCAACCCCACTTGTCCAGAC 1847
Db 1681 TGGAAATTAATGCAATGCTCCCTCCACCCAGACCTCCAAACCAACCCCACTTGTCCAGAC 1740
Qy 1848 CAGTATCAGCAGAGTGTGTGAAAGCTCTGAAAGAACTGAGTGAAGAGCCTTTTCA 1907
Db 1741 CAGTATCAGCAGAGTGTGTGAAAGCTCTGAAAGAACTGAGTGAAGAGCCTTTTCA 1800
Qy 1908 CCTCATCTCCAGCGCTGGAACAGTGAACCCCGCGCTTAACTGACCGCGTCCCG 1967
Db 1801 CCTCATCTCCAGCGCTGGAACAGTGAACCCCGCGCTTAACTGACCGCGTCCCG 1860
Qy 1968 GACCACTTCAGGAAATCAATTTGTGGAAGCCAGTTCTCTCGAAGTGTGACCGGCTC 2027
Db 1861 GACCACTTCAGGAAATCAATTTGTGGAAGCCAGTTCTCTCGAAGTGTGACCGGCTC 1920
Qy 2028 GTGGAGAAAGCTTTTTCACAGCGCTTGCAGATCACTTTCGTAAGTGTGAAGAGGCT 2087
Db 1921 GTGGAGAAAGCTTTTTCACAGCGCTTGCAGATCACTTTCGTAAGTGTGAAGAGGCT 1980
Qy 2088 TGACTTTGATGGAATGAGTGTGAGGGGATTCCTGTTGCTGTGTGGAACATATAA 2147
Db 1981 TGACTTTGATGGAATGAGTGTGAGGGGATTCCTGTTGCTGTGTGGAACATATAA 2040
Qy 2148 CAGTGGGGAGGCTTGGGCTTGGCTCTCATTTGATTAATGTGAGAGCTTGTATATG 2207
Db 2041 TACTGGGGAGGCTTGGGCTTGGCTCTCATTTGATTAATGTGAGAGGCTTGTATATG 2100
Qy 2208 ATGGAATTTAGAGATTTTCTCAGACTTATGAGCGCTGACAGTTGTATGAGAGCTC 2267
Db 2101 ATGGAATTTAGAGATTTTCTCAGACTTATGAGCGCTGACAGTTGTATGAGAGCTC 2160
Qy 2268 TAAACCAATTTCTGTGTTAACTTGTAAAAAATGTCTTAACTGTCTGATTAACAATTT 2327
Db 2161 TAAATCCCTTTCTGTGTTAACTTGTAAAAAATGTCTTAACTGTCTGATTAACAATTT 2220
Qy 2328 TGTAGATTAATGAGTAAACCACTAACAAATGTGTGGAAGAGTGAACAATTTGCCAG 2387
Db 2221 TGTAGATTAATGAGTAAACCACTAACAAATGTGTGGAAGAGTGAACAATTTGCCAG 2280
Qy 2388 ACGGTATTAAGAGCTTGTGCAATTTTATGAAAAAGCTACGTGAACAGACTTGAAGTTA 2447
Db 2281 CTGTGATTCAGCAATTTGTGAAATTTTATGAAAGTTTACTGGAACAGACTTGAAGTTA 2340
Qy 2448 TTCAAAATTTTAAAGACCATTAACAATTTCTTGAATTAATCTTTAGAAAAACCTCT 2507
Db 2341 TTCAAAATTTTAAAGACCATTAACAATTTCTTGAATTAATCTTTAGAAAAACCTCT 2400
Qy 2508 CTTTATTTGACTTATGTTGCTGCAATTAAGTAACTTTAAAAAATCTTCCAGACCTATA 2567
Db 2401 CTTTATTTGACTTATGTTGCTGCAATTAAGTAACTTTAAAAAATCTTCCAGACCTATA 2460
Qy 2568 GTCATCATTTTTCAGAGCATGGAACAGTTATCTGACACCCCAAGCTTATCATCCAGTA 2627
Db 2461 GTCATCATTTTTCAGAGCATGGAACAGTTATCTGACACCCCAAGCTTATCATCCAGTA 2520
Qy 2628 ACAGTATGCAAGACCTAGAGGAGAAATGAGTATTAATCTAGTGAAGACTTACACAAG 2687
Db 2521 GAGTATCATGCAAGACCTAGAGGAGAAATGAGTATTAATCTAGTGAAGACTTACACAAG 2580
Qy 2688 CTGGGCAAGTTAGATTAACAATTAACCGGTACTAACTATGTTGGGCTTGGCAATGAGTAC 2747
Db 2581 CTGGGCAAGTTAGATTAACAATTAACCGGTACTAACTATGTTGGGCTTGGCAATGAGTAC 2640
Qy 2748 AAGCTGGGCTTCGCAAGATGCTGTGAGCAGTGTGCAAGATTCATGACTTTAGTATA 2807
Db 2641 AAGCTGGGCTTCGCAAGATGCTGTGAGCAGTGTGCAAGATTCATGACTTTAGTATA 2700
Qy 2808 GCCAATTTGGTAAATTTGGGAAATAATCTTATACATTTGACGAGTGAAGAGAT 2867
Db 2701 GCCAATTTGGTAAATTTGGGAAATAATCTTATACATTTGACGAGTGAAGAGAT 2760

Qy 2868 TGTAAAAATATAAAAATGAAACAGGGTTTCAGACACAGAGTAAAGATTAATT 2927
Db 2761 TTTTAAAAATATAAAAATGAAACAGGGTTTCAGACACAGAGTAAAGATTAATT 2820
Qy 2928 CTTTAAAGGTGAGCTGCCCCCTGTGGCCCAATTTTCAAGAAAGTTTAAACCGAAGTCCG 2987
Db 2821 CTTTAAAGGTGAGCTGCCCCCTGTGGCCCAATTTTCAAGAAAGTTTAAACCGAAGTCCG 2880
Qy 2988 CGTACAAAGCTTCAGAAATATCCCAAGATGATCTTCAATTTTCAATGATCCAG 3047
Db 2881 CTTTAAAGGTGAGCTGCCCCCTGTGGCCCAATTTTCAAGAAAGTTTAAACCGAAGTCCG 2940
Qy 3048 CTGGTCAAGCGGGGAGGTGAGCAACCTAACAAAAGATGAGAGGAGGCTCAT 3107
Db 2941 CTGGTCAAGCGGGGAGGTGAGCAACCTAACAAAAGATGAGAGGAGGCTCAT 3000
Qy 3108 TTACTGCTAATTTCTGTAAGTGTACATTTCTAGGCAATTTTAAATTCATATGATCCAG 3167
Db 3001 TTAAGTCAAGCTCTGTAAGTGTACATTTCTAGGCAATTTTAAATTCATATGATCCAG 3060
Qy 3168 AGCATCATTAATGAGTGTCTCTCAGACGCTAGTGTGCTCCCAATGCTAGTGGAAAG 3227
Db 3061 AGCATCATTAATGAGTGTCTCTCAGACGCTAGTGTGCTCCCAATGCTAGTGGAAAG 3120
Qy 3228 AGCAAAAGTGTGCACTTAATGATCCATTAATGGGATCTACTCGTGGAGATCTAG 3287
Db 3121 AGCAAAAGTGTGCACTTAATGATCCATTAATGGGATCTACTCGTGGAGATCTAG 3180
Qy 3288 ATTTATATGCTTAAATTTGTTTCTCAACATTAAGTTTCAAGCTTAATTTGAAT 3347
Db 3181 ATTTATATGCTTAAATTTGTTTCTCAACATTAAGTTTCAAGCTTAATTTGAAT 3240
Qy 3348 ATGATGATAGCTGCAATGCTTTAACTGTAACTATTCAGAAATGCTGTAAAGATG 3407
Db 3241 ATGATGATAGCTGCAATGCTTTAACTGTAACTATTCAGAAATGCTGTAAAGATG 3300
Qy 3408 TCACAGCAAAAACAGAGAGAGTGTCAAGTTTCTGACAGCAACACAGAGCGTTGTGTA 3467
Db 3301 TCACAGCAAAAACAGAGAGAGTGTCAAGTTTCTGACAGCAACACAGAGCGTTGTGTA 3360
Qy 3468 TGTATGATGATGATGATTAATTAATCCATATGTGTAGTGTGAGGCAAGACACTAG 3527
Db 3361 TGTATGATGATGATGATTAATTAATCCATATGTGTAGTGTGAGGCAAGACACTAG 3420
Qy 3528 CTCAGAACTGCCAATTTGGGTTTACTTTCCTCCCAATGCTTAACTTAACAGTATG 3587
Db 3421 CTCAGAACTGCCAATTTGGGTTTACTTTCCTCCCAATGCTTAACTTAACAGTATG 3480
Qy 3588 AAGTAAACACAGAAATTTTCAGAGACAGCAAAAAATTTGGCTAGTGAAGATCAAGCT 3647
Db 3481 AAGTAAACACAGAAATTTTCAGAGACAGCAAAAAATTTGGCTAGTGAAGATCAAGCT 3540
Qy 3648 TTTATGTTTGAAGACAGTTCATTTGAATTTTGGGTAAGGGGAGCTGCCATATGT 3707
Db 3541 TTTATGTTTGAAGACAGTTCATTTGAATTTTGGGTAAGGGGAGCTGCCATATGT 3600
Qy 3708 CTTAATAATTTTCAGCTGTGCCCCCAAGAAACCTAAGAGGCTGACGCAATTTTATG 3767
Db 3601 CTTAATAATTTTCAGCTGTGCCCCCAAGAAACCTAAGAGGCTGACGCAATTTTATG 3660
Qy 3768 AATATGTAACCTTTTGTAGCGTTCCTGTTAGGGGTAACCTGACACATTAAGAGGGAGC 3827
Db 3661 AATATGTAACCTTTTGTAGCGTTCCTGTTAGGGGTAACCTGACACATTAAGAGGGAGC 3720
Qy 3828 CTAATTTGATCATTTGACAGAGAGACCACTTAAGCCCAAACTTTATGCTG 3887
Db 3721 CAAATTTGATTTTAAACAGATGAGACCACTTAAGCCCAAACTTTATGCTG 3780
Qy 3888 GGCACATTAATTAATGATGCTTACCAAGAGAGACAAATTTATACAGTGTGGA 3947
Db 3781 GGCACATTAATTAATGATGCTTACCAAGAGAGACAAATTTATACAGTGTGGA 3840

```

QY 3948 AAGCCCTTACGGGGCTTACTGACATGACCAAAACAGAAATTTCCCTACGCCCG 4007
DB 3841 AAGCCTTAACAGGCTTACGACAGGATCTCCAAACACATGAAATCTTACGCCCTG 3900
QY 4008 GGGCAGTATTCAGCCATACCATCACTGGGACATGATTAATATGTTACGGAAATG 4067
DB 3901 GGGCAGTATTCAGCCATACCATCACTGGGACATGATTAATATGTTACGGAAATG 3960
QY 4068 CCATTTACATGACCAAAACCATTAATGAAATGCTGAGACAAAGATATCAGCAAGG 4127
DB 3961 CCATTTACATGACCAAAACCATTAATGAAATGCTGAGACAAAGATATCAGCAAGG 4020
QY 4128 TAGAAGATTTCCAAATGAAAAAGACAGCTTAAGAGCTTAAGCTTAATGACCA 4187
DB 4021 TGGGTAGATTTCCAAATGAAAAAGACAGCTTAAGAGCTTAAGCTTAATGACCA 4080
QY 4188 CATACCTTCCCTAATTAAGGAACCCCAATATACAGACCAAAATGAAAGCCCTCTATG 4247
DB 4081 CCTACTTCCCAATTAAGGAACCCCAATATACAGACCAAAATGAAAGCCCTCTATG 4140
QY 4248 TGGGCTCTGTTTGAACAGAAAGAGCTCTCATATGAAAGTACAGCTGAGATTAAT 4307
DB 4141 TGGGCTCTGTTTGAACAGAAAGAGCTCTCATATGAAAGTACAGCTGAGATTAAT 4200
QY 4308 CTAACTTAATGACAGTTTAAATCAATTTGACAGCCCTGAGCGGTGGGTTTGATC 4367
DB 4201 CAATTTAGATGACAGTTTAAATCAATTTGACAGCCCTGAGCGGTGGGTTTGATC 4260
QY 4368 AACCAACCCCTCAATATTTTAAATATCTACCAAAAGTGGGCAATTTGAGATTA 4427
DB 4261 AGCACCTCTCAATATTTTAAATATCTACCAAAAGTGGGCAATTTGAGATTA 4320
QY 4428 AATCATGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 4487
DB 4321 AATCATGGAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 4380
QY 4488 CCTTTAATTTGAGACCTGCAAAAGCTGAGAGGTGGAATCCCAAGCTGAGCTTATC 4547
DB 4381 CAATTAATTTGAGACCTGCAAAAGCTGAGAGGTGGAATCCCAAGCTGAGCTTATC 4440
QY 4548 CTCTCATGAGCTGCTCAATTAATTAATTAATTAATTAATTAATTAATTAATTA 4607
DB 4441 CCCCAGAGCAAGAGCTCAATTAATTAATTAATTAATTAATTAATTAATTAATTA 4500
QY 4608 AGCAACACCAAGACACGATATGAAAAAGCTGAAAGATTTGGAAGTGGCAAAAGCG 4667
DB 4501 AACAACACCAAGACACGATATGAAAAAGCTGAAAGATTTGGAAGTGGCAAAAGCG 4560
QY 4668 TGACCCCATTTGTAACATTTCCCAACCGTCTGACAGCAAGACGTCACCCACGCGCA 4727
DB 4561 TGACCCCATTTGTAACATTTCCCAACCGTCTGACAGCAAGACGTCACCCACGCGCA 4620
QY 4728 CTTGTGCGCGCCAGATTAATGTCCTCCCAATACCCCGTAGGGAAC 4777
DB 4621 CCAATGACCAACGAGATGTAAGTACGCCCCCTCTAATCTAATGAAGACGCC 4670

```

RESULT 3

```

US-10-187-253A-26
; Sequence 26, Application US/10187253A
; Publication No. US20030170612A1
; GENERAL INFORMATION:
; APPLICANT: Pichante, Sergio
; APPLICANT: Shyamala, Venkatesh
; TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
; FILE REFERENCE: CHIR-17194/03US / PPI7194.004
; CURRENT APPLICATION NUMBER: US/10187,253A
; NUMBER OF SEQ ID NOS: 92
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 26
; LENGTH: 2380
; TYPE: DNA

```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: VPI from
; US-10-187-253A-26

```

Query Match

```

Best Local Similarity 38.0%; Score 1912.6; DB 15; Length 2380;
Matches 2077; Conservative 0; Mismatches 274; Indels 0; Gaps 0;

```

```

QY 2331 AGATTATGATTAACCACTAATGAGGAAAGCACTGACAAATTTGCCAGACG 2390
DB 18 ACAAATGATTAACCACTAATGAGGAAAGCACTGACAAATTTGCCAGACG 77
QY 2391 TGTATGACGCTTTGTCATTTTATGAAAAAGTACTGGAACAGACTTAAGCTTATC 2450
DB 78 TGTATGACGCTTTGTCATTTTATGAAAAAGTACTGGAACAGACTTAAGCTTATC 137
QY 2451 AAATTTAAAGACATTAACATTTCTTTAGATTAATCTTTAGAAAAACCCCTCTTCT 2510
DB 138 AAATTTAAAGACATTAATTAATTTCTTTAGATTAATCTTTAGAAAAACCCCTCTTCT 197
QY 2511 TAATTTGACCTTATGCTGCTGATTAATTAATTAATTAATTAATTAATTAATTA 2570
DB 198 TGTATGACGCTTTGTCATTTTATGAAAAAGTACTGGAACAGACTTAAGCTTATC 257
QY 2571 ATCATTTGAGGACATGAGACATTAATGACACCCCATGCTTATCAATCAAGTACA 2630
DB 258 ATCATTTGAGGACATGAGACATTAATGACACCCCATGCTTATCAATCAAGTACA 317
QY 2631 GTATGACGAACTTGAAGAGAAAAATGAGATTAATCAATTAATCAATTAATCA 2690
DB 318 GTATGACGAACTTGAAGAGAAAAATGAGATTAATCAATTAATCAATTAATCA 377
QY 2691 GGCAGTATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2750
DB 378 GGCAGTATGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 437
QY 2751 CTGGGCTCTGCGAAGTCTGTGACAGTCTCAAGATTAATGACTTAATGATAGCC 2810
DB 438 CTGGGCTCTGCGAAGTCTGTGACAGTCTCAAGATTAATGACTTAATGATAGCC 497
QY 2811 AATGCTAATGAGGAAATTAATCTTTATACATTTGACAGTGAAGATTAATGAT 2870
DB 498 AATGCTAATGAGGAAATTAATCTTTATACATTTGACAGTGAAGATTAATGAT 557
QY 2871 TAAAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2930
DB 558 TAAAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 617
QY 2931 TAAAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 2990
DB 618 TAAAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 677
QY 2991 ACAAGCTCTGAGAAAAATACCCAGACATTAATTAATTAATTAATTAATTAATTA 3050
DB 678 ACAAGCTCTGAGAAAAATACCCAGACATTAATTAATTAATTAATTAATTAATTA 737
QY 3051 GTGACAGCGGGGAGATGACAACTTACAAAAGATGGAAGGAGCTTACATTTA 3110
DB 738 GTGACAGCGGGGAGATGACAACTTACAAAAGATGGAAGGAGCTTACATTTA 797
QY 3111 CTGCTAATTTGTAACGTGTAATTTCTGAGCAATTTTAAATTTGTAATTTGTA 3170
DB 798 GTGCAAGCGGGGAGATGACAACTTACAAAAGATGGAAGGAGCTTACATTTA 857
QY 3171 ATCATTTAATGATTTCTCTGACAGCTTACAGCAATTTGTAATTTGTAATTTGTA 3230
DB 858 AOCATTTAATGATTTCTCTGACAGCTTACAGCAATTTGTAATTTGTAATTTGTA 917
QY 3231 CAAAAGTGTGACATTAATTTGCTTATGAGGATTAATTTGTAATTTGTAATTTGTA 3290
DB 918 CAAAAGTGTGACATTAATTTGCTTATGAGGATTAATTTGTAATTTGTAATTTGTA 977

```


QY 3291 TTATGCTTAAATTTGTTTCTCAACATTAAGTTTCACTTAATGAATTAAT 3350
 DB 978 TTATGCTTAAATTTATTTTCTCACTTAAGTTTCACTTAATGAATTAAT 1037
 QY 3351 GTAGTATAGCTCAAGATGCTTAACTGTAATTTCAAGAAATGCTGAAGATGTC 3410
 DB 1038 GAAGTATAGCTCAAGATGCTTAACTGTAATTTCAAGAAATGCTGAAGATGTC 1097
 QY 3411 CAGACAAACAGAGAGAGGTGTGCAAGTTACTGACAGACCAAGACGTTGTATGT 3470
 DB 1098 CAGACAAACAGAGAGAGGTGTGCAAGTTACTGACAGACCAAGACGTTGTATGT 1157
 QY 3471 TAGTGATCATGATGTAATTAATACCATATGCTAGGTGAGGACAAGACACTAGCTC 3530
 DB 1158 TAGTGATCATGATGTAATTAATACCATATGCTAGGTGAGGACAAGACACTAGCTC 1217
 QY 3531 CAGAACTGCCATTTGGGTTTACTTTCCGCCAGATGCTTAACTTAACAGTATGTAAG 3590
 DB 1218 CAGAACTGCCATTTGGGTTTACTTTCCGCCAGATGCTTAACTTAACAGTATGTAAG 1277
 QY 3591 TAAACACAGAGAAATTTCAAGACAGCAAAATTTGGCTAGTGAAGATCAGCTTTT 3650
 DB 1278 TTAACACAGAGAAATTTCTGAGACAGCAAAATTTGGCAAGTGAAGATCAGCAATTT 1337
 QY 3651 AGTGTTAGAGCAGGTCATTTGAACTTTGGGTACAGGGGGATGCGCATATGTCCT 3710
 DB 1338 AGTGTTAGAGCAGGTCATTTGAACTTTGGGTACAGGGGGATGCGCATATGTCCT 1397
 QY 3711 ACAAAATTTCCAGCTGTGCCCCGAGAAACCTAGAAAGGCTGACCAACATTTTATGAAA 3770
 DB 1398 ATTAAGTTCTCCAGTGGCCCCGAGAAATTTAGAGGGCTGACATCAACTTTTATGAAA 1457
 QY 3771 TGTACAACTTTTGTACGTTTCTGTTAGGGGTACTGACATTTAGAGGGGACCTTA 3830
 DB 1458 TGTACAACTTTTGTACGTTTCTGTTAGGGGTACTGACATTTAGAGGGGACCTTA 1517
 QY 3831 AATTTAGATCATTTGACAGAGACAGCAAGCAATTTAGAGGACCAAACTTTATGCTGGG 3890
 DB 1518 AATTTAGATCATTTGACAGAGACAGCAATTTAGAGGACCAAACTTTATGCTGGG 1577
 QY 3891 CACTAATAATTCAGTGTCTACCAAGAGAGACAAATTTAATAGAGTGTCTGAAAAG 3950
 DB 1578 CACTAATAATTCAGTGTCTACCAAGAGAGAGACAAATTTAATAGAGTGTCTGAAAAG 1637
 QY 3951 CCCTTAAGGGGCTTACTGCTGCACTAGCCAAAACACAGAAATTTCCCTAGCCCGGG 4010
 DB 1638 CCCTTAAGGGGCTTACTGCTGCACTAGCCAAAACACAGAAATTTCCCTAGCCCGGG 1697
 QY 4011 CAGTATCTCAGCCATTCACATCACTGGGACACATTAATTTGTATAGAGAAATTAAGCA 4070
 DB 1698 CAGTATCTCAGCCATTCACATCACTGGGACACATTAATTTGTATAGAGAAATTAAGCA 1757
 QY 4071 TTTCATAGTGAACAACTTATGAAATGCTGAGACAAAGATATGACAGAGGGTAG 4130
 DB 1758 TTTCATAGTGAACAACTTATGAAATGCTGAGACAAAGATATGACAGAGGGTAG 1817
 QY 4131 GAAATTTCCAAATGAAAAGAACAGCTTATAGCAAGTTACAGGCTTAACTGACACAT 4190
 DB 1818 GAAATTTCCAAATGAAAAGAACAGCTTATAGCAAGTTACAGGCTTAACTGACACAT 1877
 QY 4191 ACTTCCCTAATAAGAACCCCAACATATACAGCAAAATTTGAACCCCTCTATAGTGTG 4250
 DB 1878 ACTTCCCTAATAAGAACCCCAACATATACAGCAAAATTTGAACCCCTCTATAGTGTG 1937
 QY 4251 GCTCTGTTGGAACAGAGAGCTCTTCACTATGAAAGTCACTGTGGAATTAATCCCTA 4310
 DB 1938 GCTCTGTTGGAACAGAGAGCTCTTCACTATGAAAGTCACTGTGGAATTAATCCCTA 1997
 QY 4311 ACTTATAGTCACTTTTAAATCTCAATTTGACAGCCCTAGGCGGGGTGGGTTTSCATCAAC 4370
 DB 1998 ACTTATAGTCACTTTTAAATCTCAATTTGACAGCCCTAGGAGGAGTGGGGTTTSCATCAAC 2057

QY 4371 CACCCCTCAAAATATTTTAAATACTACCAAAAGTGGCCAAATTTGAGATTAAT 4430
 DB 2058 CACCTCTCAAAATATTTTAAATACTACCAAAAGTGGCCAAATTTGAGATTAAT 2117
 QY 4431 CCATGGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4490
 DB 2118 CCATGGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2177
 QY 4491 TTAATTTGGGACCTGAAAGGCTACTGGAAGGTGAATCCCGAGCTGGGCTTATCCTC 4550
 DB 2178 TTAATTTGGGACCTGAAAGGCTACTGGAAGGTGAATCCCGAGCTGGGCTTATCCTC 2237
 QY 4551 CTCATGAGTGGGTCAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 4610
 DB 2238 CTCATGAGTGGGTCAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 2297
 QY 4611 AACACCAAGACAGGATATGAAAAGCTGAAGAAATTTGGAAGCTGCAAAAGCGGTGTC 4670
 DB 2298 AACACCAAGACAGGATATGAAAAGCTGAAGAAATTTGGAAGCTGCAAAAGCGGTGTC 2357
 QY 4671 ACCCATTTGA 4681
 DB 2358 ACCCATTTGA 2368

RESULT 4

US-10-187-253A-32
 ; Sequence 32, Application US/10187253A
 ; Publication No. US20030170612A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Pichuanes, Sergio
 ; APPLICANT: Shyamala, Venkatesh
 ; TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
 ; FILE REFERENCE: CHIR-17194/03US / PPI17194.004
 ; CURRENT FILING DATE: 2003-03-10
 ; NUMBER OF SEQ ID NOS: 92
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO 32
 ; LENGTH: 2380
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: VPI from
 ; OTHER INFORMATION: parvovirus B19 clone 2-B6
 US-10-187-253A-32

Query Match 38.0%; Score 1911; DB 15; Length 2380;
 Best Local Similarity 88.3%; Pred. No. 0;
 Matches 2076; Conservative 0; Mismatches 275; Indels 0; Gaps 0;

QY 2331 AGATTATGATGAACCACTTAACAAATGCTGGGAAAGCAGTGAACAATTTGCCAGAGACG 2390
 DB 18 ACAAAATGATGAAGAAATGCAATGCTGGGAAAGTATGATTAATTTGCTAAAGCTG 77
 QY 2391 TGTATAGAGAGTTTGTGCAATTTTATGAAAAGCTACTGGAACAGCTTAAGAGCTATTC 2450
 DB 78 TGTATAGAGAGTTTGTGCAATTTTATGAAAAGCTACTGGAACAGCTTAAGAGCTATTC 137
 QY 2451 AAATTTTAAAGACATTAACAATTTCTTATGATTAATCTTTAGAAAACCCCTCTTCTT 2510
 DB 138 AAATTTTAAAGACATTAACAATTTCTTATGATTAATCTTTAGAAAACCCCTCTTCTT 197
 QY 2511 TAATTCATTAAGTGTGTCATTAATAAGTATCTTAATAAACTCTCCAGACTATATAGTC 2570
 DB 198 TAATTCATTAAGTGTGTCATTAATAAGTATCTTAATAAACTCTCCAGACTATATAGTC 257
 QY 2571 ATCATTTTGAAGCAGTGAAGCTTATCTGAACACCCCATGCTTATATCATCATCAATCA 2630
 DB 258 ATCATTTTGAAGCAGTGAAGCTTATCTGAACACCCCATGCTTATATCATCATCAATCA 317
 QY 2631 GTATGTCAGAACTGAGAGAGAAATGCAATTAATCTATGTAAGACTTACAAAGCTTG 2690

Db 318 GTCATGAGAACCTAGAGGAGATGCAATATCTAGTGAAGCTTACACAGCCTG 377
 QY 2691 GGCAAGTTAGCATCAATTAACCGTACTATATGTTGGGCTGGCAATAGAGTCAAG 2750
 Db 378 GGCAAGTTAGCATCAATTAACCGTACTATATGTTGGGCTGGCAATAGAGTCAAG 2750
 QY 2751 CTGGGCTGGCAATGCTGTGACAGTGTGCAAGGATTCATGATTTAGTATAGCC 2810
 Db 438 CTGGGCTGGCAATGCTGTGACAGTGTGCAAGGATTCATGATTTAGTATAGCC 2810
 QY 2811 AATTGCTAGTGGGATTAATCTTATACATTTGACATTTGACATTTGATGATGATG 2870
 Db 498 AACTGCTAGTGGGATTAATCTTATACATTTGACATTTGATGATGATGATGATG 2870
 QY 2871 TAAATAATTAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATA 557
 Db 558 TAAATAATTAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATAATA 557
 QY 2931 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 617
 Db 618 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2990
 QY 2991 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 677
 Db 678 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3050
 QY 3051 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 737
 Db 738 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3110
 QY 3111 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 797
 Db 798 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3170
 QY 3171 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 857
 Db 858 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3230
 QY 3231 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 917
 Db 918 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3290
 QY 3291 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 977
 Db 978 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3350
 QY 3351 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1037
 Db 1038 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3410
 QY 3411 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1097
 Db 1098 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3470
 QY 3471 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1157
 Db 1158 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3530
 QY 3531 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1217
 Db 1218 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3590
 QY 3591 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1277
 Db 1278 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3650
 QY 3651 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1337
 Db 1338 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3710
 QY 3711 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1397
 Db 1398 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 3770
 QY 1457 TAAAGGTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1457

QY 3771 TGAACACCTTTTGAAGCTTCTGTTAAGGGTACCTGACATTAAGAGGGAGCCCTA 3830
 Db 1458 TGAACACCTTTTGAAGCTTCTGTTAAGGGTACCTGACATTAAGAGGGAGCCCTA 1517
 QY 3831 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 3890
 Db 1518 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1577
 QY 3891 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 3950
 Db 1578 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1637
 QY 3951 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4010
 Db 1638 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1697
 QY 4011 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4070
 Db 1698 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1757
 QY 4071 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4130
 Db 1758 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1817
 QY 4131 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4190
 Db 1818 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1877
 QY 4191 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4250
 Db 1878 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1937
 QY 4251 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4310
 Db 1938 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 1997
 QY 4311 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4370
 Db 1998 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2057
 QY 4371 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4430
 Db 2058 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2117
 QY 4431 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4490
 Db 2118 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2177
 QY 4491 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4550
 Db 2178 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2237
 QY 4551 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4610
 Db 2238 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2297
 QY 4611 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 4670
 Db 2298 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2357
 QY 4671 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2410
 Db 2358 AATTAGATCAATGACACAGAGAGACCAAGCAATTAAGAGAGAGAGAGAGAGAGAG 2470

RESULT 5
 US-09-792-630-44 : Sequence 44, Application US/09/92630
 : Patent No. US20020168640A1
 : GENERAL INFORMATION:
 : APPLICANT: Li, Min
 : APPLICANT: Dahiyat, Basil I.

TITLE OF INVENTION: BIOCHIPS COMPRISING NUCLEIC ACID/PROTEIN- CONJUGATES
FILE REFERENCE: A-70295/RFT/RMS/BMK
CURRENT APPLICATION NUMBER: US/09/792,630
CURRENT FILING DATE: 2001-02-22
NUMBER OF SEQ ID NOS: 87
SOFTWARE: PatentIn version 3.1
SEQ ID NO 44
LENGTH: 2016
TYPE: DNA
ORGANISM: Erythrovirus B19
US-09-792-630-44

Query Match 31.5%; Score 1585.6; DB 9; Length 2016;
Best Local Similarity 86.7%; Pred. No. 0;
Matches 1747; Conservative 0; Mismatches 269; Indels 0; Gaps 0;

QY 328 ATGAGCTATTTGCGGGGTCTTGACATTTCTCTAATCTGACATGCTGCTAATGAT 387
DB 1 ATGAGCTATTTAGAGGGGTCTTCAAGTTTCTCTAATGTTCTGACATGCTGCTAATGAT 60
QY 388 AACTGGTGTGCTCTAATGCTAATGCTAATGCTAATGCTAATGCTAATGCTAATGCT 447
DB 61 AACTGGTGTGCTCTAATGCTAATGCTAATGCTAATGCTAATGCTAATGCTAATGCT 120
QY 448 AACGATTAATGCAATATATTTAAGAGTGTGCTTAACTGATTTTACTGGGGGG 507
DB 121 AACGATTAATGCAATATATTTAAGAGTGTGCTTAACTGATTTTACTGGGGGG 180
QY 508 CCGCTACAGGCTGCTTATATCTTTTCAAGTGTGATGATCAAAATTTGAGAGGCTAT 567
DB 181 CCACTACAGGCTGCTTATATCTTTTCAAGTGTGATGATCAAAATTTGAGAGGCTAT 240
QY 568 CATATCATGATGATTTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 627
DB 241 CATATCATGATGATTTGCTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 300
QY 628 GAAGGTTATTTAATATGTTCTTACCATCTGTAATGTAATGTAATGTAATGTAATGTA 687
DB 301 GAAGGTTATTTAATATGTTCTTACCATCTGTAATGTAATGTAATGTAATGTAATGTA 360
QY 688 TTGCGAGGATGATGATCAAAAGAAATATTTAAGATGAGAGGAGCTTATGAAAT 747
DB 361 TTGCGAGGATGATGATCAAAAGGAAATCTTGAAGTGAAGAGGAGCTTATGAAAT 420
QY 748 TACTTATGAAAAAATCTTTAATGTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 807
DB 421 TATTATTAATAAAAAATCTTTAATGTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 480
QY 808 ATGAGCAGCTGATTTCCGCTCTTTCCGCGAGAGCTGTCAATGCTAAAGACCCCGC 867
DB 481 ATGAGCAGCTGATTTCTGCTACTTTTGAAGGGGAGCTTCCATGCGAAGAAACCCCGC 540
QY 868 ATTAAGTCAATATGAGCAGTGTCTAATGAAATCTGGGAGTGTAGCTGTGAGGGGGA 927
DB 541 ATTAAGCAGCAGCAATATGATGATGATGATGATGATGATGATGATGATGATGATG 600
QY 928 GATGTGTGCTATGCTGCTGAGAGGGAACAAAGCGGGGTTAAAGTTTCAACCATGCTA 987
DB 601 GAGGTGTGCTATTAATGAGAGGGAACCTAAGCTGATTAAGTTTCAACCATGCTA 660
QY 988 AATTGCTATGTAAGAAACAGATATTTACTGAGATGAAATGGAATTAAGTGAATTTAAC 1047
DB 661 AACTGCTGTGTGTAAGAAACAGATGTTTACAGAGATGAAATGGAATTAAGTGAATTTAAC 720
QY 1048 CAATATATCTTTAATGATGAGCAGTCAAGTGGCAGCTTTCAATTTCAAGGCTTAAAG 1107
DB 721 CAGTACCTTTAATGAGATGATGATGATGATGATGATGATGATGATGATGATGATG 780
QY 1108 TTAGCTATTTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1167
DB 781 CTAGCAATTTAATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 840
QY 1168 TTGAGCAGGTTACTTGATTAAGAAATTAATAATGATTAATTAATGATGATGATG 1227

DB 841 TTGAGAGGTTATGCTATTAAGAAATTAATGATTAATGATGATGATGATGATGATG 900
QY 1228 TATGATCTCTTTTATGAGGCTCAATGTGTGATGATGATGATGATGATGATGATG 1287
DB 901 TATGATCTCTTTTATGAGGCTCAATGTGTGATGATGATGATGATGATGATGATG 960
QY 1288 AAAAATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1347
DB 961 AAAAATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1020
QY 1348 ATTGCTAAATCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1407
DB 1021 ATTGCTAAATCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1080
QY 1408 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1467
DB 1081 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1140
QY 1468 GTGGAAGCTGCAAAAGCATTGATGATGATGATGATGATGATGATGATGATGATG 1527
DB 1141 GTGGAAGCTGCAAAAGCATTGATGATGATGATGATGATGATGATGATGATGATG 1200
QY 1528 GGCAGTGTGCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1587
DB 1201 GGCAGTGTGCAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
QY 1588 GTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1647
DB 1261 GTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1320
QY 1648 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1707
DB 1321 AATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1380
QY 1708 CAACATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1767
DB 1381 CAACATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1440
QY 1768 AACTACATTTGATTTCCCTGGAATTAATGATGATGATGATGATGATGATGATG 1827
DB 1441 AACTACATTTGATTTCCCTGGAATTAATGATGATGATGATGATGATGATGATG 1500
QY 1828 ACCCATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1887
DB 1501 ACCCATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1560
QY 1888 AGTGAAGCAGCTTTTCAACTCATCACTCCAGGCTGGAACAGTGAACCCCGCGC 1947
DB 1561 AGTGAAGCAGCTTTTCAACTCATCACTCCAGGCTGGAACAGTGAACCCCGCGC 1620
QY 1948 TCTAGTACGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2007
DB 1621 TCTAGTACGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1680
QY 2008 TCCGAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2067
DB 1681 TCCGAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1740
QY 2068 CGTGAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 2127
DB 1741 CGTGAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1800
QY 2128 TGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 2187
DB 1801 TGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1860
QY 2188 GTGGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2247
DB 1861 GTGGAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1920
QY 2248 AGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 2307

Db 1921 AGCTGCCATGTGGAGCTTCTAATCCCTTTCTGCTGCTAAGCTGCAAAAATGCTTAC 1980
 Qy 2308 CTGTCTGATTAACAAGTTTGTGATTAATGCTAA 2343
 Db 1981 CTGTCTGATTAACAAGCTTGTGATTAATGCTAA 2016

RESULT 6
 US-09-953-351-44
 ; Sequence 44, Application US/09953351
 ; Publication No. US20030036643A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Li, Min
 ; APPLICANT: Melander, Christian
 ; APPLICANT: Liu, Hong-Xiang
 ; APPLICANT: Jin, Cheng He
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE CONSTRUCTION AND USE OF FUSION I
 ; FILE REFERENCE: A-70814/REP/RMS/RMK
 ; CURRENT APPLICATION NUMBER: US/09/953,351
 ; PRIOR FILING DATE: 2001-09-14
 ; PRIOR APPLICATION NUMBER: US 60/232,960
 ; NUMBER OF SEQ ID NOS: 56
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 44
 ; LENGTH: 2016
 ; TYPE: DNA
 ; ORGANISM: Erythrovirus B19
 US-09-953-351-44

Query Match 31.5%; Score 1585.6; DB 10; Length 2016;
 Best Local Similarity 86.7%; Pred. No. 0;
 Matches 1747; Conservative 0; Mismatches 269; Indels 0; Gaps 0;

Qy 328 ATGAGCTATTTGGGGGCTCTTGCACATTTCTCTTAACATTCTGACCTGTGTAATGAT 387
 Db 1 ATGAGCTATTTAGAGGGGTGCTCAAGTTCTTCTTAATGTTCTGAGCTGTGTAATGAT 60
 Qy 388 AACTGTGTGCTCTATGCTAGACTTAATCTTCTGCTGGGAAACAATACCATTT 447
 Db 61 AACTGTGTGCTCTTCTTCTGATTTAACACTTCTGAGCTGGGAAACAATACCATTT 120
 Qy 448 AACAGATTAAAGGCAATATATTTAAGCAGTTGCTCTTAAACCTTGAATTTACTGGGGG 507
 Db 121 AACAGACTTAATGCAATATCTTAAGCAGTTGCTCTTAAAGCTTGAATTTACTGGGGG 180
 Qy 508 CCGCTAGAGGTGCTTACTTCTTCTTCAAGTGAAGTAAACAATTTGAGAGGCTAT 567
 Db 181 CCACTAGCAGGGTCTGCTTCTTCTTCAAGTGAAGTAAACAATTTGAGAGGCTAT 240
 Qy 568 CATATCCATGATTAATTTGTGTGCTCCGAGCTAAATGCTGAACCTTAATCTGTGCTA 627
 Db 241 CATATTCATGTGTTATTTGGGGGCCAGGGTTAAACCCCAAGAACTCACTATGTGTGTA 300
 Qy 628 GAAGTTTATTTAATTAATGTTCTTACCATCTTGTACTGAAGTAACTTAAATTT 687
 Db 301 GAGGGTTATTTAATTAATGTTCTTACCATCTTGTACTGAAGTAACTTAAATTT 360
 Qy 688 TTGCGAGGATGACTCAAAAGAAATTTTGAAGATGAGAGCAAGTTTATAGAAAT 747
 Db 361 TTGCGAGAAATGACTCAAAAGAAATCTTGAAGATGAGAGCAAGTTTATAGAAAT 420
 Qy 748 TACTTAATGAAAAAATCTTAAATGTTGTGTGCTGCTAACAATTAATGAAGGAT 807
 Db 421 TATTTAATAAAAAATCTTAAATGTTGTGTGCTGCTAACAATTAATGAAGGAT 480
 Qy 808 ATGAGACCGCTAATTTCCGCTCTTTTGGCGAGAGCTTGTCAATGCTAAAGACCCGCG 867
 Db 481 ATGAGACCTGTAATTTCTGCTAATTTGAGAGGGAGCTTGCATGCAAGAAACCCGCG 540
 Qy 868 ATTACTGCAAAATAGACAGTGTCTACTATGAATCTGGGGAGTCTAGCTGAGAGGGGA 927
 Db 541 ATTACACAGCATTAATGATATCTAGTGTGCTGGGGAGTCTAGCGGACAGAGGGCA 600

Qy 928 GATTTGTGCCATTCGCTGGAAGAGAAACAAAGCGGGTTAAAGTTTCAACATGCTA 987
 Db 601 GAGGTGTGCATTTAATGGGAGGGAACTAAGGCTAGCAATAAAGTTTCAACATGCTA 660
 Qy 988 AATTGCTATGTAAGAAACAGAGTATTTTCTGAAGATTAATGAATTAATGATGATTTTAA 1047
 Db 661 AACTGTGTGTGTAAGAAACAGAGTATTTTCAAGAGATTAATGATGATTTTAA 720
 Qy 1048 CAATATCTTAAATTAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1107
 Db 721 CAGTACACTTAACTAAGCAGTATGATGATGATGATGATGATGATGATGATGATGATGAT 780
 Qy 1108 TTGCTATTTAAAGCTACTAATCTTAAGCCAGTATGATGATGATGATGATGATGATGAT 1167
 Db 781 CTAGCAATTAATTAAGCACTAATTTAGCTTACTAGCACTTATTTATGATGATGATGAT 840
 Qy 1168 TTGAGCAGGTACTGCTAATTAAGAAATTAATTAATTAATTAATTAATTAATTAATTA 1227
 Db 841 TTGAGCAGGTATGATGATTAATTAAGCAATTAATTAATTAATTAATTAATTAATTAAT 900
 Qy 1228 TATGATCTCTTTTGTGCTGCTAATGATGATGATGATGATGATGATGATGATGATGAT 1287
 Db 901 TATGATCTCTTATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 960
 Qy 1288 AAAAAACCTGTGCTTTTAAAGGCAACAGTACTGGAATAAATTTGGCAATGCT 1347
 Db 961 AAAAAATCACTGTGCTTTTAAAGGCAACAGTACTGGAATAAATTTGGCAATGCT 1020
 Qy 1348 ATTGCTAAATCTGATCCGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1407
 Db 1021 ATTGCTAAATCTGATCCGCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1080
 Qy 1408 AATGATGATGAGGGGAAAGTTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1467
 Db 1081 AATGATGATGAGGGGAAAGTTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
 Qy 1468 GTGAGGTGGAAGCAATTTTAAAGTGTGATGATGATGATGATGATGATGATGATGATGAT 1527
 Db 1141 GTGAGGTGGAAGCAATTTTAAAGTGTGATGATGATGATGATGATGATGATGATGATGAT 1200
 Qy 1528 GGCAGTGTGAGTGCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1587
 Db 1201 GGAAGTGTGAGTGCCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
 Qy 1588 GTTGTGAGTGTGATTAATCACTAATCACTGATGATGATGATGATGATGATGATGATGAT 1647
 Db 1261 GTTGTGAGTGTGATTAATCACTAATCACTGATGATGATGATGATGATGATGATGATGAT 1320
 Qy 1648 AAGCTAACTTAACATTAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1707
 Db 1321 AAGCTAACTTAACATTAATGATGATGATGATGATGATGATGATGATGATGATGATGAT 1380
 Qy 1708 CAACATGCTTAATCTTGTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1767
 Db 1381 CAACATGCTTAATCTTGTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1440
 Qy 1768 AACTACATTTGATTTTCCCTGGAATTAATGCAATGCTTCCCACTCAATCTTCAAC 1827
 Db 1441 AACTACATTTGATTTTCCCTGGAATTAATGCAATGCTTCCCACTCAATCTTCAAC 1500
 Qy 1828 ACCCCCATTTGCTCCAGACACAGATGATGATGATGATGATGATGATGATGATGATGATGAT 1887
 Db 1501 ACCCCCATTTGCTCCAGACACAGATGATGATGATGATGATGATGATGATGATGATGATGAT 1560
 Qy 1888 AGTGAAGCAGCTTTTCAACCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1947
 Db 1561 AGTGAAGCAGCTTTTCAACCTGATGATGATGATGATGATGATGATGATGATGATGATGAT 1620
 Qy 1948 TCTAGTACGCGCGTCCCGGAGCACTTCAAGAGATCAATTTGTGGAAGCCCACTTCC 2007
 Db 1621 TCTAGTACGCGCATCCCGGAGCACTTCAAGAGATCAATTTGTGGAAGCCCACTTCC 1680

Qy	2008	TCGCAAGGTGAAGCGCGTCCGTGGGAGGAAACCTTTTAAACAGCGCGTCCGACATGATT	2067
Db	1681	TCGCAAGTTGTAAGTCGATCGTGGGAAACCTTTTAAACACACTTTGGGAGACCAATT	1740
Qy	2068	CGTGAACCTGTTAGTAGGGGTGTGACTTTGTATAGGGAATGCTGTGAGGGATATGCTGTTGC	2127
Db	1741	CGTGAACCTGTTAGTTGGGGTTGATTTATGTGTGGACGGGTGTAAAGGGATTAACTGTGTGT	1800
Qy	2128	TGTGTGGAACAATATTAACACAGTGGGGAGGGTTGGGCTTTGGCCATCTGATTTAT	2187
Db	1801	TGTGTGGAACAATATTAACAAATAGTGGGGAGGCTTTGGGACTTTGTGCCAATTTGACTTAT	1860
Qy	2188	GTGGGAGCTTGGTATATGATGATGGAATTTAAGAGATTAACTCCAGACTTAATGTGGCGTC	2247
Db	1861	GTAGGGGCTTGGTATATGATGATGGAATTTGAGAAATTTACAGAAATTTACCCAGATTTGTGTGGGGT	1920
Qy	2248	AGTGTGATGTAAGGAGCCTTTAACCCATTTTCTGTGTAACTTTGTAAAAAAATGTGCTTAC	2307
Db	1921	AGCTGCACATGGGAGCTTTCTTAATCCCTTTTCTGTGCTAACCTGCAGAAAAAATGTGCTTAC	1980
Qy	2308	CTGTCTGATTAACAAGATTTTGTGATATATAGTTAA	2343
Db	1981	CTGTCTGATTAACAAGCTTTGTGATATATAGTTAA	2016

```

RESULT 7
US-10-080-376-44
; Sequence 44, Application US/10080376
; Publication No. US20020172968A1
; GENERAL INFORMATION:
; APPLICANT: Li, Min
; APPLICANT: Dahlvat, Basill I.
; TITLE OF INVENTION: BIOCHIPS COMPRISING NUCLEIC ACID/PROTEIN CONJUGATES
; FILE REFERENCE: A-70295-2/RFT/RMS/RMK
; CURRENT APPLICATION NUMBER: US/10/080, 376
; PRIOR FILING DATE: 2000-02-19
; PRIOR FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 44
; LENGTH: 2016
; TYPE: DNA
; ORGANISM: Erythrovirus B19
US-10-080-376-44

Query Match      31.5%; Score 1585.6; DB 14; Length 2016;
Best Local Similarity 86.7%; Pred. No. 0;
Matches 1747; Conservative 0; Mismatches 269; Indels 0; Gaps 0;

QY      328  ATGAGCGTATTTCGGGGGTCGTCGACACTTTCCTCTAACTTCGTGACCTGTGCTAAATGAT 387
DB      1   ATGAGCGCTATTTCAGAGGGGTCCTTCMACTTTCCTTAATGTCCTGGACTGTGCTAACGAT 60

QY      388  AACTGTGTGTCCTCTAATGCTAGACTTAGATTACTTCGACTGGGAAACCTAACCCATTC 447
DB      61  AACTGTGTGTCTCTTTACTGTGATTTAGACACTTCTGACTGGGAAACCTAACCTATCATCT 120

QY      448  AACGATTAAATGCGCAATATATTAAAGCAGTGTGCTTCTAAACTGATTTTACTGGGGGG 507
DB      121  AACGAGCTAAATGGCAATATACTTAAGCAGTGTGTGCTTAAAGCTTGAACCTTAAACCGGGGG 180

QY      508  CCGCTACGAGTTCCTTAATCTTTTTCAGGTGAAATGTAACAATTTGAGGAAGGCTAT 567
DB      181  CCAGTAGAGGGTCTGTGTACTTTTTCAGGTAGATGTAACAATTTGAAAGAAAGGCTAT 240

QY      568  CATATCACTAGTATTAATGTCGTCCAGGACTAAATGTCTAGAAACTTAACGTGTGCGTA 627
DB      241  CATATCACTAGTGTATTATGGGGGGGCGAGGGTTAAACCCAGAAACCTCACTATGTGTGTA 300

QY      628  GAAAGTTTATTAAATTAATGTTCTTAAACATCTTGTAATCTGAAGTGTAAACTTAATTT 687
DB      301  GAGGGGGTTATTAATTAATGTAATCTTATCACTGTGTAATGAAATGTGAACTTAATTT 360

```

QY	688	TTGCGAGGGAAGACACCAAAAGGAAAATATTTTGAAGTGGAGCGGCTTATGAAAT	747
Db	361	TTGCGAGGAAAGACACAAAGGAAAATCTTAAAGATGGAGCGGCTTATGAAAC	420
QY	748	TACTTAATGAAAAAATTCCTTTAAATGTGTGATGTGAACAAATATTGACGGGTAT	807
Db	421	TATTTAATAAAAAATATCCTTTAAATGTGTATGTGTGTATCTAATATTGATGATAT	480
QY	808	ATPAGACCTGTATTTCCGCTCTTTTCGCGAGAGAGCTGTCAATCTAAAAACCCCGC	867
Db	481	ATPAGATCCTGTATTTCTGTACTTTTAAAGAGGAGAGCTTGCATGCCAAGAAACCCGCG	540
QY	868	ATTATCTGAAATACAGACAGCTCTACTATATGAACTGGGAGCTTAGCTGTGGAGGGGA	927
Db	541	ATTACCAAGCCATTAATATGATATCTAGATCTGGGAGCTTAGCGGACAGGGGCA	600
QY	928	GATGTGTGCCATTCCGCTGGAAAGGAAACAAACCGGGGTTAAAGTTTCAACCATGTGT	987
Db	601	GAGTTGTGCCATTTAATGGAAAGGAACTTAGGCTTAGCATTAAGTTTCAACCTATGTGT	660
QY	988	AATTGGCTATGTGAAAACAGATATTTATCTGAGATTAATGAAATTAATGTAATTTTAACT	1047
Db	661	AATCGGTTGTGTGAAAAACAGGTGTTTAAAGAGATTAAGTAACATATGTAATTTTAACT	720
QY	1048	CAATATATCTTTATTAAGTACAGTCAACAGTGGCGCTTCAATTCAAAGTCCCTTAAG	1107
Db	721	CAGTATCTTTATCTAGAGATAGTCAACAGTGAAGTTTCAAAATTCAAAGTCACTAAAC	780
QY	1108	TTAGCTATTTAATAGGACTAATCTTAGTACCACTAGTACATCTTGTTACATTCAGAC	1167
Db	781	CTAGCATTTATTAAGCACTAATTTATGTGCTATCTAGCACAATTTTATGTCTATACAC	840
QY	1168	TTTGAGCAGTTACTTGATTAAGAAATTAATTAATGTAATTAATTTATTTGTGTCAAAAC	1227
Db	841	TTTGAGCAGGTTATGTGTATTAAGAACATTAATTTGTTAATTTGTACTTTGTCAAAAC	900
QY	1228	TATGATCTCTTTTATGTGGGTCAACATGTGTTAAGGTGATTTGACAAAAAATGTGTATAA	1287
Db	901	TATGACCCCTTATTTGTGGGGCACATGTGTTAAAGTGAATGTAATAAAAAATGTGGCAAA	960
QY	1288	AAAAAACCCGTGTGTTTTTACGGGCAACCAAGTACTGGAAAAACAAATTTGGCATGTGCT	1347
Db	961	AAAAATACCTGTGTGTTTTATGGGCCCGCAAGTACAGAAAAACAACTTGGCATGTGCC	1028
QY	1348	ATTGCTAAAACTGTACAGTGTATGTGAATGTGTAATTTGAAATATGAAAATCTTTCAATTT	1407
Db	1021	ATTGCTAAAAATGTTCAGTATATGCGATGTGTAATTTGAAATATGAAAACTTTCCATTT	1080
QY	1408	AATGATGTAGCGGGGAAAAATTTGTGTGTCTGGAGTAAAGCATTTAATAGTCACTAATTT	1467
Db	1081	AATGATGTAGCAGGGGAAAAAGCTGTGTGTCTGGAGTAAAGCATTTAATAGTCACTAATTT	1140
QY	1468	GTTGAGCTGCAAAAGCACTTTTATGTGTGTACGCAACCGGGGTATGATCAAAAAATGTGT	1527
Db	1141	GTTGAGCTGCAAAAGCCATTTTATGTGTGTGTACGCAACCGGGGTATGATCAAAAAATGTGT	1200
QY	1528	GGCAGTGTGCAGTGCCGCGTGTCTCTGTGTTTAAACAGCAATGTGTACATTTCAATTT	1587
Db	1201	GGAAGTGTAGCTGTGCCCTGAGATACCTGTGTATTAACAGCAATGTGTACATTTCAATTT	1266
QY	1588	GTTGTGATGTGTAATACCATTAACAATCTGTGATCTTAAAGCTTTAAAGAAACGAGATGTA	1647
Db	1261	GTTGTATAGCGGGAACACTTAACAACAATCTGTACATCTTAAAGCTTTAAAGACGATGTA	1320
QY	1648	AAGCTAAACTTTACATATAGATGTAGCCCTGTACATGTGGGTTACTTAACAGAGCGTATGTA	1707
Db	1321	AAGTTAAACTTTATCTATAGATGTAGCCCTGTACATGTGGGTTACTTAACAGAGCGTATGTA	1380
QY	1708	CAACAATGTGCTTAATCTGTGTATATGTCAAAAGCTGAGACCACTATGAAAATCTGGGCATA	1767
Db	1381	CAACAATGTGCTTAATCTGTGTATATGTCAAAAGCTGAGACCACTATGAAAATCTGGGCATA	1440

QY	1768	AACATACAACTTTGATTTCCTCGTAATAAATGCAGATCCCTCCACCAGATCTCCAAAC	1827
Dd	1441	AACATCACTTGTGAATTCCTCGAATTAATGCAATGCCCTCCACCACAACCTCCAAACC	1500
QY	1828	ACCCCATTGTCCTCAGAACACCAAGATACGACGAGTGCTGTGAANAAGCTCTGAAGAATC	1887
Dd	1501	ACCCCAAATGTCAACGACACCCAGATACGACGAGTGCTGTGAANAAGCTCTGAAGAATC	1560
QY	1888	ACTGAAACGAGTTTTTTCACCTCATCACTCCAGGGCGCTGGAAAACGAGAAAACCCGGCG	1947
Dd	1561	AGTGAAGAGAGCTTTCTTAACCTCATCACCCGAGGGCGCTGGAAACATGAAAACCCGGCG	1620
QY	1948	TCTAGTAGCCCCGTCCTCCGGGACCAAGTTCAGAGAAATCAATTTGTCGAAAGCCAGTTTC	2007
Dd	1621	TCTAGTAGCCCCATCCCGGGACCAAGTTCAGAGAAATCAATTTGTCGAAAGCCAGTTTC	1680
QY	2008	TCCGAAGTGTAAGCCGCGTGTGTGGAGAAAGCTTTTTCACGCGCGCTTGCCGATCAGTTT	2067
Dd	1661	TCCGAAGTGTAGTGATGTGATGTGGGAAAGAGCTTTCTCAACACTTTGGACACAGATT	1740
QY	2068	CGTGAACCTGTAGTAGGGGGTTGACTTTGATATGGATGTGTGTGAGGGGATTTGCTGTTTC	2127
Dd	1741	CGTGAACCTGTAGTTGGGGTTGATTTATGTGTGTGAGCGGTGTATAGGGGTTTAACTGTGTGT	1800
QY	2128	TGTGTGAACATTTAAACAACAGTGGGAGAGGTGTGGGCTTTTGCCCTCATGTATTAAT	2187
Dd	1801	TGTGTGAACATTTAAACAATGTGTGGGAGAGGCTTTGGGACTTTGTCTCCACTGTATTAAT	1860
QY	2188	GTTGGAGCTGTGTATTAATGAGTGAATTTTGAAGAGTTTACTCGAAGCTTAAGTGGCTGC	2247
Dd	1861	GTTGGAGCTTGTGTATTAATGAGTGAATTTTGAAGATTTTACCCAGATTTGTGTGGGTGT	1920
QY	2248	AGTTGTCATGTAGAGAGCTCTPAACCATTTTCTGTGTTAACTGTAAAAAATGTGTATC	2307
Dd	1921	AGCTGCAATGTGTGGAGCTTCTTAATCCCTTTCTGTGTAACTGTCAAAAAAATGTGTATC	1980
QY	2308	CTGTCTGATTTAAAGATTTTGTGATTAATGAGTAA	2343
Dd	1981	CTGTCTGATTTCAAGAGCTTTGTGATTAATGAGTAA	2016
 RESULT 8 US-10-082-671-50			
; Sequence 50, Application US/10082671			
; Publication No. US20030049647A1			
; GENERAL INFORMATION:			
; APPLICANT: DAHVIAT, BASSIL			
; TITLE OF INVENTION: USE OF NUCLEIC ACID LIBRARIES TO CREATE TOXICOLOGICAL			
; FILE REFERENCE: XEN/001			
; CURRENT APPLICATION NUMBER: US/10/082,671			
; PRIOR FILING DATE: 2002-05-17			
; PRIOR APPLICATION NUMBER: 60/270,781			
; NUMBER OF SEQ ID NOS: 58			
; SOFTWARE: PatentIn Ver. 2.1			
; SEQ ID NO 50			
; LENGTH: 2016			
; TYPE: DNA			
; ORGANISM: Erythrovirus B19			
US-10-082-671-50			

Query Match	31.5%	Score 1585.6	DB 15	Length 2016
Best Local Similarity	86.7%	Pred. No. 0		
Matches 1747	Conservative	0	Mismatches 259	Indels 0
			Gaps 0	
QY	328	ATGAGACATTTCCGGGGGTCTTGGACATTTCTCTAACATTCGACGTGTATGAT	387	
Db	1	ATGGAGCTATTAGAGGGGTCTTCAAGTTCTTCTAATTTTGGACGTGTAAACAT	60	
QY	388	AACTGTGTGTCTATGCTAGATTTGAATTAATTCTGATCGGAAACCAATCCATCT	447	

Db	61	AACGGGGGGCTCTTTTACTGCAATTTAGACAACCTTCTGACTGGGAACCACTAACCTCACTACT	120
QY	448	AACGATTTAATGGCAATATATTTAAGCAGTGTGGCTTTAACTGAATTTTAACTGGGGG	507
Db	121	AACAGACTAATGGCAATATATCTTAAGCAGTGTGGCTTTAAGCTTGAACCTTACCCGGGGG	180
QY	508	CCGCTAGCAGGTGGCTTAATCTTTTTCAGGTGGAATGTAACTAACTTTAGAGAAAGCTAT	567
Db	181	CCACTAGCAGGGTGGCTGTACTCTTTTTCAGTGAATGAATGAACAAATTTGAAAGGCTAT	240
QY	568	CATATCCATGTAGTTATGTGTGTCCAGAGCTAAATGTAGAAACTTAACTGTGTGGTA	627
Db	241	CATATTCATGTGTATATGGGGGGCCAGGGTTAAACCCAGAAACCTCACTATGTGTGTA	300
QY	628	GAAGGTTATTTAAATTAATGTTCTTTTACACTTGTGAATGAAGTGTAACTTAAATTT	687
Db	301	GAAGGTTATTTAAATTAATGTAATTTTACCTTGTAACTGAATATGTAGACTTAAATTT	360
QY	688	TTGCCAGGATGACTACCAAGGAAATATTTTAGAGTAGAGAGACAGTTATAGAAAT	747
Db	361	TTGCCAGGATGACTACCAAGGAAATCTTTTAGAGTAGAGAGACAGTTATAGAAAC	420
QY	748	TACTAATAGAAAAAATTCCTTTTAAATGTGTGTGTGTGTGAACAAATATGAAGGAT	807
Db	421	TATTTAATAAAAAATACCTTTAAATGTGTATGTGTGTGTTATCTAATATGATGATAT	480
QY	808	ATAGACACTGTATATTTCCGCTCTTTTGGGCGAGAGACTTCACTGCTAAAGACCCCG	867
Db	481	ATATATATCTGTATTTCTGTACTTTTGAAGAGGAGGCTTCCATATGCAAGAAACCCCG	540
QY	868	ATTATCGCAATATCAACACAGTGTCTATATGAACTGGGAGTGTACTGTGAGGGGGA	927
Db	541	ATTATCAAGCCCAATATATATCTATGTATGTCTGGGAGCTAGCCGACAGGGGGA	600
QY	928	GATGTGTGCATATGCTGTGAAAGGGAACAAACCGGGTTAAAGTTTCAACCATGTAT	987
Db	601	GAGTGTGTCCATTTAATGGAGAGGAACTTAGGCTATGCAATTAAGTTTCAACTATGTAT	660
QY	988	AATGTGCTATGTGAAACAGAGTATTTTCTGAATATATGAAATTAAGGATTTTATAC	1047
Db	661	AATGTGCTATGTGAAACAGAGTATTTTCTGAATATATGAAATTAAGGATTTTATAC	720
QY	1048	CAATATATCTTTAATAGTAGAGTCAACAGTGGACGCTTCAATTTCAAGTGTCTTAAAG	1107
Db	721	CAGTACACTTACTAGAGATGACACAGTGGAAAGTTTCAATTTCAAGTGTCTTAAAG	780
QY	1108	TTAGCTATTTAATAGCTATTAACCTAGTACCACTAGTACATTTCTGTATCATTCAGAC	1167
Db	781	CTAGCAATTTAATAGCACTTAATTTAGTGTCTATAGCACTTTTATTTGCTATACAGAC	840
QY	1168	TTTAGCAGGTTACTTSCATTTAAGGAAATTAATATATATTTATTTATGTGTCAAAAC	1227
Db	841	TTTAGCAGGTTATGTATTTAATAGCAATTAATTTGTAATTTGTATCTTTGTCAAAAC	900
QY	1228	TATAGATCTCTTTATGTGGGTCAACATGTGTATAGTGTGATTTGCAAAAAATGTGATAA	1287
Db	901	TATAGATCTCTTTATGTGGGTGAGCAGTGTGTATTAAGTGTATTAATTAATATGTGCAAA	960
QY	1288	AAAAACACCTGTGTGTTTAAAGGGGCAACCAAGTACTGAAAAACAATTTGGCAATGGCT	1347
Db	961	AAAAATCACTGTGTGTTTATATGGCCCGCAAGTACAGGAAAAACAACCTGGCAATGGCC	1020
QY	1348	ATTGTCAAAACTGTACAGTGTATGAAATGTGTGAATTTGAAATATGAAACTTTCAATTT	1407
Db	1021	ATTGTCAAAAGTGTCCAGTATATATGCAATGTGTATTTGAAATATGAAACTTTCAATTT	1080
QY	1408	AATGATGTATGCGGGGAAAAATTTGGTGTCTGGGATTAAGGCACTTTATTAAGTCAATTT	1467
Db	1081	AATGATGTATGCGGGGAAAAATCTGTGTGTCTGGGATTAAGTATTTATTAAGTCAATTT	1140
QY	1468	GTGGAAGCTGCAAAAGCAATTTTAAAGTGTACAGCAACAGGGTATATAGAAAATGTGCT	1527
Db	1141	GTGGAAGCTGCAAAAGCAATTTTAAAGTGTACAGCAACCAAGGATATATCAAAAAATGTGCT	1200

QY 1528 GGAGTGTGACAGTCCCGGTCCTGTGGTTATTAACGACATGTGGACATTACATTT 1587
 DB 1201 GGAAGTGTAGCTGTGCTGGAGTACCTGTGTATTAACGACATGTGGACATTACATTT 1260
 QY 1588 GTTGTGAGTGTATATACACTACATCTGTGATCTTAAGCTTAAAGAACGGATGTA 1647
 DB 1261 GTTGTAGCGGGAACATACACAACTGTACATCTTAAGCTTAAAGAACGGATGTA 1320
 QY 1648 AAGCTAACTTTACCATTAAGATGTAGCCCTGACATGGGTTTACTTACAGAGCTGATGTA 1707
 DB 1321 AAGTTAACTTTACTGTAAAGATGTAGCCCTGACATGGGTTTACTTAAAGAGCTGATGTA 1380
 QY 1708 CAACAATGGCTACTGTGTGTAAATGCAAAAGCTGGAGCACTATGAAAATCTGGGCAATA 1767
 DB 1381 CAACAATGGCTACTGTGTGTAAATGCAAAAGCTGGAGCACTATGAAAATCTGGGCAATA 1440
 QY 1768 AACTACACATTTGATTTCCCTGGAATTAATGACAGATCCCTCAACCAAGATCTCAAAAC 1827
 DB 1441 AACTACACATTTGATTTCCCTGGAATTAATGACAGATCCCTCAACCAAGATCTCAAAAC 1500
 QY 1828 ACCCCCATTTGCCAGACACACAGTATCAGACAGAGTGTGTAAAGCTCTGAAAGATC 1887
 DB 1501 ACCCCCATTTGCCAGACACACAGTATCAGACAGAGTGTGTAAAGCTCTGAAAGATC 1560
 QY 1888 AGTGAAGAGAGCTTTTCAACCTCATCATCCAGGCGCTGGAAACATGTAAACCCCGCGC 1947
 DB 1561 AGTGAAGAGAGCTTTTCAACCTCATCATCCAGGCGCTGGAAACATGTAAACCCCGCGC 1620
 QY 1948 TCTAGTAGCGCCGTCCTGGGAGCCAGTTCAGAGAAATCATTTTGCAGAACCCAGTTTC 2007
 DB 1621 TCTAGTAGCGCCGTCCTGGGAGCCAGTTCAGAGAAATCATTTTGCAGAACCCAGTTTC 1680
 QY 2008 TCCGAATGTGTACCGCGCTGTGGAGAAAGCTTTTCAACGCGCTTGCAGATCATTT 2067
 DB 1681 TCCGAATGTGTACCGCGCTGTGGAGAAAGCTTTTCAACGCGCTTGCAGATCATTT 1740
 QY 2068 CGTGAATGTGTAGAGGGTGTGACTTTGTATGGAATGTGTGAGAGGATGCTGCTTTC 2127
 DB 1741 CGTGAATGTGTAGAGGGTGTGACTTTGTATGGAATGTGTGAGAGGATGCTGCTTTC 1800
 QY 2128 TGTGTGACATATTAACAACAGTGGGAGAGGCTTTTCCCTCATTTGATTAAT 2187
 DB 1801 TGTGTGACATATTAACAACAGTGGGAGAGGCTTTTCCCTCATTTGATTAAT 1860
 QY 2188 GTGGAGCTTGTATTAATGAGAAATTTAGAGATTTTCTCCAGACTTATGTCGCTGC 2247
 DB 1861 GTGGAGCTTGTATTAATGAGAAATTTAGAGATTTTCTCCAGACTTATGTCGCTGC 1920
 QY 2248 AGTGTGATGTAGAGCTCTTAACCCATTTTCTGTGTAACTGTGAAAAATGTCTTAC 2307
 DB 1921 AGTGTGATGTAGAGCTCTTAACCCATTTTCTGTGTAACTGTGAAAAATGTCTTAC 1980
 QY 2308 CTGTCTGATTAACAAGTTTGTAGTTATGATGA 2343
 DB 1981 CTGTCTGATTAACAAGCTTGTAGTTATGATGA 2016

RESULT 9
 US-10-097-100-44
 ; Sequence 44: Application US/10097100
 ; Publication No. US20030068649A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Li, Min
 ; APPLICANT: Melander, Christian
 ; APPLICANT: Liu, Hong-Xiang
 ; APPLICANT: Jin, Cheng He
 ; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR THE CONSTRUCTION AND USE OF FUSION I
 ; FILE REFERENCE: A-70814/RFT/RMS/RMK
 ; CURRENT APPLICATION NUMBER: US/10/097,100
 ; PRIOR APPLICATION NUMBER: US/09/953,351
 ; PRIOR FILING DATE: 2001-09-14

; PRIOR APPLICATION NUMBER: US 60/232,960
 ; PRIOR FILING DATE: 2000-09-14
 ; NUMBER OF SEQ ID NOS: 56
 ; SOFTWARE: PatentIn version 3.1
 ; SEQ ID NO 44
 ; LENGTH: 2016
 ; TYPE: DNA
 ; ORGANISM: Erythrovirus B19
 US-10-097-100-44
 Query Match 31.5%; Score 1585.6; DB 15; Length 2016;
 Best Local Similarity 86.7%; Pred. No. 0;
 Matches 1747; Conservative 0; Mismatches 269; Indels 0; Gaps 0;
 QY 328 ATGAGCTATTTGGGGTGTCTTGACATTTCTCTTACATTTTGACATGTGCTATATGAT 387
 DB 1 ATGAGCTATTTAGAGGGGTGCTTCAAGTTCTTCAATGTTCTGACATGTGCTATACAT 60
 QY 388 AACGTGGTGTCTCTATAGCTTACATTAAGATCTTGAAGTGGAAACCACTAACCATTTCT 447
 DB 61 AACTGTGTGTCTCTTACTTACATTTAGACATTTCTGACGTGGAAACCACTATCATACT 120
 QY 448 AACGATTAATGGCAATATATTTAAGCAGTGTGCTTAACTTGAATTTTACTGGGGGG 507
 DB 121 AACGATTAATGGCAATATATTTAAGCAGTGTGCTTAACTTGAATTTTACTGGGGGG 180
 QY 508 CCGGTACAGAGTGTCTTATCTTTTTCAGGTGGAATGTAACTTAATTTGAGAAAGCTAT 567
 DB 181 CCACTACAGAGGTGTGTATCTTTTTCAGGTGGAATGTAACTTAATTTGAGAAAGCTAT 240
 QY 568 CATATCATGTATTTATGTGTGTGTCAGACCTAATGTCTGAACCTTAACTGTGTGCTA 627
 DB 241 CATATCATGTGTATTTATGTGTGTGTCAGACCTAATGTCTGAACCTTAACTGTGTGCTA 300
 QY 628 GAAGTTTATTTATATATGTTCTTTACCATCTTGTATCTGAAGTGTAACTTAATTT 687
 DB 301 GAAGTTTATTTATATATGTTCTTTACCATCTTGTATCTGAAGTGTAACTTAATTT 360
 QY 688 TTGCGAGGATGTACTACAAAGAAATATTTAGATGTGAAGACGTTATTAAGAAAT 747
 DB 361 TTGCGAGGATGTACTACAAAGAAATATTTAGATGTGAAGACGTTATTAAGAAAT 420
 QY 748 TACTTATGAAGAAATATCCCTTAATGTGTGTGTGTATCAATATTTGACGGGTAT 807
 DB 421 TACTTATGAAGAAATATCCCTTAATGTGTGTGTGTATCAATATTTGACGGGTAT 480
 QY 808 ATAGACACCTGTATTTCCGCTCTTTTGGCGAGAGCTTGTATGCTTAAAGACCCCGC 867
 DB 481 ATAGACACCTGTATTTCCGCTCTTTTGGCGAGAGCTTGTATGCTTAAAGACCCCGC 540
 QY 868 ATTACTGCAATACAGACAGTGTCTACTATGAATGTGGGAGTCTAGCTGTGAGGGGA 927
 DB 541 ATTACTGCAATACAGACAGTGTCTACTATGAATGTGGGAGTCTAGCTGTGAGGGGA 600
 QY 928 GATGTGTGCTATTCCTGTGAAGGGAACAAAGCGGGTTAAAGTTTCAACCATGTGTA 987
 DB 601 GATGTGTGCTATTCCTGTGAAGGGAACAAAGCGGGTTAAAGTTTCAACCATGTGTA 660
 QY 988 AATTGCTATGTGAAAAACAGAGTATTTTACAGAGATTAATGAGAAATTTAGTGAATTTAAC 1047
 DB 661 AATTGCTATGTGAAAAACAGAGTATTTTACAGAGATTAATGAGAAATTTAGTGAATTTAAC 720
 QY 1048 CAATATATCTTTATTAAGTACAGTCAAGTGTGCACTTTCAATTTCAAGTGTCTTAAG 1107
 DB 721 CAATATATCTTTATTAAGTACAGTCAAGTGTGCACTTTCAATTTCAAGTGTCTTAAG 780
 QY 1108 TTGAGTATTTATTAAGTCTACTATAGTACCACTAGTACATTTCTTGTATCACTTGAC 1167
 DB 781 TTGAGTATTTATTAAGTCTACTATAGTACCACTAGTACATTTCTTGTATCACTTGAC 840
 QY 1168 TTGAGCAGGTTACTGTCAATTAAGAAATTAATATGTAATTTATTTATGTGTCAAAAC 1227
 DB 841 TTGAGCAGGTTATGTGTATTAAGCAATTAATTTGTAATTTGTTACTTGTGTCAAAAC 900

QY 988 AATGCTATGTGAAAACAGAGTATTTACTGAAATGAAATTAAGTATTTTAC 1047
 Db 661 AACTGTTGTGTGAAAACAGAGTATTTACAGAGATTAAGTAACTAGTATTTTAC 720
 QY 1048 CAATATATCTTTATTAAGTACAGTACAGTGGCAGCTTTCAATTAAGTCCCTTAAG 1107
 Db 721 CAGTACACTTTTACTTAAGTACAGTACAGTGGAGTCTTCAATTAAGTCCCTTAAG 780
 QY 1108 TTATGCTTTTATTAAGTACATTAATTTTATTAAGTCCCTTAAGTCCCTTAAG 1167
 Db 781 CTAGCAATTTTATTAAGTACATTAATTTTATTAAGTCCCTTAAGTCCCTTAAG 840
 QY 1168 TTGAGCAGGTTTCTTCAATTAAGTAAATTAATTAATTAATTTTATTAAGTCCCTTAAG 1227
 Db 841 TTGAGCAGGTTTCTTCAATTAAGTAAATTAATTAATTTTATTAAGTCCCTTAAG 900
 QY 1228 TATGATCTCTTTATTAAGTGGTCAATGTGTAAAGTGGATTTGACAAAATGTGTAA 1287
 Db 901 TATGATCTCTTTATTAAGTGGTCAATGTGTAAAGTGGATTTGACAAAATGTGTAA 960
 QY 1288 AAAAAACCCCTGTGTGTTTACGGGCAACAGTACTGAAAAACAAATTTGGCAATGCT 1347
 Db 961 AAAAAATCACGTGTGTGTTTATGGCCGCCCAAGTACAGAAAAACAAATTTGGCAATGCT 1020
 QY 1348 ATTGCTAAAACTGATCAAGTATGAATGTGAATTTGAAATTAATTAATTTTCAATTT 1407
 Db 1021 ATTGCTAAAACTGATCAAGTATGAATGTGAATTTGAAATTAATTAATTTTCAATTT 1080
 QY 1408 AATGATGTACGGGGAAGT 1467
 Db 1081 AATGATGTACGGGGAAGT 1140
 QY 1468 GTGAGACTGCAAAAGCAATTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1527
 Db 1141 GTGAGACTGCAAAAGCAATTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1200
 QY 1528 GGCAGTGTGCAAGTCCCGGT 1587
 Db 1201 GGCAGTGTGCAAGTCCCGGT 1260
 QY 1588 GTTGTGAGTGTATATACCACTACCACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1647
 Db 1261 GTTGTGAGTGTATATACCACTACCACTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1320
 QY 1648 AAGCTAACTTTTACCATTAAGTGTAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1707
 Db 1321 AAGCTAACTTTTACCATTAAGTGTAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1380
 QY 1708 CAACAAATGTGTACTTGT 1767
 Db 1381 CAACAAATGTGTACTTGT 1440
 QY 1768 AACTACATTTTGTATTTTCCCTGTGAATTAATGTAGATGCTTCCACCAAGCTTCCAAAC 1827
 Db 1441 AACTACATTTTGTATTTTCCCTGTGAATTAATGTAGATGCTTCCACCAAGCTTCCAAAC 1500
 QY 1828 ACCCCATTTTCCAGACACCATGTATGACAGAGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1887
 Db 1501 ACCCCATTTTCCAGACACCATGTATGACAGAGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1560
 QY 1888 AGTGAAGAGAGCTTTTCAACCTGTATGATCTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1947
 Db 1561 AGTGAAGAGAGCTTTTCAACCTGTATGATCTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1620
 QY 1948 TCTAGTATGCGCCGTCCTCCGGGACAGTTCAGAGAAATCATTTTGTGTGTGTGTGTGTGT 2007
 Db 1621 TCTAGTATGCGCCGTCCTCCGGGACAGTTCAGAGAAATCATTTTGTGTGTGTGTGTGTGT 1680
 QY 2008 TCCGAAGTGTATGCGCGGT 2067
 Db 1681 TCCGAAGTGTATGCGCGGT 1740

QY 2068 CGTGAACCTGTATGAGGGGTGTGACTTTGTATGAGGATGTGTGTGTGTGTGTGTGTGTGC 2127
 Db 1741 CGTGAACCTGTATGAGGGGTGTGACTTTGTATGAGGATGTGTGTGTGTGTGTGTGTGTGC 1800
 QY 2128 TGTGTGAACATATTAACCAACAGTGGGGGAGGGTGTGGGCTTTGGCTTCAATTTATAT 2187
 Db 1801 TGTGTGAACATATTAACCAACAGTGGGGGAGGGTGTGGGCTTTGGCTTCAATTTATAT 1860
 QY 2188 GTGGGAGCTGTGTATATATGATGAATTAATTAAGAGTGTATCTCAGACTTATGCGGCTGC 2247
 Db 1861 GTGGGAGCTGTGTATATATGATGAATTAATTAAGAGTGTATCTCAGACTTATGCGGCTGC 1920
 QY 2248 AGTGTGATGTAGAGGCTTCAACCAATTTCTGTGTATCTGTATTAATTAATTAATGTCTTAC 2307
 Db 1921 AGTGTGATGTAGAGGCTTCAACCAATTTCTGTGTATCTGTATTAATTAATTAATGTCTTAC 1980
 QY 2308 CTGTGTGATTAACAAAGTTTGTATGATTAAGTAA 2343
 Db 1981 CTGTGTGATTAACAAAGTTTGTATGATTAAGTAA 2016

RESULT 11
 US-10-187-253A-24
 ; Sequence 24, Application US/10187253A
 ; Publication No. US20030170612A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Pichuanes, Sergio
 ; APPLICANT: Shyamala, Venkatakrishna
 ; TITLE OF INVENTION: DIAGNOSTIC ASSAYS FOR PARVOVIRUS B19
 ; FILE REFERENCE: CHIR-17194/03US / PP17194.004
 ; CURRENT APPLICATION NUMBER: US/10/187,253A
 ; NUMBER OF SEQ ID NOS: 92
 ; SOFTWARE: Patent In Ver. 2.0
 ; SEQ ID NO 24
 ; LENGTH: 2049
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: NS1 from
 ; OTHER INFORMATION: parovirus B19 clone 2-B1
 ; US-10-187-253A-24

Query Match 31.4%; Score 1579.6; DB 15; Length 2049;
 Best Local Similarity 85.8%; Pred. No. 0;
 Matches 1753; Conservative 0; Mismatches 289; Indels 0; Gaps 0;
 QY 312 CTTTAACTTAACTTAACAGTGGAGCTATTTCCGGGTGTCTTGCACATTTCTCTAACTTCT 371
 Db 6 CTTTGAACAAACAAATTAAGTATTTAGAGGGGTCTTCAAGTTCTTCTAATGTCTT 65
 QY 372 GAGCTGTCTTAATGATTAATGATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 431
 Db 66 GAGCTGTCTTAATGATTAATGATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 125
 QY 432 ACCACTTAACCATTTCTTAACGATTAATGTGCAATATATTTAAGAGATGTGTCTTAAC 491
 Db 126 ACCACTTAACCATTTCTTAACGATTAATGTGCAATATATTTAAGAGATGTGTCTTAAC 185
 QY 492 TGAATTTTACTGGGGGGGCGGT 551
 Db 186 TGAATTTTACTGGGGGGGCGGT 245
 QY 552 ATTGAAGAGAGCTATCATATTCATATGATTAATGTGTGTGTGTGTGTGTGTGTGTGTGT 611
 Db 246 ATTGAAGAGAGCTATCATATTCATATGATTAATGTGTGTGTGTGTGTGTGTGTGTGTGT 305
 QY 612 CTTAATGT 671
 Db 306 CTTTCAAGT 365
 QY 672 TGTAAACTTAATTTTGT 731


```

Db      66 GAGCTGCTAAGATTAAGTGTGTCTCTTACTGATTTAGACACTTCTGACGTGGGA 125
Qy      432 ACCACTAACCATTCTTAACAGATTATGCAATATATTTAAGACAGTGTCTTAACT 491
Db      126 ACCACTAACCATTCTTAACAGATTATGCAATATATTTAAGACAGTGTCTTAACT 185
Qy      492 TGAATTTACTGGGGGGCCGTAGCAGGTGCTTAACTTTTTCAGGTGGAATGTAACA 551
Db      186 TGAATTTACTGGGGGGCCGTAGCAGGTGCTTAACTTTTTCAGGTGGAATGTAACA 245
Qy      552 ATTGAGGAAGGCTATCATATCCATGATGATTTGCTGTCAGACATTAATCTAGAAA 611
Db      246 ATTGAGGAAGGCTATCATATTCATGTGTTATTTGGGGGGCCAGGGTTAAACCCAGAAA 305
Qy      612 CTTAACCTGTGCTGAGAGGTTTATTAATTAATGTTCTTTACCATCTTGAACGTAAG 671
Db      306 CCTCACAAGTGTGTAGAGGGGTTATTTAATTAATGTTACTTATCACCCTGTGAACGTA 365
Qy      672 TGTTAATCTTAATTTTGGCAGGATGATACCAAGGAATATTTTGAAGATGAGA 731
Db      366 TGTGAAGCTAAATTTTTCAGGAATGACTACAAAAGCAAAATCTTAAGAGATGAGA 425
Qy      732 GCAGTTTATGAAAAATTAATTAAGAAAAATTCCTTAAATGTTGTGTGTGTAACT 791
Db      426 GCAGTTTATGAAAAATTAATTAAGAAAAATTCCTTAAATGTTGTGTGTGTAACT 485
Qy      792 AAATATTGACGGGTATATAGACACTGTATTTCCGCTCTTTTCGGGAGAGACTGTCA 851
Db      486 TAATATTGATGACATATATATATCTGTATTTCTGTCTTATTAAGAAAGGAGACTGTCCA 545
Qy      852 TGTAAAGACCCCGCATTTCTGCAAAATACAGACAGTCTACTTAAGAACTGGGAGTC 911
Db      546 TGTCAAGAAACCCCGCATTCACACAGCATTAATGAACTAGATCTGGGAGTC 605
Qy      912 TACCTGTGAGGGGAGATTTGTGCAATCGCTGGAAGGAAACAACCCGGGTTAA 971
Db      606 TACGGCAGAGGGGAGAGTTGTGCAATTTAATGGAGAGGAACTAGGCTAGCATTA 665
Qy      972 GTTTCAACCATGTAATTAATGCTATGTGAAAAACAGATTTTAAGAGATTAATGAA 1031
Db      666 GTTTCAACCATGTAATTAATGCTATGTGAAAAACAGATTTTAAGAGATTAATGAA 725
Qy      1032 ATTATGATATTTTAACCAATTAATTTAATGAGAGTCAAGTGGACGCTTCAAT 1091
Db      726 ACTAGTGTACTTAACCAATTAATTTAATGAGAGTCAAGTGGAGTTTCAAT 785
Qy      1092 TCAAGGCTTAAAGTTAGCTATTTAATTAAGCTACTAAGTCACTAGTACAT 1151
Db      786 TCAAGGCTTAAAGTTAGCTATTTAATTAAGCTACTAAGTCACTAGTACAT 845
Qy      1152 CTGTGATACATGAGCTTTGAGCAGGTTACTTGATTAAGAAATTAATTAATTAAT 1211
Db      846 TTTATTGATACATGAGCTTTGAGCAGGTTATGTGATTAAGAAATTAATTAATTAAT 905
Qy      1212 ATTATTTGTGCAAACTATGATCTCTTTTATGAGGTCACAGTGTGTAAGGTGATGA 1271
Db      906 GTTACTTTGTCAAACTATGATCCCTTATTAAGTGGGACAGATGTGTTAAAGGTGATGA 965
Qy      1272 CAATAATGCTGTAATAAATAAACAACCCGTGTGTTTAAAGGGGCAACAAGTCTGGA 1331
Db      966 TAAATAATGCTGTAATAAATAAACAACCCGTGTGTTTAAAGGGGCAACAAGTCTGGA 1025
Qy      1332 AAATTTGCAATGCTATTTGCTAAACCTGTAACAGTGTATGAAATGGAATTA 1391
Db      1026 AAATTTGCAATGCTATTTGCTAAACCTGTAACAGTGTATGGAATGGAATTA 1085
Qy      1392 TGAATACTTTCCATTTATGATGAGCGGGAAAAAGTTGTGTCTGGGATGAAGCAT 1451
Db      1086 TGAATACTTTCCATTTATGATGAGGAAAAAGTTGTGTCTGGGATGAAGCAT 1145
Qy      1452 TATTAGTCACTATTTGTGAGAGTGAAGGCAATTTTATGAGTGTGAGCAACAGGAT 1511

```

```

Db      1146 TATTAGTCACTAATTTGTAAGAGCTGCAAAAGCATTTTATAGCGGGCAACCAAGGAT 1205
Qy      1512 AGATCAAGAAATGCGGAGAGTGTGGCAGTGGCCGGTGTGCTGTGTTAATACAGCA 1571
Db      1206 AGATCAAGAAATGCGGAGAGTGTGTAGCTGTGCTGAGTACCCGTGTATTAACAGCA 1265
Qy      1572 TGGTGAATTAATCTTTGTTGTGAGTGTATATCACTAACAATGTCATGCTTAAAGCTTT 1631
Db      1266 TGGTGAATTAATCTTTGTTGTGAGTGTATGAGCGGAACACTAACAATGTCATGCTTAAAGCTTT 1325
Qy      1632 AAAGGAAGGATGTAAGCTTAACTTAACTTAACTAATAGATGTAGCCCTGACATGGGTTACT 1691
Db      1326 AAAGGAAGGATGTAAGCTTAACTTAACTTAACTTAACTAATAGATGTAGCCCTGACATGGGTTACT 1385
Qy      1692 TACAGAGCTGTATGTAACAATAGGCTAATCTGTGTATATGCAACAAGCTGGAGCACTA 1751
Db      1386 AACAGAGGCTGTATGTAACAATAGGCTAATCTGTGTATATGCAACAAGCTGGAGCACTA 1445
Qy      1752 TGAATACTGGGCAATTAATCACTATTTATTTCCCTGGAATTAATGCAAGATCCCTCA 1811
Db      1446 TGAATACTGGGCAATTAATCACTATTTATTTCCCTGGAATTAATGCAAGATCCCTCA 1505
Qy      1812 CCCAGATCTTCCAAACCAACCCCAATTTGTCCAGACACAGATTCAGACAGATGTGTGTA 1871
Db      1506 CCCAGATCTTCCAAACCAACCCCAATTTGTCCAGACACAGATTCAGACAGATGTGTGTA 1565
Qy      1872 AAGCTTGAAGAACTAGTGAAGAGAGCTTTTCAACTTCATCTCAAGTCCAGGCTTGGAA 1931
Db      1566 AAGCTTGAAGAACTAGTGAAGAGAGCTTTTCAACTTCATCTCAAGTCCAGGCTTGGAA 1625
Qy      1932 CAGTGAACCCCGGCTCTAGTACGCGCCGTCGCCGGAACAAGTTGACAGAGATCATTTGT 1991
Db      1626 CAGTGAACCCCGGCTCTAGTACGCGCCGTCGCCGGAACAAGTTGACAGAGATCATCTGT 1685
Qy      1992 CGGAAGCCCAAGTTTCTCCGAAGTGTAGCCGCTGTGTGAGAAAGCTTTTACAGCC 2051
Db      1686 CGGAAGCCCAAGTTTCTCCGAAGTGTAGCTGTGTGTGAGAAAGCTTTTACAGACC 1745
Qy      2052 GCTTGCCGATCACTTTCGTAAGTGTAGTGTAGGAGTTGACTTTGTATAGGATGTGTAG 2111
Db      1746 TTTGGAAGACCAAGTTTCGTAAGTGTAGTGTAGGAGTTGACTTTGTATGTGTGAGCGTGTAG 1805
Qy      2112 GGGATTCGCTGTTGTGCTGTGTGGAACATTAACAACAAGTGGGAGAGGTTTGGGCTTTG 2171
Db      1806 GGGATTCGCTGTTGTGCTGTGTGGAACATTAACAACAAGTGGGAGAGGTTTGGGCTTTG 1865
Qy      2172 CCTCATTTGATTAATGTGGAGCTGTGTATTAATGATGGAATTTAGAGATTTACTCC 2231
Db      1866 TCCCATTTGATTAATGTGGAGCTGTGTATTAATGATGGAATTTAGAGATTTACTCC 1925
Qy      2232 AGACTTATGCTGCAAGTGTGTATGTATGAGAGCTCTTAACCAATTTCTGTGTTAACTTG 2291
Db      1926 AGACTTATGCTGCAAGTGTGTATGTATGAGAGCTCTTAATCCCTTTCTGTGTTAACTTG 1985
Qy      2292 TAAATAATGCTTACTGCTGTGATTTAACAAGTTTGTATGATTAATGATTAACAACCTA 2351
Db      1986 CAATAATGCTTACTGCTGTGATTTAACAAGTTTGTATGATTAATGATTAACAACCTA 2045
Qy      2352 AC 2353
Db      2046 AC 2047

```

```

RESULT 13
US-09-792-630-42
; Sequence 42, Application us/09792630
; Patient No. US2002016640A1
; GENERAL INFORMATION:
; APPLICANT: Lt. Min
; APPLICANT: Dahiyat, Basil I.
; TITLE OF INVENTION: BIOCHIPS COMPRISING NUCLEIC ACID/PROTEIN CONJUGATES
; FILE REFERENCE: A-70295/RFT/RMS/RMK
; CURRENT APPLICATION NUMBER: US/09/792, 630

```

;; CURRENT FILING DATE: 2001-02-22
;; NUMBER OF SEQ ID NOS: 87
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO: 42
;; LENGTH: 2016
;; TYPE: DNA
;; ORGANISM: B19 virus
US-09-792-630-42

Query Match 31.3%; Score 1576; DB 9; Length 2016;
Best Local Similarity 86.4%; Pred. No. 0;
Matches 1741; Conservative 0; Mismatches 275; Indels 0; Gaps 0;

```
QY 328 ATGAGCTATTTCGGGGTCTTTCACATTTCTTAACTTTCGACTGCTGTAATGAT 387
DB 1 ATGAGCTATTTCAGGGGGTCTTCAAGTTTCTTAACTTTCGACTGCTGTAATGAT 60
QY 388 AACTGCTGCTCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCTAGCT 447
DB 61 AACTGCTGCTCTTCTTACTGATTTTGAACCTTCTGACCTGACCTAGCTAGCT 120
QY 448 AACGATTATTCGCAATATTTTAAAGCACTGCTTCTTAACTTTCGACTGCTAG 507
DB 121 AACGACTTAATTCGCAATATTTTAAAGCACTGCTTCTTAACTTTCGACTGCT 180
QY 508 CCGCTAGCAGTCTGCTTATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 180
DB 181 CCACTAGCAGTCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 240
QY 568 CATTCATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 627
DB 241 CATTCATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 300
QY 628 GAAGCTTATTTTAAATGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 687
DB 301 GAAGGCTTATTTTAAATGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 360
QY 688 TTGCGCAGGATGATCTACCAAGGAAATTTTAAAGATGAGAGCAGTTTATGAA 747
DB 361 TTGCGCAGGATGATCTACCAAGGAAATTTTAAAGATGAGAGCAGTTTATGAA 420
QY 748 TACTTATGAAATTAATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 807
DB 421 TACTTATGAAATTAATCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 480
QY 808 ATAGCAGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 867
DB 481 ATAGTACTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 540
QY 868 ATTACTGCAATATACAGACAGTCTACTAATGAAATCTGGGAGCTTCTGAGG 927
DB 541 ATTAACACAGCATAATATGACATGATGATGCTGGGAGCTTCTGAGGAGCA 600
QY 928 GAGCTTGTGCTTCTGCTGAGGAAAGGAAAGGCGGGTAAAGTTTAAACCAAT 987
DB 601 GAGGTTGTGCTTCTGCTGAGGAAAGGAAAGGCGGGTAAAGTTTAAACCAAT 660
QY 988 AATTGCTATGTGAGGAAACAGAGTATTTACTGAAATGAAATTTAGTGGATTT 1047
DB 661 AACTGCTGCTGAGGAAACAGAGTATTTACTGAAATGAAATTTAGTGGATTT 1107
QY 1048 CAATATCTTATTAAGTACAGTCTACAGTCTGAGCTTCAATTTCAATGAGCT 1167
DB 721 CAGTATCACTTCTTCTAGCAGTATGCTACAGTCTGAGCTTCAATTTCAAT 780
QY 1108 TTAGCTATTTATTAAGCTCTAATCTTAACTTAACTTAACTTAACTTAACT 1167
DB 781 CTAGCAATTTATTAAGCACTAATTTAGCTCTTAACTTAACTTAACTTAACT 840
QY 1168 TTGAGCAGGTTACTGCTTAAAGAAATTAATTAATTAATTAATTAATTAAT 1227
DB 841 TTGAGCAGGTTATGCTTAAAGCACTAATTTAGCTCTTAACTTAACTTAACT 900
```

```
QY 1228 TATGATCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1287
DB 901 TATGATCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 960
QY 1288 AAAAACAACCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1347
DB 961 AAAAATACCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1020
QY 1348 ATTCCTAAATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1407
DB 1021 ATTCCTAAATCTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1080
QY 1408 AATGATGACGCGGAGGAAAGTTTCTGCTGCTGCTGCTGCTGCTGCTGCT 1467
DB 1081 AATGATGACGCGGAGGAAAGTTTCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
QY 1468 GTGGAAGCTGCAAAAGCCATTTTAAAGTGTGCAAGCAACAGGCTGATCA 1527
DB 1141 GTGGAAGCTGCAAAAGCCATTTTAAAGTGTGCAAGCAACAGGCTGATCA 1200
QY 1528 GGCAGTGTGCGAGTGTGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1587
DB 1201 GGCAGTGTGCGAGTGTGCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1260
QY 1588 GTTGTGAGTGTATTCACATCAACCTGTGCTGCTGCTGCTGCTGCTGCTG 1647
DB 1261 GTTGTGAGTGTATTCACATCAACCTGTGCTGCTGCTGCTGCTGCTGCTG 1320
QY 1648 AAGCTTAACTTTCATCAATGATGATGCTGCTGCTGCTGCTGCTGCTGCTG 1707
DB 1321 AAGCTTAACTTTCATCAATGATGATGCTGCTGCTGCTGCTGCTGCTGCTG 1380
QY 1708 CAACAATGCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1767
DB 1381 CAACAATGCTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1440
QY 1768 AACTACATTTGATTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1827
DB 1441 AACTACATTTGATTTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1500
QY 1828 ACCCCATTTGCTCCAGACACACAGTATCAGACAGTGTGCTGCTGCTGCTGCT 1887
DB 1501 ACCCCATTTGCTCCAGACACACAGTATCAGACAGTGTGCTGCTGCTGCTGCT 1560
QY 1888 AGTGAAGCAGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1947
DB 1561 AGTGAAGCAGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1620
QY 1948 TCTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2007
DB 1621 TCTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1680
QY 2008 TCCGAAGTGTGAGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2067
DB 1681 TCCGAAGTGTGAGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1740
QY 2068 CCGGAACTGTGAGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 2127
DB 1741 CCGGAACTGTGAGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1800
QY 2128 TGTGTGGAACATATTAACAACAGTGGGAGGCTTGGGAGCTTGGGAGCTTGG 2187
DB 1801 TGTGTGGAACATATTAACAACAGTGGGAGGCTTGGGAGCTTGGGAGCTTGG 1860
QY 2188 GTGGAGCTTGTGATTAATGATGAGGAAATTTAGAGATTTCTCAGACTTA 2247
DB 1861 GTGGAGCTTGTGATTAATGATGAGGAAATTTAGAGATTTCTCAGACTTA 1920
QY 2248 AGTGTGATGAGGAGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 2307
DB 1921 AGTGTGATGAGGAGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1980
QY 2308 CTGCTGATTAACAAGTTTGTGATTAATGATTA 2343
```


QY 2068 CGTGAAGTGTAGTAGGGGCTGACTTGTATGAGATGCTGTAGGGGANTTCCCTGTTTC 2127
DB 1741 CGTGAAGTGTAGTAGGGGCTGACTTGTATGAGATGCTGTAGGGGANTTCCCTGTTTC 1800
QY 2128 TGTGTGGAACATTAATTAACACAGTGGGAGAGGCTTGGGCTTGGCCCTCATTTGATTAAT 2187
DB 1801 TGTGTGGAACATTAATTAACAGTGGGAGAGGCTTGGGCTTGGCCCTCATTTGATTAAT 1860
QY 2188 GTGGAGAGTGTGTATTAATGATGGAATTTAGAGATTTATCTCAAGCTTAACTGCGCTGC 2247
DB 1861 GTAGGGCTTGTGTATTAATGATGGAATTTAGAGATTTATCTCAAGCTTAACTGCGCTGC 1920
QY 2248 AGTTGTATGTAGAGGCTTAAACCATTTCTGTGTAACTGTATTAATTAATGCTTAC 2307
DB 1921 AGCTGCATGTGGAGGCTTAACTTCTTCTGTCTAACTGCAAAAATGTGCTTAC 1980
QY 2308 CTGCTGAGATTACAAAGTTTGTAGATTTATGAGTAA 2343
DB 1981 CTGCTGAGATTACAAAGCTTGTAGATTTATGAGTAA 2016

RESULT 15
US-10-080-376-42
; Sequence 42, Application US/10080376
; Publication No. US20020172968A1
; GENERAL INFORMATION:
; APPLICANT: Ii, Min
; APPLICANT: Daiyut, Basai I.
; TITLE OF INVENTION: BIOCHIPS COMPRISING NUCLEIC ACID/PROTEIN CONJUGATES
; FILE REFERENCE: A-70295-2/Rf/RMS/BMK
; CURRENT APPLICATION NUMBER: US/10/080,376
; PRIOR FILING DATE: 2000-02-19
; PRIOR APPLICATION NUMBER: US 09/792,630
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: Patent version 3.1
; SEQ ID NO 42
; LENGTH: 2016
; TYPE: DNA
; ORGANISM: B19 virus
US-10-080-376-42

Query Match 31.3%, Score 1576, DB 14, Length 2016;
Best Local Similarity 86.4%, Pred. No. 0;
Matches 1741, Conservative 0; Mismatches 275; Indels 0; Gaps 0;

QY 328 ATGAGGCAATTTGGGGGTCTTGCACATTTCTCTAACAATTCGACTGTGCTATGAT 387
DB 1 ATGAGGCAATTTAGAGGGGTCTTCAAGTTCTTCTAATGTTCTGAGCTGTCAACAT 60
QY 388 AACTGTGTGTCTCTATGACTAGATTAATTAATCTTGAACGAGGAAACCACTTCT 447
DB 61 AACTGTGTGTCTCTTACTGATTTAGACATTTCTGACTGGGAAACCACTTCTACT 120
QY 448 AACAGATTATGCAATATTTTAAGCATGTTGCTTCAAACTGATTTTACTGGGGG 507
DB 121 AAGAGATTATGCAATATTAACCAATGTGCTTCAAGCTTGAACCTTAAACGGGGG 180
QY 508 CCGCTAGCAGGTGTCTATATCTTTTTCAGTGGAAATGTAACAATTTGAGAGGCTAT 567
DB 181 CCACTAGCGGGGTCTGTACTTTTTCAGAGATGTAACAATTTGAGAGGCTAT 240
QY 568 CATATCAGTGTATTTGTGTGTCCAGGACTTAAATGCTAGAACTTAACTGTGCTGA 627
DB 241 CATATCAGTGTATTTGTGTGTCCAGGACTTAAACCCAGAACTCAGAGTGTGTA 300
QY 628 GAAGGTTATTTAATATGTTCTTACACATCTTGAATCTGAAGTGTAAAGTAAATTT 687
DB 301 GAGGGGTATTTAATATGTTCTTACCTTGTACTGAAATGTAAGCTTAAATTT 360
QY 688 TTGCAAGGATGACTACCAAGAAATATTTTGAAGTGAAGAGGATTTATGAAT 747

DB 361 TTGCCAGGAATGACTACAAAAGCAATACTTTAGAGATGAGAGCATTTATAGAAAC 420
QY 748 TACTTAATGAAAAAATTCCTTTAAATGTTGTGTGTGTGTAAACAATATGACGGGT 807
DB 421 TATTTAATGAAAAAATTAACCTTTAAATGTTGTGTGTGTGTAAACAATATGAGAT 480
QY 808 ATAGACCTGTATTTCCCGCTTTTTCGCGAGAGCTTGTCAATGCTAAAGACCCGC 867
DB 481 ATAGATCTGTATTTCTGTACTTTTGAAGGGAGCTTGCATGCAAGAAACCCGC 540
QY 868 ATTAGCAATATACAGACAGTGTACTAATGAAATGAAATTAATGATTTATGATTTAC 1047
DB 541 ATTAGCAAGCCATTAATGACACTAGTATGATGCTGGAGATCTAGCGGACAGGGCA 600
QY 928 GATGTGTCCATTCCTCGGAAAGGAAACAAAAGCGGGTTAAAGTTCAACATGCTA 987
DB 601 GAGGTGTGCAATTAATGGAAGGAACTAAGGCTACATTAAGTTCAATATGCTA 660
QY 988 AATGTCTATGTGAAACAGATATTTACTGAATTAATGAAATTAATGATTTATGATTTAC 1047
DB 661 AACTGTGTGTGAAACAGAGTGTTCAGAGATTAATGAAATTAATGATTTATGATTTAC 720
QY 1048 CAATATCTTATTAATGATGACATGACAGTGCAGCTTCAATTCAAAGTGCCTTAA 1107
DB 721 CAGTACATTTACTAGAGAGTACACAGTGAAGTTTCAATTCAAAGTGCCTTAA 780
QY 1108 TTAGCTATTTAATTAAGTACTTAACTTGTACCCACTGTACTTCTTGTATCAATCA 1167
DB 781 CTAGCAATTTAATTAAGCACTTAACTTGTGTCTTCAAGCAATTTCTATGCAATCA 840
QY 1168 TTGAGCAGGTTACTGTATTAAGAAATTAATTAATTAATTAATTAATTAATTAAT 1227
DB 841 TTGAGCAGGTTACTGTATTAAGAAATTAATTAATTAATTAATTAATTAATTAAT 900
QY 1228 TATGATCTCTTTTATGAGGTCACATGTGTAAAGTGAATGACAAAATGTGTAA 1287
DB 901 TATGATCTCTTTATGAGGTCACATGTGTAAAGTGAATGACAAAATGTGTAA 960
QY 1288 AAAAAACCTGTGTGTAAAGGCGCAACAGTACTGSAAAAACAATTTGGCAATGGCT 1347
DB 961 AAAAAACCTGTGTGTAAAGGCGCGCAAGTACAGAAACCACTTGGCAATGGCT 1020
QY 1348 ATTGCTAAAACCTGTGTGTAAAGGCGCGCAACAGTACTGSAAAAACAATTTGGCAAT 1407
DB 1021 ATTGCTAAAACCTGTGTGTAAAGGCGCGCAACAGTACTGSAAAAACAATTTGGCAAT 1080
QY 1408 AATGATGTACCGGGAATTAATGATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1467
DB 1081 AATGATGTACCGGGAATTAATGATGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1140
QY 1468 GTGGAAGCTGCAAAAGCAATTTTAAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1527
DB 1141 GTGGAAGCTGCAAAAGCAATTTTAAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1200
QY 1528 GCGAGTGTGCAAGT 1587
DB 1201 GGAAGTGTGCAAGT 1260
QY 1588 GTGTGAGTGTATTAATCACTCAATCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1647
DB 1261 GTGTGAGTGTATTAATCACTCAATCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1320
QY 1648 AAGCTTAATTTACATTAATGATGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1707
DB 1321 AAGCTTAATTTACATTAATGATGAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1380
QY 1708 CAACATGCTTAATCTGT 1767
DB 1381 CAACATGCTTAATCTGT 1440
QY 1768 AACTTACATTTTATTTCCCTGAAATTAATGAGATGCTGTGTGTGTGTGTGTGTGTGT 1827
DB 1441 AACTTACATTTTATTTCCCTGAAATTAATGAGATGCTGTGTGTGTGTGTGTGTGTGT 1500

```
QY 1828 ACCCCATTGTCCAGACACAGATCAGAGAGTGTGTAAGCTCTGAAGACTC 1887
Db 1501 ACCCAATTGTCAAGACACAGATCAGAGAGTGTGTAAGCTCTGAAGACTC 1560
QY 1888 AGTGAAGAGAGCTTTTTCACCTCATCATCAGAGCGCTGGAACAGTGAACCCCGCGC 1947
Db 1561 AGTGAAGAGAGCTTTTTCACCTCATCATCAGAGCGCTGGAACAGTGAACCCCGCGC 1620
QY 1948 TCTAGTACGCGCGTCCCGGAGACAGTTCAGAGAAATCATTTGTGGAAGCCAGTTCC 2007
Db 1621 TCTAGTACGCGCGTCCCGGAGACAGTTCAGAGAAATCATTTGTGGAAGCTCAGTTCC 1680
QY 2008 TCCGAGTGTAGCCGCGTGTGAGAGAGCTTTTACACGCGCGCTTGCGAGTCAAGTTT 2067
Db 1681 TCCGAGTGTAGCTGTGATGTGAGAGAGCCCTTCTACACACCTTTGCGAGACAGTTT 1740
QY 2068 CGTGAACGTGTAGTGAAGGCTTGAATTGTGAGAGAGGATTCCTGTTTC 2127
Db 1741 CGTGAACGTGTAGTGAAGGCTTGAATTGTGAGAGGATTCCTGTTTC 1800
QY 2128 TGTGTGAACATATTAACAACAGTGGGGAGGGTTGGGCTTGCCCTCATTTGATTAT 2187
Db 1801 TGTGTGAACATATTAACAATAGTGGGGAGGCTTGGAATTTGCCCATTTGATTAT 1860
QY 2188 GTGGAGCTTGTATATGATGGAATTTAGAGATTACTCCAGCTAGTGGCTGC 2247
Db 1861 GTAGGGGCTTGTATATGATGGAATTTAGAGATTACTCCAGCTAGTGGCTGC 1920
QY 2248 AGTTGTATGTAGAGAGCTCTAACCCATTTTCTGTGTAACTGTAAATAATGTGCTTAC 2307
Db 1921 AGCTGCCATGTGAGAGCTCTAAATCCCTTTCTGTGTAACTGTAAATAATGTGCTTAC 1980
QY 2308 CTGTCTGATTAACAAGTTTGTAGATTATGAGTAA 2343
Db 1981 CTGTCTGATTAACAAGCTTGTAGATTATGAGTAA 2016
```

Search completed: April 21, 2004, 16:21:13
Job time : 1889 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 21, 2004, 05:02:03 ; Search time 11673 Seconds
(without alignments)
12862.764 Million cell updates/sec

Title: US-09-555-640-1
Perfect score: 5028
Sequence: 1 gagcgacacggaatgacgt.....aagctatctccctgacgacgc 5028

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 27513289 seqs, 14931090276 residues
Total number of hits satisfying chosen parameters: 55026578

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estnu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hct:*
9: gb_est1:*
10: gb_est2:*
11: gb_hct:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_hnv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rod:*
26: em_gss_pbg:*
27: em_gss_vrl:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
C 1	69.4	1.4	712	13	BX416727 BX416727
C 2	68.4	1.4	1101	29	CNS0039G AL063921 Drosophila
C 3	56	1.1	1201	9	AL532464 AL532464
C 4	55	1.1	1201	13	BX4161824 BX4161824

C 5	54.2	1.1	1101	29	CNS00LT2	AL078714 Drosophila
C 6	53.6	1.1	1201	13	BX356851	BX356851
C 7	53	1.1	1099	13	BX456575	BX456575
C 8	51.8	1.0	1201	13	BX379650	BX379650
C 9	51.8	1.0	1613	28	BZ575046	BZ575046
C 10	51.6	1.0	968	13	BX415693	BX415693
C 11	51	1.0	994	13	BX414650	BX414650
C 12	50.8	1.0	876	29	CNS008BK	AL051466 Drosophila
C 13	50.8	1.0	1001	29	CNS007BE	AL066953 Drosophila
C 14	50.6	1.0	1124	13	BX36282	BX36282
C 15	50.2	1.0	1101	29	CNS00EVL	AL069706 Drosophila
C 16	50.2	1.0	1201	29	CNS016BL	AL106431 Drosophila
C 17	49.6	1.0	829	29	CNS011NU	AL100500 Drosophila
C 18	49.6	1.0	1201	9	AL559324	AL559324
C 19	49.4	1.0	414	28	AQ798260	AQ798260
C 20	49.2	1.0	1101	29	CNS0182P	AL108811 Drosophila
C 21	49	1.0	1141	28	CC209484	CC209484
C 22	48.8	1.0	257	29	CNS000OP	AL076746 Drosophila
C 23	48.8	1.0	928	29	CNS00DKY	AL071865 Drosophila
C 24	48.8	1.0	979	29	CNS00DPH	AL060395 Drosophila
C 25	48.8	1.0	1163	13	BX415221	BX415221
C 26	48.4	1.0	389	29	AG226274	AG226274
C 27	48.4	1.0	677	28	BH685106	BH685106
C 28	48.4	1.0	1101	29	CNS003B6	AL064084 Drosophila
C 29	48.4	1.0	1201	13	BX361615	BX361615
C 30	48.2	1.0	1007	29	CNS06X9S	AL19462 T3 end of
C 31	48.2	1.0	1133	13	BX422748	BX422748
C 32	48.2	1.0	1151	29	CNS024TU	AL181216 Tetradon
C 33	48	1.0	750	29	CG823001	CG823001
C 34	47.8	1.0	652	28	BZ515984	BZ515984
C 35	47.8	1.0	712	13	BX416727	BX416727
C 36	47.8	1.0	755	28	BZ502267	BZ502267
C 37	47.8	1.0	780	28	BZ061381	BZ061381
C 38	47.8	1.0	835	28	BH675700	BH675700
C 39	47.8	1.0	1101	29	CNS000UL	AL078769 Drosophila
C 40	47.6	0.9	625	28	BZ489847	BZ489847
C 41	47.6	0.9	1200	13	BX457423	BX457423
C 42	47.4	0.9	718	29	CE746255	CE746255
C 43	47.4	0.9	1125	13	BX436449	BX436449
C 44	47.2	0.9	885	13	BX425603	BX425603
C 45	47.2	0.9	1080	29	CNS008EP	AL069494 Drosophila

ALIGNMENTS

RESULT 1
LOCUS BX416727/c
DEFINITION BX416727 Homo sapiens NEUROBLASTOMA Homo sapiens cDNA clone
ACCESSION BX416727
VERSION BX416727.1 GI:30765629
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Buttheria; Primates; Catarrhini; Homiidae; Homo.
JOURNAL 1 (bases 1 to 712)
COMMENT Full-length cDNA libraries and normalization
Contact: Genoscope - Centre National de Sequencage
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seque@genoscope.cns.fr, Web: www.genoscope.cns.fr
Invitrogen Contact: Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID: CS0DA011B07QPI.
Location/Qualifiers
1..712
/organism="Homo sapiens"


```

KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

```

EST.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 1201)
Li, W.B., Gruber, C., Jesssee, J. and Polayes, D.
Full-length cDNA libraries and normalization
unpublished (2001)
On Feb 13, 2001 this sequence version replaced gi:12795957.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: secrete@genoscope.cns.fr Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. Contact : Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CS0DM012DG05NP1.
Location/Qualifiers

```

1. 1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0DM012YN10"
/tissue_type="FETAL LIVER"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/notes="Organ: liver; Vector: pCMVSPORT_6; 1st strand cDNA
was primed with a NciI-oligo(dT) primer. Five prime end
enriched, double-strand cDNA was digested with Nci I and
cloned into the Nci I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."

```

[illegible]

```

TITLE
JOURNAL
COMMENT
Unpublished (2001)
Full-length cDNA libraries and normalization

Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
was not normalized. Library was constructed by Life Technologies, a
division of Invitrogen. This sequence belongs to sequence cluster
8170.r for more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODP034BA04QPI&cluster=8170.r. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600
Paradey Avenue Genoscope sequence ID : CSODP034BA04QPI.
Location/Qualifiers

1. 1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODP034YA08"
/tissue_type="FETAL BRAIN"
/dev stage="fetal"
/clone_lib="Homo sapiens FETAL BRAIN"
/note="Organ: brain; Vector: pCMVSPORT 6; 1st strand cDNA
was primed with a NotI-oligo (dT) primer. Five prime end
enriched, double-strand cDNA was digested with Not I and
cloned into the Not I and EcoRV sites of the pCMVSPORT 6
vector. Library was not normalized."

```

Query Match	1.1k; Score 55; DB 13; Length 1201;
Best Local Similarity	34.1k; Pred. No. 0.036;
Matches	104; Conservative 61; Mismatches 140; Indels 0; Gaps 0;
Qy 2276	TTTCTGTGTTACTGTGTAAGAAAATGCTTACCTGTCGTGATTAACAAGTTGTGATTT 2335
Db 778	TTATTTMTTAAATMTATATAAATATATATATTTTAAATATTTTAAATTTTAAATTT 837
Qy 2336	ATGAGTAAACCATACAAATGCTGGGAAAGCAGTACAAATTTGGCCAGAGCTGAT 2395
Db 838	ATMTMTAAHMTMTCTMMAAATATCMTATATMAATTTAAAAAAATHTMTATCAATATTTMTA 897
Qy 2396	AAGCAGTTTGTGCACTTTTATGAAAAAGCTACTGGAACAGACTTAGAGCTTATTCAAAT 2455
Db 898	AMTAAATATAAANAATTTATATATAAAAAAATTTCTMTTAATATMAATATMTTCTAAATATM 957
Qy 2456	TTAAAGACCATTAACAACATTTCTTAGATPATTCCTTTAGAAAACCCCTCTTCTTATTT 2515
Db 958	TAAATATATATATCAAAATMTTMTTMAAATAAATTTTTCAMATATATATATATTTT 1017
Qy 2516	GACTTATGCTGCGCATTTAAAGTAATCTTAAAAACCTCCAGACCTATATAGTCATCAT 2575
Db 1018	TTTAAATATATTTTATATMTMAHAAAHAAATMTATTTTMTTAAATTTTAAATATATTTTMT 1077
Qy 2576	TTTCA 2580
Db 1078	TTTMM 1082
RESULT 5	
CNS00LT/c	
LOCUS	1101 bp DNA linear GSS 14-JUN-1999
DEFINITION	CNS00LT2 Drosophila melanogaster genome survey sequence TET3 end of BAC: BACR484P15 of RPEC1-58 library from Drosophila melanogaster (fruit fly), genomic survey sequence.
ACCESSION	AL078714
VERSION	AL078714.1 GI:5102004
KEYWORDS	GSS.
SOURCE	Drosophila melanogaster (fruit fly)
ORGANISM	Drosophila melanogaster Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Ephydroidea; Drosophilidae; Drosophila.

KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Li, W.B., Gruber, C., Jesssee, J., and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. Contact: Feng Liang Email: fliang@life.com URL:
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID: CS0CAP02DB020PL
Location/Qualifiers
1. 1099
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0CAP02YD04"
/issue_type="THYMUS"
/clone_lib="Homo sapiens THYMUS"
/note="Vector: pCMVSPORT 6; 1st strand cDNA was primed
with a NotI-oligo(dT) primer. Five prime end enriched,
double-strand cDNA was digested with Not I and cloned into
the Not I and EcoRV sites of the pCMVSPORT 6 vector.
Library was not normalized."

ORIGIN
Query Match 1.1%; Score 53; DB 13; Length 1099;
Best Local Similarity 27.1%; Pred. No. 0.11;
Matches 191; Conservative 177; Mismatches 323; Indels 14; Gaps 2;
607 AGAAGCTTAAGTGTGCGAGAGAGTTTAAATATGTTTACATCTTGTACT 666
1094 AAAATKAKAAAKAKAKADMAADDKTAAMKRAATADAAADAAATTKKDDAAK 1035
667 GAAAGTGTAACTTAATTTTCCAGGAGTACCAAGAAATATTTAGAGAT 726
1034 ADAMTAKTKKATKATDDDDKDDKDDAAKADKAKKRAADTKKDDAKAATKAK 975
727 GGAGACAGTTTATAGAAATTAATTAAGAAATTTCTTAATATGTGTGTGTGT 786
974 AKRAAKKGGTAAATKGGTATATATATATATATATATATATATATATATAT 915
787 GTAAACAATATGACGGGTATATAGACCTGTAATTTCCGCTTTTCCGCGAGAGCT 846
914 DAAAT 855
847 TGTGATGCTAAAGAGCCGCTTACTGCAATATAGACAGCTCTACTAATGAACTGG 906
854 ATWDITTKTAADAAAAAAMRAATTTKRAMWKARAKDAAADRWKDDKGAADATKRR 795
907 GAGCTAGCTGTGAGAGGAGAGATGTTGTCCATGCTGCGAAGGAGAAAGCGGG 966
794 GTKDRDARKKGGAAKGGAAKGGAAKGGAAKGGAAKGGAAKGGAAKGGAAKGG 735
967 TTAAGTTCAACATGTAATTTGGCTATGTGAAGAAAGAGATTTTCTGAAGATAA 1026
734 KTKGAATATAATATGATTTGGGAAKGGAAKGGAAKGGAAKGGAAKGGAAKGG 682
1027 TGAAGTTAGTATTTTAAACAATATATCTTTAATAGTACAGTCACTGCGAGCTT 1086
681 GTAAAAAATGAGATTTGAAAAAAGAAAGAAAGAAAGAAAGAAAGAAAGAAAG 629
1087 CAATTCAGAGTGTCAATGATGATTTATTAAGTACTACTAATTAAGTCACTAGT 1146
628 AAAAATGAAATATATATTTTGAATGAAATTTTATATATATATATATATATAT 569
1147 ACATTTCTTTTATATATGAGCTTGAAGCTTACTGATTAAGAAATTAATATAGTA 1206

Db 568 GTAAATGADAAATAATADKTTTAAATATATATATATATATATATATATAT 509
Qy 1207 AAATTTATTTTGTGCAAAACATATGATCTCTTTAGTGGTCAACATGTTAAGTGG 1266
Db 508 DAWTAAATTTTTTTTTTTTTTTTGAASAAATTTTTTTTTTTTTTTTGGTGGCAATGATGTC 449
Qy 1267 ATGACAAAATATGCTGTAATAAAACACCTGTGTTTACGGG 1311
Db 448 AGTKMAATATATTTTTTTTGAATATATATATATATATATATATATATATAT 404
RESULT 8
BX379650/ 1201 bp mRNA linear EST 08-MAY-2003
LOCUS BX379650 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA
DEFINITION clone CS0D1036YF11 3-PRIME, mRNA sequence.
ACCESSION BX379650
VERSION BX379650.1 GI:30450783
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Bukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Li, W.B., Gruber, C., Jesssee, J., and Polayes, D.
TITLE Full-length cDNA libraries and normalization
JOURNAL Unpublished (2001)
COMMENT Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 1281.f For
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CS0D1036C06NP1c1cluster=1281.f. Contact :
Feng Liang Email: fliang@life.com URL:
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID: CS0D1036C06NP1.
Location/Qualifiers
1. 1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0D1036YF11"
/issue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)
primer. Five prime end enriched, double-strand cDNA was
digested with Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was normalized."

ORIGIN
Query Match 1.0%; Score 51.8; DB 13; Length 1201;
Best Local Similarity 33.2%; Pred. No. 0.22;
Matches 83; Conservative 61; Mismatches 106; Indels 0; Gaps 0;
1177 GTTACTTGATTAAGAAATTAATATATATATATATATATATATATATATAT 1236
Db 1052 DMMWMDAAWTTTAAAAAAMWMAAATTTTAAATATATATATATATATATATAT 993
Qy 1237 CTTTATGTTGATCAATGTGTTAAGTGTGATGACAAATATGTTAATATATATAT 1296
Db 992 GGGGAGTTTAAAT 933
Qy 1297 CTTGTTTAAAGGCAACCAAGTACTGCAATATATATATATATATATATATAT 1356
Db 932 TAAAT 873
Qy 1357 ACTGTACAGTGTATGAAATGTTAATGAAATGAAATGAAATGAAATGAAATG 1416
Db 872 RAAATATATGAGDGGGGGAGGAGGAAATGAAATGAAATGAAATGAAATGAAAT 813

Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to cluster 6015.f
Contact : Feng Liang Email : fliang@lifetech.com URL :
<http://fulllength.invitrogen.com/Invitrogen/Corporation/1600>
Faraday Avenue Genoscope sequence ID : CS0CAP001D01NP1.

FEATURES

source

1. .994

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0CAP001YN02"
/issue_type="THYMUS"
/clone_lib="Homo sapiens THYMUS"
/note="Vector: PCWSPORT 6; 1st strand cDNA was primed with a NotI-oligo (dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the PCWSPORT 6 vector.
Library was not normalized."

ORIGIN

Query Match 1.0%; Score 51; DB 13; Length 994;
Best Local Similarity 20.9%; Pred. No. 0.34;

Matches 76; Conservative 137; Mismatches 150; Indels 0; Gaps 0;

```

QY 1107 GTTAGCTATTATTAAGCTACTAAGTACCACTAGTACATTTCTTTACATTCAGA 1166
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 980 KDWANWAAADKMAAARBRWAGAAARARADWADWAAAWMDKWTAAAKKKMADWT 921
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1167 CTTTGAGCAGGTTACTGCTTAAGAAATTAATTAATTAATTAATTAATTAATTA 1226
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 920 TKTTKKADADADMDMDMDATAMWAAADWAAWAAATWTDWTDWTDWTDWTDWTD 861
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1227 CTATGATCCTCTTTAGTGGTCAACATGTTTAAAGTGAATGACAAAATGTGTA 1286
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 860 KADADDDATKTTTCTTTTWWKATWAGTAKWADATWADADWAAWAAWAAWAAW 801
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1287 AAAAAACACCTGCTGTTTACGGGCGCACCAAGTACGAAAAAATAATTTGGCAATGCG 1346
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 800 AAAAAWAAADADWAAWAAWAAWAAWAAWAAWAAWAAWAAWAAWAAWAAWAAW 741
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1347 TATGCTAAACCTGTACAGTATGATGATGATGATGATGATGATGATGATGATG 1406
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 740 ADAAGDKAARAAWMDGAGRDADWAAWADADAAARAAWAAWAAWAAWAAWAAW 681
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1407 TATGATGTAGCGGAAAGATTGCTGCTGAGTGAAGGCTTTTAAATGCTACTAT 1466
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 680 WAAWAAWMDTAKGGRKDDADWAAWTTTCTTTTAAWAAWAAWAAWAAWAAWAAW 621
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1467 TGT 1469
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 620 TTT 618
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

RESULT 12
CNS008BK
LOCUS 876 bp DNA linear GSS 03-JUN-1999
DEFINITION Drosophila melanogaster genome survey sequence T7 end of BAC #
BACR16N02 of RPCI-98 library from Drosophila melanogaster (fruit fly), genomic survey sequence.

ACCESSION
VERSION AL051466
KEYWORDS
SOURCE GSS.
ORGANISM Drosophila melanogaster (fruit fly)

REFERENCE
AUTHORS
TITLE
JOURNAL
- Web : www.genoscope.cns.fr

COMMENT

Determination of this BAC-end sequence was carried out as part of a collaboration with the Berkeley Drosophila Genome Project (BDGP). The BDGP is constructing a physical map of the Drosophila melanogaster genome using these BACs. For further information please see <http://www.fruitfly.org> The BDGP Drosophila melanogaster BAC library was prepared by Kazuo Osoegawa and Aaron Mammoler in Pieter de Jong's laboratory in the Department of Cancer Genetics at the Roswell Park Cancer Institute in Buffalo, NY. The library is named RPCI-98 and was constructed by partial EcoRI digestion of Drosophila DNA provided by the BDGP from the isogenic strain y2; cn bw sp, the same strain used for the BDGP's pl and EST libraries. A more detailed description of the library and how to order individual BAC clones, the entire library, or filters for hybridization from the BACPAC Resource Center can be found at http://bacpac.med.buffalo.edu/drosophila_bac.htm.

FEATURES

source

1. .876

/organism="Drosophila melanogaster"
/mol_type="genomic DNA"
/db_xref="taxon:7227"
/clone="BACR16N02"
/clone_lib="RPCI-98"
/note="end : T7"

ORIGIN

Query Match 1.0%; Score 50.8; DB 29; Length 876;
Best Local Similarity 36.0%; Pred. No. 0.38;

Matches 111; Conservative 59; Mismatches 134; Indels 4; Gaps 1;

```

QY 4599 CAGATCAAAAGCAACACACAGACGATATGAAAAGCTGAAAGATTGAGCTGCCA 4658
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 571 CAATGCGGAGAAATACACTTAATBTTCMTGCTACACACTAISTAGSCTN 630
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 4659 AAAGCGGTGACCACTGTAAACATTCGCCACCGTCTCAGCAGAACCGTCACC 4718
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 631 ATTACTCTCTCCACAAACAAATSYTSCCAATATCCCTCCATCTTCCSCACTA 630
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 4719 CACCGCCACCTGTGCGCCGACATATATATGTCGCCCTCCATATCCCGTAGCAACCA 4778
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 691 YTTTATATTSCTT---CCAAACAAATCTCTCTSSSSSTSSSTSSSTSSSTAW 746
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 4779 TCTATAAAGATACAGACGCTGTAGATATTAATTAATTAATTAATTAATTAATTA 4838
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 747 TTTWATTAATAATSAATGCGCAARTRTAAWAAATTAATAWAAWAAWAAWAAW 806
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 4839 ATTGAATGCTAAGATTAATATATGATGACAAAGTTTGAAAAATTAAGCTTAATA 4898
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 807 ATAAKTGSGWTTATTTATTTGTCTATBTWTTANAATAMWRAAAWAAWAAW 866
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 4899 AATTAATTC 4906
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 867 SAGCADBB 874
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

RESULT 13

CNS007BE/c
LOCUS 1001 bp DNA linear GSS 03-JUN-1999
DEFINITION Drosophila melanogaster genome survey sequence TET3 end of BAC #
BACR15H4 of RPCI-98 library from Drosophila melanogaster (fruit fly), genomic survey sequence.

ACCESSION
VERSION AL066953
KEYWORDS
SOURCE GSS.
ORGANISM Drosophila melanogaster (fruit fly)

REFERENCE
AUTHORS
TITLE
JOURNAL
- Web : www.genoscope.cns.fr

Submitted (02-JUN-1999) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : seqlref@genoscope.cns.fr)

AUTHORS
TITLE
JOURNAL

Genoscope.
Direct Submission
Submitted (02-JUN-1999) Genoscope - Centre National de Sequencage :
BP 191 91006 EVRY cedex - FRANCE (E-mail : sequef@genoscope.cns.fr
- Web : www.genoscope.cns.fr)

COMMENT

Determination of this BAC-end sequence was carried out as part of a
collaboration with the Berkeley Drosophila Genome Project (BDGP).
The BDGP is constructing a physical map of the Drosophila
melanogaster genome using these BACs. For further information
please see <http://www.fruitfly.org> The BDGP Drosophila
melanogaster BAC library was prepared by Kazuo Ooegawa and
Aaron Mammose at the Roswell Park Cancer Institute in Buffalo,
NY. The library is named RPCI-98 and was constructed by partial
EcoRI digestion of Drosophila DNA provided by the BDGP from the
isogenic strain y2; cn bw sp, the same strain used for the BDGP's
P1 and EST libraries. A more detailed description of the library
and how to order individual BAC clones, the entire library, or
filters for hybridization from the BACPAC Resource Center can be
found at http://bacpac.med.buffalo.edu/drosophila_bac.htm.

FEATURES

source

1.1101
/organism="Drosophila melanogaster"
/mol_type="genomic DNA"
/db_xref="taxon:7227"
/clone_id="RPCI-98"
/note="end : T7"

ORIGIN

Query Match 1.0%; Score 50.2; DB 29; Length 1101;
Best Local Similarity 34.5%; Pred. No. 0.55;
Matches 162; Conservative 69; Mismatches 237; Indels 1; Gaps 1;
QY 948 AAGGAGCAAAAGCGGGTTAAAGTTCAACCATGTAATGCTATGTGAAAACAG 1007
DB 538 AAAAAAAWMTAATTTAAWMAATATWMTATWMAWMTATWMTATWMTATWMTAT 597
QY 1008 AGATTTACTGAAGTAATGGAATTAAGGATTTTAAACCATATCTTATTAAGTAG 1067
DB 598 WTWATTAATTAATAAAAAATTTTWTATWMTATTTTAAATTAATTAATTAATTA 657
QY 1068 CAGTCACAGTGCAGCTTCAAAATTCAGAGCGCTTAAGCTTACCTATTATAAAGCTAC 1127
DB 658 TAAWTAATTTWMTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 717
QY 1128 TAACTTAGTACCACTAGTACATTCCTGTGTACATTCAGCTTGACGAGGTACTG 1187
DB 718 TAAWTAATTTAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATA 777
QY 1188 TAAAGAAATTAATAATGTAATTAATTAATTTGTGCAAACTATGATCCTTTAGTGG 1247
DB 778 WMAWMTATWMTATWMTATWMTATWMTATWMTATWMTATWMTATWMTATWMTAT 837
QY 1248 TCAACATGTGTAGGTGATGCAAAAATGTGTAAAAAACAACCGTGTGTTTA 1307
DB 838 ATWMAAA-TWMAAAAAAATWTAATWTAATWTAATWTAATWTAATWTAATWTAAT 896
QY 1308 CGGGCCACCAAGTACTGAAAAAATAATTTGGCAATGCTATGCTAAAACTGACCA 1367
DB 897 AAWATATTAAMWMTATWMAAAAAAATAAATAAATAAATAAATAAATAAATAAATA 956
QY 1368 GTATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGAATGGA 1416
DB 957 WTAATWMTATWMTATWMTATWMTATWMTATWMTATWMTATWMTATWMTATWMT 1005

Search completed: April 21, 2004, 15:44:16.
Job time : 11682 secs

THIS PAGE BLANK (USPTO)